nct_id,brief_title,official_title,overall_status,start_date,completion_date,last_update,study_type,phase,enrollment,enrollment_type,allocation,intervention_model,primary_purpose,masking,condition,intervention_name,intervention_type,primary_outcome_count,secondary_outcome_count,min_age,max_age,sex,healthy_volunteers,lead_sponsor_name,lead_sponsor_class,collaborator_count,location_count,countries,trial_success,is_phase1,is_phase2,is_phase3,is_phase4,is_combined_phase,phase_numeric,is_oncology,is_autoimmune,is_cns,is_cardiovascular,condition_count,log_enrollment,enrollment_size,is_small_trial,is_actual_enrollment,is_industry_sponsor,is_academic_sponsor,is_big_pharma,has_collaborators,is_multisite,is_international,is_us_trial,is_europe_trial,is_randomized,is_blinded,is_treatment_purpose,is_parallel,total_outcome_count,has_secondary_outcomes,is_drug,is_biological,is_device,intervention_count,has_multiple_interventions,start_date_dt,completion_date_dt,study_duration_days,start_year,is_recent_trial,complexity_score,is_complex_trial
NCT01151059,Safety and Immunogenicity of One Dose of Inactivated Trivalent Flu Vaccine Administered to Non-elderly Adult and Elderly Subjects,"A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of AGRIPPAL® S1 Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2010-2011, When Administered to Non-elderly Adult and Elderly Subjects",COMPLETED,2010-06,2010-07,2012-03-28,INTERVENTIONAL,PHASE2,138.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,PREVENTION,NONE,Seasonal Influenza,"Trivalent subunit inactivated flu vaccine, Formulation 2010-2011",BIOLOGICAL,1,1,18 Years,,ALL,True,Novartis Vaccines,INDUSTRY,0,5,Italy,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.9344739331306915,medium,0,1,1,0,1,0,1,0,0,1,0,0,0,0,2,1,0,1,0,1,0,2010-06-01,2010-07-01,30.0,2010.0,0,0,0
NCT03747159,Synergetic B-cell Immunomodulation in SLE - 2nd Study.,A Randomized Trial to Investigate the Reset of Humoral Autoimmunity by Combining Belimumab with Rituximab in Severe Systemic Lupus Erythematosus,ACTIVE_NOT_RECRUITING,2018-10-01,2026-06-07,2024-10-17,INTERVENTIONAL,PHASE3,70.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Lupus Erythematosus, Systemic",Belimumab Injection,DRUG,1,14,18 Years,,ALL,False,Leiden University Medical Center,OTHER,2,4,Netherlands,,0,0,1,0,0,3.0,0,1,0,0,1,4.2626798770413155,medium,1,0,0,1,0,1,1,0,0,0,1,0,1,1,15,1,1,0,0,1,0,,,,,0,1,0
NCT01122459,Evaluation of the Effect of Two Types of Fluid in the Recovery From Anaesthesia. Voluven 6% v Hartmanns,Evaluation of the Effects of Two Types of Fluid in the Recovery From Anaesthesia.,COMPLETED,2010-01,2011-01,2011-07-21,INTERVENTIONAL,PHASE3,120.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Postoperative Nausea and Vomiting,fluid administration,OTHER,1,19,18 Years,45 Years,FEMALE,True,The Rotunda Hospital,OTHER,0,1,Ireland,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.795790545596741,medium,0,1,0,1,0,0,0,0,0,0,1,1,0,1,20,1,0,0,0,1,0,2010-01-01,2011-01-01,365.0,2010.0,0,1,0
NCT04649359,"MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb","MAGNETISMM-3 AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 2 STUDY OF ELRANATAMAB (PF-06863135) MONOTHERAPY IN PARTICIPANTS WITH MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY DRUG AND ONE ANTI-CD38 ANTIBODY",ACTIVE_NOT_RECRUITING,2021-02-02,2026-12-31,2025-12-02,INTERVENTIONAL,PHASE2,187.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Multiple Myeloma,Elranatamab (PF-06863135),DRUG,1,21,18 Years,,ALL,False,Pfizer,INDUSTRY,0,87,Belgium|United States|Germany|Spain|Australia|United Kingdom|Poland|Japan|France|Canada,,0,1,0,0,0,2.0,1,0,0,0,1,5.236441962829949,medium,0,1,1,0,1,0,1,1,1,1,0,0,1,1,22,1,1,0,0,1,0,,,,,0,2,0
NCT03868423,Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers,Phase II Study of Brigatinib for Advanced Solid Cancers Harboring Genomic Alterations in ALK (Excluding Lung) and ROS1 Oncogenes,WITHDRAWN,2019-03-20,2021-12-30,2022-02-18,INTERVENTIONAL,PHASE2,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Advanced Malignant Neoplasm|ALK Fusion Protein Expression|ALK Gene Amplification|ALK Gene Mutation|Locally Advanced Malignant Solid Neoplasm|Metastatic Malignant Neoplasm in the Brain|Metastatic Malignant Neoplasm in the Central Nervous System|Metastatic Malignant Solid Neoplasm|ROS1 Fusion Positive|ROS1 Gene Amplification|ROS1 Gene Mutation,Brigatinib|Laboratory Biomarker Analysis|Quality-of-Life Assessment|Questionnaire Administration,DRUG|OTHER,1,11,18 Years,,ALL,False,Sameek Roychowdhury,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,11,0.0,,1,1,0,1,0,1,0,0,1,0,0,0,1,0,12,1,1,0,0,4,1,,,,,0,3,1
NCT00664859,"12-Month, Open-Label, Extension Study of LCP-AtorFen in Dyslipidemia","A 12-Month, Open-Label, Extension Study of the Safety and Efficacy of LCP-AtorFen in Subjects With Dyslipidemia",COMPLETED,2007-10,2009-02,2020-03-24,INTERVENTIONAL,PHASE2|PHASE3,140.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Dyslipidemia,LCP-AtorFen,DRUG,1,1,18 Years,,ALL,False,Veloxis Pharmaceuticals,INDUSTRY,0,1,United States,1.0,0,1,1,0,1,2.5,0,0,0,0,1,4.948759890378168,medium,0,1,1,0,0,0,0,0,1,0,0,0,1,0,2,1,1,0,0,1,0,2007-10-01,2009-02-01,489.0,2007.0,0,1,0
NCT01334359,Exercise Effects on Cognition in School-Aged Children,ERPs to Academics: Exercise Effects on Cognition in School-Aged Children,COMPLETED,2008-07,2012-06,2014-07-25,INTERVENTIONAL,PHASE3,252.0,ACTUAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,SINGLE,Brain Health|Cognition|Scholastic Achievement,Physical Activity,BEHAVIORAL,3,6,8 Years,9 Years,ALL,True,University of Illinois at Urbana-Champaign,OTHER,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,3,5.53338948872752,large,0,1,0,1,0,0,0,0,1,0,1,0,0,1,9,1,0,0,0,1,0,2008-07-01,2012-06-01,1431.0,2008.0,0,2,0
NCT01627379,"Cisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable,Advanced or Metastatic Esophageal Squamous Cell Cancer","An Open-label, Randomized Phase III Trial of Cisplatin and 5-fluorouracil With or Without Panitumumab for Patients With Nonresectable, Advanced or Metastatic Esophageal Squamous Cell Cancer",TERMINATED,2012-05,2017-05,2018-03-02,INTERVENTIONAL,PHASE3,300.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,NONE,Esophageal Squamous Cell Cancer,"Cisplatin, 5-FU|Panitumumab",DRUG,1,5,18 Years,,ALL,False,AIO-Studien-gGmbH,OTHER,3,1,Germany,0.0,0,0,1,0,0,3.0,1,0,0,0,1,5.707110264748875,large,0,0,0,1,0,1,0,0,0,1,1,0,1,1,6,1,1,0,0,2,1,2012-05-01,2017-05-01,1826.0,2012.0,0,2,0
NCT01979679,A D2 Receptor Occupancy and fMRI Study in Schizophrenic Subjects Treated With Lurasidone,A D2 Receptor Occupancy and fMRI Study in Schizophrenic Subjects Treated With Lurasidone,COMPLETED,2008-12,,2013-11-08,INTERVENTIONAL,PHASE3,28.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Schizophrenia,Lurasidone 80 mg|Lurasidone 120 mg|Lurasidone 160 mg,DRUG,1,0,18 Years,60 Years,ALL,False,"University of California, Irvine",OTHER,1,1,United States,1.0,0,0,1,0,0,3.0,0,0,1,0,1,3.367295829986474,small,1,1,0,1,0,1,0,0,1,0,1,1,1,1,1,0,1,0,0,3,1,2008-12-01,,,2008.0,0,1,0
NCT04738279,The CASCADE HF Soft Launch and Calibration Phase I and II,A Study to Determine the Efficacy of Continuous Ambulatory Wearable Technology and a Cascading Alert System in Reducing 30d Readmission in High Risk Heart Failure Patients,COMPLETED,2020-12-14,2021-10-30,2023-10-03,INTERVENTIONAL,PHASE2|PHASE3,20.0,ACTUAL,NON_RANDOMIZED,SEQUENTIAL,OTHER,NONE,Heart Failure,Non-Invasive Continuous Remote Patient Monitoring|Affective Analysis of Participant Response to Continuous Remote Patient Monitoring,DEVICE|OTHER,2,2,18 Years,,ALL,False,Endeavor Health,OTHER,3,1,United States,1.0,0,1,1,0,1,2.5,0,0,0,1,1,3.044522437723423,small,1,1,0,1,0,1,0,0,1,0,0,0,0,0,4,1,0,0,1,2,1,,,,,0,2,0
NCT00630279,Dose-ranging Study to Evaluate Efficacy of SLV339 in Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis,"A Multi-center, Single-blind, Parallel-design, Randomized, Placebo-controlled, Dose-ranging Study to Evaluate Oral Recombinant Microbial Lipase Efficacy in Patients With Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis",TERMINATED,2008-02,2009-03,2009-08-06,INTERVENTIONAL,PHASE2,56.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis,Placebo|Recombinant Microbial Lipase SLV339|Recombinant Microbial Lipase SLV339|Recombinant Microbial Lipase SLV339,DRUG,1,1,18 Years,,ALL,False,Solvay Pharmaceuticals,INDUSTRY,0,50,Russia|Latvia|Sweden|Hungary|Poland|Czechia|Denmark,0.0,0,1,0,0,0,2.0,0,0,0,0,1,4.04305126783455,medium,1,1,1,0,0,0,1,1,0,0,1,1,1,1,2,1,1,0,0,4,1,2008-02-01,2009-03-01,394.0,2008.0,0,2,0
NCT00671879,Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back,"Randomized, Double-Blind, Double-Dummy Trial of Two Sustained Release Formulations of Carisoprodol Compared to Placebo in Subjects With Acute, Painful, Musculoskeletal Spasm of the Lower Back",COMPLETED,2008-04,2009-03,2012-11-21,INTERVENTIONAL,PHASE3,830.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Lower Back Pain,Carisoprodol SR 700 mg|Carisoprodol SR 500 mg|Placebo,DRUG,1,1,18 Years,70 Years,ALL,False,Meda Pharmaceuticals,INDUSTRY,0,73,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.7226297948554485,xlarge,0,1,1,0,0,0,1,0,1,0,1,1,1,1,2,1,1,0,0,3,1,2008-04-01,2009-03-01,334.0,2008.0,0,1,0
NCT02118896,Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a Transplant,"A Long-term Follow up Study to Evaluate the Safety and Efficacy in Transplant Recipients Treated With Modified Release Tacrolimus, FK506E (MR4), Based Immunosuppression Regimen",COMPLETED,2003-02-24,2009-10-07,2024-11-22,INTERVENTIONAL,PHASE3,850.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Heart Transplantation|Liver Transplantation|Kidney Transplantation,FK506E,DRUG,2,3,18 Years,,ALL,False,Astellas Pharma Europe Ltd.,INDUSTRY,0,105,Germany|Switzerland|Italy|Netherlands|Finland|Spain|Czechia|Ireland|Canada|Sweden|United States|Austria|Australia|United Kingdom|Poland|Mexico|New Zealand|Denmark|South Africa|France|Belgium|Hungary|Brazil,1.0,0,0,1,0,0,3.0,0,0,0,1,3,6.7464121285733745,xlarge,0,1,1,0,0,0,1,1,1,1,0,0,1,0,5,1,1,0,0,1,0,,,,,0,2,0
NCT01432496,Peritoneal Nebulization of Ropivacaine for Pain Control After Laparoscopic Colectomy,"A Multicentric, Randomized, Controlled, Double Blinded, Phase III Clinical Trial; Comparing Peritoneal Nebulization of Ropivacaine 150 mg With Peritoneal Nebulization of Saline",TERMINATED,2011-09,2012-12,2013-02-25,INTERVENTIONAL,PHASE3,130.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Postoperative Pain,Ropivacaine 150 mg|saline 15 ml,DRUG,1,5,18 Years,80 Years,ALL,False,San Gerardo Hospital,OTHER,4,3,Italy,0.0,0,0,1,0,0,3.0,0,0,0,0,1,4.875197323201151,medium,0,0,0,1,0,1,1,0,0,1,1,1,1,1,6,1,1,0,0,2,1,2011-09-01,2012-12-01,457.0,2011.0,0,2,0
NCT06092762,A Study to Evaluate the Safety and Efficacy of AK120 in Subjects With Moderate to Severe Atopic Dermatitis,"a Multicenter, Randomized, Open Label Phase II Clinical Study to Evaluate the Safety and Efficacy of AK120 in the Treatment of Subjects With Moderate to Severe Atopic Dermatitis",COMPLETED,2023-11-06,2024-11-13,2024-11-25,INTERVENTIONAL,PHASE2,180.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Atopic Dermatitis,AK120,DRUG,1,6,18 Years,75 Years,ALL,False,Akeso,INDUSTRY,0,26,China,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.198497031265826,medium,0,1,1,0,0,0,1,0,0,0,1,0,1,1,7,1,1,0,0,1,0,,,,,0,1,0
NCT05038046,Combined Western and Traditional Chinese Medicine Daycare for DM Nephropathy Patients,Clinical Study of Combined Western Medicine and Traditional Chinese Medicine Daycare Model for Chronic Kidney Disease Patients,COMPLETED,2016-03,2018-05-16,2021-09-08,INTERVENTIONAL,PHASE3,25.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Diabetes Mellitus Nephropathy,Traditional Chinese Medicine (TCM) daycare model,OTHER,1,11,20 Years,,ALL,False,China Medical University Hospital,OTHER,1,1,Taiwan,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.258096538021482,small,1,1,0,1,0,1,0,0,0,0,0,0,1,1,12,1,0,0,0,1,0,2016-03-01,,,2016.0,1,1,0
NCT00511446,"Trial of Docetaxel, Oxaliplatin and Capecitabine (TEX) in Advanced or Metastatic Gastric Cancer","Phase II Trial of Docetaxel, Oxaliplatin and Capecitabine (TEX) in Advanced or Metastatic Gastric Cancer",COMPLETED,2007-08,2013-01,2013-06-26,INTERVENTIONAL,PHASE2,56.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Stomach Neoplasms,"docetaxel, oxaliplatin, capecitabine",DRUG,1,7,18 Years,,ALL,False,Martin-Luther-Universität Halle-Wittenberg,OTHER,0,10,Germany,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.04305126783455,medium,1,1,0,1,0,0,1,0,0,1,0,0,1,0,8,1,1,0,0,1,0,2007-08-01,2013-01-01,1980.0,2007.0,0,1,0
NCT01208688,FES Therapy:Restoring Voluntary Grasping Function in Chronic SCI,FES Therapy:Restoring Voluntary Grasping Function in Chronic SCI,COMPLETED,2009-09,2011-09,2012-09-25,INTERVENTIONAL,PHASE2,15.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Spinal Cord Injuries,FES Therapy|FES Therapy|Conventional Occupational Therapy,DEVICE|OTHER,1,4,18 Years,,ALL,False,Toronto Rehabilitation Institute,OTHER,1,1,Canada,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.772588722239781,small,1,1,0,1,0,1,0,0,0,0,1,0,1,1,5,1,0,0,1,3,1,2009-09-01,2011-09-01,730.0,2009.0,0,1,0
NCT00983788,Effect of Bezafibrate on Muscle Metabolism in Patients With Fatty Acid Oxidation Defects,Evaluation of the Effect of Bezafibrate on Muscle Metabolism During Exercise in Patients With CPTII and VLCAD Deficiency,COMPLETED,2009-10,2011-09,2012-05-30,INTERVENTIONAL,PHASE2,12.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Carnitine Palmitoyltransferase II Deficiency|Very Long Chain Acyl Coa Dehydrogenase Deficiency,Bezafibrate|Placebo,DRUG|OTHER,1,1,18 Years,70 Years,ALL,False,"Rigshospitalet, Denmark",OTHER,1,1,Denmark,1.0,0,1,0,0,0,2.0,0,0,0,0,2,2.5649493574615367,small,1,1,0,1,0,1,0,0,0,0,1,1,1,0,2,1,1,0,0,2,1,2009-10-01,2011-09-01,700.0,2009.0,0,2,0
NCT00743288,Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma,A Phase I/II Study of Oral Melphalan Combined With LBH589 for Patients With Relapsed or Refractory Multiple Myeloma (MM),COMPLETED,2008-07,2012-12,2014-05-08,INTERVENTIONAL,PHASE1|PHASE2,40.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Multiple Myeloma,Melphalan|Panobinostat,DRUG,3,2,18 Years,,ALL,False,Oncotherapeutics,INDUSTRY,1,4,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,1,3.713572066704308,small,1,1,1,0,0,1,1,0,1,0,0,0,1,0,5,1,1,0,0,2,1,2008-07-01,2012-12-01,1614.0,2008.0,0,2,0
NCT04346888,"A Study to Evaluate the Efficacy, Safety and PD and PK of HBM9161 in MG Patients","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacodynamic and Pharmacokinetic of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis",COMPLETED,2020-07-23,2021-08-24,2023-03-08,INTERVENTIONAL,PHASE2,30.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Myasthenia Gravis,HBM9161 Injection (680mg and 340 mg)|Placebos|HBM9161 Injection (340 mg),DRUG,1,11,18 Years,99 Years,ALL,False,Harbour BioMed (Guangzhou) Co. Ltd.,INDUSTRY,0,1,China,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.4339872044851463,small,1,1,1,0,0,0,0,0,0,0,1,1,1,1,12,1,1,0,0,3,1,,,,,0,2,0
NCT01001988,Long-term Follow-up of Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Toddlers,Long-term Follow-up of Immunogenicity of a Single Dose of JE-CV in Toddlers in Thailand and the Philippines,COMPLETED,2009-08-07,2013-10-16,2017-11-29,INTERVENTIONAL,PHASE3,596.0,ACTUAL,,SINGLE_GROUP,PREVENTION,NONE,Encephalitis|Japanese Encephalitis,Blood sample|JE-CV administered in Study JEC02,BIOLOGICAL|OTHER,2,0,2 Years,3 Years,ALL,True,"Sanofi Pasteur, a Sanofi Company",INDUSTRY,0,4,Philippines|Thailand,1.0,0,0,1,0,0,3.0,0,0,0,0,2,6.391917113392602,xlarge,0,1,1,0,1,0,1,1,0,0,0,0,0,0,2,0,0,1,0,2,1,,,,,0,3,1
NCT00465803,A Phase IIIb Study of DuoTrav to Treat Glaucoma or Ocular Hypertension,Compliance Study Comparing DuoTrav to TRAVATAN Plus Timolol Using the Dosing Aid,COMPLETED,2007-03,,2014-07-24,INTERVENTIONAL,PHASE3,81.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Open-angle Glaucoma|Ocular Hypertension,"Travoprost 0.004%/timolol 0.5% ophthalmic solution|Travoprost ophthalmic solution, 0.004%|Timolol maleate ophthalmic solution, 0.5%",DRUG,1,0,18 Years,,ALL,False,Alcon Research,INDUSTRY,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,1,2,4.406719247264253,medium,1,1,1,0,0,0,0,0,1,0,1,0,1,1,1,0,1,0,0,3,1,2007-03-01,,,2007.0,0,2,0
NCT01533727,CIK Cell Transfusion Plus Chemotherapy as Adjuvant Therapy for Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC),"A Phase 2,Open-label Study of Autologous Cytokine-Induced Killer Cell Transfusion Plus Chemotherapy as Adjuvant Therapy for Stage IB-IIIA Non-Small Cell Lung Cancer",WITHDRAWN,2011-08,2020-12,2013-12-09,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Non-small Cell Lung Cancer,Autologous CIK Transfusion plus Chemotherapy|chemotherapy alone,DRUG,1,0,18 Years,70 Years,ALL,False,Sun Yat-sen University,OTHER,0,1,China,0.0,0,1,0,0,0,2.0,1,0,0,0,1,0.0,,1,1,0,1,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0,2,1,2011-08-01,2020-12-01,3410.0,2011.0,0,1,0
NCT04864561,COV-COMPARE Immunogenicity of Vaccine VLA2001 Compared to AZD1222,"A Randomized, Observer-Blind, Controlled, Superiority Study To Compare The Immunogenicity Against COVID-19, Of VLA2001 Vaccine To AZD1222 Vaccine, In Adults Including a Randomized, Observer-blind, Placebo Controlled Part in Adolescents (≥12 to <18 Years)",COMPLETED,2021-04-26,2023-03-13,2023-03-20,INTERVENTIONAL,PHASE3,4034.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,SARS-CoV-2 Virus Infection,VLA2001|AZD1222|VLA2001 - adolescent part|Placebo,BIOLOGICAL,3,39,12 Years,,ALL,True,Valneva Austria GmbH,INDUSTRY,0,31,United Kingdom,1.0,0,0,1,0,0,3.0,0,0,0,0,1,8.302761580704049,xlarge,0,1,1,0,0,0,1,0,0,1,1,1,0,1,42,1,0,1,0,4,1,,,,,0,2,0
NCT00313261,Safety and Efficacy Study of L-FMAU in Chronic HBV Patients of L-FMAU-201 Placebo Group,"An Open-Label, Phase II Study to Evaluate Safety, Tolerability, Antiviral Activity and Biochemical and Immunological Responses of L-FMAU (Clevudine) in Chronic Hepatitis B Patients of L-FMAU-201 Placebo Group",TERMINATED,2003-06,2005-02,2012-10-17,INTERVENTIONAL,PHASE2,,,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Hepatitis B,Clevudine,DRUG,2,4,,,ALL,False,Bukwang Pharmaceutical,INDUSTRY,0,7,South Korea,0.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,0,0,1,0,0,0,1,0,0,0,0,0,1,0,6,1,1,0,0,1,0,2003-06-01,2005-02-01,611.0,2003.0,0,1,0
NCT02575261,CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients,Chimeric Antigen Receptor-Modified T Cells for EphA2 Positive Recurrent and Metastatic Malignant Glioma,WITHDRAWN,2015-09,2016-08-15,2020-07-16,INTERVENTIONAL,PHASE1|PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,EphA2 Positive Malignant Glioma|CAR-T Cell Immunotherapy,CAR-T cell immunotherapy,BIOLOGICAL,1,1,18 Years,80 Years,ALL,False,"Fuda Cancer Hospital, Guangzhou",OTHER,0,1,China,0.0,1,1,0,0,1,1.5,1,0,0,0,2,0.0,,1,1,0,1,0,0,0,0,0,0,1,0,1,1,2,1,0,1,0,1,0,2015-09-01,,,2015.0,1,2,0
NCT00302861,A Study to Evaluate the Treatment of Previously Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL),Phase 1/2 Study to Evaluate the Feasibility and Tolerability of Treatment of Previously Untreated B-CLL Chronic Lymphocytic Leukemia (B-CLL) Patients With Recombinant Idiotype Conjugated to KLH (Id-KLH) Administered With GM-CSF,TERMINATED,2006-03,,2008-03-18,INTERVENTIONAL,PHASE1|PHASE2,86.0,,,,,,B-Cell Chronic Lymphocytic Leukemia,MyVax,BIOLOGICAL,2,0,18 Years,,ALL,,Genitope Corporation,INDUSTRY,0,0,,0.0,1,1,0,0,1,1.5,1,0,0,0,1,4.465908118654584,medium,1,0,1,0,0,0,0,0,0,0,0,0,0,0,2,0,0,1,0,1,0,2006-03-01,,,2006.0,0,1,0
NCT03167242,Efficacy and Safety of KAF156 in Combination With LUM-SDF in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria,"A Phase 2 Interventional, Multicenter, Randomized Open Label Study to Determine the Effective and Tolerable Dose of KAF156 and Lumefantrine Solid Dispersion Formulation in Combination, Given Once Daily for 1, 2 and 3-days to Adults and Children With Uncomplicated Plasmodium Falciparum Malaria",COMPLETED,2017-08-02,2021-06-28,2022-02-10,INTERVENTIONAL,PHASE2,524.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Acute Uncomplicated Plasmodium Falciparum Malaria,KAF156|Coartem|Lumefantrine Solid Dispersion Formulation,DRUG,2,11,2 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,1,11,Thailand|India|Mali|Gabon|Vietnam|Mozambique|Burkina Faso|Uganda|Kenya,1.0,0,1,0,0,0,2.0,0,0,0,0,1,6.263398262591624,xlarge,0,1,1,0,1,1,1,1,0,0,1,0,1,1,13,1,1,0,0,3,1,,,,,0,3,1
NCT02536742,Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer,A Phase II Study of Palbociclib Plus Fulvestrant for Pretreated Patients With ER+/HER2- Metastatic Breast Cancer,COMPLETED,2016-08-30,2022-12-22,2024-02-26,INTERVENTIONAL,PHASE2,124.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Metastatic Breast Cancer,Palbociclib|Fulvestrant,DRUG,1,2,18 Years,,FEMALE,False,ETOP IBCSG Partners Foundation,NETWORK,1,19,Italy|Belgium|United Kingdom,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.8283137373023015,medium,0,1,0,0,0,1,1,1,0,1,0,0,1,0,3,1,1,0,0,2,1,,,,,0,2,0
NCT00008242,"Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple Myeloma","A Phase II Clinical Trial Of Thalidomide, Adramycin And Dexamethasone (TAD) As Initial Therapy For The Treatment Of Multiple Myeloma",COMPLETED,2000-08,2006-01,2013-03-07,INTERVENTIONAL,PHASE2,,,,,TREATMENT,,Multiple Myeloma and Plasma Cell Neoplasm,dexamethasone|doxorubicin hydrochloride|thalidomide,DRUG,0,0,18 Years,,ALL,False,Memorial Sloan Kettering Cancer Center,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,0.0,,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,3,1,2000-08-01,2006-01-01,1979.0,2000.0,0,1,0
NCT00794586,Study Evaluating Fosfomycin/Tobramycin for Inhalation in Cystic Fibrosis Patients With Pseudomonas Aeruginosa Lung Infection,"A Phase 2, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Fosfomycin/Tobramycin for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa",COMPLETED,2008-11,2010-03,2013-12-27,INTERVENTIONAL,PHASE2,120.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Cystic Fibrosis,"FTI, AZLI|Placebo, AZLI",DRUG,1,0,18 Years,,ALL,False,Gilead Sciences,INDUSTRY,0,36,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.795790545596741,medium,0,0,1,0,1,0,1,0,1,0,1,1,1,1,1,0,1,0,0,2,1,2008-11-01,2010-03-01,485.0,2008.0,0,1,0
NCT04988386,Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants,An Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants With Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial (AG10-301),ACTIVE_NOT_RECRUITING,2021-10-27,2028-05-15,2025-10-14,INTERVENTIONAL,PHASE3,389.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Amyloid Cardiomyopathy, Transthyretin-Related",Acoramidis (AG10),DRUG,1,4,18 Years,90 Years,ALL,False,"Eidos Therapeutics, a BridgeBio company",INDUSTRY,0,72,Italy|Belgium|Netherlands|South Korea|United States|Spain|Brazil|Australia|United Kingdom|Czechia|Denmark|Ireland|New Zealand|Israel|Portugal|Greece|Canada,,0,0,1,0,0,3.0,0,0,0,0,1,5.966146739123692,large,0,1,1,0,0,0,1,1,1,1,0,0,1,0,5,1,1,0,0,1,0,,,,,0,1,0
NCT01863186,"Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal","Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)",COMPLETED,2013-06,2014-12,2022-03-22,INTERVENTIONAL,PHASE3,603.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Opioid Dependence|Acute Opioid Withdrawal Syndrome,Lofexidine HCl|Placebo|Open Label Lofexidine HCL,DRUG,1,1,18 Years,,ALL,False,"USWM, LLC (dba US WorldMeds)",INDUSTRY,1,18,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,2,6.403574197934815,xlarge,0,1,1,0,0,1,1,0,1,0,1,1,1,1,2,1,1,0,0,3,1,2013-06-01,2014-12-01,548.0,2013.0,0,2,0
NCT06956170,All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma,"A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Pomalidomide and Dexamethasone (B-Pd) Versus Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 8)",ACTIVE_NOT_RECRUITING,2022-02-10,2029-11-30,2025-06-11,INTERVENTIONAL,PHASE3,21.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Multiple Myeloma,Belantamab mafodotin|Pomalidomide|Dexamethasone|Bortezomib,DRUG,1,28,18 Years,,ALL,False,GlaxoSmithKline,INDUSTRY,0,13,Japan,,0,0,1,0,0,3.0,1,0,0,0,1,3.091042453358316,small,1,1,1,0,0,0,1,0,0,0,1,0,1,1,29,1,1,0,0,4,1,,,,,0,2,0
NCT01237873,Long Term Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension,"A Open-label, 52 Week, Extension to an 8-week, Double Blind, Multicenter, 6-arm, Placebo-controlled, Parallel Group Study to Evaluate the Long Term Safety of SPA100 (Aliskiren/Amlodipine)",COMPLETED,2011-01,2012-02,2017-02-23,INTERVENTIONAL,PHASE3,150.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Essential Hypertension,Ali/Amlo 150/2.5 mg,DRUG,1,2,20 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,13,Japan,1.0,0,0,1,0,0,3.0,0,0,0,1,1,5.017279836814924,medium,0,1,1,0,1,0,1,0,0,0,0,0,1,0,3,1,1,0,0,1,0,2011-01-01,2012-02-01,396.0,2011.0,0,0,0
NCT00151983,Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy,"A Prospective, Open-Label, Multi-Center Study Evaluating the Safety and Tolerability of Methylphenidate Transdermal System (MTS) in Children Aged 6-12 Previously Treated With Extended-Release Methylphenidate Product.",COMPLETED,2005-06,2006-07,2015-07-09,INTERVENTIONAL,PHASE3,175.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Attention Deficit Disorder With Hyperactivity,Methylphenidate Transdermal System,DRUG,1,6,6 Years,12 Years,ALL,False,Noven Therapeutics,INDUSTRY,1,18,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.170483995038151,medium,0,1,1,0,0,1,1,0,1,0,0,0,1,0,7,1,1,0,0,1,0,2005-06-01,2006-07-01,395.0,2005.0,0,1,0
NCT00396383,Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for Transplantation,Treatment With AMD3100 in Multiple Myeloma Patients to Mobilize Peripheral Blood Progenitor Cells For Collection and for Transplantation,TERMINATED,2004-11,2007-05,2014-03-13,INTERVENTIONAL,PHASE2,9.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Multiple Myeloma,plerixafor,DRUG,2,3,18 Years,75 Years,ALL,False,"Genzyme, a Sanofi Company",INDUSTRY,1,2,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,2.302585092994046,small,1,1,1,0,1,1,1,0,1,0,0,0,1,0,5,1,1,0,0,1,0,2004-11-01,2007-05-01,911.0,2004.0,0,0,0
NCT01967641,Prescription Opioid Abuse Among Pain Patients: Predictors of Relapse,Prescription Opioid Abuse Among Pain Patients: Predictors of Relapse,COMPLETED,2005-11,2011-06,2019-04-24,INTERVENTIONAL,PHASE2,51.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Opioid Dependence,buprenorphine/naloxone combination,DRUG,1,2,18 Years,65 Years,ALL,False,New York State Psychiatric Institute,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.9512437185814275,medium,1,1,0,1,0,0,0,0,1,0,0,0,1,0,3,1,1,0,0,1,0,2005-11-01,2011-06-01,2038.0,2005.0,0,0,0
NCT05526066,Study for Adolescents and Adults With Ornithine Transcarbamylase Deficiency to Evaluate Safety and Tolerability of ARCT-810,"Phase 2, Randomized, Double-Blind, Placebo-Controlled, Nested Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ARCT-810 in Adolescent and Adult Participants With Ornithine Transcarbamylase Deficiency",TERMINATED,2022-10-17,2024-10-31,2025-09-26,INTERVENTIONAL,PHASE2,8.0,ACTUAL,RANDOMIZED,SEQUENTIAL,TREATMENT,QUADRUPLE,Ornithine Transcarbamylase Deficiency|OTC Deficiency|OTCD,ARCT-810|Placebo,BIOLOGICAL|OTHER,1,11,12 Years,65 Years,ALL,False,"Arcturus Therapeutics, Inc.",INDUSTRY,0,14,Italy|Belgium|Sweden|Spain|United Kingdom|France,0.0,0,1,0,0,0,2.0,0,0,0,0,3,2.1972245773362196,small,1,1,1,0,0,0,1,1,0,1,1,1,1,0,12,1,0,1,0,2,1,,,,,0,4,1
NCT01243866,Effect of Dental Treatment on Children's Growth,Effect of Dental Treatment on Children's Growth,COMPLETED,2007-02,2008-01,2010-11-19,INTERVENTIONAL,PHASE1|PHASE2,86.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Dental Decay,comprehensive dental treatment|Only emergency dental treatment,OTHER,1,1,72 Months,95 Months,ALL,,King Fahad Armed Forces Hospital,OTHER_GOV,0,0,,1.0,1,1,0,0,1,1.5,0,0,0,0,1,4.465908118654584,medium,1,1,0,1,0,0,0,0,0,0,1,0,1,1,2,1,0,0,0,2,1,2007-02-01,2008-01-01,334.0,2007.0,0,2,0
NCT00335166,SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease,"A Multicenter, Randomized, Double Blind, Parallel-Group Placebo and Pramipexole Controlled Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients With Early Stage Parkinson's Disease.",COMPLETED,2006-11,2008-02,2008-04-03,INTERVENTIONAL,PHASE3,330.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Early Stage Parkinson Disease,Pardaprunox|pramipexole|Placebo Comparator,DRUG,1,1,30 Years,,ALL,False,Solvay Pharmaceuticals,INDUSTRY,0,89,Italy|Netherlands|South Africa|India|United States|Germany|Spain|Australia|United Kingdom|Lithuania|Malaysia|Poland|Estonia|Czechia|Taiwan|Portugal|France|Thailand,1.0,0,0,1,0,0,3.0,0,0,1,0,1,5.802118375377063,large,0,0,1,0,0,0,1,1,1,1,1,1,1,1,2,1,1,0,0,3,1,2006-11-01,2008-02-01,457.0,2006.0,0,2,0
NCT01435356,Safety and Efficacy Study of MAGE-A3 + AS-15 in Patients With Muscle-invasive Bladder Cancer After Cystectomy,"A Randomized, Double Blind, Placebo Controlled Phase II Trial to Evaluate the Safety and Efficacy of recMAGE-A3 + AS15 ASCI in Patients With MAGE-A3 Positive Muscle Invasive Bladder Cancer After Cystectomy",TERMINATED,2011-08,2017-04-07,2019-01-09,INTERVENTIONAL,PHASE2,83.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Urinary Bladder Neoplasms,recMAGE-A3 + AS15 ASCI|Placebo,BIOLOGICAL,1,3,18 Years,,ALL,False,European Association of Urology Research Foundation,OTHER,1,50,Netherlands|Italy|Russia|Spain|Germany|Romania|Poland|Czechia|Ukraine|France,0.0,0,1,0,0,0,2.0,0,0,0,0,1,4.430816798843313,medium,1,1,0,1,0,1,1,1,0,1,1,1,0,1,4,1,0,1,0,2,1,2011-08-01,,,2011.0,0,2,0
NCT02867956,Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer,A Phase II Study of Apatinib In Combination With Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer,COMPLETED,2016-08-10,2019-09-10,2020-12-04,INTERVENTIONAL,PHASE2,35.0,ESTIMATED,,SINGLE_GROUP,TREATMENT,NONE,Ovarian Cancer,Apatinib|Etoposide,DRUG,1,4,18 Years,70 Years,FEMALE,False,Sun Yat-sen University,OTHER,0,1,China,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.58351893845611,small,1,0,0,1,0,0,0,0,0,0,0,0,1,0,5,1,1,0,0,2,1,,,,,0,1,0
NCT03374956,Individualized Obesity Pharmacotherapy,Individualized Pharmacological Approach to Obesity Management: A Randomized Clinical Trial,COMPLETED,2017-12-11,2022-05-26,2023-07-18,INTERVENTIONAL,PHASE3,193.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Obesity,Phentermine-Topiramate|Liraglutide|Naltrexone/bupropion|Phentermine,DRUG,1,2,18 Years,75 Years,ALL,False,Mayo Clinic,OTHER,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.267858159063328,medium,0,1,0,1,0,0,0,0,1,0,1,1,1,1,3,1,1,0,0,4,1,,,,,0,1,0
NCT02433522,Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab,Extended Follow Up of the Mainritsan 2 Study. Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab: a Placebo- Controlled Randomized Trial,COMPLETED,2015-03-31,2018-08-16,2025-11-20,INTERVENTIONAL,PHASE3,97.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,ANCA-associated Vasculitides,rituximab|Placebo,DRUG,1,17,18 Years,,ALL,False,Assistance Publique - Hôpitaux de Paris,OTHER,2,1,France,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.584967478670572,medium,1,1,0,1,0,1,0,0,0,1,1,1,1,1,18,1,1,0,0,2,1,,,,,0,2,0
NCT02449122,Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） for Lung Carcinoma,Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） for Lung Carcinoma：Clinical Trial,COMPLETED,2015-05,2016-02,2016-02-25,INTERVENTIONAL,PHASE1|PHASE2,60.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Lung Cancer,interventional therapy,PROCEDURE,1,3,18 Years,80 Years,ALL,False,"Fuda Cancer Hospital, Guangzhou",OTHER,0,1,China,1.0,1,1,0,0,1,1.5,1,0,0,0,1,4.110873864173311,medium,1,1,0,1,0,0,0,0,0,0,1,0,1,1,4,1,0,0,0,1,0,2015-05-01,2016-02-01,276.0,2015.0,1,1,0
NCT02103322,Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed Conditions,"A Randomized, Open Label, Two-Treatment, Multiple Dose, Steady State, Two-period, Cross-over, Multi-Centre Comparative Bioequivalence Study of Imatinib Mesylate Tablet 400 mg of Amneal Pharmaceuticals, USA With GLEEVEC® (Imatinib Mesylate) Tablets 400 mg Distributed by Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936 in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed Conditions",COMPLETED,2014-02,2014-06,2014-06-27,INTERVENTIONAL,PHASE2|PHASE3,48.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Chronic Myeloid Leukemia|Gastrointestinal Stromal Tumor,"Imatinib Mesylate Tablets, 400 mg|Imatinib Mesylate Tablets, 400 mg",DRUG,2,5,18 Years,55 Years,ALL,False,"Amneal Pharmaceuticals, LLC",INDUSTRY,1,5,India,1.0,0,1,1,0,1,2.5,1,0,0,0,2,3.8918202981106265,small,1,1,1,0,0,1,1,0,0,0,1,0,1,0,7,1,1,0,0,2,1,2014-02-01,2014-06-01,120.0,2014.0,0,4,1
NCT00895622,"Observation or Radiation Therapy in Treating Patients With Grade I, Grade II, or Grade III Meningioma",Phase II Trial of Observation for Low-Risk Meningiomas and of Radiotherapy for Intermediate- and High-Risk Meningiomas,COMPLETED,2009-06,2023-08-15,2023-09-08,INTERVENTIONAL,PHASE2,244.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Brain and Central Nervous System Tumors,54 Gy radiotherapy|60 Gy radiotherapy,RADIATION,1,10,18 Years,,ALL,False,Radiation Therapy Oncology Group,NETWORK,2,78,Canada|United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,5.501258210544727,large,0,1,0,0,0,1,1,1,1,0,0,0,1,1,11,1,0,0,0,2,1,2009-06-01,,,2009.0,0,3,1
NCT03654729,Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer (POLAR-M),"A Phase 3, Double-blind, Multicenter, Placebo-controlled Study of PledOx Used on Top of Modified FOLFOX6 (5-FU/FA and Oxaliplatin) to Prevent Chemotherapy Induced Peripheral Neuropathy (CIPN) in Patients With First-line mCRC",TERMINATED,2018-11-07,2020-08-31,2021-12-17,INTERVENTIONAL,PHASE3,291.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Colorectal Cancer|Chemotherapy-induced Peripheral Neuropathy,Calmangafodipir (2 µmol/kg)|Calmangafodipir (5 µmol/kg)|Placebo,DRUG,1,9,18 Years,,ALL,False,Egetis Therapeutics,INDUSTRY,1,98,Italy|Belgium|Hungary|South Korea|United States|Germany|Spain|United Kingdom|Hong Kong|Japan|Czechia|Taiwan|France,0.0,0,0,1,0,0,3.0,1,0,0,0,2,5.676753802268282,large,0,1,1,0,0,1,1,1,1,1,1,1,0,1,10,1,1,0,0,3,1,,,,,0,4,1
NCT02445859,Continuous Antibiotic Prophylaxis in Colorectal Surgery,Colo-Pro Pilot: A Pilot Study to Compare Standard Single Dose Antibiotic Prophylaxis to Bolus-continuous Infusion Dosed Antibiotic Prophylaxis for the Prevention of Infections After Colorectal Surgery,COMPLETED,2015-08,2017-05,2019-10-10,INTERVENTIONAL,PHASE2,90.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,SINGLE,Surgical Site Infection,Cefuroxime 4 hourly bolus,DRUG,1,0,18 Years,,ALL,False,University of Leeds,OTHER,0,1,United Kingdom,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.51085950651685,medium,1,1,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,0,1,0,2015-08-01,2017-05-01,639.0,2015.0,1,0,0
NCT02854059,IdeS in Asymptomatic Antibody-Mediated Thrombotic Thrombocytopenic Purpura (TTP) Patients,"A Phase II Pilot Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacodynamics and Pharmacokinetics of IdeS in Asymptomatic Antibody-Mediated Thrombotic Thrombocytopenic Purpura (TTP) Patients With Low ADAMTS13 Activity",TERMINATED,2016-09,2017-01,2019-09-13,INTERVENTIONAL,PHASE2,2.0,ACTUAL,NON_RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,"Purpura, Thrombotic Thrombocytopenic",IdeS (0.25 mg/kg)|IdeS (0.50 mg/kg),BIOLOGICAL,1,8,18 Years,,ALL,False,Hansa Biopharma AB,INDUSTRY,1,1,United Kingdom,0.0,0,1,0,0,0,2.0,0,0,0,0,1,1.0986122886681098,small,1,1,1,0,0,1,0,0,0,1,0,0,1,0,9,1,0,1,0,2,1,2016-09-01,2017-01-01,122.0,2016.0,1,2,0
NCT02600559,Open-Label Study of OTO-201 in Pediatric Subjects With a History of Otitis Media Requiring Tympanostomy Tubes,"An 8-Week, Prospective, Multicenter, Open-Label Study of OTO-201 Given as a Single Administration in Pediatric Subjects With a History of Otitis Media Requiring Tympanostomy Tubes",COMPLETED,2015-10,2016-07,2020-10-19,INTERVENTIONAL,PHASE3,501.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Otitis Media,OTO-201 (ciprofloxacin),DRUG,2,4,6 Months,17 Years,ALL,False,"Otonomy, Inc.",INDUSTRY,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.218600119691729,xlarge,0,1,1,0,0,0,0,0,1,0,0,0,1,0,6,1,1,0,0,1,0,2015-10-01,2016-07-01,274.0,2015.0,1,1,0
NCT04363359,Clinical Trial of Quadrivalent Influenza Virus Split Vaccine,"Immunogenicity and Safety of Quadrivalent Influenza Vaccine In 6 to 35 Months Population: a Randomized, Double-blind, Parallel-group Ⅱ Phase of Clinical Trials",COMPLETED,2020-01-15,2021-09-14,2023-12-26,INTERVENTIONAL,PHASE2,1980.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Influenza,0.5ml Quadrivalent influenza vaccine|0.25ml Quadrivalent influenza vaccine|0.25ml Trivalent influenza vaccine(B/V)|0.25ml Trivalent influenza vaccine(B/Y),BIOLOGICAL,3,1,6 Months,35 Months,ALL,True,Shanghai Institute Of Biological Products,INDUSTRY,0,1,China,1.0,0,1,0,0,0,2.0,0,0,0,0,1,7.591357046698551,xlarge,0,1,1,0,0,0,0,0,0,0,1,1,0,1,4,1,0,1,0,4,1,,,,,0,1,0
NCT03609359,Lenvatinib and Pembrolizumab Simultaneous Combination Study,An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab in Patients With Advanced Gastric Cancer,COMPLETED,2018-10-03,2021-04-30,2025-04-16,INTERVENTIONAL,PHASE2,29.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Advanced Gastric Cancer,Lenvatinib|Pembrolizumab,DRUG,1,5,20 Years,,ALL,False,National Cancer Center Hospital East,OTHER,2,1,Japan,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.4011973816621555,small,1,1,0,1,0,1,0,0,0,0,0,0,1,0,6,1,1,0,0,2,1,,,,,0,2,0
NCT02371759,Lidocaine + Clonidine for Intraoral Anesthesia in Patients With Diabetes Mellitus Type 2,Efficacy and Safety of Intraoral Local Anesthesia by Lidocaine + Clonidine in Patients With Diabetes Mellitus Type 2,COMPLETED,2013-06,2016-01,2017-05-03,INTERVENTIONAL,PHASE3,256.0,ACTUAL,RANDOMIZED,PARALLEL,SUPPORTIVE_CARE,QUADRUPLE,Diabetes Mellitus|Local Anesthesia,L+C maxillary anesthesia|L+C mandibular anesthesia|L+E maxillary anesthesia|L+E mandibular anesthesia,DRUG,21,4,18 Years,65 Years,ALL,False,University of Belgrade,OTHER,0,1,Serbia,1.0,0,0,1,0,0,3.0,0,0,0,0,2,5.54907608489522,large,0,1,0,1,0,0,0,0,0,0,1,1,0,1,25,1,1,0,0,4,1,2013-06-01,2016-01-01,944.0,2013.0,0,3,1
NCT00856323,Contingency Management for Methamphetamine Abstinence and HIV Post-Exposure Prophylaxis in Men Who Have Sex With Men,Biobehavioral Interventions for HIV-negative Methamphetamine-using MSM,COMPLETED,2009-01,2010-12,2016-09-20,INTERVENTIONAL,PHASE2,53.0,ACTUAL,,SINGLE_GROUP,PREVENTION,NONE,Amphetamine-Related Disorders|HIV|HIV Infections,Truvada|CM,BEHAVIORAL|DRUG,1,3,18 Years,,MALE,False,"Friends Research Institute, Inc.",OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,3,3.9889840465642745,medium,1,1,0,1,0,1,0,0,1,0,0,0,0,0,4,1,1,0,0,2,1,2009-01-01,2010-12-01,699.0,2009.0,0,2,0
NCT00904423,Ph I/II of Vitamin D on Bone Mineral Density & Markers of Bone Resorption,"A Phase I/II Randomized, Double-blind, Controlled Study to Evaluate Efficacy and Safety of Vitamin D on Bone Mineral Density and Markers of Bone Resorption in Aromatase Inhibitor-induced Bone Loss in Women With Breast Cancer.",TERMINATED,2009-04,2011-04,2017-02-14,INTERVENTIONAL,PHASE1|PHASE2,8.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Breast Cancer|Bone Diseases,Vitamin D,DRUG,1,4,18 Years,85 Years,FEMALE,False,Mark Pegram,OTHER,1,1,United States,0.0,1,1,0,0,1,1.5,1,0,0,0,2,2.1972245773362196,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,5,1,1,0,0,1,0,2009-04-01,2011-04-01,730.0,2009.0,0,2,0
NCT01048723,Study of RAD001 in Soft Tissue Extremity and/or Retroperitoneal Sarcomas,"A Single-arm, Open Label Phase II Study of RAD001 in Soft Tissue Extremity and/or Retroperitoneal Sarcomas",TERMINATED,2010-01,2011-10,2013-12-16,INTERVENTIONAL,PHASE2,2.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Sarcoma,RAD001,DRUG,1,3,18 Years,,ALL,False,H. Lee Moffitt Cancer Center and Research Institute,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,1.0986122886681098,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,4,1,1,0,0,1,0,2010-01-01,2011-10-01,638.0,2010.0,0,0,0
NCT02607423,Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery,Role of Early 18F-FDG-PET/CT Scan in Predicting Mediastinal Downstaging With Neoadjuvant Chemotherapy in Resectable Stage III A NSCLC,WITHDRAWN,2015-11-19,2017-01-31,2023-05-25,INTERVENTIONAL,PHASE2,0.0,ACTUAL,,SINGLE_GROUP,DIAGNOSTIC,NONE,Stage IIIA Non-Small Cell Lung Cancer,Cisplatin|Computed Tomography|Docetaxel|Fludeoxyglucose F-18|Gemcitabine Hydrochloride|Pemetrexed Disodium|Positron Emission Tomography,DRUG|RADIATION|PROCEDURE,1,6,18 Years,,ALL,False,ECOG-ACRIN Cancer Research Group,NETWORK,1,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,0.0,,1,1,0,0,0,1,0,0,1,0,0,0,0,0,7,1,1,0,0,7,1,,,,,0,2,0
NCT01585259,Anfibatide Phase Ib-IIa Clinical Trial,"A Multi-center, Randomized, Double-blind, Multi-dose Group, Parallel Group and Placebo Controlled Phase Ib-IIa Clinical Study to Evaluate the Safety and Efficacy of Antiplatelet Thrombolysin for Injection for the Treatment of Patients With Non-ST Segment Elevation Myocardial Infarction (NSTEMI).",COMPLETED,2012-07,2015-07,2021-07-14,INTERVENTIONAL,PHASE1|PHASE2,90.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Non-ST Segment Elevation Myocardial Infarction,Anfibatide|Placebo,DRUG,2,6,18 Years,70 Years,ALL,False,Lee's Pharmaceutical Limited,INDUSTRY,0,1,China,1.0,1,1,0,0,1,1.5,0,0,0,1,1,4.51085950651685,medium,1,1,1,0,0,0,0,0,0,0,1,1,1,1,8,1,1,0,0,2,1,2012-07-01,2015-07-01,1095.0,2012.0,0,3,1
NCT03570359,A Study to Test a Potential New Treatment for COPD Patients Suffering From the Common Cold or Influenza,"A Randomised, Double-blind, Placebo-controlled Study, in COPD Patients With and Without a Confirmed Respiratory Virus Infection Assessing Anti-viral Biomarker Responses and Clinical Effects of Inhaled SNG001 Compared to Placebo",COMPLETED,2018-01-29,2020-05-05,2023-01-04,INTERVENTIONAL,PHASE2,122.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Chronic Obstructive Pulmonary Disease (COPD),Interferon Beta-1A|Placebo,DRUG|OTHER,4,28,40 Years,85 Years,ALL,False,Synairgen Research Ltd.,INDUSTRY,0,16,United Kingdom,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.812184355372417,medium,0,1,1,0,0,0,1,0,0,1,1,1,1,1,32,1,1,0,0,2,1,,,,,0,2,0
NCT00443079,A Study of Siliphos in Adults With Non-alcoholic Steatohepatitis (NASH),"A Single-center, Single-blinded, Placebo-controlled Pilot Study of IdB 1016 (Siliphos) in Adult Patients With Non-alcoholic Steatohepatitis (NASH)",COMPLETED,2007-03,2009-12,2021-03-24,INTERVENTIONAL,PHASE2,6.0,ACTUAL,NON_RANDOMIZED,CROSSOVER,TREATMENT,SINGLE,Fatty Liver,IdB 1016 (Siliphos)|Matched placebo,DRUG,1,1,18 Years,,ALL,False,Heather Patton,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,1.9459101490553132,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,2,1,1,0,0,2,1,2007-03-01,2009-12-01,1006.0,2007.0,0,1,0
NCT01723696,Vitamin C to Decrease Effects of Smoking in Pregnancy on Infant Lung Function,Vitamin C to Decrease Effects of Smoking in Pregnancy on Infant Lung Function,COMPLETED,2012-12,2017-12,2019-04-17,INTERVENTIONAL,PHASE2|PHASE3,252.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,"Pulmonary Function; Newborn, Abnormal|Infant Wheeze|In-utero Nicotine|Second Hand Smoke",Vitamin C +prenatal vitamin|Placebo tablet+prenatal vitamin,DIETARY_SUPPLEMENT,1,2,15 Years,,FEMALE,True,Oregon Health and Science University,OTHER,2,2,United States,1.0,0,1,1,0,1,2.5,0,0,0,0,4,5.53338948872752,large,0,1,0,1,0,1,1,0,1,0,1,1,0,1,3,1,0,0,0,2,1,2012-12-01,2017-12-01,1826.0,2012.0,0,3,1
NCT03773796,Nabilone for Non-motor Symptoms in Parkinson's Disease,Nabilone for Non-motor Symptoms in Parkinson's Disease: An Open-label Study to Evaluate Long-term Safety and Efficacy,COMPLETED,2018-08-06,2020-01-31,2021-03-02,INTERVENTIONAL,PHASE3,22.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Parkinson Disease,Nabilone 0.25 mg,DRUG,9,11,30 Years,100 Years,ALL,False,Medical University Innsbruck,OTHER,0,1,Austria,1.0,0,0,1,0,0,3.0,0,0,1,0,1,3.1354942159291497,small,1,1,0,1,0,0,0,0,0,0,0,0,1,0,20,1,1,0,0,1,0,,,,,0,1,0
NCT04561362,Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies,"Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT8009 in Patients With Nectin-4 Expressing Advanced Malignancies",ACTIVE_NOT_RECRUITING,2020-07-17,2026-12,2025-11-14,INTERVENTIONAL,PHASE1|PHASE2,329.0,ESTIMATED,NON_RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,"Urinary Bladder Neoplasm|Triple Negative Breast Neoplasms|Hormone Receptor Positive, HER2-negative Neoplasms|Hormone Receptor Positive, HER2-low Neoplasms|Breast Neoplasms|Non-Small-Cell Lung Neoplasms|Ovarian Neoplasm|Advanced Solid Tumor",BT8009|Pembrolizumab,DRUG,8,21,18 Years,,ALL,False,BicycleTx Limited,INDUSTRY,0,24,Italy|Spain|United States|United Kingdom|France|Canada,,1,1,0,0,1,1.5,1,0,0,0,8,5.799092654460526,large,0,0,1,0,0,0,1,1,1,1,0,0,1,0,29,1,1,0,0,2,1,,2026-12-01,,,0,5,1
NCT04611503,PDE6A Gene Therapy for Retinitis Pigmentosa,PIGMENT - PDE6A Gene Therapy for Retinitis Pigmentosa,ACTIVE_NOT_RECRUITING,2019-09-24,2027-07,2024-04-18,INTERVENTIONAL,PHASE1|PHASE2,9.0,ACTUAL,,SEQUENTIAL,TREATMENT,NONE,Retinitis Pigmentosa,subretinal injection of rAAV.hPDE6A,DRUG,3,6,18 Years,,ALL,False,STZ eyetrial,OTHER,0,1,Germany,,1,1,0,0,1,1.5,0,0,0,0,1,2.302585092994046,small,1,1,0,1,0,0,0,0,0,1,0,0,1,0,9,1,1,0,0,1,0,,2027-07-01,,,0,2,0
NCT01709903,"A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149","A 26-week Treatment Randomized, Double-blind, Double Dummy, Parallel-group Study to Assess the Efficacy and Safety of QVA149 (Indacaterol / Glycopyrronium Bromide) Compared to Fluticasone/Salmeterol in Patients With Moderate to Severe COPD",COMPLETED,2012-11,2014-02,2015-03-17,INTERVENTIONAL,PHASE3,744.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Chronic Obstructive Pulmonary Disease,QVA149|Fluticasone/salmeterol|Placebo to QVA149|Placebo to fluticasone/salmeterol,DRUG,1,8,40 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,55,China|Taiwan|Argentina|Chile,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.61338421837956,xlarge,0,1,1,0,1,0,1,1,0,0,1,1,1,1,9,1,1,0,0,4,1,2012-11-01,2014-02-01,457.0,2012.0,0,3,1
NCT04337827,Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder,Phase II Study of Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder (PTLD),TERMINATED,2020-09-02,2022-12-19,2024-04-10,INTERVENTIONAL,PHASE2,6.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Post-transplant Lymphoproliferative Disorder,Rituximab|Acalabrutinib|CT scans,DRUG|DIAGNOSTIC_TEST,1,13,18 Years,,ALL,False,Deepa Jagadeesh,OTHER,0,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,1.9459101490553132,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,14,1,1,0,0,3,1,,,,,0,2,0
NCT01314027,Adjuvant Versus Neoadjuvant Plus Adjuvant Chemotherapy in Resectable Pancreatic Cancer,Adjuvant Gemcitabine Versus NEOadjuvant Gemcitabine/Oxaliplatin Plus Adjuvant Gemcitabine in Resectable PAncreatic Cancer: a Randomized Multicenter Phase III Study (NEOPAC Study),TERMINATED,2009-09,2019-05,2019-07-25,INTERVENTIONAL,PHASE3,38.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Pancreatic Cancer,Neoadjuvant Chemotherapy with gemcitabine/oxaliplatin|adjuvant chemotherapy with gemcitabine,DRUG,1,5,18 Years,,ALL,False,University of Zurich,OTHER,0,5,Germany|Belgium|Switzerland|France,0.0,0,0,1,0,0,3.0,1,0,0,0,1,3.6635616461296463,small,1,1,0,1,0,0,1,1,0,1,1,0,1,1,6,1,1,0,0,2,1,2009-09-01,2019-05-01,3529.0,2009.0,0,3,1
NCT07001527,Dressing Impregnated With Chlorhexidine and Vancomycin for the Prophylaxis of Central Venous Catheter-related Infections - a Randomized Trial,Dressing Impregnated With Chlorhexidine and Vancomycin for the Prophylaxis of Central Venous Catheter-related Infections - a Randomized Trial,COMPLETED,2022-06-01,2023-06-01,2025-06-03,INTERVENTIONAL,PHASE3,516.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Chlorhexidine,Chlorhexidine|Chlorhexidine,DEVICE,1,0,18 Years,,ALL,False,Hospital Universitario Evangelico de Curitiba,OTHER,0,1,Brazil,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.248042874508429,xlarge,0,1,0,1,0,0,0,0,0,0,1,1,0,1,1,0,0,0,1,2,1,,,,,0,1,0
NCT01467427,"Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B.","Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B",COMPLETED,2012-05-16,2023-11-17,2025-12-23,INTERVENTIONAL,PHASE3,25.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Congenital Bleeding Disorder|Haemophilia B,nonacog beta pegol,DRUG,2,27,0 Years,12 Years,MALE,False,Novo Nordisk A/S,INDUSTRY,0,51,Italy|Turkey (Türkiye)|United States|Croatia|Brazil|Germany|United Kingdom|Malaysia|Japan|Taiwan|France|Canada,1.0,0,0,1,0,0,3.0,0,0,0,0,2,3.258096538021482,small,1,1,1,0,0,0,1,1,1,1,0,0,1,0,29,1,1,0,0,1,0,,,,,0,3,1
NCT02303327,Comparative Study of Radiotherapy Treatments to Treat High Risk Prostate Cancer Patients,"Phase III Study of Hypofractionated, Dose Escalation Radiotherapy Vs. Conventional Pelvic Radiation Therapy Followed by HDR Brachy Boost for High Risk Adenocarcinoma of the Prostate (PCS-VI)",ACTIVE_NOT_RECRUITING,2015-01,2029-01,2024-12-09,INTERVENTIONAL,PHASE3,307.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Prostate Cancer,EBRT + HDR brachytherapy boost|Hypofractionated Dose Escalation Radiotherapy|Androgen deprivation therapy,DRUG|RADIATION,1,9,18 Years,,MALE,True,Sir Mortimer B. Davis - Jewish General Hospital,OTHER,0,12,Canada,,0,0,1,0,0,3.0,1,0,0,0,1,5.730099782973574,large,0,1,0,1,0,0,1,0,0,0,1,0,1,1,10,1,1,0,0,3,1,2015-01-01,2029-01-01,5114.0,2015.0,1,2,0
NCT03904927,Local Therapy for Oligorecurrent and Oligometastatic Esophageal Squamous Cell Carcinoma,"Role of Local Therapy for Patients with Oligorecurrent and Oligometastatic Esophageal Squamous Cell Carcinoma After Radical Treatment: a Prospective, Randomized Phase II Clinical Study",COMPLETED,2019-02-01,2024-09-15,2024-10-23,INTERVENTIONAL,PHASE2,104.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Oligorecurrent and Oligometastatic Esophageal Squamous Cell Carcinoma,"Radiation, Surgery or Radiofrequency ablation|Systemic therapy",DRUG|OTHER,1,2,18 Years,,ALL,False,Fudan University,OTHER,0,1,China,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.653960350157523,medium,0,1,0,1,0,0,0,0,0,0,1,0,1,1,3,1,1,0,0,2,1,,,,,0,1,0
NCT05801627,SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled by Metformin,"A Multi-center, Randomized, Double-blind, Placebo Parallel Controlled Phase III Clinical Trial for the Efficacy and Safety of Fugliglitinate Benzoate Tablets in Patients With Type 2 Diabetes Who Cannot be Effectively Controlled by Metformin",COMPLETED,2020-05-06,2022-05-24,2023-04-06,INTERVENTIONAL,PHASE3,408.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2",SAL067|Placebo,DRUG,1,7,18 Years,75 Years,ALL,False,"Shenzhen Salubris Pharmaceuticals Co., Ltd.",INDUSTRY,0,1,China,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.013715156042802,large,0,1,1,0,0,0,0,0,0,0,1,1,1,1,8,1,1,0,0,2,1,,,,,0,2,0
NCT03123627,"Randomized Clinical Trial, Open, Multicenter Parallel, no Suspension Inferiority Prophylactic Treatment With Valganciclovir in Kidney Transplant CMV-seropositive Cellular Immunity to Develop CD8 + CMV-specific Treatment After Induction Thymoglobulin.","Randomized Clinical Trial, Open, Multicenter Parallel, no Suspension Inferiority Prophylactic Treatment With Valganciclovir in Kidney Transplant CMV-seropositive Cellular Immunity to Develop CD8 + CMV-specific Treatment After Induction Thymoglobulin.",COMPLETED,2016-08-23,2019-10-21,2021-02-02,INTERVENTIONAL,PHASE3,150.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Kidney Transplant Infection,New profilaxis|Profilaxis recommended,DRUG,1,2,18 Years,,ALL,False,Maimónides Biomedical Research Institute of Córdoba,OTHER,0,1,Spain,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.017279836814924,medium,0,1,0,1,0,0,0,0,0,1,1,0,1,1,3,1,1,0,0,2,1,,,,,0,1,0
NCT00334061,Study to Assess the Safety and Effectiveness of the Penumbra System,Evaluation of the Penumbra™ Stroke System in the Revascularization of Patients With Acute Ischemic Stroke Secondary to Intracranial Large Vessel Occlusive Disease,COMPLETED,2006-06,2007-11,2019-09-18,INTERVENTIONAL,PHASE2,125.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Stroke,Penumbra System,DEVICE,2,4,18 Years,79 Years,ALL,False,Penumbra Inc.,INDUSTRY,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.836281906951478,medium,0,1,1,0,0,0,0,0,1,0,0,0,1,0,6,1,0,0,1,1,0,2006-06-01,2007-11-01,518.0,2006.0,0,1,0
NCT00735761,Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis in Immunocompromised Patients,"A Randomized, Double-Blind, Active-Controlled, Subject Initiated Study Comparing ME-609 to Acyclovir Cream for Treatment of Recurrent Herpes Simplex Labialis in Immunocompromised Patients",COMPLETED,2006-12,2007-09,2008-08-15,INTERVENTIONAL,PHASE3,201.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Herpes Labialis,ME-609|Acyclovir in ME-609 vehicle (5% acyclovir),DRUG,1,1,18 Years,,ALL,False,Medivir,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.308267697401205,large,0,1,1,0,0,0,0,0,0,0,1,1,1,1,2,1,1,0,0,2,1,2006-12-01,2007-09-01,274.0,2006.0,0,1,0
NCT02679261,Evaluating the Effectiveness of Atorvastatin on the Progression of Aortic Dilatation and Valvular Degeneration in Patients With Bicuspid Aortic Valve,Evaluating the Effectiveness of Atorvastatin on the Progression of Aortic Dilatation and Valvular Degeneration in Patients With Bicuspid Aortic Valve (BICATOR),COMPLETED,2016-06,2021-02,2021-02-18,INTERVENTIONAL,PHASE3,220.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Bicuspid Aortic Valve,Atorvastatin|Placebo,DRUG,1,11,18 Years,,ALL,False,Hospital Universitari Vall d'Hebron Research Institute,OTHER,0,10,Spain,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.3981627015177525,large,0,1,0,1,0,0,1,0,0,1,1,1,1,1,12,1,1,0,0,2,1,2016-06-01,2021-02-01,1706.0,2016.0,1,2,0
NCT00821561,A Study to Investigate the Safety and Clinical Effect of Nexagon® to Treat Persistent Epithelial Defects,"A Phase 2, Randomized, Prospective, Double-masked, Vehicle-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Nexagon® in Subjects With Persistent Corneal Epithelial Defects (PED) From Chemical Burn Injuries.",WITHDRAWN,2009-03,2010-03,2010-02-26,INTERVENTIONAL,PHASE2,90.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Persistent Epithelial Defect,Nexagon®|Nexagon® vehicle,DRUG,1,0,18 Years,,ALL,False,"OcuNexus Therapeutics, Inc.",INDUSTRY,0,0,,0.0,0,1,0,0,0,2.0,0,0,0,0,1,4.51085950651685,medium,1,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,1,0,0,2,1,2009-03-01,2010-03-01,365.0,2009.0,0,1,0
NCT00003961,Sargramostim After Bone Marrow Transplantation in Treating Patients With Myelodysplastic Syndrome,Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) After T-Lymphocyte Depleted Allogeneic BMT for Myelodysplastic Syndromes,COMPLETED,1999-04,2007-12,2014-04-17,INTERVENTIONAL,PHASE2,,,,,TREATMENT,NONE,Leukemia|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases,sargramostim,BIOLOGICAL,0,0,18 Years,65 Years,ALL,False,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,3,0.0,,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1999-04-01,2007-12-01,3166.0,1999.0,0,1,0
NCT05642442,A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease,"A 17-week, Phase 2, Randomized, Double-blind, Placebo-controlled, Flexible-dosing, Parallel-group, Multicenter Study of the Efficacy and Safety of Suvecaltamide in the Treatment of Moderate to Severe Residual Tremor in Participants With Parkinson's Disease",COMPLETED,2022-12-01,2024-11-11,2026-01-15,INTERVENTIONAL,PHASE2,169.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Parkinson Disease|Tremor,Placebo|Suvecaltamide,DRUG,1,8,40 Years,85 Years,ALL,False,Jazz Pharmaceuticals,INDUSTRY,0,37,Germany|Spain|Poland|United States,1.0,0,1,0,0,0,2.0,0,0,1,0,2,5.135798437050262,medium,0,1,1,0,0,0,1,1,1,1,1,1,1,1,9,1,1,0,0,2,1,,,,,0,4,1
NCT00266786,Safety and Efficacy of Multiple Doses of Intranasal Ketorolac in Postoperative Pain Following Major Abdominal Surgery,"A Phase 3, Double-Blind, Randomized Study of the Safety, Tolerability, and Analgesic Efficacy of Multiple Doses of Ketorolac Tromethamine Administered Intranasally for Postoperative Pain Following Major Abdominal Surgery",COMPLETED,2005-12,,2017-02-08,INTERVENTIONAL,PHASE3,321.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Postoperative Pain,Intranasal Ketorolac Tromethamine|Intranasal Placebo,DRUG,1,4,18 Years,64 Years,ALL,False,Egalet Ltd,INDUSTRY,0,6,New Zealand|United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.7745515455444085,large,0,1,1,0,0,0,1,1,1,0,1,1,1,1,5,1,1,0,0,2,1,2005-12-01,,,2005.0,0,2,0
NCT01086670,"Physical, Functional and Neural Effects of Two Lower Extremity Exercise Protocols in Children With Cerebral Palsy","Physical, Functional and Neural Effects of Two Lower Extremity Exercise Programs in Children With Cerebral Palsy",COMPLETED,2010-03-30,2016-05-09,2022-03-29,INTERVENTIONAL,PHASE1|PHASE2,55.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Cerebral Palsy|Children|Adolescents,Physical Exercise,OTHER,1,1,5 Years,17 Years,ALL,False,National Institutes of Health Clinical Center (CC),NIH,0,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,3,4.02535169073515,medium,1,1,0,1,0,0,0,0,1,0,1,0,1,1,2,1,0,0,0,1,0,,,,,0,2,0
NCT00014170,Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,Phase II Study Of ZD1839 (NSC 715055) In Newly Diagnosed Patients With Glioblastoma (Grade 4 Astrocytoma),COMPLETED,2001-03,,2013-07-16,INTERVENTIONAL,PHASE2,92.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma,gefitinib|pharmacological study|laboratory biomarker analysis|questionnaire administration|quality-of-life assessment,DRUG|OTHER|PROCEDURE,1,2,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,3,4.532599493153256,medium,1,1,0,1,0,0,0,0,1,0,0,0,1,0,3,1,1,0,0,5,1,2001-03-01,,,2001.0,0,2,0
NCT02923570,Study of Proton Versus Photon Beam Radiotherapy in the Treatment of Head and Neck Cancer,A Phase II Randomized Study of Proton Versus Photon Beam Radiotherapy in the Treatment of Unilateral Head and Neck Cancer,ACTIVE_NOT_RECRUITING,2016-10-03,2026-10,2025-11-05,INTERVENTIONAL,PHASE2,108.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Head and Neck Cancer,Photon intensity modulated radiation therapy (IMRT)|Proton beam radiotherapy (PBRT),RADIATION,1,0,18 Years,,ALL,False,Memorial Sloan Kettering Cancer Center,OTHER,1,9,United States,,0,1,0,0,0,2.0,1,0,0,0,1,4.6913478822291435,medium,0,1,0,1,0,1,1,0,1,0,1,0,1,1,1,0,0,0,0,2,1,,2026-10-01,,,0,1,0
NCT01592773,"Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)","An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)",TERMINATED,2012-10,2014-03,2015-02-16,INTERVENTIONAL,PHASE2,747.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Autism Spectrum Disorder (ASD)|Autism|Autistic Disorder|Asperger's Disorder|Asperger's|Pediatric Autism|Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS),Memantine Hydrochloride (HCl),DRUG,1,0,6 Years,12 Years,ALL,False,Forest Laboratories,INDUSTRY,0,106,Italy|Belgium|South Africa|Hungary|South Korea|United States|Spain|Iceland|Poland|Serbia|Estonia|New Zealand|Ukraine|Colombia|France|Canada,0.0,0,1,0,0,0,2.0,0,0,0,0,7,6.617402977974478,xlarge,0,1,1,0,0,0,1,1,1,1,0,0,1,0,1,0,1,0,0,1,0,2012-10-01,2014-03-01,516.0,2012.0,0,2,0
NCT02124473,Addition of Homeopathy in Patients With Resistant Arterial Hypertension,"Phase II Randomized, Double-Blind, Placebo-Controlled Trial of Homeopathy in Resistant Arterial Hypertension",COMPLETED,2013-08,2014-03,2014-04-28,INTERVENTIONAL,PHASE2,79.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Hypertension, Resistant to Conventional Therapy",Homeopathy|Placebo,OTHER,1,1,18 Years,85 Years,ALL,False,Macmillan Research Group UK,INDUSTRY,1,2,India,1.0,0,1,0,0,0,2.0,0,0,0,1,1,4.382026634673881,medium,1,1,1,0,0,1,1,0,0,0,1,1,1,1,2,1,0,0,0,2,1,2013-08-01,2014-03-01,212.0,2013.0,0,1,0
NCT00074269,"Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer",Pilot Study Of Allogeneic Peripheral Blood Progenitor Cell Transplantation In Patients With Chemotherapy-Refractory Or Poor-Prognosis Metastatic Breast Cancer,TERMINATED,2003-07,2008-03,2023-06-05,INTERVENTIONAL,PHASE2,5.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Breast Cancer,anti-thymocyte globulin|filgrastim|graft-versus-tumor induction therapy|therapeutic allogeneic lymphocytes|cyclosporine|fludarabine phosphate|melphalan|methotrexate|peripheral blood stem cell transplantation,DRUG|BIOLOGICAL|PROCEDURE,3,4,18 Years,60 Years,FEMALE,False,"University of California, San Diego",OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,1.791759469228055,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,7,1,1,1,0,9,1,2003-07-01,2008-03-01,1705.0,2003.0,0,2,0
NCT03527069,Efficacy and Safety of Cipros 10 Association on the Isolated Hypertriglyceridemia and Dyslipidemia Treatment,"Phase III, National, Multicenter, Randomized, Double Blind Clinical Trial, to Evaluate the Efficacy and Safety of Cipros 10 Association on Dyslipidemia Treatment",COMPLETED,2021-01-29,2025-07-25,2025-12-08,INTERVENTIONAL,PHASE3,146.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Hypertriglyceridemia|Dyslipidemia,Cipros 10 association|Crestor 10 mg,DRUG,1,1,18 Years,,ALL,False,EMS,INDUSTRY,0,1,Brazil,1.0,0,0,1,0,0,3.0,0,0,0,0,2,4.990432586778736,medium,0,1,1,0,0,0,0,0,0,0,1,1,1,1,2,1,1,0,0,2,1,,,,,0,2,0
NCT00244569,Development of a Breath Test for Monitoring Patients With Liver Disease,Development of a Breath Test for Monitoring Liver Metabolic Function in Patients With Chronic Liver Disease and Cirrhosis,COMPLETED,2005-09,2007-04,2017-03-20,INTERVENTIONAL,PHASE3,120.0,ESTIMATED,NON_RANDOMIZED,SINGLE_GROUP,DIAGNOSTIC,NONE,Fatty Liver|Cirrhosis,13C-Methacetin|Breath ID Machine,DRUG|DEVICE,2,1,18 Years,,ALL,False,Virginia Commonwealth University,OTHER,1,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,2,4.795790545596741,medium,0,0,0,1,0,1,0,0,1,0,0,0,0,0,3,1,1,0,1,2,1,2005-09-01,2007-04-01,577.0,2005.0,0,2,0
NCT03260569,Inhaled Nitric Oxide in Brain Injury,Respiratory Mechanics Following Brain Injury: The Role of Inhaled Nitric Oxide,COMPLETED,2018-12-12,2023-12-28,2025-04-30,INTERVENTIONAL,PHASE3,13.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Traumatic Brain Injury,Inhaled Nitric Oxide|Placebo,DRUG,1,0,18 Years,,ALL,False,University of Cincinnati,OTHER,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,2.6390573296152584,small,1,1,0,1,0,0,0,0,1,0,1,1,1,1,1,0,1,0,0,2,1,,,,,0,1,0
NCT00227669,"Gemcitabine With or Without Docetaxel as Second-Line Therapy in Treating Patients With Metastatic or Relapsed, Unresectable Uterine or Soft Tissue Leiomyosarcoma",Randomized Phase II Study Evaluating the Efficacy of Gemcitabine Versus the Gemcitabine/Docetaxel Combination as Second Line Treatment in Metastatic or Relapsed and Inoperable Uterine or Soft Tissue Leiomyosarcomas,COMPLETED,2005-10,2012-08,2016-08-30,INTERVENTIONAL,PHASE2,90.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Sarcoma,docetaxel|gemcitabine hydrochloride,DRUG,1,6,18 Years,120 Years,FEMALE,False,UNICANCER,OTHER,0,32,France,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.51085950651685,medium,1,1,0,1,0,0,1,0,0,1,1,0,1,1,7,1,1,0,0,2,1,2005-10-01,2012-08-01,2496.0,2005.0,0,2,0
NCT00977041,Neurofeedback Treatment of Pain in Persons With Spinal Cord Injury (SCI),Neurofeedback Treatment of Pain in Persons With SCI: Phase 2,COMPLETED,2010-08,2011-10,2013-06-06,INTERVENTIONAL,PHASE2,13.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Spinal Cord Injuries|Pain,Neurofeedback,BEHAVIORAL,1,6,18 Years,85 Years,ALL,False,University of Washington,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,2.6390573296152584,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,7,1,0,0,0,1,0,2010-08-01,2011-10-01,426.0,2010.0,0,2,0
NCT03738241,2017 A/H7N9 IIV Revaccination,"A Phase II Study to Assess the Safety, Reactogenicity and Immunogenicity of a Single Dose of 2017 A/H7N9 Inactivated Influenza Vaccine (IIV) Administered Intramuscularly With or Without AS03 Adjuvant in 2013 A/H7N9 IIV Primed or A/H7 IIV Naïve Subjects",COMPLETED,2018-12-18,2020-06-19,2021-07-30,INTERVENTIONAL,PHASE2,304.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Avian Influenza|Influenza Immunisation,A/H7N9|AS03|Phosphate Buffered Saline (PBS) diluent,DRUG|BIOLOGICAL|OTHER,10,20,19 Years,70 Years,ALL,True,National Institute of Allergy and Infectious Diseases (NIAID),NIH,0,9,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,5.720311776607412,large,0,1,0,1,0,0,1,0,1,0,1,1,0,1,30,1,1,1,0,3,1,,,,,0,3,1
NCT04909905,Glutamine Supplementation and Short-term Mortality in Covid-19,The Impact of Glutamine Supplementation Upon the Short-term Mortality of COVID-19 Diseased Patients Admitted in ICU: A Double Blind Randomized Clinical Trial,COMPLETED,2021-05-30,2021-10-30,2021-11-05,INTERVENTIONAL,PHASE3,60.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Covid19,Standard enteral nutrition|Glutamine,COMBINATION_PRODUCT|DIETARY_SUPPLEMENT,1,3,18 Years,,ALL,False,Assiut University,OTHER,0,1,Egypt,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.110873864173311,medium,1,1,0,1,0,0,0,0,0,0,1,1,1,1,4,1,0,0,0,2,1,,,,,0,1,0
NCT02714205,Flushing Reduction Associated With Nitrates,Flushing Reduction Associated With Nitrates,COMPLETED,2017-04-24,2022-04-05,2025-03-28,INTERVENTIONAL,PHASE2,141.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Menopausal Hot Flashes,transdermal nitroglycerin|Placebo,DRUG,1,7,40 Years,62 Years,FEMALE,True,"Alison Huang, MD",OTHER,1,2,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.955827057601261,medium,0,1,0,1,0,1,1,0,1,0,1,1,1,1,8,1,1,0,0,2,1,,,,,0,2,0
NCT00207805,The Optimal Timing of a Second Autologous Peripheral Blood Stem Cell Transplantation in Patients (<61 Years) With Multiple Myeloma,,COMPLETED,2003-05,,2009-01-27,INTERVENTIONAL,PHASE3,202.0,,RANDOMIZED,PARALLEL,TREATMENT,NONE,Multiple Myeloma,autologous PBSC transplant,PROCEDURE,1,1,,61 Years,ALL,False,Centre National de Greffe de Moelle Osseuse,OTHER_GOV,0,1,Tunisia,1.0,0,0,1,0,0,3.0,1,0,0,0,1,5.313205979041787,large,0,0,0,1,0,0,0,0,0,0,1,0,1,1,2,1,0,0,0,1,0,2003-05-01,,,2003.0,0,0,0
NCT00462605,MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia,"A Phase II Study of and Oral Histone Deacytylase Inhibitor, MS-275 (NSC 706995), in Combination With Sargramostim (GM-CSF, Berlex, Inc.) Treating Relapsed and Refractory Myeloid Malignancies",COMPLETED,2007-04,2011-03,2017-07-18,INTERVENTIONAL,PHASE2,24.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Chronic Myelomonocytic Leukemia|de Novo Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Refractory Anemia|Refractory Anemia With Excess Blasts|Refractory Anemia With Ringed Sideroblasts|Refractory Cytopenia With Multilineage Dysplasia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia",entinostat|sargramostim,DRUG,1,4,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,28,3.2188758248682006,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,5,1,1,0,0,2,1,2007-04-01,2011-03-01,1430.0,2007.0,0,2,0
NCT01936805,ROsuvastatin LOading and Clinical Outcomes Trial,,COMPLETED,2008-01,2012-01,2013-09-06,INTERVENTIONAL,PHASE3,299.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Atherosclerosis,Rosuvastatin,DRUG,1,2,18 Years,,ALL,False,Yuksek Ihtisas Hospital,OTHER,0,1,Turkey (Türkiye),1.0,0,0,1,0,0,3.0,0,0,0,1,1,5.703782474656201,large,0,1,0,1,0,0,0,0,0,0,1,1,1,1,3,1,1,0,0,1,0,2008-01-01,2012-01-01,1461.0,2008.0,0,0,0
NCT02976766,Gypenosides Treatment for Optic Neuritis,"Gypenosides Treatment for Optic Neuritis: a Randomised, Double-blind, Placebo-controlled Trial",TERMINATED,2017-02-04,2020-12-31,2025-12-19,INTERVENTIONAL,PHASE2,10.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Optic Neuritis,Gypenosides|Placebo,DRUG,1,5,18 Years,60 Years,ALL,False,First Affiliated Hospital of Guangxi Medical University,OTHER,0,1,China,0.0,0,1,0,0,0,2.0,0,0,0,0,1,2.3978952727983707,small,1,1,0,1,0,0,0,0,0,0,1,1,1,1,6,1,1,0,0,2,1,,,,,0,2,0
NCT00004466,Pilot Study of Atorvastatin in Children With Chronic Hyperlipidemia Secondary to Nephrotic Syndrome,,TERMINATED,1998-10,1999-12,2017-09-15,INTERVENTIONAL,PHASE2,5.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Nephrotic Syndrome|Hyperlipidemia,Atorvastatin|Placebo,DRUG,1,0,6 Years,17 Years,ALL,False,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),NIH,1,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,2,1.791759469228055,small,1,1,0,1,0,1,0,0,1,0,1,1,1,1,1,0,1,0,0,2,1,1998-10-01,1999-12-01,426.0,1998.0,0,2,0
NCT00210366,Salvage Therapy With Idarubicin in Relapsing CNS Lymphoma,Salvage Therapy With Idarubicin in Immunocompetent Patients With Relapsed or Refractory Primary Central Nervous System Lymphomas,TERMINATED,2004-11,,2010-07-30,INTERVENTIONAL,PHASE2,25.0,ESTIMATED,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,"Lymphoma, B-Cell",Idarubicin,DRUG,1,3,18 Years,75 Years,ALL,False,International Extranodal Lymphoma Study Group (IELSG),OTHER,0,1,Italy,0.0,0,1,0,0,0,2.0,1,0,0,0,1,3.258096538021482,small,1,0,0,1,0,0,0,0,0,1,0,0,1,0,4,1,1,0,0,1,0,2004-11-01,,,2004.0,0,0,0
NCT01312766,Safety and Efficacy Study in in Vitro Fertilisation (IVF) Patients,Safety and Efficacy Study Comparing a New hMG Formulation (hMG-IBSA) to a Reference Product (Menopur®) in Patients Undergoing Ovarian Stimulation for in Vitro Fertilisation (IVF),COMPLETED,2011-02,2013-12,2016-07-22,INTERVENTIONAL,PHASE3,270.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Infertility,Menotropins|Menotropins,DRUG,1,12,18 Years,40 Years,FEMALE,False,IBSA Institut Biochimique SA,INDUSTRY,0,6,Hungary|United Kingdom|Switzerland|Denmark|France,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.602118820879701,large,0,1,1,0,0,0,1,1,0,1,1,0,1,1,13,1,1,0,0,2,1,2011-02-01,2013-12-01,1034.0,2011.0,0,3,1
NCT00133666,Improving Asthma Communication in Minority Families,Improving Asthma Communication in Minority Families,COMPLETED,2004-09,2008-05,2008-07-17,INTERVENTIONAL,PHASE2,231.0,ACTUAL,RANDOMIZED,PARALLEL,,SINGLE,Asthma,Asthma Communication Education|Standard Asthma Education,BEHAVIORAL,1,3,6 Years,12 Years,ALL,False,National Institute of Nursing Research (NINR),NIH,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.44673737166631,large,0,1,0,1,0,1,0,0,1,0,1,0,0,1,4,1,0,0,0,2,1,2004-09-01,2008-05-01,1338.0,2004.0,0,1,0
NCT00082966,Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma,A Phase II Study of PS-341 (Bortezomib) in Patients With Relapsed or Refractory Hodgkin's Lymphoma,COMPLETED,2004-03,,2015-12-04,INTERVENTIONAL,PHASE2,43.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Adult Lymphocyte Depletion Hodgkin Lymphoma|Adult Mixed Cellularity Hodgkin Lymphoma|Adult Nodular Sclerosis Hodgkin Lymphoma|Recurrent Adult Hodgkin Lymphoma,17-N-allylamino-17-demethoxygeldanamycin/bortezomib,DRUG,3,0,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,4,3.784189633918261,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,3,0,1,0,0,1,0,2004-03-01,,,2004.0,0,1,0
NCT04866056,Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.,A Multicentric Phase I/II Study of Jaktinib Hydrochloride Tablets in Combination With Azacitidine for Injection in Patients With Myelodysplastic Syndromes(MDS) With Myelofibrosis(MF) or MDS/Myeloproliferative Neoplasms With MF,TERMINATED,2021-09-30,2022-06-10,2022-12-01,INTERVENTIONAL,PHASE1|PHASE2,1.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Myelodysplastic Syndromes|Myeloproliferative Neoplasms|Myelofibrosis,Jaktinib|azacitidine,DRUG,2,3,18 Years,,ALL,False,"Suzhou Zelgen Biopharmaceuticals Co.,Ltd",INDUSTRY,0,1,China,0.0,1,1,0,0,1,1.5,0,0,0,0,3,0.6931471805599453,small,1,1,1,0,0,0,0,0,0,0,0,0,1,0,5,1,1,0,0,2,1,,,,,0,3,1
NCT00785122,IMA910 Plus GM-CSF With Low-dose Cyclophosphamide Pre-treatment in Advanced Colorectal Carcinoma Patients Following a Successful 12 Week First-line Treatment With Oxaliplatin-based Chemotherapy (IMA910-101),"An Open Label, Multicenter Phase 1-2 Study to Investigate the Effectiveness, Safety and Immunogenicity of a Monotherapy With Intradermal IMA910 Plus GM-CSF Following Pre-treatment With Low-dose Cyclophosphamide in Advanced Colorectal Carcinoma Patients Who Have Successfully Completed a 12 Week First-line Treatment With Oxaliplatin-based Chemotherapy.",COMPLETED,2008-06,2013-05,2013-05-16,INTERVENTIONAL,PHASE1|PHASE2,92.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Colorectal Carcinoma,"Endoxana, Leukine, IMA910|Endoxana, Leukine, IMA910, Aldara",DRUG,2,11,18 Years,,ALL,False,Immatics Biotechnologies GmbH,INDUSTRY,0,41,Belgium|Latvia|Bulgaria|Hungary|Germany|United Kingdom|Romania|Poland|Serbia,1.0,1,1,0,0,1,1.5,1,0,0,0,1,4.532599493153256,medium,1,1,1,0,0,0,1,1,0,1,0,0,1,0,13,1,1,0,0,2,1,2008-06-01,2013-05-01,1795.0,2008.0,0,4,1
NCT03334422,Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Patients With Moderate to Severe Atopic Dermatitis",COMPLETED,2017-11-27,2018-12-12,2020-01-22,INTERVENTIONAL,PHASE3,615.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Atopic Dermatitis,Baricitinib|Placebo,DRUG,1,23,18 Years,,ALL,False,Eli Lilly and Company,INDUSTRY,1,80,Argentina|Hungary|South Korea|Spain|Austria|Australia|Poland|Japan|Switzerland|Israel,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.423246963533519,xlarge,0,1,1,0,1,1,1,1,0,1,1,1,1,1,24,1,1,0,0,2,1,,,,,0,3,1
NCT02742051,"A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer","A Randomised Pilot Study of Neoadjuvant Everolimus Plus Letrozole Compared With FEC in Postmenopausal Patients With ER-positive, HER2-negative Breast Cancer",COMPLETED,2016-06,2020-03-14,2021-09-23,INTERVENTIONAL,PHASE2,40.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Breast Cancer,Everolimus|Letrozole|Fluorouracil|Epirubicin|Cyclophosphamide,DRUG,1,11,18 Years,70 Years,FEMALE,False,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,OTHER,0,1,China,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.713572066704308,small,1,1,0,1,0,0,0,0,0,0,1,0,1,1,12,1,1,0,0,5,1,2016-06-01,,,2016.0,1,2,0
NCT04044651,Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection,"A Randomized, Phase IIb Study of Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma (HCC) With Hepatitis B Virus (HBV) Infection",WITHDRAWN,2019-10-30,2022-09-30,2020-01-09,INTERVENTIONAL,PHASE2|PHASE3,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Hepatocellular Carcinoma,Lenvatinib|Nivolumab,DRUG,1,5,18 Years,,ALL,False,Shi Ming,OTHER,4,5,China,0.0,0,1,1,0,1,2.5,1,0,0,0,1,0.0,,1,1,0,1,0,1,1,0,0,0,1,0,1,1,6,1,1,0,0,2,1,,,,,0,3,1
NCT00994851,Evaluation of Cassia Fistula + Senna Alexandrina Miller in the Chronic Functional Constipation Treatment.,"National Study, Phase III, Parallel, Double Blind, Placebo Comparative and Randomized to Evaluate the Therapeutic Efficacy and Tolerability of the Combination Naturetti® (Cassia Fistula + Senna Alexandrina Miller) in the Chronic Functional Constipation.",COMPLETED,2009-09,2012-08,2013-03-29,INTERVENTIONAL,PHASE3,96.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Constipation,SENNA+CASSIA|placebo,DRUG,3,9,18 Years,59 Years,ALL,False,Sanofi,INDUSTRY,0,1,Brazil,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.574710978503383,medium,1,1,1,0,1,0,0,0,0,0,1,1,1,1,12,1,1,0,0,2,1,2009-09-01,2012-08-01,1065.0,2009.0,0,2,0
NCT02422290,Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD),Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD),COMPLETED,2015-03,2020-07-31,2020-08-17,INTERVENTIONAL,PHASE1|PHASE2,5.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Obsessive-Compulsive Disorder,Ketamine,DRUG,2,2,14 Years,22 Years,ALL,False,New York State Psychiatric Institute,OTHER,1,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,1.791759469228055,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,4,1,1,0,0,1,0,2015-03-01,,,2015.0,1,1,0
NCT01035190,Efficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dysplasia,Efficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dysplasia,COMPLETED,2010-04,2016-07,2016-07-06,INTERVENTIONAL,PHASE3,863.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Bronchopulmonary Dysplasia,Budesonide,DRUG,1,1,,12 Hours,ALL,False,University Children's Hospital Tuebingen,OTHER,1,40,Italy|Belgium|Finland|Netherlands|Germany|Czechia|Israel|France,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.761572768804055,xlarge,0,1,0,1,0,1,1,1,0,1,1,1,0,1,2,1,1,0,0,1,0,2010-04-01,2016-07-01,2283.0,2010.0,0,1,0
NCT05066997,A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1),"A Phase 2/3 Double-Masked, Randomized, 2 Stage, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema",ACTIVE_NOT_RECRUITING,2021-10-19,2026-04,2026-01-13,INTERVENTIONAL,PHASE2|PHASE3,552.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Diabetic Macular Edema,Dexamethasone ophthalmic suspension (OCS-01)|Vehicle,DRUG,1,3,18 Years,85 Years,ALL,False,Oculis,INDUSTRY,0,52,Taiwan|Hong Kong|India|United States,,0,1,1,0,1,2.5,0,0,0,0,1,6.315358001522335,xlarge,0,1,1,0,0,0,1,1,1,0,1,1,1,1,4,1,1,0,0,2,1,,2026-04-01,,,0,3,1
NCT05941897,A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy,"A Phase II, Open-label, Multicentre, Non-comparative, Single-arm Local Study of Ceralasertib Plus Durvalumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy",ACTIVE_NOT_RECRUITING,2023-06-21,2027-01-01,2025-09-24,INTERVENTIONAL,PHASE2,39.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Advanced or Metastatic NSCLC,Ceralasertib|Durvalumab,DRUG,1,6,18 Years,,ALL,False,AstraZeneca,INDUSTRY,0,8,Russia,,0,1,0,0,0,2.0,1,0,0,0,1,3.6888794541139363,small,1,1,1,0,1,0,1,0,0,0,0,0,1,0,7,1,1,0,0,2,1,,,,,0,2,0
NCT00005097,Green Tea Extract in Treating Patients With Actinic Keratosis,"A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Polyphenon E Against Various Endpoints of Actinic Keratosis Pathobiology",TERMINATED,1999-08,2002-08,2018-04-05,INTERVENTIONAL,PHASE2,88.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Non-melanomatous Skin Cancer,Polyphenon E and Placebo,DRUG,1,0,18 Years,,ALL,False,Frank Meyskens,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,4.48863636973214,medium,1,1,0,1,0,1,0,0,1,0,1,1,0,1,1,0,1,0,0,1,0,1999-08-01,2002-08-01,1096.0,1999.0,0,0,0
NCT03973697,Penn Microbiome Therapy for Recurrent Clostridium Difficile Infection,"A Phase II, Randomized Trial to Evaluate the Optimal Dosing of Fecal Microbiota Transplantation Using the Penn Microbiome Therapy Products for Recurrent Clostridium Difficile Infection",TERMINATED,2020-01-13,2021-12-31,2023-11-01,INTERVENTIONAL,PHASE2,9.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Recurrent Clostridium Difficile Infection,Penn Microbiome Therapy - 001|Penn Microbiome Therapy - 002|Penn Microbiome Therapy - 003,DRUG,1,7,18 Years,,ALL,False,University of Pennsylvania,OTHER,0,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,2.302585092994046,small,1,1,0,1,0,0,0,0,1,0,1,0,1,1,8,1,1,0,0,3,1,,,,,0,2,0
NCT03395210,A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP),"An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients With Relapsed Immune Thrombocytopenia",ACTIVE_NOT_RECRUITING,2018-03-22,2025-12-18,2025-11-14,INTERVENTIONAL,PHASE2,86.0,ACTUAL,,SEQUENTIAL,TREATMENT,NONE,Immune Thrombocytopenia,Rilzabrutinib,DRUG,4,22,18 Years,80 Years,ALL,False,"Principia Biopharma, a Sanofi Company",INDUSTRY,0,31,Netherlands|Bulgaria|United States|United Kingdom|Australia|Norway|Czechia|Canada,,0,1,0,0,0,2.0,0,0,0,0,1,4.465908118654584,medium,1,1,1,0,1,0,1,1,1,1,0,0,1,0,26,1,1,0,0,1,0,,,,,0,2,0
NCT00513513,TMC114-C227: A Study to Evaluate the Effectiveness and Safety of TMC114 (Darunavir) With a Low Dose of Ritonavir as Monotherapy (no Other Anti-HIV Drugs Will be Given) in Patients Who Have Never Been Treated With Antiretrovirals (Anti-HIV Drugs) Previously,"A Phase II, Open Label Trial in Treatment na�ve, HIV 1 Infected Subjects Who Will Receive TMC114/Rtv as a Monotherapy",TERMINATED,2006-09,2007-10,2010-04-26,INTERVENTIONAL,PHASE2,7.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,HIV Infections,TMC114 (darunavir) / ritonavir,DRUG,1,1,18 Years,,ALL,False,"Tibotec Pharmaceuticals, Ireland",INDUSTRY,0,0,,0.0,0,1,0,0,0,2.0,0,0,0,0,1,2.0794415416798357,small,1,1,1,0,0,0,0,0,0,0,0,0,1,0,2,1,1,0,0,1,0,2006-09-01,2007-10-01,395.0,2006.0,0,0,0
NCT00869713,"Safety and Immunogenicity Study of Rift Valley Fever Vaccine, Inactivated","Long-Term Open-Label Primary Vaccination and Booster Dose Study of the Safety and Immunogenicity of Rift Valley Fever Vaccine, Inactivated, Dried (TSI-GSD 200) in At-Risk Adults",COMPLETED,2009-09,2021-05,2022-03-04,INTERVENTIONAL,PHASE2,98.0,ACTUAL,,SINGLE_GROUP,PREVENTION,NONE,Rift Valley Fever,"Inactivated, Dried (TSI-GSD 200), RVF Vaccine",BIOLOGICAL,6,4,18 Years,65 Years,ALL,True,U.S. Army Medical Research and Development Command,FED,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.59511985013459,medium,1,1,0,0,0,0,0,0,1,0,0,0,0,0,10,1,0,1,0,1,0,2009-09-01,2021-05-01,4260.0,2009.0,0,1,0
NCT02282813,Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002,"A Long-term Safety and Efficacy Study of CTAP101 Capsules in Subjects With Stages 3 or 4 Chronic Kidney Disease, Secondary Hyperparathyroidism and Vitamin D Insufficiency (Extension of Study CTAP101-CL-3001 or CTAP101-CL-3002)",COMPLETED,2013-04,2015-05,2016-09-29,INTERVENTIONAL,PHASE3,298.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Chronic Kidney Disease|Hyperparathyroidism, Secondary|Vitamin D Deficiency",CTAP101 Capsules|Calcitriol|Doxercalciferol|Paricalcitol,DRUG,1,3,18 Years,,ALL,False,"OPKO Health, Inc.",INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,3,5.700443573390687,large,0,1,1,0,0,0,0,0,0,0,1,0,1,1,4,1,1,0,0,4,1,2013-04-01,2015-05-01,760.0,2013.0,0,2,0
NCT01318590,Prospective Study on Endoscopic Ultrasound (EUS) Celiac Bloc Efficacy in Chronic Pancreatitis,Prospective Study on Endoscopic Ultrasound (EUS) Celiac Bloc Efficacy in Chronic Pancreatitis,TERMINATED,2011-11-18,2019-06-14,2020-05-13,INTERVENTIONAL,PHASE3,2.0,ACTUAL,RANDOMIZED,PARALLEL,SUPPORTIVE_CARE,DOUBLE,"Pancreatitis, Chronic",EUS procedure with drug injection|EUS procedure,DRUG|OTHER,1,1,18 Years,,ALL,False,Centre hospitalier de l'Université de Montréal (CHUM),OTHER,2,2,Belgium|Canada,0.0,0,0,1,0,0,3.0,0,0,0,0,1,1.0986122886681098,small,1,1,0,1,0,1,1,1,0,0,1,1,0,1,2,1,1,0,0,2,1,,,,,0,2,0
NCT00004390,Phase III Randomized Controlled Study of Morphine and Nortriptyline in the Management of Postherpetic Neuralgia,,COMPLETED,1995-02,,2005-06-24,INTERVENTIONAL,PHASE3,120.0,,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Pain|Herpes Zoster,desipramine|methadone|morphine|nortriptyline,DRUG,0,0,18 Years,90 Years,ALL,False,National Center for Research Resources (NCRR),NIH,2,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,2,4.795790545596741,medium,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,4,1,1995-02-01,,,1995.0,0,2,0
NCT00209690,Phase I/II Study of TPF as First-line Chemotherapy in Patients With Metastatic Esophageal Cancer.,"Phase I/II Study of Docetaxel, Cisplatin and 5-fluorouracil(TPF) as 1st-line Chemotherapy in Patients With Metastatic Esophageal Cancer.",COMPLETED,2003-10,2010-04,2010-05-26,INTERVENTIONAL,PHASE1|PHASE2,30.0,ESTIMATED,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Esophageal Cancer,Taxotere|5-FU|Briplatin,DRUG,1,1,20 Years,75 Years,ALL,False,Hokkaido Gastrointestinal Cancer Study Group,OTHER,1,1,Japan,1.0,1,1,0,0,1,1.5,1,0,0,0,1,3.4339872044851463,small,1,0,0,1,0,1,0,0,0,0,0,0,1,0,2,1,1,0,0,3,1,2003-10-01,2010-04-01,2374.0,2003.0,0,2,0
NCT01774097,Patients With Intermittent Claudication Injected With ALDH Bright Cells,Clinical and MR Imaging Assessments in Patients With Intermittent Claudication Following Injection of Bone Marrow Derived ALDH Bright Cells,COMPLETED,2013-06,2017-03,2017-04-21,INTERVENTIONAL,PHASE2,82.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Peripheral Artery Disease|Intermittent Claudication,ALD-301|Placebo (vehicle),BIOLOGICAL,4,8,40 Years,,ALL,False,"The University of Texas Health Science Center, Houston",OTHER,3,9,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.418840607796598,medium,1,1,0,1,0,1,1,0,1,0,1,1,1,1,12,1,0,1,0,2,1,2013-06-01,2017-03-01,1369.0,2013.0,0,3,1
NCT00823797,Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma,A Phase II Study of Bendamustine in the Treatment of Recurrent High-Grade Gliomas (Anaplastic Gliomas and Glioblastoma),COMPLETED,2008-10,2017-04,2017-07-07,INTERVENTIONAL,PHASE2,45.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Adult Anaplastic Astrocytoma|Adult Anaplastic Oligodendroglioma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Neoplasm,Bendamustine Hydrochloride|Quality-of-Life Assessment,DRUG|OTHER,1,3,18 Years,,ALL,False,University of Washington,OTHER,2,3,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,6,3.828641396489095,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,4,1,1,0,0,2,1,2008-10-01,2017-04-01,3104.0,2008.0,0,2,0
NCT00003213,Drugs to Reduce the Side Effects of Chemotherapy,"A Randomized, Double-Blind Trial to Compare the Clinical Efficacy and Safety of Granisetron vs. Metoclopramide Combined to Dexamethasone in the Prophylaxis of Chemotherapy-Induced Delayed Emesis",COMPLETED,1996-05,1999-08,2012-07-11,INTERVENTIONAL,PHASE3,267.0,ACTUAL,RANDOMIZED,PARALLEL,SUPPORTIVE_CARE,DOUBLE,"Nausea and Vomiting|Unspecified Adult Solid Tumor, Protocol Specific",dexamethasone|granisetron hydrochloride|metoclopramide hydrochloride,DRUG,1,0,18 Years,,ALL,False,Swiss Cancer Institute,OTHER,0,10,Italy|Switzerland,1.0,0,0,1,0,0,3.0,1,0,0,0,2,5.5909869805108565,large,0,1,0,1,0,0,1,1,0,1,1,1,0,1,1,0,1,0,0,3,1,1996-05-01,1999-08-01,1187.0,1996.0,0,3,1
NCT00567697,A Randomized Study Comparing Ranibizumab to Sham in Patients With Macular Edema Secondary to CRVO,A Randomized Study Comparing the Safty Anf Efficacy of Ranibizumab (Lucentis®) to Sham in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO,COMPLETED,2007-03,2008-10,2012-01-19,INTERVENTIONAL,PHASE3,32.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,TRIPLE,Central Retinal Vein Occlusion|Macular Edema,ranibizumab|ranibizumab,DRUG,1,1,50 Years,,ALL,False,Aleris Helse,OTHER,1,4,Norway,1.0,0,0,1,0,0,3.0,0,0,0,0,2,3.4965075614664802,small,1,1,0,1,0,1,1,0,0,0,1,1,1,0,2,1,1,0,0,2,1,2007-03-01,2008-10-01,580.0,2007.0,0,2,0
NCT01465997,Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older,"A Multicenter, Double-blind, Double-dummy, Follow up Study Evaluating the Long-term Safety of Lacosamide in Comparison With Controlled-release Carbamazepine Used as Monotherapy in Subjects With Partial-onset or Generalized Tonic-clonic Seizures ≥16 Years of Age Coming From the SP0993 Study.",COMPLETED,2012-05,2017-01,2018-07-18,INTERVENTIONAL,PHASE3,551.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Epilepsy|Monotherapy,Lacosamide|Carbamazepine-Controlled Release (CBZ-CR),DRUG,3,0,,,ALL,False,UCB BIOSCIENCES GmbH,INDUSTRY,1,150,Bulgaria|Latvia|Germany|Japan|Switzerland|Greece|Thailand|Italy|Finland|South Korea|Spain|Czechia|Portugal|Canada|Russia|Sweden|United States|United Kingdom|Australia|Romania|Lithuania|Poland|Mexico|Philippines|Ukraine|France|Belgium|Hungary|Slovakia,1.0,0,0,1,0,0,3.0,0,0,1,0,2,6.313548046277095,xlarge,0,1,1,0,0,1,1,1,1,1,0,1,1,1,3,0,1,0,0,2,1,2012-05-01,2017-01-01,1706.0,2012.0,0,3,1
NCT04878510,Non-invasive Ventilation and Dex in Critically Ill Adults,Non-invasive Ventilation and Dexmedetomidine in Critically Ill Adults: a Vanguard Pragmatic Randomized Controlled Trial (inDEX Trial),COMPLETED,2022-03-07,2024-04-21,2024-10-28,INTERVENTIONAL,PHASE3,24.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Respiratory Insufficiency,Dexmedetomidine|Placebo,DRUG|OTHER,3,20,18 Years,,ALL,False,St. Joseph's Healthcare Hamilton,OTHER,0,3,Australia|Saudi Arabia|Canada,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.2188758248682006,small,1,1,0,1,0,0,1,1,0,0,1,1,1,1,23,1,1,0,0,2,1,,,,,0,3,1
NCT01098110,6-week Trial of the Efficacy and Safety of Asenapine Compared to Placebo in Participants With an Acute Exacerbation of Schizophrenia (P06124),"A Multicenter, Randomized, Double-blind, Fixed-dose, 6-week Trial of the Efficacy and Safety of Asenapine Compared With Placebo in Subjects With an Acute Exacerbation of Schizophrenia (Phase 3)",COMPLETED,2010-05-25,2014-04-14,2024-06-20,INTERVENTIONAL,PHASE3,532.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Schizophrenia,Asenapine 5 mg|Asenapine 10 mg|Placebo,DRUG,1,11,20 Years,64 Years,ALL,False,Organon and Co,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,1,0,1,6.278521424165844,xlarge,0,1,1,0,0,0,0,0,0,0,1,1,1,1,12,1,1,0,0,3,1,,,,,0,2,0
NCT05964413,Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum,"A Randomized, Double-blind, Placebo-controlled, Multicenter, Adaptive Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in the Treatment of Ulcerative Pyoderma Gangrenosum",TERMINATED,2023-11-01,2025-07-11,2025-11-04,INTERVENTIONAL,PHASE3,54.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Pyoderma Gangrenosum,vilobelimab|Placebo,DRUG,1,2,18 Years,,ALL,False,InflaRx GmbH,INDUSTRY,0,50,Italy|Belgium|Hungary|United States|Germany|Spain|Australia|Poland|Switzerland|France,0.0,0,0,1,0,0,3.0,0,0,0,0,1,4.007333185232471,medium,1,1,1,0,0,0,1,1,1,1,1,1,1,1,3,1,1,0,0,2,1,,,,,0,2,0
NCT00522197,ACAPHA in Preventing Lung Cancer in Former Smokers With Bronchial Intraepithelial Neoplasia,A Phase II Trial of ACAPHA in Former Smokers With Intraepithelial Neoplasia,COMPLETED,2002-09,2008-11,2012-03-09,INTERVENTIONAL,PHASE2,90.0,ACTUAL,RANDOMIZED,CROSSOVER,PREVENTION,DOUBLE,Lung Cancer|Precancerous Condition,multi-herbal agent ACAPHA|Sugar Pill,DIETARY_SUPPLEMENT,1,6,45 Years,74 Years,ALL,False,British Columbia Cancer Agency,OTHER,1,0,,1.0,0,1,0,0,0,2.0,1,0,0,0,2,4.51085950651685,medium,1,1,0,1,0,1,0,0,0,0,1,1,0,0,7,1,0,0,0,2,1,2002-09-01,2008-11-01,2253.0,2002.0,0,3,1
NCT00234910,Efficacy of Simplified Two Drug Kaletra Regimen vs. Kaletra Triple Drug Standard of Care Regimen in Treatment naïve HIV Infected Patients,"A Phase III, Open Label, Randomized, Comparative Study of the Antiviral Efficacy of ARV Therapy With Lopinavir/Ritonavir (LPV/r-Kaletra) in Combination With Tenofovir (TDF) Versus Standard of Care (Kaletra in Combination With 2 Nucleoside RTIs) in naïve-HIV-1 Positive Patients",COMPLETED,2005-01,2008-06,2008-07-10,INTERVENTIONAL,PHASE3,152.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,HIV Infection,Tenofovir DF|lopinavir/ritonavir with 2 Nucleoside RTIs,DRUG,2,1,18 Years,,ALL,False,Abbott,INDUSTRY,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.030437921392435,medium,0,1,1,0,0,0,0,0,1,0,1,0,1,1,3,1,1,0,0,2,1,2005-01-01,2008-06-01,1247.0,2005.0,0,1,0
NCT01515410,Study in Advanced Parkinson's Disease Patients With Predictable Motor Fluctuations,"A Phase 2, Randomized, Open-Label, Crossover Study to Compare DM-1992, a Novel Gastric-Retentive Extended-Release Formulation of Levodopa/Carbidopa, to an Immediate-Release Carbidopa Tablet in Patients With Advanced Parkinson's Disease With Motor Fluctuations",COMPLETED,2012-01,2012-10,2014-03-10,INTERVENTIONAL,PHASE2,34.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Parkinson's Disease|Motor Fluctuations,DM-1992|Sinemet IR,DRUG,1,0,30 Years,,ALL,False,Depomed,INDUSTRY,0,7,United States,1.0,0,1,0,0,0,2.0,0,0,1,0,2,3.5553480614894135,small,1,1,1,0,0,0,1,0,1,0,1,0,1,0,1,0,1,0,0,2,1,2012-01-01,2012-10-01,274.0,2012.0,0,2,0
NCT01656590,High Protein and Exercise Therapy Plus Nocturnal Enteral Feeding in Juvenile-onset Pompe Disease,High Protein Nutrition and Exercise Therapy (HPET) Plus Nocturnal Enteral Feeding (NEF) in Juvenile-onset Pompe Disease.,WITHDRAWN,2012-10,2013-08,2015-04-13,INTERVENTIONAL,PHASE2,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Glycogen Storage Disease Type II,High Protein and Exercise Therapy along-with Nocturnal Enteral Feeding,OTHER,1,1,8 Years,17 Years,ALL,False,Columbia University,OTHER,0,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,1,1,0,1,0,0,0,0,1,0,0,0,1,0,2,1,0,0,0,1,0,2012-10-01,2013-08-01,304.0,2012.0,0,0,0
NCT02430090,Comparison of Intratechal Levobupivacaine and Adding With Sufetanil and Fentanyl in Ceserean Section,Comparison of Intratechal Low-Dose Levobupivacaine With Levobupivacaine-Fentanyl and Levobupivacaine-Sufentanil Combinations for Cesarean Section,COMPLETED,2006-11,2007-03,2021-11-19,INTERVENTIONAL,PHASE2,45.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Anesthesia,Levobupivacaine|Fentanyl|Sufentanil|Levobupivacaine|Levobupivacaine,DRUG,1,1,18 Years,45 Years,FEMALE,True,Ankara City Hospital Bilkent,OTHER,0,0,,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.828641396489095,small,1,1,0,1,0,0,0,0,0,0,1,1,1,1,2,1,1,0,0,5,1,2006-11-01,2007-03-01,120.0,2006.0,0,1,0
NCT04884490,The Role of High Dose Co-trimoxazole in Severe Covid-19 Patients,The Role of High Dose Co-trimoxazole in Severe Covid-19 Patients- a Double Blind Placebo Controlled Randomized Trial,COMPLETED,2021-05-15,2021-11-14,2025-03-26,INTERVENTIONAL,PHASE2|PHASE3,94.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,COVID-19 Pneumonia,Co-trimoxazole|Placebo,DRUG,1,8,18 Years,,ALL,False,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",OTHER,0,1,Bangladesh,1.0,0,1,1,0,1,2.5,0,0,0,0,1,4.553876891600541,medium,1,1,0,1,0,0,0,0,0,0,1,1,1,1,9,1,1,0,0,2,1,,,,,0,3,1
NCT01494610,Pharmacokinetic and Pharmacodynamic (PK and PD) Study of Fluticasone Propionate and Salmeterol Combination Product Delivered in a Capsule-based Inhaler and in a Multi-dose Dry Powder Inhaler in Moderate Asthma Patients and Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients.,"A Comparative Bioavailability Study to Compare the Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of Fluticasone Propionate and Salmeterol Delivered by Fluticasone Propionate/ Salmeterol Combination in a Capsule-based Inhaler and a Multi-dose Dry Powder Inhaler, in Moderate Asthma Patients and Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients.",COMPLETED,2010-10-25,2011-06-08,2019-02-26,INTERVENTIONAL,PHASE1|PHASE2,60.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,TRIPLE,Asthma,SERETIDE Rotacaps|SERETIDE Diskus,DRUG,2,27,18 Years,80 Years,ALL,False,GlaxoSmithKline,INDUSTRY,0,2,Australia|New Zealand,1.0,1,1,0,0,1,1.5,0,0,0,0,1,4.110873864173311,medium,1,1,1,0,0,0,1,1,0,0,1,1,1,0,29,1,1,0,0,2,1,,,,,0,4,1
NCT00162513,Allogeneic Tumor Cell Vaccination in Patients With Chronic Myeloid Leukemia,Allogeneic Tumor Cell Vaccination in Patients With Chronic Myeloid Leukemia,WITHDRAWN,2006-12,,2011-04-28,INTERVENTIONAL,PHASE1|PHASE2,,,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Chronic Myeloid Leukemia,Allogeneic tumor cell vaccine,BIOLOGICAL,1,1,55 Years,,ALL,False,Hadassah Medical Organization,OTHER,0,1,Israel,0.0,1,1,0,0,1,1.5,1,0,0,0,1,0.0,,0,0,0,1,0,0,0,0,0,0,0,0,1,0,2,1,0,1,0,1,0,2006-12-01,,,2006.0,0,1,0
NCT00381810,A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus,"An Open-label, Single-arm, Multicenter Phase II/III Extension Study to Evaluate the Safety of Rituximab Re-treatment in Subjects With Moderate to Severe Systemic Lupus Erythematosus Previously Enrolled in Protocol U2971g",TERMINATED,2006-06-22,2012-02-29,2017-08-01,INTERVENTIONAL,PHASE3,31.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Lupus Erythematosus, Systemic",Rituximab|Methylprednisolone|Acetaminophen|Diphenhydramine,DRUG,1,0,16 Years,75 Years,ALL,False,"Genentech, Inc.",INDUSTRY,0,11,United States,0.0,0,0,1,0,0,3.0,0,1,0,0,1,3.4657359027997265,small,1,1,1,0,0,0,1,0,1,0,0,0,1,0,1,0,1,0,0,4,1,,,,,0,1,0
NCT03147690,Contrast-Enhanced Ultrasound in the Evaluation of Abdominal Injuries in Children,A Multicenter Trial of Contrast-Enhanced Ultrasound in the Evaluation of Abdominal Solid Organ Injuries in Pediatric Trauma,TERMINATED,2017-11-01,2019-10-07,2021-06-11,INTERVENTIONAL,PHASE1|PHASE2,74.0,ACTUAL,,SINGLE_GROUP,DIAGNOSTIC,NONE,Abdominal Injury,Lumason,DRUG,1,4,8 Years,17 Years,ALL,False,David Mooney,OTHER,0,8,United States,0.0,1,1,0,0,1,1.5,0,0,0,0,1,4.31748811353631,medium,1,1,0,1,0,0,1,0,1,0,0,0,0,0,5,1,1,0,0,1,0,,,,,0,1,0
NCT00890890,"A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease","Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of BMS-708163 in the Treatment of Patients With Prodromal Alzheimer's Disease",TERMINATED,2009-05,2013-07,2015-10-12,INTERVENTIONAL,PHASE2,263.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Alzheimer's Disease,Avagacestat|Placebo,DRUG,4,1,45 Years,90 Years,ALL,False,Bristol-Myers Squibb,INDUSTRY,0,64,Finland|Sweden|United States|Denmark|France|Canada,0.0,0,1,0,0,0,2.0,0,0,1,0,1,5.575949103146316,large,0,1,1,0,1,0,1,1,1,1,1,1,1,1,5,1,1,0,0,2,1,2009-05-01,2013-07-01,1522.0,2009.0,0,2,0
NCT01733290,Botulinum Toxin Urethral Sphincter Injection for Dysfunctional Voiding,"Botulinum Toxin Urethral Sphincter Injection for Dysfunctional Voiding - A Multicenter Study, Randomized, Double-Blind, Placebo Control",COMPLETED,2012-10,2017-02,2017-03-08,INTERVENTIONAL,PHASE2,70.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Dysfunctional Voiding,Botulinum toxin A|Normal saline instillation,DRUG,1,9,20 Years,65 Years,ALL,False,Buddhist Tzu Chi General Hospital,OTHER,0,1,Taiwan,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.2626798770413155,medium,1,1,0,1,0,0,0,0,0,0,1,1,1,1,10,1,1,0,0,2,1,2012-10-01,2017-02-01,1584.0,2012.0,0,2,0
NCT00337597,Continuous Regional Analgesia After Total Knee Arthroplasty,Continuous Regional Analgesia After Total Knee Arthroplasty. Normal Saline or Dextrose 5% in Water as Fluid Medium for Pre-Placement Expansion in Order to Facilitate the Catheter Passing,COMPLETED,2006-05,2007-12,2008-07-21,INTERVENTIONAL,PHASE3,50.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Analgesia,Glucose 5%|NaCl 0.9%,OTHER,1,1,18 Years,90 Years,ALL,False,Nantes University Hospital,OTHER,0,2,France,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.9318256327243257,small,1,1,0,1,0,0,1,0,0,1,1,1,1,1,2,1,0,0,0,2,1,2006-05-01,2007-12-01,579.0,2006.0,0,1,0
NCT04784897,A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19,"A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19",COMPLETED,2021-02-22,2021-07-30,2022-09-16,INTERVENTIONAL,PHASE2,120.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,COVID-19,Brilacidin|Placebo|Standard of Care (SoC),DRUG,2,12,18 Years,80 Years,ALL,False,"Innovation Pharmaceuticals, Inc.",INDUSTRY,0,12,Russia|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.795790545596741,medium,0,1,1,0,0,0,1,1,1,0,1,1,1,1,14,1,1,0,0,3,1,,,,,0,3,1
NCT03867110,"An Efficacy and Safety Study of Ezetimibe (MK-0653, SCH 58235) in Addition to Atorvastatin Compared to Placebo in Participants With Primary Hypercholesterolemia (MK-0653-013)","A Phase 3, Double-Blind Efficacy and Safety Study of Ezetimibe (SCH 58235) 10 mg in Addition to Atorvastatin Compared to Placebo in Subjects With Primary Hypercholesterolemia (Protocol P00692)",COMPLETED,2000-03-06,2001-07-27,2024-05-10,INTERVENTIONAL,PHASE3,628.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Hypercholesterolemia,Placebo|Ezetimibe 10 mg|Atorvastatin 10 mg|Atorvastatin 20 mg|Atorvastatin 40 mg|Atorvastatin 80 mg,DRUG,1,13,18 Years,,ALL,False,Organon and Co,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.444131256700441,xlarge,0,1,1,0,0,0,0,0,0,0,1,1,1,1,14,1,1,0,0,6,1,,,,,0,2,0
NCT00190710,A Trial of Carboplatin and Gemcitabine Versus Gemcitabine Alone in Patients With Non-Small-Cell Lung Cancer,A Randomized Phase III Trial of Paraplatin (Carboplatin) + Gemzar Versus Gemzar Alone in Patients With Advanced Non-Small Cell Lung Cancer,COMPLETED,2004-03,2007-08,2007-11-14,INTERVENTIONAL,PHASE3,242.0,,RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Non-Small Cell Lung Cancer,Gemcitabine|Carboplatin,DRUG,1,4,18 Years,,ALL,False,Eli Lilly and Company,INDUSTRY,0,1,United States,1.0,0,0,1,0,0,3.0,1,0,0,0,1,5.493061443340548,large,0,0,1,0,1,0,0,0,1,0,1,0,1,0,5,1,1,0,0,2,1,2004-03-01,2007-08-01,1248.0,2004.0,0,1,0
NCT03464097,A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease",TERMINATED,2018-06-27,2024-10-03,2025-10-09,INTERVENTIONAL,PHASE3,550.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Crohn Disease,Ozanimod|Placebo,DRUG|OTHER,2,15,18 Years,75 Years,ALL,False,Celgene,INDUSTRY,0,765,China|Bulgaria|Latvia|Germany|Moldova|Serbia|Switzerland|Belarus|Georgia|Taiwan|Greece|Italy|Netherlands|Finland|South Korea|Spain|Saudi Arabia|Chile|Czechia|Portugal|Ireland|Canada|Russia|Argentina|Sweden|Turkey (Türkiye)|India|United States|Austria|Australia|Romania|United Kingdom|Lithuania|Poland|Mexico|Denmark|Slovenia|Israel|Ukraine|South Africa|France|Belgium|Hungary|Bosnia and Herzegovina|Croatia|Slovakia|Hong Kong|Senegal|Colombia,0.0,0,0,1,0,0,3.0,0,1,0,0,1,6.311734809152915,xlarge,0,1,1,0,0,0,1,1,1,1,1,1,1,1,17,1,1,0,0,2,1,,,,,0,3,1
NCT05541510,Evaluating the Safety and Efficacy of AD17002 Intranasal Spray in Treating Participants With Mild to Moderate COVID-19,"A Phase 2/3, Double-blind, Randomized, Placebo-controlled, 3-arm Study to Evaluate the Safety, and Efficacy of AD17002 (LTh[αK]) Intranasal Spray in Male and Female Participants Aged 18 to 65 Years With Mild to Moderate COVID 19",TERMINATED,2022-12-01,2024-08-25,2025-09-10,INTERVENTIONAL,PHASE2|PHASE3,180.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,COVID-19,AD17002 + Formulation buffer|Placebo,BIOLOGICAL,2,17,18 Years,65 Years,ALL,False,Advagene Biopharma Co. Ltd.,INDUSTRY,1,3,Indonesia,0.0,0,1,1,0,1,2.5,0,0,0,0,1,5.198497031265826,medium,0,1,1,0,0,1,1,0,0,0,1,1,1,1,19,1,0,1,0,2,1,,,,,0,3,1
NCT02040090,Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects,"A Prospective, Randomized, Double-Blind, Non Inferiority, Phase II/III Study of the Safety and Efficacy of Simulated Post-Exposure Prophylaxis With Kamada Human Rabies Immune Globulin (KamRAB) and Active Rabies Vaccine in Healthy Subjects",COMPLETED,2013-04,2014-08,2021-09-29,INTERVENTIONAL,PHASE2|PHASE3,118.0,ACTUAL,RANDOMIZED,PARALLEL,HEALTH_SERVICES_RESEARCH,DOUBLE,Rabies,Active rabies vaccine (US-FDA approved),DRUG,1,0,18 Years,75 Years,ALL,True,"Kamada, Ltd.",INDUSTRY,0,1,United States,1.0,0,1,1,0,1,2.5,0,0,0,0,1,4.77912349311153,medium,0,1,1,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,1,0,2013-04-01,2014-08-01,487.0,2013.0,0,1,0
NCT01895790,Endoscopic Pancreatic Duct Stenting for Relief of Obstructive Pain in Patients With Pancreatic Cancer,Endoscopic Pancreatic Duct Stenting for Relief of Obstructive Pain in Patients: A Prospective Pilot Study,WITHDRAWN,2014-07,2016-05,2017-03-06,INTERVENTIONAL,PHASE1|PHASE2,0.0,ACTUAL,,SINGLE_GROUP,SUPPORTIVE_CARE,NONE,Pancreatic Cancer,Pancreatic Duct Stent Placement,DEVICE,2,10,18 Years,80 Years,ALL,False,Johns Hopkins University,OTHER,0,1,United States,0.0,1,1,0,0,1,1.5,1,0,0,0,1,0.0,,1,1,0,1,0,0,0,0,1,0,0,0,0,0,12,1,0,0,1,1,0,2014-07-01,2016-05-01,670.0,2014.0,0,2,0
NCT01757990,The Effect of Stevia Rebaudiana Extracts on Different Variables Related to Caries: an in Vitro and in Vivo Evaluation.,A Comparative Clinical Evaluation of the Effect of Stevia Rebaudiana Extracts and Sucrose on Dental Plaque pH (Stephan Curve Trend) Using a Microtouch Electrode in Healthy Volunteers. A Phase II Study.,COMPLETED,2012-03,2012-06,2013-01-15,INTERVENTIONAL,PHASE2,20.0,ACTUAL,RANDOMIZED,CROSSOVER,PREVENTION,TRIPLE,Dental Caries,Effect of Stevioside and Rebaudioside on plaque pH,DIETARY_SUPPLEMENT,1,0,20 Years,55 Years,ALL,True,Università degli Studi di Sassari,OTHER,1,0,,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.044522437723423,small,1,1,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,2012-03-01,2012-06-01,92.0,2012.0,0,0,0
NCT02365597,An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer,"A Phase 2, Two-arm Multicenter, Open-Label Study to Determine the Efficacy and the Safety of Two Different Dose Regimens of a Pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Subjects With Metastatic or Surgically Unresectable Urothelial Cancer With FGFR Genomic Alterations",ACTIVE_NOT_RECRUITING,2015-04-22,2027-03-31,2026-01-30,INTERVENTIONAL,PHASE2,239.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Urothelial Cancer,Erdafitinib|Midazolam|Metformin,DRUG,13,6,18 Years,,ALL,False,"Janssen Research & Development, LLC",INDUSTRY,0,105,Belgium|Russia|Taiwan|Turkey (Türkiye)|India|South Korea|United States|Germany|Austria|Romania|Spain|United Kingdom|Moldova|Israel|France,,0,1,0,0,0,2.0,1,0,0,0,1,5.480638923341991,large,0,1,1,0,0,0,1,1,1,1,0,0,1,0,19,1,1,0,0,3,1,,,,,0,3,1
NCT01458197,A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder.,"A Prospective, Multi-center, Placebo-controlled, Randomized, Double-blind, Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo Administered as Oral Daily Dose for Three Months in Patients Suffering From Overactive Bladder.",COMPLETED,2011-09,2012-11,2014-03-12,INTERVENTIONAL,PHASE2,235.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Overactive Bladder,Tarafenacin 0.2 mg|Placebo|Tarafenacin 0.4 mg,DRUG,1,5,20 Years,80 Years,ALL,False,"Kwang Dong Pharmaceutical co., ltd.",INDUSTRY,0,1,South Korea,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.4638318050256105,large,0,1,1,0,0,0,0,0,0,0,1,1,1,1,6,1,1,0,0,3,1,2011-09-01,2012-11-01,427.0,2011.0,0,2,0
NCT00193297,Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma,A Phase II Study of a Three-Day Schedule of Topotecan Plus Paclitaxel and Carboplatin on Day Three in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma,COMPLETED,2002-02,2006-06,2011-05-03,INTERVENTIONAL,PHASE2,50.0,,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Ovary Cancer,Topotecan|Paclitaxel|Carboplatin,DRUG,1,1,18 Years,,FEMALE,False,"SCRI Development Innovations, LLC",OTHER,1,0,,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.9318256327243257,small,1,0,0,1,0,1,0,0,0,0,0,0,1,0,2,1,1,0,0,3,1,2002-02-01,2006-06-01,1581.0,2002.0,0,1,0
NCT00805597,Clinical Trial of Postmastectomy Radiotherapy in Breast Cancer With One to Three Positive Nodes,A Phase Ⅲ Randomized Clinical Trial of Postmastectomy Radiotherapy in Breast Cancer With One to Three Positive Nodes,TERMINATED,2008-06,2012-02,2016-08-08,INTERVENTIONAL,PHASE3,40.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Breast Cancer,radiation|no radiation,RADIATION,1,1,18 Years,75 Years,FEMALE,False,Chinese Academy of Medical Sciences,OTHER,0,1,China,0.0,0,0,1,0,0,3.0,1,0,0,0,1,3.713572066704308,small,1,1,0,1,0,0,0,0,0,0,1,0,1,1,2,1,0,0,0,2,1,2008-06-01,2012-02-01,1340.0,2008.0,0,1,0
NCT00003118,Surgery With or Without Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus,"A Prospective Randomized Phase III Trial Comparing Trimodality Therapy (Cisplatin, 5-FU, Radiotherapy, and Surgery) to Surgery Alone for Esophageal Cancer",COMPLETED,1997-10,2000-03,2016-07-04,INTERVENTIONAL,PHASE3,56.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Esophageal Cancer,cisplatin|fluorouracil|surgical procedure|radiation therapy,DRUG|RADIATION|PROCEDURE,1,0,18 Years,,ALL,False,Alliance for Clinical Trials in Oncology,OTHER,1,38,United States,1.0,0,0,1,0,0,3.0,1,0,0,0,1,4.04305126783455,medium,1,1,0,1,0,1,1,0,1,0,1,0,1,1,1,0,1,0,0,4,1,1997-10-01,2000-03-01,882.0,1997.0,0,1,0
NCT02264990,Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers,"A Randomized, Open-Label, Multicenter, Phase 3 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers",COMPLETED,2014-09-30,2020-02-21,2021-02-26,INTERVENTIONAL,PHASE3,595.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Non-squamous Non-small Cell Lung Cancer,Paclitaxel|Carboplatin|Cisplatin|Veliparib|Pemetrexed,DRUG,1,5,18 Years,,ALL,False,AbbVie,INDUSTRY,0,140,Germany|Japan|Taiwan|Netherlands|Finland|South Korea|Spain|Czechia|Canada|Russia|Argentina|Turkey (Türkiye)|United States|United Kingdom|Australia|New Zealand|Denmark|Israel|South Africa|Hungary,1.0,0,0,1,0,0,3.0,1,0,0,0,1,6.39024066706535,xlarge,0,1,1,0,1,0,1,1,1,1,1,0,1,1,6,1,1,0,0,5,1,,,,,0,3,1
NCT01134497,Carboplatin With or Without ZD4054 in Patients With Metastatic Breast Cancer,A Randomised Phase II Study of Carboplatin With or Without the Addition of the ETAR Inhibitor ZD4054 as Treatment for Patients With Metastatic Breast Cancer,WITHDRAWN,,2011-08-16,2018-05-22,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Metastatic Breast Cancer,Placebo|ZD4054,DRUG,1,3,18 Years,,ALL,False,Cardiff University,OTHER,0,1,United Kingdom,0.0,0,1,0,0,0,2.0,1,0,0,0,1,0.0,,1,1,0,1,0,0,0,0,0,1,1,1,1,1,4,1,1,0,0,2,1,,,,,0,1,0
NCT02600897,"A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination With Polatuzumab Vedotin and Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma,COMPLETED,2016-03-24,2021-12-15,2023-12-26,INTERVENTIONAL,PHASE1|PHASE2,114.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma",Lenalidomide|Obinutuzumab|Polatuzumab Vedotin|Rituximab,DRUG,3,17,18 Years,,ALL,False,Hoffmann-La Roche,INDUSTRY,0,28,United Kingdom|Spain|United States,1.0,1,1,0,0,1,1.5,1,0,0,0,1,4.74493212836325,medium,0,1,1,0,1,0,1,1,1,1,0,0,1,1,20,1,1,0,0,4,1,,,,,0,4,1
NCT00866697,"Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have Not Progressed After First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",COMPLETED,2009-05-26,2017-08-24,2021-02-16,INTERVENTIONAL,PHASE3,940.0,ACTUAL,RANDOMIZED,,TREATMENT,DOUBLE,Ovarian Cancer,Pazopanib|Placebo,DRUG,1,18,18 Years,,FEMALE,False,Novartis Pharmaceuticals,INDUSTRY,1,318,China|Belgium|Italy|Sweden|South Korea|United States|Germany|Austria|Australia|Spain|Hong Kong|Norway|Japan|Denmark|Taiwan|France|Ireland,1.0,0,0,1,0,0,3.0,1,0,0,0,1,6.846943139585379,xlarge,0,1,1,0,1,1,1,1,1,1,1,1,1,0,19,1,1,0,0,2,1,,,,,0,3,1
NCT04571710,A Trial of SHR1258 in Patients With Biliary Tract Cancer,A Phase 2 Study of Pyrotinib in Patients With Advanced/ Metastatic HER2-Altered Biliary Tract Cancers Who Have Failed One or Two Prior Lines of Therapies,WITHDRAWN,2020-11-01,2025-06-05,2025-07-24,INTERVENTIONAL,PHASE2,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Biliary Tract Cancer,SHR1258,DRUG,1,6,18 Years,,ALL,False,"Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,0,0,,0.0,0,1,0,0,0,2.0,1,0,0,0,1,0.0,,1,1,1,0,0,0,0,0,0,0,0,0,1,0,7,1,1,0,0,1,0,,,,,0,1,0
NCT05008510,P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC .,Phase 2 Clinical Efficacy and Safety Study of Sabizabulin (VERU-111) Monotherapy and Sacituzumab Govitecan-hziy/Sabizabulin Combination Therapy for the Treatment of Metastatic Triple Negative Breast Cancer,WITHDRAWN,2021-12-30,2023-06-30,2022-02-08,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Metastatic Triple Negative Breast Cancer,Sabizabulin|Sacituzumab Govitecan-hziy|Sabizabulin/Sacituzumab govitecan-hziy Combo,DRUG,2,1,18 Years,100 Years,ALL,False,Veru Inc.,INDUSTRY,0,0,,0.0,0,1,0,0,0,2.0,1,0,0,0,1,0.0,,1,1,1,0,0,0,0,0,0,0,1,0,1,1,3,1,1,0,0,3,1,,,,,0,1,0
NCT06247410,Clinical Trial to Investigate Patch Adhesion of Rotigotine Containing Patches in Patients With Parkinson's Disease,"Comparative, Randomized, Open, Crossover Clinical Trial to Investigate Adhesiveness of a Newly Developed Rotigotine-containing Transdermal Patch in Patients With Parkinson's Disease",COMPLETED,2021-08-23,2021-10-30,2024-05-01,INTERVENTIONAL,PHASE2,38.0,ACTUAL,RANDOMIZED,CROSSOVER,OTHER,NONE,Parkinson Disease,Rotigotine 8Mg/24Hrs Patch,DRUG,2,2,18 Years,,ALL,False,SocraTec R&D GmbH,OTHER,2,8,Germany,1.0,0,1,0,0,0,2.0,0,0,1,0,1,3.6635616461296463,small,1,1,0,1,0,1,1,0,0,1,1,0,0,0,4,1,1,0,0,1,0,,,,,0,0,0
NCT02993510,A Randomized Controlled Trial Comparing Chondro-Gide® to Microfracture Alone for Treatment of Knee Cartilage Defects.,Randomised Multi-Center Study: Microfracturing With Chondro-Gide® for the Treatment of Isolated Cartilage Defects in the Knee Project-Nr.: 10830-003,COMPLETED,2003-12,2016-07,2017-02-23,INTERVENTIONAL,PHASE3,67.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Cartilage Injury|Osteochondritis Dissecans,Microfracture|Chondro-Gide sutured|Chondro-Gide glued,DEVICE|PROCEDURE,2,4,18 Years,50 Years,ALL,True,Geistlich Pharma AG,INDUSTRY,0,7,Germany,1.0,0,0,1,0,0,3.0,0,0,0,0,2,4.219507705176107,medium,1,1,1,0,0,0,1,0,0,1,1,0,1,1,6,1,0,0,1,3,1,2003-12-01,2016-07-01,4596.0,2003.0,0,3,1
NCT05011513,Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).,"AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2/3, DOUBLE-BLIND, 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332/RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID-19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS",TERMINATED,2021-08-25,2022-07-25,2023-08-14,INTERVENTIONAL,PHASE2|PHASE3,1440.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,COVID-19,PF-07321332|Ritonavir|Placebo|Placebo,DRUG,1,13,18 Years,,ALL,False,Pfizer,INDUSTRY,0,225,Bulgaria|Japan|Thailand|South Korea|Spain|Czechia|Argentina|Turkey (Türkiye)|Puerto Rico|United States|Romania|Poland|Mexico|Ukraine|South Africa|Hungary|Brazil|Slovakia|Malaysia|Colombia,0.0,0,1,1,0,1,2.5,0,0,0,0,1,7.273092595999522,xlarge,0,1,1,0,1,0,1,1,1,1,1,1,1,1,14,1,1,0,0,4,1,,,,,0,4,1
NCT04126213,"Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants","A Phase II, Randomised, Observer-blind, Placebo Controlled Multi-country Study to Assess the Safety, Reactogenicity and Immunogenicity of a Single Intramuscular Dose of GSK Biologicals' Investigational RSV Maternal Unadjuvanted Vaccine (GSK3888550A), in Healthy Pregnant Women Aged 18 to 40 Years and Infants Born to Vaccinated Mothers",COMPLETED,2019-11-05,2021-05-14,2021-12-13,INTERVENTIONAL,PHASE2,534.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Respiratory Syncytial Virus Infections,RSV MAT 60 µg|RSV MAT 120 µg|Placebo,DRUG|BIOLOGICAL,19,27,18 Years,40 Years,FEMALE,True,GlaxoSmithKline,INDUSTRY,0,32,Finland|United States|Spain|Australia|Panama|New Zealand|South Africa|France|Canada,1.0,0,1,0,0,0,2.0,0,0,0,0,1,6.282266746896006,xlarge,0,1,1,0,0,0,1,1,1,1,1,1,0,1,46,1,1,1,0,3,1,,,,,0,3,1
NCT00226460,"Phase 2, Double-blind, Randomized, Controlled Multi-center Clinical Trial of the Safety and Efficacy of Transplanted Fetal Porcine Cells in Patients With Parkinson's Disease.",,COMPLETED,1997-08,2001-01,2015-03-18,INTERVENTIONAL,PHASE2,,,RANDOMIZED,SINGLE_GROUP,TREATMENT,DOUBLE,Parkinson's Disease,"Fetal porcine cells, Neurocell-PD",DRUG,1,1,40 Years,70 Years,ALL,False,"Genzyme, a Sanofi Company",INDUSTRY,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,1,0,1,0.0,,0,0,1,0,1,1,0,0,1,0,1,1,1,0,2,1,1,0,0,1,0,1997-08-01,2001-01-01,1249.0,1997.0,0,0,0
NCT02329860,Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP),"A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study (AHELP) of Apatinib in Patients With Hepatocellular Carcinoma After Systemic Therapy（Chemotherapy and/or Targeted Therapy）",COMPLETED,2014-03-26,2019-08-14,2024-01-22,INTERVENTIONAL,PHASE3,400.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,"Carcinoma, Hepatocellular",Apatinib|Placebo,DRUG,1,4,18 Years,,ALL,False,"Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,1,1,China,1.0,0,0,1,0,0,3.0,1,0,0,0,1,5.993961427306569,large,0,1,1,0,0,1,0,0,0,0,1,1,1,1,5,1,1,0,0,2,1,,,,,0,1,0
NCT00002920,"S9630, Medroxyprogesterone in Treating Women With Breast Cancer","A Randomized Comparison Of Medroxyprogesterone Acetate (MA) And Observation For Prevention Of Endometrial Pathology In Postmenopausal Breast Cancer Patients Treated With Tamoxifen, Phase III",COMPLETED,1997-03,2009-12,2012-10-31,INTERVENTIONAL,PHASE3,313.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Breast Cancer|Endometrial Cancer,medroxyprogesterone|tamoxifen citrate|adjuvant therapy,DRUG|PROCEDURE,1,1,18 Years,,FEMALE,False,SWOG Cancer Research Network,NETWORK,2,122,United States,1.0,0,0,1,0,0,3.0,1,0,0,0,2,5.749392985908253,large,0,1,0,0,0,1,1,0,1,0,1,0,0,1,2,1,1,0,0,3,1,1997-03-01,2009-12-01,4658.0,1997.0,0,2,0
NCT01830920,A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI),"A Multi-Center, Parallel-Group, Randomized, Double Blind, Adaptive Study Investigating the Safety and Efficacy of THR-184 in Patients at Increased Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)",COMPLETED,2013-05,2015-09,2017-04-20,INTERVENTIONAL,PHASE2,452.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Acute Kidney Injury,THR-184|Placebo,DRUG,1,3,18 Years,85 Years,ALL,False,"Thrasos Innovation, Inc.",INDUSTRY,0,41,Canada|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,6.115892125483034,large,0,1,1,0,0,0,1,1,1,0,1,1,1,1,4,1,1,0,0,2,1,2013-05-01,2015-09-01,853.0,2013.0,0,2,0
NCT01013324,Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma,A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma,COMPLETED,2010-01,2013-03,2016-06-03,INTERVENTIONAL,PHASE2,67.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Endometrial Cancer|Endometrial Neoplasms,XL147 (SAR245408),DRUG,2,2,18 Years,,FEMALE,False,Sanofi,INDUSTRY,0,13,Belgium|United States,1.0,0,1,0,0,0,2.0,1,0,0,0,2,4.219507705176107,medium,1,1,1,0,1,0,1,1,1,0,0,0,1,0,4,1,1,0,0,1,0,2010-01-01,2013-03-01,1155.0,2010.0,0,2,0
NCT01955824,A Trial on Clinical Efficacy of 1% Versus 2% Lignocaine in Cough Suppression and Pain Relief in Patients Undergoing Flexible Bronchoscopy,"""A RCT ON CLINICAL EFFICACY OF 1% vs. 2% LIGNOCAINE IN COUGH SUPPRESSION AND PAIN RELIEF IN PATIENTS UNDERGOING FLEXIBLE BRONCHOSCOPY""",COMPLETED,2014-05,2014-11,2014-12-30,INTERVENTIONAL,PHASE2|PHASE3,500.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Lung Cancer|Tuberculosis|Sarcoidosis|Interstitial Lung Disease,1% lignocaine|2% lignocaine,DRUG,2,0,12 Years,80 Years,ALL,False,"Post Graduate Institute of Medical Education and Research, Chandigarh",OTHER,0,1,India,1.0,0,1,1,0,1,2.5,1,0,0,0,4,6.2166061010848646,large,0,1,0,1,0,0,0,0,0,0,1,0,1,1,2,0,1,0,0,2,1,2014-05-01,2014-11-01,184.0,2014.0,0,3,1
NCT00052910,Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer,Phase III Intergroup Trial of Adjuvant Chemoradiation After Resection of Gastric or Gastroesophageal Adenocarcinoma,COMPLETED,2002-12,2016-12,2020-05-07,INTERVENTIONAL,PHASE3,546.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Esophageal Cancer|Gastric Cancer,cisplatin|epirubicin hydrochloride|fluorouracil|leucovorin calcium|radiation therapy,DRUG|RADIATION,1,1,18 Years,,ALL,False,Alliance for Clinical Trials in Oncology,OTHER,1,535,Canada|United States,1.0,0,0,1,0,0,3.0,1,0,0,0,2,6.304448802421981,xlarge,0,1,0,1,0,1,1,1,1,0,1,0,1,1,2,1,1,0,0,5,1,2002-12-01,2016-12-01,5114.0,2002.0,0,3,1
NCT02401113,Effect of Ursolic Acid of Loquat Extract on Function of Muscle,Effect of Ursolic Acid of Loquat Extract on Function of Muscle in Human,COMPLETED,2014-11,2015-10,2015-11-03,INTERVENTIONAL,PHASE2|PHASE3,54.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Sarcopenia,UA group,DIETARY_SUPPLEMENT,1,2,19 Years,65 Years,ALL,True,Pusan National University Hospital,OTHER,0,0,,1.0,0,1,1,0,1,2.5,0,0,0,0,1,4.007333185232471,medium,1,1,0,1,0,0,0,0,0,0,1,1,0,1,3,1,0,0,0,1,0,2014-11-01,2015-10-01,334.0,2014.0,0,1,0
NCT05007613,Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma,A Single-arm Phase II Study of Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma Who Failed a Platinum-based Chemotherapy,COMPLETED,2021-06-23,2024-12-01,2025-01-01,INTERVENTIONAL,PHASE2,24.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Esophageal Cancer|Metastatic Cancer|Squamous Cell Carcinoma,Cabozantinib 40 MG|Atezolizumab Injection,DRUG,1,3,20 Years,,ALL,False,National Taiwan University Hospital,OTHER,2,1,Taiwan,1.0,0,1,0,0,0,2.0,1,0,0,0,3,3.2188758248682006,small,1,1,0,1,0,1,0,0,0,0,0,0,1,0,4,1,1,0,0,2,1,,,,,0,2,0
NCT04071613,Tenecteplase Versus Alteplase for Stroke Thrombolysis Evaluation Trial in the Ambulance,Tenecteplase Versus Alteplase for Stroke Thrombolysis Evaluation Trial in the Ambulance,COMPLETED,2019-06-20,2021-11-16,2021-12-08,INTERVENTIONAL,PHASE2,104.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,"Stroke, Acute, Stroke Ischemic",Tenecteplase|Intravenous tissue plasminogen activator (tPA),DRUG,1,12,18 Years,,ALL,False,Melbourne Health,OTHER,0,5,Australia,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.653960350157523,medium,0,1,0,1,0,0,1,0,0,0,1,0,1,1,13,1,1,0,0,2,1,,,,,0,2,0
NCT02264613,ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas,A Phase 1/2a Open-Label Study to Determine the Safety and Tolerability of ALRN-6924 Alone or in Combination in Patients With Advanced Solid Tumors or Lymphomas Expressing Wild-Type p53 Protein,COMPLETED,2014-10,2020-04,2026-01-13,INTERVENTIONAL,PHASE1|PHASE2,142.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Solid Tumor|Lymphoma|Peripheral T-Cell Lymphoma,ALRN-6924,DRUG,4,2,18 Years,,ALL,False,"Aileron Therapeutics, Inc.",INDUSTRY,0,13,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,3,4.962844630259907,medium,0,1,1,0,0,0,1,0,1,0,0,0,1,0,6,1,1,0,0,1,0,2014-10-01,2020-04-01,2009.0,2014.0,0,3,1
NCT01439360,An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children,An Efficacy Study of GSK Biologicals' Quadrivalent Influenza Vaccine GSK2321138A (FLU D-QIV) When Administered in Children,COMPLETED,2011-10-01,2014-12-31,2018-09-26,INTERVENTIONAL,PHASE3,12046.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Influenza,Quadrivalent seasonal influenza vaccine(Flu D-QIV) GSK2321138A|Havrix Junior|Prevenar 13|Varivax/ProVarivax|Varilrix,BIOLOGICAL,2,20,6 Months,35 Months,ALL,True,GlaxoSmithKline,INDUSTRY,0,103,Belgium|Turkey (Türkiye)|India|Spain|Lebanon|Dominican Republic|United Kingdom|Honduras|Poland|Czechia|Bangladesh|Philippines|Thailand,1.0,0,0,1,0,0,3.0,0,0,0,0,1,9.396570945266852,,0,1,1,0,0,0,1,1,0,1,1,1,0,1,22,1,0,1,0,5,1,,,,,0,3,1
NCT01015560,"S0916, MLN1202 in Treating Patients With Bone Metastases","S0916, A Phase II, Window Trial of the Anti-CCR2 Antibody MLN1202 in Patients With Bone Metastases",COMPLETED,2010-03,2012-12,2018-08-09,INTERVENTIONAL,PHASE2,44.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Metastatic Cancer|Unspecified Adult Solid Tumor, Protocol Specific",anti-CCR2 monoclonal antibody MLN1202|polymorphism analysis|laboratory biomarker analysis,DRUG|OTHER|GENETIC,1,0,18 Years,120 Years,ALL,False,SWOG Cancer Research Network,NETWORK,1,47,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,2,3.8066624897703196,small,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,0,1,0,0,3,1,2010-03-01,2012-12-01,1006.0,2010.0,0,2,0
NCT02648360,Text Messaging for Physical Activity & Healthy Eating,Evaluation of a Text Messaging Program for Physical Activity and Healthy Eating for Underserved Hispanic Patients,COMPLETED,2016-01,2016-08,2016-12-28,INTERVENTIONAL,PHASE3,12.0,ACTUAL,,SINGLE_GROUP,SUPPORTIVE_CARE,NONE,Overweight,Text Messaging,BEHAVIORAL,2,0,18 Years,,ALL,True,University of Miami,OTHER,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,2.5649493574615367,small,1,1,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,1,0,2016-01-01,2016-08-01,213.0,2016.0,1,0,0
NCT00549913,Study of 3 Doses of NeoFuse Combined With MasterGraft Granules in Subjects Requiring Posterolateral Lumbar Fusion (PLF),A Dose-escalation Study to Assess the Feasibility and Safety of 3 Different Doses of NeoFuse When Combined With MasterGraft Granules in Subjects Requiring Posterolateral Lumbar Fusion With Instrumentation.,COMPLETED,2007-10,2013-09,2020-06-29,INTERVENTIONAL,PHASE1|PHASE2,6.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Degenerative Disc Disease|Spondylolisthesis|Spinal Stenosis,NeoFuse|posterolateral spinal fusion with instrumentation,BIOLOGICAL|PROCEDURE,1,3,18 Years,,ALL,False,"Mesoblast, Ltd.",INDUSTRY,0,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,3,1.9459101490553132,small,1,1,1,0,0,0,0,0,1,0,1,0,1,1,4,1,0,1,0,2,1,2007-10-01,2013-09-01,2162.0,2007.0,0,3,1
NCT01412424,Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly,Efficacy and Safety of Oral Octreolin™ in Patients With Acromegaly Who Are Currently Receiving Parenteral Somatostatin Analogs,COMPLETED,2012-03,2014-05,2017-08-17,INTERVENTIONAL,PHASE3,155.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Acromegaly,Octreotide capsules,DRUG,2,6,18 Years,75 Years,ALL,False,"Chiasma, Inc.",INDUSTRY,0,36,Italy|Netherlands|Hungary|United States|Germany|Slovakia|Romania|United Kingdom|Lithuania|Poland|Serbia|Mexico|Slovenia,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.049856007249537,medium,0,1,1,0,0,0,1,1,1,1,0,0,1,0,8,1,1,0,0,1,0,2012-03-01,2014-05-01,791.0,2012.0,0,2,0
NCT03896724,"Safety, Immunogenicity and Efficacy of R21 Matrix-M in 5-17 Month Old Children in Nanoro, Burkina Faso","A Phase Ib/IIb Randomised Controlled Trial of the Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine, R21 Adjuvanted With Matrix-M (R21/MM), in 5-17 Month Old Children in Nanoro, Burkina Faso",COMPLETED,2019-05-07,2023-07-07,2025-07-11,INTERVENTIONAL,PHASE1|PHASE2,450.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Malaria,Falciparum",R21 adjuvanted with 25mcg Matrix-M|Rabies Vaccine|R21 adjuvanted with 50mcg Matrix-M,BIOLOGICAL,1,4,5 Months,17 Months,ALL,True,University of Oxford,OTHER,2,1,Burkina Faso,1.0,1,1,0,0,1,1.5,0,0,0,0,1,6.111467339502679,large,0,1,0,1,0,1,0,0,0,0,1,1,1,1,5,1,0,1,0,3,1,,,,,0,2,0
NCT02595424,Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas,Randomized Phase II Study of Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas,ACTIVE_NOT_RECRUITING,2016-04-06,2029-01-01,2025-12-29,INTERVENTIONAL,PHASE2,67.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Gastric Neuroendocrine Carcinoma|Intestinal Neuroendocrine Carcinoma|Pancreatic Neuroendocrine Carcinoma,Capecitabine|Carboplatin|Cisplatin|Etoposide|Laboratory Biomarker Analysis|Temozolomide,DRUG|OTHER,1,3,18 Years,,ALL,False,ECOG-ACRIN Cancer Research Group,NETWORK,1,673,United States,,0,1,0,0,0,2.0,1,0,0,0,3,4.219507705176107,medium,1,1,0,0,0,1,1,0,1,0,1,0,1,1,4,1,1,0,0,6,1,,,,,0,2,0
NCT00300924,A Study of Rizatriptan Co-Administered With Acetaminophen for the Treatment of Acute Migraine,"A Double-Blind, Double-Dummy, Randomized, Parallel-Group, Placebo Controlled Study to Evaluate the Efficacy and Tolerability of Rizatriptan 10mg Co-Administered With Acetaminophen for the Treatment of Acute Migraine.",COMPLETED,2006-03,2007-01,2008-05-28,INTERVENTIONAL,PHASE3,200.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Migraine,Rizatriptan co-administered with Acetaminophen,DRUG,1,8,18 Years,,ALL,False,Diamond Headache Clinic,OTHER,1,7,United States,1.0,0,0,1,0,0,3.0,0,0,1,0,1,5.303304908059076,medium,0,0,0,1,0,1,1,0,1,0,1,1,1,1,9,1,1,0,0,1,0,2006-03-01,2007-01-01,306.0,2006.0,0,1,0
NCT02272413,Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer,"A Multicenter, Randomized, Double-blind Phase III Trial to Evaluate Efficacy and Safety of BI 695502 Plus Chemotherapy Versus Avastin® Plus Chemotherapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer",COMPLETED,2015-07-08,2018-11-16,2020-01-13,INTERVENTIONAL,PHASE3,671.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Carcinoma, Non-Small-Cell Lung",BI 695502|Avastin,DRUG,1,4,18 Years,,ALL,False,Boehringer Ingelheim,INDUSTRY,0,189,Bulgaria|Germany|Japan|Serbia|Vietnam|Greece|Thailand|Italy|South Korea|Spain|Chile|Portugal|Russia|Argentina|Turkey (Türkiye)|United States|United Kingdom|Romania|Poland|Mexico|Philippines|South Africa|Ukraine|Hungary|Croatia|Brazil|Malaysia|Egypt,1.0,0,0,1,0,0,3.0,1,0,0,0,1,6.51025834052315,xlarge,0,1,1,0,0,0,1,1,1,1,1,1,1,1,5,1,1,0,0,2,1,,,,,0,2,0
NCT02460913,Acupuncture Versus Intravenous Morphine in the Management of Acute Pain in the Emergency Department,Acupuncture Versus Intravenous Morphine in the Management of Acute Pain in the Emergency Department. An Efficacy and Safety Study,COMPLETED,2012-04,2013-03,2020-02-21,INTERVENTIONAL,PHASE2,300.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Acute Pain,Acupuncture|Morphine titration,DRUG|PROCEDURE,1,2,18 Years,,ALL,False,University of Monastir,OTHER,0,0,,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.707110264748875,large,0,1,0,1,0,0,0,0,0,0,1,0,1,1,3,1,1,0,0,2,1,2012-04-01,2013-03-01,334.0,2012.0,0,1,0
NCT04547660,Convalescent Plasma for Severe COVID-19 Patients,"Convalescent Plasma for Severe COVID-19 Patients: a Randomized, Open-label, Phase 3 Trial",COMPLETED,2020-07-16,2021-01-07,2021-02-09,INTERVENTIONAL,PHASE3,160.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Covid19,Convalescent Plasma|Best Supportive Care,BIOLOGICAL|OTHER,1,21,18 Years,,ALL,False,Hospital de Clinicas de Porto Alegre,OTHER,2,1,Brazil,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.081404364984463,medium,0,1,0,1,0,1,0,0,0,0,1,0,1,1,22,1,0,1,0,2,1,,,,,0,2,0
NCT03341260,Effect of Preoperative Diclofenac Potassium on Postoperative Endodontic Pain,"Effect of Preoperative, Single-dose Diclofenac Potassium on Postoperative Endodontic Pain in Patients With Symptomatic Irreversible Pulpitis: A Double Blind Randomized Controlled Trial",COMPLETED,2016-12,2018-04,2018-04-09,INTERVENTIONAL,PHASE2|PHASE3,70.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Pulpitis - Irreversible,Diclofenac Potassium 50mg Tab.|Placebo,DRUG,1,1,18 Years,60 Years,ALL,False,Cairo University,OTHER,0,1,Egypt,1.0,0,1,1,0,1,2.5,0,0,0,0,1,4.2626798770413155,medium,1,1,0,1,0,0,0,0,0,0,1,1,0,1,2,1,1,0,0,2,1,2016-12-01,2018-04-01,486.0,2016.0,1,2,0
NCT01842360,Evaluation of the Efficacy and Safety of MV130 in Chronic Obstructive Pulmonary Disease (COPD),"Randomized Double-blind Placebo-controlled Multicenter Clinical Trial of Bacterial Polyvalent Vaccine (BACTEK®), Administered Sublingually in COPD Patients, to Evaluate Efficacy, Safety, and Immunomodulatory Response.",COMPLETED,2013-05-06,2023-08-02,2025-10-02,INTERVENTIONAL,PHASE2|PHASE3,198.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Chronic Obstructive Pulmonary Disease (COPD),Placebo|MV130,BIOLOGICAL,1,11,35 Years,85 Years,ALL,False,Inmunotek S.L.,INDUSTRY,0,7,Spain,1.0,0,1,1,0,1,2.5,0,0,0,0,1,5.293304824724492,medium,0,1,1,0,0,0,1,0,0,1,1,1,0,1,12,1,0,1,0,2,1,,,,,0,3,1
NCT00529620,Three Alternative Drug Regimens for Malaria Seasonal Preventive Treatment in Senegal,Randomized Trial of Effectiveness and Acceptability of Three Alternative Regimens for Malaria Seasonal Intermittent Preventive Treatment in Senegal,COMPLETED,2007-09,2007-12,2010-05-27,INTERVENTIONAL,PHASE3,1833.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Malaria,sulfalene-pyrimethamine plus amodiaquine|dihydroartemisinin plus piperaquine|sulfadoxine pyrimethamine plus piperaquine,DRUG,1,5,2 Months,59 Months,ALL,True,London School of Hygiene and Tropical Medicine,OTHER,1,1,Senegal,1.0,0,0,1,0,0,3.0,0,0,0,0,1,7.51425465281641,xlarge,0,1,0,1,0,1,0,0,0,0,1,0,0,1,6,1,1,0,0,3,1,2007-09-01,2007-12-01,91.0,2007.0,0,2,0
NCT04164082,"Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer",Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer,ACTIVE_NOT_RECRUITING,2020-03-18,2026-03-31,2026-02-03,INTERVENTIONAL,PHASE2,161.0,ESTIMATED,,SINGLE_GROUP,TREATMENT,NONE,Bladder Flat Urothelial Carcinoma In Situ|Non-Muscle Invasive Bladder Urothelial Carcinoma|Stage 0a Bladder Cancer AJCC v8|Stage 0is Bladder Cancer AJCC v8|Stage I Bladder Cancer AJCC v8,Biopsy Procedure|Biospecimen Collection|Computed Tomography|Cystoscopy|Gemcitabine Hydrochloride|Magnetic Resonance Imaging|Pembrolizumab|Transurethral Resection of Bladder Tumor,DRUG|BIOLOGICAL|PROCEDURE,2,6,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,391,Guam|Puerto Rico|United States,,0,1,0,0,0,2.0,1,0,0,0,5,5.087596335232384,medium,0,0,0,1,0,0,1,1,1,0,0,0,1,0,8,1,1,1,0,8,1,,,,,0,4,1
NCT00045682,CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer,A Phase II Evaluation of CT-2103 in the Third-Line Treatment of Recurrent or Persistent Epithelial Ovarian or Primary Peritoneal Cancer,COMPLETED,2002-09,,2017-07-13,INTERVENTIONAL,PHASE2,78.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Primary Peritoneal Carcinoma|Recurrent Ovarian Carcinoma,Paclitaxel Poliglumex,DRUG,4,2,18 Years,,FEMALE,False,Gynecologic Oncology Group,NETWORK,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,2,4.3694478524670215,medium,1,1,0,0,0,1,0,0,1,0,0,0,1,0,6,1,1,0,0,1,0,2002-09-01,,,2002.0,0,2,0
NCT04500210,Comparative Study of Turmeric Extract in Patients With Arthrosis.,"A Double-blind, Randomized, Parallel Group, Phase III Comparative Study of Turmeric Extract and Placebo to Patients With Mild to Moderate Arthrosis of the Knee and or Hip.",COMPLETED,2020-01-01,2020-09-07,2021-10-25,INTERVENTIONAL,PHASE3,120.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Arthralgia|Stiffness of Unspecified Joint, Not Elsewhere Classified|Disturbance of Activity and Attention|Quality of Life",Placebo|Turmeric,DIETARY_SUPPLEMENT,6,4,40 Years,100 Years,ALL,True,Kaj Winther Hansen,OTHER,0,1,Denmark,1.0,0,0,1,0,0,3.0,0,0,0,0,4,4.795790545596741,medium,0,1,0,1,0,0,0,0,0,0,1,1,1,1,10,1,0,0,0,2,1,,,,,0,3,1
NCT00294710,A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazide Based Treatment Regimen With Optional Addition of Amlodipine,"A Twenty Six-week, Dose Titration Study to Evaluate the Efficacy and Safety of Aliskiren Compared to HCTZ With the Optional Addition of Amlodipine, Followed by a Second Twenty Six Weeks of Blinded Treatment, in Patients With Essential Hypertension",COMPLETED,2005-03,2006-07,2011-11-08,INTERVENTIONAL,PHASE3,976.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Hypertension,Aliskiren,DRUG,1,3,18 Years,80 Years,ALL,False,Novartis,INDUSTRY,0,2,Germany|United States,1.0,0,0,1,0,0,3.0,0,0,0,1,1,6.884486652042782,xlarge,0,1,1,0,1,0,1,1,1,1,1,1,1,1,4,1,1,0,0,1,0,2005-03-01,2006-07-01,487.0,2005.0,0,1,0
NCT02334813,Daily Prednisone Versus Pulsed Dexamethasone in Treatment-naïve Adult Patients With Immune Thrombocytopenia,A Randomized Trial of Daily Prednisone Versus Pulsed Dexamethasone in Treatment-naïve Adult Patients With Immune Thrombocytopenia,COMPLETED,2002-07,2015-01,2017-06-09,INTERVENTIONAL,PHASE3,26.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Purpura, Thrombocytopenic, Idiopathic",Prednisone|Dexamethasone,DRUG,1,0,18 Years,,ALL,False,"University Hospital, Essen",OTHER,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.295836866004329,small,1,1,0,1,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0,2,1,2002-07-01,2015-01-01,4567.0,2002.0,0,1,0
NCT00913913,"Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients","A Phase II Study of VEGF Blockade With Bevacizumab Combined With Autologous Tumor/Dendritic Cell Vaccine (DC Vaccine), Interleukin-2 (IL-2) and Interferon-α-2b (IFNα-2b) in Patients With Metastatic Renal Cell Carcinoma (RCC)",TERMINATED,2009-02,2013-01,2015-12-01,INTERVENTIONAL,PHASE2,8.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Metastatic Renal Cell Carcinoma,DC vaccine|Bevacizumab|IL-2|IFN,DRUG|BIOLOGICAL,1,1,18 Years,,ALL,False,Dartmouth-Hitchcock Medical Center,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,2.1972245773362196,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,2,1,1,1,0,4,1,2009-02-01,2013-01-01,1430.0,2009.0,0,1,0
NCT04269213,CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old,A Phase II Study of CPX-351 in Younger Patients &lt; 60 Years Old With Secondary Acute Myeloid Leukemia,ACTIVE_NOT_RECRUITING,2021-07-29,2027-01-29,2025-12-23,INTERVENTIONAL,PHASE2,21.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Acute Myeloid Leukemia With Myelodysplasia-Related Changes|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia,Liposome-encapsulated Daunorubicin-Cytarabine,DRUG,1,5,18 Years,59 Years,ALL,False,Roswell Park Cancer Institute,OTHER,1,4,United States,,0,1,0,0,0,2.0,1,0,0,0,4,3.091042453358316,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,6,1,1,0,0,1,0,,,,,0,2,0
NCT02345460,Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study,Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study,TERMINATED,2015-09,2016-03,2018-07-13,INTERVENTIONAL,PHASE2,1.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Pancreatic Adenocarcinoma|Poorly Differentiated Malignant Neoplasm|Resectable Pancreatic Cancer|Stage IA Pancreatic Cancer|Stage IB Pancreatic Cancer|Stage IIA Pancreatic Cancer|Stage IIB Pancreatic Cancer|Stage III Pancreatic Cancer|Undifferentiated Pancreatic Carcinoma,Irinotecan Hydrochloride|Oxaliplatin|Leucovorin Calcium|Fluorouracil|Laboratory Biomarker Analysis,DRUG|OTHER,1,7,18 Years,75 Years,ALL,False,Case Comprehensive Cancer Center,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,9,0.6931471805599453,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,8,1,1,0,0,5,1,2015-09-01,2016-03-01,182.0,2015.0,1,3,1
NCT05763160,An Open-label Study That Will Test a Second Treatment Session of RZL-012.,An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of a Second Treatment Session of RZL-012 Into Submental Fat in Subjects Seeking Further Improvement,COMPLETED,2023-05-29,2023-10-20,2023-11-18,INTERVENTIONAL,PHASE2,15.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Submental Fat,RZL-012,DRUG,1,1,18 Years,65 Years,ALL,True,Raziel Therapeutics Ltd.,INDUSTRY,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.772588722239781,small,1,1,1,0,0,0,0,0,1,0,0,0,1,0,2,1,1,0,0,1,0,,,,,0,0,0
NCT01224860,Telmisartan Versus Losartan in Kidney Transplantation,"A Prospective, Randomized, Open Label Blinded End Point (Probe), Crossover Study to Compare the Effects of Telmisartan and Losartan on Metabolic Profile of Renal Transplant Patients",COMPLETED,2009-01,2014-01,2014-02-25,INTERVENTIONAL,PHASE2,20.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Renal Transplant,Telmisartan|Losartan,DRUG,2,6,18 Years,80 Years,ALL,False,Mario Negri Institute for Pharmacological Research,OTHER,0,1,Italy,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.044522437723423,small,1,1,0,1,0,0,0,0,0,1,1,0,1,0,8,1,1,0,0,2,1,2009-01-01,2014-01-01,1826.0,2009.0,0,2,0
NCT00003520,Antineoplaston Therapy in Treating Patients With Stage IV Kidney Cancer,Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Kidney,TERMINATED,1996-03-27,2005-01-23,2017-09-29,INTERVENTIONAL,PHASE2,15.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Stage IV Kidney Cancer,Antineoplaston therapy (Atengenal + Astugenal),DRUG,0,0,18 Years,99 Years,ALL,False,Burzynski Research Institute,OTHER,0,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,2.772588722239781,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,,,,,0,0,0
NCT02336620,Balanced Salt Solution VS. Normal Saline Solution in Septic Shock,Balanced Salt Solution Versus Normal Saline Solution During Initial Resuscitation in Severe Sepsis or Septic Shock Children: A Randomized Controlled Trial,COMPLETED,2014-12,2017-01-30,2017-04-26,INTERVENTIONAL,PHASE3,60.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,"Shock, Septic|Sepsis",Ringer acetate|Normal saline,DRUG,1,1,1 Month,18 Years,ALL,False,Ramathibodi Hospital,OTHER,0,1,Thailand,1.0,0,0,1,0,0,3.0,0,0,0,0,2,4.110873864173311,medium,1,1,0,1,0,0,0,0,0,0,1,1,1,1,2,1,1,0,0,2,1,2014-12-01,,,2014.0,0,2,0
NCT03710889,Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption,"An Open-Label, Single-Arm, Multicenter Study to Evaluate the Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption",COMPLETED,2018-09-20,2020-07-15,2021-10-15,INTERVENTIONAL,PHASE3,23.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Osteoporosis, Postmenopausal|Osteoporosis|Osteoporosis Vertebral|Osteoporosis Risk|Osteoporosis Fracture|Osteoporosis Localized to Spine|Osteoporosis, Age-Related|Osteoporosis Senile|Osteoporosis of Vertebrae",Abaloparatide,DRUG,1,3,50 Years,85 Years,FEMALE,False,"Radius Health, Inc.",INDUSTRY,0,4,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,9,3.1780538303479458,small,1,1,1,0,0,0,1,0,1,0,0,0,1,0,4,1,1,0,0,1,0,,,,,0,1,0
NCT05135468,A Phase 3 Clinical Study Patients With Androgenetic Alopecia (AGA),"A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Finasteride Spray (CU-40102) in Chinese Adult Male Patients With Androgenetic Alopecia (AGA)",COMPLETED,2021-12-06,2023-05-15,2023-08-01,INTERVENTIONAL,PHASE3,270.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,AGA,CU-40102 Spray,DRUG,1,0,18 Years,41 Years,MALE,False,"Cutia Therapeutics（Wuxi）Co.,Ltd",INDUSTRY,0,1,China,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.602118820879701,large,0,1,1,0,0,0,0,0,0,0,1,1,1,1,1,0,1,0,0,1,0,,,,,0,0,0
NCT00415350,Bronchiectasis and Long Term Azithromycin Treatment,Bronchiectasis and Long Term Azithromycin Treatment: A Randomised Placebo-controlled Trial Studying Disease Modifying Effects of Immunomodulating Treatment,COMPLETED,2008-04,2010-12,2020-05-28,INTERVENTIONAL,PHASE3,72.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Bronchiectasis|Inflammation,Azithromycin|Placebo,DRUG|OTHER,2,5,18 Years,,ALL,True,W.G.Boersma,OTHER,0,16,Netherlands,1.0,0,0,1,0,0,3.0,0,0,0,0,2,4.290459441148391,medium,1,1,0,1,0,0,1,0,0,0,1,1,1,1,7,1,1,0,0,2,1,2008-04-01,2010-12-01,974.0,2008.0,0,3,1
NCT03827850,FGFR Inhibitor in FGFR Dysregulated Cancer,A Phase II Trial to Evaluate Efficacy and Safety of Erdafitinib in Patients With Advanced Non Small Cell Lung Carcinoma (NSCLC) Harboring Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations After Relapse of Standard Therapy.,TERMINATED,2019-03-25,2022-10-14,2023-06-09,INTERVENTIONAL,PHASE2,22.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Lung Cancer|NSCLC|Pulmonary Neoplasm|Squamous Cell Lung Cancer|NSCLC Stage IV,ERDAFITINIB,DRUG,1,3,18 Years,,ALL,False,Lung Cancer Group Cologne,OTHER,0,11,Germany,0.0,0,1,0,0,0,2.0,1,0,0,0,5,3.1354942159291497,small,1,1,0,1,0,0,1,0,0,1,0,0,1,1,4,1,1,0,0,1,0,,,,,0,1,0
NCT00117650,Safety and Efficacy Study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 Gene Transfer in Patients With Intermittent Claudication,"A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-Selection Study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 in Patients With Intermittent Claudication",COMPLETED,2005-02,2010-03,2015-04-03,INTERVENTIONAL,PHASE2,289.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Intermittent Claudication|Peripheral Vascular Disease|Atherosclerosis,Ad2/HIF-1α/VP16|Ad2/HIF-1α/VP16|Ad2/HIF-1α/VP16|Saline (Placebo Control),BIOLOGICAL|OTHER,1,4,40 Years,80 Years,ALL,False,"Genzyme, a Sanofi Company",INDUSTRY,0,47,Germany|United Kingdom|United States,1.0,0,1,0,0,0,2.0,0,0,0,1,3,5.66988092298052,large,0,1,1,0,1,0,1,1,1,1,1,1,1,1,5,1,0,1,0,4,1,2005-02-01,2010-03-01,1854.0,2005.0,0,3,1
NCT01729091,"Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma","Phase II Study of Umbilical Cord Blood-Derived Natural Killer Cells in Conjunction With Elotuzumab, Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant for Patients With Multiple Myeloma",COMPLETED,2013-06-10,2024-06-25,2025-05-09,INTERVENTIONAL,PHASE2,72.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Plasma Cell Leukemia|Plasma Cell Myeloma,Autologous Hematopoietic Stem Cell Transplantation|Elotuzumab|Laboratory Biomarker Analysis|Lenalidomide|Melphalan|Natural Killer Cell Therapy|Umbilical Cord Blood-Derived Lymphocyte Therapy,DRUG|BIOLOGICAL|OTHER|PROCEDURE,2,1,18 Years,75 Years,ALL,False,M.D. Anderson Cancer Center,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,2,4.290459441148391,medium,1,1,0,1,0,1,0,0,1,0,0,0,1,0,3,1,1,1,0,7,1,,,,,0,2,0
NCT02457091,Project Get Fit With MS: Guidelines for Exercise Training and Fitness Outcomes in MS,Project GET FIT With MS: Guidelines for Exercise Training and Fitness Outcomes in MS,COMPLETED,2013-10,2014-12,2015-12-03,INTERVENTIONAL,PHASE2,32.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Multiple Sclerosis,Resistance exercise|Stretching exercise,BEHAVIORAL,5,4,18 Years,54 Years,ALL,False,University of Illinois at Urbana-Champaign,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,0,1,0,0,1,3.4965075614664802,small,1,1,0,1,0,0,0,0,1,0,1,0,1,1,9,1,0,0,0,2,1,2013-10-01,2014-12-01,426.0,2013.0,0,2,0
NCT00054873,Tezacitabine With or Without 5-Fluorouracil (5-FU) for Advanced Esophageal Cancer or Gastric Cancer,,COMPLETED,2003-11,2004-12,2006-07-11,INTERVENTIONAL,PHASE2,,,,,TREATMENT,,Esophageal Neoplasms|Stomach Neoplasms|Adenocarcinoma,tezacitabine|5-fluorouracil,DRUG,0,0,18 Years,,ALL,False,Chiron Corporation,INDUSTRY,0,29,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,3,0.0,,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,2,1,2003-11-01,2004-12-01,396.0,2003.0,0,2,0
NCT00889473,Study of the Efficacy of Larazotide Acetate to Treat Celiac Disease,"A Phase IIb, Randomized, Double-blind, Placebo Controlled, Dose Ranging, Multicenter Study to Determine the Safety, Tolerance, and Efficacy of Larazotide Acetate (AT-1001) in Celiac Disease Subjects During a Gluten Challenge",COMPLETED,2009-04,2010-04,2017-09-20,INTERVENTIONAL,PHASE2,42.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Celiac Disease,Larazotide acetate|Placebo|Gluten 900 mg,DRUG|DIETARY_SUPPLEMENT,1,1,18 Years,72 Years,ALL,False,"9 Meters Biopharma, Inc.",INDUSTRY,0,15,Canada|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.7612001156935624,small,1,1,1,0,0,0,1,1,1,0,1,1,1,1,2,1,1,0,0,3,1,2009-04-01,2010-04-01,365.0,2009.0,0,2,0
NCT00946569,A Study of the Safety and Effectiveness of JNJ-39758979 in the Treatment of Adults With Persistent Asthma,"A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Exploratory Study of the Safety and Efficacy of JNJ-39758979 in the Treatment of Adults With Persistent Asthma",COMPLETED,2009-08,2010-09,2014-04-29,INTERVENTIONAL,PHASE2,116.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Asthma,JNJ39758979|Placebo,DRUG,1,14,18 Years,65 Years,ALL,False,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INDUSTRY,0,24,Canada|Romania|India|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.762173934797756,medium,0,1,1,0,0,0,1,1,1,0,1,1,1,1,15,1,1,0,0,2,1,2009-08-01,2010-09-01,396.0,2009.0,0,3,1
NCT02380742,Topical Anesthetic Use In Pessary Management,Topical Anesthetic Use In Pessary Management: A Randomized Double Blinded Placebo Controlled Trial,COMPLETED,2015-07,2016-02,2017-02-23,INTERVENTIONAL,PHASE2,54.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Pain,lidocaine-prilocaine cream|Placebo cream,DRUG,1,3,18 Years,,FEMALE,False,Loyola University,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.007333185232471,medium,1,1,0,1,0,0,0,0,1,0,1,1,1,1,4,1,1,0,0,2,1,2015-07-01,2016-02-01,215.0,2015.0,1,1,0
NCT00919542,Ciclosporin in the Management of New Erythema Nodosum Leprosum,A Pilot (Double Blind Controlled) Study Randomizing Patients With New Acute ENL to Treatment Either With Ciclosporin or Prednisolone.,COMPLETED,2010-07,2013-07,2015-03-24,INTERVENTIONAL,PHASE2,12.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Leprosy,Ciclosporin|prednisolone,DRUG,1,4,18 Years,65 Years,FEMALE,False,London School of Hygiene and Tropical Medicine,OTHER,3,1,Ethiopia,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.5649493574615367,small,1,1,0,1,0,1,0,0,0,0,1,1,1,1,5,1,1,0,0,2,1,2010-07-01,2013-07-01,1096.0,2010.0,0,1,0
NCT01222689,Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer,A Phase 2 Study of AZD6244 Plus Erlotinib for the Second-Line Treatment of Advanced Pancreatic Adenocarcinoma,COMPLETED,2010-11,2014-09,2020-07-31,INTERVENTIONAL,PHASE2,46.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Adenocarcinoma of the Pancreas|Recurrent Pancreatic Cancer|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer,erlotinib hydrochloride|selumetinib|laboratory biomarker analysis,DRUG|OTHER,2,5,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,2,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,4,3.8501476017100584,small,1,1,0,1,0,0,1,0,1,0,0,0,1,0,7,1,1,0,0,3,1,2010-11-01,2014-09-01,1400.0,2010.0,0,3,1
NCT00667368,Bacterial Vaginosis Home Screening to Prevent STDs,Home Screening for Bacterial Vaginosis to Prevent STDs,COMPLETED,2008-07-28,2014-12-31,2020-02-18,INTERVENTIONAL,PHASE3,1370.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Bacterial Vaginosis,Metronidazole,DRUG,1,1,15 Years,25 Years,FEMALE,False,National Institute of Allergy and Infectious Diseases (NIAID),NIH,0,7,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,7.223295679562314,xlarge,0,1,0,1,0,0,1,0,1,0,1,0,1,1,2,1,1,0,0,1,0,,,,,0,0,0
NCT00506168,Study of Irinotecan & Capecitabine in Metastatic Colorectal Cancer,Phase II Study of Irinotecan in Combination With Capecitabine in Previously Untreated Patients With Metastatic Colorectal Cancer,TERMINATED,2001-11,2007-07,2007-07-25,INTERVENTIONAL,PHASE2,37.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Colorectal Neoplasms|Secondary|Drug Therapy, Combination","Irinotecan, Capecitabine",DRUG,1,1,18 Years,,ALL,False,"National Cancer Center, Korea",OTHER_GOV,0,1,South Korea,0.0,0,1,0,0,0,2.0,0,0,0,0,3,3.6375861597263857,small,1,1,0,1,0,0,0,0,0,0,0,0,1,0,2,1,1,0,0,1,0,2001-11-01,2007-07-01,2068.0,2001.0,0,1,0
NCT00658268,Bisphosphonates and Impaction Grafting in Hip Revision,"Bisphosphonates and Impaction Grafting in Hip Revision Evaluated With Radiostereophotogrametri. A Randomized, Double-blind Study in Patients Operated for Aseptic Loosening and Osteolysis.",COMPLETED,2008-03,2017-08-01,2017-08-15,INTERVENTIONAL,PHASE2,32.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Aseptic Loosening of the Hip Prosthesis,Clodronate|Placebo,DRUG,1,1,45 Years,80 Years,ALL,False,Region Skane,OTHER,0,1,Sweden,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.4965075614664802,small,1,1,0,1,0,0,0,0,0,0,1,1,1,1,2,1,1,0,0,2,1,2008-03-01,,,2008.0,0,1,0
NCT03247686,A Study of RSLV-132 in Subjects With Primary Sjogren's Syndrome,"A Phase 2, Double-blind, Placebo-controlled Study of RSLV-132 in Subjects With Primary Sjogren's Syndrome",COMPLETED,2017-02-01,2019-08-01,2021-04-02,INTERVENTIONAL,PHASE2,28.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Sjogren's Syndrome,RSLV-132|Placebo,DRUG,1,1,18 Years,70 Years,ALL,False,Resolve Therapeutics,INDUSTRY,2,2,United Kingdom,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.367295829986474,small,1,1,1,0,0,1,1,0,0,1,1,1,1,1,2,1,1,0,0,2,1,,,,,0,1,0
NCT01566786,Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII in Acute Intracerebral Haemorrhage,"Randomised, Double-Blind, Placebo-Controlled, Multicentre, Dose-Escalation Study to Evaluate the Safety and Preliminary Efficacy of Activated Recombinant Factor VII (NovoSeven®) in Acute Intracerebral Haemorrhage",COMPLETED,2001-08,2002-10,2017-01-12,INTERVENTIONAL,PHASE2,48.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Acquired Bleeding Disorder|Intracerebral Haemorrhage,activated recombinant human factor VII|placebo,DRUG,1,2,18 Years,,ALL,False,Novo Nordisk A/S,INDUSTRY,0,9,Italy|Finland|Spain|Germany|United Kingdom|Australia|Denmark|Taiwan|Singapore,1.0,0,1,0,0,0,2.0,0,0,0,0,2,3.8918202981106265,small,1,1,1,0,0,0,1,1,0,1,1,1,1,1,3,1,1,0,0,2,1,2001-08-01,2002-10-01,426.0,2001.0,0,3,1
NCT02462772,"Safety and Acceptability of Cabotegravir in HIV Uninfected Women in KwaZulu-Natal, South Africa","Phase II Trial to Assess the Safety and Acceptability of the Long-acting Injectable HIV Integrase Inhibitor, Cabotegravir (GSK1265744), in HIV Uninfected Women in KwaZulu-Natal, South Africa",WITHDRAWN,2015-10,2018-09,2015-11-05,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Human Immunodeficiency Virus,cabotegravir|Placebo,DRUG,1,6,18 Years,30 Years,FEMALE,True,Centre for the AIDS Programme of Research in South Africa,NETWORK,1,2,South Africa,0.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,1,1,0,0,0,1,1,0,0,0,1,1,0,1,7,1,1,0,0,2,1,2015-10-01,2018-09-01,1066.0,2015.0,1,2,0
NCT03535272,Bismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea,Bismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea and Impact on Acquisition of Gut Antimicrobial Resistance Genes,TERMINATED,2018-05-20,2023-12-31,2025-03-12,INTERVENTIONAL,PHASE3,482.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Diarrhea Travelers|Antibiotic Resistant Infection,Bismuth subsalicylate|Placebo Oral Tablet,DRUG,1,1,18 Years,69 Years,ALL,True,Centers for Disease Control and Prevention,FED,2,1,United States,0.0,0,0,1,0,0,3.0,0,0,0,0,2,6.180016653652572,large,0,1,0,0,0,1,0,0,1,0,1,1,0,1,2,1,1,0,0,2,1,,,,,0,2,0
NCT01781572,A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma,"A Phase Ib/II, Multicenter, Open Label, Study of LEE011 in Combination With MEK162 in Adult Patients With NRAS Mutant Melanoma",COMPLETED,2013-06,2018-02-20,2020-12-07,INTERVENTIONAL,PHASE1|PHASE2,102.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Locally Advanced or Metastatic NRAS Mutant Melanoma,LEE011|MEK162,DRUG,2,26,18 Years,,ALL,False,Pfizer,INDUSTRY,0,17,Netherlands|Italy|United States|Germany|Australia,1.0,1,1,0,0,1,1.5,1,0,0,0,1,4.634728988229636,medium,0,1,1,0,1,0,1,1,1,1,0,0,1,0,28,1,1,0,0,2,1,2013-06-01,,,2013.0,0,4,1
NCT02891759,Compare Outcomes Between Two Acellular Dermal Matrices,"A Single-Blinded Randomized Prospective Trial to Compare Outcomes Between Two Acellular Dermal Matrices Used for Immediate, Post-Mastectomy Breast Reconstruction",COMPLETED,2017-01-31,2022-10-27,2023-05-06,INTERVENTIONAL,PHASE2,320.0,ACTUAL,RANDOMIZED,PARALLEL,SUPPORTIVE_CARE,SINGLE,Breast Cancer,Alloderm RTU|Cortiva 1mm Allograft Dermis|Skin or nipple-sparing mastectomy|Breast Q|Surgery,OTHER|PROCEDURE,1,16,22 Years,70 Years,FEMALE,False,Washington University School of Medicine,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,5.771441123130016,large,0,1,0,1,0,1,0,0,1,0,1,0,0,1,17,1,0,0,0,5,1,,,,,0,2,0
NCT01884259,Induction Chemotherapy With TP+5-FU or TP+Cetuximab Followed by Radioimmuptherapy for Locally Advanced or Not Resectable SCCHNN,"Randomised Phase II Pilot Study: Induction Chemotherapy With Docetaxel, Cisplatin and Cetuximab Versus Docetaxel, Cisplatin and 5 FU Followed by Radiotherapy With Cetuximab for Locally Advanced or Not Resectable Carcinoma of the Head and Neck",COMPLETED,2013-05,2022-01-13,2022-05-26,INTERVENTIONAL,PHASE2,100.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Squamous Cell Carcinoma of the Hypopharynx Stage III|Squamous Cell Carcinoma of the Hypopharynx Stage IV|Squamous Cell Carcinoma of the Larynx Stage III|Squamous Cell Carcinoma of the Larynx Stage IV|Squamous Cell Carcinoma of the Oropharynx Stage III|Squamous Cell Carcinoma of the Oropharynx Stage IV|Squamous Cell Carcinoma of the Oral Cavity Stage III|Squamous Cell Carcinoma of the Oral Cavity Stage IV,Docetaxel|Cisplatin|5-fluorouracil|Cetuximab Induction|Cetuximab Radioimmunotherapy|Boost irradiation,DRUG|BIOLOGICAL|RADIATION,1,5,18 Years,75 Years,ALL,False,Arbeitsgemeinschaft medikamentoese Tumortherapie,OTHER,0,8,Austria,1.0,0,1,0,0,0,2.0,1,0,0,0,8,4.61512051684126,medium,0,1,0,1,0,0,1,0,0,0,1,0,1,1,6,1,1,1,0,6,1,2013-05-01,,,2013.0,0,3,1
NCT04360980,The Effects of Standard Protocol With or Without Colchicine in Covid-19 Infection,Effects of Standard Protocol Therapy With or Without Colchicine in Covid-19 Infection: A Randomized Double Blind Clinical Trial,COMPLETED,2020-03-20,2021-01-30,2022-01-28,INTERVENTIONAL,PHASE2,80.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,COVID-19,Colchicine Tablets,DRUG,4,1,18 Years,,ALL,False,Shahid Beheshti University of Medical Sciences,OTHER,0,2,Iran,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.394449154672439,medium,1,1,0,1,0,0,1,0,0,0,1,1,1,1,5,1,1,0,0,1,0,,,,,0,0,0
NCT05032859,Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102),A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Moderate to Severe Atopic Dermatitis in Children and Adults,COMPLETED,2021-09-23,2023-02-08,2025-09-02,INTERVENTIONAL,PHASE3,406.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Atopic Dermatitis,"tapinarof cream, 1%|vehicle cream",DRUG,1,4,2 Years,,ALL,False,Organon and Co,INDUSTRY,0,62,Canada|United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.008813185442595,large,0,1,1,0,0,0,1,1,1,0,1,1,1,1,5,1,1,0,0,2,1,,,,,0,2,0
NCT02343679,Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies,"A Phase II Study of the ALK Inhibitor, Ceritinib (LDK378), in Relapsed/Refractory ALK+ Hematologic Malignancies",WITHDRAWN,2015-05,2022-10,2017-02-01,INTERVENTIONAL,PHASE2,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Hematologic Malignancies,ceritinib,DRUG,1,1,18 Years,,ALL,False,"Anne Beaven, MD",OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,1,1,0,1,0,1,0,0,1,0,0,0,1,0,2,1,1,0,0,1,0,2015-05-01,2022-10-01,2710.0,2015.0,1,0,0
NCT00345696,1stline Study Capecitabine Administered on Continuous Way Plus Oxaliplatin&Bevacizumab Every 2weeks in Metastatic CCR.,Phase II Study of First Line Capecitabine Administered on Continuous Way Combined With Oxaliplatin and Bevacizumab Every Two Weeks in Metastatic Colorectal Cancer Patients.,COMPLETED,2006-06,2011-01,2011-08-24,INTERVENTIONAL,PHASE2,32.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Metastatic Colorectal Cancer,Bevacizumab|Capecitabine|Oxaliplatine,DRUG,1,4,18 Years,,ALL,False,Unidad Integral de Investigación en Oncología S.L.,OTHER,1,1,Spain,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.4965075614664802,small,1,1,0,1,0,1,0,0,0,1,0,0,1,0,5,1,1,0,0,3,1,2006-06-01,2011-01-01,1675.0,2006.0,0,1,0
NCT01091662,Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic,"Double-Blind, Randomized, Historical Control Study of the Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs",COMPLETED,2010-06,2012-11,2016-10-24,INTERVENTIONAL,PHASE3,172.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Epilepsy,Eslicarbazepine acetate 1600 mg|Eslicarbazepine acetate 1200 mg,DRUG,1,15,16 Years,70 Years,ALL,False,"Sumitomo Pharma America, Inc.",INDUSTRY,0,62,Bulgaria|United States|Serbia|Czechia|Ukraine,1.0,0,0,1,0,0,3.0,0,0,1,0,1,5.153291594497779,medium,0,1,1,0,0,0,1,1,1,0,1,1,1,1,16,1,1,0,0,2,1,2010-06-01,2012-11-01,884.0,2010.0,0,3,1
NCT04680962,MabionCD20® Compared to MabThera® and Rituxan® in Patients With Rheumatoid Arthritis,"A Double-Blind, Randomized, Parallel-Group Study to Investigate the Pharmacokinetic and Clinical Similarity Between MabionCD20, EU-approved MabThera® and US-licensed Rituxan® in Patients With Moderate-to-Severe Rheumatoid Arthritis",WITHDRAWN,2023-08-03,2023-08-03,2023-08-07,INTERVENTIONAL,PHASE3,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Rheumatoid Arthritis,MabionCD20 (candidate biosimilar to rituximab)|MabThera®|Rituxan®,BIOLOGICAL,2,20,18 Years,80 Years,ALL,False,Mabion SA,INDUSTRY,1,0,,0.0,0,0,1,0,0,3.0,0,1,0,0,1,0.0,,1,1,1,0,0,1,0,0,0,0,1,1,1,1,22,1,0,1,0,3,1,,,,,0,2,0
NCT00123162,Viagra in the Treatment of Primary Dysmenorrhea,Sildenafil Citrate in the Treatment of Primary Dysmenorrhea,COMPLETED,2007-05,2011-08,2015-12-23,INTERVENTIONAL,PHASE1|PHASE2,25.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Dysmenorrhea,Sildenafil Citrate|Placebo,DRUG,1,1,18 Years,35 Years,FEMALE,True,Milton S. Hershey Medical Center,OTHER,1,1,Croatia,1.0,1,1,0,0,1,1.5,0,0,0,0,1,3.258096538021482,small,1,1,0,1,0,1,0,0,0,0,1,0,1,1,2,1,1,0,0,2,1,2007-05-01,2011-08-01,1553.0,2007.0,0,2,0
NCT02337946,Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Participants With Chemotherapy-naïve Unresectable Advanced Recurrent Colorectal Carcinoma,A Phase 2 Randomized Study Comparing the Efficacy and Safety of mFOLFOX6+Panitumumab Combination Therapy and 5-FU/LV+Panitumumab Combination Therapy in the Patients With Chemotherapy-Naive Unresectable Advanced Recurrent Colorectal Carcinoma of KRAS Wild-Type After 6 Cycles of Combination Therapy With mFOLFOX6+Panitumumab,COMPLETED,2014-10-16,2017-08-31,2019-09-10,INTERVENTIONAL,PHASE2,164.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Colorectal Carcinoma,"oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab",DRUG,1,8,20 Years,,ALL,False,Takeda,INDUSTRY,0,49,Japan,1.0,0,1,0,0,0,2.0,1,0,0,0,1,5.10594547390058,medium,0,1,1,0,1,0,1,0,0,0,1,0,1,1,9,1,1,0,0,2,1,,,,,0,2,0
NCT00053846,Buspirone in Reducing Shortness of Breath in Patients With Cancer,Buspirone in Reducing Shortness of Breath in Patients With Cancer,COMPLETED,2002-11,2011-01,2015-11-24,INTERVENTIONAL,PHASE2|PHASE3,432.0,ACTUAL,RANDOMIZED,PARALLEL,SUPPORTIVE_CARE,DOUBLE,"Dyspnea|Pulmonary Complications|Unspecified Adult Solid Tumor, Protocol Specific",buspirone hydrochloride|Placebo,DRUG,1,0,18 Years,120 Years,ALL,False,University of Rochester,OTHER,1,15,United States,1.0,0,1,1,0,1,2.5,1,0,0,0,3,6.07073772800249,large,0,1,0,1,1,1,1,0,1,0,1,1,0,1,1,0,1,0,0,2,1,2002-11-01,2011-01-01,2983.0,2002.0,0,3,1
NCT01269346,Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer,"A Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Positive Breast Cancer",COMPLETED,2010-12,2016-05,2023-06-22,INTERVENTIONAL,PHASE2,52.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Breast Cancer,Eribulin Mesylate,DRUG,1,4,18 Years,,FEMALE,False,Eisai Inc.,INDUSTRY,0,26,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.970291913552122,medium,1,1,1,0,0,0,1,0,1,0,0,0,1,0,5,1,1,0,0,1,0,2010-12-01,2016-05-01,1978.0,2010.0,0,0,0
NCT03669588,An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Trial to Evaluate the Efficacy, Safety and Tolerability of ARGX-113 in Patients With Myasthenia Gravis Having Generalized Muscle Weakness",COMPLETED,2018-08-22,2020-04-06,2022-02-08,INTERVENTIONAL,PHASE3,167.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Generalized Myasthenia Gravis,ARGX-113|Placebo,BIOLOGICAL,1,5,18 Years,,ALL,False,argenx,INDUSTRY,0,66,Italy|Belgium|Netherlands|Russia|Hungary|United States|Germany|United Kingdom|Poland|Japan|Serbia|Czechia|Denmark|Georgia|France|Canada,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.123963979403259,medium,0,1,1,0,0,0,1,1,1,1,1,1,1,1,6,1,0,1,0,2,1,,,,,0,3,1
NCT02421588,Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients,Phase III Randomized Clinical Trial of Lurbinectedin (PM01183) Versus Pegylated Liposomal Doxorubicin or Topotecan in Patients With Platinum-resistant Ovarian Cancer (CORAIL Trial),COMPLETED,2015-05,2018-10-12,2020-04-03,INTERVENTIONAL,PHASE3,442.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Ovarian Cancer,Lurbinectedin (PM01183)|Pegylated liposomal doxorubicin (PLD)|Topotecan,DRUG,1,7,18 Years,,ALL,False,PharmaMar,INDUSTRY,0,28,United States,1.0,0,0,1,0,0,3.0,1,0,0,0,1,6.093569770045136,large,0,1,1,0,0,0,1,0,1,0,1,0,1,1,8,1,1,0,0,3,1,2015-05-01,,,2015.0,1,2,0
NCT06411288,Global Study of Del-desiran for the Treatment of DM1,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Global Study to Evaluate the Efficacy and Safety of Intravenous AOC 1001 for the Treatment of Myotonic Dystrophy Type 1",ACTIVE_NOT_RECRUITING,2024-05-30,2026-09,2026-01-22,INTERVENTIONAL,PHASE3,159.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,DM1|Myotonic Dystrophy|Myotonic Dystrophy 1|Myotonia|Myotonic Dystrophy Type 1 (DM1)|Dystrophy Myotonic|Myotonic Disorders|Steinert Disease|Steinert|Myotonic Muscular Dystrophy,AOC 1001 (del-desiran)|Placebo,DRUG,1,4,16 Years,65 Years,ALL,False,"Avidity Biosciences, Inc.",INDUSTRY,0,34,Italy|Netherlands|United States|Germany|Spain|United Kingdom|Japan|Denmark|France|Canada,,0,0,1,0,0,3.0,0,0,0,0,10,5.075173815233827,medium,0,1,1,0,0,0,1,1,1,1,1,1,1,1,5,1,1,0,0,2,1,,2026-09-01,,,0,3,1
NCT00858403,Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target Modulation,Phase II Study of Dasatinib in Advanced Non-small Cell Lung Cancer With Ex Vivo and In Vivo Assessment of Tumor Target Modulation,TERMINATED,2009-03,2010-07,2014-01-15,INTERVENTIONAL,PHASE2,7.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Lung Cancer,Dasatinib,DRUG,1,6,18 Years,,ALL,False,H. Lee Moffitt Cancer Center and Research Institute,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,2.0794415416798357,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,7,1,1,0,0,1,0,2009-03-01,2010-07-01,487.0,2009.0,0,1,0
NCT01969903,Study of Use of Dexmedetomidine for Regional Anesthesia,Effect of Dexmedetomidine Added to Lidocaine for Infra- and Supraclavicular Brachial Plexus Block,WITHDRAWN,2014-11,2014-11,2016-12-08,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Anesthesia,Precedex injection,DRUG,1,0,21 Years,70 Years,ALL,False,NYU Langone Health,OTHER,0,0,,0.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,1,1,0,1,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0,1,0,2014-11-01,2014-11-01,0.0,2014.0,0,0,0
NCT00101127,"Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma",A Phase II Evaluation of Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus,COMPLETED,2003-12,,2014-02-14,INTERVENTIONAL,PHASE2,,,,,TREATMENT,NONE,Sarcoma,filgrastim|pegfilgrastim|docetaxel|gemcitabine hydrochloride,DRUG|BIOLOGICAL,2,0,18 Years,,FEMALE,False,Gynecologic Oncology Group,NETWORK,1,60,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,0.0,,0,0,0,0,0,1,1,0,1,0,0,0,1,0,2,0,1,1,0,4,1,2003-12-01,,,2003.0,0,1,0
NCT01574027,Efficacy of Vitamin D in Colorectal Cancer Chemoprevention,,COMPLETED,2008-04,2011-10,2012-04-10,INTERVENTIONAL,PHASE2,55.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Colorectal Cancer,Vitamin D3 (cholecalciferol)|Placebo,DRUG,1,0,50 Years,,ALL,True,University of Illinois at Chicago,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.02535169073515,medium,1,1,0,1,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,2,1,2008-04-01,2011-10-01,1278.0,2008.0,0,1,0
NCT06871761,A Trial Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes,"A Randomized, Open-label, Parallel, Treat to Target Study Comparing the Efficacy and Safety of HR17031 Injection With Insulin Glargine in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin, Metformin in Combination With or Without One Other Oral Antidiabetic Drug (OAD)",COMPLETED,2024-05-08,2025-05-13,2026-01-13,INTERVENTIONAL,PHASE3,393.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Adult Patients With Type 2 Diabetes,HR17031 injection|insulin glargine,DRUG,1,8,18 Years,75 Years,ALL,False,"Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,0,1,China,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.976350909297934,large,0,1,1,0,0,0,0,0,0,0,1,0,1,1,9,1,1,0,0,2,1,,,,,0,2,0
NCT02489461,"Efficacy, Safety and Optimal Dose of VM-1500 in Comparison to Efavirenz Added to Standard-of-care Antiretroviral Therapy","International, Multicenter, Randomized, Partially Blind Study to Evaluate Efficacy, Safety and Selection of the Optimal Dose for VM-1500 in Comparison to Efavirenz in Combination With Two NRTIs in Treatment-naïve, HIV-1 Infected Patients",COMPLETED,2014-08-05,2017-09-18,2018-09-25,INTERVENTIONAL,PHASE2|PHASE3,150.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,HIV-1-infection,VM-1500|Efavirenz|Antiretroviral therapy (ART),DRUG,1,5,18 Years,,ALL,False,Viriom,INDUSTRY,0,13,Russia,1.0,0,1,1,0,1,2.5,0,0,0,0,1,5.017279836814924,medium,0,1,1,0,0,0,1,0,0,0,1,1,1,1,6,1,1,0,0,3,1,,,,,0,3,1
NCT03506061,Trikafta in Cystic Fibrosis Patients,iPS Cell Response to CFTR Modulators: Study of Trikafta in CF Patients Carrying Partial Function Mutations or N1303K CFTR,COMPLETED,2019-09-04,2024-02-13,2025-09-11,INTERVENTIONAL,PHASE2,42.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Cystic Fibrosis,Trikafta,DRUG,3,6,12 Years,,ALL,False,Emory University,OTHER,3,2,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.7612001156935624,small,1,1,0,1,0,1,1,0,1,0,0,0,1,1,9,1,1,0,0,1,0,,,,,0,1,0
NCT00947661,Efficacy and Safety of SPARC0912 and Reference0912 in Open Angle Glaucoma or Ocular Hypertension,,COMPLETED,2010-07,2012-05,2021-03-09,INTERVENTIONAL,PHASE3,578.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Open Angle Glaucoma|Ocular Hypertension,SPARC0912|Reference0912,DRUG,1,0,18 Years,,ALL,False,Sun Pharma Advanced Research Company Limited,INDUSTRY,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,1,2,6.361302477572996,xlarge,0,1,1,0,0,0,0,0,1,0,1,1,1,1,1,0,1,0,0,2,1,2010-07-01,2012-05-01,670.0,2010.0,0,2,0
NCT00217061,Effect of a Decision Aid About Statin Use in Patients With Type 2 Diabetes Mellitus,The Statin Choice Decision Aid and Its Effects on Statin Decisions in Patients With Type 2 Diabetes Mellitus. A Clustered Randomized Trial,COMPLETED,2005-04,2005-10,2011-05-23,INTERVENTIONAL,PHASE3,98.0,,RANDOMIZED,PARALLEL,,SINGLE,Diabetes Mellitus|Dyslipidemia|Hypercholesterolemia|Cardiovascular Disease,Decision Aid Statin Choice,DEVICE,1,5,18 Years,,ALL,False,Mayo Clinic,OTHER,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,1,4,4.59511985013459,medium,1,0,0,1,0,0,0,0,1,0,1,0,0,1,6,1,0,0,1,1,0,2005-04-01,2005-10-01,183.0,2005.0,0,2,0
NCT00002442,A Study to Compare the Safety and Effectiveness of Two Dosing Schedules of Lamivudine in Combination With Two Other Anti-HIV Drugs,"A Phase II, Open-Label, Randomized Study of the Efficacy and Safety of Epivir 150 Mg BID Versus Epivir 300 Mg Once-Daily When Administered for 24 Weeks in Combination With FDA-Approved Dosage Regimens of Zerit and Either Crixivan or Viracept in Subjects With HIV-1 Infection",COMPLETED,1999-06,,2005-06-24,INTERVENTIONAL,PHASE2,,,,,TREATMENT,NONE,HIV Infections,Indinavir sulfate|Nelfinavir mesylate|Lamivudine|Stavudine,DRUG,0,0,18 Years,,ALL,False,Glaxo Wellcome,INDUSTRY,0,12,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,4,1,1999-06-01,,,1999.0,0,1,0
NCT01825642,Prospective Randomized Trial of Seminal Vesicle-Sparing Prostatectomy and Nerve-Sparing Radical Prostatectomy in Men With Clinically Localized Prostate Cancer,Prospective Randomized Trial of Seminal Vesicle-Sparing Prostatectomy and Nerve-Sparing Radical Prostatectomy in Men With Clinically Localized Prostate Cancer,COMPLETED,2006-09,2012-12,2013-04-05,INTERVENTIONAL,PHASE2|PHASE3,140.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Prostate Cancer,nerve-sparing radical prostatectomy|seminal vesicle-sparing radical prostatectomy,PROCEDURE,1,3,18 Years,,MALE,False,University of Michigan,OTHER,0,1,United States,1.0,0,1,1,0,1,2.5,1,0,0,0,1,4.948759890378168,medium,0,1,0,1,0,0,0,0,1,0,1,0,1,1,4,1,0,0,0,2,1,2006-09-01,2012-12-01,2283.0,2006.0,0,2,0
NCT00244842,Randomized Placebo-controlled Study of ISA247 in Plaque Psoriasis,"A Phase III, Randomized, Multicentre, Double-Blind, Placebo-Controlled Study of ISA247 in Plaque Psoriasis Patients",COMPLETED,2004-12,2005-10,2023-03-27,INTERVENTIONAL,PHASE3,451.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Psoriasis,voclosporin|Placebo,DRUG,1,3,18 Years,65 Years,ALL,False,Aurinia Pharmaceuticals Inc.,INDUSTRY,0,31,Canada,1.0,0,0,1,0,0,3.0,0,1,0,0,1,6.113682179832232,large,0,1,1,0,0,0,1,0,0,0,1,1,1,1,4,1,1,0,0,2,1,2004-12-01,2005-10-01,304.0,2004.0,0,1,0
NCT03156842,Combination of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and Dyslipidemia,"A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and Dyslipidemia Who Fail to Respond Adequately to Fimasartan Monotherapy",COMPLETED,2017-05-29,2018-12-07,2019-06-10,INTERVENTIONAL,PHASE3,138.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Essential Hypertension|Dyslipidemia,"Fimasartan/Amlodipine, Rosuvastatin|Fimasartan/Amlodipine|Fimasartan, Rosuvastatin",DRUG,2,2,20 Years,70 Years,ALL,False,"Boryung Pharmaceutical Co., Ltd",INDUSTRY,0,1,South Korea,1.0,0,0,1,0,0,3.0,0,0,0,1,2,4.9344739331306915,medium,0,1,1,0,0,0,0,0,0,0,1,1,1,1,4,1,1,0,0,3,1,,,,,0,2,0
NCT04738942,A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease,"An Open-Label, Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Intravenous (IV) Vedolizumab Administered Every 4 Weeks (Q4W) in Japanese Patients With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Experienced Secondary Loss of Response During Maintenance Therapy With Vedolizumab IV Administered Every 8 Weeks (Q8W)",ACTIVE_NOT_RECRUITING,2021-06-04,2027-11-30,2025-07-28,INTERVENTIONAL,PHASE3,57.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Ulcerative Colitis|Crohn's Disease,Vedolizumab,DRUG,2,6,18 Years,80 Years,ALL,False,Takeda,INDUSTRY,0,20,Japan,,0,0,1,0,0,3.0,0,1,0,0,2,4.060443010546419,medium,1,1,1,0,1,0,1,0,0,0,0,0,1,1,8,1,1,0,0,1,0,,,,,0,2,0
NCT00282386,A Study to Evaluate the Effect of MK0966 (Rofecoxib) on the Recurrence of Colorectal Adenomas (0966-122),"A Multicenter, Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Study With In-House Blinding to Determine the Effect of 156 Weeks of Treatment With MK0966 on the Recurrence of Neoplastic Polyps of the Large Bowel in Patients With a History of Colorectal Adenomas",COMPLETED,1999-12-23,2004-09-01,2017-05-09,INTERVENTIONAL,PHASE3,2586.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Colorectal Adenoma,MK0966; Rofecoxib / Duration of Treatment: 156 weeks|Placebo/ Duration of Treatment: 156 weeks,DRUG,1,3,40 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,7.8582541821860294,xlarge,0,1,1,0,1,0,0,0,0,0,1,1,0,1,4,1,1,0,0,2,1,,,,,0,1,0
NCT02852486,Study of Imatinib Discontinuation in Chronic Myeloid Leukemia With Deep Molecular Response,Pilot Study of Imatinib Discontinuation in Patients With Chronic Myeloid Leukemia With Deep Molecular Response - Evaluation of Pioglitazone in Treatment-free Remission (EDI-PIO),COMPLETED,2016-06-22,2024-02-07,2025-03-30,INTERVENTIONAL,PHASE2,31.0,ACTUAL,,SINGLE_GROUP,OTHER,NONE,"Leukemia, Chronic Myeloid",Pioglitazone 30 Mg Oral Tablet|imatinib discontinuation,DRUG|OTHER,2,8,18 Years,,ALL,False,"University of Campinas, Brazil",OTHER,0,1,Brazil,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.4657359027997265,small,1,1,0,1,0,0,0,0,0,0,0,0,0,0,10,1,1,0,0,2,1,,,,,0,2,0
NCT01987986,"A Phase 2, Randomized, Double-blind, Placebo Controlled Dose Ranging Study of Repeat Doses of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy","A Phase 2, Double-blind and Placebo Dose Ranging Study of Repeat Doses of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy",COMPLETED,2013-10,2014-08,2017-10-05,INTERVENTIONAL,PHASE2,150.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Edematous Fibrosclerotic Panniculopathy (EFP),Collagenase Clostridium Histolyticum|Placebo,BIOLOGICAL,1,0,18 Years,45 Years,FEMALE,False,Endo Pharmaceuticals,INDUSTRY,0,10,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.017279836814924,medium,0,1,1,0,0,0,1,0,1,0,1,1,1,1,1,0,0,1,0,2,1,2013-10-01,2014-08-01,304.0,2013.0,0,1,0
NCT04685070,Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer,"Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer: A Single-Arm, Open-Label, Phase II Clinical Trial",ACTIVE_NOT_RECRUITING,2021-12-14,2027-12-31,2024-08-14,INTERVENTIONAL,PHASE2,56.0,ESTIMATED,,SINGLE_GROUP,TREATMENT,NONE,Non-small Cell Lung Cancer Stage III,HS-10296 (Almonertinib),DRUG,1,6,18 Years,75 Years,ALL,False,"Shanghai Pulmonary Hospital, Shanghai, China",OTHER,0,1,China,,0,1,0,0,0,2.0,1,0,0,0,1,4.04305126783455,medium,1,0,0,1,0,0,0,0,0,0,0,0,1,0,7,1,1,0,0,1,0,,,,,0,1,0
NCT03407170,Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161),"An Open-Label, Phase II Study to Determine the Immunologic Correlates of Pembrolizumab-Mediated Tumor Regression in Subjects With Advanced Melanoma (KEYNOTE-161)",TERMINATED,2018-06-28,2019-08-14,2020-07-15,INTERVENTIONAL,PHASE2,1.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Advanced Melanoma,pembrolizumab,BIOLOGICAL,3,7,18 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,2,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,0.6931471805599453,small,1,1,1,0,1,0,1,0,1,0,0,0,1,0,10,1,0,1,0,1,0,,,,,0,1,0
NCT00695370,Evaluation of Pegfilgrastim for Stem Cell Mobilization in Children,Hematopoietic Progenitor Cell Mobilization in Children With Malignancies: Evaluation of Pegfilgrastim at 300µg/kg in Hematological Steady State,TERMINATED,2006-01,2008-01,2008-06-13,INTERVENTIONAL,PHASE2,30.0,ESTIMATED,NON_RANDOMIZED,,TREATMENT,NONE,Solid Malignancies,Pegfilgrastim (drug),DRUG,1,1,,18 Years,ALL,False,"University Hospital, Clermont-Ferrand",OTHER,1,0,,0.0,0,1,0,0,0,2.0,0,0,0,0,1,3.4339872044851463,small,1,0,0,1,0,1,0,0,0,0,0,0,1,0,2,1,1,0,0,1,0,2006-01-01,2008-01-01,730.0,2006.0,0,0,0
NCT02029573,Efficacy and Safety of Atorvastatin in Combination With Radiotherapy and Temozolomide in Glioblastoma,Phase II Study of Atorvastatin in Combination With Radiotherapy and Temozolomide in Glioblastoma,COMPLETED,2014-01-01,2016-12-31,2017-08-18,INTERVENTIONAL,PHASE2,36.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Glioblastoma Multiforme,Atorvastatin|Temozolomide|Radiotherapy,DRUG|RADIATION,1,3,18 Years,70 Years,ALL,False,King Fahad Medical City,OTHER_GOV,0,1,Saudi Arabia,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.6109179126442243,small,1,1,0,1,0,0,0,0,0,0,0,0,1,0,4,1,1,0,0,3,1,,,,,0,1,0
NCT03060473,Treatment of ppROM With Erythromycin vs. Azithromycin Trial,TREAT: Treatment of ppROM With Erythromycin vs. Azithromycin Trial,TERMINATED,2017-02-23,2023-12-08,2024-06-25,INTERVENTIONAL,PHASE3,21.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Preterm Premature Rupture of Membranes (PPROM),Azithromycin|Erythromycin|Ampicillin|Amoxicillin,DRUG,1,1,18 Years,,FEMALE,False,"The University of Texas Medical Branch, Galveston",OTHER,0,3,United States,0.0,0,0,1,0,0,3.0,0,0,0,0,1,3.091042453358316,small,1,1,0,1,0,0,1,0,1,0,1,0,1,1,2,1,1,0,0,4,1,,,,,0,1,0
NCT00580073,Phase II Trial of Neoadjuvant FOLFOX4 and Cetuximab for Localized Adenocarcinoma of Rectum,A Phase II Trial of Neoadjuvant FOLFOX4 and Cetuximab for Localized Adenocarcinoma of the Rectum,TERMINATED,2007-12,2009-11,2019-12-13,INTERVENTIONAL,PHASE2,6.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Rectal Cancer,FOLFOX4|Cetuximab,DRUG,1,2,18 Years,,ALL,False,"University of Wisconsin, Madison",OTHER,3,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,1.9459101490553132,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,3,1,1,0,0,2,1,2007-12-01,2009-11-01,701.0,2007.0,0,1,0
NCT02414269,Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin,A Phase I/II Clinical Trial of Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin,ACTIVE_NOT_RECRUITING,2015-05,2026-04-30,2025-10-08,INTERVENTIONAL,PHASE1|PHASE2,113.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Malignant Pleural Disease|Mesothelioma|Metastases|Lung Cancer|Breast Cancer,iCasp9M28z T cell infusions|cyclophosphamide|pembrolizumab,DRUG|GENETIC,2,1,18 Years,,ALL,False,Memorial Sloan Kettering Cancer Center,OTHER,2,6,United States,,1,1,0,0,1,1.5,1,0,0,0,5,4.736198448394496,medium,0,1,0,1,0,1,1,0,1,0,0,0,1,1,3,1,1,0,0,3,1,2015-05-01,,,2015.0,1,3,1
NCT03647969,Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer,Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction - A Randomized Phase 2 Trial.,COMPLETED,2018-11-07,2024-07-19,2024-08-09,INTERVENTIONAL,PHASE2,262.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Adenocarcinoma of the Stomach|GastroEsophageal Cancer,Nivolumab|Ipilimumab|mFOLFOX|FLOT,DRUG,2,9,18 Years,,ALL,False,Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest,OTHER,0,27,Germany,1.0,0,1,0,0,0,2.0,1,0,0,0,2,5.572154032177765,large,0,1,0,1,0,0,1,0,0,1,1,0,1,1,11,1,1,0,0,4,1,,,,,0,3,1
NCT00000369,Maintenance Therapies in Bipolar Disorders,,COMPLETED,1997-06,2002-12,2013-06-25,INTERVENTIONAL,PHASE3,,,RANDOMIZED,,TREATMENT,,Bipolar Disorder,Individual psychotherapy|Lithium carbonate,BEHAVIORAL|DRUG,0,0,18 Years,,ALL,,University of Pittsburgh,OTHER,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,0.0,,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,2,1,1997-06-01,2002-12-01,2009.0,1997.0,0,1,0
NCT02492269,"Stress Response and Neurodevelopmental Outcome After Cardiac Surgery Utilizing CPB in Children: A Prospective, Double Blinded and Randomized Study",,COMPLETED,2014-05,2024-12,2025-08-07,INTERVENTIONAL,PHASE2,30.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Congenital Heart Disease,Dexmedetomidine|Placebo,DRUG,3,2,1 Month,12 Months,ALL,False,Aymen N Naguib,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,1,1,3.4339872044851463,small,1,1,0,1,0,0,0,0,1,0,1,1,0,1,5,1,1,0,0,2,1,2014-05-01,2024-12-01,3867.0,2014.0,0,1,0
NCT03215069,Empagliflozin and the Preservation of Beta-cell Function in Women with Recent Gestational Diabetes,Empagliflozin and the Preservation of Beta-cell Function in Women with Recent Gestational Diabetes,COMPLETED,2018-07-01,2024-12-31,2025-03-07,INTERVENTIONAL,PHASE3,91.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Gestational Diabetes,Empagliflozin 10 MG|Placebo oral capsule,DRUG,1,1,20 Years,50 Years,FEMALE,False,"Mount Sinai Hospital, Canada",OTHER,1,1,Canada,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.5217885770490405,medium,1,1,0,1,0,1,0,0,0,0,1,1,0,1,2,1,1,0,0,2,1,,,,,0,1,0
NCT04921969,A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3),"A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages≥ 2 Years to < 12 Years) With Atopic Dermatitis ((TRuE-AD3)",COMPLETED,2021-07-19,2024-04-08,2025-03-28,INTERVENTIONAL,PHASE3,330.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Atopic Dermatitis,Ruxolitinib|Vehicle Cream,DRUG,1,11,2 Years,11 Years,ALL,False,Incyte Corporation,INDUSTRY,0,67,Canada|United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.802118375377063,large,0,1,1,0,0,0,1,1,1,0,1,1,1,1,12,1,1,0,0,2,1,,,,,0,3,1
NCT05032183,Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,Phase Ib/II Study of the Combination of Low-Intensity Chemotherapy and Tagraxofusp in Patients With Acute Lymphoblastic Leukemia (ALL),TERMINATED,2022-02-17,2024-07-31,2025-08-11,INTERVENTIONAL,PHASE1|PHASE2,4.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Recurrent Adult Lymphoblastic Lymphoma|Recurrent B Acute Lymphoblastic Leukemia|Recurrent T Acute Lymphoblastic Leukemia|Refractory B Acute Lymphoblastic Leukemia|Refractory Lymphoblastic Lymphoma|Refractory T Acute Lymphoblastic Leukemia,Cyclophosphamide|Cytarabine|Dexamethasone|Filgrastim-sndz|Leucovorin|Mercaptopurine|Mesna|Methotrexate|Pegfilgrastim|Prednisone|Rituximab|Tagraxofusp-erzs|Vincristine,DRUG|BIOLOGICAL,1,3,18 Years,70 Years,ALL,False,M.D. Anderson Cancer Center,OTHER,0,1,United States,0.0,1,1,0,0,1,1.5,1,0,0,0,6,1.6094379124341003,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,4,1,1,1,0,13,1,,,,,0,3,1
NCT05619783,Extension Study Evaluating The Safety And Tolerability of AMX0035,"A Phase IIIb, Open Label Extension Study Evaluating The Safety And Tolerability of AMX0035 Up To 108 Weeks In Adult Participants With Amyotrophic Lateral Sclerosis (ALS) Previously Enrolled In Study A35-004 (PHOENIX)",COMPLETED,2022-12-29,2024-10-30,2025-01-13,INTERVENTIONAL,PHASE3,352.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Amyotrophic Lateral Sclerosis,AMX0035,DRUG,1,1,18 Years,,ALL,False,Amylyx Pharmaceuticals Inc.,INDUSTRY,0,46,Italy|Belgium|Netherlands|Sweden|Spain|Germany|United Kingdom|Poland|Portugal|France|Ireland,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.8664680569332965,large,0,1,1,0,0,0,1,1,0,1,0,0,1,0,2,1,1,0,0,1,0,,,,,0,1,0
NCT00870883,N-acetylcysteine Plus Deferoxamine for Patients With Hypotension,"Prospective, Randomized, Double-blinded, Placebo-controlled Study of N-acetylcysteine Plus Deferoxamine for Patients With Hypotension as Prophylaxis for Acute Renal Failure",COMPLETED,2009-03,2015-05,2015-05-28,INTERVENTIONAL,PHASE2,81.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Hypotension|Acute Renal Failure,N-acetylcysteine and deferoxamine,DRUG,1,2,18 Years,,ALL,False,Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude,OTHER,1,1,Brazil,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.406719247264253,medium,1,1,0,1,0,1,0,0,0,0,1,1,1,1,3,1,1,0,0,1,0,2009-03-01,2015-05-01,2252.0,2009.0,0,1,0
NCT02259283,Prospective Study on the Feasibility and Results of POEM in Idiopathic Achalasia,Prospective Study on the Feasibility and Results of the Treatment of Idiopathic Achalasia With the POEM (Per Oral Endoscopic Myotomy) Technique,COMPLETED,2012-12,2014-09,2014-10-08,INTERVENTIONAL,PHASE2,10.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Achalasia,Hybrid Knife,DEVICE,2,5,18 Years,75 Years,ALL,False,Istituto Clinico Humanitas,OTHER,0,1,Italy,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.3978952727983707,small,1,1,0,1,0,0,0,0,0,1,0,0,1,0,7,1,0,0,1,1,0,2012-12-01,2014-09-01,639.0,2012.0,0,1,0
NCT03765983,GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases,Phase II Trial of GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases,TERMINATED,2019-02-11,2024-05-14,2026-01-22,INTERVENTIONAL,PHASE2,17.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Breast Cancer,Trastuzumab|GDC-0084,DRUG,2,6,18 Years,,ALL,False,Dana-Farber Cancer Institute,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,2.8903717578961645,small,1,1,0,1,0,1,0,0,1,0,0,0,1,1,8,1,1,0,0,2,1,,,,,0,2,0
NCT00099983,Risperidone Treatment for Military Service Related Chronic Post Traumatic Stress Disorder,CSP #504 - Risperidone Treatment for Military Service Related Chronic Post-Traumatic Stress Disorder,COMPLETED,2006-10,2011-01,2014-08-22,INTERVENTIONAL,PHASE2,296.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Stress Disorders|Post-Traumatic,Risperidone|Placebo,DRUG,1,0,18 Years,,ALL,False,US Department of Veterans Affairs,FED,1,20,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,5.6937321388027,large,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,0,1,0,0,2,1,2006-10-01,2011-01-01,1553.0,2006.0,0,2,0
NCT04988841,Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma,Prospective randomIzed Clinical Trial Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma Treated With CTLA-4 and PD1 Inhibitors,COMPLETED,2022-01-20,2025-04-22,2025-08-28,INTERVENTIONAL,PHASE2,70.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Melanoma,MaaT013|Ipilimumab|Nivolumab|MoviPrep|Normacol|Placebo of Maat013,DRUG,1,14,18 Years,80 Years,ALL,False,Assistance Publique - Hôpitaux de Paris,OTHER,0,5,France,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.2626798770413155,medium,1,1,0,1,0,0,1,0,0,1,1,1,1,1,15,1,1,0,0,6,1,,,,,0,2,0
NCT00005641,Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation,T-Cell Depletion for Graft-Versus-Host Disease (GVHD) Prevention in High Risk Matched and Mismatched Allogeneic Bone Marrow Transplantation,TERMINATED,1997-09,2000-09,2012-12-11,INTERVENTIONAL,PHASE2,,,,,TREATMENT,,Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes,anti-thymocyte globulin|busulfan|cyclophosphamide|cyclosporine|leucovorin calcium|methotrexate|methylprednisolone|allogeneic bone marrow transplantation|in vitro-treated bone marrow transplantation|radiation therapy,DRUG|BIOLOGICAL|RADIATION|PROCEDURE,0,0,15 Years,60 Years,ALL,False,H. Lee Moffitt Cancer Center and Research Institute,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,5,0.0,,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,10,1,1997-09-01,2000-09-01,1096.0,1997.0,0,2,0
NCT07035054,Phase Ⅱ Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine,Evaluation of the Safety and Tolerability of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine in Individuals Aged 18 Years and Above: A Random PhaseⅡClinical Trial.,COMPLETED,2024-04-20,2024-11-30,2025-06-24,INTERVENTIONAL,PHASE2,992.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Streptococcus Pneumoniae Pneumonia,low dose-1|low dose-2|high dose|positive control,BIOLOGICAL,1,2,18 Years,,ALL,True,Jiangsu Province Centers for Disease Control and Prevention,NETWORK,0,1,China,1.0,0,1,0,0,0,2.0,0,0,0,0,1,6.900730664045173,xlarge,0,1,0,0,0,0,0,0,0,0,1,1,0,1,3,1,0,1,0,4,1,,,,,0,1,0
NCT04344054,Mixed Schedule Study of Live Oral Rotavirus Vaccines and Trivalent P2-VP8 Subunit Rotavirus Vaccine,"A Phase II, Observer-blinded, Randomized, Active-controlled Study to Examine the Immunogenicity and Safety of Rotarix® and RV3-BB When Co-administered/Boosted With Trivalent P2-VP8 Subunit Rotavirus Vaccine Candidate in Healthy Infants in South Africa",COMPLETED,2021-02-22,2022-09-09,2022-11-29,INTERVENTIONAL,PHASE2,850.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Rotavirus Vaccine,RV3-BB|Trivalent P2-VP8|Rotarix|RV3-BB birth dose|Trivalent P2-VP8 Booster dose,BIOLOGICAL,7,8,,56 Days,ALL,True,PATH,OTHER,4,2,South Africa,1.0,0,1,0,0,0,2.0,0,0,0,0,1,6.7464121285733745,xlarge,0,1,0,1,0,1,1,0,0,0,1,1,1,1,15,1,0,1,0,5,1,,,,,0,2,0
NCT00036205,"Open Label Sumanirole Study of Safety, Tolerability, and Therapeutic Response In Patients With Parkinson's Disease","Open-Label, Long Term, Flexible Dose Study Of Safety, Tolerability, And Therapeutic Response In Patients With Parkinson's Disease.",TERMINATED,2000-08,2004-12,2007-01-18,INTERVENTIONAL,PHASE3,984.0,,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Parkinson Disease,sumanirole,DRUG,1,4,30 Years,,ALL,False,Pfizer,INDUSTRY,0,110,Puerto Rico|Argentina|Colombia|United States,0.0,0,0,1,0,0,3.0,0,0,1,0,1,6.892641641172089,xlarge,0,0,1,0,1,0,1,1,1,0,0,0,1,0,5,1,1,0,0,1,0,2000-08-01,2004-12-01,1583.0,2000.0,0,1,0
NCT02715505,Safety and Exploratory Efficacy of HSC835 in Patients With Inherited Metabolic Disorders (IMD),"A Single-arm, Open-label, Study to Evaluate the Safety and Exploratory Efficacy of HSC835 in Patients With Inherited Metabolic Disorders (IMD) Undergoing Stem Cell Transplantation After Reduced Intensity Conditioning",WITHDRAWN,2017-10-10,2020-05-18,2018-11-28,INTERVENTIONAL,PHASE1|PHASE2,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Inherited Metabolic Disorders IMD,Umbilical cord blood transplantation with HSC835,DRUG,3,5,12 Months,25 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,0,,0.0,1,1,0,0,1,1.5,0,0,0,0,1,0.0,,1,1,1,0,1,0,0,0,0,0,0,0,1,0,8,1,1,0,0,1,0,,,,,0,2,0
NCT01056705,The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains (IPV),The Phase Ⅱ Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains,COMPLETED,2009-07,2010-08,2016-08-02,INTERVENTIONAL,PHASE2,500.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,SINGLE,Poliomyelitis,Inactivated Poliomyelitis Vaccine (Sabin strains)|Inactivated Poliomyelitis Vaccine (Sabin strains)|Inactivated Poliomyelitis Vaccine (Sabin strains)|Oral Poliomyelitis Vaccine|Inactivated Poliomyelitis Vaccine (Salk strains).,BIOLOGICAL,1,0,60 Days,90 Days,ALL,True,Chinese Academy of Medical Sciences,OTHER,2,1,China,1.0,0,1,0,0,0,2.0,0,0,0,0,1,6.2166061010848646,large,0,1,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,5,1,2009-07-01,2010-08-01,396.0,2009.0,0,1,0
NCT00993005,CICATRIX in the Treatment of Hypertrophic Scars and Keloids Scars,Efficacy of CICATRIX (Asian Gotu Kola or Pennywort) in the Treatment of Hypertrophic Scars and Keloids Scars.,COMPLETED,2009-10,2010-12,2010-12-08,INTERVENTIONAL,PHASE3,90.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Hypertrophic Scars|Keloids,Cicatrix|Placebo,OTHER,1,2,18 Years,55 Years,ALL,False,Catalysis SL,INDUSTRY,0,1,Cuba,1.0,0,0,1,0,0,3.0,0,0,0,0,2,4.51085950651685,medium,1,0,1,0,0,0,0,0,0,0,1,1,1,1,3,1,0,0,0,2,1,2009-10-01,2010-12-01,426.0,2009.0,0,2,0
NCT02789605,Effectiveness and Safety of Lactobacillus Rhamnosus Lcr35® in the Treatment of Recurrent Aphthous Stomatitis,"Treatment of Idiopathic and Recurrent Aphthous Stomatitis by a Probiotic, the Lactobacillus Rhamnosus Lcr35® : a Randomized, Double Blind and Placebo-controlled Trial",COMPLETED,2018-01-04,2020-07-15,2020-11-10,INTERVENTIONAL,PHASE2,20.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Aphthous Stomatitis,Bacilor|Placebo,DRUG,1,2,18 Years,,ALL,False,Centre Hospitalier Universitaire de Nice,OTHER,0,1,France,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.044522437723423,small,1,1,0,1,0,0,0,0,0,1,1,1,1,1,3,1,1,0,0,2,1,,,,,0,1,0
NCT01228994,Baclofen for Smoking Cessation in a Non-Psychiatric Population,Testing the GABAergic Hypothesis of Nicotine Dependence: a Randomized Clinical Trial of Baclofen,TERMINATED,2010-10,2012-08,2013-09-12,INTERVENTIONAL,PHASE2,6.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Nicotine Dependence,Baclofen 30 mg/day|placebo pill|Baclofen 60 mg/day,DRUG,3,2,18 Years,75 Years,ALL,True,Centre for Addiction and Mental Health,OTHER,1,1,Canada,0.0,0,1,0,0,0,2.0,0,0,0,0,1,1.9459101490553132,small,1,1,0,1,0,1,0,0,0,0,1,1,1,1,5,1,1,0,0,3,1,2010-10-01,2012-08-01,670.0,2010.0,0,1,0
NCT02246894,A Study to Investigate the Safety and Efficacy of Optivate® in Children Under 6 Years of Age With Haemophilia A.,An Open Multicentre Phase III Study to Investigate the Safety and Efficacy of Optivate® in Children Under 6 Years of Age With Severe Haemophilia A.,COMPLETED,2003-11,,2018-02-15,INTERVENTIONAL,PHASE3,,,,,,,Haemophilia A,Optivate® (Human Coagulation Factor VIII),BIOLOGICAL,1,0,,6 Years,ALL,False,Bio Products Laboratory,OTHER,0,5,Poland,1.0,0,0,1,0,0,3.0,0,0,0,0,1,0.0,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,2003-11-01,,,2003.0,0,0,0
NCT01130194,"Immunochemotherapy, Zevalin, and Bone Marrow Transplant for Follicular Lymphoma","A Pilot Phase II Study Of Sequential Treatment With Chemotherapy, Radioimmunotherapy and Autologous Hematopoietic Stem Cell Transplantation in Patients With Follicular Lymphoma",COMPLETED,2006-07,2012-06,2014-05-12,INTERVENTIONAL,PHASE2,29.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Follicular Lymphoma,Combination of treatment modalities,OTHER,1,1,18 Years,80 Years,ALL,False,St. Louis University,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.4011973816621555,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,2,1,0,0,0,1,0,2006-07-01,2012-06-01,2162.0,2006.0,0,0,0
NCT00454194,Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,Phase II Randomized Study of Pemetrexed With Sorafenib Versus Pemetrexed Alone as Second-Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer,COMPLETED,2007-09,2013-05,2017-03-21,INTERVENTIONAL,PHASE2,110.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Lung Cancer,pemetrexed disodium|sorafenib tosylate,DRUG,1,5,18 Years,120 Years,ALL,False,Alliance for Clinical Trials in Oncology,OTHER,1,207,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.709530201312334,medium,0,1,0,1,0,1,1,0,1,0,1,0,1,1,6,1,1,0,0,2,1,2007-09-01,2013-05-01,2069.0,2007.0,0,2,0
NCT01280266,Efficacy Study of PDE-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon,"Comparison of Phosphodiesterase-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon, Double Blind, Randomized, Cross-over Trial",COMPLETED,2011-01,2011-06,2012-12-11,INTERVENTIONAL,PHASE2|PHASE3,29.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Raynaud Phenomenon,Udenafil or Amlodipine,DRUG,1,8,18 Years,75 Years,ALL,False,Seoul National University Hospital,OTHER,1,1,South Korea,1.0,0,1,1,0,1,2.5,0,0,0,0,1,3.4011973816621555,small,1,1,0,1,0,1,0,0,0,0,1,1,1,0,9,1,1,0,0,1,0,2011-01-01,2011-06-01,151.0,2011.0,0,2,0
NCT03668366,S-1 Combined With IMRT Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma,S-1 Combined With IMRT Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma,COMPLETED,2013-08-01,2020-08-01,2021-02-11,INTERVENTIONAL,PHASE2,133.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Nasopharyngeal Carcinoma,S-1,DRUG,1,0,18 Years,80 Years,ALL,True,Fudan University,OTHER,0,1,China,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.897839799950911,medium,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,,,,,0,0,0
NCT00609466,A Trial to Evaluate CG5503 Efficacy and Safety in Acute Pain After Bunionectomy,"A Randomized, Double-blind, Parallel-group, Multi-center, Active- and Placebo-controlled Trial to Evaluate the Analgesic Efficacy and Safety of Multiple Doses of CG5503 IR for Postoperative Pain Following Bunionectomy",COMPLETED,2007-09,2008-02,2011-11-16,INTERVENTIONAL,PHASE3,291.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Bunionectomy|Pain|Postoperative Pain|Acute Pain,CG5503 IR|Morphine|Placebo,DRUG,1,6,18 Years,80 Years,ALL,False,Grünenthal GmbH,INDUSTRY,1,6,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,4,5.676753802268282,large,0,1,1,0,0,1,1,0,1,0,1,1,1,1,7,1,1,0,0,3,1,2007-09-01,2008-02-01,153.0,2007.0,0,3,1
NCT01023256,Safety and Preliminary Efficacy of MOR103 in Patients With Active Rheumatoid Arthritis,"A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Preliminary Clinical Activity and Immunogenicity of Multiple Doses of MOR103 Administered Intravenously to Patients With Active Rheumatoid Arthritis",COMPLETED,2009-12,2012-06,2014-10-24,INTERVENTIONAL,PHASE1|PHASE2,96.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,DOUBLE,Rheumatoid Arthritis,MOR103|MOR103|MOR103,DRUG,1,5,18 Years,,ALL,False,MorphoSys AG,INDUSTRY,0,5,Netherlands|Bulgaria|Germany|Poland|Ukraine,1.0,1,1,0,0,1,1.5,0,1,0,0,1,4.574710978503383,medium,1,1,1,0,0,0,1,1,0,1,1,1,1,0,6,1,1,0,0,3,1,2009-12-01,2012-06-01,913.0,2009.0,0,4,1
NCT00080756,Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease,"Biomarkers, Breast Density And Risk Reduction Perspectives In BRCA Carriers",ACTIVE_NOT_RECRUITING,2004-03-11,2024-10-15,2024-08-28,INTERVENTIONAL,PHASE2,11.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,PREVENTION,NONE,brca1 Mutation Carrier|brca2 Mutation Carrier|Breast Cancer,therapeutic estradiol|deslorelin|therapeutic testosterone|therapeutic conventional surgery|active surveillance|quality-of-life assessment|laboratory biomarker analysis,DRUG|BIOLOGICAL|OTHER|PROCEDURE,2,0,21 Years,48 Years,FEMALE,False,City of Hope Medical Center,OTHER,1,1,United States,,0,1,0,0,0,2.0,1,0,0,0,3,2.4849066497880004,small,1,1,0,1,0,1,0,0,1,0,0,0,0,0,2,0,1,1,0,7,1,,,,,0,2,0
NCT00582556,Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy,Phase II Trial of Zometa on Bone Mineral Density on Patients With Stage D Prostate Cancer Undergoing Androgen Ablation Therapy,COMPLETED,2003-04,2013-03,2019-11-26,INTERVENTIONAL,PHASE2,44.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Prostate Cancer,Zometa|zometa|Zometa,DRUG,1,3,18 Years,,MALE,False,"University of Wisconsin, Madison",OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.8066624897703196,small,1,1,0,1,0,1,0,0,1,0,1,0,1,1,4,1,1,0,0,3,1,2003-04-01,2013-03-01,3622.0,2003.0,0,1,0
NCT05197556,A Study to Evaluate the Safety and Efficacy of HSG4112 in Overweight and Obese Patients,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Groups, Phase 2a Clinical Trial to Evaluate the Safety and Efficacy of HSG4112 in Overweight and Obese Patients Following 12 Weeks of Oral Treatment",COMPLETED,2022-02-24,2023-04-04,2024-03-19,INTERVENTIONAL,PHASE2,81.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Obesity,HSG4112|Placebo,DRUG,2,4,19 Years,70 Years,ALL,False,Glaceum,INDUSTRY,5,1,South Korea,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.406719247264253,medium,1,1,1,0,0,1,0,0,0,0,1,1,1,1,6,1,1,0,0,2,1,,,,,0,2,0
NCT02388724,Efficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Participants With Erosive Esophagitis,"A Randomized, Double-Blind, Double-Dummy Phase 3 Study to Evaluate the Efficacy and Safety of Oral Once-Daily Administration of TAK-438 20 mg Compared to Lansoprazole 30 mg in the Treatment of Subjects With Erosive Esophagitis",COMPLETED,2015-03-24,2017-07-27,2019-06-03,INTERVENTIONAL,PHASE3,481.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Erosive Esophagitis,Vonoprazan|Lansoprazole|Vonoprazan Placebo|Lansoprazole Placebo,DRUG,1,8,18 Years,,ALL,False,Takeda,INDUSTRY,0,64,China|South Korea|Taiwan|Malaysia,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.1779441140506,large,0,1,1,0,1,0,1,1,0,0,1,1,1,1,9,1,1,0,0,4,1,,,,,0,3,1
NCT01172223,Primary Chemotherapy in Patients With HER2-positive Early Breast Cancer,"Phase I/II Trial of Primary Chemotherapy With Non-pegylated Liposomal Doxorubicin, Paclitaxel and Lapatinib in Patients With HER2-positive Early",COMPLETED,2007-09,2013-12,2016-11-02,INTERVENTIONAL,PHASE1|PHASE2,81.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Breast Cancer,"Myocet (Non-pegylated liposomal doxorubicin (NPLD))|Paclitaxel|Lapatinib (GW572016, Tykerb)",DRUG,2,0,18 Years,,FEMALE,False,Prof Dirk Elling,OTHER,0,1,Germany,1.0,1,1,0,0,1,1.5,1,0,0,0,1,4.406719247264253,medium,1,1,0,1,0,0,0,0,0,1,0,0,1,0,2,0,1,0,0,3,1,2007-09-01,2013-12-01,2283.0,2007.0,0,2,0
NCT02776059,Pegfilgrastim in Patients With Alcoholic Hepatitis,"A Phase II, Multicenter, Randomized, Open-label Study to Investigate the Safety and Efficacy of Pegfilgrastim (Neulasta®) in Patients With Alcoholic Hepatitis",COMPLETED,2017-01-21,2021-03-31,2021-09-29,INTERVENTIONAL,PHASE2,34.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Alcoholic Hepatitis,Standard of care + pegfiltrastim|Standard of care,DRUG,1,4,18 Years,,ALL,False,"Timothy Morgan, MD",OTHER,1,5,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.5553480614894135,small,1,1,0,1,0,1,1,0,1,0,1,0,1,1,5,1,1,0,0,2,1,,,,,0,1,0
NCT01389024,Hydroxyurea to Prevent Brain Injury in Sickle Cell Disease,Hydroxyurea to Prevent Central Nervous System (CNS) Complications of Sickle Cell Disease in Children,COMPLETED,2012-08-16,2022-05-24,2024-07-10,INTERVENTIONAL,PHASE2,28.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Sickle Cell Disease|Stroke,Hydroxyurea|Placebo,DRUG,1,3,12 Months,54 Months,ALL,False,Johns Hopkins University,OTHER,10,5,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,3.367295829986474,small,1,1,0,1,0,1,1,0,1,0,1,1,0,1,4,1,1,0,0,2,1,,,,,0,2,0
NCT05431179,A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Zilovertamab (an ROR1 Antibody) Plus Ibrutinib Versus Ibrutinib Plus Placebo in Subjects With Relapsed or Refractory Mantle Cell Lymphoma",WITHDRAWN,2023-03,2026-12,2023-04-21,INTERVENTIONAL,PHASE3,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Lymphoma, Mantle-Cell|Lymphoma|Lymphoproliferative Disorders|Lymphatic Diseases|Immunoproliferative Disorders|Immune System Diseases|Lymphoma, Non-Hodgkin|Lymphoma, B-Cell",Zilovertamab|Ibrutinib|Placebo,DRUG,1,6,18 Years,,ALL,False,"Oncternal Therapeutics, Inc",INDUSTRY,1,0,,0.0,0,0,1,0,0,3.0,1,0,0,0,8,0.0,,1,1,1,0,0,1,0,0,0,0,1,1,1,1,7,1,1,0,0,3,1,2023-03-01,2026-12-01,1371.0,2023.0,1,3,1
NCT02019979,Metformin and Carbohydrate Restriction With Platinum Based Chemotherapy In Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NS-NSCLC),Metformin With a Carbohydrate Restricted Diet In Combination With Platinum Based Chemotherapy In Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NS-NSCLC) - METRO Study,TERMINATED,2013-12,2016-12,2018-05-04,INTERVENTIONAL,PHASE2,14.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Non-small Cell Lung Cancer Stage IIIB/IV|Non-small Cell Lung Cancer Metastatic|Nonsquamous Nonsmall Cell Neoplasm of Lung,metformin|carbohydrate restricted diet,BEHAVIORAL|DRUG,1,2,18 Years,,ALL,False,Beth Israel Medical Center,OTHER,1,4,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,3,2.70805020110221,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,3,1,1,0,0,2,1,2013-12-01,2016-12-01,1096.0,2013.0,0,2,0
NCT03515096,Eltrombopag vs. rhTPO to Increase Platelet Level After HSCT,"Eltrombopag vs. Recombinant Human Thrombopoietin to Increase Platelet Level After Hematopoietic Stem Cell Transplantation: a Non-inferiority, Open-label, Randomized-controlled Study",COMPLETED,2018-07-01,2022-07-01,2022-07-27,INTERVENTIONAL,PHASE3,98.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Eltrombopag|Hematopoietic Stem Cell Transplantation|Thrombocytopenia,Eltrombopag|rhTPO,DRUG,1,4,18 Years,,ALL,False,Shenzhen Second People's Hospital,OTHER,0,1,China,1.0,0,0,1,0,0,3.0,0,0,0,0,3,4.59511985013459,medium,1,1,0,1,0,0,0,0,0,0,1,1,1,1,5,1,1,0,0,2,1,,,,,0,2,0
NCT03295396,ONC201 in Adults With Recurrent H3 K27M-mutant Glioma,"A Phase II, Open-label Study of ONC201 in Adults With Recurrent High-grade Glioma",TERMINATED,2017-10-30,2023-07-19,2025-07-28,INTERVENTIONAL,PHASE2,73.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Glioma,Dordaviprone (ONC201),DRUG,1,1,18 Years,,ALL,False,Jazz Pharmaceuticals,INDUSTRY,1,9,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,4.30406509320417,medium,1,1,1,0,0,1,1,0,1,0,0,0,1,0,2,1,1,0,0,1,0,,,,,0,0,0
NCT01389362,The Healing Effect of a Two-Herb Recipe on Foot Ulcer in Chinese Patients With Type 2 Diabetes,"The Healing Effect of a Two-Herb Recipe on Foot Ulcer in Chinese Patients With Type 2 Diabetes: A Randomized, Placebo-Controlled Study",COMPLETED,2009-05,2011-05,2011-07-28,INTERVENTIONAL,PHASE2|PHASE3,16.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Diabetic Foot Ulcer,Chinese herbal medicine (Radix Rehmanniae and Radix Astragali)|Placebo comparator,DRUG,1,1,20 Years,75 Years,ALL,False,Chinese University of Hong Kong,OTHER,0,1,China,1.0,0,1,1,0,1,2.5,0,0,0,0,1,2.833213344056216,small,1,1,0,1,0,0,0,0,0,0,1,1,1,1,2,1,1,0,0,2,1,2009-05-01,2011-05-01,730.0,2009.0,0,2,0
NCT00697762,Effectiveness and Safety Study for RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset Seizures,A Double-Blind Study to Evaluate the Effectiveness and Safety of RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset Seizures,TERMINATED,2007-10,2008-05,2013-01-23,INTERVENTIONAL,PHASE3,56.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Seizures,RWJ-333369|RWJ-333369|Placebo,DRUG,1,1,16 Years,,ALL,False,"SK Life Science, Inc.",INDUSTRY,0,0,,0.0,0,0,1,0,0,3.0,0,0,0,0,1,4.04305126783455,medium,1,1,1,0,0,0,0,0,0,0,1,1,1,1,2,1,1,0,0,3,1,2007-10-01,2008-05-01,213.0,2007.0,0,1,0
NCT00130962,ALGRX 4975 in the Treatment of Patients With Morton's Neuroma,"A Randomized, Double-Blind, Placebo-Controlled Trial of ALGRX 4975 in Subjects With Painful Intermetatarsal Neuroma",COMPLETED,2004-09,2006-02,2005-10-03,INTERVENTIONAL,PHASE2,60.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Neuroma,ALGRX 4975,DRUG,1,3,18 Years,,ALL,False,AlgoRx Pharmaceuticals,INDUSTRY,0,2,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.110873864173311,medium,1,0,1,0,0,0,1,0,1,0,1,1,1,1,4,1,1,0,0,1,0,2004-09-01,2006-02-01,518.0,2004.0,0,0,0
NCT04656262,Low Dose Continuous Cyclophosphamide vs Standard Doxorubicin in Advanced Sarcoma Elderly Patients,"The METROPHOLYS Study Metronomic Cyclophosphamide vs Doxorubicin in Elderly Patients With Advanced Soft Tissue Sarcomas Randomized, Controlled Open Label Clinical Trial",TERMINATED,2018-09-10,2024-05-23,2024-07-08,INTERVENTIONAL,PHASE3,79.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Soft Tissue Sarcoma Adult,Cyclophosphamide|Doxorubicin,DRUG,1,3,70 Years,,ALL,False,Istituto Oncologico Veneto IRCCS,OTHER,1,13,Italy,0.0,0,0,1,0,0,3.0,1,0,0,0,1,4.382026634673881,medium,1,1,0,1,0,1,1,0,0,1,1,0,1,1,4,1,1,0,0,2,1,,,,,0,1,0
NCT01515462,Gene Therapy for Wiskott-Aldrich Syndrome,A Phase I/II Clinical Trial of Hematopoietic Stem Cell Gene Therapy for the Wiskott-Aldrich Syndrome,COMPLETED,2010-04-20,2023-10-04,2025-04-04,INTERVENTIONAL,PHASE1|PHASE2,8.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Wiskott-Aldrich Syndrome (WAS),TLT003,GENETIC,8,7,,,ALL,False,Fondazione Telethon,OTHER,1,1,Italy,1.0,1,1,0,0,1,1.5,0,0,0,0,1,2.1972245773362196,small,1,1,0,1,0,1,0,0,0,1,0,0,1,0,15,1,0,0,0,1,0,,,,,0,2,0
NCT00730262,Efficacy Study of TLN-4601 in Patients With Recurring Glioblastoma Multiforme,A Phase II Study of TLN-4601 in Patients With Glioblastoma Multiforme,TERMINATED,2008-08,2010-06,2009-12-30,INTERVENTIONAL,PHASE2,40.0,ESTIMATED,,SINGLE_GROUP,TREATMENT,NONE,Glioblastoma Multiforme,TLN-4601,DRUG,1,1,18 Years,,ALL,False,Thallion Pharmaceuticals,INDUSTRY,0,8,Canada|United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,3.713572066704308,small,1,0,1,0,0,0,1,1,1,0,0,0,1,0,2,1,1,0,0,1,0,2008-08-01,2010-06-01,669.0,2008.0,0,1,0
NCT03416062,Remaxol® in Malignant Mechanical Jaundice,"A Multicenter, Double-blind, Placebo-controlled, Randomized Trial of the Efficacy and Safety of Remaxol®, a Solution for Infusions Produced by STPF POLYSAN (Russia), in Patients With Malignant Mechanical Jaundice",COMPLETED,2017-04-03,2020-03-04,2020-07-10,INTERVENTIONAL,PHASE3,240.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Jaundice; Malignant,Remaxol®|Ringer's Solution,DRUG,1,12,18 Years,,ALL,False,POLYSAN Scientific & Technological Pharmaceutical Company,INDUSTRY,0,18,Russia,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.484796933490655,large,0,1,1,0,0,0,1,0,0,0,1,1,1,1,13,1,1,0,0,2,1,,,,,0,2,0
NCT05450562,Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors,"A Phase 1/2 Open-label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR444200-based Regimen in Participants With Advanced Solid Tumors.",TERMINATED,2022-09-20,2025-12-22,2026-01-14,INTERVENTIONAL,PHASE1|PHASE2,33.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Neoplasm,SAR444200|Atezolizumab,BIOLOGICAL,3,9,18 Years,,ALL,False,Sanofi,INDUSTRY,0,13,China|South Korea|United States|Singapore|Canada,0.0,1,1,0,0,1,1.5,0,0,0,0,1,3.5263605246161616,small,1,1,1,0,1,0,1,1,1,0,0,0,1,1,12,1,0,1,0,2,1,,,,,0,4,1
NCT02183246,Porfiromycin Used as an Adjuvant to Radiation Therapy in Postoperative Head and Neck Cancer Patients,"A Phase III, Double-Blind, Randomized, Placebo-Controlled Study of Porfiromycin Used as an Adjuvant to Radiation Therapy in Postoperative Head and Neck Cancer Patients",TERMINATED,2000-05,,2014-07-08,INTERVENTIONAL,PHASE3,3.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Head and Neck Neoplasms,Porfiromycin|Placebo|Radiotherapy,DRUG|RADIATION,4,7,18 Years,,ALL,False,Boehringer Ingelheim,INDUSTRY,0,0,,0.0,0,0,1,0,0,3.0,0,0,0,0,1,1.3862943611198906,small,1,1,1,0,0,0,0,0,0,0,1,1,1,1,11,1,1,0,0,3,1,2000-05-01,,,2000.0,0,2,0
NCT06475846,A Trial of HRS5580 in Prevention of Postoperative Nausea and Vomiting of Adults,"A Evaluate HRS5580 for Injection for Prevention of Postoperative Nausea and Vomiting Efficacy and Safety of Ⅱ Period, Randomized, Multicenter, Dose of Exploration, Positive Control, Placebo-controlled, Double-blind, Double Simulation Trials",COMPLETED,2024-06-25,2024-10-29,2025-01-20,INTERVENTIONAL,PHASE2,235.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Preventing of Postoperative Nausea and Vomiting in Adults,HRS5580|HRS5580|HRS5580|Ondansetron|blank preparation,DRUG,1,4,18 Years,,ALL,False,"Fujian Shengdi Pharmaceutical Co., Ltd.",INDUSTRY,0,2,China,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.4638318050256105,large,0,1,1,0,0,0,1,0,0,0,1,1,1,1,5,1,1,0,0,5,1,,,,,0,1,0
NCT02413346,A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris,A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris,COMPLETED,2015-03-20,2016-08-26,2019-02-01,INTERVENTIONAL,PHASE3,490.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Acne Vulgaris,Sarecycline,DRUG,1,0,9 Years,,ALL,False,"Almirall, S.A.",INDUSTRY,1,56,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.19644412779452,large,0,1,1,0,0,1,1,0,1,0,0,0,1,0,1,0,1,0,0,1,0,,,,,0,0,0
NCT02382588,Comparison of Topical 0.15% Gancyclovir Gel Versus 0.3% Hypromellose Gel for the Treatment of Herpes Zoster Keratitis,"A Prospective, Double-masked, Placebo Controlled Comparison of Topical 0.15% Gancyclovir Gel (Zirgan) Versus 0.3% Hypromellose Gel (Genteal Gel; Placebo) for the Treatment of Herpes Zoster Keratitis",TERMINATED,2013-12-10,2020-05-11,2021-07-08,INTERVENTIONAL,PHASE2,8.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Herpes Zoster Keratitis,gancyclovir gel|Hypromellose gel,DRUG,1,0,18 Years,95 Years,ALL,True,Northwestern University,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,2.1972245773362196,small,1,1,0,1,0,1,0,0,1,0,1,1,1,1,1,0,1,0,0,2,1,,,,,0,1,0
NCT01245088,Chondroitin Sulfate for Crohn's Disease,A Pilot Study of Chondroitin Sulfate (CS) for the Treatment of Mild to Moderate Crohn's Disease,WITHDRAWN,2011-01,2012-05,2012-08-31,INTERVENTIONAL,PHASE1|PHASE2,0.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Crohn's Disease,chondroitin sulfate,DRUG,1,0,18 Years,80 Years,ALL,False,University Hospitals Cleveland Medical Center,OTHER,0,1,United States,0.0,1,1,0,0,1,1.5,0,1,0,0,1,0.0,,1,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,2011-01-01,2012-05-01,486.0,2011.0,0,1,0
NCT03444103,A Pilot Trial of Clazakizumab in Late ABMR,"Safety, Tolerability and Efficacy of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Rejection After Kidney Transplantation - a Pilot Trial",COMPLETED,2018-01-16,2020-06-30,2020-09-09,INTERVENTIONAL,PHASE2,20.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Antibody-mediated Rejection,Clazakizumab / Clazakizumab|Placebo / Clazakizumab,DRUG,1,26,18 Years,100 Years,ALL,False,Medical University of Vienna,OTHER,3,2,Germany|Austria,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.044522437723423,small,1,1,0,1,0,1,1,1,0,1,1,1,1,1,27,1,1,0,0,2,1,,,,,0,3,1
NCT01000103,Using Repetitive Transcranial Magnetic Stimulation (rTMS) in the Rehabilitation of Chronic Spatial Neglect After Stroke,Using Repetitive Transcranial Magnetic Stimulation (rTMS) in the Rehabilitation of Chronic Spatial Neglect After Stroke: A Double Blind Study,COMPLETED,2010-03-24,2014-10-15,2021-02-25,INTERVENTIONAL,PHASE3,34.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Cerebrovascular Disorders|Cerebral Stroke|VISIO-spatial Neglect|VISUO-spatial Extinction,Real rTMS|Sham rTMS,DEVICE,1,12,18 Years,75 Years,ALL,False,Assistance Publique - Hôpitaux de Paris,OTHER,0,1,France,1.0,0,0,1,0,0,3.0,0,0,0,0,4,3.5553480614894135,small,1,1,0,1,0,0,0,0,0,1,1,1,1,1,13,1,0,0,1,2,1,,,,,0,3,1
NCT05873803,The Study of GR1802 in Patients with Chronic Rhinosinusitis with Nasal Polyps,"A Randomized, Double Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy, Safety of GR1802 Injection in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)",ACTIVE_NOT_RECRUITING,2023-02-08,2024-12-30,2024-09-25,INTERVENTIONAL,PHASE2,70.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Chronic Rhinosinusitis with Nasal Polyps,GR1802 injection|placebo,BIOLOGICAL,2,12,18 Years,75 Years,ALL,False,"Genrix (Shanghai) Biopharmaceutical Co., Ltd.",INDUSTRY,0,1,China,,0,1,0,0,0,2.0,0,0,0,0,1,4.2626798770413155,medium,1,0,1,0,0,0,0,0,0,0,1,1,1,1,14,1,0,1,0,2,1,,,,,0,2,0
NCT03533803,Indomethacin Prior to Difficult Embryo Transfer is it a Solution?,Indomethacin Prior to Difficult Embryo Transfer is it a Solution?,COMPLETED,2018-06-02,2018-12-02,2018-12-14,INTERVENTIONAL,PHASE3,200.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Difficult Embryo Transfer,Indomethacin 100Mg Suppository|IVF/ICSI,DRUG|PROCEDURE,1,2,20 Years,38 Years,FEMALE,True,Cairo University,OTHER,1,1,Egypt,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.303304908059076,medium,0,1,0,1,0,1,0,0,0,0,1,0,0,1,3,1,1,0,0,2,1,,,,,0,1,0
NCT01451203,Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis,"A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of CDP870 in Patients With Early-stage Rheumatoid Arthritis Who Are Naïve to Methotrexate and Have Poor Prognostic Factors",COMPLETED,2011-10-11,2014-10-20,2024-12-09,INTERVENTIONAL,PHASE3,319.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Rheumatoid Arthritis,Placebo|CZP|methotrexate (MTX),DRUG,1,4,20 Years,64 Years,ALL,False,Astellas Pharma Inc,INDUSTRY,1,8,Japan,1.0,0,0,1,0,0,3.0,0,1,0,0,1,5.768320995793772,large,0,1,1,0,0,1,1,0,0,0,1,1,1,1,5,1,1,0,0,3,1,,,,,0,1,0
NCT00426127,Docetaxel and Liposomal Doxorubicin Chemotherapy With Enoxaparin in Patients With Advanced Pancreatic Cancer,Phase II Trial of Docetaxel and Liposomal Doxorubicin (Doxil) Chemotherapy Combined With Enoxaparin in Patients With Advanced Pancreatic Cancer,TERMINATED,2006-11,2009-08,2017-12-29,INTERVENTIONAL,PHASE2,2.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Pancreatic Cancer,Docetaxel|Liposomal Doxorubicin|Enoxaparin,DRUG,1,2,18 Years,,ALL,False,University of Iowa,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,1.0986122886681098,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,3,1,1,0,0,3,1,2006-11-01,2009-08-01,1004.0,2006.0,0,1,0
NCT00346827,"Apomorphine Nasal Powder in the Treatment of Parkinson's Disease ""Off"" Periods.",,COMPLETED,2006-07,2007-08,2019-07-10,INTERVENTIONAL,PHASE2|PHASE3,36.0,ACTUAL,,SEQUENTIAL,TREATMENT,DOUBLE,Parkinson's Disease,Apomorphine Nasal Powder,DRUG,0,0,18 Years,85 Years,ALL,False,Britannia Pharmaceuticals Ltd.,INDUSTRY,0,0,,1.0,0,1,1,0,1,2.5,0,0,1,0,1,3.6109179126442243,small,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,2006-07-01,2007-08-01,396.0,2006.0,0,1,0
NCT01946061,A Phase II Trial of Adjuvant Chemotherapy With S-1 Plus Oxaliplatin for Locally Advanced Gastric Cancer,,TERMINATED,2015-05,2016-03,2016-08-19,INTERVENTIONAL,PHASE2,3.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Advanced Gastric Cancer,S-1 plus oxaliplatin,DRUG,1,0,19 Years,75 Years,ALL,False,Yonsei University,OTHER,0,1,South Korea,0.0,0,1,0,0,0,2.0,1,0,0,0,1,1.3862943611198906,small,1,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,2015-05-01,2016-03-01,305.0,2015.0,1,0,0
NCT00030186,Open Study of CEP-701 in Patients With Refractory Acute Myeloid Leukemia With FLT-3 Mutation,"An Open-Label Study of CEP-701 in Patients With Refractory, Relapsed, or Poor Risk Acute Myeloid Leukemia Expressing FLT-3 Activating Mutations",COMPLETED,2002-01,2003-02,2012-08-23,INTERVENTIONAL,PHASE2,37.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,"Leukemia, Myeloid",CEP-701 60mg|Cep-701 80mg|Cep-701 40mg,DRUG,1,3,18 Years,,ALL,False,Cephalon,INDUSTRY,0,0,,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.6375861597263857,small,1,1,1,0,0,0,0,0,0,0,0,0,1,0,4,1,1,0,0,3,1,2002-01-01,2003-02-01,396.0,2002.0,0,1,0
NCT00005086,Combination Chemotherapy in Treating Patients With Stage IV Locally Advanced or Metastatic Bladder Cancer,"A Phase II Trial of ""Sequential Doublets"" Chemotherapy in Patients With Locally Advanced or Metastatic Bladder Cancer",COMPLETED,1999-08,2005-04,2013-09-05,INTERVENTIONAL,PHASE2,6.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Bladder Cancer,cisplatin|docetaxel|gemcitabine hydrochloride|methotrexate,DRUG,1,0,18 Years,,ALL,False,University of Chicago,OTHER,1,4,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,1.9459101490553132,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,1,0,1,0,0,4,1,1999-08-01,2005-04-01,2070.0,1999.0,0,1,0
NCT00073970,Celecoxib in Treating Patients With Relapsed Prostate Cancer Following Radiation Therapy or Radical Prostatectomy,A Trial Of COX-2 Inhibitors In PSA Recurrence After Definitive Radiation Or Radical Prostatectomy For Prostate Cancer,TERMINATED,2003-04,2006-01,2012-05-23,INTERVENTIONAL,PHASE2,37.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Prostate Cancer,celecoxib,DRUG,1,1,18 Years,,MALE,False,UNC Lineberger Comprehensive Cancer Center,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,3.6375861597263857,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,2,1,1,0,0,1,0,2003-04-01,2006-01-01,1006.0,2003.0,0,0,0
NCT02788773,Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer,A Phase II Study of Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Metastatic Castration Resistant Prostate Cancer,COMPLETED,2016-12-15,2025-05-01,2025-05-15,INTERVENTIONAL,PHASE2,52.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Prostate Cancer,Durvalumab|Tremelimumab,DRUG,2,2,18 Years,,MALE,False,Canadian Cancer Trials Group,NETWORK,1,11,Canada,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.970291913552122,medium,1,1,0,0,0,1,1,0,0,0,1,0,1,1,4,1,1,0,0,2,1,,,,,0,1,0
NCT00985673,Safety and Immunogenicity of H1N1 Vaccine With Trivalent Inactivated Seasonal Influenza Vaccine in Adults,A Study to Evaluate the Safety and Immunogenicity of an A/California/7/2009 (H1N1)V-like Vaccine GSK2340274A or GSK2340273A Co-administered With Trivalent Inactivated Seasonal Influenza Vaccine in Adults 19 to 40 Years of Age,COMPLETED,2009-10-01,2010-12-29,2018-08-01,INTERVENTIONAL,PHASE2,611.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Influenza,GSK2340274A|GSK2340273A|Seasonal trivalent influenza vaccine (TIV)|Saline placebo,BIOLOGICAL,2,38,19 Years,40 Years,ALL,True,GlaxoSmithKline,INDUSTRY,0,7,Canada|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,6.416732282512326,xlarge,0,1,1,0,0,0,1,1,1,0,1,1,0,1,40,1,0,1,0,4,1,,,,,0,3,1
NCT00001073,Safety and Effectiveness of Giving Isotretinoin to HIV-Infected Women to Treat Cervical Tumors,A Randomized Phase III Trial of Oral Isotretinoin Versus Observation for Low-Grade Squamous Intraepithelial Lesions in HIV-Infected Women,COMPLETED,,2001-03,2021-11-04,INTERVENTIONAL,PHASE3,150.0,,,,TREATMENT,,"HIV Infections|Cervix, Dysplasia",Isotretinoin,DRUG,0,0,13 Years,,FEMALE,False,National Institute of Allergy and Infectious Diseases (NIAID),NIH,0,40,Tanzania|Puerto Rico|United States,1.0,0,0,1,0,0,3.0,0,0,0,0,2,5.017279836814924,medium,0,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,,2001-03-01,,,0,2,0
NCT05817669,A Study of the Safety and Effectiveness of Efgartigimod in Patients With Primary Sjögren's Syndrome (pSS),"A Phase 2, Randomized, Placebo-controlled, Parallel-group, Double-blinded, proof-of Concept Study to Evaluate the Safety and Efficacy of Intravenous Efgartigimod in Adult Participants With Primary Sjögren's Syndrome",COMPLETED,2023-04-04,2024-02-12,2025-07-18,INTERVENTIONAL,PHASE2,34.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Primary Sjögren's Syndrome,Efgartigimod|Placebo,BIOLOGICAL,1,13,18 Years,,ALL,False,argenx,INDUSTRY,1,17,Netherlands|Belgium|Hungary|Poland,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.5553480614894135,small,1,1,1,0,0,1,1,1,0,0,1,1,1,1,14,1,0,1,0,2,1,,,,,0,3,1
NCT02644369,Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors,Investigator-initiated Phase II Study of Pembrolizumab Immunological Response Evaluation,ACTIVE_NOT_RECRUITING,2016-03-21,2026-12,2025-03-26,INTERVENTIONAL,PHASE2,100.0,ESTIMATED,,SINGLE_GROUP,TREATMENT,NONE,Squamous Cell Cancer of Head and Neck|Triple Negative Breast Cancer|Epithelial Ovarian Cancer|Malignant Melanoma|Advanced Solid Tumors,Pembrolizumab,BIOLOGICAL,1,9,18 Years,,ALL,False,"University Health Network, Toronto",OTHER,1,1,Canada,,0,1,0,0,0,2.0,1,0,0,0,5,4.61512051684126,medium,0,0,0,1,0,1,0,0,0,0,0,0,1,0,10,1,0,1,0,1,0,,2026-12-01,,,0,2,0
NCT04071769,Genentech Xenon MRI Idiopathic Pulmonary Fibrosis,Using Xenon MRI to Evaluate the Efficacy of Therapies for Idiopathic Pulmonary Fibrosis,ACTIVE_NOT_RECRUITING,2020-08-03,2029-09-30,2026-01-02,INTERVENTIONAL,PHASE2,34.0,ACTUAL,,SINGLE_GROUP,DIAGNOSTIC,NONE,Idiopathic Pulmonary Fibrosis,Hyperpolarized 129 Xenon Gas Comparing Idiopathic Pulmonary Fibrosis (IPF) Treatment,DRUG,1,2,18 Years,,ALL,False,Duke University,OTHER,0,1,United States,,0,1,0,0,0,2.0,0,0,0,0,1,3.5553480614894135,small,1,1,0,1,0,0,0,0,1,0,0,0,0,0,3,1,1,0,0,1,0,,,,,0,0,0
NCT05027269,Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients,"A Randomized, Double-Blind, Placebo-Controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple-Doses of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) Patients",COMPLETED,2021-10-28,2023-02-14,2024-02-05,INTERVENTIONAL,PHASE1|PHASE2,38.0,ACTUAL,RANDOMIZED,SEQUENTIAL,TREATMENT,QUADRUPLE,DM1|Myotonic Dystrophy 1|Myotonic Dystrophy|Myotonic Dystrophy Type 1 (DM1)|Dystrophy Myotonic|Myotonic Disorders|Steinert Disease|Myotonic Muscular Dystrophy,AOC 1001|Placebo,DRUG,1,8,18 Years,65 Years,ALL,False,"Avidity Biosciences, Inc.",INDUSTRY,0,8,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,8,3.6635616461296463,small,1,1,1,0,0,0,1,0,1,0,1,1,1,0,9,1,1,0,0,2,1,,,,,0,4,1
NCT04326283,"Trial of Safety, Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS)","A Sequential Dose-Escalation, Randomized, Active-Controlled, Multi-Center, Phase 1/2a Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of SNR1611 in Patients With Amyotrophic Lateral Sclerosis",TERMINATED,2020-04-02,2023-04-28,2023-05-09,INTERVENTIONAL,PHASE1|PHASE2,23.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Amyotrophic Lateral Sclerosis,Trametinib (0.5 mg)|Trametinib (1 mg)|Riluzole (100 mg),DRUG,1,5,19 Years,75 Years,ALL,False,Genuv Inc.,INDUSTRY,0,5,South Korea,0.0,1,1,0,0,1,1.5,0,0,0,0,1,3.1780538303479458,small,1,1,1,0,0,0,1,0,0,0,1,0,1,1,6,1,1,0,0,3,1,,,,,0,3,1
NCT01262183,Radio-chemotherapy With or Without Panitumumab (Vectibix®) in Irresectable Squamous Cell Carcinoma or Adenocarcinoma of the Oesophagus,A Randomised Phase II Study of Radio-chemotherapy With or Without Panitumumab (Vectibix®) in Irresectable Squamous Cell Carcinoma or Adenocarcinoma of the Oesophagus,TERMINATED,2011-01,2012-10,2012-05-11,INTERVENTIONAL,PHASE2,4.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Irresectable Squamous Cell or Adenocarcinoma of the Oesophagus,CRT + Panitumumab|Concurrent chemoradiation therapy without panitumumab,DRUG,1,6,18 Years,70 Years,ALL,False,Radboud University Medical Center,OTHER,0,1,Netherlands,0.0,0,1,0,0,0,2.0,1,0,0,0,1,1.6094379124341003,small,1,1,0,1,0,0,0,0,0,0,1,0,1,1,7,1,1,0,0,2,1,2011-01-01,2012-10-01,639.0,2011.0,0,2,0
NCT01249183,"Safety and Immunogenicity Study of Concomitant Versus Non Concomitant Administration of a Diphtheria, Tetanus, Pertussis and Poliomyelitis Vaccine (REPEVAX) and Influenza Vaccine (VAXIGRIP) in Subjects Aged From 60 Years Old","An Open-label, Randomised, Multicentre Study to Evaluate the Immunogenicity and Safety of a Booster Dose of Diphtheria, Tetanus, Acellular Pertussis and Inactivated Poliomyelitis Adsorbed Vaccine (REPEVAX) Administered Concomitantly Versus Non-concomitantly With an Influenza Vaccine (VAXIGRIP) to Subjects of 60 Years of Age and Older",COMPLETED,2010-10,2011-09,2017-09-11,INTERVENTIONAL,PHASE3,954.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Diphtheria|Tetanus|Pertussis|Poliomyelitis,Concomitant administration|Separate administration,BIOLOGICAL,5,3,60 Years,99 Years,ALL,True,"Sanofi Pasteur, a Sanofi Company",INDUSTRY,0,20,Germany|France,1.0,0,0,1,0,0,3.0,0,0,0,0,4,6.86171134048073,xlarge,0,1,1,0,1,0,1,1,0,1,1,0,0,1,8,1,0,1,0,2,1,2010-10-01,2011-09-01,335.0,2010.0,0,4,1
NCT02153983,Effects of Colchicine in Non-Diabetic Adults With Metabolic Syndrome,Pilot Study of the Effects of Colchicine in Non-Diabetic Adults With Metabolic Syndrome,COMPLETED,2014-05-31,2018-08-15,2019-08-13,INTERVENTIONAL,PHASE1|PHASE2,77.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Obesity|Metabolic Disease,Colchicine 0.6Mg Cap|Placebo capsules given|Colchicine 0.6Mg Tab,DRUG,1,2,18 Years,100 Years,ALL,True,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),NIH,2,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,2,4.356708826689592,medium,1,1,0,1,0,1,0,0,1,0,1,1,1,1,3,1,1,0,0,3,1,,,,,0,3,1
NCT02404441,Phase I/II Study of PDR001 in Patients With Advanced Malignancies,Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients With Advanced Malignancies,COMPLETED,2015-04-27,2020-07-21,2022-08-03,INTERVENTIONAL,PHASE1|PHASE2,319.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Melanoma|Non-small Sell Lung Cancer (NSCLC)|Triple Negative Breast Cancer|Anaplastic Thyroid Cancer|Other Solid Tumors,PDR001,BIOLOGICAL,3,23,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,41,Italy|Netherlands|Thailand|Turkey (Türkiye)|Hungary|United States|Germany|Lebanon|Spain|Norway|Poland|Taiwan|France|Canada,1.0,1,1,0,0,1,1.5,1,0,0,0,5,5.768320995793772,large,0,1,1,0,1,0,1,1,1,1,0,0,1,0,26,1,0,1,0,1,0,,,,,0,4,1
NCT02194205,Comparison of Safety and Efficacy of COMBIVENT HFA to COMBIVENT (CFC) in Patients With Chronic Obstructive Pulmonary Disease (COPD),"A One-year Randomized, Double-blind, Placebo and Active-controlled Parallel Design Safety and Efficacy Comparison of COMBIVENT HFA Inhalation Aerosol to COMBIVENT (CFC) Inhalation Aerosol in Patients With COPD",TERMINATED,2000-10,,2014-07-18,INTERVENTIONAL,PHASE3,360.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Pulmonary Disease, Chronic Obstructive",COMBIVENT HFA|Placebo HFA|COMBIVENT CFC|Placebo CFC,DRUG,1,23,40 Years,,ALL,False,Boehringer Ingelheim,INDUSTRY,0,0,,0.0,0,0,1,0,0,3.0,0,0,0,0,1,5.8888779583328805,large,0,1,1,0,0,0,0,0,0,0,1,1,1,1,24,1,1,0,0,4,1,2000-10-01,,,2000.0,0,2,0
NCT01790594,Optimization of NULOJIX® Usage Towards Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation,Optimization of NULOJIX® (Belatacept) Usage as a Means of Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation (CTOT-15),TERMINATED,2013-02,2016-08,2021-07-20,INTERVENTIONAL,PHASE2,46.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Simultaneous Kidney and Pancreas Transplantation,Belatacept|methylprednisolone|Anti-thymocyte Globulin (Rabbit)|Tacrolimus|Mycophenolate mofetil,DRUG|BIOLOGICAL,1,30,18 Years,55 Years,ALL,False,National Institute of Allergy and Infectious Diseases (NIAID),NIH,3,5,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,3.8501476017100584,small,1,1,0,1,0,1,1,0,1,0,1,0,1,1,31,1,1,1,0,5,1,2013-02-01,2016-08-01,1277.0,2013.0,0,2,0
NCT00003694,Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase,A Phase II Study of Newly Diagnosed Patients With BCR/ABL (+) Chronic Myelogenous Leukemia Treated With Combined Homoharringtonine (NSC #141633) and Low-Dose Cytarabine,COMPLETED,1999-03,,2013-06-05,INTERVENTIONAL,PHASE2,60.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Phase Chronic Myelogenous Leukemia",omacetaxine mepesuccinate|cytarabine|laboratory biomarker analysis,DRUG|OTHER,1,3,16 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,2,4.110873864173311,medium,1,1,0,1,0,0,0,0,1,0,0,0,1,0,4,1,1,0,0,3,1,1999-03-01,,,1999.0,0,2,0
NCT00005594,ISIS 2503 in Treating Patients With Advanced Cancer of the Pancreas,"Phase II Trial of ISIS 2503, an Antisense Inhibitor of H-Ras, in Patients With Advanced Pancreatic Cancer",COMPLETED,2000-07,,2011-01-04,INTERVENTIONAL,PHASE2,4.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Pancreatic Cancer,ISIS 2503,DRUG,1,1,18 Years,,ALL,False,University of Alabama at Birmingham,OTHER,2,2,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,1.6094379124341003,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,2,1,1,0,0,1,0,2000-07-01,,,2000.0,0,0,0
NCT00295594,Comparing Efficacy & Safety of Tacrolimus With/Without MMF or Monoclonal Anti-IL2R Antibody in Liver Transplantation.,"An Open, Randomised, Multicenter, Clinical Study to Compare the Safety and Efficacy of Tacrolimus and Minimal Steroids in Combination With Either a Monoclonal Anti-IL2R Antibody (Daclizumab) or Mycophenolate Mofetil in Liver Allograft Transplantation.",COMPLETED,2005-03,2007-06,2014-08-26,INTERVENTIONAL,PHASE3,627.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Liver Transplantation,tacrolimus,DRUG,1,1,18 Years,,ALL,False,Astellas Pharma Inc,INDUSTRY,0,41,Italy|Belgium|Finland|Sweden|Hungary|Spain|Germany|United Kingdom|Poland|Switzerland|Denmark,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.4425401664681985,xlarge,0,1,1,0,0,0,1,1,0,1,1,0,0,1,2,1,1,0,0,1,0,2005-03-01,2007-06-01,822.0,2005.0,0,1,0
NCT03905694,A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1,"ILLUMINATE-B: An Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1",COMPLETED,2019-04-22,2024-07-26,2025-02-14,INTERVENTIONAL,PHASE3,18.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Primary Hyperoxaluria|Primary Hyperoxaluria Type 1 (PH1),Lumasiran,DRUG,1,17,0 Years,5 Years,ALL,False,Alnylam Pharmaceuticals,INDUSTRY,0,9,United States|Germany|United Kingdom|Israel|France,1.0,0,0,1,0,0,3.0,0,0,0,0,2,2.9444389791664403,small,1,1,1,0,0,0,1,1,1,1,0,0,1,0,18,1,1,0,0,1,0,,,,,0,3,1
NCT02395666,Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission,A Phase II Preventative Trial of DFMO (Eflornithine HCl) as a Single Agent in Patients With High Risk Neuroblastoma in Remission,COMPLETED,2015-03-05,2023-08-24,2024-08-06,INTERVENTIONAL,PHASE2,140.0,ACTUAL,,SINGLE_GROUP,PREVENTION,NONE,Neuroblastoma,DFMO,DRUG,1,6,,21 Years,ALL,False,Giselle Sholler,OTHER,3,22,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.948759890378168,medium,0,1,0,1,0,1,1,0,1,0,0,0,0,0,7,1,1,0,0,1,0,,,,,0,1,0
NCT00088166,XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors,"A Phase III Randomized, Double-Blind, Dexamethasone-Sparing Study Comparing Human Corticotropin-Releasing Factor (hCRF) to Placebo for Control of Symptoms Associated With Peritumoral Brain Edema in Patients With Malignant Brain Tumor Who Require Chronic Administration of High-Dose Dexamethasone",COMPLETED,2004-05,2008-03,2014-08-13,INTERVENTIONAL,PHASE3,200.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Brain Edema|Brain Tumor,hCRF|placebo hCRF,DRUG,1,8,18 Years,,ALL,False,Celtic Pharma Development Services,INDUSTRY,1,34,Canada|United States,1.0,0,0,1,0,0,3.0,1,0,0,0,2,5.303304908059076,medium,0,1,1,0,0,1,1,1,1,0,1,1,1,1,9,1,1,0,0,2,1,2004-05-01,2008-03-01,1400.0,2004.0,0,4,1
NCT03618966,Neuromuscular Magnetic Stimulation in ALS Patients,Neuromuscular Magnetic Stimulation Counteracts Muscle Decline in ALS Patients,COMPLETED,2014-11-01,2017-11-01,2018-08-07,INTERVENTIONAL,PHASE2,22.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Amyotrophic Lateral Sclerosis,Neuromuscular magnetic stimulation (NMMS),DEVICE,1,6,,,ALL,False,University of Roma La Sapienza,OTHER,0,0,,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.1354942159291497,small,1,1,0,1,0,0,0,0,0,0,1,1,1,1,7,1,0,0,1,1,0,,,,,0,1,0
NCT00738582,An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma,An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma,COMPLETED,2008-12-31,2014-01-10,2022-09-22,INTERVENTIONAL,PHASE2,89.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Malignant Pleural Mesothelioma,MORAb-009 (Amatuximab)|Pemetrexed|Cisplatin,DRUG,1,5,18 Years,,ALL,False,Morphotek,INDUSTRY,0,28,Netherlands|Spain|Germany|United States|Canada,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.499809670330265,medium,1,1,1,0,0,0,1,1,1,1,0,0,1,0,6,1,1,0,0,3,1,,,,,0,3,1
NCT01316523,Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma,Phase II Study of Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non Hodgkin's Lymphoma,TERMINATED,2010-12,2024-04-14,2025-11-21,INTERVENTIONAL,PHASE2,30.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Non Hodgkin's Lymphoma,Rituximab|Lenalidomide,DRUG,1,4,18 Years,,ALL,False,"University of California, Davis",OTHER,1,2,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,3.4339872044851463,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,5,1,1,0,0,2,1,2010-12-01,,,2010.0,0,1,0
NCT01524679,Peg-interferon ADDed to an Ongoing Nucleos(t)Ide Based Treatment in Patients With Chronic Hepatitis B to Induce Decrease of HBs-Antigen,"A Prospective, Randomised, Open-label Phase IIb Clinical Trial Assessing the Effect of Pegylated Interferon Alfa-2a (Pegasys®)180 μg Once Weekly for 48 Weeks in Addition to an Ongoing Nucelos(t)Ide Based Treatment on Quantitative HBsAg Levels in Patients With Chronic HBeAg-negative Hepatitis B",COMPLETED,2012-08,2017-08-28,2020-02-18,INTERVENTIONAL,PHASE2,170.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Chronic Hepatitis B,Pegylated interferon alfa-2a plus nucleos(t)ide(s),DRUG,1,2,18 Years,70 Years,ALL,False,Johannes Gutenberg University Mainz,OTHER,1,24,Germany,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.14166355650266,medium,0,1,0,1,0,1,1,0,0,1,1,0,1,1,3,1,1,0,0,1,0,2012-08-01,,,2012.0,0,0,0
NCT01000779,Comparison of Endoscopic Variceal Ligation (EVL) With Propranolol in Non Cirrhotic Portal Hypertension (NCPH),Comparison of Endoscopic Variceal Ligation (EVL) and Propranolol in Secondary Prophylaxis of Variceal Bleeding in Patients With Non Cirrhotic Portal Hypertension (NCPH): A Prospective Randomized Controlled Trial,COMPLETED,2005-01,2009-10,2010-12-22,INTERVENTIONAL,PHASE3,100.0,ESTIMATED,RANDOMIZED,PARALLEL,PREVENTION,NONE,Non Cirrhotic Portal Hypertension,Propranolol|multi band ligator for esophageal varices,DRUG|DEVICE,1,1,2 Years,75 Years,ALL,False,Govind Ballabh Pant Hospital,OTHER_GOV,0,1,India,1.0,0,0,1,0,0,3.0,0,0,0,1,1,4.61512051684126,medium,0,0,0,1,0,0,0,0,0,0,1,0,0,1,2,1,1,0,1,2,1,2005-01-01,2009-10-01,1734.0,2005.0,0,1,0
NCT01736579,"Long-Term Study of IGIV, 10% in Alzheimer´s Disease","A Study of the Long-Term Safety and Efficacy of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) in Mild to Moderate Alzheimer´s Disease",TERMINATED,2012-11-29,2013-06-04,2021-05-19,INTERVENTIONAL,PHASE3,6.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Alzheimer´s Disease,"Immune Globulin Intravenous (Human), 10% (IGIV, 10%)",DRUG,4,11,51 Years,,ALL,False,Baxalta now part of Shire,INDUSTRY,0,1,United States,0.0,0,0,1,0,0,3.0,0,0,1,0,1,1.9459101490553132,small,1,1,1,0,0,0,0,0,1,0,0,0,1,1,15,1,1,0,0,1,0,,,,,0,1,0
NCT00090779,Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV,The SETPOINT Study - A Randomized Study of the Effect of Immediate Treatment With Potent Antiretroviral Therapy Versus Observation With Treatment as Indicated in Newly Infected HIV-1 Infected Subjects: Does Early Therapy After the Virologic Setpoint?,TERMINATED,2005-01,2011-05,2018-10-11,INTERVENTIONAL,PHASE2,130.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,HIV Infections,Emtricitabine/ tenofovir disoproxil fumarate|Lopinavir/Ritonavir,DRUG,3,6,18 Years,,ALL,False,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections,NETWORK,2,27,Peru|United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,4.875197323201151,medium,0,1,0,0,0,1,1,1,1,0,1,0,1,1,9,1,1,0,0,2,1,2005-01-01,2011-05-01,2311.0,2005.0,0,3,1
NCT05496179,The Effect of Prucalopride on Gastric Emptying in Intensive Care Unit Patients,The Effect of Prucalopride on Gastric Emptying in Intensive Care Unit Patients,COMPLETED,2022-08-30,2023-07-15,2024-04-12,INTERVENTIONAL,PHASE1|PHASE2,70.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Enteral Feeding Intolerance,Prucalopride|Metoclopramide,DRUG,1,4,18 Years,65 Years,ALL,False,Ain Shams University,OTHER,1,1,Egypt,1.0,1,1,0,0,1,1.5,0,0,0,0,1,4.2626798770413155,medium,1,1,0,1,0,1,0,0,0,0,1,1,1,1,5,1,1,0,0,2,1,,,,,0,2,0
NCT00432679,A Study Of BRL49653C For The Treatment Of Type 2 Diabetes (Combination Therapy With Sulfonyl Urea) -With Placebo Study,Clinical Evaluation of Rosiglitazone Maleate (BRL49653C) in Patients With Type 2 Diabetes Mellitus (Combination Therapy With Sulfonyl Urea) - A Placebo-Controlled Double-Blind Study -,COMPLETED,2006-05-24,2007-03-28,2022-12-12,INTERVENTIONAL,PHASE3,149.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2",Rosiglitazone (BRL49653C),DRUG,1,8,20 Years,,ALL,False,GlaxoSmithKline,INDUSTRY,0,4,|Japan,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.0106352940962555,medium,0,1,1,0,0,0,1,1,0,0,1,1,1,1,9,1,1,0,0,1,0,,,,,0,2,0
NCT00634179,A Phase I/II Trial of VR-CHOP in Lymphoma Patients,A Phase I/II Trial of VR-CHOP for Patients With Untreated Follicular Lymphoma and Other Low Grade B-Cell Lymphomas,COMPLETED,2008-02,2015-11,2016-10-27,INTERVENTIONAL,PHASE1|PHASE2,37.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Lymphoma, B-Cell|Follicular Lymphoma",Bortezomib|Rituximab|Doxorubicin|Cyclophosphamide|Vincristine|Prednisone,DRUG|BIOLOGICAL,1,1,18 Years,,ALL,False,Emory University,OTHER,1,1,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,2,3.6375861597263857,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,2,1,1,1,0,6,1,2008-02-01,2015-11-01,2830.0,2008.0,0,3,1
NCT00392496,Sunitinib in Treating Patients With Relapsed or Refractory Diffuse or Mediastinal Large B-Cell Lymphoma,"A Phase II Study of Sunitinib (SU11248; NSC 736511; IND 74019), an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",COMPLETED,2007-02,2012-01,2014-05-15,INTERVENTIONAL,PHASE2,19.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma,sunitinib malate,DRUG,1,0,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,1,Canada,1.0,0,1,0,0,0,2.0,1,0,0,0,3,2.995732273553991,small,1,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,2007-02-01,2012-01-01,1795.0,2007.0,0,1,0
NCT04315896,Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial),Hydroxychloroquine Treatment for Severe COVID-19 Respiratory Disease: Randomised Clinical Trial (HYDRA Trial),COMPLETED,2020-04-14,2020-08-15,2022-02-01,INTERVENTIONAL,PHASE3,320.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,COVID-19|Severe Acute Respiratory Syndrome,Hydroxychloroquine|Placebo oral tablet,DRUG,1,4,18 Years,80 Years,ALL,False,"National Institute of Respiratory Diseases, Mexico",OTHER_GOV,0,1,Mexico,1.0,0,0,1,0,0,3.0,0,0,0,0,2,5.771441123130016,large,0,1,0,1,0,0,0,0,0,0,1,1,1,1,5,1,1,0,0,2,1,,,,,0,2,0
NCT00591162,Bone Disease in Severely Burned Children,Bone Disease in Severely Burned Children,TERMINATED,1992-10,2008-06,2014-06-06,INTERVENTIONAL,PHASE2|PHASE3,254.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Burn,Tetracycline|Duel Energy X-Ray Absorptiometry (DEXA)|Bone Biopsy,DRUG|RADIATION|PROCEDURE,1,0,5 Years,18 Years,ALL,False,"The University of Texas Medical Branch, Galveston",OTHER,0,1,United States,0.0,0,1,1,0,1,2.5,0,0,0,0,1,5.541263545158426,large,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,3,1,1992-10-01,2008-06-01,5722.0,1992.0,0,2,0
NCT00879762,High Dose IMVAMUNE® in Vaccinia-Naive Individuals,Comparison of Safety and Immunogenicity of a High Dose (5 x 10^8 TCID50) and a Standard Dose (1 x 10^8 TCID50) of IMVAMUNE® in Healthy Vaccinia-Naive Individuals,COMPLETED,2009-05-29,2011-03-09,2025-06-13,INTERVENTIONAL,PHASE2,91.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Smallpox,MVA Smallpox Vaccine|Placebo,BIOLOGICAL|OTHER,7,2,18 Years,38 Years,ALL,True,National Institute of Allergy and Infectious Diseases (NIAID),NIH,0,2,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.5217885770490405,medium,1,1,0,1,0,0,1,0,1,0,1,1,0,1,9,1,0,1,0,2,1,,,,,0,2,0
NCT00011362,Dexamethasone Therapy in VLBW Infants at Risk of CLD,Randomized Clinical Trial of Dexamethasone Therapy in Very-Low-Birth-Weight Infants at Risk for Chronic Lung Disease (CLD),COMPLETED,1992-09,1994-04,2019-03-22,INTERVENTIONAL,PHASE3,371.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,"Infant, Newborn|Infant, Low Birth Weight|Infant, Small for Gestational Age|Infant, Premature|Bronchopulmonary Dysplasia",Dexamethasone Early|Dexamethasone Late,DRUG,1,6,13 Days,15 Days,ALL,False,NICHD Neonatal Research Network,NETWORK,1,13,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,5,5.918893854273146,large,0,1,0,0,0,1,1,0,1,0,1,1,1,1,7,1,1,0,0,2,1,1992-09-01,1994-04-01,577.0,1992.0,0,3,1
NCT02369146,To Investigate the Safety and Efficacy of UB-421 Monotherapy in HIV Infected Adults,"A Phase II, Open-label, Multiple-dose Trial to Investigate the Safety and Efficacy of UB-421 Monotherapy in Substitution for Stable Antiretroviral Therapy in HIV Infected Adults",COMPLETED,2015-06,2016-07,2017-10-31,INTERVENTIONAL,PHASE2,29.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,HIV-1 Infection,UB-421,DRUG,1,2,20 Years,,ALL,False,United BioPharma,INDUSTRY,3,1,Taiwan,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.4011973816621555,small,1,1,1,0,0,1,0,0,0,0,0,0,1,1,3,1,1,0,0,1,0,2015-06-01,2016-07-01,396.0,2015.0,1,0,0
NCT03439046,"Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant","A Phase IIIb, Open-label, Local, Multicenter Study of the Molecular Features of Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative Advanced Breast Cancer on First-line Treatment With Ribociclib Plus Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant (BioItaLEE)",COMPLETED,2018-02-02,2023-12-11,2024-08-01,INTERVENTIONAL,PHASE3,287.0,ACTUAL,,SEQUENTIAL,TREATMENT,NONE,Breast Cancer,Ribociclib|Letrozole|Alpelisib|Fulvestrant,DRUG,1,11,18 Years,,FEMALE,False,Novartis Pharmaceuticals,INDUSTRY,0,41,Italy,1.0,0,0,1,0,0,3.0,1,0,0,0,1,5.662960480135946,large,0,1,1,0,1,0,1,0,0,1,0,0,1,0,12,1,1,0,0,4,1,,,,,0,2,0
NCT03292588,A Trial of Mepolizumab Adjunctive Therapy for the Prevention of Asthma Exacerbations in Urban Children,Mechanisms Underlying Asthma Exacerbations Prevented and Persistent With Immune-Based Therapy: A Systems Approach Phase 2 (ICAC-30),COMPLETED,2017-11-07,2021-04-20,2022-07-20,INTERVENTIONAL,PHASE2,335.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Asthma,Mepolizumab|Placebo,DRUG|BIOLOGICAL,1,12,6 Years,17 Years,ALL,False,National Institute of Allergy and Infectious Diseases (NIAID),NIH,3,9,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.817111159963204,large,0,1,0,1,0,1,1,0,1,0,1,1,1,1,13,1,1,1,0,2,1,,,,,0,2,0
NCT00782288,Phase II Study of Digitoxin to Treat Cystic Fibrosis,Phase II Study of Digitoxin to Treat Cystic Fibrosis,COMPLETED,2010-08,2016-08,2022-04-21,INTERVENTIONAL,PHASE2,24.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Cystic Fibrosis,digitoxin|digitoxin|placebo,DRUG|OTHER,4,9,18 Years,45 Years,ALL,False,National Jewish Health,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.2188758248682006,small,1,1,0,1,0,0,0,0,1,0,1,1,1,1,13,1,1,0,0,3,1,2010-08-01,2016-08-01,2192.0,2010.0,0,2,0
NCT02065388,Pharmacogenetic Dosing of Warfarin,,COMPLETED,2009-09,2013-12,2014-02-19,INTERVENTIONAL,PHASE3,300.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Stroke|Venous Thrombosis|Atrial Fibrillation|Atrial Flutter,Standard of care dosing for warfarin|Genotype-guided dosingTaiwan algorithm for warfarin|Genotype-guided dosing IWPC algorithm for warfarin,BEHAVIORAL|GENETIC,1,0,20 Years,,ALL,False,"Academia Sinica, Taiwan",OTHER,3,3,Taiwan,1.0,0,0,1,0,0,3.0,0,0,0,0,4,5.707110264748875,large,0,1,0,1,0,1,1,0,0,0,1,1,1,1,1,0,0,0,0,3,1,2009-09-01,2013-12-01,1552.0,2009.0,0,2,0
NCT03516903,Effect of Methotrexate Carried by a Lipid Nanoemulsion on Left Ventricular Remodeling After STEMI,Effect of Methotrexate Carried by a Lipid Nanoemulsion on Left Ventricular Remodeling After ST-elevation Myocardial Infarction,TERMINATED,2018-04-17,2020-12-17,2021-01-11,INTERVENTIONAL,PHASE2|PHASE3,35.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Myocardial Infarction, Anterior Wall|Myocardial Remodeling, Ventricular",Methotrexate|Placebo|Folic Acid,DRUG,1,15,18 Years,75 Years,ALL,False,University of Sao Paulo,OTHER,1,1,Brazil,0.0,0,1,1,0,1,2.5,0,0,0,1,2,3.58351893845611,small,1,1,0,1,0,1,0,0,0,0,1,1,1,1,16,1,1,0,0,3,1,,,,,0,4,1
NCT04692103,Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy,Serial [F-18] Fluoroestradiol (FES) PET Imaging to Evaluate Endocrine-targeted Therapy,ACTIVE_NOT_RECRUITING,2021-07-10,2041-04-30,2026-01-22,INTERVENTIONAL,PHASE2,2.0,ACTUAL,,SINGLE_GROUP,DIAGNOSTIC,NONE,Estrogen Receptor Positive|Primary or Recurrent Breast Carcinoma|Stage IV Breast Cancer AJCC v6 and v7,F-18 16 Alpha-Fluoroestradiol|Positron Emission Tomography|Computed Tomography|Fludeoxyglucose F-18|Positron Emission Tomography|Computed Tomography|Laboratory Biomarker Analysis,DRUG|OTHER|PROCEDURE,3,1,18 Years,,ALL,False,University of Washington,OTHER,0,1,United States,,0,1,0,0,0,2.0,1,0,0,0,3,1.0986122886681098,small,1,1,0,1,0,0,0,0,1,0,0,0,0,0,4,1,1,0,0,7,1,,,,,0,2,0
NCT05287503,Ambroxol as a Disease-modifying Treatment in GBA-PD,"Ambroxol as a Disease-modifying Treatment to Reduce the Risk of Cognitive Impairment in GBA-associated Parkinson's Disease. A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Trial",COMPLETED,2022-03-09,2024-12-20,2025-08-14,INTERVENTIONAL,PHASE2,65.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Parkinson Disease|GBA Gene Mutation,Ambroxol Hydrochloride|Placebo,DRUG,2,9,21 Years,80 Years,ALL,False,Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta,OTHER,2,3,Italy,1.0,0,1,0,0,0,2.0,0,0,1,0,2,4.189654742026425,medium,1,1,0,1,0,1,1,0,0,1,1,1,1,1,11,1,1,0,0,2,1,,,,,0,3,1
NCT02450903,LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.,"A Phase II, Multi-center, Open-label, Single-Arm Study to Evaluate the Efficacy and Safety of Oral LDK378 Treatment for Patients With ALK-Positive Non-Small Cell Lung Cancer Previously Treated With Alectinib",COMPLETED,2015-08-21,2018-05-24,2021-03-30,INTERVENTIONAL,PHASE2,20.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Non-Small-Cell Lung Cancer,LDK378,DRUG,1,6,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,9,Japan,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.044522437723423,small,1,1,1,0,1,0,1,0,0,0,0,0,1,0,7,1,1,0,0,1,0,,,,,0,1,0
NCT00483561,Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy,A Phase II Study Evaluating the Efficacy of Iressa Plus Etoposide in Patients With Advanced Hormone Refractory Prostate Cancer,TERMINATED,2004-01,2010-01,2023-09-13,INTERVENTIONAL,PHASE2,26.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Prostate Cancer,Gefitinib plus etoposide,DRUG,1,1,19 Years,120 Years,MALE,False,University of Nebraska,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,3.295836866004329,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,2,1,1,0,0,1,0,2004-01-01,2010-01-01,2192.0,2004.0,0,0,0
NCT01146561,Safety And Efficacy Of Tanezumab In Patients With Chronic Pancreatitis,"A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN PATIENTS WITH CHRONIC PANCREATITIS",TERMINATED,2010-10-13,2011-03-22,2021-03-23,INTERVENTIONAL,PHASE2,2.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Chronic Pancreatitis,Tanezumab|Placebo,BIOLOGICAL|OTHER,1,16,18 Years,99 Years,ALL,False,Pfizer,INDUSTRY,0,9,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,1.0986122886681098,small,1,1,1,0,1,0,1,0,1,0,1,1,1,1,17,1,0,1,0,2,1,,,,,0,2,0
NCT00903942,Abraxane and RT for Non-Small Cell Lung Cancer (NSCLC),A Modified Two Stage Phase II Study of Combination Abraxane and Radiation for Stage III Non-Small Cell Lung Cancer,WITHDRAWN,2008-03,,2015-04-27,INTERVENTIONAL,PHASE2,0.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,"Non-small Cell Lung Cancer, Stage III","radiation therapy|Paclitaxel Protein-Bound, and CARBOPLATIN",DRUG|RADIATION,1,4,18 Years,,ALL,False,University of Rochester,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,0.0,,1,1,0,1,1,1,0,0,1,0,0,0,1,0,5,1,1,0,0,2,1,2008-03-01,,,2008.0,0,1,0
NCT05265286,A Study of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection,"A Phase II, Multicentre, Open-label Study to Evaluate the Pharmacokinetic, Safety and Preliminary Efficacy of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Subjects With Severe Hemophilia A",COMPLETED,2022-04-14,2022-08-21,2023-05-15,INTERVENTIONAL,PHASE2,15.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Severe Hemophilia A,FRSW117,DRUG,6,3,12 Years,65 Years,MALE,False,Jiangsu Gensciences lnc.,INDUSTRY,0,5,China,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.772588722239781,small,1,1,1,0,0,0,1,0,0,0,0,0,1,0,9,1,1,0,0,1,0,,,,,0,1,0
NCT00758186,Randomized Trial of Colonic Stents as a Bridge to Surgery,Endoscopic Stenting and Elective Surgery Versus Emergency Surgery for Left-sided Malignant Colonic Obstruction: A Prospective Randomized Trial.,COMPLETED,2004-10,2008-06,2018-04-18,INTERVENTIONAL,PHASE3,40.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Colorectal Cancer|Intestinal Obstruction,Emergency endoscopic colonic stenting|Emergency surgery,PROCEDURE,1,1,18 Years,,ALL,False,Singapore General Hospital,OTHER,0,1,Singapore,1.0,0,0,1,0,0,3.0,1,0,0,0,2,3.713572066704308,small,1,1,0,1,0,0,0,0,0,0,1,0,1,1,2,1,0,0,0,2,1,2004-10-01,2008-06-01,1339.0,2004.0,0,2,0
NCT05838170,Study of TP-04 in Participants With Papulopustular Rosacea,"A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety, Tolerability, and Efficacy of TP-04 in Participants With Papulopustular Rosacea",COMPLETED,2023-03-01,2023-11-13,2023-11-24,INTERVENTIONAL,PHASE2,37.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Papulopustular Rosacea,"Lotilaner Gel, 2.0%|Vehicle control gel",DRUG|OTHER,13,8,18 Years,59 Years,ALL,True,"Tarsus Pharmaceuticals, Inc.",INDUSTRY,0,5,Canada,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.6375861597263857,small,1,1,1,0,0,0,1,0,0,0,1,1,1,1,21,1,1,0,0,2,1,,,,,0,2,0
NCT01810770,Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis,"A Single-arm, International, Prospective, Interventional, Open-label, Multicenter Study of Radium-223 Dichloride in the Treatment of Patients With Castration-Resistant Prostate Cancer (CRPC) With Bone Metastasis.",COMPLETED,2013-03-26,2017-09-25,2018-09-19,INTERVENTIONAL,PHASE3,243.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Prostatic Neoplasms,"Radium-223 dichloride (Xofigo, BAY88-8223)",DRUG,5,12,18 Years,,MALE,False,Bayer,INDUSTRY,0,27,China|Taiwan|Singapore|South Korea,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.497168225293202,large,0,1,1,0,0,0,1,1,0,0,0,0,1,0,17,1,1,0,0,1,0,,,,,0,2,0
NCT03474770,BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures,Evaluation of Safety and Efficacy of BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures,ACTIVE_NOT_RECRUITING,2018-04-10,2026-12-30,2022-08-30,INTERVENTIONAL,PHASE1|PHASE2,16.0,ESTIMATED,,SINGLE_GROUP,TREATMENT,NONE,Focal Impaired Awareness Seizures,BIS-001ER,DRUG,1,6,18 Years,65 Years,ALL,False,"Supernus Pharmaceuticals, Inc.",INDUSTRY,0,2,Australia,,1,1,0,0,1,1.5,0,0,0,0,1,2.833213344056216,small,1,0,1,0,0,0,1,0,0,0,0,0,1,0,7,1,1,0,0,1,0,,,,,0,2,0
NCT00249873,Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A),"A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation",COMPLETED,2003-06,2009-03,2015-06-15,INTERVENTIONAL,PHASE3,7554.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Atrial Fibrillation|Vascular Risk,clopidogrel (SR25990C)|placebo,DRUG,1,3,18 Years,,ALL,False,Sanofi,INDUSTRY,1,30,Germany|Norway|Switzerland|Taiwan|Singapore|Greece|Italy|Netherlands|Finland|Spain|Chile|Czechia|Portugal|Canada|Argentina|Sweden|United States|Austria|Australia|United Kingdom|Poland|Mexico|Denmark|South Africa|France|Belgium|Hungary|Brazil|Hong Kong|Malaysia,1.0,0,0,1,0,0,3.0,0,0,0,0,2,8.92996487470684,xlarge,0,1,1,0,1,1,1,1,1,1,1,1,0,1,4,1,1,0,0,2,1,2003-06-01,2009-03-01,2100.0,2003.0,0,3,1
NCT02390869,Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients,A Randomized Phase III Multicenter Trial Assessing Efficacy and Toxicity of a Combination of Rituximab and Lenalidomide (R2) vs Rituximab Alone as Maintenance After Chemoimmunotherapy With Rituximab-chemotherapy (R-CHT) for Relapsed/Refractory FL Patients Not Eligible for Autologous Transplantation (ASCT).,ACTIVE_NOT_RECRUITING,2014-05,2027-08,2025-12-02,INTERVENTIONAL,PHASE3,128.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,"Lymphoma, Follicular",R2-MANT|R-MANT,DRUG,1,7,18 Years,,ALL,False,Fondazione Italiana Linfomi - ETS,OTHER,0,28,Italy,,0,0,1,0,0,3.0,1,0,0,0,1,4.859812404361672,medium,0,1,0,1,0,0,1,0,0,1,1,0,1,0,8,1,1,0,0,2,1,2014-05-01,2027-08-01,4840.0,2014.0,0,2,0
NCT05217069,FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC,Avelumab Added to FOLFIRI Plus Cetuximab Followed by Avelumab Maintenance in Patients With Previously Untreated RAS Wild-type Colorectal Cancer. The Phase II FIRE-6 Study,COMPLETED,2019-09-27,2023-10-18,2025-04-16,INTERVENTIONAL,PHASE2,57.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Treatment Related Cancer,5-FU|Folinic Acid|Irinotecan|Cetuximab|Avelumab,DRUG,1,3,18 Years,,ALL,False,Ludwig-Maximilians - University of Munich,OTHER,2,1,Germany,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.060443010546419,medium,1,1,0,1,0,1,0,0,0,1,0,0,1,0,4,1,1,0,0,5,1,,,,,0,1,0
NCT00104169,Idiopathic Anemia of Aging (IAA),Pilot Study of Epoetin Alfa in Idiopathic Anemia of Aging (IAA),TERMINATED,2004-08,2007-05,2008-08-29,INTERVENTIONAL,PHASE2,0.0,ACTUAL,NON_RANDOMIZED,,TREATMENT,,Anemia|Aging,Epoetin Alfa,DRUG,1,1,70 Years,,ALL,False,National Institute on Aging (NIA),NIH,0,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,2,0.0,,1,1,0,1,0,0,0,0,1,0,0,0,1,0,2,1,1,0,0,1,0,2004-08-01,2007-05-01,1003.0,2004.0,0,1,0
NCT00190983,A Trial for Patients With Advanced/Recurrent Cervical Cancer,A Phase II Evaluation of Pemetrexed (Alimta) in the Treatment of Recurrent Carcinoma of the Cervix,COMPLETED,2005-02,2007-10,2009-11-20,INTERVENTIONAL,PHASE2,29.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,"Cervical Intraepithelial Neoplasia|Uterine Neoplasms|Genital Neoplasms, Female",Pemetrexed,DRUG,1,3,,,FEMALE,False,Eli Lilly and Company,INDUSTRY,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,3,3.4011973816621555,small,1,1,1,0,1,1,0,0,1,0,0,0,1,0,4,1,1,0,0,1,0,2005-02-01,2007-10-01,972.0,2005.0,0,1,0
NCT00805441,A Study in the Treatment of Alcohol Dependence.,A Phase 2 Study of LY686017 Compared With Placebo for the Treatment of Alcohol Dependence,COMPLETED,2008-12,2009-07,2019-09-17,INTERVENTIONAL,PHASE2,190.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Alcohol Dependence,LY686017|Placebo,DRUG,1,12,21 Years,65 Years,ALL,False,Eli Lilly and Company,INDUSTRY,0,21,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.25227342804663,medium,0,1,1,0,1,0,1,0,1,0,1,1,1,1,13,1,1,0,0,2,1,2008-12-01,2009-07-01,212.0,2008.0,0,2,0
NCT04959305,A Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential Hypertension,"A Multicenter, Randomized, Double-blind, Parallel, Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential Hypertension",COMPLETED,2021-04-22,2022-02-28,2022-07-14,INTERVENTIONAL,PHASE2,245.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Hypertension,HCP1803-3|RLD2003|RLD2004|RLD2005|HPP2003-3|HPP2005,DRUG,1,5,19 Years,,ALL,False,Hanmi Pharmaceutical Company Limited,INDUSTRY,0,1,South Korea,1.0,0,1,0,0,0,2.0,0,0,0,1,1,5.5053315359323625,large,0,1,1,0,0,0,0,0,0,0,1,1,1,1,6,1,1,0,0,6,1,,,,,0,2,0
NCT00263705,Adjuvant Capecitabine in Elderly Patients With Breast Cancer: a Phase II Study,Adjuvant Capecitabine in Elderly Patients With Breast Cancer: a Phase II Study,COMPLETED,2003-01,2009-08,2011-02-24,INTERVENTIONAL,PHASE2,43.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Elderly Patients|Breast Cancer,Adjuvant capecitabine|capecitabine in aduvant setting,DRUG,1,0,70 Years,,FEMALE,False,Jules Bordet Institute,OTHER,0,1,Belgium,1.0,0,1,0,0,0,2.0,1,0,0,0,2,3.784189633918261,small,1,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,2,1,2003-01-01,2009-08-01,2404.0,2003.0,0,2,0
NCT03258905,Phone App for Grounding,Phone App for Grounding (De-escalation) of Substance-abusing Transition-age Youth,COMPLETED,2019-11-01,2020-09-03,2021-12-14,INTERVENTIONAL,PHASE2,62.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Substance-Related Disorders,Grounding enhanced app|Grounding text-only app,BEHAVIORAL,1,3,18 Years,25 Years,ALL,False,Treatment Innovations,INDUSTRY,2,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.143134726391533,medium,1,1,1,0,0,1,0,0,1,0,1,0,1,1,4,1,0,0,0,2,1,,,,,0,1,0
NCT02382094,Clinical Trial to Study Quality of Life in Prostate Cancer Patients by Randomizing Anti-androgen Versus Total Androgen Blockage Prior to Curative Intended Radiation Therapy,,COMPLETED,2005-06,2012-07,2015-03-06,INTERVENTIONAL,PHASE3,110.0,ACTUAL,RANDOMIZED,PARALLEL,HEALTH_SERVICES_RESEARCH,NONE,Prostate Cancer,Bicalutamide,DRUG,1,3,,,MALE,False,Karolinska University Hospital,OTHER,0,0,,1.0,0,0,1,0,0,3.0,1,0,0,0,1,4.709530201312334,medium,0,1,0,1,0,0,0,0,0,0,1,0,0,1,4,1,1,0,0,1,0,2005-06-01,2012-07-01,2587.0,2005.0,0,0,0
NCT00136994,IM and Oral in Acute Exacerbation of Schizophrenia (BIZET Study),An Open Trial to Evaluate the Efficacy and Tolerability of Ziprasidone IM and Oral in Patients With Psychosis and Acute Agitation.,COMPLETED,2003-03,2005-11,2021-02-21,INTERVENTIONAL,PHASE3,160.0,,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Schizophrenia,Ziprasidone,DRUG,1,0,18 Years,60 Years,ALL,False,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,INDUSTRY,0,34,Italy,1.0,0,0,1,0,0,3.0,0,0,1,0,1,5.081404364984463,medium,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,0,1,0,0,1,0,2003-03-01,2005-11-01,976.0,2003.0,0,0,0
NCT00803023,Safety and Tolerability Study Comparing Sodium Oxybate Given as an Oral Solution to a Single-blinded Combination of Oral Tablets Plus Oral Solution in Subjects With Fibromyalgia,Safety and Tolerability Study Comparing Sodium Oxybate Given as an Oral Solution to a Single-blinded Combination of Oral Tablets Plus Oral Solution in Subjects With Fibromyalgia,COMPLETED,2010-03,,2011-08-19,INTERVENTIONAL,PHASE3,129.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,SINGLE,Fibromyalgia,Sodium Oxybate|Sodium Oxybate & 6 Tablets|Sodium Oxybate & 8 Tablets|Sodium Oxybate Oral Solution (6 grams),DRUG,1,1,18 Years,,ALL,False,Jazz Pharmaceuticals,INDUSTRY,0,32,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.867534450455582,medium,0,1,1,0,0,0,1,0,1,0,1,0,1,0,2,1,1,0,0,4,1,2010-03-01,,,2010.0,0,1,0
NCT02741323,Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients,Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients,COMPLETED,2017-01-01,2022-05-10,2023-08-21,INTERVENTIONAL,PHASE2,97.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,HIV Infections|Kidney Diseases,Maraviroc|Placebo,DRUG,2,27,18 Years,,ALL,False,National Institute of Allergy and Infectious Diseases (NIAID),NIH,0,10,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.584967478670572,medium,1,1,0,1,0,0,1,0,1,0,1,1,1,1,29,1,1,0,0,2,1,,,,,0,3,1
NCT05987423,"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease","A Phase III, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Moderate-to-Severe Thyroid Eye Disease",ACTIVE_NOT_RECRUITING,2023-10-26,2026-07-01,2026-02-03,INTERVENTIONAL,PHASE3,131.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Thyroid Eye Disease|TED,Satralizumab|Placebo,DRUG,1,17,18 Years,,ALL,False,Hoffmann-La Roche,INDUSTRY,0,46,Italy|Argentina|Hungary|United States|Germany|Austria|Australia|Hong Kong|Japan|Singapore,,0,0,1,0,0,3.0,0,0,0,0,2,4.882801922586371,medium,0,1,1,0,1,0,1,1,1,1,1,1,1,1,18,1,1,0,0,2,1,,,,,0,4,1
NCT00110123,Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma,Intravenous Versus Intra-Arterial Fotemustine Chemotherapy in Patients With Liver Metastases From Uveal Melanoma: A Randomized Phase III Study of the EORTC Melanoma Group,TERMINATED,2005-01,,2012-09-24,INTERVENTIONAL,PHASE3,171.0,ACTUAL,RANDOMIZED,,TREATMENT,NONE,Intraocular Melanoma|Metastatic Cancer,fotemustine|isolated perfusion,DRUG,1,4,18 Years,,ALL,False,European Organisation for Research and Treatment of Cancer - EORTC,NETWORK,0,8,Italy|United Kingdom|Switzerland|Poland,0.0,0,0,1,0,0,3.0,1,0,0,0,2,5.147494476813453,medium,0,1,0,0,0,0,1,1,0,1,1,0,1,0,5,1,1,0,0,2,1,2005-01-01,,,2005.0,0,3,1
NCT03594123,A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type,"A 12-week, Multicenter, Active-treatment Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type",COMPLETED,2018-10-11,2022-09-19,2023-11-14,INTERVENTIONAL,PHASE3,259.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,QUADRUPLE,Alzheimer's Disease,Brexpiprazole|Brexpiprazole,DRUG,1,0,55 Years,91 Years,ALL,False,"Otsuka Pharmaceutical Development & Commercialization, Inc.",INDUSTRY,1,1,United States,1.0,0,0,1,0,0,3.0,0,0,1,0,1,5.560681631015528,large,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,2,1,,,,,0,1,0
NCT00606723,"Allogenic Stem Cell Transplantation for Children, Adolescents and Young Adults With Relapsed or Refractory AML","Allogenic Stem Cell Transplantation for Children, Adolescents and Young Adults With Relapsed or Refractory AML; Multi Center Therapy Concept",COMPLETED,2010-04,2021-02-24,2021-03-22,INTERVENTIONAL,PHASE3,154.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Acute Myeloid Leukemia (AML),Hematopoietic stem cells from bone marrow or peripheral blood,BIOLOGICAL,3,5,,21 Years,ALL,False,Hannover Medical School,OTHER,0,24,Germany|Austria|Czechia,1.0,0,0,1,0,0,3.0,1,0,0,0,1,5.043425116919247,medium,0,1,0,1,0,0,1,1,0,1,0,0,1,0,8,1,0,1,0,1,0,2010-04-01,,,2010.0,0,2,0
NCT06984159,"The Study Will Evaluate if Leuprolide Mesylate is Safe and Effective in the Treatment of Subjects With Advanced Prostate Carcinoma, When Administered as Two Injections Six Months Apart.","An Open-Label, Single-Arm, Multicenter Clinical Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Leuprolide Injectable Emulsion in Advanced Prostate Cancer",COMPLETED,2022-07-12,2024-04-24,2025-05-22,INTERVENTIONAL,PHASE3,137.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Advanced Prostate Cancer,Leuprolide Injectable Emulsion (CAMCEVI®),DRUG,2,0,18 Years,,MALE,False,"Changchun GeneScience Pharmaceutical Co., Ltd.",INDUSTRY,0,1,China,1.0,0,0,1,0,0,3.0,1,0,0,0,1,4.927253685157205,medium,0,1,1,0,0,0,0,0,0,0,0,0,1,0,2,0,1,0,0,1,0,,,,,0,0,0
NCT03419559,Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer,A Phase 2 Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combination With Anti-PD-L1 Inhibitor Durvalumab (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC),WITHDRAWN,2018-02-28,2024-12,2019-04-16,INTERVENTIONAL,PHASE2,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Non Small Cell Lung Cancer,LN-145|Durvalumab,DRUG|BIOLOGICAL,2,3,18 Years,,ALL,False,"Iovance Biotherapeutics, Inc.",INDUSTRY,0,8,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,0.0,,1,1,1,0,0,0,1,0,1,0,0,0,1,0,5,1,1,1,0,2,1,,2024-12-01,,,0,1,0
NCT00814359,Magic Mouthwash Plus Sucralfate Versus Benzydamine Hydrochloride for the Treatment of Radiation-induced Mucositis,A Phase III Study of Magic Mouthwash Plus Sucralfate Versus Benzydamine HCl for Treatment of Radiation-induced Oral Mucositis in Head and Neck Cancer Patients.,COMPLETED,2009-05,2010-09,2011-01-20,INTERVENTIONAL,PHASE3,67.0,ACTUAL,RANDOMIZED,PARALLEL,SUPPORTIVE_CARE,NONE,Head and Neck Cancer|Mucositis,Combination of Magic Mouthwash Plus Sucralfate|0.15% Benzydamine HCl,DRUG,1,2,18 Years,,ALL,False,Juravinski Cancer Centre Foundation,OTHER,0,1,Canada,1.0,0,0,1,0,0,3.0,1,0,0,0,2,4.219507705176107,medium,1,1,0,1,0,0,0,0,0,0,1,0,0,1,3,1,1,0,0,2,1,2009-05-01,2010-09-01,488.0,2009.0,0,2,0
NCT00973479,An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy,"A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFalpha Monoclonal Antibody, Administered Intravenously, in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy",COMPLETED,2009-09,2013-02,2013-12-25,INTERVENTIONAL,PHASE3,592.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Arthritis, Rheumatoid",Golimumab|Placebo|methotrexate (MTX),DRUG|OTHER,1,4,18 Years,,ALL,False,"Centocor, Inc.",INDUSTRY,1,88,Russia|Argentina|Hungary|South Korea|United States|Australia|Lithuania|Malaysia|Poland|Mexico|New Zealand|Ukraine|Colombia,1.0,0,0,1,0,0,3.0,0,1,0,0,1,6.385194398997726,xlarge,0,1,1,0,0,1,1,1,1,0,1,1,1,1,5,1,1,0,0,3,1,2009-09-01,2013-02-01,1249.0,2009.0,0,2,0
NCT02788279,A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370),"A Phase III, Open-Label, Multicenter, Three-Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy vs. Regorafenib in Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Adenocarcinoma",COMPLETED,2016-07-05,2018-12-26,2019-12-11,INTERVENTIONAL,PHASE3,363.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Colorectal Cancer,"Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody|Cobimetinib|Regorafenib",DRUG,1,9,18 Years,,ALL,False,Hoffmann-La Roche,INDUSTRY,0,73,Italy|Belgium|Russia|South Korea|United States|Spain|United Kingdom|Australia|Hong Kong|Poland|Canada,1.0,0,0,1,0,0,3.0,1,0,0,0,1,5.8971538676367405,large,0,1,1,0,1,0,1,1,1,1,1,0,1,1,10,1,1,0,0,3,1,,,,,0,3,1
NCT05475379,Non-inferiority Trial of Locally Manufactured Typhoid Conjugate Vaccine 'Typhocon' in Bangladesh,"A Randomized Control, Double Blinded, Non-inferiority Trial to Evaluate the Immunogenicity and Safety of Typhoid Vi Conjugate Vaccine 'Typhocon' in Bangladeshi Healthy Population",COMPLETED,2022-07-01,2023-07-31,2024-12-24,INTERVENTIONAL,PHASE1|PHASE2,630.0,ACTUAL,RANDOMIZED,SEQUENTIAL,PREVENTION,QUADRUPLE,Typhoid,Typhoid Vi polysaccharide-diphtheria toxoid conjugate vaccine (Vi-DT),BIOLOGICAL,1,1,6 Months,60 Years,ALL,True,"International Centre for Diarrhoeal Disease Research, Bangladesh",OTHER,0,1,Bangladesh,1.0,1,1,0,0,1,1.5,0,0,0,0,1,6.447305862541213,xlarge,0,1,0,1,0,0,0,0,0,0,1,1,0,0,2,1,0,1,0,1,0,,,,,0,1,0
NCT01169779,Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin,"Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin (With or Without Sulfonylurea): a Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study With 24-week Treatment Period",COMPLETED,2010-07,2011-12,2016-10-13,INTERVENTIONAL,PHASE3,391.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,Lixisenatide (AVE0010)|Placebo|Pen auto-injector|Metformin|Sulfonylurea,DRUG|DEVICE,1,7,18 Years,,ALL,False,Sanofi,INDUSTRY,0,35,China|Hong Kong|Malaysia|Thailand,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.971261839790462,large,0,1,1,0,1,0,1,1,0,0,1,1,1,1,8,1,1,0,1,5,1,2010-07-01,2011-12-01,518.0,2010.0,0,3,1
NCT01216696,Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1,Phase II Trial of Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1,COMPLETED,2010-11,2016-08,2016-08-12,INTERVENTIONAL,PHASE2,25.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Metastatic Melanoma,ipilimumab,DRUG,1,3,18 Years,,ALL,False,"National Center for Tumor Diseases, Heidelberg",OTHER,1,1,Germany,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.258096538021482,small,1,1,0,1,0,1,0,0,0,1,0,0,1,0,4,1,1,0,0,1,0,2010-11-01,2016-08-01,2100.0,2010.0,0,0,0
NCT05775796,Evaluate the Efficacy and Safety of Serplulimab Plus Chemotherapy in Neoadjuvant and Adjuvant Treatment of Resectable NSCLC (ECTOP-1013),"A Single-arm, Multicenter, and Phase II Clinical Study to Evaluate the Efficacy and Safety of Serplulimab Combined With Chemotherapy in Neoadjuvant and Adjuvant Treatment of Resectable Stage II-IIIA NSCLC",COMPLETED,2023-03-15,2025-09-01,2025-10-01,INTERVENTIONAL,PHASE2,30.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Non-small Cell Lung Cancer|Stage II-IIIA|Immunotherapy|Neoadjuvant Therapy,Serplulimab and Chemotherapy,DRUG,1,5,18 Years,75 Years,ALL,False,Fudan University,OTHER,0,1,China,1.0,0,1,0,0,0,2.0,1,0,0,0,4,3.4339872044851463,small,1,1,0,1,0,0,0,0,0,0,0,0,1,0,6,1,1,0,0,1,0,,,,,0,2,0
NCT00065962,Secretin for the Treatment of Autism,Multisite Controlled Secretin Trial in Autism,COMPLETED,1999-06,2000-05,2005-06-24,INTERVENTIONAL,PHASE3,85.0,,RANDOMIZED,FACTORIAL,TREATMENT,DOUBLE,Autism,"secretin, synthetic porcine|secretin, biologically derived porcine",DRUG,0,0,3 Years,12 Years,ALL,False,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),NIH,1,2,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.454347296253507,medium,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,1,0,0,2,1,1999-06-01,2000-05-01,335.0,1999.0,0,1,0
NCT00614003,Evaluation of an Intervention Designed to Enhance the Quality of Decision Support Provided to Patients Making Decisions About End-of-life Place of Care,Efficacy of a Training Intervention on the Quality of Case Coordinators and Nurses' Decision Support for Patients Deciding About the Place of Care at the End Of-Life: A Randomized Control Trial,COMPLETED,2007-04,2008-06,2015-05-25,INTERVENTIONAL,PHASE2,90.0,ACTUAL,RANDOMIZED,PARALLEL,,SINGLE,Palliative Care,Decision support skills building Intervention,BEHAVIORAL,1,1,,,ALL,True,Ottawa Hospital Research Institute,OTHER,0,5,Canada,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.51085950651685,medium,1,1,0,1,0,0,1,0,0,0,1,0,0,1,2,1,0,0,0,1,0,2007-04-01,2008-06-01,427.0,2007.0,0,0,0
NCT05179603,A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205],"Phase 2 Non-randomized, Open-label, Multi-cohort, Multicenter Study Assessing the Clinical Benefit of SAR444245 (THOR-707) With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma",TERMINATED,2021-12-07,2024-09-06,2025-12-24,INTERVENTIONAL,PHASE2,14.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Classic Hodgkin Lymphoma|Diffuse Large B-cell Lymphoma,THOR-707|Pembrolizumab,DRUG,1,10,12 Years,,ALL,False,Sanofi,INDUSTRY,1,8,Argentina|Chile|Spain,0.0,0,1,0,0,0,2.0,1,0,0,0,2,2.70805020110221,small,1,1,1,0,1,1,1,1,0,1,0,0,1,1,11,1,1,0,0,2,1,,,,,0,4,1
NCT03114527,Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS),Phase II Trial of Ribociclib in Combination With Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS),ACTIVE_NOT_RECRUITING,2017-08-08,2025-12,2025-04-04,INTERVENTIONAL,PHASE2,48.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Soft Tissue Sarcoma,Ribociclib|Everolimus,DRUG,1,4,18 Years,,ALL,False,Fox Chase Cancer Center,OTHER,0,2,United States,,0,1,0,0,0,2.0,1,0,0,0,1,3.8918202981106265,small,1,1,0,1,0,0,1,0,1,0,0,0,1,1,5,1,1,0,0,2,1,,2025-12-01,,,0,1,0
NCT00002727,Radiation Therapy in Treating Patients With Stage II Cancer of the Vocal Cord,A RANDOMIZED STUDY OF HYPERFRACTIONATION VERSUS CONVENTIONAL FRACTIONATION IN T2 SQUAMOUS CELL CARCINOMA OF THE VOCAL CORD,COMPLETED,1996-04,2016-12,2017-01-04,INTERVENTIONAL,PHASE3,250.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Head and Neck Cancer,radiation therapy,RADIATION,1,4,18 Years,120 Years,ALL,False,Radiation Therapy Oncology Group,NETWORK,1,237,Canada|United States,1.0,0,0,1,0,0,3.0,1,0,0,0,1,5.5254529391317835,large,0,1,0,0,0,1,1,1,1,0,1,0,1,1,5,1,0,0,0,1,0,1996-04-01,2016-12-01,7549.0,1996.0,0,1,0
NCT04548427,Study to Evaluate the Efficacy and Safety of CKD-352,"Active Controlled, Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-352 Eye Drops in Patients With Dry Eye Disease",COMPLETED,2020-09-22,2021-05-07,2021-06-01,INTERVENTIONAL,PHASE3,283.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Dry Eye Disease,CKD-352|Diquafosol Sodium 3%,DRUG,1,5,19 Years,,ALL,False,Chong Kun Dang Pharmaceutical,INDUSTRY,0,1,South Korea,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.648974238161206,large,0,1,1,0,0,0,0,0,0,0,1,1,1,1,6,1,1,0,0,2,1,,,,,0,2,0
NCT03872427,"Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study","A Phase II Basket Trial of Glutaminase Inhibitor (BEGIN) Telaglenastat (CB-839) HCL in Patients With NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant Tumors",ACTIVE_NOT_RECRUITING,2019-12-14,2026-04-16,2025-11-14,INTERVENTIONAL,PHASE2,54.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Advanced Malignant Solid Neoplasm|Metastatic Malignant Solid Neoplasm|NF1 Mutation Positive Malignant Peripheral Nerve Sheath Tumor|Unresectable Malignant Solid Neoplasm,Biospecimen Collection|Computed Tomography|Magnetic Resonance Imaging|Pharmacodynamic Study|Positron Emission Tomography|Telaglenastat Hydrochloride,DRUG|OTHER|PROCEDURE,1,6,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,31,United States,,0,1,0,0,0,2.0,1,0,0,0,4,4.007333185232471,medium,1,1,0,1,0,0,1,0,1,0,0,0,1,0,7,1,1,0,0,6,1,,,,,0,3,1
NCT03012061,Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma,"A Phase IIb, 24 Week, Randomized, Double-blind, 3 Arm Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of Two Doses of Umeclidinium Bromide Administered Once-daily Via a Dry Powder Inhaler, Versus Placebo, in Participants With Asthma",COMPLETED,2017-01-25,2018-05-30,2020-10-28,INTERVENTIONAL,PHASE2,425.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Asthma,Placebo|UMEC|Fluticasone Furoate|Albuterol/salbutamol,DRUG,1,5,18 Years,,ALL,False,GlaxoSmithKline,INDUSTRY,0,70,Russia|United States|Romania|Poland|Canada,1.0,0,1,0,0,0,2.0,0,0,0,0,1,6.054439346269371,large,0,1,1,0,0,0,1,1,1,0,1,1,1,1,6,1,1,0,0,4,1,,,,,0,3,1
NCT00853242,"Randomized Study Comparing Genz-644470, Placebo, and Sevelamer Carbonate in Chronic Kidney Disease Patients on Hemodialysis","A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study Using Genz-644470 and Sevelamer Carbonate in Hyperphosphatemic Chronic Kidney Disease Patients on Hemodialysis",COMPLETED,2009-02,2009-08,2015-05-01,INTERVENTIONAL,PHASE2,349.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Kidney Failure, Chronic",Placebo|Genz-644470|Sevelamer carbonate,DRUG,1,4,18 Years,,ALL,False,"Genzyme, a Sanofi Company",INDUSTRY,0,53,Puerto Rico|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.857933154483459,large,0,1,1,0,1,0,1,1,1,0,1,1,1,1,5,1,1,0,0,3,1,2009-02-01,2009-08-01,181.0,2009.0,0,2,0
NCT06159842,Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (isSCC),An Investigator Initiated Study to Evaluate the Safety and Efficacy of Aminolevulinic Acid 20% Topical Solution (Levulan® Kerastick®) (ALA) + Blue Light in the Treatment of Facial Cutaneous Squamous Cell Carcinoma in Situ (isSCC),COMPLETED,2023-08-08,2024-11-13,2025-02-12,INTERVENTIONAL,PHASE2,32.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Facial Cutaneous Squamous Cell Carcinoma in Situ,Aminolevulinic Acid 20% Topical Solution with Blue Light,COMBINATION_PRODUCT,1,2,18 Years,,ALL,False,The Center for Clinical and Cosmetic Research,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.4965075614664802,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,3,1,0,0,0,1,0,,,,,0,0,0
NCT00610142,Comparison of Atrophogenic Effect of Hydrocortison 1% Cream and Pimecrolimus 1% Cream Assessed by Optical Coherence Tomography (OCT) and 20-MHz Ultrasound of Uninvolved Skin in Patients With Atopic Dermatitis,Comparison of Atrophogenic Effect of Hydrocortison 1% Cream and Pimecrolimus 1% Cream Assessed by Optical Coherence Tomography (OCT) and 20-MHz Ultrasound of Uninvolved Skin in Patients With Atopic Dermatitis,COMPLETED,2007-12,2009-01,2014-06-11,INTERVENTIONAL,PHASE2,20.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Atopic Dermatitis,pimecrolimus 1% cream|hydrocortison 1% cream,DRUG,1,1,18 Years,60 Years,ALL,False,Technische Universität Dresden,OTHER,0,1,Germany,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.044522437723423,small,1,1,0,1,0,0,0,0,0,1,1,0,1,1,2,1,1,0,0,2,1,2007-12-01,2009-01-01,397.0,2007.0,0,1,0
NCT01243242,"Clinical Efficacy & Safety, of Metadoxine (MG01CI) Extended Release in Attention-Deficit Hyperactivity Disorder (ADHD)","Randomized, Double-blind, Placebo-controlled, Multi-center Study Designed to Evaluate the Efficacy, Safety and Tolerability of Metadoxine Extended Release in Adults With Attention Deficit Hyperactive Disorder",COMPLETED,2011-02,2011-09,2012-04-20,INTERVENTIONAL,PHASE2,120.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,ADHD,Metadoxine (MG01CI),DRUG,1,3,18 Years,50 Years,ALL,False,Alcobra Ltd.,INDUSTRY,0,2,Israel,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.795790545596741,medium,0,1,1,0,0,0,1,0,0,0,1,1,1,1,4,1,1,0,0,1,0,2011-02-01,2011-09-01,212.0,2011.0,0,0,0
NCT04590586,Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients,Industry Alliance Platform Trial to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients,COMPLETED,2020-11-24,2021-08-03,2022-06-29,INTERVENTIONAL,PHASE3,515.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,COVID-19,Standard of care|Apremilast|Apremilast placebo|Lanadelumab|Lanadelumab placebo|Zilucoplan|Zilucoplan placebo,DRUG,3,30,18 Years,,ALL,False,Amgen,INDUSTRY,0,59,Russia|Argentina|United States|Brazil|Chile|Mexico|Ukraine|South Africa,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.246106765481563,xlarge,0,1,1,0,1,0,1,1,1,0,1,1,1,1,33,1,1,0,0,7,1,,,,,0,3,1
NCT00851370,Exploratory Study of Xolair in Chronic Obstructive Pulmonary Disease in Patients With Elevated IgE Levels,"Exploratory Study of Xolair (Omalizumab)to Improve Outcomes in Patients With COPD and Elevated IgE Levels, and Positive RAST or Skin Prick Tests",WITHDRAWN,2009-01,2011-02,2017-03-29,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,"Pulmonary Disease, Chronic Obstructive",Omalizumab (Xolair)|Placebo,DRUG,1,0,40 Years,70 Years,ALL,False,National Jewish Health,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,1,1,0,1,0,1,0,0,1,0,1,1,0,1,1,0,1,0,0,2,1,2009-01-01,2011-02-01,761.0,2009.0,0,1,0
NCT00354770,N-Acetyl Cysteine in Trichotillomania,"A Double-Blind, Placebo-Controlled Study of N-Acetyl Cysteine in Trichotillomania",COMPLETED,2006-07,2008-09,2023-02-23,INTERVENTIONAL,PHASE2,50.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Trichotillomania,Placebo|N-Acetyl Cysteine,DRUG,1,0,18 Years,65 Years,ALL,False,University of Chicago,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.9318256327243257,small,1,1,0,1,0,0,0,0,1,0,1,1,1,1,1,0,1,0,0,2,1,2006-07-01,2008-09-01,793.0,2006.0,0,1,0
NCT00215670,"Study of the Safety, Tolerability and Pharmacokinetics of 1 Mg/Eye and 3 Mg/Eye Pegaptanib Sodium in Patients With Exudative Age-Related Macular Degeneration (AMD)","A Randomized, Double-Masked, Multi-Center Trial of the Safety, Tolerability and Pharmacokinetics of 1 Mg/Eye and 3 Mg/Eye Intravitreal Injections of Pegaptanib Sodium (Anti-Vegf Pegylated Aptamer) Given Every 6 Weeks for 54 Weeks, in Patients With Exudative Age-Related Macular Degeneration (AMD)",COMPLETED,2002-11,2006-05,2006-05-03,INTERVENTIONAL,PHASE2|PHASE3,125.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Age-Related Macular Degeneration,pegaptanib sodium (Macugen),DRUG,0,0,50 Years,,ALL,False,Eyetech Pharmaceuticals,INDUSTRY,1,0,,1.0,0,1,1,0,1,2.5,0,0,0,0,1,4.836281906951478,medium,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,0,1,0,0,1,0,2002-11-01,2006-05-01,1277.0,2002.0,0,1,0
NCT00728273,Efficacy of Multiple Micronutrient Fortified Biscuits and Deworming in Vietnamese School Children,"Efficacy of Multiple Micronutrient Fortified Biscuits and Deworming on Reducing Anemia Prevalence, and Improving Micronutrient Status, Cognitive Function, and Growth in Vietnamese School Children",COMPLETED,2007-01,2007-06,2008-12-04,INTERVENTIONAL,PHASE2,510.0,ACTUAL,RANDOMIZED,FACTORIAL,BASIC_SCIENCE,QUADRUPLE,Healthy,worm treatment and multiple micronutrient fortified biscuits,DIETARY_SUPPLEMENT,1,2,6 Years,8 Years,ALL,True,"Neys-van Hoogstraten Foundation, The Netherlands",OTHER,0,1,Thailand,1.0,0,1,0,0,0,2.0,0,0,0,0,1,6.236369590203704,xlarge,0,1,0,1,0,0,0,0,0,0,1,1,0,0,3,1,0,0,0,1,0,2007-01-01,2007-06-01,151.0,2007.0,0,0,0
NCT00338273,A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole in the Treatment of Patients With Bipolar I Disorder With a Major Depressive Episode",WITHDRAWN,2006-12,2007-11,2013-11-08,INTERVENTIONAL,PHASE3,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Bipolar Disorder,Aripiprazole|Placebo,DRUG,1,1,18 Years,65 Years,ALL,,"Otsuka Pharmaceutical Development & Commercialization, Inc.",INDUSTRY,1,8,India|United States,0.0,0,0,1,0,0,3.0,0,0,0,0,1,0.0,,1,1,1,0,0,1,1,1,1,0,1,1,1,1,2,1,1,0,0,2,1,2006-12-01,2007-11-01,335.0,2006.0,0,2,0
NCT04489173,"TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer","A Phase 2 Study of Trifluridine/Tipiracil in Patients With ER-positive, HER2-negative Advanced Breast Cancer That Previously Received Chemotherapy",ACTIVE_NOT_RECRUITING,2020-09-25,2025-11,2025-09-19,INTERVENTIONAL,PHASE2,52.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Breast Neoplasm|Chemotherapy Effect,trifluridine/tipiracil,DRUG,1,2,18 Years,,FEMALE,False,Borstkanker Onderzoek Groep,NETWORK,4,10,Netherlands,,0,1,0,0,0,2.0,0,0,0,0,2,3.970291913552122,medium,1,1,0,0,0,1,1,0,0,0,0,0,1,0,3,1,1,0,0,1,0,,2025-11-01,,,0,1,0
NCT00759473,D-Cycloserine Facilitation of Cocaine - Cue Extinction,D-Cycloserine Facilitation of Cocaine - Cue Extinction,COMPLETED,2008-09,2011-10,2016-04-13,INTERVENTIONAL,PHASE2,79.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Cocaine Use Disorders,D-Cycloserine (DCS)|Placebo,DRUG,1,0,18 Years,65 Years,ALL,False,Medical University of South Carolina,OTHER,1,2,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.382026634673881,medium,1,1,0,1,0,1,1,0,1,0,1,1,1,1,1,0,1,0,0,2,1,2008-09-01,2011-10-01,1125.0,2008.0,0,1,0
NCT02088073,Safety & Efficacy of Zirconium Silicate Dosed for 28 Days in Hyperkalemia.,"Multicenter, Multi-phase, Multi-dose, Prospective, Double-blind, Placebo-controlled, Maintenance Study of Safety and Efficacy of ZS (Microporous, Fractionated, Protonated Zirconium Silicate) in Hyperkalemia.",COMPLETED,2014-03-31,2015-01-31,2018-12-07,INTERVENTIONAL,PHASE3,258.0,ACTUAL,RANDOMIZED,PARALLEL,SUPPORTIVE_CARE,QUADRUPLE,Hyperkalemia,Sodium zirconium cyclosilicate|Placebo,DRUG,1,14,18 Years,,ALL,False,"ZS Pharma, Inc.",INDUSTRY,0,46,South Africa|Australia|United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.556828061699537,large,0,1,1,0,0,0,1,1,1,0,1,1,0,1,15,1,1,0,0,2,1,,,,,0,3,1
NCT00040469,Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies,"Allogeneic Bone Marrow Transplant From HLA Identical Related Donors for Patients With High Risk Hemoglobinopathies: Hemoglobin SS, Hemoglobin SC, Hemoglobin SB0/+ Thalassemia, or Homozygous B0/+ Thalassemia or Severe Variants of B0/+ Thalassemia",TERMINATED,2000-08,2003-11-21,2020-01-18,INTERVENTIONAL,PHASE2,15.0,,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Sickle Cell Anemia|Hemoglobinopathy|Thalassemia,Campath -1H|Dilantin|Busulfan|Cyclophosphamide,DRUG,0,0,1 Day,64 Years,ALL,False,Baylor College of Medicine,OTHER,2,2,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,3,2.772588722239781,small,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,4,1,2000-08-01,,,2000.0,0,2,0
NCT00669669,O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas,Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cells for Patients With Malignant Gliomas,TERMINATED,2009-02-25,2021-01-20,2022-05-18,INTERVENTIONAL,PHASE1|PHASE2,12.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Glioblastoma|Gliosarcoma,3-Dimensional Conformal Radiation Therapy|Autologous Hematopoietic Stem Cell Transplantation|Carmustine|Filgrastim|In Vitro-Treated Peripheral Blood Stem Cell Transplantation|Intensity-Modulated Radiation Therapy|Laboratory Biomarker Analysis|O6-Benzylguanine|Plerixafor|Proton Beam Radiation Therapy|Temozolomide,RADIATION|PROCEDURE|DRUG|BIOLOGICAL|OTHER,2,8,18 Years,,ALL,False,Fred Hutchinson Cancer Center,OTHER,0,1,United States,0.0,1,1,0,0,1,1.5,1,0,0,0,2,2.5649493574615367,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,10,1,1,1,0,11,1,,,,,0,4,1
NCT00882869,XIAP Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC),"A Phase 1-2, Open-Label Study of The X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)",COMPLETED,2009-03,2011-05,2011-07-13,INTERVENTIONAL,PHASE1|PHASE2,75.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,NONE,Advanced Hepatocellular Carcinoma,AEG35156 antisense IV infusion|Sorafenib,DRUG,2,2,18 Years,,ALL,False,Aegera Therapeutics,INDUSTRY,1,3,China,1.0,1,1,0,0,1,1.5,1,0,0,0,1,4.330733340286331,medium,1,0,1,0,0,1,1,0,0,0,1,0,1,1,4,1,1,0,0,2,1,2009-03-01,2011-05-01,791.0,2009.0,0,2,0
NCT04724369,Open-Label Study of 18F-mFBG for Imaging Neuroblastoma,A Prospective Phase 3 Multi-center Study to Assess the Efficacy and Safety of 18F-mFBG PET Imaging in Subjects with Neuroblastoma,COMPLETED,2021-11-18,2024-05-01,2025-03-26,INTERVENTIONAL,PHASE3,43.0,ACTUAL,,SINGLE_GROUP,DIAGNOSTIC,NONE,Neuroblastoma,18F-MFBG,DRUG,1,2,,,ALL,False,Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC),INDUSTRY,2,8,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.784189633918261,small,1,1,1,0,0,1,1,0,1,0,0,0,0,0,3,1,1,0,0,1,0,,,,,0,0,0
NCT00467883,Pilot Study of High Dose Liposomal Amphotericin B Efficacy in Initial Zygomycosis Treatment,AMBIZYGO: Efficacy of High Dose [10 mg/kg/j] Liposomal Amphotericin B (Ambisome)Efficacy in Initial Zygomycosis Treatment:Phase II Trial,COMPLETED,2007-06,2013-03,2014-07-18,INTERVENTIONAL,PHASE2,40.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Zygomycosis,Liposomal Amphotericin B,DRUG,1,1,,,ALL,False,Assistance Publique - Hôpitaux de Paris,OTHER,0,2,France,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.713572066704308,small,1,1,0,1,0,0,1,0,0,1,0,0,1,0,2,1,1,0,0,1,0,2007-06-01,2013-03-01,2100.0,2007.0,0,0,0
NCT00114283,Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer,A Phase 2 Trial of GW572016 in Patients With Metastatic and Recurrent Squamous Cell Carcinomas of the Head and Neck,COMPLETED,2005-03,2006-10,2015-04-15,INTERVENTIONAL,PHASE2,30.0,ESTIMATED,,SINGLE_GROUP,TREATMENT,NONE,Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Salivary Gland Squamous Cell Carcinoma|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IVA Salivary Gland Cancer|Stage IVA Squamous Cell Carcinoma of the Larynx|Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVA Squamous Cell Carcinoma of the Oropharynx|Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVA Verrucous Carcinoma of the Larynx|Stage IVA Verrucous Carcinoma of the Oral Cavity|Stage IVB Salivary Gland Cancer|Stage IVB Squamous Cell Carcinoma of the Larynx|Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVB Squamous Cell Carcinoma of the Oropharynx|Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVB Verrucous Carcinoma of the Larynx|Stage IVB Verrucous Carcinoma of the Oral Cavity|Stage IVC Salivary Gland Cancer|Stage IVC Squamous Cell Carcinoma of the Larynx|Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVC Squamous Cell Carcinoma of the Oropharynx|Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVC Verrucous Carcinoma of the Larynx|Stage IVC Verrucous Carcinoma of the Oral Cavity|Tongue Cancer,lapatinib ditosylate|laboratory biomarker analysis,DRUG|OTHER,1,3,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,34,3.4339872044851463,small,1,0,0,1,0,0,0,0,1,0,0,0,1,0,4,1,1,0,0,2,1,2005-03-01,2006-10-01,579.0,2005.0,0,2,0
NCT05862883,"Studying the Efficiency of the Natural Preparation Rutan in Children in the Treatment of COVID-19, ARVI","Studying the Efficiency of the Natural Preparation Rutan in Children in the Treatment of COVID-19, Acute Respiratory Viral Infections, and Developing Treatment Protocols",COMPLETED,2021-06-01,2022-07-01,2023-05-17,INTERVENTIONAL,PHASE2,301.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,COVID-19 Respiratory Infection,Rutan 25 mg|Control group,DRUG|OTHER,1,0,6 Years,18 Years,ALL,False,"Research Institute of Virology, Ministry of Health of the Republic of Uzbekistan",OTHER_GOV,0,1,Uzbekistan,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.71042701737487,large,0,1,0,1,0,0,0,0,0,0,1,1,1,1,1,0,1,0,0,2,1,,,,,0,1,0
NCT00343941,Tucaresol As Add-On To HAART (Highly Active Antiretroviral Therapy) In Chronic HIV-1 Infected Adults,"A Phase II Multicentre, Randomized, Double Blind, Parallel Group, Placebo Controlled Pilot Study of Tucaresol at Two Dosing Levels (25,50 mg) in HIV-1 Infected Adult Subjects With Plasma HIV-1 RNA < 50 Copies/ml on Stable Highly Active Antiretroviral Therapy Regimen for at Least 3 Months",COMPLETED,2004-11,,2008-10-13,INTERVENTIONAL,PHASE2,45.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,HIV Infection,Tucaresol tablets 25 mg,DRUG,1,1,18 Years,64 Years,ALL,False,GlaxoSmithKline,INDUSTRY,0,7,Italy,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.828641396489095,small,1,0,1,0,0,0,1,0,0,1,1,1,1,1,2,1,1,0,0,1,0,2004-11-01,,,2004.0,0,0,0
NCT01317641,Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer,"Safety and Pharmacokinetics of ODM-201 in Patients With Castrate Resistant Prostate Cancer: Open, Non-randomised, Uncontrolled, Multicentre, Multiple Dose Escalation Study With a Randomised Phase II Expansion Component",COMPLETED,2011-03,2013-07,2017-03-29,INTERVENTIONAL,PHASE1|PHASE2,136.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Prostate Cancer,ODM-201,DRUG,2,15,18 Years,,MALE,False,"Orion Corporation, Orion Pharma",INDUSTRY,1,23,Finland|United States|United Kingdom|Estonia|Czechia|France,1.0,1,1,0,0,1,1.5,1,0,0,0,1,4.919980925828125,medium,0,1,1,0,0,1,1,1,1,1,1,0,1,1,17,1,1,0,0,1,0,2011-03-01,2013-07-01,853.0,2011.0,0,3,1
NCT00979641,Biweekly Avastin and Docetaxel as the First Line Treatment for Patients With Metastatic Breast Cancer,Single Arm Study of the Combination of Biweekly Avastin and Docetaxel as the First Line Treatment for Patients With Metastatic Breast Cancer,TERMINATED,2009-01,2014-12,2019-03-28,INTERVENTIONAL,PHASE2,65.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Neoplasms,Docetaxel,DRUG,1,6,18 Years,,FEMALE,False,Tampere University Hospital,OTHER,2,1,Finland,0.0,0,1,0,0,0,2.0,0,0,0,0,1,4.189654742026425,medium,1,1,0,1,0,1,0,0,0,0,0,0,1,0,7,1,1,0,0,1,0,2009-01-01,2014-12-01,2160.0,2009.0,0,1,0
NCT00332241,Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD),"A Multicenter Double-Blind, Randomized, Placebo-Controlled, Flexible-Dosed, Parallel-Group Study of Aripiprazole Flexibly Dosed in the Treatment of Children and Adolescents With Autistic Disorder (AD)",COMPLETED,2006-06,2008-04,2013-12-02,INTERVENTIONAL,PHASE3,98.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Autistic Disorder,Aripiprazole|Placebo,DRUG,1,7,6 Years,17 Years,ALL,False,"Otsuka Pharmaceutical Development & Commercialization, Inc.",INDUSTRY,1,9,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.59511985013459,medium,1,1,1,0,0,1,1,0,1,0,1,1,1,1,8,1,1,0,0,2,1,2006-06-01,2008-04-01,670.0,2006.0,0,2,0
NCT05569954,"Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10)","A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older",COMPLETED,2022-11-07,2025-02-07,2026-02-02,INTERVENTIONAL,PHASE3,1484.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Pneumococcal Disease,V116|PPSV23,BIOLOGICAL,5,6,50 Years,,ALL,True,Merck Sharp & Dohme LLC,INDUSTRY,0,55,Taiwan|Argentina|Turkey (Türkiye)|South Korea|Spain|Germany|United Kingdom|Australia|New Zealand|Israel|Colombia,1.0,0,0,1,0,0,3.0,0,0,0,0,1,7.3031700512368,xlarge,0,1,1,0,1,0,1,1,0,1,1,1,0,1,11,1,0,1,0,2,1,,,,,0,3,1
NCT00161824,Safety Study in Volunteers From 16 to 65 Years of Age: FSME IMMUN NEW vs. ENCEPUR,"Single-blind, Randomized, Multicenter Comparison of FSME IMMUN NEW and ENCEPUR: Safety and Tolerability of Two Vaccinations in Healthy Volunteers Aged 16 to 65 Years.",COMPLETED,2001-10,2002-01,2015-05-21,INTERVENTIONAL,PHASE3,3800.0,,RANDOMIZED,PARALLEL,,SINGLE,"Encephalitis, Tick-borne",Tick-Borne Encephalitis (TBE) Vaccine (Inactivated),BIOLOGICAL,0,0,16 Years,65 Years,ALL,True,Pfizer,INDUSTRY,0,7,Poland,1.0,0,0,1,0,0,3.0,0,0,0,0,1,8.24301946898925,xlarge,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,2001-10-01,2002-01-01,92.0,2001.0,0,0,0
NCT04774224,Baricitinib in New-onset Type 1 Diabetes,"A Phase 2, Randomised, Placebo Controlled Study Investigating the Efficacy of Baricitinib in New Onset Type 1 Diabetes Mellitus",COMPLETED,2020-10-30,2024-05-06,2024-12-03,INTERVENTIONAL,PHASE2,91.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 1 Diabetes,Baricitinib|Placebo,DRUG,1,7,10 Years,30 Years,ALL,False,St Vincent's Institute of Medical Research,OTHER,2,4,Australia,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.5217885770490405,medium,1,1,0,1,0,1,1,0,0,0,1,1,1,1,8,1,1,0,0,2,1,,,,,0,2,0
NCT02972424,PTH(1-34) and Pelvic Fracture Healing - a Randomized Controlled Trial,PTH(1-34) and Pelvic Fracture Healing - a Randomized Controlled Trial,COMPLETED,2017-05-01,2021-07-08,2022-07-27,INTERVENTIONAL,PHASE2,35.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Osteoporotic Fractures,Teriparatide Prefilled Syringe|Placebo,DRUG,1,4,65 Years,,ALL,False,"Hospital for Special Surgery, New York",OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.58351893845611,small,1,1,0,1,0,1,0,0,1,0,1,1,1,1,5,1,1,0,0,2,1,,,,,0,1,0
NCT00789724,Anakinra to Prevent Post-infarction Remodeling,"Recombinant Human Interleukin-1 Receptor Antagonist, Anakinra, to Prevent Post-infarction Remodeling: the Virginia Commonwealth University Anakinra Remodeling Trial (VCU-ART)",COMPLETED,2008-11,2009-08,2017-11-30,INTERVENTIONAL,PHASE3,10.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,ST Segment Elevation Acute Myocardial Infarction,Anakinra|Placebo,DRUG,1,0,18 Years,,ALL,False,Virginia Commonwealth University,OTHER,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,1,1,2.3978952727983707,small,1,1,0,1,0,0,0,0,1,0,1,1,1,1,1,0,1,0,0,2,1,2008-11-01,2009-08-01,273.0,2008.0,0,1,0
NCT06688123,Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects,"A Randomized, Open-label, Treat-to-target, Parallel-controlled, Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR-3167 and Insulin Glargine in Patients With Type 2 Diabetes Mellitus With Metformin Alone or in Combination With SGLT2 Inhibitors",ACTIVE_NOT_RECRUITING,2025-01-08,2026-04-30,2025-11-24,INTERVENTIONAL,PHASE2,275.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Type 2 Diabetes,SHR-3167|SHR-3167|Insulin glargine,DRUG,1,4,18 Years,65 Years,ALL,False,"Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,0,2,China,,0,1,0,0,0,2.0,0,0,0,0,1,5.62040086571715,large,0,1,1,0,0,0,1,0,0,0,1,0,1,1,5,1,1,0,0,3,1,,,,,0,1,0
NCT02495623,A Study of the Effect of SYN-010 on Subjects With IBS-C,"A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multi-Dose Study of the Effect of Two Dosage Strengths of SYN-010 Compared With Placebo on Breath Methane Production in Breath Methane-Positive Subjects With IBS-C",COMPLETED,2015-06,2015-11,2018-11-27,INTERVENTIONAL,PHASE2,63.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Irritable Bowel Syndrome With Constipation (IBS-C),SYN-010 21 mg|SYN-010 42 mg|Placebo,DRUG,1,0,18 Years,65 Years,ALL,False,"Theriva Biologics, Inc.",INDUSTRY,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.1588830833596715,medium,1,1,1,0,0,0,0,0,1,0,1,1,1,1,1,0,1,0,0,3,1,2015-06-01,2015-11-01,153.0,2015.0,1,1,0
NCT02008123,Effect of Primidone on Platelet Responsiveness in Patients Determined to be Clopidogrel Resistant,Effect of Primidone on Platelet Responsiveness in Patients Determined to be Clopidogrel Resistant,WITHDRAWN,2013-08,,2016-08-03,INTERVENTIONAL,PHASE2,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Clopidogrel Resistance|Secondary Stroke Prevention,Primidone,DRUG,1,1,18 Years,90 Years,ALL,False,Dent Neuroscience Research Center,OTHER,0,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,2,0.0,,1,1,0,1,0,0,0,0,1,0,0,0,1,0,2,1,1,0,0,1,0,2013-08-01,,,2013.0,0,1,0
NCT01052779,A Trial Comparing Ferumoxytol to Iron Sucrose for the Treatment of Iron Deficiency Anemia in Adult Subjects With Chronic Kidney Disease,"Ferumoxytol Compared to Iron Sucrose Trial (FIRST): A Randomized, Multicenter, Trial of Ferumoxytol Compared to Iron Sucrose for the Treatment of Iron Deficiency Anemia in Adult Subjects With Chronic Kidney Disease",COMPLETED,2010-03-01,2012-04-19,2023-07-25,INTERVENTIONAL,PHASE2,162.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Iron Deficiency|Anemia|Kidney Disease,Ferumoxytol|Iron Sucrose,DRUG,2,0,18 Years,,ALL,False,"AMAG Pharmaceuticals, Inc.",INDUSTRY,0,36,Belgium|India|United States|Germany|United Kingdom|Poland|Canada,1.0,0,1,0,0,0,2.0,0,0,0,0,3,5.093750200806762,medium,0,1,1,0,0,0,1,1,1,1,1,0,1,1,2,0,1,0,0,2,1,,,,,0,3,1
NCT00375596,A Study Of The Safety And Effectiveness Of A New Treatment For Allergic Conjunctivitis,Study Withdrawn Prior to Determining Official Title,WITHDRAWN,,,2015-02-20,INTERVENTIONAL,PHASE2,0.0,ACTUAL,,PARALLEL,,,Allergic Conjunctivitis,Ketotifen/vasoconstrictor,DRUG,1,0,6 Years,,ALL,False,Bausch & Lomb Incorporated,INDUSTRY,0,0,,0.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,,,,,0,0,0
NCT01605162,Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma,Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma,TERMINATED,2012-05,2014-02,2016-07-28,INTERVENTIONAL,PHASE2,8.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Wild Type BRAF Stage IV Melanoma|Unresectable Stage III Melanoma,TMZ|E7016,DRUG,1,0,18 Years,,ALL,False,Eisai Inc.,INDUSTRY,0,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,2,2.1972245773362196,small,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,2,1,2012-05-01,2014-02-01,641.0,2012.0,0,2,0
NCT01360762,Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients With Pentamidine: a Cohort Study,Secondary Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients Using Pentamidine as a Prophylactic Agent: a Prospective Cohort Study,COMPLETED,2011-11,2015-11,2019-02-15,INTERVENTIONAL,PHASE3,74.0,ACTUAL,,SINGLE_GROUP,PREVENTION,NONE,Visceral Leishmaniosis|HIV-infection/Aids,Pentamidine,DRUG,2,3,18 Years,,ALL,False,"Institute of Tropical Medicine, Belgium",OTHER,7,3,Ethiopia,1.0,0,0,1,0,0,3.0,0,0,0,0,2,4.31748811353631,medium,1,1,0,1,0,1,1,0,0,0,0,0,0,0,5,1,1,0,0,1,0,2011-11-01,2015-11-01,1461.0,2011.0,0,1,0
NCT02337062,Phase IIIb Study of APD421 in Combination as PONV Prophylaxis,"Randomised, Double-blind, Placebo-controlled Phase III Study of APD421 (Amisulpride for IV Injection) as Combination Prophylaxis Against Post-operative Nausea and Vomiting in High-risk Patients",COMPLETED,2015-02,2015-09,2019-03-20,INTERVENTIONAL,PHASE3,1147.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,PONV,APD421|Placebo,DRUG,1,5,18 Years,,ALL,False,Acacia Pharma Ltd,INDUSTRY,0,25,Germany|France|United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,7.045776576879511,xlarge,0,1,1,0,0,0,1,1,1,1,1,1,0,1,6,1,1,0,0,2,1,2015-02-01,2015-09-01,212.0,2015.0,1,3,1
NCT00370162,Acceptability Dermacyd Delicata - New Fragrance - Lactoserum - Hygiene,Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Delicata New Fragrance,COMPLETED,2006-06,,2008-05-16,INTERVENTIONAL,PHASE3,30.0,,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Hygiene,lactoserum,DRUG,1,0,18 Years,60 Years,FEMALE,True,Sanofi,INDUSTRY,0,1,Brazil,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.4339872044851463,small,1,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,2006-06-01,,,2006.0,0,0,0
NCT05037162,Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19,"A Phase IIb, Double Blind, Placebo-controlled Clinical Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19",COMPLETED,2022-10-11,2023-03-01,2023-03-15,INTERVENTIONAL,PHASE2,240.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Covid19|Corona Virus Infection,Biochemistry blood test|Hematology blood test|D-Dimer test (coagulation)|Inflammatory markers|Vital signs|VAS scale|WHO Ordinal Score|COVID-19-Related Symptoms assessment|COVID-19-Impact on Quality-of-Life Questionnaire|POST- COVID-19 Functional Status Scale:|Pregnancy test|Physical examination|PK parameters|SARS-CoV-2 test (PCR)|ECG|Treatment administration (twice a day),DRUG|DIAGNOSTIC_TEST,8,17,18 Years,,ALL,False,MGC Pharmaceuticals d.o.o,INDUSTRY,0,1,Israel,1.0,0,1,0,0,0,2.0,0,0,0,0,2,5.484796933490655,large,0,1,1,0,0,0,0,0,0,0,1,1,1,1,25,1,1,0,0,16,1,,,,,0,3,1
NCT00129246,Low-Dose Naltrexone Combined With Bupropion to Stop Smoking With Less Weight Gain,Naltrexone & Bupropion to Stop Smoking With Less Weight Gain,COMPLETED,2004-12,2005-12,2020-12-03,INTERVENTIONAL,PHASE1|PHASE2,40.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Smoking|Nicotine Dependence,Naltrexone|Bupropion,DRUG,3,1,18 Years,,ALL,False,Yale University,OTHER,1,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,2,3.713572066704308,small,1,1,0,1,0,1,0,0,1,0,0,0,1,1,4,1,1,0,0,2,1,2004-12-01,2005-12-01,365.0,2004.0,0,3,1
NCT00541346,A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms,Phase III Study of Autism Co-Morbid for Attention Deficit Hyperactivity Disorder,COMPLETED,2007-09,2010-02,2014-02-06,INTERVENTIONAL,PHASE3,16.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Autism|Attention Deficit Hyperactivity Disorder,Methylphenidate Transdermal System,DRUG,1,10,6 Years,11 Years,ALL,False,University of Oklahoma,OTHER,1,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,2,2.833213344056216,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,11,1,1,0,0,1,0,2007-09-01,2010-02-01,884.0,2007.0,0,2,0
NCT01368588,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial,ACTIVE_NOT_RECRUITING,2011-07,2031-07,2025-10-28,INTERVENTIONAL,PHASE3,2592.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Prostate Cancer,radiation therapy|Whole-pelvic radiotherapy (WPRT),RADIATION,1,8,18 Years,,MALE,False,Radiation Therapy Oncology Group,NETWORK,2,478,United States|Hong Kong|Switzerland|Israel|Singapore|Canada,,0,0,1,0,0,3.0,1,0,0,0,1,7.860570785538664,xlarge,0,1,0,0,0,1,1,1,1,0,1,0,1,1,9,1,0,0,0,2,1,2011-07-01,2031-07-01,7305.0,2011.0,0,3,1
NCT00952588,"Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients","A Randomised, Open-label, Multi-centre, 2-stage, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC) in Comparison With LDAC Alone in Patients Aged ≥ 60 With Newly Diagnosed Acute Myeloid Leukaemia (AML)",COMPLETED,2009-07,2011-06,2020-02-24,INTERVENTIONAL,PHASE2|PHASE3,74.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Acute Myeloid Leukemia,AZD1152|LDAC,DRUG,1,6,60 Years,,ALL,False,AstraZeneca,INDUSTRY,0,45,Italy|United States|Germany|Spain|Australia|Romania|United Kingdom|Japan|France,1.0,0,1,1,0,1,2.5,1,0,0,0,1,4.31748811353631,medium,1,1,1,0,1,0,1,1,1,1,1,0,1,1,7,1,1,0,0,2,1,2009-07-01,2011-06-01,700.0,2009.0,0,4,1
NCT02220088,The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a Randomized Controlled Trial,The Efficacy and Safety of Retreatment With Transcatheter Arterial Infusion (TAI) for Patients Who Showed TACE-resistant: a Randomized Controlled Trial,TERMINATED,2014-12,2018-07,2019-01-11,INTERVENTIONAL,PHASE2|PHASE3,79.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Hepatocellular Carcinoma,TAI of FOLFOX|Sorafenib,DRUG|PROCEDURE,1,2,18 Years,70 Years,ALL,False,Sun Yat-sen University,OTHER,2,1,China,0.0,0,1,1,0,1,2.5,1,0,0,0,1,4.382026634673881,medium,1,1,0,1,0,1,0,0,0,0,1,0,1,1,3,1,1,0,0,2,1,2014-12-01,2018-07-01,1308.0,2014.0,0,2,0
NCT02224703,GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome,"A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome.",COMPLETED,2015-04-13,2018-04-09,2022-09-28,INTERVENTIONAL,PHASE3,199.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Epilepsy|Dravet Syndrome,GWP42003-P|Placebo Control,DRUG,1,3,2 Years,18 Years,ALL,False,Jazz Pharmaceuticals,INDUSTRY,0,38,Netherlands|United States|Spain|Australia|Poland|Israel,1.0,0,0,1,0,0,3.0,0,0,1,0,2,5.298317366548036,medium,0,1,1,0,0,0,1,1,1,1,1,1,1,1,4,1,1,0,0,2,1,,,,,0,3,1
NCT02354703,Pharmacogenetic Study of Ondansetron in Alcohol Use Disorder,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Pharmacogenetic Study of Ondansetron in Alcohol Use Disorder",COMPLETED,2015-08,2020-03-31,2022-01-14,INTERVENTIONAL,PHASE2,293.0,ACTUAL,RANDOMIZED,FACTORIAL,TREATMENT,QUADRUPLE,Alcohol Use Disorder,Ondansetron|Placebo,DRUG,1,2,18 Years,70 Years,ALL,False,"University of Maryland, Baltimore",OTHER,1,3,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.683579767338681,large,0,1,0,1,0,1,1,0,1,0,1,1,1,0,3,1,1,0,0,2,1,2015-08-01,,,2015.0,1,1,0
NCT01254227,Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Severe Cardiac Iron Overload,"Phase II, Open-label, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Patients With Severe Cardiac Iron Overload Due to Chronic Blood Transfusion (HYPERION)",COMPLETED,2011-01,2013-11,2021-07-26,INTERVENTIONAL,PHASE2,60.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Cardiac Iron Overload,Deferasirox and Deferoxamine,DRUG,1,6,10 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,15,Italy|Thailand|Turkey (Türkiye)|United Kingdom|Egypt|Taiwan|Greece|Canada,1.0,0,1,0,0,0,2.0,0,0,0,1,1,4.110873864173311,medium,1,1,1,0,1,0,1,1,0,1,0,0,1,0,7,1,1,0,0,1,0,2011-01-01,2013-11-01,1035.0,2011.0,0,2,0
NCT02702427,Virus-specific ImmunoTherapy Following Allogeneic Stem Cell Transplantation,Phase I/II: Treatment of Adenovirus and Cytomegalovirus Infection Post Human Allogeneic Stem Cell Transplantation With Short-term Expanded Virus-specific T Cells,WITHDRAWN,2016-08-03,2019-04-01,2019-05-09,INTERVENTIONAL,PHASE1|PHASE2,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Cytomegalovirus Infection|Adenovirus Infection,virus-specific T-Cells,BIOLOGICAL,3,3,,18 Years,ALL,False,St. Anna Kinderkrebsforschung,OTHER,0,1,Austria,0.0,1,1,0,0,1,1.5,0,0,0,0,2,0.0,,1,1,0,1,0,0,0,0,0,0,0,0,1,0,6,1,0,1,0,1,0,,,,,0,3,1
NCT01658527,TAK-700 in Castration Resistant Prostate Cancer,Phase II Randomized Comparative Trial of TAK-700 (Orteronel) Versus Bicalutamide in Metastatic Prostate Cancer Patients Failing 1st Line Treatment With LHRH Agonists or Surgical Castration.,WITHDRAWN,2014-01,2017-01,2016-06-10,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Prostate Cancer,Orteronel|Bicalutamide,DRUG,1,6,18 Years,,MALE,False,European Organisation for Research and Treatment of Cancer - EORTC,NETWORK,0,4,Belgium,0.0,0,1,0,0,0,2.0,1,0,0,0,1,0.0,,1,1,0,0,0,0,1,0,0,0,1,0,1,1,7,1,1,0,0,2,1,2014-01-01,2017-01-01,1096.0,2014.0,0,2,0
NCT00713661,Evaluation of TachoSil® Application on a Colorectal Anastomosis (TC-029-IM),"Non-randomised, Open, Multi-center Trial Evaluating Feasibility and Safety of TachoSil® Application on a Colorectal Anastomosis.",COMPLETED,2008-06,2010-07,2012-05-08,INTERVENTIONAL,PHASE2,25.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Colorectal Anastomosis,TachoSil®,DRUG,1,1,18 Years,,ALL,False,Nycomed,INDUSTRY,0,3,Germany|United Kingdom|Netherlands,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.258096538021482,small,1,1,1,0,0,0,1,1,0,1,0,0,1,0,2,1,1,0,0,1,0,2008-06-01,2010-07-01,760.0,2008.0,0,1,0
NCT06081361,"Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort","A Multicenter, Randomized, Open-Label Study To Evaluate The Efficacy And Safety Of A Contezolid, Delamanid and Bedaquiline-Containing Short Regimen For The Treatment Of Rifampicin-Resistant Pulmonary Tuberculosis",ACTIVE_NOT_RECRUITING,2023-12-22,2026-12-31,2025-04-01,INTERVENTIONAL,PHASE3,186.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,NONE,Pulmonary Tuberculosis|Rifampicin-resistant Tuberculosis,Bedaquiline|Delamanid|Contezolid|Levofloxacin|Moxifloxacin|Clofazimine|Linezolid|Cycloserine|Prothionamide|Pyrazinamide|Para-Aminosalicylic Acid|Ethambutol,DRUG,1,3,18 Years,70 Years,ALL,False,Beijing Chest Hospital,OTHER,1,39,China,,0,0,1,0,0,3.0,0,0,0,0,2,5.231108616854587,medium,0,0,0,1,0,1,1,0,0,0,1,0,1,1,4,1,1,0,0,12,1,,,,,0,2,0
NCT02078661,Safety and Efficacy of PG101 for Dry Eye Syndrome,"A Single Center, Randomized, Double-Masked, Placebo Controlled Study Evaluating the Safety and Efficacy of 0.25% PG101 and 1.0% PG101 in Subjects With Dry Eye Syndrome",COMPLETED,2013-12,2014-01,2014-03-05,INTERVENTIONAL,PHASE1|PHASE2,72.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Dry Eye Syndrome,PG101,DRUG,1,1,18 Years,,ALL,False,"Rhodes Pharmaceuticals, L.P.",INDUSTRY,1,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,4.290459441148391,medium,1,1,1,0,0,1,0,0,1,0,1,1,1,1,2,1,1,0,0,1,0,2013-12-01,2014-01-01,31.0,2013.0,0,1,0
NCT01830361,Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AML,A Single-arm Phase II Trial to Assess the Efficacy of Midostaurin (PKC412) Added to Standard Primary Therapy in Patients With Newly Diagnosed c-KIT or FLT3-ITD Mutated t(8;21) AML,COMPLETED,2013-03-13,2019-10-30,2020-08-06,INTERVENTIONAL,PHASE2,18.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Acute Myeloid Leukemia,midostaurin (PKC412),DRUG,1,7,18 Years,65 Years,ALL,False,Technische Universität Dresden,OTHER,1,10,Germany,1.0,0,1,0,0,0,2.0,1,0,0,0,1,2.9444389791664403,small,1,1,0,1,0,1,1,0,0,1,0,0,1,0,8,1,1,0,0,1,0,,,,,0,1,0
NCT00943761,A Study of Vaniprevir (MK-7009) in Participants With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028),A Phase II Open Label Study of MK-7009 Administered Concomitantly With Pegylated Interferon Alfa-2a and Ribavirin to Patients With Chronic Hepatitis C Infection After Participation in Other MK-7009 Clinical Trials,COMPLETED,2009-10-23,2013-05-29,2021-02-08,INTERVENTIONAL,PHASE2,45.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Hepatitis C, Chronic",Vaniprevir 600 mg b.i.d.|Vaniprevir 300 mg b.i.d.|Pegylated interferon|Ribavirin,DRUG,4,0,18 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,0,,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.828641396489095,small,1,1,1,0,1,0,0,0,0,0,0,0,1,1,4,0,1,0,0,4,1,,,,,0,1,0
NCT00109161,"Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis","A Phase II Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis",COMPLETED,2005-04,2006-10,2008-08-05,INTERVENTIONAL,PHASE2,270.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Multiple Sclerosis,Daclizumab (Anti-CD25 Humanized Monoclonal Antibody),DRUG,1,3,18 Years,55 Years,ALL,False,"PDL BioPharma, Inc.",INDUSTRY,0,36,Canada|United States,1.0,0,1,0,0,0,2.0,0,1,0,0,1,5.602118820879701,large,0,0,1,0,0,0,1,1,1,0,1,1,1,1,4,1,1,0,0,1,0,2005-04-01,2006-10-01,548.0,2005.0,0,1,0
NCT01283542,Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma.,"An Open-Label, Single Arm, Phase II Study to Evaluate the Efficacy and Safety of Pasireotide LAR on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma",COMPLETED,2012-11-26,2017-09-12,2019-04-26,INTERVENTIONAL,PHASE2,20.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Non-functioning Pituitary Adenoma,Pasireotide LAR,DRUG,1,19,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,7,Brazil,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.044522437723423,small,1,1,1,0,1,0,1,0,0,0,0,0,1,0,20,1,1,0,0,1,0,,,,,0,1,0
NCT05785442,Use of Presepsin as a Marker for Immunotherapy Administration in Pneumonia,"Immunotherapy Navigated by Serum Presepsin for Infections of the Respiratory Tract: the INSPIRE Double-blind, Randomized, Phase IIa Exploratory Trial.",COMPLETED,2023-03-06,2024-06-28,2024-07-31,INTERVENTIONAL,PHASE2,60.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Community-acquired Pneumonia|Hospital-acquired Pneumonia,Anakinra Prefilled Syringe|Placebo,DRUG,1,11,18 Years,,ALL,False,Hellenic Institute for the Study of Sepsis,OTHER,0,5,Greece,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.110873864173311,medium,1,1,0,1,0,0,1,0,0,0,1,1,1,1,12,1,1,0,0,2,1,,,,,0,3,1
NCT01168986,The Effectiveness of a Mechanical Manual Therapy Device in the Treatment of Neck Pain,The Effectiveness of a Mechanical Manual Therapy Device in the Treatment of Neck Pain,COMPLETED,2009-09,2015-05,2016-06-20,INTERVENTIONAL,PHASE1|PHASE2,62.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Neck Pain,Pulstar Multiple Impulse Therapy|Exercise,OTHER,3,1,18 Years,60 Years,ALL,False,University of Florida,OTHER,0,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,4.143134726391533,medium,1,1,0,1,0,0,0,0,1,0,1,0,1,1,4,1,0,0,0,2,1,2009-09-01,2015-05-01,2068.0,2009.0,0,2,0
NCT00462670,"A Double-blind, Placebo-controlled Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)","A Double-blind, Placebo-controlled Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)",COMPLETED,2007-04,2008-10,2014-02-04,INTERVENTIONAL,PHASE3,110.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Edema, Cardiac",OPC-41061(Tolvaptan),DRUG,1,1,20 Years,85 Years,ALL,False,"Otsuka Pharmaceutical Co., Ltd.",INDUSTRY,0,8,Japan,1.0,0,0,1,0,0,3.0,0,0,0,1,1,4.709530201312334,medium,0,1,1,0,0,0,1,0,0,0,1,1,1,1,2,1,1,0,0,1,0,2007-04-01,2008-10-01,549.0,2007.0,0,0,0
NCT05657470,Rescue Thrombolysis for Medium Vessel Occlusion (RESCUE-TNK),"Rescue Thrombolysis for Medium Vessel Occlusion (RESCUE-TNK): a Prospective, Randomized, Open-label, Blinded End Point, and Multicenter Trial",COMPLETED,2023-03-21,2025-06-16,2025-06-17,INTERVENTIONAL,PHASE2|PHASE3,80.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,"Stroke, Ischemic",Tenecteplase,DRUG,1,11,18 Years,,ALL,False,General Hospital of Shenyang Military Region,OTHER,1,1,China,1.0,0,1,1,0,1,2.5,0,0,0,0,1,4.394449154672439,medium,1,1,0,1,0,1,0,0,0,0,1,0,1,1,12,1,1,0,0,1,0,,,,,0,2,0
NCT04919473,Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravitreal vMCO-I in Patients With Advanced Retinitis Pigmentosa,"A Phase I/IIa Open Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravitreal vMCO-I in Patients With Advanced Retinitis Pigmentosa",COMPLETED,2019-10-23,2020-10-31,2021-06-09,INTERVENTIONAL,PHASE1|PHASE2,11.0,ACTUAL,NON_RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,Retinitis Pigmentosa|Retinal Diseases|Retinal Degeneration,Gene Therapy product:vMCO-I,BIOLOGICAL,1,9,18 Years,,ALL,False,Nanoscope Therapeutics Inc.,INDUSTRY,0,1,India,1.0,1,1,0,0,1,1.5,0,0,0,0,3,2.4849066497880004,small,1,1,1,0,0,0,0,0,0,0,0,0,1,0,10,1,0,1,0,1,0,,,,,0,3,1
NCT00697073,Study to Assess the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients,"A Phase III Open-Label, Single Group Extension Study of the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients",COMPLETED,2008-07,2010-05,2023-07-11,INTERVENTIONAL,PHASE3,68.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Friedreich's Ataxia,Idebenone,DRUG,1,3,8 Years,18 Years,ALL,False,Santhera Pharmaceuticals,INDUSTRY,0,2,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.23410650459726,medium,1,1,1,0,0,0,1,0,1,0,0,0,1,0,4,1,1,0,0,1,0,2008-07-01,2010-05-01,669.0,2008.0,0,0,0
NCT01847469,Zonisamide in Addition to E-CPT-C for Veterans With PTSD and Comorbid Alcohol Dependence,Zonisamide in Addition to Enhanced Cognitive Processing Therapy-C (E-CPT-C) for Veterans With PTSD and Comorbid Alcohol Dependence,COMPLETED,2013-06,2019-01-01,2020-03-16,INTERVENTIONAL,PHASE2,24.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Alcohol Dependence|Post-Traumatic Stress Disorder (PTSD),Enhanced-Cognitive Processing Therapy-C (E-CPT-C)|Zonisamide|Placebo,BEHAVIORAL|DRUG,3,0,21 Years,65 Years,ALL,False,Yale University,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,3.2188758248682006,small,1,1,0,1,0,1,0,0,1,0,1,1,1,1,3,0,1,0,0,3,1,2013-06-01,,,2013.0,0,2,0
NCT02636569,Topical Chemoprevention of Skin Cancer Biomarkers,Topical Chemoprevention of Skin Cancer Biomarkers,COMPLETED,2017-10-25,2025-12-31,2026-01-21,INTERVENTIONAL,PHASE2,24.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Non-melanoma Skin Cancer,topical diclofenac daily|placebo,DRUG,2,0,18 Years,,ALL,False,University of Alabama at Birmingham,OTHER,2,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.2188758248682006,small,1,1,0,1,0,1,0,0,1,0,1,1,0,1,2,0,1,0,0,2,1,,,,,0,1,0
NCT02497469,An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis,"A Randomized, Double-Blind, Double-Dummy, Multicenter, Active-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab IV Compared to Adalimumab SC in Subjects With Ulcerative Colitis",COMPLETED,2015-06-29,2019-01-18,2020-01-28,INTERVENTIONAL,PHASE3,771.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Colitis, Ulcerative",Vedolizumab|Adalimumab placebo|Adalimumab|Vedolizumab placebo,DRUG,1,2,18 Years,85 Years,ALL,False,Takeda,INDUSTRY,0,330,Bulgaria|Latvia|Germany|Serbia|Taiwan|Italy|Netherlands|South Korea|Spain|Estonia|Czechia|Portugal|Canada|Russia|Argentina|Turkey (Türkiye)|United States|United Kingdom|Australia|Romania|Lithuania|Poland|Mexico|Denmark|Israel|Ukraine|France|Belgium|Hungary|Bosnia and Herzegovina|Croatia|Slovakia|Hong Kong|Colombia,1.0,0,0,1,0,0,3.0,0,1,0,0,1,6.648984550024776,xlarge,0,1,1,0,1,0,1,1,1,1,1,1,1,1,3,1,1,0,0,4,1,,,,,0,2,0
NCT02384083,Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients,"Phase I/II, Multicenter, Open Label, Clinical Trial of Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients",COMPLETED,2015-09,2020-03-23,2022-07-27,INTERVENTIONAL,PHASE1|PHASE2,47.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Multiple Myeloma,"Filanesib, pomalidomide and dexamethasone",DRUG,1,1,18 Years,,ALL,False,PETHEMA Foundation,OTHER,2,10,Spain,1.0,1,1,0,0,1,1.5,1,0,0,0,1,3.871201010907891,small,1,1,0,1,0,1,1,0,0,1,0,0,1,0,2,1,1,0,0,1,0,2015-09-01,,,2015.0,1,1,0
NCT03656783,Effects of Biktarvy on CFR in Stable HIV Patients,Effects of Biectegravir-Emtricitabine-Tenofovir Alafenamide on Coronary Flow Reserve in Stable HIV Patients (B/F/TAF-CFR) - Pilot Study,COMPLETED,2018-09-14,2021-09-15,2023-02-08,INTERVENTIONAL,PHASE3,25.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,HIV,Biktarvy,DRUG,1,4,18 Years,95 Years,ALL,False,Brigham and Women's Hospital,OTHER,2,3,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.258096538021482,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,5,1,1,0,0,1,0,,,,,0,0,0
NCT00211341,Trial of the Impact of Vitamin A on Maternal Mortality,Randomised Double-blind Placebo-controlled Trial to Evaluate the Impact of Vitamin A on Maternal Mortality in Ghana,COMPLETED,2000-12,2008-10,2010-02-18,INTERVENTIONAL,PHASE3,100000.0,ESTIMATED,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Vitamin A Deficiency|Maternal Mortality|Maternal Morbidity,Vitamin A,DIETARY_SUPPLEMENT,1,3,15 Years,45 Years,FEMALE,True,London School of Hygiene and Tropical Medicine,OTHER,1,1,Ghana,1.0,0,0,1,0,0,3.0,0,0,0,0,3,11.51293546492023,,0,0,0,1,0,1,0,0,0,0,1,1,0,1,4,1,0,0,0,1,0,2000-12-01,2008-10-01,2861.0,2000.0,0,1,0
NCT01948141,Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens,FGFR1 Amplification as A Predictor of Efficacy in A Biomarker-Driven Phase II Study of BIBF 1120 in Advanced Squamous Cell Lung Cancer Patients Who Have Failed Up to Two Prior Chemotherapeutic Regimens,COMPLETED,2014-01-30,2016-08-16,2017-06-08,INTERVENTIONAL,PHASE2,6.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Recurrent Non-small Cell Lung Cancer|Squamous Cell Lung Cancer|Stage III Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer,nintedanib,DRUG,1,7,18 Years,,ALL,False,Roswell Park Cancer Institute,OTHER,2,2,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,4,1.9459101490553132,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,8,1,1,0,0,1,0,,,,,0,2,0
NCT01103180,Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder,SSRIs and Self-harm in Borderline Personality Disorder,TERMINATED,2010-09,2014-11,2019-06-14,INTERVENTIONAL,PHASE2,70.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Borderline Personality Disorder,Escitalopram,DRUG,1,1,18 Years,40 Years,ALL,False,University of Chicago,OTHER,3,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,4.2626798770413155,medium,1,1,0,1,0,1,0,0,1,0,1,1,1,1,2,1,1,0,0,1,0,2010-09-01,2014-11-01,1522.0,2010.0,0,0,0
NCT00272480,Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial,Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial,COMPLETED,1999-11-08,2002-07-30,2021-08-25,INTERVENTIONAL,PHASE2|PHASE3,16.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,HTLV-I-associated Myelopathy,Zidovudine/lamivudine|Placebos,DRUG,5,2,16 Years,75 Years,ALL,False,Imperial College London,OTHER,0,1,United Kingdom,1.0,0,1,1,0,1,2.5,0,0,0,0,1,2.833213344056216,small,1,1,0,1,0,0,0,0,0,1,1,1,1,0,7,1,1,0,0,2,1,,,,,0,3,1
NCT03692780,Careseng 1370 for Chemotherapy-Induced Myelosuppression,"A Phase I Dose-Finding Followed by Phase IIa Randomized, Double-Blind, Placebo-Controlled, Parallel, Add-on to Cisplatin Plus Docetaxel Study to Evaluate the Safety, Tolerability and Efficacy Profiles of Careseng 1370 to Treat Chemotherapy-Induced Myelosuppression in Advanced Non-Small Cell Lung Cancer (NSCLC) Subjects",WITHDRAWN,2019-03,2021-06,2018-12-17,INTERVENTIONAL,PHASE1|PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Chemotherapy-Induced Myelosuppression,Careseng 1370|Placebo,DRUG,1,10,20 Years,,ALL,False,"Careseng Biotech Co., Ltd.",INDUSTRY,0,0,,0.0,1,1,0,0,1,1.5,0,0,0,0,1,0.0,,1,1,1,0,0,0,0,0,0,0,1,1,1,1,11,1,1,0,0,2,1,2019-03-01,2021-06-01,823.0,2019.0,1,3,1
NCT01481779,A Study in Participants With Type 1 Diabetes Mellitus,"The Impact of LY2605541 Versus Insulin Glargine for Patients With Type 1 Diabetes Mellitus Treated With Preprandial Insulin Lispro: An Open-Label, Randomized, 78-Week Study - The IMAGINE 1 Study",COMPLETED,2012-01,2014-06,2018-04-17,INTERVENTIONAL,PHASE3,455.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 1",Glargine|LY2605541|Insulin Lispro,DRUG,1,20,18 Years,,ALL,False,Eli Lilly and Company,INDUSTRY,0,51,Italy|Russia|United States|Germany|Austria|Poland|Japan|Mexico|France,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.1224928095143865,large,0,1,1,0,1,0,1,1,1,1,1,0,1,1,21,1,1,0,0,3,1,2012-01-01,2014-06-01,882.0,2012.0,0,3,1
NCT02420496,Enteral Fish Oil is Superior to Ursodeoxycholic Acid (UDCA) and Placebo for the Treatment of Cholestasis in Infants,Enteral Fish Oil is Superior to Ursodeoxycholic Acid (UDCA) and Placebo (?) for the Treatment of Cholestasis in Infants,WITHDRAWN,2016-06,2016-06,2016-06-21,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Cholestasis|Liver Disease,Enteral fish oil|Ursodeoxycholic Acid|Placebo,DRUG,1,0,14 Days,24 Months,ALL,False,The University of Texas Health Science Center at San Antonio,OTHER,0,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,2,0.0,,1,1,0,1,0,0,0,0,1,0,1,0,1,1,1,0,1,0,0,3,1,2016-06-01,2016-06-01,0.0,2016.0,1,2,0
NCT02044796,"Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes","A Phase 1/2 Trial of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)",COMPLETED,2014-01-23,2018-04-16,2020-01-10,INTERVENTIONAL,PHASE1|PHASE2,199.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Acute Biphenotypic Leukemia|de Novo Myelodysplastic Syndrome|Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia,Cladribine|Cytarabine|Filgrastim|Laboratory Biomarker Analysis|Mitoxantrone Hydrochloride,DRUG|BIOLOGICAL|OTHER,2,2,18 Years,,ALL,False,Fred Hutchinson Cancer Center,OTHER,1,1,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,6,5.298317366548036,medium,0,1,0,1,0,1,0,0,1,0,0,0,1,0,4,1,1,1,0,5,1,,,,,0,3,1
NCT04003896,A Study to Evaluate Abemaciclib in Advanced Biliary Tract Carcinoma,A Pilot Study to Evaluate the Response and Tolerability of Verzenio (Abemaciclib) in Patients With Advanced Biliary Tract Carcinoma,TERMINATED,2021-09-24,2023-08-15,2024-10-08,INTERVENTIONAL,PHASE2,4.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Biliary Tract Carcinoma,Abemaciclib,DRUG,1,8,18 Years,,ALL,False,Milton S. Hershey Medical Center,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,1.6094379124341003,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,9,1,1,0,0,1,0,,,,,0,1,0
NCT03921996,Extended Pelvic Lymph Node Dissection vs. no Pelvic Lymph Node Dissection at Radical Prostatectomy for intermediate-and High-risk Prostate Cancer,"Extended Pelvic Lymph Node Dissection vs. no Pelvic Lymph Node Dissection at Radical Prostatectomy for intermediate-and High-risk Prostate Cancer: An International, Multicenter, Randomized Phase III Trial",TERMINATED,2019-08-27,2021-11-11,2023-03-09,INTERVENTIONAL,PHASE3,57.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Prostate Cancer,Radical prostatectomy (RP) followed by ePLND|Radical prostatectomy (RP) only,PROCEDURE,1,9,18 Years,80 Years,MALE,False,Swiss Cancer Institute,OTHER,0,11,Switzerland,0.0,0,0,1,0,0,3.0,1,0,0,0,1,4.060443010546419,medium,1,1,0,1,0,0,1,0,0,0,1,0,1,1,10,1,0,0,0,2,1,,,,,0,2,0
NCT00480662,A Research Study to Test the Effectiveness of MK0217 in Patients With Paget's Bone Disease (0217-206)(COMPLETED),"A 6-Month, Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Alendronate 280-mg Oral Buffered Solution Once Weekly in Patients With Paget's Disease of Bone",COMPLETED,2001-10,2002-10,2024-08-14,INTERVENTIONAL,PHASE3,60.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Paget's Disease of Bone,alendronate,DRUG,1,1,18 Years,90 Years,ALL,False,Organon and Co,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.110873864173311,medium,1,1,1,0,0,0,0,0,0,0,1,1,1,1,2,1,1,0,0,1,0,2001-10-01,2002-10-01,365.0,2001.0,0,0,0
NCT00245362,A Phase II Trial of CG 8020 and CG 2505 in Patients With Nonresectable or Metastatic Pancreatic Cancer,A Phase II Trial of CG 8020 and CG 2505 in Patients With Nonresectable or Metastatic Pancreatic Cancer,COMPLETED,2002-06,2004-06,2005-10-28,INTERVENTIONAL,PHASE2,50.0,,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Metastatic Pancreatic Cancer|Nonresectable Pancreatic Cancer,CG 8020 and CG 2505,BIOLOGICAL,4,0,18 Years,,ALL,False,Cell Genesys,INDUSTRY,0,2,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,2,3.9318256327243257,small,1,0,1,0,0,0,1,0,1,0,0,0,1,1,4,0,0,1,0,1,0,2002-06-01,2004-06-01,731.0,2002.0,0,1,0
NCT05644262,Life's End Benefits of cannaBidiol and tetrahYdrocannabinol,Life's End Benefits of cannaBidiol and tetrahYdrocannabinol (LiBBY),ACTIVE_NOT_RECRUITING,2023-12-18,2026-03,2026-01-07,INTERVENTIONAL,PHASE2,120.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Agitation|Dementia,T2:C100|Placebo,DRUG,1,2,40 Years,,ALL,False,University of Southern California,OTHER,4,10,United States,,0,1,0,0,0,2.0,0,0,0,0,2,4.795790545596741,medium,0,0,0,1,0,1,1,0,1,0,1,1,1,1,3,1,1,0,0,2,1,,2026-03-01,,,0,2,0
NCT05212662,Study of Cysteamine-pantetheine Disulfide (TTI-0102) in Mild to Moderate COVID-19,"A Multi-center, Randomized, Double-blind, Placebo-controlled, Study to Assess the Safety, Tolerability, Pharmacodynamics (PD) and Efficacy of TTI-0102 for the Treatment of Patients With Mild to Moderate COVID-19",WITHDRAWN,2024-09-27,2024-09-27,2024-10-01,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,COVID-19|COVID-19 Acute Respiratory Distress Syndrome,TTI-0102|Placebo,DRUG,1,2,18 Years,80 Years,ALL,False,"Thiogenesis Therapeutics, Inc.",INDUSTRY,0,0,,0.0,0,1,0,0,0,2.0,0,0,0,0,2,0.0,,1,1,1,0,0,0,0,0,0,0,1,1,1,1,3,1,1,0,0,2,1,,,,,0,2,0
NCT01497262,Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis,"A 4-month, Open-label, Multi-center Study to Explore the Safety and Tolerability of Fingolimod 0.5 mg in Patients With Relapsing-remitting Multiple Sclerosis",COMPLETED,2012-02,2014-04,2015-03-19,INTERVENTIONAL,PHASE3,162.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Multiple Sclerosis,Fingolimod,DRUG,1,1,18 Years,65 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,29,Argentina|Brazil|Panama|Malaysia|Jordan|Mexico|Peru|Colombia,1.0,0,0,1,0,0,3.0,0,1,0,0,1,5.093750200806762,medium,0,1,1,0,1,0,1,1,0,0,0,0,1,0,2,1,1,0,0,1,0,2012-02-01,2014-04-01,790.0,2012.0,0,1,0
NCT01203462,The PRIDE Study Probiotics on Regulation and Improving Digestive hEalth,"A Probiotic Double-blind Randomized Placebo Crossover Trial of Colonic Transit Time in Adult Females, The PRIDE Study The Study to Determine the Effects of Probiotics on Regulation and Improving Digestive hEalth",COMPLETED,2010-10,2011-07,2013-02-11,INTERVENTIONAL,PHASE3,68.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Digestive Irregularity|Digestive Discomfort|History of Straining During Bowel Movements|History of Hard or Lumpy Stools,Probiotic strain of Bifidobacterium|No Bifidobacterium,OTHER,1,10,18 Years,65 Years,FEMALE,True,Georgetown University,OTHER,1,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,4,4.23410650459726,medium,1,1,0,1,0,1,0,0,1,0,1,1,1,0,11,1,0,0,0,2,1,2010-10-01,2011-07-01,273.0,2010.0,0,3,1
NCT01427946,Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer,A Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in Patients With KRAS Mutant NSCLC,COMPLETED,2011-07,2014-10,2014-11-13,INTERVENTIONAL,PHASE1|PHASE2,47.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Non-small Cell Lung Cancer,IPI-504|Everolimus,DRUG,1,3,18 Years,,ALL,False,"Infinity Pharmaceuticals, Inc.",INDUSTRY,0,5,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,1,3.871201010907891,small,1,1,1,0,0,0,1,0,1,0,0,0,1,0,4,1,1,0,0,2,1,2011-07-01,2014-10-01,1188.0,2011.0,0,2,0
NCT04346446,Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients,Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients: A Pilot Randomized Controlled Trial,COMPLETED,2020-04-20,2020-05-30,2020-06-12,INTERVENTIONAL,PHASE2,29.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,COVID,Convalescent Plasma Transfusion|Supportive Care|Random Donor Plasma,DRUG|OTHER,1,9,18 Years,,ALL,False,"Institute of Liver and Biliary Sciences, India",OTHER,0,2,India,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.4011973816621555,small,1,1,0,1,0,0,1,0,0,0,1,0,1,1,10,1,1,0,0,3,1,,,,,0,2,0
NCT01669746,A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0006931),"A Multi-center, Phase 2 Study of Ji Gami(TM) CN That Evaluates the Efficacy and Safety of ex Vivo-cultured, Expanded, Occipital Autologous Dermal and Epidermal Cells, Injected Into the Hair Loss Area of the Scalp of Male and Female Subjects With Alopecia",COMPLETED,2012-06,,2013-07-11,INTERVENTIONAL,PHASE2,34.0,ACTUAL,,SINGLE_GROUP,TREATMENT,SINGLE,Androgenetic Alopecia|Male Pattern Baldness|Female Pattern Baldness,Autologous cultured mixed population of dermal cells,BIOLOGICAL,3,0,18 Years,50 Years,ALL,True,Aderans Research Institute,INDUSTRY,0,7,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,3,3.5553480614894135,small,1,1,1,0,0,0,1,0,1,0,0,0,1,0,3,0,0,1,0,1,0,2012-06-01,,,2012.0,0,1,0
NCT03387046,A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS),Evaluation of clINical reCovery After a Relapse: a Pilot Study assEssing the Neuronal Effects of D-Aspartate in RR-MS Subjects Treated With IntErferon Beta 1a 44 mcg TIW (INCREASE),TERMINATED,2018-03-26,2019-01-11,2020-02-10,INTERVENTIONAL,PHASE2,7.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Multiple Sclerosis, Relapsing-Remitting",D-aspartate|Placebo|IFN beta-1a|Methylprednisolone,DRUG|BIOLOGICAL|DIETARY_SUPPLEMENT,1,9,18 Years,55 Years,ALL,False,"Merck KGaA, Darmstadt, Germany",INDUSTRY,0,17,Italy,0.0,0,1,0,0,0,2.0,0,1,0,0,1,2.0794415416798357,small,1,1,1,0,1,0,1,0,0,1,1,1,1,1,10,1,1,1,0,4,1,,,,,0,2,0
NCT00631488,A Study to Test the Effectiveness and Safety of MK0893 in Combination With Other Drugs Used to Treat Type 2 Diabetes (0893-015),"A Phase IIa, Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of MK0893 in Combination With Sitagliptin or in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control",COMPLETED,2008-02,2009-01,2017-01-02,INTERVENTIONAL,PHASE2,146.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2",MK-0893|Sitagliptin|Metformin|Placebo for MK-0893|Placebo for Sitagliptin|Placebo for Metformin,DRUG,1,4,21 Years,65 Years,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,0,,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.990432586778736,medium,0,1,1,0,1,0,0,0,0,0,1,1,1,1,5,1,1,0,0,6,1,2008-02-01,2009-01-01,335.0,2008.0,0,1,0
NCT02983188,Berberine as Adjuvant Treatment for Schizophrenia Patients,"A Double-blind, Randomized, Placebo-controlled Trial of Berberine as an Adjuvant to Treat Antipsychotic-induced Metabolic Syndrome in Patients With Schizophrenia Spectrum Disorders",COMPLETED,2018-04-25,2021-01-04,2021-01-22,INTERVENTIONAL,PHASE2|PHASE3,113.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Schizophrenia|Schizophrenia Spectrum and Other Psychotic Disorders|Metabolic Syndrome x,Berberine|Placebos|Antipsychotic Agents,DRUG,1,11,18 Years,65 Years,ALL,False,The University of Hong Kong,OTHER,4,1,Hong Kong,1.0,0,1,1,0,1,2.5,0,0,1,0,3,4.736198448394496,medium,0,1,0,1,0,1,0,0,0,0,1,1,1,1,12,1,1,0,0,3,1,,,,,0,4,1
NCT04180488,"Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)","Master Protocol of Three Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients naïve to Omalizumab and in Patients Who Are Intolerant or Incomplete Responders to Omalizumab",COMPLETED,2019-12-11,2024-10-25,2025-08-20,INTERVENTIONAL,PHASE3,397.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Chronic Spontaneous Urticaria,Dupilumab SAR231893|Placebo|non sedating H1-antihistamine,DRUG,1,24,6 Years,80 Years,ALL,False,Sanofi,INDUSTRY,1,98,China|Russia|Argentina|Hungary|United States|Germany|Spain|United Kingdom|Japan|France|Canada,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.986452005284438,large,0,1,1,0,1,1,1,1,1,1,1,1,1,1,25,1,1,0,0,3,1,,,,,0,3,1
NCT03760003,Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis,"A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Dose, Induction Study to Evaluate the Safety, Tolerability and Optimal Dose of ABX464 Compared With Placebo in Patients With Moderate to Severe Ulcerative Colitis Who Have Inadequate Response, Loss of Response, or Intolerance With at Least One of the Following Agents: Immunosuppressant Treatment (i.e. Azathioprine, 6-mercaptopurine, Methotrexate), Tumor Necrosis Factor Alpha [TNF-α] Inhibitors, Vedolizumab, JAK Inhibitors and/or Corticosteroid Treatment",COMPLETED,2019-08-13,2021-04-16,2025-11-28,INTERVENTIONAL,PHASE2,355.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Ulcerative Colitis,ABX464 100 mg|ABX464 50 mg|ABX464 25 mg|Placebo,DRUG,1,27,18 Years,75 Years,ALL,False,Abivax S.A.,INDUSTRY,0,130,Italy|Belgium|Hungary|United States|Germany|Austria|Slovakia|Spain|United Kingdom|Poland|Serbia|Belarus|Czechia|Slovenia|Ukraine|France|Canada,1.0,0,1,0,0,0,2.0,0,1,0,0,1,5.87493073085203,large,0,1,1,0,0,0,1,1,1,1,1,1,1,1,28,1,1,0,0,4,1,,,,,0,3,1
NCT04508803,Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer,Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer: a muLti-centEr Phase II Study,COMPLETED,2020-09-14,2023-02-28,2024-09-27,INTERVENTIONAL,PHASE2,37.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Treatment Efficacy,HX008，Niraparib|HX008，Niraparib|HX008，Niraparib，Trastuzumab|HX008，Niraparib，Pyrrolitinib,DRUG,1,4,18 Years,75 Years,ALL,False,Fudan University,OTHER,0,1,China,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.6375861597263857,small,1,1,0,1,0,0,0,0,0,0,0,0,1,0,5,1,1,0,0,4,1,,,,,0,1,0
NCT02595827,Non-inferiority Trial of Conditional vs Universal Follow up for Children With Fever in Democratic Republic of Congo,"Universal Versus Conditional Follow Up for Children With Unclassified Fever at the Community Level: A Cluster-Randomized, Community-based, Non-Inferiority Trial in Kalemie, Democratic Republic of Congo (DRC)",COMPLETED,2015-10-09,2016-12-05,2017-02-23,INTERVENTIONAL,PHASE3,4451.0,ACTUAL,RANDOMIZED,PARALLEL,HEALTH_SERVICES_RESEARCH,NONE,Fever,Conditional Advice,OTHER,1,0,2 Months,60 Months,ALL,True,Johns Hopkins Bloomberg School of Public Health,OTHER,3,1,Democratic Republic of the Congo,1.0,0,0,1,0,0,3.0,0,0,0,0,1,8.401108712395436,xlarge,0,1,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,,,,,0,0,0
NCT00870727,Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders,Pharmacotherapy of Pervasive Developmental Disorders,COMPLETED,2009-02,2015-05,2019-01-02,INTERVENTIONAL,PHASE3,33.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Pervasive Developmental Disorder,Aripiprazole oral product|Placebo oral capsule,DRUG,2,4,5 Years,17 Years,ALL,False,Indiana University,OTHER,2,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.5263605246161616,small,1,1,0,1,0,1,0,0,1,0,1,1,1,1,6,1,1,0,0,2,1,2009-02-01,2015-05-01,2280.0,2009.0,0,2,0
NCT00924027,A Study of Patients Receiving High-Dose Rate Brachytherapy,A Pilot Study of High Dose Rate Brachytherapy in The Radiation Oncology Branch,COMPLETED,2009-04-14,2025-07-24,2025-09-05,INTERVENTIONAL,PHASE2,43.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Cervical Cancer|Endometrial Cancer|Esophageal Cancer|Prostate Cancer|Biliary Cancer,High Dose Radiation (HDR) Brachytherapy|MRI|CT|PET Scan,RADIATION|DIAGNOSTIC_TEST,1,4,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,5,3.784189633918261,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,5,1,0,0,0,4,1,,,,,0,2,0
NCT04019561,A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH.,"A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Pharmacodynamic Effects of MEDI0382 in Obese Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)/ Non-Alcoholic Steatohepatitis (NASH)",COMPLETED,2019-09-23,2021-05-06,2023-01-17,INTERVENTIONAL,PHASE2,74.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Non-alcoholic Fatty Liver Disease (NAFLD)|Non-alcoholic Steatohepatitis (NASH),MEDI0382 high dose|Placebo for MEDI0382 high dose|MEDI0382 low dose|Placebo for MEDI0382 low dose,DRUG,1,15,18 Years,101 Years,ALL,False,MedImmune LLC,INDUSTRY,0,27,Puerto Rico|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.31748811353631,medium,1,1,1,0,0,0,1,1,1,0,1,1,1,1,16,1,1,0,0,4,1,,,,,0,4,1
NCT03340961,"A Controlled Study to Assess the Efficacy, Safety and Tolerability of Oral DFD-29 Extended Release Capsules","A Multi-Center, Randomized, Double-Blind, Parallel-Group, Controlled Study to Assess the Efficacy, Safety and Tolerability of Oral DFD-29 Extended Release Capsules for the Treatment of Inflammatory Lesions of Rosacea Over 16 Weeks",COMPLETED,2017-10-01,2019-03-31,2021-03-01,INTERVENTIONAL,PHASE2,205.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Rosacea,DFD-29 Extended Release Capsules (40 mg)|DFD-29 Extended Release Capsules (20 mg)|Oraycea® (doxycycline) Capsules|Placebo Capsules,DRUG,2,1,18 Years,,ALL,False,Dr. Reddy's Laboratories Limited,INDUSTRY,0,14,Germany,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.327876168789581,large,0,1,1,0,0,0,1,0,0,1,1,1,1,1,3,1,1,0,0,4,1,,,,,0,1,0
NCT05803161,Congrong Runtong Oral Liquid in the Treatment of Functional Constipation (Yang-deficiency Type),"A Randomized, Double-blind, Dose-exploration, Parallel-controlled, Multicenter Phase II Clinical Study of Congrong Runtong Oral Liquid in the Treatment of Functional Constipation (Yang-deficiency Type)",COMPLETED,2023-03-29,2024-04-01,2024-10-28,INTERVENTIONAL,PHASE2,180.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Functional Constipation,Congrong Runtong oral liquid|Placental Congrong Runtong oral liquid,DRUG,1,11,18 Years,70 Years,ALL,False,Beijing Hospital of Traditional Chinese Medicine,OTHER,0,1,China,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.198497031265826,medium,0,1,0,1,0,0,0,0,0,0,1,1,1,1,12,1,1,0,0,2,1,,,,,0,2,0
NCT01066442,Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's Disease,"A Randomised, Multicenter 12-Week Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson's Disease Followed by a 38 Week Open Label Extension Phase",COMPLETED,2010-03,2012-08,2013-04-12,INTERVENTIONAL,PHASE3,273.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Parkinson's Disease,BF2.649 (Pitolisant),DRUG,1,1,30 Years,80 Years,ALL,False,Bioprojet,OTHER,0,1,Germany,1.0,0,0,1,0,0,3.0,0,0,1,0,1,5.6131281063880705,large,0,1,0,1,0,0,0,0,0,1,1,1,1,1,2,1,1,0,0,1,0,2010-03-01,2012-08-01,884.0,2010.0,0,0,0
NCT00953342,Impact of Aerobic Exercise on Asthma Morbidity,Impact of Aerobic Exercise on Asthma Morbidity,COMPLETED,2010-01,2014-08,2018-02-12,INTERVENTIONAL,PHASE3,66.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Asthma,Aerobic exercise|Usual care,BEHAVIORAL,1,3,18 Years,,ALL,False,Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal,OTHER,2,3,Canada,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.204692619390966,medium,1,1,0,1,0,1,1,0,0,0,1,0,1,1,4,1,0,0,0,2,1,2010-01-01,2014-08-01,1673.0,2010.0,0,1,0
NCT05266586,Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy,"A Placebo-Controlled, Double-Blind, Randomized, Phase 2 Study to Evaluate the Effect of Obicetrapib 10 mg Daily in Combination With Ezetimibe 10 mg Daily as an Adjunct to High-Intensity Statin Therapy: The ROSE 2 Study",COMPLETED,2022-03-09,2022-09-08,2024-07-03,INTERVENTIONAL,PHASE2,119.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Dyslipidemias|High Cholesterol|Hypercholesterolemia,Obicetrapib|Ezetimibe 10mg|Obicetrapib placebo|Ezetimibe placebo,DRUG|OTHER,6,12,18 Years,75 Years,ALL,False,NewAmsterdam Pharma,INDUSTRY,0,16,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,3,4.787491742782046,medium,0,1,1,0,0,0,1,0,1,0,1,1,1,1,18,1,1,0,0,4,1,,,,,0,3,1
NCT00092586,Study of an Approved Drug With a Statin (a Medication That Lowers Cholesterol Levels) as Compared to Statin Therapy Alone in Patients With High Cholesterol (0653-040),"A Multi-center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe 10 mg/Day When Added to Ongoing Therapy With a Statin Versus Statin Therapy Alone, in Patients With Hypercholesterolemia Who Have Not Reached National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Target LDL-Cholesterol Level",COMPLETED,2002-09,2003-10,2024-08-15,INTERVENTIONAL,PHASE3,2904.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Hypercholesterolemia,"MK0653, ezetimibe|Comparator: statins",DRUG,1,1,18 Years,,ALL,False,Organon and Co,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,7.974188669286011,xlarge,0,1,1,0,0,0,0,0,0,0,1,1,1,1,2,1,1,0,0,2,1,2002-09-01,2003-10-01,395.0,2002.0,0,1,0
NCT00713986,Non-Pharmacologic Interventions to Relief Pain in Healthy Newborns Submitted to Vaccination to Hepatitis B,"Non-Pharmacologic Interventions to Relief Pain in Healthy Newborns Submitted to Vaccination to Hepatitis B: a Comparison Between Skin-to-Skin Contact, Glucose 25% and Both of Them",COMPLETED,2006-03,2008-07,2008-07-14,INTERVENTIONAL,PHASE3,640.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Pain|Analgesia,Water 2mL PO 2 minutes prior to intra-muscular injection|skin-to-skin contact|Glucose 25% 2 mL PO 2 minutes prior to injection|neonates will receive skin-to-skin contact beginning 2 minutes after the intra-muscular injection and stopping 2 minutes afterwards.,PROCEDURE,1,1,12 Hours,72 Hours,ALL,False,Federal University of São Paulo,OTHER,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,2,6.46302945692067,xlarge,0,1,0,1,0,0,0,0,0,0,1,0,1,1,2,1,0,0,0,4,1,2006-03-01,2008-07-01,853.0,2006.0,0,2,0
NCT04516070,Stereotactic Radiosurgery for the Treatment of Patients With Small Cell Lung Cancer Brain Metastasis,Stereotactic Radiosurgery (SRS) as Definitive Management for a Limited Number of Small Cell Lung Cancer (SCLC) Brain Metastasis,ACTIVE_NOT_RECRUITING,2020-08-28,2026-12-31,2025-09-05,INTERVENTIONAL,PHASE2,55.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Metastatic Lung Small Cell Carcinoma|Metastatic Malignant Neoplasm in the Brain|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8,Questionnaire Administration|Stereotactic Radiosurgery,RADIATION|OTHER,2,13,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,1,United States,,0,1,0,0,0,2.0,1,0,0,0,5,4.02535169073515,medium,1,1,0,1,0,1,0,0,1,0,0,0,1,0,15,1,0,0,0,2,1,,,,,0,3,1
NCT05604170,Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy,"A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Complex (TSC)-Related Epilepsy (TrustTSC OLE)",TERMINATED,2022-05-16,2025-04-02,2025-10-01,INTERVENTIONAL,PHASE3,117.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Tuberous Sclerosis Complex,Ganaxolone,DRUG,10,1,1 Year,65 Years,ALL,False,Marinus Pharmaceuticals,INDUSTRY,0,54,China|Italy|United States|Germany|Spain|Australia|United Kingdom|Israel|France|Canada,0.0,0,0,1,0,0,3.0,0,0,0,0,1,4.770684624465665,medium,0,1,1,0,0,0,1,1,1,1,0,0,1,0,11,1,1,0,0,1,0,,,,,0,2,0
NCT03283670,Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies,Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies,COMPLETED,2016-11-22,2020-02-18,2022-04-04,INTERVENTIONAL,PHASE2,24.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Depressive Disorder, Major|Depressive Disorder, Treatment-Resistant",Nitrous Oxide 25%|Nitrous Oxide 50%|Placebo Gas,DRUG,1,0,18 Years,75 Years,ALL,False,Washington University School of Medicine,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,3.2188758248682006,small,1,1,0,1,0,1,0,0,1,0,1,1,1,0,1,0,1,0,0,3,1,,,,,0,2,0
NCT02465970,Effects of Transcranial Direct Current Stimulation (TDCS) in Drug-resistant Partial Epilepsy,BRAINSTIM : Effects of Transcranial Direct Current Stimulation (TDCS) in Drug-resistant Partial Epilepsy,COMPLETED,2015-11-13,2018-12,2019-01-09,INTERVENTIONAL,PHASE2,5.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,SINGLE,Epilepsy,STARSTIM|sham TDCS,DEVICE,1,6,15 Years,,ALL,False,Rennes University Hospital,OTHER,0,1,France,1.0,0,1,0,0,0,2.0,0,0,1,0,1,1.791759469228055,small,1,1,0,1,0,0,0,0,0,1,1,0,1,0,7,1,0,0,1,2,1,,2018-12-01,,,0,2,0
NCT01258673,A Clinical Study to Evaluate Efficacy and Safety of Fimasartan/Hydrochlorothiazide Combination-therapy,"A Randomized, Double-blind, Multicenter Clinical Study to Evaluate Efficacy and Safety of Fimasartan/Hydrochlorothiazide Combination-therapy in Comparison With Fimasartan Monotherapy for Essential Hypertension Patients Not Controlled by Fimasartan 60mg(Phase 3)",COMPLETED,2010-11,,2012-01-05,INTERVENTIONAL,PHASE3,263.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Essential Hypertension,Fimasartan/HCTZ combination|Fimasartan,DRUG,1,1,18 Years,,ALL,False,"Boryung Pharmaceutical Co., Ltd",INDUSTRY,18,1,South Korea,1.0,0,0,1,0,0,3.0,0,0,0,1,1,5.575949103146316,large,0,1,1,0,0,1,0,0,0,0,1,1,1,1,2,1,1,0,0,2,1,2010-11-01,,,2010.0,0,1,0
NCT01254773,Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center, Biomarker, Safety, and Pharmacokinetic Study of Bapineuzumab (AAB-001) Administered Subcutaneously at Monthly Intervals in Subjects With Mild to Moderate Alzheimer's Disease",COMPLETED,2010-12,2013-03,2014-05-09,INTERVENTIONAL,PHASE2,146.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Alzheimer's Disease,Experimental Bapineuzumab,DRUG,1,2,50 Years,89 Years,ALL,False,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",INDUSTRY,1,28,United States,1.0,0,1,0,0,0,2.0,0,0,1,0,1,4.990432586778736,medium,0,1,1,0,0,1,1,0,1,0,1,1,1,1,3,1,1,0,0,1,0,2010-12-01,2013-03-01,821.0,2010.0,0,0,0
NCT01349569,Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission,Administration of an Allogeneic Myeloma GM-CSF Vaccine in Conjunction With a Lenalidomide Containing Regimen in Myeloma Patients With Near Complete Remission,COMPLETED,2012-01,2016-10,2019-01-15,INTERVENTIONAL,PHASE2,19.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Multiple Myeloma,Lenalidomide|Allogeneic Myeloma Vaccine|Prevnar-13,DRUG|BIOLOGICAL,1,4,18 Years,,ALL,False,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,2.995732273553991,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,5,1,1,1,0,3,1,2012-01-01,2016-10-01,1735.0,2012.0,0,1,0
NCT00865969,Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma,"A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma",COMPLETED,2008-12-15,2014-10-27,2021-10-29,INTERVENTIONAL,PHASE2,129.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Peripheral T-cell Lymphoma,Belinostat,DRUG,1,6,18 Years,,ALL,False,"Spectrum Pharmaceuticals, Inc",INDUSTRY,1,117,Italy|Belgium|Netherlands|Russia|Hungary|United States|Croatia|Germany|Slovakia|Spain|United Kingdom|Poland|Denmark|Israel|South Africa|France|Canada,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.867534450455582,medium,0,1,1,0,0,1,1,1,1,1,0,0,1,0,7,1,1,0,0,1,0,,,,,0,2,0
NCT00106587,Treatment of In-Stent Restenosis by Paclitaxel Coated PTCA Balloons (PACCOCATH - ISR I),Treatment of In-Stent Restenosis by Paclitaxel Coated PTCA Balloons,COMPLETED,2003-12,2012-03,2023-04-27,INTERVENTIONAL,PHASE1|PHASE2,52.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Coronary Restenosis,PTCA|paclitaxel coated balloon catheter (device with drug),COMBINATION_PRODUCT|DEVICE,1,2,18 Years,,ALL,False,"University Hospital, Saarland",OTHER,0,5,Germany,1.0,1,1,0,0,1,1.5,0,0,0,0,1,3.970291913552122,medium,1,1,0,1,0,0,1,0,0,1,1,0,1,1,3,1,0,0,1,2,1,2003-12-01,2012-03-01,3013.0,2003.0,0,2,0
NCT01635621,A Phase II Study to Assess the Efficacy and Safety of Olokizumab in Patients With Crohn's Disease,"A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Olokizumab Administered Subcutaneously to Subjects With Moderate to Severe Crohn's Disease",WITHDRAWN,2012-06,2013-08,2012-10-30,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Crohn's Disease,Olokizumab (OKZ)|Placebo,DRUG,1,6,18 Years,65 Years,ALL,False,UCB BIOSCIENCES GmbH,INDUSTRY,0,0,,0.0,0,1,0,0,0,2.0,0,1,0,0,1,0.0,,1,1,1,0,0,0,0,0,0,0,1,1,1,1,7,1,1,0,0,2,1,2012-06-01,2013-08-01,426.0,2012.0,0,2,0
NCT00211393,A Pilot Study of the Treatment of Central Serous Chorioretinopathy With Ketoconazole,A Pilot Study of The Treatment of Central Serous Chorioretinopathy With Ketoconazole.,COMPLETED,2005-05,2008-04,2012-10-25,INTERVENTIONAL,PHASE2,5.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Chronic Central Serous Chorioretinopathy,ketoconazole,DRUG,1,1,18 Years,60 Years,ALL,False,"Manhattan Eye, Ear & Throat Hospital",OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,1.791759469228055,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,2,1,1,0,0,1,0,2005-05-01,2008-04-01,1066.0,2005.0,0,0,0
NCT06035393,A Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease,"A Phase II, Randomized, Double Blind, Double Dummy, Active-controlled, Parallel-group Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease",TERMINATED,2024-01-15,2025-02-17,2025-12-22,INTERVENTIONAL,PHASE2,82.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Chronic Obstructive Pulmonary Disease,HRG2005 inhalation|Placebo to match HRG2005 inhalation|Placebo to match Indacaterol Maleate and Glycopyrronium Bromide Powder for inhalation|Indacaterol Maleate and Glycopyrronium Bromide Powder for inhalation,DRUG,1,10,40 Years,,ALL,False,"Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,0,1,China,0.0,0,1,0,0,0,2.0,0,0,0,0,1,4.418840607796598,medium,1,1,1,0,0,0,0,0,0,0,1,1,1,1,11,1,1,0,0,4,1,,,,,0,2,0
NCT03571516,"Safety, Efficacy and Pharmacokinetic Study of Teduglutide in Infants 4 to 12 Months of Age With Short Bowel Syndrome","A Randomized, Open-label, 24-Week Safety, Efficacy, and Pharmacokinetic Study of Teduglutide in Infants 4 to 12 Months of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support",COMPLETED,2018-08-31,2020-09-24,2021-05-11,INTERVENTIONAL,PHASE3,10.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Short Bowel Syndrome,Teduglutide|Standard Medical Therapy|Syringe|Needle,DRUG|DEVICE|OTHER,1,22,4 Months,12 Months,ALL,False,Shire,INDUSTRY,0,8,Italy|United Kingdom|Finland|France,1.0,0,0,1,0,0,3.0,0,0,0,0,1,2.3978952727983707,small,1,1,1,0,0,0,1,1,0,1,1,0,1,1,23,1,1,0,1,4,1,,,,,0,3,1
NCT01494506,"Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer","A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy",COMPLETED,2011-11,2015-10,2016-06-17,INTERVENTIONAL,PHASE3,417.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Metastatic Pancreatic Cancer,MM-398|5 Fluorouracil|Leucovorin,DRUG,1,7,18 Years,,ALL,False,Merrimack Pharmaceuticals,INDUSTRY,0,79,Italy|Argentina|Hungary|South Korea|United States|Germany|Brazil|Australia|Spain|United Kingdom|Czechia|Taiwan|South Africa|France|Canada,1.0,0,0,1,0,0,3.0,1,0,0,0,1,6.035481432524756,large,0,1,1,0,0,0,1,1,1,1,1,0,1,1,8,1,1,0,0,3,1,2011-11-01,2015-10-01,1430.0,2011.0,0,3,1
NCT05198804,A Study of ZN-c3 and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer,A Phase 1/2 Dose-Escalation and Dose-Expansion Study of ZN-c3 in Combination With Niraparib and ZN-c3 Monotherapy in Subjects With Platinum-Resistant Ovarian Cancer,ACTIVE_NOT_RECRUITING,2022-01-27,2025-05,2024-06-24,INTERVENTIONAL,PHASE1|PHASE2,117.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Ovarian Cancer|Platinum-resistant Ovarian Cancer|Primary Peritoneal Carcinoma|Fallopian Tube Cancer,ZN-c3|Niraparib,DRUG,5,10,18 Years,,FEMALE,False,"K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc",INDUSTRY,0,20,France|United States,,1,1,0,0,1,1.5,1,0,0,0,4,4.770684624465665,medium,0,1,1,0,0,0,1,1,1,1,0,0,1,0,15,1,1,0,0,2,1,,2025-05-01,,,0,5,1
NCT05628233,SENS-401 to Prevent the Ototoxicity Induced by Cisplatin in Adult Subjects With a Neoplastic Disease,"A Phase IIa, Multicenter, Randomized, Controlled, Open Label Study to Evaluate the Efficacy of SENS-401 to Prevent the Ototoxicity Induced by Cisplatin in Adult Subjects With a Neoplastic Disease",COMPLETED,2022-12-30,2025-06-11,2025-07-16,INTERVENTIONAL,PHASE2,48.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Hearing Loss Ototoxic,SENS-401 (R-Azasetron Besylate),DRUG,1,7,18 Years,,ALL,False,Sensorion,INDUSTRY,0,1,France,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.8918202981106265,small,1,1,1,0,0,0,0,0,0,1,1,0,0,1,8,1,1,0,0,1,0,,,,,0,1,0
NCT00526604,Work Related Rehabilitation in Patients With Low Back Pain,A Study on the Effect of Employment Follow-up on Return to Work in Sick Listed Patients With Low Back Pain,TERMINATED,2008-01,2011-09,2011-07-06,INTERVENTIONAL,PHASE3,260.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Low Back Pain,work related rehabilitation,BEHAVIORAL,1,1,18 Years,65 Years,ALL,False,Ullevaal University Hospital,OTHER,0,1,Norway,0.0,0,0,1,0,0,3.0,0,0,0,0,1,5.564520407322694,large,0,0,0,1,0,0,0,0,0,0,1,0,1,1,2,1,0,0,0,1,0,2008-01-01,2011-09-01,1339.0,2008.0,0,0,0
NCT01614184,Fluorescein for Sentinel Lymph Node Biopsy (SLNB) in Breast Cancer,Fluorescein for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Operable Breast Cancer,WITHDRAWN,2008-05,2013-06,2013-07-10,INTERVENTIONAL,PHASE1|PHASE2,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Breast Cancer,Fluorescein,DRUG,1,5,18 Years,,FEMALE,False,University of Utah,OTHER,0,0,,0.0,1,1,0,0,1,1.5,1,0,0,0,1,0.0,,1,1,0,1,0,0,0,0,0,0,0,0,1,0,6,1,1,0,0,1,0,2008-05-01,2013-06-01,1857.0,2008.0,0,2,0
NCT00507247,Daptomycin in the Treatment of Catheter-Related Staphylococcus Aureus,"Phase II, Open-Label Study to Evaluate the Safety and Efficacy of Daptomycin in the Treatment of Catheter-Related Staphylococcus Aureus Bloodstream Infections",COMPLETED,2006-05,2012-09,2016-07-20,INTERVENTIONAL,PHASE2,11.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Staphylococcus Aureus,Daptomycin,DRUG,1,0,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.4849066497880004,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,2006-05-01,2012-09-01,2315.0,2006.0,0,0,0
NCT00644449,"A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Levofloxacin for the Treatment of Acute Symptoms of Chronic Bronchitis","A Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial of Azithromycin SR Versus Levofloxacin for the Treatment of Acute Exacerbation of Chronic Bronchitis (AECB)",COMPLETED,2003-01,2004-03,2011-05-16,INTERVENTIONAL,PHASE3,551.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Bronchitis, Chronic","placebo|azithromycin SR (Zithromax; compound: CP-62,993)|placebo|levofloxacin",DRUG|OTHER,1,9,35 Years,,ALL,False,Pfizer,INDUSTRY,0,75,Netherlands|Russia|Venezuela|India|United States|Germany|Brazil|Costa Rica|Spain|United Kingdom|Lithuania|Mexico|Canada,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.313548046277095,xlarge,0,1,1,0,1,0,1,1,1,1,1,1,1,1,10,1,1,0,0,4,1,2003-01-01,2004-03-01,425.0,2003.0,0,3,1
NCT00003549,S9716: Combination Chemotherapy in Treating Patients With Merkel Cell Cancer,"A Phase II Trial of Cyclophosphamide, Methotrexate and 5-Fluorouracil (CMF) in Neuroendocrine Carcinoma of the Skin (Merkel Cell Carcinoma)",COMPLETED,1998-10,2003-01,2012-10-08,INTERVENTIONAL,PHASE2,80.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Neuroendocrine Carcinoma of the Skin,CMF regimen|cyclophosphamide|fluorouracil|methotrexate,DRUG,0,0,18 Years,,ALL,False,SWOG Cancer Research Network,NETWORK,1,84,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.394449154672439,medium,1,1,0,0,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,4,1,1998-10-01,2003-01-01,1553.0,1998.0,0,1,0
NCT01469338,Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel,A Phase II Clinical Trial of Cabazitaxel Plus Prednisone With Octreotide in the Treatment of Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel,TERMINATED,2012-07,2014-11,2014-11-24,INTERVENTIONAL,PHASE2,9.0,ACTUAL,,SINGLE_GROUP,SUPPORTIVE_CARE,NONE,Diarrhea|Hormone-resistant Prostate Cancer|Recurrent Prostate Cancer|Stage I Prostate Cancer|Stage IIA Prostate Cancer|Stage IIB Prostate Cancer|Stage III Prostate Cancer|Stage IV Prostate Cancer,cabazitaxel|prednisone|octreotide pamoate|questionnaire administration|octreotide acetate,DRUG|OTHER,1,6,18 Years,,MALE,False,University of Southern California,OTHER,2,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,8,2.302585092994046,small,1,1,0,1,0,1,0,0,1,0,0,0,0,0,7,1,1,0,0,5,1,2012-07-01,2014-11-01,853.0,2012.0,0,3,1
NCT02378038,PNT2258 for Treatment of Patients With Richter's Transformation (Brighton),A Phase II Study of PNT2258 in Patients With Richter's Transformation (RT),TERMINATED,2015-08,2016-06,2023-06-29,INTERVENTIONAL,PHASE2,5.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Richter's Transformation,PNT2258,DRUG,1,6,18 Years,,ALL,False,Sierra Oncology LLC - a GSK company,INDUSTRY,0,9,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,1.791759469228055,small,1,1,1,0,1,0,1,0,1,0,0,0,1,0,7,1,1,0,0,1,0,2015-08-01,2016-06-01,305.0,2015.0,1,1,0
NCT01042938,Curcumin for the Prevention of Radiation-induced Dermatitis in Breast Cancer Patients,Curcumin for the Prevention of Radiation-induced Dermatitis in Breast Cancer Patients,COMPLETED,2008-01,2011-04,2012-06-25,INTERVENTIONAL,PHASE2,35.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Breast Cancer,Curcumin C3 Complex|Placebo,DRUG,1,3,21 Years,,FEMALE,False,University of Rochester,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.58351893845611,small,1,1,0,1,1,0,0,0,1,0,1,1,1,1,4,1,1,0,0,2,1,2008-01-01,2011-04-01,1186.0,2008.0,0,1,0
NCT02990858,An Extension Protocol for Subjects Who Successfully Completed PRO140_CD02 or PRO140_CD02_Open Label Study,An Extension Protocol for Subjects Who Successfully Completed PRO140_CD02 or PRO140_CD02_Open Label Study,TERMINATED,2016-11-03,2022-07-10,2025-11-12,INTERVENTIONAL,PHASE2|PHASE3,43.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Human Immunodeficiency Virus (HIV),PRO 140,DRUG,1,6,18 Years,,ALL,False,"CytoDyn, Inc.",INDUSTRY,0,0,,0.0,0,1,1,0,1,2.5,0,0,0,0,1,3.784189633918261,small,1,1,1,0,0,0,0,0,0,0,0,0,1,0,7,1,1,0,0,1,0,,,,,0,2,0
NCT00555048,"Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer","A Prospective Trial to Evaluate the Role of In Vivo T Cell Depletion by Campath® (Alemtuzumab) in Reduction of Transplant Related Mortality in Transplantation From HLA-Class I or Class II Mismatched, Unrelated Donors",TERMINATED,2007-09,,2017-05-24,INTERVENTIONAL,PHASE1|PHASE2,1.0,ACTUAL,,,TREATMENT,,Graft Versus Host Disease|Leukemia|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases,alemtuzumab|busulfan|cyclophosphamide|methotrexate|tacrolimus|allogeneic hematopoietic stem cell transplantation|peripheral blood stem cell transplantation,DRUG|BIOLOGICAL|PROCEDURE,1,6,,50 Years,ALL,False,Fred Hutchinson Cancer Center,OTHER,1,2,United States,0.0,1,1,0,0,1,1.5,1,0,0,0,4,0.6931471805599453,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,7,1,1,1,0,7,1,2007-09-01,,,2007.0,0,4,1
NCT06178055,A Study of the Efficacy and Safety of KUS121 in Participants With Acute Non-Arteritic Central Retinal Artery Occlusion (CRAO),"A Phase 2, Double-masked, Randomized, Sham-controlled, Multiple-dose Study of the Efficacy and Safety of Intravitreal KUS121 in the Treatment of Non-Arteritic Central Retinal Artery Occlusion (CRAO)",ACTIVE_NOT_RECRUITING,2024-04-16,2025-12,2025-05-28,INTERVENTIONAL,PHASE2,75.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Central Retinal Artery Occlusion,KUS121 high dose|KUS121 low dose|Sham procedure,DRUG,1,8,20 Years,,ALL,False,"Kyoto Drug Discovery and Development Co., Ltd.",INDUSTRY,0,11,United States,,0,1,0,0,0,2.0,0,0,0,0,1,4.330733340286331,medium,1,0,1,0,0,0,1,0,1,0,1,1,1,1,9,1,1,0,0,3,1,,2025-12-01,,,0,2,0
NCT00287755,Clinical Trial of Chemosensitivity Test,Chemosensitivity Test to Evaluate the Effect of Adjuvant Cancer Chemotherapy (S-1) After Gastric Surgery,COMPLETED,2006-03,2011-03,2011-06-29,INTERVENTIONAL,PHASE2,300.0,ESTIMATED,NON_RANDOMIZED,SINGLE_GROUP,DIAGNOSTIC,SINGLE,Gastric Cancer,S-1,DRUG,1,1,20 Years,80 Years,ALL,True,Japan Clinical Cancer Research Organization,OTHER,1,36,Japan,1.0,0,1,0,0,0,2.0,1,0,0,0,1,5.707110264748875,large,0,0,0,1,0,1,1,0,0,0,0,0,0,0,2,1,1,0,0,1,0,2006-03-01,2011-03-01,1826.0,2006.0,0,0,0
NCT00646126,Antimalarial Treatments for Clearing Low Density P. Falciparum and Its Impact on Malaria Transmission,Validation of the Use of Istope-Based Molecular Techniques for Malaria Control,COMPLETED,2005-08,,2008-03-28,INTERVENTIONAL,PHASE3,,,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Plasmodium Falciparum|Asymptomatic Parataemia|Sub Patent Parasitaemia,Sulfadoxine / Pyrimethamine (SP) plus artesunate (AS)|placebo tablet similar to active drug in shape and size,DRUG,1,1,1 Year,,ALL,True,Tropical Medicine Research Institute,OTHER,2,1,Sudan,1.0,0,0,1,0,0,3.0,0,0,0,0,3,0.0,,0,0,0,1,0,1,0,0,0,0,1,1,1,1,2,1,1,0,0,2,1,2005-08-01,,,2005.0,0,2,0
NCT02286778,Eradication of Malignant Carcinoma in the Breast Tissue,The Eradication of Malignant Carcinoma in the Breast Tissue Using an ATP (Adenosine-5'-Triphosphate) Inhibitor,COMPLETED,2016-02,2017-08-01,2017-08-03,INTERVENTIONAL,PHASE2|PHASE3,60.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Breast Cancer,Acetogenins|Placebo,DIETARY_SUPPLEMENT,1,0,35 Years,75 Years,FEMALE,False,Optimal Health Research,OTHER,0,0,,1.0,0,1,1,0,1,2.5,1,0,0,0,1,4.110873864173311,medium,1,1,0,1,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,2,1,2016-02-01,,,2016.0,1,2,0
NCT01694485,Abrilumab (AMG 181) in Adults With Moderate to Severe Ulcerative Colitis,"A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis",COMPLETED,2012-11-16,2018-04-10,2019-06-27,INTERVENTIONAL,PHASE2,359.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Ulcerative Colitis,Abrilumab|Placebo,DRUG|BIOLOGICAL,1,3,18 Years,65 Years,ALL,False,Amgen,INDUSTRY,0,123,Latvia|Germany|Norway|Switzerland|Greece|Italy|Netherlands|Estonia|Czechia|Canada|Russia|United States|Austria|Australia|United Kingdom|Poland|Denmark|France|Belgium|Hungary,1.0,0,1,0,0,0,2.0,0,1,0,0,1,5.886104031450156,large,0,1,1,0,1,0,1,1,1,1,1,1,1,1,4,1,1,1,0,2,1,,,,,0,2,0
NCT00408785,A Study Of BOTOX For The Treatment Of Glabellar Lines,"A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of BOTOX? (Botulinum Toxin Type A) in Subjects With Glabellar Lines",COMPLETED,2006-11-01,2007-05-09,2017-05-31,INTERVENTIONAL,PHASE3,256.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Glabellar Lines,Botulinum Toxin Type A|sodium chloride,DRUG,1,1,18 Years,65 Years,ALL,False,GlaxoSmithKline,INDUSTRY,0,4,China,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.54907608489522,large,0,0,1,0,0,0,1,0,0,0,1,1,1,1,2,1,1,0,0,2,1,,,,,0,1,0
NCT01543243,Application of Whole-body Vibration With Stochastic Resonance in Frail Elderly: The Effects on Postural Control,Application of Whole-body Vibration With Stochastic Resonance in Frail Elderly: The Effects on Postural Control: a Pilot Study,COMPLETED,2011-11,2012-12,2016-06-14,INTERVENTIONAL,PHASE2,30.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,TRIPLE,"Equilibration Disorder, Vestibular Nerve",Stochastic resonance whole-body vibration A|Stochastic resonance whole-body vibration B,DEVICE,1,8,65 Years,,ALL,False,Bern University of Applied Sciences,OTHER,3,1,Switzerland,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.4339872044851463,small,1,1,0,1,0,1,0,0,0,0,1,1,1,0,9,1,0,0,1,2,1,2011-11-01,2012-12-01,396.0,2011.0,0,2,0
NCT05153343,Safety of Flonoltinib Maleate Tablets for the Treatment of Patients With Myeloproliferative,"Safety of Flonoltinib Maleate Tablets for the Treatment of Patients With Myeloproliferative Neoplasms Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of the Phase I/II Trial",COMPLETED,2021-12-27,2025-03-19,2025-10-01,INTERVENTIONAL,PHASE1|PHASE2,31.0,ACTUAL,NON_RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,Myeloproliferative Neoplasm (MPN)|Myelofibrosis，MF,flonoltinib 25mg|flonoltinib 100mg|flonoltinib 150mg|flonoltinib 225mg|flonoltinib 50mg,DRUG,10,0,18 Years,,ALL,False,"Chengdu Zenitar Biomedical Technology Co., Ltd",INDUSTRY,0,1,China,1.0,1,1,0,0,1,1.5,0,0,0,0,2,3.4657359027997265,small,1,1,1,0,0,0,0,0,0,0,0,0,1,0,10,0,1,0,0,5,1,,,,,0,4,1
NCT01217515,Diltiazem Hydrochloride Cream for Anal Fissure,"A Randomised,Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Diltiazem Hydrochloride Cream in Subjects With Anal Fissure",COMPLETED,2010-10,2012-05,2014-07-17,INTERVENTIONAL,PHASE3,465.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Chronic Anal Fissure,Diltiazem hydrochloride 4% cream|Diltiazem hydrochloride 2% cream|Placebo,DRUG|OTHER,1,2,18 Years,,ALL,False,S.L.A. Pharma AG,INDUSTRY,0,27,Bulgaria|Spain|Germany|United Kingdom|Romania|Lithuania,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.144185634125646,large,0,1,1,0,0,0,1,1,0,1,1,1,1,1,3,1,1,0,0,3,1,2010-10-01,2012-05-01,578.0,2010.0,0,2,0
NCT01767415,Intra-operative Use of Indigo Carmine Dye for the Delineation of Ill Defined Tumor Borders Using Stereotactic Injection,Intra-operative Use of Indigo Carmine Dye for the Delineation of Ill Defined Tumor Borders Using Stereotactic Injection,COMPLETED,2012-04,2014-09,2018-12-11,INTERVENTIONAL,PHASE1|PHASE2,10.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Brain Tumors With Ill-defined Margins,Indigo carmine,DRUG,1,1,18 Years,65 Years,ALL,False,Weill Medical College of Cornell University,OTHER,0,1,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,1,2.3978952727983707,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,2,1,1,0,0,1,0,2012-04-01,2014-09-01,883.0,2012.0,0,1,0
NCT05020015,A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL),"A Phase 2, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",ACTIVE_NOT_RECRUITING,2021-11-12,2038-12-20,2025-08-12,INTERVENTIONAL,PHASE2,27.0,ACTUAL,NON_RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL),TAK-007|Chemotherapy Agents,DRUG|BIOLOGICAL,3,13,18 Years,,ALL,False,Takeda,INDUSTRY,0,15,United States,,0,1,0,0,0,2.0,1,0,0,0,1,3.332204510175204,small,1,1,1,0,1,0,1,0,1,0,0,0,1,0,16,1,1,1,0,2,1,,,,,0,2,0
NCT01419535,Mifepristone Effects on Glucose Intolerance in Obese/Overweight Adults,"Effects of the Glucocorticoid Antagonist, Mifepristone, on Glucose Intolerance in Obese and Overweight Individuals",COMPLETED,2011-11-29,2015-11-24,2021-04-14,INTERVENTIONAL,PHASE1|PHASE2,19.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,TRIPLE,Endocrine Disease|Diabetes,Mifepristone|Placebo,DRUG,1,5,35 Years,70 Years,ALL,True,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),NIH,1,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,2,2.995732273553991,small,1,1,0,1,0,1,0,0,1,0,1,1,1,0,6,1,1,0,0,2,1,,,,,0,4,1
NCT00694135,Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Anterior Uveitis,"A Prospective, Multi-Center, Randomized, Double-Masked, Safety, Tolerability and Efficacy Study of Four Iontophoretic Doses of Dexamethasone Phosphate Ophthalmic Solution in Patients With Non-Infectious Anterior Segment Uveitis",COMPLETED,2008-06,2009-08,2010-08-31,INTERVENTIONAL,PHASE2,40.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Uveitis, Anterior",EGP-437 1.6 mA-min at 0.4 with EyeGate® II System|EGP-437 4.8 mA-min at 1.2 mA with EyeGate® II System|EGP-437 10.0 mA-min at 2.5 mA with EyeGate® II System|EGP-437 14.0 mA-min at 3.5 mA with EyeGate® II System,DRUG,1,4,12 Years,85 Years,ALL,False,"Eyegate Pharmaceuticals, Inc.",INDUSTRY,0,19,India|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.713572066704308,small,1,1,1,0,0,0,1,1,1,0,1,1,1,1,5,1,1,0,0,4,1,2008-06-01,2009-08-01,426.0,2008.0,0,2,0
NCT02410317,Ropivacaine Through Continuous Infusion Versus Epidural Morphine for Postoperative Analgesia After Emergency Cesarean Section,Ropivacaine Through Continuous Infusion Versus Epidural Morphine for Postoperative Analgesia After Emergency Cesarean Section,COMPLETED,2015-02,2021-12-28,2022-11-08,INTERVENTIONAL,PHASE3,101.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Postoperative Pain,Ropivacaine|Morphine,DRUG,1,11,18 Years,,FEMALE,False,"University Hospital, Grenoble",OTHER,0,1,France,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.624972813284271,medium,0,1,0,1,0,0,0,0,0,1,1,0,1,1,12,1,1,0,0,2,1,2015-02-01,,,2015.0,1,2,0
NCT01884740,Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22,Phase I/II Trial Of Super-Selective Intraarterial Infusion Of Erbitux (Cetuximab) And Avastin (Bevacizumab)For Treatment Of Relapsed/Refractory Intracranial Glioma In Patients Under 22 Years Of Age,TERMINATED,2013-06,2018-10,2022-08-09,INTERVENTIONAL,PHASE1|PHASE2,13.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Glioblastoma Multiforme|Fibrillary Astrocytoma of Brain|Glioma of Brainstem|Anaplastic Astrocytoma|Pilomyxoid Astrocytoma|Mixed Oligodendroglioma-Astrocytoma|Brain Stem Glioma|Diffuse Intrinsic Pontine Glioma,SIACI of Erbitux and Bevacizumab,DRUG,2,2,1 Year,21 Years,ALL,False,Weill Medical College of Cornell University,OTHER,0,1,United States,0.0,1,1,0,0,1,1.5,1,0,0,0,8,2.6390573296152584,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,4,1,1,0,0,1,0,2013-06-01,2018-10-01,1948.0,2013.0,0,2,0
NCT00688740,Docetaxel in Node Positive Adjuvant Breast Cancer,A Multicenter Phase III Randomized Trial Comparing Docetaxel in Combination With Doxorubicin and Cyclophosphamide (TAC) Versus 5-fluorouracil in Combination With Doxorubicin and Cyclophosphamide (FAC) as Adjuvant Treatment of Operable Breast Cancer Patients With Positive Axillary Lymph Nodes.,COMPLETED,1997-06,2010-01,2011-02-16,INTERVENTIONAL,PHASE3,1491.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Breast Cancer,Docetaxel|5-fluorouracil|Doxorubicin|Cyclophosphamide,DRUG,1,2,18 Years,70 Years,FEMALE,False,Sanofi,INDUSTRY,1,20,Germany|Greece|Spain|Czechia|Portugal|Canada|Argentina|Sweden|United States|Austria|United Kingdom|Uruguay|Poland|Israel|South Africa|France|Hungary|Brazil|Slovakia|Egypt,1.0,0,0,1,0,0,3.0,1,0,0,0,1,7.307872780763706,xlarge,0,1,1,0,1,1,1,1,1,1,1,0,1,1,3,1,1,0,0,4,1,1997-06-01,2010-01-01,4597.0,1997.0,0,2,0
NCT06366568,Efficacy of a Eugenol-based Product to Improve the Quality of Toothbrushing and Relieving Gum Discomfort Areas,Clinical Investigation to Assess the Efficacy of a Eugenol-based Product in Improving the Quality of Toothbrushing Measured by Plaque Assessment and Patient Perception Questionnaire and Relieving Gum Discomfort Areas,COMPLETED,2024-02-19,2024-03-06,2024-04-16,INTERVENTIONAL,PHASE3,86.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,"Plaque, Dental",fluoride toothpaste containing 1450 ppm of MFP in a PCC base and eugenol gum product|fluoride toothpaste containing 1450 ppm of MFP in a PCC base,DRUG,1,1,18 Years,70 Years,ALL,True,Colgate Palmolive,INDUSTRY,0,1,Germany,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.465908118654584,medium,1,1,1,0,0,0,0,0,0,1,1,1,1,1,2,1,1,0,0,2,1,,,,,0,1,0
NCT02814968,PET/CT and WB MRI for Staging and Response in CRPC Patients Receiving Enzalutamide,"A Phase 2, Open-label, Single-arm, Efficacy and Imaging Study of Oral Enzalutamide in Chemo-Naïve Patients With Progressive Prostate Cancer Who Have Failed Androgen Deprivation Therapy (Castration-resistant Prostate Cancer Patients)",COMPLETED,2015-02,2020-12,2022-04-14,INTERVENTIONAL,PHASE2,66.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Prostate Cancer Metastatic,Enzalutamide|18-FDG PET/CT|Whole body MRI|Bone scan,DRUG|DEVICE,2,19,18 Years,,MALE,False,The European Uro-Oncology Group,OTHER,1,1,Netherlands,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.204692619390966,medium,1,1,0,1,0,1,0,0,0,0,0,0,1,0,21,1,1,0,1,4,1,2015-02-01,2020-12-01,2130.0,2015.0,1,2,0
NCT05419050,Study of Denosumab for Prevention of Skeletal Disease Progression in Children With Fibrous Dysplasia,A Phase 2 Study of Denosumab for Prevention of Skeletal Disease Progression in Children With Fibrous Dysplasia,COMPLETED,2022-10-12,2026-01-09,2026-01-20,INTERVENTIONAL,PHASE2,15.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Fibrous Dysplasia,denosumab,DRUG,1,6,4 Years,14 Years,ALL,False,National Institute of Dental and Craniofacial Research (NIDCR),NIH,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.772588722239781,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,7,1,1,0,0,1,0,,,,,0,1,0
NCT00363350,Rituximab Treatment in Sjogren's Syndrome,Rituximab for the Treatment of Primary Sjögren's Syndrome: a Double Blinded Randomized Placebo-Controlled Trial,COMPLETED,2006-08,2008-10,2009-02-24,INTERVENTIONAL,PHASE1|PHASE2,30.0,ESTIMATED,RANDOMIZED,SINGLE_GROUP,TREATMENT,QUADRUPLE,Sjogren's Syndrome,rituximab (anti-CD20),DRUG,1,4,18 Years,85 Years,ALL,False,University Medical Center Groningen,OTHER,1,1,Netherlands,1.0,1,1,0,0,1,1.5,0,0,0,0,1,3.4339872044851463,small,1,0,0,1,0,1,0,0,0,0,1,1,1,0,5,1,1,0,0,1,0,2006-08-01,2008-10-01,792.0,2006.0,0,1,0
NCT00308191,A Phase IIIB Study to Compare the Efficacy and Safety of Concomitant Treatment in Patients With COPD,"A 6-Week Double-Blind, Parallel-Group, Active-Controlled Trial to Compare the Efficacy and Safety of Concomitant Treatment of Formoterol Fumarate Inhalation Solution 20 Mcg Twice Daily and Tiotropium 18 Mcg Once Daily to Tiotropium 18 Mcg Once Daily Alone in the Treatment of Patients With Chronic Obstructive Pulmonary Disease",COMPLETED,2006-04,2006-12,2008-03-07,INTERVENTIONAL,PHASE3,128.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,COPD,Formoterol Fumarate|Tiotropium Bromide,DRUG,1,1,40 Years,,ALL,False,Dey,INDUSTRY,0,17,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.859812404361672,medium,0,0,1,0,0,0,1,0,1,0,1,1,1,1,2,1,1,0,0,2,1,2006-04-01,2006-12-01,244.0,2006.0,0,1,0
NCT03093974,Efficacy and Safety of Inhaled CMS in Bronchiectasis Subjects With Chronic P. Aeruginosa Infection. (PROMIS-I),"Double-blind, Placebo-controlled, Clinical Trial on Efficacy and Safety of 12-months Therapy With Inhaled Colistimethate Sodium in the Treatment of Subjects With Non-cystic Fibrosis Bronchiectasis Chronically Infected With P. Aeruginosa",COMPLETED,2017-06-06,2021-04-09,2023-11-15,INTERVENTIONAL,PHASE3,377.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Non Cystic Fibrosis Bronchiectasis,CMS|Placebo,DRUG|OTHER,1,0,18 Years,,ALL,False,Zambon SpA,INDUSTRY,0,85,Italy|Belgium|Netherlands|Spain|Germany|United Kingdom|Australia|Switzerland|New Zealand|Israel|Portugal|Greece,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.934894195619588,large,0,1,1,0,0,0,1,1,0,1,1,1,0,1,1,0,1,0,0,2,1,,,,,0,2,0
NCT00548574,"Efficacy and Safety of Two Doses of SPD476 (Mesalazine) 2.4g and 4.8g Once Daily, With Reference to Asacol 0.8g Three Times Daily in Subjects With Acute, Mild to Moderate Ulcerative Colitis","A Phase III, Randomized, Multi-Centre, Double-blind, Double Dummy, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Two Doses of SPD476 (Mesalazine) 2.4g and 4.8g Once Daily, With Reference to ASACOL 0.8g Three Times Daily, in Subjects With Mild to Moderate Ulcerative Colitis",COMPLETED,2003-12-04,2004-10-20,2021-06-11,INTERVENTIONAL,PHASE3,343.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Ulcerative Colitis,SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine|Mesalazine,DRUG,1,4,18 Years,,ALL,False,Shire,INDUSTRY,0,1,Belgium,1.0,0,0,1,0,0,3.0,0,1,0,0,1,5.840641657373398,large,0,1,1,0,0,0,0,0,0,0,1,1,1,1,5,1,1,0,0,2,1,,,,,0,1,0
NCT04119674,Pilot Study of Anlotinib With STUPP Regimen for Patients With Newly Diagnosed Glioblastoma,Pilot Study of Anlotinib in Combination With STUPP Regimen for Treatment of Patients With Newly Diagnosed Glioblastoma,COMPLETED,2019-03-19,2022-08-23,2023-09-22,INTERVENTIONAL,PHASE1|PHASE2,33.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Glioblastoma,Drug is Anlotinib.|Drug is Temozolomide Capsule.|Radiotherapy was initiated 4 to 6 weeks postoperatively.,DRUG|RADIATION,1,4,18 Years,70 Years,ALL,False,Zhejiang Cancer Hospital,OTHER,0,1,China,1.0,1,1,0,0,1,1.5,0,0,0,0,1,3.5263605246161616,small,1,1,0,1,0,0,0,0,0,0,0,0,1,0,5,1,1,0,0,3,1,,,,,0,2,0
NCT03554018,Ibuprofen With or Without Acetaminophen for Low Back Pain,"Ibuprofen With or Without Acetaminophen for Acute, Non-radicular Low Back Pain: A Randomized Trial",COMPLETED,2018-10-16,2019-09-30,2024-02-28,INTERVENTIONAL,PHASE3,120.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Low Back Pain,Acetaminophen|Ibuprofen 600 mg|Educational intervention|Placebo oral capsule,BEHAVIORAL|DRUG,1,2,18 Years,69 Years,ALL,False,Montefiore Medical Center,OTHER,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.795790545596741,medium,0,1,0,1,0,0,0,0,1,0,1,1,1,1,3,1,1,0,0,4,1,,,,,0,1,0
NCT04705818,Combining Epigenetic And Immune Therapy to Beat Cancer.,Combining Epigenetic And Immune Therapy to Beat Cancer. CAIRE Study,ACTIVE_NOT_RECRUITING,2021-07-23,2027-12,2025-10-02,INTERVENTIONAL,PHASE2,173.0,ESTIMATED,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Advanced Solid Tumor|Advanced Colorectal Carcinoma|Advanced Soft-tissue Sarcoma|Advanced Pancreatic Adenocarcinoma|Adult Solid Tumor,Durvalumab|Tazemetostat,DRUG,4,13,18 Years,,ALL,False,Institut Bergonié,OTHER,2,3,France,,0,1,0,0,0,2.0,1,0,0,0,5,5.159055299214529,medium,0,0,0,1,0,1,1,0,0,1,0,0,1,1,17,1,1,0,0,2,1,,2027-12-01,,,0,3,1
NCT03288818,Low Dose Total Skin Electron Beam Radiation Therapy and Mechlorethamine Hydrochloride Gel in Treating Patients With Mycosis Fungoides,IIS: Phase II Study of Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides,WITHDRAWN,2018-08,2021-12,2025-04-29,INTERVENTIONAL,PHASE2,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Mycosis Fungoides,Mechlorethamine Hydrochloride Gel|Total Skin Electron Beam Radiation Therapy,DRUG|PROCEDURE,1,0,18 Years,,ALL,False,Sidney Kimmel Cancer Center at Thomas Jefferson University,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,1,1,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,2,1,2018-08-01,2021-12-01,1218.0,2018.0,1,1,0
NCT01188174,Clofarabine/Ara-C Treatment Combined With Reduced-intensity Conditioning Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Primary Treatment Failure,Clofarabine/Ara-C Treatment Combined With Reduced-intensity Conditioning Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Primary Treatment Failure,COMPLETED,2010-07,2014-12,2014-12-05,INTERVENTIONAL,PHASE2,26.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,AML,Clofarabine,DRUG,1,0,18 Years,55 Years,ALL,False,Nantes University Hospital,OTHER,0,9,France,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.295836866004329,small,1,1,0,1,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,1,0,2010-07-01,2014-12-01,1614.0,2010.0,0,0,0
NCT00151190,"Community Diabetes Education Program Evaluation ""Code Evaluation""",Community Diabetes Education Program Evaluation,COMPLETED,2005-04,2006-08,2010-01-11,INTERVENTIONAL,PHASE3,180.0,,RANDOMIZED,PARALLEL,,NONE,Diabetes Mellitus,Education for diabetes self-management,BEHAVIORAL,1,1,18 Years,,ALL,,"The University of Texas Health Science Center, Houston",OTHER,1,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.198497031265826,medium,0,0,0,1,0,1,0,0,1,0,1,0,0,1,2,1,0,0,0,1,0,2005-04-01,2006-08-01,487.0,2005.0,0,0,0
NCT04757090,89Zr-Trastuzumab PET/CT in Subjects With Previously Treated HER2-Positive Solid Tumors Scheduled to Receive Treatment With MT-5111,A Pilot Study of 89Zr-Trastuzumab PET/CT in Subjects With Previously Treated HER2-Positive Solid Tumors Scheduled to Receive Treatment With MT-5111,WITHDRAWN,2021-12-31,2023-12-31,2021-12-23,INTERVENTIONAL,PHASE2,0.0,ACTUAL,,SINGLE_GROUP,DIAGNOSTIC,NONE,HER2-positive Solid Tumor|HER-2 Positive Cancer,89Zr-trastuzumab,DRUG,1,3,18 Years,,ALL,False,Washington University School of Medicine,OTHER,1,0,,0.0,0,1,0,0,0,2.0,1,0,0,0,2,0.0,,1,1,0,1,0,1,0,0,0,0,0,0,0,0,4,1,1,0,0,1,0,,,,,0,1,0
NCT01334918,A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT),"A Phase 2, Open-Label, Randomized, Cross-Over Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging by Multidetector Computed Tomography (MDCT) and Single Photon Emission Computed Tomography (SPECT)",COMPLETED,2011-04-26,2012-07-02,2024-12-04,INTERVENTIONAL,PHASE2,124.0,ACTUAL,RANDOMIZED,CROSSOVER,DIAGNOSTIC,NONE,Coronary Artery Disease (CAD),regadenoson|technetium Tc99m sestamibi /technetium Tc99m tetrafosmin|Contrast|Single Photon Emission Computed Tomography|Multidetector Computed Tomography,DRUG|RADIATION|PROCEDURE,1,6,45 Years,,ALL,False,Astellas Pharma Inc,INDUSTRY,0,11,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.8283137373023015,medium,0,1,1,0,0,0,1,0,1,0,1,0,0,0,7,1,1,0,0,5,1,,,,,0,2,0
NCT04308590,A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas,"Glucocorticoid Receptor Antagonism in the Treatment of Hypercortisolism in Patients With Cortisol-Secreting Adrenal Adenomas or Hyperplasia (GRADIENT): A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Relacorilant",COMPLETED,2020-07-27,2024-09-19,2025-09-04,INTERVENTIONAL,PHASE3,137.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Hypercortisolism,Relacorilant|Placebo,DRUG|OTHER,2,15,18 Years,80 Years,ALL,False,Corcept Therapeutics,INDUSTRY,0,45,Italy|Bulgaria|United States|Germany|Austria|Romania|Spain|Poland|Israel,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.927253685157205,medium,0,1,1,0,0,0,1,1,1,1,1,1,1,1,17,1,1,0,0,2,1,,,,,0,3,1
NCT01039090,Efficacy of Continuous Apomorphine Infusion on Cognitive and Neuropsychological Functions in Parkinson's Disease,"Prospective, Randomised, Comparative Study Comparing Efficacy of Continuous Apomorphine Infusion Versus Usual Dopaminergic Per os Treatment on Cognitive and Neuropsychological Functions in Parkinson's Disease: a Clinical and PET-scan Study",COMPLETED,2009-02,2015-02,2023-05-24,INTERVENTIONAL,PHASE3,21.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Parkinsons's Disease,Continuous Apomorphine infusion|Usual dopaminergic per os treatment,DRUG,1,0,18 Years,,ALL,False,Rennes University Hospital,OTHER,0,1,France,1.0,0,0,1,0,0,3.0,0,0,1,0,1,3.091042453358316,small,1,1,0,1,0,0,0,0,0,1,1,0,1,1,1,0,1,0,0,2,1,2009-02-01,2015-02-01,2191.0,2009.0,0,1,0
NCT01625897,A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia,A Long-term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia,COMPLETED,2012-05,2015-03,2026-01-05,INTERVENTIONAL,PHASE2|PHASE3,125.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Schizophrenia,MP-214|Risperidone,DRUG,1,0,20 Years,74 Years,ALL,False,Tanabe Pharma Corporation,INDUSTRY,0,1,Japan,1.0,0,1,1,0,1,2.5,0,0,1,0,1,4.836281906951478,medium,0,1,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0,2,1,2012-05-01,2015-03-01,1034.0,2012.0,0,2,0
NCT04467697,Ambulatory Blood Pressure Monitoring (ABPM) Extension Study of Oral Testosterone Undecanoate in Hypogonadal Men,"A 6 Month, Open Label, Ambulatory Blood Pressure Monitoring (ABPM) Extension Study",COMPLETED,2018-09-18,2020-05-01,2024-06-28,INTERVENTIONAL,PHASE3,155.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Hypogonadism, Male",SOV2012-F1,DRUG,2,8,18 Years,65 Years,MALE,False,Marius Pharmaceuticals,INDUSTRY,1,19,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.049856007249537,medium,0,1,1,0,0,1,1,0,1,0,0,0,1,0,10,1,1,0,0,1,0,,,,,0,1,0
NCT03001310,Gene Therapy for Achromatopsia (CNGB3),"An Open Label, Multi-centre, Phase I/II Dose Escalation Trial of a Recombinant Adeno-associated Virus Vector (AAV2/8-hCARp.hCNGB3) for Gene Therapy of Adults and Children With Achromatopsia Owing to Defects in CNGB3",COMPLETED,2017-01-16,2019-10-25,2023-03-08,INTERVENTIONAL,PHASE1|PHASE2,23.0,ACTUAL,NON_RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,Achromatopsia,AAV - CNGB3,BIOLOGICAL,1,4,3 Years,,ALL,False,MeiraGTx UK II Ltd,INDUSTRY,1,2,United Kingdom|United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,3.1780538303479458,small,1,1,1,0,0,1,1,1,1,1,0,0,1,0,5,1,0,1,0,1,0,,,,,0,2,0
NCT01001910,"Pemetrexed and Carboplatin in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","Phase II Trial of Combination Pemetrexed (Alimta) and Carboplatin (Paraplatin) in Platinum Sensitive Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Carcinoma",COMPLETED,2008-07,2015-02,2024-02-28,INTERVENTIONAL,PHASE2,22.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma,Carboplatin|Laboratory Biomarker Analysis|Pemetrexed Disodium,DRUG|OTHER,1,3,18 Years,,FEMALE,False,Albert Einstein College of Medicine,OTHER,1,3,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,3,3.1354942159291497,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,4,1,1,0,0,3,1,2008-07-01,2015-02-01,2406.0,2008.0,0,2,0
NCT04167813,Trial of Ondansetron as a Parkinson's HAllucinations Treatment,Trial of Ondansetron as a Parkinson's HAllucinations Treatment,ACTIVE_NOT_RECRUITING,2021-10-01,2024-08-30,2024-03-27,INTERVENTIONAL,PHASE2,168.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Parkinson's Hallucinations|Dementia With Lewy Bodies,Ondansetron 8mg or matched placebo tablets,DRUG,1,11,18 Years,,ALL,False,"University College, London",OTHER,6,23,United Kingdom,,0,1,0,0,0,2.0,0,0,1,0,2,5.1298987149230735,medium,0,1,0,1,0,1,1,0,0,1,1,1,1,1,12,1,1,0,0,1,0,,,,,0,2,0
NCT03257813,Non-inferiority of PRO-122 Ophthalmic Solution vs KRYTANTEK Ofteno® in Glaucoma or Ocular Hypertension (CONFORTK),"Clinical Study to Evaluate the Non-inferiority of PRO-122 an Ophthlamic Solution Manufactured by Laboratorios Sophia, Previous Treatment With Krytantek Ofteno ®, in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension.",COMPLETED,2016-04-01,2017-06-18,2019-12-09,INTERVENTIONAL,PHASE3,60.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Primary Open Angle Glaucoma|Ocular Hypertension,PRO-122|Krytantek Ofteno®,DRUG,1,1,18 Years,,ALL,False,Laboratorios Sophia S.A de C.V.,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,1,2,4.110873864173311,medium,1,1,1,0,0,0,0,0,0,0,1,1,1,0,2,1,1,0,0,2,1,,,,,0,2,0
NCT02064413,Essure (Model ESS310) Placement Rate Study,"A Multi-Center, United States Clinical Study to Evaluate Placement Success of the ESS310 Essure® System",COMPLETED,2014-03-17,2014-11-26,2021-04-08,INTERVENTIONAL,PHASE3,134.0,ACTUAL,,SINGLE_GROUP,PREVENTION,NONE,Contraception,ESS310 (BAY1454032),DEVICE,1,6,21 Years,44 Years,FEMALE,True,Bayer,INDUSTRY,0,16,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.90527477843843,medium,0,1,1,0,0,0,1,0,1,0,0,0,0,0,7,1,0,0,1,1,0,,,,,0,1,0
NCT00333320,Positive Effect of Ischemic Postconditioning During Acute Myocardial Infarction,Positive Effect of Ischemic Postconditioning During Acute Myocardial Infarction,COMPLETED,2006-09,2011-11,2012-10-23,INTERVENTIONAL,PHASE1|PHASE2,46.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Acute Myocardial Infarction,postconditioning|Control group,PROCEDURE,1,5,18 Years,,ALL,False,French Cardiology Society,OTHER,0,1,France,1.0,1,1,0,0,1,1.5,0,0,0,1,1,3.8501476017100584,small,1,1,0,1,0,0,0,0,0,1,1,0,1,1,6,1,0,0,0,2,1,2006-09-01,2011-11-01,1887.0,2006.0,0,3,1
NCT04251182,Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects,"A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Evaluate the Safety and Efficacy of Three Dose Strengths of T3D-959 in Subjects With Mild-to-Moderate Alzheimer's Disease",COMPLETED,2021-03-01,2023-02-17,2024-07-19,INTERVENTIONAL,PHASE2,250.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Alzheimer Disease,15mg T3D-959|30 mg T3D-959|45 mg T3D-959|Placebos,DRUG,3,2,50 Years,90 Years,ALL,False,"T3D Therapeutics, Inc.",INDUSTRY,3,1,United States,1.0,0,1,0,0,0,2.0,0,0,1,0,1,5.5254529391317835,large,0,1,1,0,0,1,0,0,1,0,1,1,1,1,5,1,1,0,0,4,1,,,,,0,1,0
NCT02905682,Trial of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Female Subjects,"A Randomised, Double-blind, Placebo-controlled, Multi-centre Trial Investigating the Efficacy and Safety of Desmopressin (FE 992026) Orally Disintegrating Tablets During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Japanese Female Subjects",COMPLETED,2016-09,2017-09-27,2019-09-11,INTERVENTIONAL,PHASE3,190.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Nocturia,Desmopressin|Placebo,DRUG,1,7,20 Years,,FEMALE,False,Ferring Pharmaceuticals,INDUSTRY,0,1,Japan,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.25227342804663,medium,0,1,1,0,0,0,0,0,0,0,1,1,1,1,8,1,1,0,0,2,1,2016-09-01,,,2016.0,1,2,0
NCT02123524,Rivaroxaban Anticoagulation for Superficial Vein Thrombosis,"A Phase III, Multi-centre, Randomized Trial to Compare Rivaroxaban With Placebo for the Treatment of Symptomatic Leg Superficial Vein Thrombosis",COMPLETED,2014-11-11,2018-12-03,2018-12-04,INTERVENTIONAL,PHASE3,85.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Symptomatic Superficial Vein Thrombosis,Rivaroxaban|Placebo,DRUG,2,5,18 Years,,ALL,False,McMaster University,OTHER,1,11,Canada,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.454347296253507,medium,1,1,0,1,0,1,1,0,0,0,1,1,1,1,7,1,1,0,0,2,1,,,,,0,2,0
NCT04210193,Is Intralymphatic Allergen Immunotherapy Effective and Safe?,Is Intralymphatic Allergen Immunotherapy Effective and Safe: a Human Randomized Clinical Trial- Substudy Borås With a Randomized Preseasonal Booster,COMPLETED,2014-04-25,2019-12-01,2019-12-24,INTERVENTIONAL,PHASE2|PHASE3,15.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Allergic Rhinitis Due to Grass Pollen,ALK Alutard 5-grasses|ALK Diluent,DRUG,4,0,18 Years,55 Years,ALL,False,Lars Olaf Cardell,OTHER,0,1,Sweden,1.0,0,1,1,0,1,2.5,0,0,0,0,1,2.772588722239781,small,1,1,0,1,0,0,0,0,0,0,1,1,1,1,4,0,1,0,0,2,1,,,,,0,2,0
NCT04480593,The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19.,"The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19: a Randomized, Open and Pilot Clinical Study.",COMPLETED,2020-06-02,2020-08-30,2020-09-30,INTERVENTIONAL,PHASE2|PHASE3,120.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Covid19,Brazilian Green Propolis Extract (EPP-AF)|Standard care,DRUG|OTHER,1,8,18 Years,,ALL,False,D'Or Institute for Research and Education,OTHER,1,1,Brazil,1.0,0,1,1,0,1,2.5,0,0,0,0,1,4.795790545596741,medium,0,1,0,1,0,1,0,0,0,0,1,0,1,1,9,1,1,0,0,2,1,,,,,0,3,1
NCT02505893,Minimal Islet Transplant at Diabetes Onset,"A Monocentric, Open-label Pilot Study to Assess the Safety and Efficacy of Minimal Islet Transplantation in Patients With New-onset Type 1 Diabetes",COMPLETED,2015-04,2023-12,2024-02-22,INTERVENTIONAL,PHASE2,6.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Diabetes Mellitus, Type 1",Human pancreatic islet|ATG|Pegylated G-CSF|Rapamycin,DRUG|BIOLOGICAL,2,7,18 Years,45 Years,ALL,False,Ospedale San Raffaele,OTHER,1,1,Italy,1.0,0,1,0,0,0,2.0,0,0,0,0,1,1.9459101490553132,small,1,1,0,1,0,1,0,0,0,1,0,0,1,0,9,1,1,1,0,4,1,2015-04-01,2023-12-01,3166.0,2015.0,1,2,0
NCT00113321,Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure,Phase II Study of Low-Dose Decitabine (5-AZA-2'-Deoxycytidine) in Myelodysplastic Syndrome (MDS) Post Azacytidine (AZA) Failure,TERMINATED,2005-03,2008-11,2012-08-07,INTERVENTIONAL,PHASE2,16.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Myelodysplastic Syndrome|Chronic Myelomonocytic Leukemia,Decitabine,DRUG,1,0,,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,2,2.833213344056216,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,2005-03-01,2008-11-01,1341.0,2005.0,0,1,0
NCT01444521,Genotype-drive Study of Irinotecan-Cisplatin Combination for Advanced Gastric Cancer,Genotype-drive Phase II Study of Novel Irinotecan-Cisplatin Combination as First-line Therapy for Advanced Gastric Cancer,COMPLETED,2011-04,2014-05,2014-05-06,INTERVENTIONAL,PHASE2,50.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Gastric Cancer,irinotecan and cisplatin,DRUG,1,1,18 Years,70 Years,ALL,False,Chinese Academy of Medical Sciences,OTHER,0,1,China,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.9318256327243257,small,1,1,0,1,0,0,0,0,0,0,0,0,1,0,2,1,1,0,0,1,0,2011-04-01,2014-05-01,1126.0,2011.0,0,0,0
NCT02989714,"Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer","Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer",COMPLETED,2017-03-16,2020-06-23,2021-07-13,INTERVENTIONAL,PHASE1|PHASE2,13.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Renal Cell Carcinoma,Interleukin-2|Nivolumab,DRUG,2,3,18 Years,,ALL,False,University of Michigan Rogel Cancer Center,OTHER,0,4,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,1,2.6390573296152584,small,1,1,0,1,0,0,1,0,1,0,0,0,1,0,5,1,1,0,0,2,1,,,,,0,2,0
NCT01582516,Safety Study of Replication-competent Adenovirus (Delta-24-rgd) in Patients With Recurrent Glioblastoma,A Phase I/II Trial of a Conditionally Replication-competent Adenovirus (Delta-24-rgd) Administered by Convection Enhanced Delivery in Patients With Recurrent Glioblastoma,COMPLETED,2010-06,2014-12,2015-03-09,INTERVENTIONAL,PHASE1|PHASE2,20.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Brain Tumor|Recurring Glioblastoma,delta-24-RGD adenovirus,BIOLOGICAL,1,1,18 Years,75 Years,ALL,False,Erasmus Medical Center,OTHER,1,1,Netherlands,1.0,1,1,0,0,1,1.5,1,0,0,0,2,3.044522437723423,small,1,1,0,1,0,1,0,0,0,0,0,0,1,0,2,1,0,1,0,1,0,2010-06-01,2014-12-01,1644.0,2010.0,0,2,0
NCT01953406,The Efficacy of 5-fluorouracil/Mitomycin for the Patients With Pulmonary Metastasis of Hepatocellular Carcinoma,Phase II Study Evaluating the Efficacy of 5-fluorouracil/Mitomycin for the Patients With Pulmonary Metastasis of Hepatocellular Carcinoma Who Had Progressive Disease With Sorafenib,WITHDRAWN,2015-11,2015-11,2016-04-27,INTERVENTIONAL,PHASE2,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Hepatocellular Carcinoma|Lung Metastasis,5-fluorouracil|Mitomycin,DRUG,1,5,18 Years,80 Years,ALL,False,Seoul National University Hospital,OTHER,0,1,South Korea,0.0,0,1,0,0,0,2.0,1,0,0,0,2,0.0,,1,1,0,1,0,0,0,0,0,0,0,0,1,0,6,1,1,0,0,2,1,2015-11-01,2015-11-01,0.0,2015.0,1,3,1
NCT02734004,A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.,A Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Olaparib (PARP Inhibitor) in Patients With Advanced Solid Tumors,ACTIVE_NOT_RECRUITING,2016-03-17,2026-09-17,2026-01-29,INTERVENTIONAL,PHASE1|PHASE2,264.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Ovarian|Breast|SCLC|Gastric Cancers,Olaparib|MEDI4736|Bevacizumab,DRUG,3,15,18 Years,130 Years,ALL,False,AstraZeneca,INDUSTRY,1,47,Netherlands|South Korea|United States|United Kingdom|Switzerland|Israel|France,,1,1,0,0,1,1.5,1,0,0,0,4,5.579729825986222,large,0,1,1,0,1,1,1,1,1,1,0,0,1,0,18,1,1,0,0,3,1,,,,,0,5,1
NCT00000604,Influence of CPB Temperature on CABG Morbidity,,COMPLETED,1994-01,1996-12,2015-12-14,INTERVENTIONAL,PHASE2,,,RANDOMIZED,,TREATMENT,,Cardiovascular Diseases|Coronary Disease|Heart Diseases|Myocardial Ischemia|Neurologic Manifestations,"cardiopulmonary bypass|heart arrest, induced",PROCEDURE,0,0,18 Years,70 Years,ALL,False,Baystate Medical Center,OTHER,1,0,,1.0,0,1,0,0,0,2.0,0,0,0,1,5,0.0,,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,2,1,1994-01-01,1996-12-01,1065.0,1994.0,0,2,0
NCT03667404,Resistant Maltodextrin for Gut Microbiome in Parkinson's Disease: Safety and Tolerability Study,Gut Microbial Remodeling with Resistant Maltodextrin for Motor and Non-motor Symptoms in Parkinson's Disease: Safety and Tolerability Study,ACTIVE_NOT_RECRUITING,2018-11-06,2026-03-31,2025-02-19,INTERVENTIONAL,PHASE2,30.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Parkinson Disease|Intestinal Bacteria Flora Disturbance|Dietary Modification,Resistant maltodextrin|maltodextrin,DIETARY_SUPPLEMENT,1,1,60 Years,,ALL,False,Northwestern University,OTHER,1,1,United States,,0,1,0,0,0,2.0,0,0,1,0,3,3.4339872044851463,small,1,0,0,1,0,1,0,0,1,0,1,1,1,1,2,1,0,0,0,2,1,,,,,0,2,0
NCT02337933,Effect of Ursolic Acid Administration on Insulin Sensitivity and Metabolic Syndrome,Effect of Ursolic Acid Administration on Insulin Sensitivity and Metabolic Syndrome,COMPLETED,2014-09,2015-09,2020-10-08,INTERVENTIONAL,PHASE2,24.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Metabolic Syndrome X,Ursolic acid|Placebo,DRUG,7,6,30 Years,60 Years,ALL,False,University of Guadalajara,OTHER,0,1,Mexico,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.2188758248682006,small,1,1,0,1,0,0,0,0,0,0,1,1,1,1,13,1,1,0,0,2,1,2014-09-01,2015-09-01,365.0,2014.0,0,2,0
NCT01709747,Single-arm Study to Assess the Safety of Hydromorphone Hydrochloride by Intrathecal Administration,"A Phase 3, Open-Label, Single-Arm Study To Assess The Safety Of Hydromorphone Hydrochloride Delivered By Intrathecal Administration",COMPLETED,2013-06,2018-02,2021-08-25,INTERVENTIONAL,PHASE3,364.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Chronic Pain,Hydromorphone Hydrochloride|Programmable Implantable pump,DRUG|DEVICE,1,3,18 Years,75 Years,ALL,False,"Piramal Critical Care, Ltd.",INDUSTRY,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.8998973535824915,large,0,1,1,0,0,0,0,0,1,0,0,0,1,0,4,1,1,0,1,2,1,2013-06-01,2018-02-01,1706.0,2013.0,0,1,0
NCT00258349,Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast Cancer,A Phase I/II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination With Trastuzumab (Herceptin) in Patients With Advanced Metastatic and/or Local Chest Wall Recurrent Her-2 Amplified Breast Cancer,COMPLETED,2006-08,2010-09,2014-06-02,INTERVENTIONAL,PHASE1|PHASE2,16.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer,vorinostat|trastuzumab,DRUG,1,2,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,25,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,6,2.833213344056216,small,1,1,0,1,0,0,1,0,1,0,0,0,1,0,3,1,1,0,0,2,1,2006-08-01,2010-09-01,1492.0,2006.0,0,3,1
NCT01003938,Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer,Continuous Infusion Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer: Tumor Features and Phase II/Pharmacokinetic Evaluation,TERMINATED,2009-08,2012-12,2016-06-30,INTERVENTIONAL,PHASE2,6.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Ovarian Cancer,Topotecan|Erlotinib,DRUG,1,5,18 Years,,FEMALE,False,NYU Langone Health,OTHER,1,3,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,1.9459101490553132,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,6,1,1,0,0,2,1,2009-08-01,2012-12-01,1218.0,2009.0,0,2,0
NCT00259558,Dose Finding Study for Retarded Phosphatidylcholine in Pancolitis,"Prospektive, Randomisierte Doppelblinde Studie Zur Dosisfindung Von Intestinal Redardiert Freigesetztem Phosphatidylcholin Bei Chronisch Aktiver Pancolitis Ulcerosa",COMPLETED,2003-04,2006-03,2007-02-12,INTERVENTIONAL,PHASE2,60.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Ulcerative Colitis,retarded release phosphatidylcholine,DRUG,1,2,16 Years,90 Years,ALL,False,Heidelberg University,OTHER,2,1,Germany,1.0,0,1,0,0,0,2.0,0,1,0,0,1,4.110873864173311,medium,1,0,0,1,0,1,0,0,0,1,1,1,1,1,3,1,1,0,0,1,0,2003-04-01,2006-03-01,1065.0,2003.0,0,0,0
NCT03553758,EEG Studies of Ketamine General Anesthesia,Electroencephalogram Studies of Induction and Recovery From Ketamine-Induced General Anesthesia,COMPLETED,2018-11-01,2019-08-01,2020-08-26,INTERVENTIONAL,PHASE2|PHASE3,16.0,ACTUAL,,SINGLE_GROUP,BASIC_SCIENCE,NONE,Anesthesia,Ketamine,DRUG,1,2,18 Years,45 Years,ALL,True,Massachusetts General Hospital,OTHER,0,1,United States,1.0,0,1,1,0,1,2.5,0,0,0,0,1,2.833213344056216,small,1,1,0,1,0,0,0,0,1,0,0,0,0,0,3,1,1,0,0,1,0,,,,,0,1,0
NCT00016458,Phase II Pilot Study of Cyclophosphamide and Rabbit Anti-Thymocyte Globulin as Salvage Therapy in Patients With Diffuse Systemic Sclerosis,,COMPLETED,2000-06,,2008-09-03,INTERVENTIONAL,PHASE2,20.0,,,,TREATMENT,,Systemic Sclerosis,anti-thymocyte globulin|cyclophosphamide,DRUG,0,0,,64 Years,ALL,False,Fred Hutchinson Cancer Center,OTHER,0,3,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.044522437723423,small,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,2,1,2000-06-01,,,2000.0,0,1,0
NCT01367158,"Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study Vaccines","Phase 2, Observer-Blind, Controlled, Randomized, Multi-Center Extension Study to Evaluate Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY in Adolescents Who Previously Received the Same Study Vaccines",COMPLETED,2011-07,2012-07,2014-11-19,INTERVENTIONAL,PHASE2,440.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,SINGLE,Meningococcal Disease|Meningococcal Meningitis,"Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine|Meningococcal (group B) multicomponent recombinant adsorbed vaccine|Tdap",BIOLOGICAL,2,17,11 Years,18 Years,ALL,True,Novartis Vaccines,INDUSTRY,0,7,Colombia|Panama|Chile,1.0,0,1,0,0,0,2.0,0,0,0,0,2,6.089044875446846,large,0,1,1,0,1,0,1,1,0,0,1,0,0,1,19,1,0,1,0,3,1,2011-07-01,2012-07-01,366.0,2011.0,0,4,1
NCT00893048,The Use of Oral Steroids in the Treatment of Cellulitis,Utility of Prednisone in the Treatment of Cellulitis,WITHDRAWN,2010-01-15,2010-08-31,2017-07-25,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Cellulitis|Erysipelas,Prednisone|Placebo Oral Tablet,DRUG,1,1,18 Years,70 Years,ALL,False,Milton S. Hershey Medical Center,OTHER,0,0,,0.0,0,1,0,0,0,2.0,0,0,0,0,2,0.0,,1,1,0,1,0,0,0,0,0,0,1,1,1,1,2,1,1,0,0,2,1,,,,,0,2,0
NCT01396148,A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor,A PHASE I/II STUDY OF SUNITINIB IN YOUNG PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR,COMPLETED,2012-06,2017-08,2019-03-27,INTERVENTIONAL,PHASE2,6.0,ACTUAL,NON_RANDOMIZED,,TREATMENT,NONE,Gastrointestinal Stromal Tumors,sunitinib malate dose escalation|sunitinib malate,DRUG,6,16,6 Years,20 Years,ALL,False,Pfizer,INDUSTRY,0,9,France|Czechia|United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,1.9459101490553132,small,1,1,1,0,1,0,1,1,1,1,0,0,1,0,22,1,1,0,0,2,1,2012-06-01,2017-08-01,1887.0,2012.0,0,3,1
NCT00421655,A Trial of Grazax in Subjects With Hayfever,A Phase III Trial Assessing the Efficacy and Safety of Grazax in Subjects With Seasonal Grass Pollen Induced Rhinoconjunctivitis With or Without Asthma,COMPLETED,2006-12,2007-10,2015-06-24,INTERVENTIONAL,PHASE3,329.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Allergy,Grazax,DRUG,1,0,18 Years,65 Years,ALL,False,ALK-Abelló A/S,INDUSTRY,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.799092654460526,large,0,1,1,0,0,0,0,0,1,0,1,1,1,1,1,0,1,0,0,1,0,2006-12-01,2007-10-01,304.0,2006.0,0,0,0
NCT04449926,BCG and Plasma Amyloid in Non-Demented Adults,BCG and Plasma Amyloid in Non-Demented Adults,COMPLETED,2020-11-09,2021-12-05,2021-12-23,INTERVENTIONAL,PHASE2,49.0,ACTUAL,,SINGLE_GROUP,PREVENTION,NONE,"Alzheimer Disease, Late Onset",Bacillus of Calmette and Guerin (BCG),BIOLOGICAL,1,1,50 Years,80 Years,ALL,True,"Mindful Diagnostics and Therapeutics, LLC",INDUSTRY,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,1,0,1,3.912023005428146,small,1,1,1,0,0,0,0,0,1,0,0,0,0,0,2,1,0,1,0,1,0,,,,,0,0,0
NCT00536926,Telecommunication Via Cell Phones During Post-Operative Treatment After Lung Transplantation,"Telecommunication Via Cell Phones During Post-Operative Treatment After Lung Transplantation - an Open, Randomised Trial",COMPLETED,2007-07,2009-07,2011-07-20,INTERVENTIONAL,PHASE3,56.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Lung Transplantation,Home spirometry with data transfer via cell phone|Home spirometer with BT-cellphone|Home spirometer w/o BT,DEVICE,1,1,18 Years,,ALL,False,Hannover Medical School,OTHER,1,1,Germany,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.04305126783455,medium,1,1,0,1,0,1,0,0,0,1,1,0,0,1,2,1,0,0,1,3,1,2007-07-01,2009-07-01,731.0,2007.0,0,1,0
NCT01475578,Study of STA-1 Capsule in Patients With Vascular Dementia (Marrow-Sea Deficiency),"A Randomized, Double-Blind, Double-Dummy, Active-Controlled, Parallel, Comparative, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of STA-1 Capsule in Patients With Vascular Dementia (Marrow-Sea Deficiency)",COMPLETED,2002-03,2002-10,2011-11-21,INTERVENTIONAL,PHASE2,240.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Vascular Dementia,STA-1|Ergoloid Mesylates tablet,DRUG,3,1,45 Years,80 Years,ALL,False,"Sinphar Pharmaceutical Co., Ltd",OTHER,0,5,China,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.484796933490655,large,0,1,0,1,0,0,1,0,0,0,1,1,1,1,4,1,1,0,0,2,1,2002-03-01,2002-10-01,214.0,2002.0,0,1,0
NCT05013385,A Study to Test Whether Spesolimab Helps People With Crohn's Disease Who Have Symptoms of Bowel Obstruction,"Multi-center, Double-blind, Randomized, Placebo-controlled, Phase IIa Trial to Evaluate Spesolimab (BI 655130) Efficacy in Patients With Fibrostenotic Crohn's Disease",TERMINATED,2021-11-09,2022-05-31,2025-02-24,INTERVENTIONAL,PHASE2,5.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Fibrostenotic Crohn´s Disease,Spesolimab|Placebo,DRUG,2,2,18 Years,75 Years,ALL,False,Boehringer Ingelheim,INDUSTRY,0,4,Canada|Japan|Sweden|United States,0.0,0,1,0,0,0,2.0,0,1,0,0,1,1.791759469228055,small,1,1,1,0,0,0,1,1,1,0,1,1,1,1,4,1,1,0,0,2,1,,,,,0,2,0
NCT06732635,Enhanced Recovery After Surgery (ERAS) for Laparoscopic Hysterectomy at Low Risk Endometrial Cancer,Enhanced Recovery After Surgery (ERAS) for Laparoscopic Hysterectomy at Low Risk Endometrial Cancer: A Randomized Controlled Trial,COMPLETED,2019-06-01,2022-03-01,2024-12-13,INTERVENTIONAL,PHASE3,68.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Endometrial Cancer,Enhanced recovery after surgery (ERAS),PROCEDURE,3,0,18 Years,,FEMALE,False,Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia,OTHER,0,1,Spain,1.0,0,0,1,0,0,3.0,1,0,0,0,1,4.23410650459726,medium,1,1,0,1,0,0,0,0,0,1,1,0,1,1,3,0,0,0,0,1,0,,,,,0,0,0
NCT02212535,Assessment of Tolerance of Mobilizing Peripheral Hematopoietic Stem Cells by Plerixafor in Sickle Cell Patients,Open Study of Phase I / II Evaluating Tolerance and Efficacy of Mobilization and Collection of Peripheral Hematopoietic Stem Cells Device After a Single Injection of 0.24mg/kg of Plerixafor in Sickle Cell Patients,COMPLETED,2016-01-15,2017-09-27,2025-09-05,INTERVENTIONAL,PHASE1|PHASE2,3.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Major Sickle Cell Syndrome of Type SS or Sβ Thalassemia,Plerixafor,DRUG,1,2,18 Years,,ALL,False,Assistance Publique - Hôpitaux de Paris,OTHER,1,1,France,1.0,1,1,0,0,1,1.5,0,0,0,0,1,1.3862943611198906,small,1,1,0,1,0,1,0,0,0,1,0,0,1,0,3,1,1,0,0,1,0,,,,,0,1,0
NCT01708876,P. Knowlesi Trial of Artesunate-mefloquine Versus Chloroquine,"Artesunate-mefloquine vs Chloroquine in Patients With Acute Uncomplicated P. Knowlesi and P. Vivax Malaria: a Randomized Open Label Trial in Sabah, Malaysia",COMPLETED,2012-10,2014-12,2015-04-09,INTERVENTIONAL,PHASE3,250.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,NONE,Uncomplicated Plasmodium Knowlesi Malaria,Artesunate-mefloquine|Chloroquine|Primaquine,DRUG,1,6,1 Year,,ALL,False,Menzies School of Health Research,OTHER,1,3,Malaysia,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.5254529391317835,large,0,0,0,1,0,1,1,0,0,0,1,0,1,1,7,1,1,0,0,3,1,2012-10-01,2014-12-01,791.0,2012.0,0,2,0
NCT01646476,Covered Versus Uncovered Self-expandable Metallic Stents for Malignant Gastric Outlet Obstruction,"Comparison of Efficacy of Covered Versus Uncovered Self-expandable Metallic Stents for Treatment of Malignant Gastric Outlet Obstruction: a Prospective, Randomized Study",COMPLETED,2012-07,2014-12,2017-03-01,INTERVENTIONAL,PHASE3,102.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Gastric Outlet Obstruction Due to Gastric Adenocarcinoma,"Covered stent (Bona stent pyloric/duodenal covered) insertion|Uncovered stent (Bona stent, pyloric/duodenal) insertion",DEVICE,1,1,20 Years,80 Years,ALL,False,Samsung Medical Center,OTHER,0,1,South Korea,1.0,0,0,1,0,0,3.0,1,0,0,0,1,4.634728988229636,medium,0,1,0,1,0,0,0,0,0,0,1,0,1,1,2,1,0,0,1,2,1,2012-07-01,2014-12-01,883.0,2012.0,0,1,0
NCT00002476,Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Head and Neck Cancer,Phase III Randomized Study of Radiotherapy Alone vs With Concurrent Chemotherapy With MTX or VBMF (VCR/BLEO/MTX/5-FU) vs Subsequent Chemotherapy vs Concurrent and Subsequent Chemotherapy in Patients With Advanced Head and Neck Cancer,COMPLETED,1990-01,2010-01,2013-08-02,INTERVENTIONAL,PHASE3,,,,,TREATMENT,,Head and Neck Cancer,bleomycin sulfate|fluorouracil|leucovorin calcium|methotrexate|vincristine sulfate|low-LET cobalt-60 gamma ray therapy|low-LET photon therapy|radiation therapy,DRUG|BIOLOGICAL|RADIATION,0,0,18 Years,,ALL,False,Cancer Research UK,OTHER,0,7,United Kingdom|India,1.0,0,0,1,0,0,3.0,1,0,0,0,1,0.0,,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,8,1,1990-01-01,2010-01-01,7305.0,1990.0,0,2,0
NCT01625117,Mental Health and Aggression in Congolese Ex-combatants,,COMPLETED,2011-05,2012-09,2013-06-26,INTERVENTIONAL,PHASE2,38.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Appetitive Aggression|Posttraumatic Stress Disorder,A variant of Narrative Exposure Therapy,BEHAVIORAL,2,2,16 Years,35 Years,MALE,False,University of Konstanz,OTHER,1,1,Republic of the Congo,1.0,0,1,0,0,0,2.0,0,0,0,0,2,3.6635616461296463,small,1,1,0,1,0,1,0,0,0,0,1,0,1,1,4,1,0,0,0,1,0,2011-05-01,2012-09-01,489.0,2011.0,0,1,0
NCT02017717,A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients,A Randomized Phase 3 Open Label Study of Nivolumab Versus Bevacizumab and Multiple Phase 1 Safety Cohorts of Nivolumab or Nivolumab in Combination With Ipilimumab Across Different Lines of Glioblastoma,COMPLETED,2014-02-07,2024-06-21,2025-04-04,INTERVENTIONAL,PHASE3,529.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Recurrent Glioblastoma,Nivolumab|Bevacizumab|Ipilimumab,BIOLOGICAL,6,4,18 Years,,ALL,False,Bristol-Myers Squibb,INDUSTRY,0,112,Italy|Belgium|Netherlands|United States|Germany|Spain|Australia|United Kingdom|Poland|Switzerland|Denmark|France,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.272877006546167,xlarge,0,1,1,0,1,0,1,1,1,1,1,0,1,1,10,1,0,1,0,3,1,,,,,0,3,1
NCT01818440,Fluoroscopy or 3-D Roadmap Imaging Software for Liver Tumor Treatment,Prospective Randomized Trial Comparing Navigation With 3D Roadmap vs. Conventional Angiography During Transarterial Embolization,COMPLETED,2013-03-21,2018-08-22,2018-08-31,INTERVENTIONAL,PHASE2,28.0,ACTUAL,RANDOMIZED,PARALLEL,DIAGNOSTIC,NONE,Image-Guided Surgery,3D Roadmap software|Fluoroscopy,OTHER,1,0,18 Years,99 Years,ALL,False,National Institutes of Health Clinical Center (CC),NIH,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.367295829986474,small,1,1,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,2,1,,,,,0,1,0
NCT02504489,Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC,Randomized Blinded Phase III Assessment of Second or Third-Line Chemotherapy With Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced Non-Small Cell Lung Cancer and With at Least One Measurable Lung Lesion,COMPLETED,2015-12,2021-05-23,2022-09-10,INTERVENTIONAL,PHASE3,559.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Non-Small Cell Lung Cancer,Docetaxel + Plinabulin (DP)|Docetaxel (D),DRUG,1,13,18 Years,,ALL,False,BeyondSpring Pharmaceuticals Inc.,INDUSTRY,0,57,China|Australia|United States,1.0,0,0,1,0,0,3.0,1,0,0,0,1,6.327936783729195,xlarge,0,1,1,0,0,0,1,1,1,0,1,0,1,1,14,1,1,0,0,2,1,2015-12-01,,,2015.0,1,3,1
NCT01481350,Sildenafil for Post-capillary Pulmonary Hypertension in Patients Undergoing Cardiac Surgery,Phase 2 Use of Sildenafil for the Treatment of Post-capillary Hypertension in Patients Undergoing Cardiac Surgery,COMPLETED,2012-02,2013-12,2014-12-09,INTERVENTIONAL,PHASE2,20.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Pulmonary Hypertension,sildenafil,DRUG,1,1,18 Years,,ALL,False,"University of Turin, Italy",OTHER,0,1,Italy,1.0,0,1,0,0,0,2.0,0,0,0,1,1,3.044522437723423,small,1,1,0,1,0,0,0,0,0,1,0,0,1,0,2,1,1,0,0,1,0,2012-02-01,2013-12-01,669.0,2012.0,0,0,0
NCT02556450,Bioprofiling Response to Mineralocorticoid Receptor Antagonists for the Prevention of Heart Failure,"Bioprofiling Response to Mineralocorticoid Receptor Antagonists for the Prevention of Heart Failure. A Proof of Concept Clinical Trial Within the EU FP 7 (European Union FP7) ""HOMAGE"" Programme "" Heart OMics in AGing """,COMPLETED,2016-01,2019-01-31,2022-03-08,INTERVENTIONAL,PHASE2,528.0,ACTUAL,RANDOMIZED,PARALLEL,OTHER,SINGLE,Heart Failure,Spironolacton,DRUG,1,10,60 Years,,ALL,False,ACS Biomarker,OTHER,2,9,Italy|Netherlands|Germany|United Kingdom|France|Ireland,1.0,0,1,0,0,0,2.0,0,0,0,1,1,6.270988431858299,xlarge,0,1,0,1,0,1,1,1,0,1,1,0,0,1,11,1,1,0,0,1,0,2016-01-01,,,2016.0,1,2,0
NCT02553889,"A Study of Safety, PK, & PD of ISIS 416858 Administered Subcutaneously to Patients With End-Stage Renal Disease on Hemodialysis","A Phase 2, Randomized, Double Blind, Placebo Controlled Study of the Safety, PK, and PD of Multiple Doses of ISIS 416858 (ISIS-FXI RX), Administered Subcutaneously to Patients With End-Stage Renal Disease on Hemodialysis",COMPLETED,2015-10,2016-11,2016-12-13,INTERVENTIONAL,PHASE2,49.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,End-stage Renal Disease (ESRD),ISIS 416858|Placebo,DRUG,1,6,18 Years,80 Years,ALL,False,"Ionis Pharmaceuticals, Inc.",INDUSTRY,1,8,Canada,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.912023005428146,small,1,1,1,0,0,1,1,0,0,0,1,1,0,1,7,1,1,0,0,2,1,2015-10-01,2016-11-01,397.0,2015.0,1,2,0
NCT01999868,Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris,Efficacy of Ustekinumab (Anti-IL-12/23) Followed by Abatacept (CTLA4-Ig) for the Treatment of Psoriasis Vulgaris (ITN059AI),COMPLETED,2014-03-19,2018-03-01,2019-01-15,INTERVENTIONAL,PHASE2,108.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Psoriasis,Ustekinumab|Abatacept|UST Placebo|ABA Placebo,DRUG|BIOLOGICAL,1,10,18 Years,65 Years,ALL,False,National Institute of Allergy and Infectious Diseases (NIAID),NIH,1,10,Canada|United States,1.0,0,1,0,0,0,2.0,0,1,0,0,1,4.6913478822291435,medium,0,1,0,1,0,1,1,1,1,0,1,1,1,1,11,1,1,1,0,4,1,,,,,0,3,1
NCT00092768,A Study of MK0663 and an Approved Drug in the Treatment of Osteoarthritis (0663-076)(COMPLETED),"A 26-Week, Randomized, Placebo- and Active-Comparator-Controlled, Parallel-Group, Double-Blind, 2-Part Study to Assess the Safety and Efficacy of Etoricoxib 30 mg Versus Celecoxib 200 mg in Patients With Osteoarthritis (Study 1)",COMPLETED,2004-03-01,2005-02-01,2024-08-15,INTERVENTIONAL,PHASE3,500.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Osteoarthritis,"MK0663, etoricoxib|Comparator: celecoxib",DRUG,1,1,40 Years,,ALL,False,Organon and Co,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,1,0,0,1,6.2166061010848646,large,0,1,1,0,0,0,0,0,0,0,1,1,1,1,2,1,1,0,0,2,1,,,,,0,1,0
NCT00668668,Dermatological Evaluation of Topic Compatibility-Dermacyd Tina Gel Sweet Flower,"Study for Dermatological Evaluation of Topic Compatibility (Primary and Accumulated Dermical Irritability, Dermical Sensitivity) of Dermacyd Tina Gel Sweet Flower.",COMPLETED,2007-12,,2009-01-29,INTERVENTIONAL,PHASE3,52.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,SUPPORTIVE_CARE,NONE,Hygiene,Lactic acid (Dermacid),DRUG,1,0,18 Years,60 Years,FEMALE,True,Sanofi,INDUSTRY,0,1,Brazil,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.970291913552122,medium,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,2007-12-01,,,2007.0,0,0,0
NCT05695950,A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis,"A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered GLPG3667 Once Daily for 24 Weeks in Adult Subjects With Dermatomyositis",ACTIVE_NOT_RECRUITING,2023-02-27,2026-04,2025-12-23,INTERVENTIONAL,PHASE2,40.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Dermatomyositis,GLPG3667|Placebo,DRUG,1,8,18 Years,75 Years,ALL,False,Galapagos NV,INDUSTRY,0,54,Italy|Belgium|Argentina|United States|Croatia|Germany|Romania|Spain|United Kingdom|Chile|Poland|Mexico|Czechia|Colombia|France,,0,1,0,0,0,2.0,0,0,0,0,1,3.713572066704308,small,1,1,1,0,0,0,1,1,1,1,1,1,1,1,9,1,1,0,0,2,1,,2026-04-01,,,0,3,1
NCT03737474,A Long-Term Study of Brexpiprazole in Patients With Major Depressive Disorder,"A Multi-center, Open-label Trial to Assess the Long-term Safety and Efficacy of Brexpiprazole as Adjunctive Therapy in Patients With Major Depressive Disorder",COMPLETED,2018-10-04,2021-04-13,2024-04-29,INTERVENTIONAL,PHASE3,248.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Major Depressive Disorder,Brexpiprazole,DRUG,1,5,20 Years,,ALL,False,"Otsuka Pharmaceutical Co., Ltd.",INDUSTRY,0,1,Japan,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.517452896464707,large,0,1,1,0,0,0,0,0,0,0,0,0,1,0,6,1,1,0,0,1,0,,,,,0,1,0
NCT01270074,Prevention of Bronchiectasis in Infants With Cystic Fibrosis,A Phase 3 Multi-centre Randomised Placebo-controlled Study of Azithromycin in the Primary Prevention of Radiologically-defined Bronchiectasis in Infants With Cystic Fibrosis.,COMPLETED,2012-04,2021-03,2021-09-16,INTERVENTIONAL,PHASE3,130.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Cystic Fibrosis|Bronchiectasis,Azithromycin|Placebo control,DRUG,2,9,6 Weeks,6 Months,ALL,False,The University of Queensland,OTHER,1,10,Australia|New Zealand,1.0,0,0,1,0,0,3.0,0,0,0,0,2,4.875197323201151,medium,0,1,0,1,0,1,1,1,0,0,1,1,0,1,11,1,1,0,0,2,1,2012-04-01,2021-03-01,3256.0,2012.0,0,4,1
NCT06038474,Descartes-08 for Patients With Systemic Lupus Erythematosus,Descartes-08 for Patients With Systemic Lupus Erythematosus,ACTIVE_NOT_RECRUITING,2024-02-12,2026-11-01,2025-11-24,INTERVENTIONAL,PHASE2,6.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Systemic Lupus Erythematosus (SLE),Descartes-08,DRUG,1,4,18 Years,,ALL,False,Cartesian Therapeutics,INDUSTRY,0,1,United States,,0,1,0,0,0,2.0,0,1,0,0,1,1.9459101490553132,small,1,1,1,0,0,0,0,0,1,0,0,0,1,0,5,1,1,0,0,1,0,,,,,0,0,0
NCT04326790,The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention,The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention,TERMINATED,2020-04-03,2020-04-27,2021-04-06,INTERVENTIONAL,PHASE2,105.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Corona Virus Disease 19 (Covid 19),Colchicine|Standard treatment,DRUG,2,0,18 Years,,ALL,False,National and Kapodistrian University of Athens,OTHER,0,1,Greece,0.0,0,1,0,0,0,2.0,0,0,0,0,1,4.663439094112067,medium,0,1,0,1,0,0,0,0,0,0,1,0,1,1,2,0,1,0,0,2,1,,,,,0,1,0
NCT01969890,STem cElls Mobilization in Acute Myocardial Infarction Outcome Trial,Phase III Study on STem cElls Mobilization in Acute Myocardial Infarction,TERMINATED,2013-10,2018-05,2021-02-03,INTERVENTIONAL,PHASE3,532.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Anterior Acute Myocardial Infarction|Left Ventricular Systolic Dysfunction,G-CSF administration,DRUG,1,1,18 Years,75 Years,ALL,False,Heart Care Foundation,OTHER,2,53,Italy,0.0,0,0,1,0,0,3.0,0,0,0,1,2,6.278521424165844,xlarge,0,1,0,1,0,1,1,0,0,1,1,0,1,1,2,1,1,0,0,1,0,2013-10-01,2018-05-01,1673.0,2013.0,0,1,0
NCT01620190,Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer,A Phase II Study of Weekly Abraxane for Patients With Advanced NSCLC With EGFR Mutations or With Durable Response to an EGFR Tyrosine Kinase Inhibitor Following Front Line Therapy With EGFR Tyrosine Kinase Inhibitors,COMPLETED,2012-12-02,2019-04-29,2021-07-16,INTERVENTIONAL,PHASE2,26.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Recurrent Non-Small Cell Lung Carcinoma|Stage IV Non-Small Cell Lung Cancer,Laboratory Biomarker Analysis|Paclitaxel Albumin-Stabilized Nanoparticle Formulation,DRUG|OTHER,1,4,18 Years,,ALL,False,University of Washington,OTHER,2,12,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,2,3.295836866004329,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,5,1,1,0,0,2,1,,,,,0,2,0
NCT04062890,Inhibiting GABA Transaminase to Relieve Obesity Induced Hyperinsulinemia and Insulin Resistance,Inhibiting GABA Transaminase to Relieve Obesity Induced Hyperinsulinemia and Insulin Resistance,WITHDRAWN,2030-04-15,2030-12-30,2025-07-30,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Hyperinsulinism|Insulin Resistance|Insulin Sensitivity|Glucose Intolerance|Hypertension,Vigabatrin Pill|Placebo oral tablet,DRUG,4,0,18 Years,60 Years,ALL,False,University of Arizona,OTHER,1,0,,0.0,0,1,0,0,0,2.0,0,0,0,1,5,0.0,,1,1,0,1,0,1,0,0,0,0,1,1,1,1,4,0,1,0,0,2,1,,,,,0,2,0
NCT03064490,"Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED)","Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED)",COMPLETED,2017-10-17,2023-11-22,2025-04-10,INTERVENTIONAL,PHASE2,35.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Locally Advanced Esophageal and Gastric Cancers (EGC),Pembrolizumab,DRUG,1,1,18 Years,,ALL,False,Duke University,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.58351893845611,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,2,1,1,0,0,1,0,,,,,0,0,0
NCT02947490,Effectiveness of Self-monitoring and Treatment of Blood Pressure Following Stroke or Transient Ischaemic Attack,Trial of the Effectiveness and Cost Effectiveness of Self-monitoring and Treatment of Blood Pressure in Secondary Prevention Following Stroke or Transient Ischaemic Attack (TIA),COMPLETED,2013-09,2016-10,2016-10-28,INTERVENTIONAL,PHASE3,165.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Stroke,Self BP measurement|Standard Care|Standard BP management|Treatment,OTHER,1,0,18 Years,,ALL,False,University of East Anglia,OTHER,0,1,United Kingdom,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.111987788356544,medium,0,1,0,1,0,0,0,0,0,1,1,0,1,1,1,0,0,0,0,4,1,2013-09-01,2016-10-01,1126.0,2013.0,0,1,0
NCT03792490,Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALS,Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALS,COMPLETED,2019-02-20,2023-11-01,2023-11-30,INTERVENTIONAL,PHASE2,120.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Amyotrophic Lateral Sclerosis,Fasudil|Placebo,DRUG,1,7,18 Years,,ALL,False,University Medical Center Goettingen,OTHER,0,15,Germany|Switzerland|France,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.795790545596741,medium,0,1,0,1,0,0,1,1,0,1,1,1,1,1,8,1,1,0,0,2,1,,,,,0,3,1
NCT04579510,Immunogenicity nOPV2 With and Without bOPV,Immunogenicity of Novel Monovalent Oral Poliovirus Vaccine Type 2 (nOPV2) With and Without Bivalent OPV,COMPLETED,2021-02-08,2021-12-23,2024-10-04,INTERVENTIONAL,PHASE2,795.0,ACTUAL,RANDOMIZED,PARALLEL,OTHER,NONE,Poliomyelitis,Novel monovalent oral poliovirus vaccine type 2 (nOPV2)|Bivalent oral poliovirus vaccine (bOPV),BIOLOGICAL,1,3,42 Days,48 Days,ALL,True,Centers for Disease Control and Prevention,FED,1,1,Bangladesh,1.0,0,1,0,0,0,2.0,0,0,0,0,1,6.679599185844383,xlarge,0,1,0,0,0,1,0,0,0,0,1,0,0,1,4,1,0,1,0,2,1,,,,,0,1,0
NCT01112813,The Neurotrophic Effects of Lithium Carbonate Following Stroke: A Feasibility Study,The Neurotrophic Effects of Lithium Carbonate Following Stroke: A Feasibility Study,COMPLETED,2010-04,2017-07-25,2024-01-31,INTERVENTIONAL,PHASE3,12.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Stroke,Lithium Carbonate,DRUG,1,3,40 Years,,ALL,False,Sunnybrook Health Sciences Centre,OTHER,0,1,Canada,1.0,0,0,1,0,0,3.0,0,0,0,0,1,2.5649493574615367,small,1,1,0,1,0,0,0,0,0,0,0,0,1,0,4,1,1,0,0,1,0,2010-04-01,,,2010.0,0,0,0
NCT00717860,A Clinical Study of MK0991 (Caspofungin) in Japanese Patients With Deep-seated Candida or Aspergillus Infections (0991-062)(COMPLETED),"A Multicenter, Double-Blind, Comparative Study of MK0991 (Caspofungin) Versus Micafungin in Adult Japanese Patients With Deep-seated Candida or Aspergillus Infections",COMPLETED,2008-08,2010-07,2017-03-23,INTERVENTIONAL,PHASE3,121.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Fungal Infection,caspofungin acetate|Comparator: Micafungin sodium,DRUG,1,2,20 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.804021044733257,medium,0,1,1,0,1,0,0,0,0,0,1,1,1,1,3,1,1,0,0,2,1,2008-08-01,2010-07-01,699.0,2008.0,0,1,0
NCT02108860,"Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)","Abatacept (CTLA4-Ig) for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's) (ABROGATE)",COMPLETED,2015-04-25,2023-12-20,2024-07-29,INTERVENTIONAL,PHASE3,65.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Granulomatosis With Polyangiitis (Wegener's)|Granulomatosis With Polyangiitis|Wegener's Granulomatosis|ANCA-Associated Vasculitis,Abatacept|placebo,DRUG,1,5,15 Years,,ALL,False,University of South Florida,OTHER,5,20,United States|Germany|United Kingdom|Ireland|Canada,1.0,0,0,1,0,0,3.0,0,0,0,0,4,4.189654742026425,medium,1,1,0,1,0,1,1,1,1,1,1,1,1,1,6,1,1,0,0,2,1,,,,,0,4,1
NCT00825760,Clinical Trial to Investigate Treatment With Photodynamic Therapy to Reduce Levels of Bacteria in Leg Ulcers,"Phase II Randomised, Placebo Controlled Trial to Investigate Repeat Dose Antimicrobial Photodynamic Therapy in Patients With Chronic Leg Ulcers.",COMPLETED,2009-01,2011-09,2013-01-24,INTERVENTIONAL,PHASE2,57.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Chronic Leg Ulcers|Wound Healing,Topical PPA904 gel and light|Topical placebo gel plus light,DRUG,1,6,18 Years,,ALL,False,Photopharmica,INDUSTRY,0,4,United Kingdom,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.060443010546419,medium,1,1,1,0,0,0,1,0,0,1,1,1,1,1,7,1,1,0,0,2,1,2009-01-01,2011-09-01,973.0,2009.0,0,3,1
NCT02718820,Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic Head and Neck Cancer,Immunomodulation of Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (HNSCC) After Platinum Failure,COMPLETED,2016-03,2021-12,2024-01-09,INTERVENTIONAL,PHASE1|PHASE2,22.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Head and Neck Carcinoma,Docetaxel|Pembrolizumab,DRUG,1,3,18 Years,,ALL,False,Medical University of Vienna,OTHER,0,1,Austria,1.0,1,1,0,0,1,1.5,1,0,0,0,1,3.1354942159291497,small,1,1,0,1,0,0,0,0,0,0,0,0,1,0,4,1,1,0,0,2,1,2016-03-01,2021-12-01,2101.0,2016.0,1,2,0
NCT02370420,Intra-Articular Injections of Platelet-Rich Plasma in Knee Osteoarthritis: Unique Application Versus Triple Application,Intra-Articular Injections of Platelet-Rich Plasma in Knee Osteoarthritis: Unique Application Versus Triple Application,COMPLETED,2015-03,2016-08,2018-02-19,INTERVENTIONAL,PHASE3,56.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Osteoarthritis,Platelet-Rich Plasma|rehabilitation exercises,BEHAVIORAL|BIOLOGICAL,1,2,18 Years,90 Years,ALL,True,Universidad Autonoma de Nuevo Leon,OTHER,0,1,Mexico,1.0,0,0,1,0,0,3.0,0,1,0,0,1,4.04305126783455,medium,1,1,0,1,0,0,0,0,0,0,1,1,1,1,3,1,0,1,0,2,1,2015-03-01,2016-08-01,519.0,2015.0,1,1,0
NCT00368121,EMMA-1 (Erbitux for Multiple Myeloma),Phase II Study of Cetuximab for the Refractory or Relapsed Multiple Myeloma EMMA-1(Erbitux for Multiple Myeloma),TERMINATED,2006-08,2012-06,2012-07-13,INTERVENTIONAL,PHASE2,13.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Multiple Myeloma,Cetuximab +/- Dexamethasone,DRUG,1,5,18 Years,,ALL,False,Prof. Dr. Andreas Engert,OTHER,1,3,Germany,0.0,0,1,0,0,0,2.0,1,0,0,0,1,2.6390573296152584,small,1,1,0,1,0,1,1,0,0,1,0,0,1,0,6,1,1,0,0,1,0,2006-08-01,2012-06-01,2131.0,2006.0,0,1,0
NCT00378521,Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon,"Phase II Dose Response Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment of Raynaud's Phenomenon",COMPLETED,2006-07,2006-07,2007-05-30,INTERVENTIONAL,PHASE2,15.0,ESTIMATED,RANDOMIZED,SINGLE_GROUP,TREATMENT,DOUBLE,Raynaud's Disease|Raynaud's Disease Secondary to Scleroderma|Raynaud's Disease Secondary to Autoimmune Disease,MQX-503,DRUG,1,2,18 Years,75 Years,ALL,,MediQuest Therapeutics,INDUSTRY,0,1,United States,1.0,0,1,0,0,0,2.0,0,1,0,0,3,2.772588722239781,small,1,0,1,0,0,0,0,0,1,0,1,1,1,0,3,1,1,0,0,1,0,2006-07-01,2006-07-01,0.0,2006.0,0,1,0
NCT00741221,Pemetrexed Plus Bevacizumab in Non Small Cell Lung Cancer,"Pemetrexed Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)",COMPLETED,2008-06,2016-10,2016-10-04,INTERVENTIONAL,PHASE2,50.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Non-small-cell Lung Cancer,Pemetrexed|Bevacizumab,DRUG,1,4,18 Years,,ALL,False,Hellenic Oncology Research Group,OTHER,0,10,Greece,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.9318256327243257,small,1,1,0,1,0,0,1,0,0,0,0,0,1,0,5,1,1,0,0,2,1,2008-06-01,2016-10-01,3044.0,2008.0,0,1,0
NCT00953121,Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG),Phase II Study of Bevacizumab Plus Irinotecan and Carboplatin for Recurrent Malignant Glioma Patients,COMPLETED,2009-09,2013-01,2013-09-16,INTERVENTIONAL,PHASE2,104.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Malignant Glioma,bevacizumab and CPT-11 and Carboplatin,DRUG,1,4,18 Years,,ALL,False,Annick Desjardins,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.653960350157523,medium,0,1,0,1,0,0,0,0,1,0,0,0,1,1,5,1,1,0,0,1,0,2009-09-01,2013-01-01,1218.0,2009.0,0,0,0
NCT02439814,Pregnenolone and Marijuana Dependence,Effect of Pregnenolone on Cue-reactivity in Marijuana-dependent Individuals,COMPLETED,2015-06,2016-04,2018-06-18,INTERVENTIONAL,PHASE2,21.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Marijuana Dependence,Pregnenolone|Placebo,DRUG|OTHER,1,0,18 Years,65 Years,ALL,False,Medical University of South Carolina,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.091042453358316,small,1,1,0,1,0,0,0,0,1,0,1,1,1,1,1,0,1,0,0,2,1,2015-06-01,2016-04-01,305.0,2015.0,1,1,0
NCT00151333,Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD),"A Randomized, Double-blind, Placebo-controlled, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics Trial of Multiple Ascending Fixed Doses of SRA-333 in Subjects With Mild to Moderate Alzheimer's Disease.",COMPLETED,2005-02,2005-04,2009-09-04,INTERVENTIONAL,PHASE2,16.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Alzheimer's Disease,SRA-333,DRUG,1,1,50 Years,85 Years,ALL,False,Wyeth is now a wholly owned subsidiary of Pfizer,INDUSTRY,0,3,United States,1.0,0,1,0,0,0,2.0,0,0,1,0,1,2.833213344056216,small,1,0,1,0,1,0,1,0,1,0,1,1,1,1,2,1,1,0,0,1,0,2005-02-01,2005-04-01,59.0,2005.0,0,0,0
NCT02284906,AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease,A Blinded Long-term Extension Study to Evaluate the Safety and Efficacy of Pioglitazone (AD-4833 Sustained Release 0.8 mg Daily) to Slow the Progression of Cognitive Decline in Subjects Who Have Completed the AD-4833/TOMM40_301 Study With Diagnosis of Mild Cognitive Impairment Due to Alzheimer Disease,TERMINATED,2015-02-12,2018-05-08,2019-07-02,INTERVENTIONAL,PHASE3,40.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Mild Cognitive Impairment Due to Alzheimer's Disease,Pioglitazone|Placebo,DRUG,1,1,65 Years,,ALL,False,Takeda,INDUSTRY,0,43,United Kingdom|Australia|Switzerland|United States,0.0,0,0,1,0,0,3.0,0,0,1,0,1,3.713572066704308,small,1,1,1,0,1,0,1,1,1,1,0,1,1,1,2,1,1,0,0,2,1,,,,,0,2,0
NCT02205606,Efficacy/Safety of HCP1306 Tablet Versus HGP0816 Tablet in Patients With Primary Hypercholesterolemia,"A Randomized, Double-Blind, Multicenter, Phase 3 Study to Evaluate Efficacy and Safety of HCP1306 Tablet in Patients With Primary Hypercholesterolemia",COMPLETED,2014-06,2015-04,2015-09-22,INTERVENTIONAL,PHASE3,412.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Primary Hypercholesterolemia,HGP0816 5mg|HGP0816 10mg|HGP0816 20mg|HCP1306 5/10mg|HCP1306 10/10mg|HCP1306 20/10mg,DRUG,1,5,19 Years,,ALL,False,Hanmi Pharmaceutical Company Limited,INDUSTRY,0,1,South Korea,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.023447592961033,large,0,1,1,0,0,0,0,0,0,0,1,1,1,1,6,1,1,0,0,6,1,2014-06-01,2015-04-01,304.0,2014.0,0,2,0
NCT03381833,A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-Dependent Beta Thalassemia,"A Multi-Center, Randomized, Open-Label, Parallel-Group Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-Dependent Beta Thalassemia",TERMINATED,2017-11-30,2020-01-14,2021-07-29,INTERVENTIONAL,PHASE2,84.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Beta-Thalassemia,LJPC-401|LJPC-401,DRUG,1,12,14 Years,,ALL,False,La Jolla Pharmaceutical Company,INDUSTRY,0,22,Italy|Turkey (Türkiye)|United States|Lebanon|Australia|United Kingdom|Greece|Thailand,0.0,0,1,0,0,0,2.0,0,0,0,0,1,4.442651256490317,medium,1,1,1,0,0,0,1,1,1,1,1,0,1,1,13,1,1,0,0,2,1,,,,,0,3,1
NCT03342404,A Study to Determine the Efficacy and Safety of Luspatercept in Adults With Non Transfusion Dependent Beta (β)-Thalassemia,"A Phase 2, Double-Blind, Randomized, Placebo-Controlled Multicenter Study to Determine the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Adults With Non-Transfusion Dependent Beta (β)-Thalassemia (The BEYOND™ Study)",COMPLETED,2018-02-05,2022-11-28,2023-12-20,INTERVENTIONAL,PHASE2,145.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Thalassemia,Luspatercept|Placebo|Best Supportive Care (BSC),DRUG|OTHER,1,29,18 Years,,ALL,False,Celgene,INDUSTRY,1,16,Italy|United States|Lebanon|United Kingdom|Greece|Thailand,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.983606621708336,medium,0,1,1,0,0,1,1,1,1,1,1,1,1,1,30,1,1,0,0,3,1,,,,,0,3,1
NCT02999633,Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia,"Phase 2, Safety and Efficacy Study of Isatuximab, an Anti-CD38 Monoclonal Antibody, Administered by Intravenous (IV) Infusion in Patients With Relapsed or Refractory T-acute Lymphoblastic Leukemia (T-ALL) or T-lymphoblastic Lymphoma (T-LBL)",TERMINATED,2017-03-08,2017-11-14,2022-03-21,INTERVENTIONAL,PHASE2,14.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,T-cell Type Acute Leukemia-Precursor|T-lymphoblastic Lymphoma/Leukaemia,Isatuximab SAR650984|dexamethasone|dexamethasone|acetaminophen|ranitidine|diphenhydramine,DRUG,1,4,16 Years,,ALL,False,Sanofi,INDUSTRY,0,17,Italy|Russia|Finland|Hungary|United States|Lithuania|France,0.0,0,1,0,0,0,2.0,1,0,0,0,2,2.70805020110221,small,1,1,1,0,1,0,1,1,1,1,0,0,1,0,5,1,1,0,0,6,1,,,,,0,3,1
NCT01725152,Ganaxolone Treatment in Children With Fragile X Syndrome,"A Controlled, Double-blind, Crossover Trial of Ganaxolone in Children With Fragile X Syndrome",COMPLETED,2012-11,2016-11-01,2023-04-10,INTERVENTIONAL,PHASE2,59.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Fragile x Syndrome,Ganaxolone|Placebo,DRUG,1,5,6 Years,17 Years,ALL,False,Marinus Pharmaceuticals,INDUSTRY,2,2,Belgium|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.0943445622221,medium,1,1,1,0,0,1,1,1,1,0,1,1,1,0,6,1,1,0,0,2,1,2012-11-01,,,2012.0,0,3,1
NCT01414738,Hippocampal-Avoiding Whole Brain Irradiation With Simultaneous Integrated Boost for Treatment of Brain Metastases,Phase II Trial of Hippocampal-Avoiding Whole Brain Irradiation With Simultaneous Integrated Boost for Treatment of Brain Metastases,COMPLETED,2011-10-18,2019-12-16,2021-01-26,INTERVENTIONAL,PHASE2,50.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Brain Neoplasms, Adult, Malignant",Radiotherapy,RADIATION,1,17,18 Years,99 Years,ALL,False,University of Texas Southwestern Medical Center,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.9318256327243257,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,18,1,0,0,0,1,0,,,,,0,1,0
NCT05345938,A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia,"A Phase I/II Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia",TERMINATED,2022-06-14,2022-11-19,2024-02-23,INTERVENTIONAL,PHASE1|PHASE2,1.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Relapsed or Refractory Acute Myeloid Leukemia (AML),Mitoxantrone Hydrochloride Liposome,DRUG,2,13,18 Years,,ALL,False,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",INDUSTRY,0,1,China,0.0,1,1,0,0,1,1.5,1,0,0,0,1,0.6931471805599453,small,1,1,1,0,0,0,0,0,0,0,0,0,1,0,15,1,1,0,0,1,0,,,,,0,2,0
NCT01759238,Chemoradiotherapy for Patients With Oligometastatic Colorectal Cancer,Capecitabine and Bevacizumab With Radiotherapy After 3-6 Months Chemotherapy for Patients With Oligometastatic Colorectal Cancer (OLGA Trial),TERMINATED,2013-05,2014-10,2022-07-01,INTERVENTIONAL,PHASE2,1.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Colorectal Cancer|Metastases,Capecitabine|Bevacizumab|Radiotherapy,DRUG|RADIATION,1,6,18 Years,,ALL,False,Universitätsklinikum Hamburg-Eppendorf,OTHER,0,1,Germany,0.0,0,1,0,0,0,2.0,1,0,0,0,2,0.6931471805599453,small,1,1,0,1,0,0,0,0,0,1,0,0,1,0,7,1,1,0,0,3,1,2013-05-01,2014-10-01,518.0,2013.0,0,3,1
NCT04629248,A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy,"A Phase III Randomized, Open-Label Active Comparator-Controlled Multicenter Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients With Primary Membranous Nephropathy",ACTIVE_NOT_RECRUITING,2021-06-25,2027-12-21,2026-01-07,INTERVENTIONAL,PHASE3,142.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Primary Membranous Nephropathy,Obinutuzumab|Tacrolimus|Methylprednisolone|Acetaminophen|Diphenhydramine,DRUG,1,14,18 Years,75 Years,ALL,False,Hoffmann-La Roche,INDUSTRY,0,50,China|Italy|Argentina|Russia|Turkey (Türkiye)|United States|Spain|Brazil|Poland|Israel|France,,0,0,1,0,0,3.0,0,0,0,0,1,4.962844630259907,medium,0,1,1,0,1,0,1,1,1,1,1,0,1,1,15,1,1,0,0,5,1,,,,,0,3,1
NCT02033226,"Clinical, Anti-Inflammatory And Anti-Infective Properties Of Amniotic Membranes Used For Guided Tissue Regeneration","Evaluation of Clinical, Anti-Inflammatory and Anti-Infective Properties of Amniotic Membranes Used For Guided Tissue Regeneration in Contained Defects",COMPLETED,2012-03,2013-09,2015-12-22,INTERVENTIONAL,PHASE3,54.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,DOUBLE,Chronic Periodontitis,Amniotic Membrane|Control group (Hydroxyapatite only),DEVICE,1,1,30 Years,55 Years,ALL,True,SVS Institute of Dental Sciences,OTHER,0,1,India,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.007333185232471,medium,1,1,0,1,0,0,0,0,0,0,1,1,1,0,2,1,0,0,1,2,1,2012-03-01,2013-09-01,549.0,2012.0,0,1,0
NCT05275426,"A Study of LY2880070 and Gemcitabine in People With Ewing Sarcoma,Ewing-Like Sarcoma, and Desmoplastic Small Round Cell Tumor","A Phase II Study of Oral CHK1 Inhibitor LY2880070 in Combination With Low-Dose Gemcitabine in Patients With Relapsed or Refractory Ewing Sarcoma, Ewing-like Sarcoma, and Desmoplastic Small Round Cell Tumor",COMPLETED,2022-03-02,2025-08-11,2025-08-15,INTERVENTIONAL,PHASE2,14.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Ewing Sarcoma|Ewing-Like Sarcoma,LY2880070|Gemcitabine,DRUG,1,0,,,ALL,False,Memorial Sloan Kettering Cancer Center,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,2,2.70805020110221,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,2,1,,,,,0,2,0
NCT00469326,Atorvastatin Pre-Treatment Influences the Risk of Percutaneous Coronary Intervention Study,Atorvastatin Pre-Treatment Influences the Risk of Percutaneous Coronary Intervention Study,COMPLETED,2005-04,2008-12,2009-01-27,INTERVENTIONAL,PHASE3,200.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Coronary Artery Disease,Atorvastatin,DRUG,1,1,,,ALL,False,"University Hospital, Motol",OTHER,0,1,Czechia,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.303304908059076,medium,0,1,0,1,0,0,0,0,0,0,1,0,0,1,2,1,1,0,0,1,0,2005-04-01,2008-12-01,1340.0,2005.0,0,0,0
NCT00417326,Controlled Study of ONO-5046Na in Patients With Acute Respiratory Failure Associated With Community-Acquired Pneumonia,ONO-5046Na Phase II Study - A Pilot Study for Patients With Acute Respiratory Failure,COMPLETED,2006-12,,2012-06-13,INTERVENTIONAL,PHASE2,174.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Community-acquired Pneumonia,ONO-5046Na|ONO-5046Na,DRUG,1,2,20 Years,79 Years,ALL,False,Ono Pharmaceutical Co. Ltd,INDUSTRY,0,9,Japan,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.1647859739235145,medium,0,1,1,0,0,0,1,0,0,0,1,1,1,1,3,1,1,0,0,2,1,2006-12-01,,,2006.0,0,1,0
NCT00003126,Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer,A Randomized Controlled Phase III Adjuvant Trial of High-Dose Bolus IL-2 in Patients With High-Risk Renal Cell Carcinoma,COMPLETED,1997-06,2002-08,2017-01-04,INTERVENTIONAL,PHASE3,69.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Kidney Cancer,Interleukin-2,DRUG,1,1,16 Years,,ALL,False,Loyola University,OTHER,1,15,United States,1.0,0,0,1,0,0,3.0,1,0,0,0,1,4.248495242049359,medium,1,1,0,1,0,1,1,0,1,0,1,0,1,1,2,1,1,0,0,1,0,1997-06-01,2002-08-01,1887.0,1997.0,0,0,0
NCT00276978,Aripiprazole Augmentation Therapy in Treatment-resistant Depression,Aripiprazole Augmentation Therapy in Treatment-resistant Depression,WITHDRAWN,2005-06,2009-11,2022-08-10,INTERVENTIONAL,PHASE3,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Therapy-resistant Depression,Aripiprazole,DRUG,1,0,18 Years,70 Years,ALL,False,University Hospital Freiburg,OTHER,0,1,Germany,0.0,0,0,1,0,0,3.0,0,0,1,0,1,0.0,,1,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,2005-06-01,2009-11-01,1614.0,2005.0,0,0,0
NCT00574678,Analyzing the Composition of Tears to Identify Cancer,"ACT: Analyzing the Composition of Tears to Identify Cancer (Breast, Ovarian, Colon)",COMPLETED,2006-12,2016-02,2021-08-05,INTERVENTIONAL,PHASE1|PHASE2,150.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,DIAGNOSTIC,NONE,Breast Cancer|Ovarian Cancer|Colon Cancer|Benign Disease,Tear collection,OTHER,1,0,18 Years,,ALL,False,University of Arkansas,OTHER,1,1,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,4,5.017279836814924,medium,0,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,2006-12-01,2016-02-01,3349.0,2006.0,0,2,0
NCT00293878,Study on the Safety and Effects on Lipids of FM-VP4 in Subjects With Primary Hypercholesterolemia,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Safety and Effects on Lipids of 12 Weeks of 2 Doses of FM-VP4 in Subjects With Primary Hypercholesterolemia",COMPLETED,2005-11,,2007-02-26,INTERVENTIONAL,PHASE2,150.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Hypercholesterolemia,Disodium Ascorbyl Phytostanol Phosphate (FM-VP4),DRUG,1,3,18 Years,75 Years,ALL,,Forbes Medi-Tech,INDUSTRY,0,14,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.017279836814924,medium,0,0,1,0,0,0,1,0,1,0,1,1,1,1,4,1,1,0,0,1,0,2005-11-01,,,2005.0,0,0,0
NCT00313378,Effects of Perioperative Systemic Ketamine on Development of Long-term Neuropathic Pain After Thoracotomy,Effects of Perioperative Systemic Ketamine on Development of Long-term Neuropathic Pain After Thoracotomy.,COMPLETED,2004-04,2008-05,2013-04-04,INTERVENTIONAL,PHASE3,78.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Partial Pneumonectomy Under Lateral or Posterolateral Thoracotomy.,Hypothetica,DRUG,1,2,20 Years,75 Years,ALL,False,"University Hospital, Clermont-Ferrand",OTHER,0,1,France,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.3694478524670215,medium,1,1,0,1,0,0,0,0,0,1,1,1,1,1,3,1,1,0,0,1,0,2004-04-01,2008-05-01,1491.0,2004.0,0,0,0
NCT01621243,M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer,"A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer",TERMINATED,2012-05,2016-10-24,2018-08-29,INTERVENTIONAL,PHASE1|PHASE2,128.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Metastatic Pancreatic Cancer,nab-paclitaxel|gemcitabine|placebo|Necuparanib,DRUG,2,2,18 Years,,ALL,False,"Momenta Pharmaceuticals, Inc.",INDUSTRY,0,37,Canada|United States,0.0,1,1,0,0,1,1.5,1,0,0,0,1,4.859812404361672,medium,0,1,1,0,0,0,1,1,1,0,1,1,1,1,4,1,1,0,0,4,1,2012-05-01,,,2012.0,0,3,1
NCT03410043,"Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study",Randomized Phase II Trial of Osimertinib With or Without Local Consolidation Therapy (LCT) for Patients With EGFR-Mutant Metastatic NSCLC (NORTHSTAR),ACTIVE_NOT_RECRUITING,2018-01-17,2026-04-01,2025-12-26,INTERVENTIONAL,PHASE2,173.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Lung Non-Small Cell Carcinoma|Recurrent Lung Non-Small Cell Carcinoma|Stage IIIB Lung Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8,Osimertinib|Radiation Therapy|Therapeutic Conventional Surgery,DRUG|RADIATION|PROCEDURE,1,5,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,2,4,United States,,0,1,0,0,0,2.0,1,0,0,0,6,5.159055299214529,medium,0,1,0,1,0,1,1,0,1,0,1,0,1,1,6,1,1,0,0,3,1,,,,,0,3,1
NCT02545543,A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age,"A Phase 3, Randomized, Multicenter, Observer-Blinded, Noninferiority Study to Evaluate the Immunogenicity and Safety of a Seqirus Quadrivalent Inactivated Influenza Virus Vaccine (Seqirus QIV) With a US-Licensed 2015-2016 Quadrivalent Inactivated Comparator Influenza Vaccine (Comparator QIV) in a Pediatric Population 5 Through 17 Years of Age",COMPLETED,2015-09,2016-06,2018-05-23,INTERVENTIONAL,PHASE3,2278.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,"Influenza, Human",Seqirus QIV|Comparator QIV,BIOLOGICAL,2,9,5 Years,17 Years,ALL,True,Seqirus,INDUSTRY,0,32,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,7.731492029245684,xlarge,0,1,1,0,0,0,1,0,1,0,1,1,0,1,11,1,0,1,0,2,1,2015-09-01,2016-06-01,274.0,2015.0,1,2,0
NCT03798743,Phase II Study on Sintilimab Combined With Docetaxel for Chemotherapy Failure Advanced NSCLC: the SUCCESS Study,"Single Center, Single Arm Phase II Study on Efficacy Evaluation and Bio-marker Analysis of Sintilimab Combined With Docetaxel for Double Platinum-based Chemotherapy Failure Advanced Non-small Cell Lung Cancer",COMPLETED,2019-01-01,2022-03-01,2022-03-02,INTERVENTIONAL,PHASE2,30.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Non-small Cell Lung Cancer,Sintilimab Combined With Docetaxel,DRUG,1,5,18 Years,75 Years,ALL,False,Hunan Province Tumor Hospital,OTHER,0,1,China,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.4339872044851463,small,1,1,0,1,0,0,0,0,0,0,0,0,1,0,6,1,1,0,0,1,0,,,,,0,1,0
NCT05846243,"Study on Immunogenicity, Reactogenicity and Safety of the VACΔ6 Vaccine in Volunteers Aged 18-60 Years","Double-blind, Comparative, Randomized, Placebo-controlled Study on Immunogenicity, Reactogenicity and Safety of Live Cell-based Vaccine Against Smallpox and Other Orthopoxvirus Infections (VACΔ6 Vaccine) in Volunteers Aged 18-60 Years",COMPLETED,2021-10-01,2022-04-01,2023-05-06,INTERVENTIONAL,PHASE2|PHASE3,334.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Smallpox|Monkeypox|Cowpox|Vaccinia Virus Infection,"VAC∆6 vaccine (10⁷ PFU)|VAC∆6 vaccine (10⁶ PFU)|Live Smallpox Vaccine|Placebo (Sodium chloride bufus, 0.9%)",BIOLOGICAL|OTHER,1,7,18 Years,60 Years,ALL,True,"Federal Budgetary Research Institution State Research Center of Virology and Biotechnology ""Vector""",OTHER_GOV,0,2,Russia,1.0,0,1,1,0,1,2.5,0,0,0,0,4,5.814130531825066,large,0,1,0,1,0,0,1,0,0,0,1,1,0,1,8,1,0,1,0,4,1,,,,,0,4,1
NCT00158535,Liver Transplantation in Patients With Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Coinfection,Liver Transplantation in Patients With Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Coinfection ANRS HC08 Thevic,TERMINATED,2002-06,,2005-09-12,INTERVENTIONAL,PHASE2,15.0,,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,HIV Infections|Hepatitis C,liver transplantation,PROCEDURE,1,6,18 Years,69 Years,ALL,False,French National Agency for Research on AIDS and Viral Hepatitis,OTHER_GOV,0,1,France,0.0,0,1,0,0,0,2.0,0,0,0,0,2,2.772588722239781,small,1,0,0,1,0,0,0,0,0,1,0,0,1,0,7,1,0,0,0,1,0,2002-06-01,,,2002.0,0,2,0
NCT02919735,"Efficacy, Safety and Tolerability of CG428 Cutaneous Solution on Chemotherapy Induced Alopecia; Controlled Study (ELAN)","A Randomized, Double Blind, Single Center, Controlled Study to Compare the Efficacy, Safety and Tolerability of CG 428 Cutaneous Solution With Placebo on Alopecia in Cancer Female Patients Under Chemotherapy",COMPLETED,2016-10,2019-03-01,2019-08-13,INTERVENTIONAL,PHASE2,40.0,ACTUAL,RANDOMIZED,PARALLEL,SUPPORTIVE_CARE,DOUBLE,Alopecia,CG 428 cutaneous solution|Placebo cutaneous solution,DRUG,1,6,18 Years,,FEMALE,False,Legacy Healthcare SA,INDUSTRY,0,1,Switzerland,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.713572066704308,small,1,1,1,0,0,0,0,0,0,0,1,1,0,1,7,1,1,0,0,2,1,2016-10-01,,,2016.0,1,2,0
NCT04347135,Evaluating Endometriosis With 16α-(18)F-fluoro-17β-estradiol ([F-18] FES) PET/MRI,Pilot Study Evaluating Endometriosis With 16α-(18)F-fluoro-17β-estradiol ([F-18] FES) PET/MRI,WITHDRAWN,2022-10-07,2024-04-30,2024-05-10,INTERVENTIONAL,PHASE1|PHASE2,0.0,ACTUAL,,SINGLE_GROUP,DIAGNOSTIC,NONE,Endometriosis,F-18 FES,DRUG,1,0,18 Years,50 Years,FEMALE,False,Annie (Annie) T. Packard,OTHER,0,1,United States,0.0,1,1,0,0,1,1.5,0,0,0,0,1,0.0,,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,,,,,0,1,0
NCT00470535,Erlotinib in Treating Patients With Stage III or Stage IV Pancreatic Cancer,Phase II Study of Erlotinib (Tarceva®) in Patients With Advanced Pancreatic Adenocarcinoma,TERMINATED,2007-01,2010-09,2017-02-23,INTERVENTIONAL,PHASE2,18.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Pancreatic Cancer,erlotinib hydrochloride|immunohistochemistry staining method|laboratory biomarker analysis,DRUG|OTHER,1,5,18 Years,120 Years,ALL,False,Roswell Park Cancer Institute,OTHER,0,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,2.9444389791664403,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,6,1,1,0,0,3,1,2007-01-01,2010-09-01,1339.0,2007.0,0,2,0
NCT04629508,"To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)","A 2-Part, Phase 2, Open-Label Study of the Safety, Tolerability, and Efficacy of Itacitinib Immediate Release in Participants With Primary Myelofibrosis or Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis) Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy",COMPLETED,2021-07-12,2023-08-24,2025-09-02,INTERVENTIONAL,PHASE2,4.0,ACTUAL,NON_RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,Myelofibrosis|Polycythemia Vera|Thrombocythemia,itacitinib,DRUG,3,5,18 Years,,ALL,False,Incyte Corporation,INDUSTRY,0,21,Italy|Belgium|United States|Germany|Austria|Spain|Poland,1.0,0,1,0,0,0,2.0,0,0,0,0,3,1.6094379124341003,small,1,1,1,0,0,0,1,1,1,1,0,0,1,0,8,1,1,0,0,1,0,,,,,0,3,1
NCT02435108,A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line Chemotherapy,A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line Chemotherapy,COMPLETED,2014-05-15,2016-07-15,2017-02-17,INTERVENTIONAL,PHASE2,2.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,c-MET Positive Gastric Cancer,crizotinib,DRUG,1,3,20 Years,,ALL,False,Samsung Medical Center,OTHER,0,1,South Korea,1.0,0,1,0,0,0,2.0,1,0,0,0,1,1.0986122886681098,small,1,1,0,1,0,0,0,0,0,0,0,0,1,0,4,1,1,0,0,1,0,,,,,0,0,0
NCT02227108,Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma,"A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Origin",TERMINATED,2014-08,2015-11,2017-04-06,INTERVENTIONAL,PHASE2,37.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,B-Cell Pediatric ALL,Moxetumomab Pasudotox,DRUG,1,23,6 Months,18 Years,ALL,False,MedImmune LLC,INDUSTRY,0,21,Italy|Netherlands|United States|Spain|United Kingdom|Australia|France|Canada,0.0,0,1,0,0,0,2.0,0,0,0,0,1,3.6375861597263857,small,1,1,1,0,0,0,1,1,1,1,0,0,1,0,24,1,1,0,0,1,0,2014-08-01,2015-11-01,457.0,2014.0,0,2,0
NCT05287425,The Effect of Antibiotic Eye Drops on the Nasal Microbiome in Healthy Subjects,"The Effect of Antibiotic Eye Drops on the Nasal Microbiome in Healthy Subjects, a Phase II Study",COMPLETED,2019-08-12,2023-08-28,2025-05-16,INTERVENTIONAL,PHASE2,20.0,ACTUAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,Nasal and Pharyngeal Microbiome,Gentamicin Ophthalmic|Ciprofloxacin Ophthalmic|Povidone Ophthalmic|Povidone and Benzalkonium Chloride Ophthalmic,DRUG,1,4,18 Years,45 Years,ALL,True,Medical University of Vienna,OTHER,0,1,Austria,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.044522437723423,small,1,1,0,1,0,0,0,0,0,0,1,1,0,1,5,1,1,0,0,4,1,,,,,0,1,0
NCT01725776,Inhaled Milrinone in Cardiac Surgery,Pharmacokinetic and Pharmacodynamic of Inhaled Milrinone in Cardiac Surgical Patients,COMPLETED,2006-12,2012-06,2012-11-14,INTERVENTIONAL,PHASE2,40.0,ACTUAL,,SINGLE_GROUP,PREVENTION,NONE,Pulmonary Hypertension,Inhaled milrinone 5 mg,DRUG,1,3,18 Years,90 Years,ALL,False,Montreal Heart Institute,OTHER,3,1,Canada,1.0,0,1,0,0,0,2.0,0,0,0,1,1,3.713572066704308,small,1,1,0,1,0,1,0,0,0,0,0,0,0,0,4,1,1,0,0,1,0,2006-12-01,2012-06-01,2009.0,2006.0,0,0,0
NCT01302340,Delta-THC in Behavioral Disturbances in Dementia,"Two Phase, Repeated Crossover Study With Dose Escalation on Delta(9)-Tetrahydrocannabinol (Delta-THC) in Behavioral Disturbances in Dementia",COMPLETED,2011-09,2013-12,2014-01-22,INTERVENTIONAL,PHASE2,22.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Dementia,Delta-THC|placebo|Delta-THC,DRUG,1,8,18 Years,,ALL,False,Radboud University Medical Center,OTHER,1,2,Netherlands,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.1354942159291497,small,1,1,0,1,0,1,1,0,0,0,1,1,1,0,9,1,1,0,0,3,1,2011-09-01,2013-12-01,822.0,2011.0,0,2,0
NCT00306540,Use of Quetiapine as an Add on Therapy in the Treatment of Post Traumatic Stress Disorder,"A Multicentre, Parallel Group, Randomised, Double Blind, Placebo Controlled Study of the Use of Quetiapine as an Add on Therapy in the Treatment of Post Traumatic Stress Disorder",COMPLETED,2004-12,2008-08,2010-12-09,INTERVENTIONAL,PHASE3,90.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Post-Traumatic Stress Disorder,Quetiapine Fumarate|quetiapine fumarate placebo,DRUG,1,4,18 Years,65 Years,ALL,False,AstraZeneca,INDUSTRY,0,3,Australia,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.51085950651685,medium,1,0,1,0,1,0,1,0,0,0,1,1,1,1,5,1,1,0,0,2,1,2004-12-01,2008-08-01,1339.0,2004.0,0,1,0
NCT04778189,Effect of Intravenous Dexamethasone on Duration of Hyperbaric Bupivacaine Spinal Anesthesia in Lower Abdominal Surgery,"Effect of Intravenous Dexamethasone on the Duration of Hyperbaric Bupivacaine Spinal Anesthesia in Lower Abdominal Surgery, Randomized Controlled Trial",COMPLETED,2021-12-01,2023-05-01,2023-05-25,INTERVENTIONAL,PHASE2,200.0,ACTUAL,RANDOMIZED,PARALLEL,OTHER,QUADRUPLE,Spinal Anesthesia,Placebo|i.v dexmethasone,DRUG,1,0,18 Years,60 Years,ALL,False,Assiut University,OTHER,0,1,Egypt,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.303304908059076,medium,0,1,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,0,0,2,1,,,,,0,1,0
NCT05753189,Phase 3 Safety Study for the Treatment of Presbyopia Subjects,"Safety Study: A Multi-Center, Double-Masked Phase 3 Safety Study Evaluation of the Long-Term Safety of LNZ101 in Presbyopic Subjects",COMPLETED,2023-02-21,2024-02-09,2024-12-18,INTERVENTIONAL,PHASE3,362.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Presbyopia|Near Vision|Miosis|Eye Diseases,Aceclidine+Brimonidine combination ophthalmic solution|Placebo|Aceclidine Ophthalmic Solution,DRUG,1,0,45 Years,75 Years,ALL,True,"LENZ Therapeutics, Inc",OTHER,1,36,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,4,5.8944028342648505,large,0,1,0,1,0,1,1,0,1,0,1,1,1,1,1,0,1,0,0,3,1,,,,,0,2,0
NCT02466568,Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung,A Randomized Phase I/II Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung,WITHDRAWN,2018-07,2020-07,2019-09-09,INTERVENTIONAL,PHASE1|PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Lung Cancer|Adenocarcinoma of the Lung,Nivolumab|GM.CD40L Vaccine,DRUG|BIOLOGICAL,2,2,18 Years,,ALL,False,H. Lee Moffitt Cancer Center and Research Institute,OTHER,0,0,,0.0,1,1,0,0,1,1.5,1,0,0,0,2,0.0,,1,1,0,1,0,0,0,0,0,0,1,0,1,1,4,1,1,1,0,2,1,2018-07-01,2020-07-01,731.0,2018.0,1,3,1
NCT05363891,Natrunix or Placebo in Combination With Methotrexate in Rheumatoid Arthritis,"Phase II, Double-blind, Placebo-Controlled, Randomized Trial Examining Natrunix in Combination With Methotrexate (+Folate) for the Treatment of Rheumatoid Arthritis",COMPLETED,2023-08-08,2024-10-31,2025-01-16,INTERVENTIONAL,PHASE2,243.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Rheumatoid Arthritis,Natrunix|Placebo,DRUG,1,2,18 Years,,ALL,False,"XBiotech, Inc.",INDUSTRY,0,26,United States,1.0,0,1,0,0,0,2.0,0,1,0,0,1,5.497168225293202,large,0,1,1,0,0,0,1,0,1,0,1,1,1,1,3,1,1,0,0,2,1,,,,,0,1,0
NCT01763918,Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2,"A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 on LDL-C in Subjects With Heterozygous Familial Hypercholesterolemia",COMPLETED,2013-02-07,2013-12-19,2019-06-17,INTERVENTIONAL,PHASE3,331.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Hyperlipidemia,Evolocumab|Placebo,DRUG|BIOLOGICAL,2,20,18 Years,80 Years,ALL,False,Amgen,INDUSTRY,0,39,Netherlands|Sweden|United States|Germany|Spain|Australia|United Kingdom|Hong Kong|Norway|Switzerland|New Zealand|South Africa|France|Canada,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.805134968916488,large,0,1,1,0,1,0,1,1,1,1,1,1,1,1,22,1,1,1,0,2,1,,,,,0,3,1
NCT00415818,Immunotherapy With TG4010 in Patients With Advanced Non-Small Cell Lung Cancer,A Phase IIb Multicentric Controlled Study Evaluating the Therapeutic Vaccine TG4010(MVA-MUC1-IL2) as an Adjunct to Standard Chemotherapy in Advanced Non Small Cell Lung Cancer,COMPLETED,2005-12,2010-03,2014-07-16,INTERVENTIONAL,PHASE2|PHASE3,148.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Carcinoma, Non-Small-Cell Lung",MVA-MUC1-IL2|1st line Chemotherapy,DRUG|BIOLOGICAL,1,4,18 Years,,ALL,False,Transgene,INDUSTRY,0,23,Germany|France|Hungary|Poland,1.0,0,1,1,0,1,2.5,1,0,0,0,1,5.003946305945459,medium,0,1,1,0,0,0,1,1,0,1,1,0,1,1,5,1,1,1,0,2,1,2005-12-01,2010-03-01,1551.0,2005.0,0,3,1
NCT00082290,Massage Therapy in Treating Patients With Cancer Pain,Massage for the Treatment of Pain in Cancer: A Randomized Phase II Study,COMPLETED,2003-05,,2015-12-18,INTERVENTIONAL,PHASE2,92.0,ACTUAL,RANDOMIZED,PARALLEL,SUPPORTIVE_CARE,NONE,"Pain|Unspecified Adult Solid Tumor, Protocol Specific",massage therapy|visit with a volunteer|period of quiet time|questionaire about pain,BEHAVIORAL|OTHER,1,0,18 Years,120 Years,ALL,False,Memorial Sloan Kettering Cancer Center,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,2,4.532599493153256,medium,1,1,0,1,0,1,0,0,1,0,1,0,0,1,1,0,0,0,0,4,1,2003-05-01,,,2003.0,0,2,0
NCT04231318,Study of Cingal® and Triamcinolone Hexacetonide for the Relief of Knee Osteoarthritis Pain,"A Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of a Single Injection Cross-Linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide (Cingal®) to Provide Symptomatic Relief of Osteoarthritis of the Knee",COMPLETED,2020-09-11,2022-05-16,2023-08-09,INTERVENTIONAL,PHASE3,231.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Osteoarthritis, Knee",Cingal|Triamcinolone Hexacetonide (TH)|Placebo,DRUG,6,9,40 Years,75 Years,ALL,False,"Anika Therapeutics, Inc.",INDUSTRY,0,26,United States,1.0,0,0,1,0,0,3.0,0,1,0,0,1,5.44673737166631,large,0,1,1,0,0,0,1,0,1,0,1,1,1,1,15,1,1,0,0,3,1,,,,,0,2,0
NCT00320190,Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib,"An Open-label, Randomized Study of Dasatinib vs High-dose (800-mg) Imatinib in the Treatment of Subjects With Chronic Phase Chronic Myeloid Leukemia Who Have Had a Suboptimal Response After at Least 3 Months of Therapy With 400 mg Imatinib",TERMINATED,2006-08,2010-01,2013-10-30,INTERVENTIONAL,PHASE2,52.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Leukemia, Myeloid, Chronic",Imatinib|Dasatinib,DRUG,1,6,18 Years,,ALL,False,Bristol-Myers Squibb,INDUSTRY,0,27,Italy|Belgium|Finland|Russia|Sweden|Spain|Germany|United Kingdom|Norway|Portugal|France,0.0,0,1,0,0,0,2.0,1,0,0,0,1,3.970291913552122,medium,1,1,1,0,1,0,1,1,0,1,1,0,1,1,7,1,1,0,0,2,1,2006-08-01,2010-01-01,1249.0,2006.0,0,3,1
NCT00763490,Trial Of Double Umbilical Cord Blood Transplantation,Trial Of Double Umbilical Cord Blood Transplantation,COMPLETED,2008-12,2015-10,2016-12-23,INTERVENTIONAL,PHASE2,20.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Hematological Malignancies,"Full intensity, double umbilical cord, stem cell transplant|Flu/Bu4 conditioning regimen|Total Lymphoid Irradiation (TLI)|Graft versus Host Disease prevention (GVHD prophylaxis)|Mycophenolate Mofetil",DRUG|RADIATION|PROCEDURE,1,3,,65 Years,ALL,False,University of Michigan Rogel Cancer Center,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.044522437723423,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,4,1,1,0,0,5,1,2008-12-01,2015-10-01,2495.0,2008.0,0,1,0
NCT02122874,Percutaneous Electric Neurostimulation of Dermatome T7 Improves Glycemic Profile in Obese and Typo 2 Diabetic Patients,,COMPLETED,2013-01,2014-04,2014-04-25,INTERVENTIONAL,PHASE3,60.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Diabetes Mellitus Type 2 in Obese|Type 2 Diabetes Mellitus With Features of Insulin Resistance,Percutaneous Neurostimulation (PENS) of dermatome T7|1200 Kcal diet,DEVICE|OTHER,1,1,18 Years,,ALL,False,Hospital General Universitario Elche,OTHER,0,1,Spain,1.0,0,0,1,0,0,3.0,0,0,0,0,2,4.110873864173311,medium,1,1,0,1,0,0,0,0,0,1,1,0,1,1,2,1,0,0,1,2,1,2013-01-01,2014-04-01,455.0,2013.0,0,2,0
NCT00544674,PR104 in Treating Patients With Previously Untreated or Relapsed Small Cell Lung Cancer,"A Phase II, Multi-Center, Open-Label, Trial of PR104 in Treatment Naive and Sensitive-relapse Small Cell Lung Cancer",TERMINATED,2007-08,2009-01,2012-12-10,INTERVENTIONAL,PHASE2,5.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Lung Cancer,PR104|F-18-fluoromisonidazole,DRUG|OTHER,2,4,18 Years,,ALL,False,"Proacta, Incorporated",INDUSTRY,0,18,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,1.791759469228055,small,1,1,1,0,0,0,1,0,1,0,0,0,1,0,6,1,1,0,0,2,1,2007-08-01,2009-01-01,519.0,2007.0,0,2,0
NCT01338818,Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder,"A 6-month, Open-label Extension to a 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in the Treatment of Adult Patients With Childhood-onset ADHD",COMPLETED,2011-04,2013-02,2014-11-24,INTERVENTIONAL,PHASE3,299.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Attention Deficit/Hyperactivity Disorder,Ritalin LA (methylphenidate hydrochloride extended release),DRUG,1,2,18 Years,60 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,48,Belgium|Sweden|United States|Germany|Denmark|Colombia,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.703782474656201,large,0,1,1,0,1,0,1,1,1,1,0,0,1,0,3,1,1,0,0,1,0,2011-04-01,2013-02-01,672.0,2011.0,0,1,0
NCT00969618,A Long Term Follow-Up Study for Asian Adult Patients With Attention Deficit Hyperactivity Disorder,"Long-Term, Open-Label Safety and Efficacy Study of Atomoxetine Hydrochloride in Adult Patients With Attention-Deficit/Hyperactivity Disorder (ADHD)",COMPLETED,2009-11,2012-01,2012-12-12,INTERVENTIONAL,PHASE3,211.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Attention Deficit Hyperactivity Disorder,Atomoxetine,DRUG,1,7,18 Years,,ALL,False,Eli Lilly and Company,INDUSTRY,0,12,Japan,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.356586274672012,large,0,1,1,0,1,0,1,0,0,0,0,0,1,0,8,1,1,0,0,1,0,2009-11-01,2012-01-01,791.0,2009.0,0,1,0
NCT02027818,Study of the ICG Distribution in the Margins of Breast Cancer After Tumorectomy,Study of the (Intravenously Injected) Indocyanine Green Distribution in the Margins of Breast Cancer After Tumorectomy,COMPLETED,2014-01,2014-10,2023-12-15,INTERVENTIONAL,PHASE2,20.0,ESTIMATED,,SINGLE_GROUP,DIAGNOSTIC,NONE,Breast Cancer,Indocyanine Green,DRUG,1,1,18 Years,,FEMALE,False,Jules Bordet Institute,OTHER,0,1,Belgium,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.044522437723423,small,1,0,0,1,0,0,0,0,0,0,0,0,0,0,2,1,1,0,0,1,0,2014-01-01,2014-10-01,273.0,2014.0,0,0,0
NCT03431597,Effectiveness of a Micronutrient Supplement to Lower Plasma Homocysteine MDEG2 Pilot Supplementation Trial,Effectiveness of a Micronutrient Supplement to Lower Plasma Homocysteine in Non-pregnant Women of Reproductive Age,COMPLETED,2018-04-26,2018-11-26,2019-01-22,INTERVENTIONAL,PHASE2,298.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Micronutrient Deficiencies|Hyperhomocysteinemia,"novel micronutrient|existing micronutrient supplement, UNIMMAP",DIETARY_SUPPLEMENT,1,3,18 Years,45 Years,FEMALE,True,London School of Hygiene and Tropical Medicine,OTHER,0,1,The Gambia,1.0,0,1,0,0,0,2.0,0,0,0,0,2,5.700443573390687,large,0,1,0,1,0,0,0,0,0,0,1,0,1,1,4,1,0,0,0,2,1,,,,,0,2,0
NCT00420810,Adult Polysomnography Primary Insomnia Cross Over Study (0928-049)(TERMINATED),"A Double-Blind, Placebo Controlled, Randomized, Cross-Over Polysomnographic Study of MK0928 15 mg in Adult Patients With Primary Insomnia",TERMINATED,2006-09,,2015-01-14,INTERVENTIONAL,PHASE3,138.0,,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Primary Insomnia,MK0928 / Duration of Treatment : 8 Weeks,DRUG,1,1,18 Years,64 Years,ALL,False,H. Lundbeck A/S,INDUSTRY,0,0,,0.0,0,0,1,0,0,3.0,0,0,0,0,1,4.9344739331306915,medium,0,0,1,0,0,0,0,0,0,0,1,1,1,0,2,1,1,0,0,1,0,2006-09-01,,,2006.0,0,0,0
NCT02495493,"S-1, Cisplatin-based Chemoradiotherapy, Induction Chemotherapy, Locally Advanced Gastric Adenocarcinoma",S-1 Plus Cisplatin-based Chemoradiotherapy After Induction Chemotherapy for Locally Advanced Gastric Adenocarcinoma : Phase II Trial,COMPLETED,2013-07,2019-07,2020-01-14,INTERVENTIONAL,PHASE2,42.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Gastric Adenocarcinoma,Induction DCS chemotherapy,DRUG,1,1,20 Years,,ALL,False,Yonsei University,OTHER,0,1,South Korea,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.7612001156935624,small,1,1,0,1,0,0,0,0,0,0,0,0,1,0,2,1,1,0,0,1,0,2013-07-01,2019-07-01,2191.0,2013.0,0,0,0
NCT04978493,A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease,"A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of BI 706321 Orally Administered for 12 Weeks in Patients With Crohn's Disease (CD) Receiving Ustekinumab Induction Treatment",TERMINATED,2021-12-02,2024-08-08,2025-09-04,INTERVENTIONAL,PHASE2,49.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Crohn Disease,BI 706321|Ustekinumab|Placebo,DRUG,1,11,18 Years,75 Years,ALL,False,Boehringer Ingelheim,INDUSTRY,0,49,Italy|Belgium|Netherlands|Hungary|United States|Germany|Spain|United Kingdom|Poland|Czechia|Denmark,0.0,0,1,0,0,0,2.0,0,1,0,0,1,3.912023005428146,small,1,1,1,0,0,0,1,1,1,1,1,1,1,1,12,1,1,0,0,3,1,,,,,0,3,1
NCT04417621,Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma,"A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma",ACTIVE_NOT_RECRUITING,2020-10-30,2026-03-27,2025-10-21,INTERVENTIONAL,PHASE2,134.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Melanoma,LXH254|LTT462|Trametinib|Ribociclib,DRUG,1,13,12 Years,120 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,36,Italy|Belgium|Argentina|Netherlands|United States|Germany|United Kingdom|Australia|Norway|Switzerland|Israel|France,,0,1,0,0,0,2.0,1,0,0,0,1,4.90527477843843,medium,0,1,1,0,1,0,1,1,1,1,1,0,1,1,14,1,1,0,0,4,1,,,,,0,3,1
NCT01566214,Vet-Harts Pilot Intervention for Veterans With Coronary Heart Disease,Representational Telehealth Nursing Intervention for Veterans With CHD,COMPLETED,2012-04-30,2012-10-31,2018-12-24,INTERVENTIONAL,PHASE2,12.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Heart Disease,Motivational Interview,BEHAVIORAL,13,0,18 Years,,ALL,False,VA Office of Research and Development,FED,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,1,1,2.5649493574615367,small,1,1,0,0,0,1,0,0,1,0,1,1,1,1,13,0,0,0,0,1,0,,,,,0,1,0
NCT01314014,Imexon for Relapsed Follicular and Aggressive Lymphomas,A Phase II Study of Amplimexon® (Imexon for Injection) for the Treatment of Previously Treated Follicular and Aggressive Lymphoma in Adults,COMPLETED,2011-05,2014-08,2016-01-06,INTERVENTIONAL,PHASE2,22.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Follicular Lymphoma|Small Lymphocytic Lymphoma|Marginal Zone Lymphoma|Lymphoplasmacytic Lymphoma|Diffuse Large B Cell Lymphoma|Mantle Cell Lymphoma|Burkitt's Lymphoma,Imexon,DRUG,1,1,18 Years,,ALL,False,University of Rochester,OTHER,1,2,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,7,3.1354942159291497,small,1,1,0,1,1,1,1,0,1,0,0,0,1,0,2,1,1,0,0,1,0,2011-05-01,2014-08-01,1188.0,2011.0,0,1,0
NCT03338114,Study to Evaluate the Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Upper or Lower Extremity Muscles Most Affected in Subjects With ALS,An Open Label Study to Evaluate the Safety and Efficacy of FLX-787-ODT for Treatment of Fasciculations in the Tongue and Upper or Lower Extremity Muscles Most Affected in Subjects With Amyotrophic Lateral Sclerosis (ALS),WITHDRAWN,2017-11,2018-08,2018-01-23,INTERVENTIONAL,PHASE1|PHASE2,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Amyotrophic Lateral Sclerosis|Fasciculation,FLX-787-ODT (orally disintigrating tablet),DRUG,7,2,18 Years,,ALL,False,"Flex Pharma, Inc.",INDUSTRY,0,1,United States,0.0,1,1,0,0,1,1.5,0,0,0,0,2,0.0,,1,1,1,0,0,0,0,0,1,0,0,0,1,0,9,1,1,0,0,1,0,2017-11-01,2018-08-01,273.0,2017.0,1,3,1
NCT00080314,Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depression Episode,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole in the Treatment of Patients With Bipolar I Disorder With a Major Depressive Episode",COMPLETED,2004-01,2006-10,2013-11-11,INTERVENTIONAL,PHASE3,400.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Bipolar Disorder,Aripiprazole|Placebo,DRUG,1,1,18 Years,65 Years,ALL,False,"Otsuka Pharmaceutical Development & Commercialization, Inc.",INDUSTRY,1,28,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.993961427306569,large,0,0,1,0,0,1,1,0,1,0,1,1,1,1,2,1,1,0,0,2,1,2004-01-01,2006-10-01,1004.0,2004.0,0,1,0
NCT02565316,Efficacy of Nepeta Menthoides Extract on Anxiety of Patients With Depression: a Double-blind Randomized Controlled Clinical Trial,Efficacy of Nepeta Menthoides Boiss & Bohse Freeze Dried Extract on Anxiety of Patients With Depression: a Double-blind Randomized Controlled Clinical Trial,COMPLETED,2014-11,2015-03,2015-10-01,INTERVENTIONAL,PHASE2|PHASE3,70.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Depression|Anxiety,Nepeta menthoides Boiss & Bohse freeze dried extract|Sertraline,DRUG,1,1,18 Years,65 Years,ALL,False,Shiraz University of Medical Sciences,OTHER,0,0,,1.0,0,1,1,0,1,2.5,0,0,1,0,2,4.2626798770413155,medium,1,1,0,1,0,0,0,0,0,0,1,1,1,1,2,1,1,0,0,2,1,2014-11-01,2015-03-01,120.0,2014.0,0,3,1
NCT00258206,"Rituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory, or Relapsed Multiple Myeloma",Phase II Study of High Dose Cyclophosphamide and Rituximab in Multiple Myeloma,COMPLETED,2004-12,2007-09-07,2017-12-06,INTERVENTIONAL,PHASE2,21.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Multiple Myeloma and Plasma Cell Neoplasm,rituximab|cyclophosphamide,DRUG|BIOLOGICAL,2,4,18 Years,120 Years,ALL,False,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.091042453358316,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,6,1,1,1,0,2,1,2004-12-01,,,2004.0,0,2,0
NCT02728206,Sofosbuvir/Velpatasvir Fixed-Dose Combination in HCV-Infected Adults Who Are Undergoing Liver Transplantation,"A Phase 2, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir Fixed Dose Combination Administered for Four Weeks in Patients Infected With Chronic HCV in the Peri-Operative Liver Transplantation Setting",COMPLETED,2016-06-12,2018-01-16,2019-02-06,INTERVENTIONAL,PHASE2,9.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Hepatitis C Virus Infection,SOF/VEL,DRUG,2,3,18 Years,,ALL,False,Gilead Sciences,INDUSTRY,0,1,New Zealand,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.302585092994046,small,1,1,1,0,1,0,0,0,0,0,0,0,1,0,5,1,1,0,0,1,0,,,,,0,0,0
NCT05142904,Radiofrequency Ablation Versus I-131 for Solitary Autonomous Thyroid Nodules,Ultrasound-guided Radiofrequency Ablation Versus Radioactive Iodine as Treatment for Hyperthyroidism Caused by Solitary Autonomous Thyroid Nodules,TERMINATED,2021-11-17,2024-11-01,2025-07-17,INTERVENTIONAL,PHASE3,40.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Thyroid Nodule, Toxic or With Hyperthyroidism|Autonomous Thyroid Function|Thyroid Nodule; Hyperthyroidism|Radiofrequency Ablation|Iodine Hyperthyroidism|Iodine Adverse Reaction",Radiofrequency ablation|Radioactive iodine|Radioactive iodine,DRUG|DEVICE,1,7,18 Years,,ALL,False,Rijnstate Hospital,OTHER,3,14,Netherlands,0.0,0,0,1,0,0,3.0,0,0,0,0,6,3.713572066704308,small,1,1,0,1,0,1,1,0,0,0,1,0,1,1,8,1,1,0,1,3,1,,,,,0,3,1
NCT01138384,Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer,A Phase I/II Study of Foretinib in Combination With Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2(HER2)Over-Expressing Metastatic Breast Cancer,COMPLETED,2010-10-27,2015-02-13,2023-08-04,INTERVENTIONAL,PHASE1|PHASE2,19.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Breast Cancer,Foretinib|Lapatinib,DRUG,1,2,18 Years,,FEMALE,False,NCIC Clinical Trials Group,NETWORK,1,5,Canada,1.0,1,1,0,0,1,1.5,1,0,0,0,1,2.995732273553991,small,1,1,0,0,0,1,1,0,0,0,0,0,1,0,3,1,1,0,0,2,1,,,,,0,2,0
NCT00737633,Open-Label Study to Evaluate the Long-Term Safety and Efficacy of VI-0521 in Type 2 Diabetic Adults,"An Open-Label, Non-Randomized Multicenter Study to Evaluate the Long-Term Safety and Efficacy of VI-0521 in Providing and Maintaining Glycemic Control in Type 2 Diabetic Adults",TERMINATED,2008-08,2009-06,2012-09-10,INTERVENTIONAL,PHASE2,101.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Diabetes,VI-0521,DRUG,1,1,19 Years,70 Years,ALL,False,VIVUS LLC,INDUSTRY,2,9,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,4.624972813284271,medium,0,1,1,0,0,1,1,0,1,0,0,0,1,0,2,1,1,0,0,1,0,2008-08-01,2009-06-01,304.0,2008.0,0,0,0
NCT01451047,A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002012),A Phase 2 Randomized Study to Evaluate and Compare the Efficacy of Injections of ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells vs. Dermal Cells Into the Balding Scalp of Subjects With Hair Loss,COMPLETED,2009-07,,2012-02-29,INTERVENTIONAL,PHASE2,31.0,ACTUAL,,SINGLE_GROUP,TREATMENT,SINGLE,Androgenetic Alopecia|Male Pattern Baldness|Female Pattern Baldness,Autologous cultured dermal and epidermal cells,BIOLOGICAL,3,0,18 Years,65 Years,ALL,True,Aderans Research Institute,INDUSTRY,0,7,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,3,3.4657359027997265,small,1,1,1,0,0,0,1,0,1,0,0,0,1,0,3,0,0,1,0,1,0,2009-07-01,,,2009.0,0,1,0
NCT01249547,Nasopharyngeal Carcinoma (NPC) Axitinib,Phase 2 Study of Axitinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma,COMPLETED,2010-12,2016-12,2017-04-25,INTERVENTIONAL,PHASE2,37.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Recurrent or Metastatic NPC,axitinib,DRUG,1,7,18 Years,,ALL,False,Chinese University of Hong Kong,OTHER,0,1,Hong Kong,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.6375861597263857,small,1,1,0,1,0,0,0,0,0,0,0,0,1,0,8,1,1,0,0,1,0,2010-12-01,2016-12-01,2192.0,2010.0,0,1,0
NCT04475549,"Phase 2a Study of IW-6463 in Adults Diagnosed With Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS)","A Phase 2a Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Individuals With Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS)",TERMINATED,2020-11-13,2022-01-23,2024-08-29,INTERVENTIONAL,PHASE2,8.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,MELAS,IW-6463 Tablets,DRUG,2,0,18 Years,,ALL,False,Tisento Therapeutics,INDUSTRY,0,5,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,2.1972245773362196,small,1,1,1,0,0,0,1,0,1,0,0,0,1,0,2,0,1,0,0,1,0,,,,,0,0,0
NCT02734147,High Dose Intravenous Ascorbic Acid in Severe Sepsis,The Efficacy of Intravenous Ascorbic Acid in Patients With Severe Sepsis,TERMINATED,2016-04-01,2017-11-23,2021-02-16,INTERVENTIONAL,PHASE2,24.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Sepsis,Ascorbic Acid|Normal Saline,DRUG|OTHER,1,6,18 Years,,ALL,False,Christiana Care Health Services,OTHER,0,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,3.2188758248682006,small,1,1,0,1,0,0,0,0,1,0,1,1,1,1,7,1,1,0,0,2,1,,,,,0,2,0
NCT03017547,A Phase 2 Study of IC14 in Acute Respiratory Distress Syndrome,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Preliminary Efficacy Study of IC14 in Acute Respiratory Distress Syndrome",WITHDRAWN,2019-06,2020-06,2025-08-20,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,QUADRUPLE,Acute Respiratory Distress Syndrome,IC14|Placebo,DRUG|OTHER,2,1,18 Years,70 Years,ALL,False,Implicit Bioscience,INDUSTRY,0,0,,0.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,1,1,1,0,0,0,0,0,0,0,1,1,1,0,3,1,1,0,0,2,1,2019-06-01,2020-06-01,366.0,2019.0,1,1,0
NCT01202058,An Observational Safety Evaluation of Patients Treated With the NEVO™ Sirolimus-eluting Coronary Stent. (NEVO II),An Observational Safety Evaluation of Patients Treated With the NEVO™ Sirolimus-eluting Coronary Stent.,TERMINATED,2010-08,2012-10,2012-10-25,INTERVENTIONAL,PHASE3,156.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Atherosclerotic Coronary Artery Disease,NEVO™ Sirolimus-eluting Coronary Stent System|XIENCE V®/XIENCE PRIME™/PROMUS® Everolimus-eluting Coronary Stent System),DEVICE,1,5,18 Years,,ALL,False,Cordis US Corp.,INDUSTRY,0,3,Netherlands|Switzerland|Spain,0.0,0,0,1,0,0,3.0,0,0,0,0,1,5.056245805348308,medium,0,1,1,0,0,0,1,1,0,1,1,0,1,1,6,1,0,0,1,2,1,2010-08-01,2012-10-01,792.0,2010.0,0,3,1
NCT00744848,Study to Evaluate Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy,"Phase 3, Multicenter, Randomized, Double-Blind, Parallel-group, Active-control Study to Evaluate the Safety and Efficacy of a Single Administration of SKY0402 for Prolonged Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy",COMPLETED,2008-08,2009-02,2013-08-06,INTERVENTIONAL,PHASE3,204.0,ACTUAL,RANDOMIZED,PARALLEL,SUPPORTIVE_CARE,DOUBLE,Hemorrhoids,Bupivacaine HCl|SKY0402,DRUG,1,1,18 Years,,ALL,False,"Pacira Pharmaceuticals, Inc",INDUSTRY,0,20,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.3230099791384085,large,0,1,1,0,0,0,1,0,1,0,1,1,0,1,2,1,1,0,0,2,1,2008-08-01,2009-02-01,184.0,2008.0,0,1,0
NCT00395655,Hydralazine and Valproate Added to Chemotherapy for Breast Cancer,A Phase II Clinical Study of Hydralazine and Valproic Acid in Combination With Neoadjuvant Cytotoxic Chemotherapy in Stage IIB and IIIA Breast Carcinoma,TERMINATED,2005-06,2006-08,2006-11-03,INTERVENTIONAL,PHASE2,43.0,,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Locally Advanced Breast Cancer,Hydralazine and magnesium valproate administration|Core-needle biopsy of the breast,DRUG|PROCEDURE,3,3,18 Years,,FEMALE,False,National Institute of Cancerología,OTHER_GOV,2,1,Mexico,0.0,0,1,0,0,0,2.0,1,0,0,0,1,3.784189633918261,small,1,0,0,1,0,1,0,0,0,0,0,0,1,0,6,1,1,0,0,2,1,2005-06-01,2006-08-01,426.0,2005.0,0,2,0
NCT00070655,Evaluating the Use of SR34006 Compared to Warfarin or Acenocoumarol in Patients With Atrial Fibrillation (AMADEUS),"The AMADEUS Trial, A Multicenter, Randomized, Open-label, Assessor Blind, Non-inferiority Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous Idraparinux (SR34006) With Adjusted-dose Oral Vitamin-K Antagonists in the Prevention of Thromboembolic Events in Patients With Atrial Fibrillation",COMPLETED,2003-09,2006-03,2011-04-06,INTERVENTIONAL,PHASE3,4673.0,ACTUAL,RANDOMIZED,,TREATMENT,NONE,Atrial Fibrillation,SR34006 (idraparinux sodium) Injection|vitamin K antagonist (warfarin or acenocoumarol) tablets,DRUG,1,1,18 Years,,ALL,False,Sanofi,INDUSTRY,0,84,Italy|Netherlands|United States|United Kingdom|Australia|Poland|New Zealand|Denmark|France|Canada,1.0,0,0,1,0,0,3.0,0,0,0,0,1,8.449770515098804,xlarge,0,1,1,0,1,0,1,1,1,1,1,0,1,0,2,1,1,0,0,2,1,2003-09-01,2006-03-01,912.0,2003.0,0,2,0
NCT02075255,Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy,"A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3 Efficacy and Safety Study of Benralizumab (MEDI-563) to Reduce Oral Corticosteroid Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus Long-acting β2 Agonist and Chronic Oral Corticosteroid Therapy (ZONDA)",COMPLETED,2014-04-28,2016-08-08,2018-06-08,INTERVENTIONAL,PHASE3,220.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Asthma,Benralizumab|Placebo|Benralizumab,BIOLOGICAL,1,33,18 Years,75 Years,ALL,False,AstraZeneca,INDUSTRY,0,87,Bulgaria|Argentina|Turkey (Türkiye)|South Korea|United States|Germany|Spain|Chile|Poland|Ukraine|France|Canada,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.3981627015177525,large,0,1,1,0,1,0,1,1,1,1,1,1,1,1,34,1,0,1,0,3,1,,,,,0,3,1
NCT03268226,Functional Respiratory Imaging Study (FRI),"Open Label, Prospective, Exploratory Study to Investigate the Effect of Inhaled CHF5993 pMDI on Central and Peripheral Airway Dimensions in COPD Patients by Functional Respiratory Imaging",COMPLETED,2017-11-20,2019-01-30,2020-03-04,INTERVENTIONAL,PHASE3,20.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Chronic Obstructive Pulmonary Disease,Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium,DRUG,2,14,40 Years,,ALL,False,Chiesi Farmaceutici S.p.A.,INDUSTRY,0,5,Belgium|Hungary,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.044522437723423,small,1,1,1,0,0,0,1,1,0,0,0,0,1,0,16,1,1,0,0,1,0,,,,,0,2,0
NCT01478126,Effects of Glutamine in Ischemic Heart Disease Patients Following Cardiopulmonary Bypass,Prospective Randomized Study of Glutamin Protective Properties in Cardiac Surgery.,COMPLETED,2012-01,2013-09,2013-11-01,INTERVENTIONAL,PHASE3,24.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Coronary Artery Disease,N(2)-L-Alanine L-Glutamine dipeptide|Placebo,DRUG,1,8,18 Years,70 Years,ALL,False,Meshalkin Research Institute of Pathology of Circulation,NETWORK,0,1,Russia,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.2188758248682006,small,1,1,0,0,0,0,0,0,0,0,1,1,1,1,9,1,1,0,0,2,1,2012-01-01,2013-09-01,609.0,2012.0,0,2,0
NCT00507026,Efficacy and Safety of IV Diclofenac (DIV075V)for Pain After Elective Orthopedic Surgery,"Randomized, Double-Blind, Active-and Placebo-Controlled Study of the Analgesic Efficacy and Safety of Repeated Dosing of DIC075V Versus Parenteral Ketorolac and Placebo in Acute Post-Operative Pain After Elective Orthopedic Surgery",COMPLETED,2007-07-25,2008-10-14,2021-10-29,INTERVENTIONAL,PHASE3,277.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Postoperative Pain,IV Diclofenac|IV ketorolac|Placebo,DRUG,5,10,18 Years,85 Years,ALL,False,Pfizer,INDUSTRY,0,8,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.627621113690637,large,0,1,1,0,1,0,1,0,1,0,1,1,1,1,15,1,1,0,0,3,1,,,,,0,2,0
NCT03837626,ENAC Blockade and Arterial Stiffness,Estrogen Receptor Alpha Signaling in Endothelial Cells Exacerbates Arterial Stiffening Via Upregulation of ENaC in Insulin Resistant Females,COMPLETED,2019-07-15,2025-04-30,2025-12-30,INTERVENTIONAL,PHASE2|PHASE3,137.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Overweight and Obesity|Insulin Resistance,Placebo - Cap|Amiloride Pill,DRUG,1,0,30 Years,70 Years,ALL,False,University of Missouri-Columbia,OTHER,0,1,United States,1.0,0,1,1,0,1,2.5,0,0,0,0,2,4.927253685157205,medium,0,1,0,1,0,0,0,0,1,0,1,1,1,1,1,0,1,0,0,2,1,,,,,0,3,1
NCT01417026,Intranasal Oxytocin and Learning in Autism,Promoting Social Perceptual Learning With Oxytocin in Autism,COMPLETED,2011-09,2015-04,2017-03-30,INTERVENTIONAL,PHASE2,36.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Autism Spectrum Disorders,Intranasal Oxytocin (Trade name: Syntocinon),DRUG,2,1,12 Years,17 Years,MALE,False,Robert Schultz,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.6109179126442243,small,1,1,0,1,0,0,0,0,1,0,1,1,1,1,3,1,1,0,0,1,0,2011-09-01,2015-04-01,1308.0,2011.0,0,0,0
NCT04763135,Mirtazapine in Cancer-related Poly-symptomatology,What is the Effectiveness and Safety of Mirtazapine Versus Escitalopram in Alleviating Cancer-associated Poly-symptomatology (MIR-P)? A Mixed-method Randomized Controlled Trial Protocol,TERMINATED,2021-12-15,2021-12-17,2023-06-08,INTERVENTIONAL,PHASE3,1.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Cancer|Neoplasms|Neoplasm Metastasis,Mirtazapine|Escitalopram,DRUG,1,22,18 Years,,ALL,False,Hospices Civils de Lyon,OTHER,0,11,France,0.0,0,0,1,0,0,3.0,1,0,0,0,3,0.6931471805599453,small,1,1,0,1,0,0,1,0,0,1,1,0,1,1,23,1,1,0,0,2,1,,,,,0,3,1
NCT02663908,A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease,"A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients With Prostate Cancer and Cardiovascular Disease Receiving Degarelix (Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist) or Leuprolide (GnRH Receptor Agonist)",TERMINATED,2016-04-19,2021-03-29,2022-06-29,INTERVENTIONAL,PHASE3,545.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Prostate Cancer,Degarelix|Leuprolide,DRUG,1,18,,,MALE,False,Ferring Pharmaceuticals,INDUSTRY,2,133,Russia|Finland|United States|Germany|Slovakia|United Kingdom|Poland|Czechia|South Africa|France|Greece|Canada,0.0,0,0,1,0,0,3.0,1,0,0,0,1,6.302618975744905,xlarge,0,1,1,0,0,1,1,1,1,1,1,0,1,1,19,1,1,0,0,2,1,,,,,0,3,1
NCT00003176,Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma,A Phase II Trial of Temozolomide and BCNU for Anaplastic Gliomas,COMPLETED,1998-03-25,2004-01-06,2018-06-27,INTERVENTIONAL,PHASE2,82.0,,,,TREATMENT,,Brain and Central Nervous System Tumors,carmustine|temozolomide,DRUG,0,0,18 Years,120 Years,ALL,False,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,OTHER,1,10,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.418840607796598,medium,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,2,1,,,,,0,1,0
NCT03831776,Long-acting Low Dose Ropeginterferon for Chronic Myeloid Leukemia Treated With Bosutinib From Diagnosis,A Study of Efficacy and Safety of Long-acting Low Dose Ropeginterferon in Patients With Chronic Myeloid Leukemia Treated With Bosutinib From Diagnosis: a Randomized Prospective Trial,COMPLETED,2019-03-25,2024-12-31,2025-06-08,INTERVENTIONAL,PHASE2,212.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Chronic Myeloid Leukemia,Bosutinib|Ropeginterferon,DRUG,1,12,18 Years,75 Years,ALL,False,St. Olavs Hospital,OTHER,9,18,Finland|Sweden|Denmark|Norway,1.0,0,1,0,0,0,2.0,1,0,0,0,1,5.3612921657094255,large,0,1,0,1,0,1,1,1,0,0,1,0,1,1,13,1,1,0,0,2,1,,,,,0,3,1
NCT00008476,Capsaicin to Control Pain Following Third Molar Extraction,Evaluation of Vanilloid Receptor Inactivation for Preemptive Analgesia,COMPLETED,2001-01,2004-01,2008-03-04,INTERVENTIONAL,PHASE2,162.0,,,,TREATMENT,,Facial Pain,Capsaicin,DRUG,0,0,,,ALL,False,National Institute of Dental and Craniofacial Research (NIDCR),NIH,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.093750200806762,medium,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,2001-01-01,2004-01-01,1095.0,2001.0,0,0,0
NCT02576717,"A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis","A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients",COMPLETED,2015-10-16,2023-01-05,2024-01-30,INTERVENTIONAL,PHASE3,2494.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Multiple Sclerosis,RPC1063,DRUG,18,15,18 Years,55 Years,ALL,False,Celgene,INDUSTRY,0,175,Bulgaria|Latvia|Germany|Moldova|Serbia|Belarus|Georgia|Greece|Italy|Spain|Estonia|Portugal|Sweden|United States|United Kingdom|Romania|Lithuania|Poland|New Zealand|Ukraine|South Africa|Belgium|Hungary|Bosnia and Herzegovina|Croatia|Slovakia,1.0,0,0,1,0,0,3.0,0,1,0,0,1,7.822044008185619,xlarge,0,1,1,0,0,0,1,1,1,1,0,0,1,0,33,1,1,0,0,1,0,,,,,0,2,0
NCT01940640,Effect of Mother DHA Supplementation on Premature Newborn.,Multidisciplinary Study of the Effect of the Mother suplementación During the Lactation With High Doses of DHA on Diverse Aspects Related to the Development of the Premature Newborn in the First Year of Life.,COMPLETED,2012-01,2015-11,2015-12-02,INTERVENTIONAL,PHASE2|PHASE3,40.0,ACTUAL,RANDOMIZED,PARALLEL,SUPPORTIVE_CARE,TRIPLE,Oxidative Stress,DHA|control,DIETARY_SUPPLEMENT,1,1,1 Hour,6 Months,ALL,True,Universidad de Granada,OTHER,0,1,Spain,1.0,0,1,1,0,1,2.5,0,0,0,0,1,3.713572066704308,small,1,1,0,1,0,0,0,0,0,1,1,1,0,1,2,1,0,0,0,2,1,2012-01-01,2015-11-01,1400.0,2012.0,0,2,0
NCT02554240,Study to Evaluate the Efficacy and Safety of Intra-articular DA-5202 in Patients With Osteoarthritis of the Knee,"Active-controlled, Dose-Response, Randomized, Double-blind, Therapeutic Exploratory Clinical Trial to Evaluate the Efficacy and Safety of Intra-articular DA-5202 in Patients With Osteoarthritis of the Knee",COMPLETED,2014-12-23,2016-10-14,2021-04-14,INTERVENTIONAL,PHASE2,115.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Osteoarthritis, Knee",DA-5202 20mg|DA-5202 10mg|Na Hyaluronate 20mg,DRUG,1,8,20 Years,80 Years,ALL,False,"Dong-A ST Co., Ltd.",INDUSTRY,0,1,South Korea,1.0,0,1,0,0,0,2.0,0,1,0,0,1,4.7535901911063645,medium,0,1,1,0,0,0,0,0,0,0,1,1,1,1,9,1,1,0,0,3,1,,,,,0,2,0
NCT04341389,A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector),"A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector) in Healthy Adults Aged Above 18 Years",COMPLETED,2020-04-12,2020-12-31,2023-05-24,INTERVENTIONAL,PHASE2,508.0,ACTUAL,RANDOMIZED,CROSSOVER,PREVENTION,DOUBLE,COVID-19,Recombinant novel coronavirus vaccine (Adenovirus type 5 vector)|Placebo,BIOLOGICAL|OTHER,3,6,18 Years,,ALL,True,"Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China",OTHER,4,1,China,1.0,0,1,0,0,0,2.0,0,0,0,0,1,6.2324480165505225,xlarge,0,1,0,1,0,1,0,0,0,0,1,1,0,0,9,1,0,1,0,2,1,,,,,0,2,0
NCT02926950,Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin,"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Added to Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin",COMPLETED,2016-11,2019-03-22,2021-05-11,INTERVENTIONAL,PHASE3,518.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,Sotagliflozin (SAR439954)|Placebo|Metformin,DRUG,1,7,18 Years,,ALL,False,Lexicon Pharmaceuticals,INDUSTRY,1,93,Canada|Slovakia|Hungary|United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.251903883165888,xlarge,0,1,1,0,0,1,1,1,1,0,1,1,1,1,8,1,1,0,0,3,1,2016-11-01,,,2016.0,1,3,1
NCT01238991,"Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease","A Phase Iia, Multicenter, Treatment Assigned, Open-label, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Japanese Subjects With Mild To Moderate Alzheimer's Disease",TERMINATED,2010-12,2013-12,2014-12-22,INTERVENTIONAL,PHASE2,53.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Alzheimer's Disease,ACC-001|ACC-001|ACC-001,BIOLOGICAL,3,0,52 Years,87 Years,ALL,False,Pfizer,INDUSTRY,1,11,Japan,0.0,0,1,0,0,0,2.0,0,0,1,0,1,3.9889840465642745,medium,1,1,1,0,1,1,1,0,0,0,0,0,1,1,3,0,0,1,0,3,1,2010-12-01,2013-12-01,1096.0,2010.0,0,1,0
NCT01667874,Use of Collatamp G Antibiotic Impregnated Sponges in the Treatment of Peri-prosthetic Total Joint Infections,Use of Collatamp G Antibiotic Impregnated Sponges in the Treatment of Peri-prosthetic Total Joint Infections,TERMINATED,2013-01,2016-09-01,2017-02-15,INTERVENTIONAL,PHASE3,17.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Infection,Collatamp G sponge,DRUG,1,0,18 Years,,ALL,False,London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's,OTHER,0,1,Canada,0.0,0,0,1,0,0,3.0,0,0,0,0,1,2.8903717578961645,small,1,1,0,1,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0,1,0,2013-01-01,,,2013.0,0,0,0
NCT00001474,Pharmacodynamics of Intermittent IL-2 Infusions in HIV Seropositive Patients,Pharmacodynamics of Intermittent IL-2 Infusions in HIV Seropositive Patients,COMPLETED,1995-05,2002-03,2008-03-04,INTERVENTIONAL,PHASE2,36.0,,,,TREATMENT,,HIV Infection,Interleukin-2,DRUG,0,0,,,ALL,False,National Institute of Allergy and Infectious Diseases (NIAID),NIH,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.6109179126442243,small,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1995-05-01,2002-03-01,2496.0,1995.0,0,0,0
NCT00482274,Docetaxel in Treating Patients With Relapsed Prostate Cancer,Phase II Study of the Early Use of Docetaxel in Patients With Biochemical Relapse After Primary Therapy for Prostate Cancer and an Incomplete Response to Androgen Deprivation Therapy.,TERMINATED,2007-05,2009-07,2017-04-28,INTERVENTIONAL,PHASE2,3.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Prostate Cancer,docetaxel,DRUG,1,4,18 Years,,MALE,False,OHSU Knight Cancer Institute,OTHER,1,2,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,1.3862943611198906,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,5,1,1,0,0,1,0,2007-05-01,2009-07-01,792.0,2007.0,0,0,0
NCT00096174,"Phase II Study of Concurrent C225, Cisplatin and Radiation in Stage IV Squamous Cell Carcinoma of the Head and Neck",Phase II Study of C225 (Erbitux or Cetuximab) in Combination With Cisplatin and Definitive Radiation in Unresectable Stage IV Squamous Cell Carcinoma of the Head and Neck,COMPLETED,2005-04-08,2016-07,2023-06-29,INTERVENTIONAL,PHASE2,69.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Head and Neck Cancer,cetuximab C225|cisplatin|radiation therapy,DRUG|BIOLOGICAL|RADIATION,1,2,18 Years,,ALL,False,Eastern Cooperative Oncology Group,NETWORK,1,0,,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.248495242049359,medium,1,1,0,0,0,1,0,0,0,0,0,0,1,0,3,1,1,1,0,3,1,,2016-07-01,,,0,1,0
NCT02466074,Augmenting Cerebral Blood Flow to Treat Established Multiple Sclerosis,Augmenting Cerebral Blood Flow to Treat Established Multiple Sclerosis,TERMINATED,2016-08-17,2022-02-07,2023-04-27,INTERVENTIONAL,PHASE2,5.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Multiple Sclerosis,Acetazolamide|Placebo,DRUG,1,2,18 Years,55 Years,ALL,False,"The University of Texas Health Science Center, Houston",OTHER,0,1,United States,0.0,0,1,0,0,0,2.0,0,1,0,0,1,1.791759469228055,small,1,1,0,1,0,0,0,0,1,0,1,1,1,1,3,1,1,0,0,2,1,,,,,0,1,0
NCT03844074,A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD),"A Clinical Effectiveness, Multicenter, Randomized, Double-masked, Controlled Study of the Efficacy and Safety of ONS-5010 in Subjects With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration",COMPLETED,2018-10-01,2020-08-13,2025-03-19,INTERVENTIONAL,PHASE3,61.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Age-related Macular Degeneration|Neovascular Age-related Macular Degeneration|Wet Macular Degeneration,bevacizumab|ranibizumab,BIOLOGICAL,1,6,50 Years,,ALL,False,"Outlook Therapeutics, Inc.",INDUSTRY,0,9,Australia,1.0,0,0,1,0,0,3.0,0,0,0,0,3,4.127134385045092,medium,1,1,1,0,0,0,1,0,0,0,1,1,1,1,7,1,0,1,0,2,1,,,,,0,3,1
NCT00585390,Omega-3 Fatty Acid Deficiency Replacement in Early Schizophrenia,"Randomized, Double-Blind, Placebo-Controlled Pilot Trial of Essential Fatty Acid Deficiency Replacement in Early Schizophrenia",COMPLETED,2008-01,2009-11,2011-08-02,INTERVENTIONAL,PHASE2|PHASE3,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Schizophrenia|Fatty Acid Deficiency,Omega-3 Fatty Acids|Olive oil placebo|EPA fish oil concentrate; DHA fish oil concentrate|Placebo,DRUG|OTHER|DIETARY_SUPPLEMENT,1,1,8 Years,25 Years,ALL,False,University of Cincinnati,OTHER,0,1,United States,1.0,0,1,1,0,1,2.5,0,0,1,0,2,0.0,,1,1,0,1,0,0,0,0,1,0,1,1,1,1,2,1,1,0,0,4,1,2008-01-01,2009-11-01,670.0,2008.0,0,3,1
NCT01625390,A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150,"A Phase 2/3, Multicenter, Open-label Clinical Study to Assess the Safety and Efficacy of BAY86-6150 in Subjects With Hemophilia A or B With Inhibitors, Composed of 2 Parts (A & B). Part A: Sequential Cohorts of Four Dose Levels of the Modified rFVIIa BAY86-6150 Assessed in a Non-controlled Dose Response Design in Acutely Bleeding Subjects and for PK/ PD in an Intra-individual Crossover Design Compared With One Fixed Dose of Eptacog Alfa in Non-bleeding Subjects. Part B: Confirmatory Study to Further Investigate the Efficacy and Safety of BAY86-6150",COMPLETED,2012-06,2014-03,2015-07-01,INTERVENTIONAL,PHASE2|PHASE3,10.0,ACTUAL,NON_RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Hemophilia A, Hemophilia B",BAY86-6150|eptacog alfa [activated]|BAY86-6150,DRUG,2,6,12 Years,62 Years,MALE,False,Bayer,INDUSTRY,0,61,China|Bulgaria|Germany|Japan|Taiwan|Singapore|Italy|Netherlands|South Korea|Chile|Russia|Sweden|Turkey (Türkiye)|India|United States|United Kingdom|Australia|Romania|Poland|Mexico|New Zealand|Denmark|Israel|Ukraine|South Africa|France|Hungary|Brazil|Colombia,1.0,0,1,1,0,1,2.5,0,0,0,0,1,2.3978952727983707,small,1,1,1,0,0,0,1,1,1,1,0,0,1,0,8,1,1,0,0,3,1,2012-06-01,2014-03-01,638.0,2012.0,0,4,1
NCT01740297,Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma,"Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety and Efficacy of Talimogene Laherparepvec and Ipilimumab Compared to Ipilimumab Alone in Subjects With Unresected, Stage IIIB-IV Melanoma",COMPLETED,2013-02-07,2021-03-09,2024-05-14,INTERVENTIONAL,PHASE1|PHASE2,217.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Melanoma,Talimogene laherparepvec|Ipilimumab,DRUG,2,14,18 Years,,ALL,False,Amgen,INDUSTRY,0,40,Germany|France|United States,1.0,1,1,0,0,1,1.5,1,0,0,0,1,5.384495062789089,large,0,1,1,0,1,0,1,1,1,1,1,0,1,1,16,1,1,0,0,2,1,,,,,0,4,1
NCT05576597,Effect of Butyrate Supplement on Rheumatoid Arthritis,A Pilot Study to Evaluate Efficacy and Safety of Butyrate Supplement in the Treatment of Rheumatoid Arthritis,COMPLETED,2022-08-23,2024-06-15,2024-08-22,INTERVENTIONAL,PHASE2,30.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Rheumatoid Arthritis,Sodium Butyrate,DRUG,1,9,18 Years,,ALL,False,Peking University People's Hospital,OTHER,0,1,China,1.0,0,1,0,0,0,2.0,0,1,0,0,1,3.4339872044851463,small,1,1,0,1,0,0,0,0,0,0,0,0,1,0,10,1,1,0,0,1,0,,,,,0,1,0
NCT00486291,Study of VI-0521 Compared to Placebo in the Glycemic Management of Obese Diabetics,"A Phase 2, Randomized, Double Blind, Parallel Design Study Comparing the Efficacy and Safety of VI-0521 to Placebo in the Glycemic Management of Obese Diabetic Adults",COMPLETED,2007-06,2008-04,2012-09-10,INTERVENTIONAL,PHASE2,210.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes Mellitus,VI-0521|Placebo,DRUG,1,1,18 Years,65 Years,ALL,False,VIVUS LLC,INDUSTRY,1,9,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.351858133476067,large,0,1,1,0,0,1,1,0,1,0,1,1,1,1,2,1,1,0,0,2,1,2007-06-01,2008-04-01,305.0,2007.0,0,1,0
NCT05206591,Study to Demonstrate the Efficacy and Safety of Secukinumab up to 224 Weeks in Subjects With Active Peripheral Spondyloarthritis (pSpA).,"A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Study to Investigate the Efficacy and Safety of Secukinumab (Cosentyx®) 300 mg Administered Subcutaneously in Patients With Active Peripheral Spondyloarthritis (pSpA).",WITHDRAWN,2022-08-16,2028-06-12,2023-01-09,INTERVENTIONAL,PHASE3,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Active Peripheral Spondyloarthritis (pSpA),Secukinumab|Placebo,BIOLOGICAL|OTHER,1,0,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,0,,0.0,0,0,1,0,0,3.0,0,1,0,0,1,0.0,,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,0,0,1,0,2,1,,,,,0,1,0
NCT00176774,"Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal Carcinoma","A Pilot Trial of Irinotecan, 5-Fluorouracil, and Leucovorin Combined With the Anti-Angiogenesis Agent Tetrathiomolybdate in Metastatic Colorectal Carcinoma (UMCC 0075)",COMPLETED,2001-02,2004-04,2012-02-07,INTERVENTIONAL,PHASE2,24.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Colorectal Carcinoma,Irinotecan|5-Fluorouracil|Leucovorin|Tetrathiomolybdate,DRUG,3,3,18 Years,,ALL,False,University of Michigan Rogel Cancer Center,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.2188758248682006,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,6,1,1,0,0,4,1,2001-02-01,2004-04-01,1155.0,2001.0,0,2,0
NCT00521274,Study of Trovax® Plus Docetaxel Versus Docetaxel Alone in Patients With Progressive Hormone Refractory Prostate Cancer,A Phase II Trial to Assess the Activity of MVA 5T4 (Trovax®) Plus Docetaxel Versus Docetaxel Alone in Patients With Progressive Hormone Refractory Prostate Cancer (HRPC),TERMINATED,2007-08,2008-08,2016-03-17,INTERVENTIONAL,PHASE2,11.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Prostatic Neoplasms,MVA 5T4|Docetaxel,DRUG|BIOLOGICAL,1,1,18 Years,,MALE,False,The Methodist Hospital Research Institute,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,2.4849066497880004,small,1,1,0,1,0,1,0,0,1,0,1,0,1,0,2,1,1,1,0,2,1,2007-08-01,2008-08-01,366.0,2007.0,0,1,0
NCT01888874,Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Participants (DARWIN1),"Randomized, Double-blind, Placebo-controlled, Multicenter, Phase IIb Dose Finding Study of GLPG0634 Administered for 24 Weeks in Combination With Methotrexate to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Alone",COMPLETED,2013-07-17,2015-05-14,2020-11-17,INTERVENTIONAL,PHASE2,599.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Rheumatoid Arthritis,GLPG0634|Placebo,DRUG,1,10,18 Years,,ALL,False,Galapagos NV,INDUSTRY,0,142,Bulgaria|Latvia|Germany|Moldova|Spain|Chile|Czechia|Russia|Argentina|United States|Austria|Australia|Poland|Mexico|New Zealand|Israel|Ukraine|France|Belgium|Guatemala|Hungary|Colombia,1.0,0,1,0,0,0,2.0,0,1,0,0,1,6.396929655216146,xlarge,0,1,1,0,0,0,1,1,1,1,1,1,1,1,11,1,1,0,0,2,1,,,,,0,3,1
NCT02649218,A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients,"An Open Label, Multicenter, Extension Study to Evaluate the Long-term Safety of QGE031 240 mg s.c. Given Every 4 Weeks for 52 Weeks in Chronic Spontaneous Urticaria Patients Who Completed Study CQGE031C2201",COMPLETED,2016-05-24,2019-05-02,2021-10-11,INTERVENTIONAL,PHASE2,226.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Chronic Spontaneous Urticaria,Ligelizumab,BIOLOGICAL,1,2,18 Years,75 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,67,Russia|United States|Germany|Spain|Australia|United Kingdom|Japan|Taiwan|Greece|Canada,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.424950017481403,large,0,1,1,0,1,0,1,1,1,1,0,0,1,0,3,1,0,1,0,1,0,,,,,0,1,0
NCT02057718,Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis,"Open Label Study of the Efficacy and Long Term Safety of LUM001 (Maralixibat), an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Pediatric Patients With Progressive Familial Intrahepatic Cholestasis",COMPLETED,2014-03-01,2020-05-08,2023-10-23,INTERVENTIONAL,PHASE2,33.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Progressive Familial Intrahepatic Cholestasis (PFIC),LUM001 (Maralixibat),DRUG,1,5,12 Months,18 Years,ALL,False,"Mirum Pharmaceuticals, Inc.",INDUSTRY,0,10,Poland|United Kingdom|France|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.5263605246161616,small,1,1,1,0,0,0,1,1,1,1,0,0,1,0,6,1,1,0,0,1,0,,,,,0,2,0
NCT04992494,Treatment for Migraine and Mood (Team-M),Treatment for Migraine and Mood (Team-M): A Pilot Trial of a Mindfulness-based Training Program,COMPLETED,2021-11-11,2022-06-13,2023-07-18,INTERVENTIONAL,PHASE2,27.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Migraine|Depression,MBCT-Telephone|MBCT-Video,BEHAVIORAL,4,0,18 Years,,ALL,False,NYU Langone Health,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,1,0,2,3.332204510175204,small,1,1,0,1,0,1,0,0,1,0,0,0,1,1,4,0,0,0,0,2,1,,,,,0,2,0
NCT00539994,Retapamulin Ointment in Healthy Adults Nasally Colonized With Staphylococcus Aureus,"Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Efficacy of Retapamulin Ointment, 1% Applied Twice Daily for 3 or 5 Days to the Anterior Nares of Healthy Adult Subjects Nasally Colonized With Staphylococcus Aureus",COMPLETED,2007-09,2008-01,2016-12-15,INTERVENTIONAL,PHASE2,57.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,DOUBLE,"Infections, Bacterial",retapamulin|Retapamulin|Placebo,DRUG,5,7,18 Years,65 Years,ALL,True,GlaxoSmithKline,INDUSTRY,0,4,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.060443010546419,medium,1,1,1,0,0,0,1,0,1,0,1,1,1,0,12,1,1,0,0,3,1,2007-09-01,2008-01-01,122.0,2007.0,0,2,0
NCT01208766,Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma,"A Randomized Phase III Study to Compare Bortezomib, Melphalan, Prednisone (VMP) With High Dose Melphalan Followed by Bortezomib, Lenalidomide, Dexamethasone (VRD) Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma",COMPLETED,2011-01,2025-01,2026-01-06,INTERVENTIONAL,PHASE3,1503.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Multiple Myeloma,"Bortezomib, Melphalan, Prednisone (VMP)|1 or 2 cycle(s) HDM (High Dose Melphalan)|2 cycles of Bortezomib, Lenalidomide, Dexamethasone (VRD)",DRUG,3,3,18 Years,65 Years,ALL,False,Stichting Hemato-Oncologie voor Volwassenen Nederland,OTHER,5,208,Italy|Belgium|Finland|Luxembourg|Netherlands|Hungary|Sweden|Turkey (Türkiye)|Austria|Australia|Norway|Switzerland|Czechia|Denmark|Portugal|Greece,1.0,0,0,1,0,0,3.0,1,0,0,0,1,7.315883504509785,xlarge,0,1,0,1,0,1,1,1,0,1,1,0,1,1,6,1,1,0,0,3,1,2011-01-01,2025-01-01,5114.0,2011.0,0,3,1
NCT01213056,Mindfulness-Based Cognitive Therapy for the Treatment of Chronic Headache Pain,Mindfulness-Based Cognitive Therapy for the Treatment of Chronic Headache Pain,COMPLETED,2010-04,2013-12,2015-12-02,INTERVENTIONAL,PHASE1|PHASE2,32.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Headache|Pain,Mindfulness Based Cognitive Therapy,BEHAVIORAL,1,1,19 Years,,ALL,False,"University of Alabama, Tuscaloosa",OTHER,0,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,2,3.4965075614664802,small,1,1,0,1,0,0,0,0,1,0,1,0,1,0,2,1,0,0,0,1,0,2010-04-01,2013-12-01,1340.0,2010.0,0,2,0
NCT04644822,Safety and Efficacy of [18F]PSMA-1007 Injection in Suspected Persistent or Recurrent Prostate Cancer.,"A Phase 3, Non-randomized, Open Label, Multi-centre Clinical Trial to Investigate the Safety and Efficacy of [18F]PSMA-1007 Injection in Men With Suspected Persistent or Recurrent Prostate Cancer.",COMPLETED,2020-12-21,2024-01-08,2024-02-07,INTERVENTIONAL,PHASE3,100.0,ACTUAL,,SINGLE_GROUP,DIAGNOSTIC,NONE,Prostate Cancer Recurrent|Recurrent Prostate Cancer,[18F] PSMA-1007 Injection,DIAGNOSTIC_TEST,1,3,18 Years,,MALE,False,Centre for Probe Development and Commercialization,OTHER,1,2,Canada,1.0,0,0,1,0,0,3.0,1,0,0,0,2,4.61512051684126,medium,0,1,0,1,0,1,1,0,0,0,0,0,0,0,4,1,0,0,0,1,0,,,,,0,1,0
NCT02994251,A Trial of Systemic Chemotherapy in Combination With Conventional Transarterial Chemoembolization in Patients With Advanced Intra-Hepatic Cholangiocarcinoma,A Phase II Trial of Systemic Chemotherapy (Gemcitabine and Cisplatin) in Combination With Conventional Transarterial Chemoembolization (cTACE) in Patients With Advanced Intra-Hepatic Cholangiocarcinoma (ICC),TERMINATED,2017-06-21,2018-11-06,2019-12-30,INTERVENTIONAL,PHASE2,1.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Unresectable Intrahepatic Cholangiocarcinoma,gemcitabine|Cisplatin|Conventional TACE (transarterial chemoembolization) with Doxorubicin/Mitomycin-C,DRUG,1,6,18 Years,,ALL,False,Yale University,OTHER,0,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,0.6931471805599453,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,7,1,1,0,0,3,1,,,,,0,2,0
NCT00984022,Aquacel Versus Iodoform Gauze for Filling Abscess Cavity Following Incision and Drainage,Aquacel vs. Iodoform Gauze for Filling Abscess Cavity Following Incision and Drainage: A Randomized Control Study,COMPLETED,2008-03,2010-02-23,2017-10-04,INTERVENTIONAL,PHASE2,92.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Abscess|Cellulitis,Type of dressing - Iodoform|Type of dressing - Aquacel,DEVICE,1,2,18 Years,65 Years,ALL,False,Valleywise Health,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.532599493153256,medium,1,1,0,1,0,0,0,0,1,0,1,0,1,1,3,1,0,0,1,2,1,2008-03-01,,,2008.0,0,2,0
NCT01675622,Immediate-Release Oxycodone Capsules Study in Cancer Pain,A Comparative Study of Immediate-Release Oxycodone Capsules Versus Immediate-Release Morphine Tablets for the Treatment of Chinese Patients With Cancer Pain.,COMPLETED,2011-01,2012-07,2018-05-21,INTERVENTIONAL,PHASE3,242.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Cancer,Oxycodone|Morphine,DRUG,1,9,18 Years,80 Years,ALL,False,Mundipharma (China) Pharmaceutical Co. Ltd,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,1,0,0,0,1,5.493061443340548,large,0,1,1,0,0,0,0,0,0,0,1,1,1,1,10,1,1,0,0,2,1,2011-01-01,2012-07-01,547.0,2011.0,0,2,0
NCT02363751,Study of Gemcitabine+Platinum Salt+Bevacizumab Combination for Metastatic Collecting Duct Carcinoma (GETUG-AFU 24),Prospective Phase II Study of Gemcitabine Plus Platinum Salt in Combination With Bevacizumab (Avastin®) for Metastatic Collecting Duct Carcinoma,COMPLETED,2014-12,2020-08,2021-03-09,INTERVENTIONAL,PHASE2,36.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Collecting Duct Carcinoma (Kidney),Bevacizumab,DRUG,1,3,18 Years,,ALL,False,UNICANCER,OTHER,0,19,France,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.6109179126442243,small,1,1,0,1,0,0,1,0,0,1,0,0,1,0,4,1,1,0,0,1,0,2014-12-01,2020-08-01,2070.0,2014.0,0,0,0
NCT04567329,Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study),"A Phase 3, Multi-Center, Randomized, Double-Masked, Saline-Controlled Trial to Evaluate the Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study)",COMPLETED,2020-11-18,2021-08-30,2024-08-19,INTERVENTIONAL,PHASE3,620.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Dry Eye Disease,NOV03|Saline Solution,DRUG,2,4,18 Years,,ALL,False,Bausch & Lomb Incorporated,INDUSTRY,0,35,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.431331081933479,xlarge,0,1,1,0,0,0,1,0,1,0,1,1,1,1,6,1,1,0,0,2,1,,,,,0,2,0
NCT00280631,Study of TLK199 Tablets in Myelodysplastic Syndrome (MDS),Phase 1-2a Dose-Ranging Study of TLK199 Tablets in Myelodysplastic Syndrome (MDS),COMPLETED,2006-02,2008-06,2012-05-31,INTERVENTIONAL,PHASE1|PHASE2,49.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Myelodysplastic Syndrome (MDS),Ezatiostat Hydrochlorine,DRUG,1,1,18 Years,,ALL,False,Telik,INDUSTRY,0,3,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,3.912023005428146,small,1,1,1,0,0,0,1,0,1,0,0,0,1,0,2,1,1,0,0,1,0,2006-02-01,2008-06-01,851.0,2006.0,0,1,0
NCT02949531,Use of Oxygen in Heart Failure With Preserved Ejection Fraction,"Randomised, Cross Over, Single Blind, Control Trial of Short Term Oxygen Use During Cycle Ergometry in Patients With Chronic Heart Failure With Preserved Ejection Fraction",COMPLETED,2016-11-03,2017-02-15,2019-06-26,INTERVENTIONAL,PHASE2,50.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,SINGLE,Heart Failure,oxygen,DRUG,1,2,50 Years,,ALL,False,Hull University Teaching Hospitals NHS Trust,OTHER_GOV,0,0,,1.0,0,1,0,0,0,2.0,0,0,0,1,1,3.9318256327243257,small,1,1,0,1,0,0,0,0,0,0,1,0,1,0,3,1,1,0,0,1,0,,,,,0,0,0
NCT00391872,A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome,"A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of Ticagrelor Compared With Clopidogrel for Prevention of Vascular Events in Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO- a Study of PLATelet Inhibition and Patient Outcomes]",COMPLETED,2006-10,2009-03,2012-03-13,INTERVENTIONAL,PHASE3,18624.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Acute Coronary Syndrome,Ticagrelor|Clopidogrel,DRUG,2,14,18 Years,,ALL,False,AstraZeneca,INDUSTRY,0,672,China|Bulgaria|Germany|Norway|Switzerland|Georgia|Taiwan|Singapore|Greece|Thailand|Italy|Netherlands|Finland|South Korea|Spain|Czechia|Indonesia|Portugal|Canada|Russia|Argentina|Sweden|Turkey (Türkiye)|India|Puerto Rico|United States|Austria|Australia|Romania|United Kingdom|Poland|Mexico|Denmark|Israel|Philippines|South Africa|Ukraine|France|Belgium|Hungary|Brazil|Slovakia|Hong Kong|Malaysia,1.0,0,0,1,0,0,3.0,0,0,0,0,1,9.83226004324776,,0,1,1,0,1,0,1,1,1,1,1,1,1,1,16,1,1,0,0,2,1,2006-10-01,2009-03-01,882.0,2006.0,0,3,1
NCT04388839,Evolutionary Therapy for Rhabdomyosarcoma,"Evolutionary Inspired Therapy for Newly Diagnosed, Metastatic, Fusion Positive Rhabdomyosarcoma",ACTIVE_NOT_RECRUITING,2020-12-29,2027-08,2025-11-26,INTERVENTIONAL,PHASE2,12.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Rhabdomyosarcoma,Vincristine|Cyclophosphamide|Vinorelbine|Actinomycin D|Cyclophosphamide Pill,DRUG,3,2,,,ALL,False,H. Lee Moffitt Cancer Center and Research Institute,OTHER,1,18,United States,,0,1,0,0,0,2.0,1,0,0,0,1,2.5649493574615367,small,1,1,0,1,0,1,1,0,1,0,0,0,1,1,5,1,1,0,0,5,1,,2027-08-01,,,0,1,0
NCT01007175,Study Evaluating Multiple Ascending Doses Of ATN-103 In Japanese Subjects With Rheumatoid Arthritis,"A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study Of The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Clinical Efficacy Of ATN-103 Administered To Japanese Subjects With Active Rheumatoid Arthritis On A Background Of Methotrexate",COMPLETED,2009-11,2010-09,2013-09-04,INTERVENTIONAL,PHASE1|PHASE2,60.0,ACTUAL,RANDOMIZED,FACTORIAL,TREATMENT,QUADRUPLE,Rheumatoid Arthritis,ATN-103 10 mg q4wks|ATN-103 30 mg q4wks|ATN-103 80 mg q4wks|ATN-103 10 mg q8wks|ATN-103 80 mg q8wks,BIOLOGICAL,1,1,20 Years,75 Years,ALL,False,"Ablynx, a Sanofi company",INDUSTRY,0,15,Japan,1.0,1,1,0,0,1,1.5,0,1,0,0,1,4.110873864173311,medium,1,1,1,0,1,0,1,0,0,0,1,1,1,0,2,1,0,1,0,5,1,2009-11-01,2010-09-01,304.0,2009.0,0,2,0
NCT04508075,"Efficacy, Safety and Immunogenicity Study of SARS-CoV-2 Inactivated Vaccine","A Phase III, Observer-blind, Randomized, Placebo-controlled Study of the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 Years in Indonesia",COMPLETED,2020-08-10,2021-08-31,2022-01-13,INTERVENTIONAL,PHASE3,1620.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,SARS-CoV2 Infection,SARS-CoV-2 vaccine (inactivated)|Placebo,BIOLOGICAL,1,6,18 Years,59 Years,ALL,True,PT Bio Farma,INDUSTRY,3,1,Indonesia,1.0,0,0,1,0,0,3.0,0,0,0,0,1,7.390798521735676,xlarge,0,1,1,0,0,1,0,0,0,0,1,1,0,1,7,1,0,1,0,2,1,,,,,0,2,0
NCT03629275,Investigation of Neural Stem Cells in Ischemic Stroke,"A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Intracerebral Stem Cells (CTX0E03) in Subjects With Disability Following an Ischemic Stroke",TERMINATED,2018-08-31,2021-03-02,2021-08-13,INTERVENTIONAL,PHASE2,15.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Ischemic Stroke|Chronic Stroke|Hemiparesis|Arm Paralysis,CTX0E03 Drug Product and delivery device|Placebo,DRUG|COMBINATION_PRODUCT,1,13,35 Years,75 Years,ALL,False,ReNeuron Limited,INDUSTRY,0,23,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,4,2.772588722239781,small,1,1,1,0,0,0,1,0,1,0,1,1,1,1,14,1,1,0,0,2,1,,,,,0,3,1
NCT04469075,Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields,"The PROTECT Study: A Phase II, Open-Label Trial of PROphylactic Skin Toxicity ThErapy With Clindamycin and Triamcinolone in Glioblastoma Patients Treated With Tumor Treating Fields",ACTIVE_NOT_RECRUITING,2020-07-09,2026-07,2025-08-08,INTERVENTIONAL,PHASE2,48.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Glioblastoma|Recurrent Glioblastoma|Skin Toxicity,Clindamycin Phosphate|Triamcinolone Acetonide,DRUG,1,1,18 Years,,ALL,False,Memorial Sloan Kettering Cancer Center,OTHER,0,8,United States,,0,1,0,0,0,2.0,0,0,0,0,3,3.8918202981106265,small,1,1,0,1,0,0,1,0,1,0,0,0,1,0,2,1,1,0,0,2,1,,2026-07-01,,,0,2,0
NCT02987257,NATIENS: Optimal Management and Mechanisms of SJS/TEN,NATIENS: A Phase III Randomized Double-Blinded Placebo Controlled Study to Determine the Optimal Management and Mechanisms of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis,COMPLETED,2023-03-21,2025-10-31,2025-12-17,INTERVENTIONAL,PHASE3,2.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Stevens-Johnson Syndrome|Toxic Epidermal Necrolyses,Harmonized supportive care|Etanercept 50 mg sc day 1 and day 4,DRUG,1,7,18 Years,,ALL,False,Vanderbilt University Medical Center,OTHER,2,14,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,2,1.0986122886681098,small,1,1,0,1,0,1,1,0,1,0,1,1,1,1,8,1,1,0,0,2,1,,,,,0,3,1
NCT03079557,Feasibility Pilot for the ReBOO-trial,"A Non-randomised, Open Feasibility Pilot for the 'REpurposing BOtulinum Toxin in Treatment of Obesity in Adolescents' (ReBOO) Trial",COMPLETED,2017-03-14,2019-04-30,2020-09-22,INTERVENTIONAL,PHASE2,10.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Obesity,Intragastric botulinum toxin type A,DRUG,1,3,12 Years,18 Years,ALL,False,St. Olavs Hospital,OTHER,1,1,Norway,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.3978952727983707,small,1,1,0,1,0,1,0,0,0,0,0,0,1,0,4,1,1,0,0,1,0,,,,,0,0,0
NCT02153957,Trial Evaluating an Enhanced Physical Activity Intervention to Improve Cognitive Late Effects in Children Treated With Cranial Radiation for Brain Tumors,A Randomized Controlled Trial Evaluating an Enhanced Physical Activity Intervention to Improve Cognitive Late Effects in Children Treated With Cranial Radiation for Brain Tumors,COMPLETED,2014-08-21,2023-02-14,2025-12-24,INTERVENTIONAL,PHASE2,36.0,ACTUAL,RANDOMIZED,PARALLEL,SUPPORTIVE_CARE,NONE,Brain Tumor,Physical Activity,BEHAVIORAL,1,6,8 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.6109179126442243,small,1,1,0,1,0,0,0,0,1,0,1,0,0,1,7,1,0,0,0,1,0,,,,,0,1,0
NCT07020377,Dapagliflozin in Nonalcoholic Fatty Liver Disease (NAFLD) and Type 2 Diabetes Mellitus Patients (T2DM).,The Hepato-protective Effect of Dapagliflozin in Type 2 Diabetes Mellitus Patients (T2DM) With Nonalcoholic Fatty Liver Disease (NAFLD),ACTIVE_NOT_RECRUITING,2024-01-15,2025-12-30,2025-06-13,INTERVENTIONAL,PHASE1|PHASE2,60.0,ESTIMATED,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Diabetes Mellitus|Non Alcholic Fatty Liver Disease,Dapagliflozin (DAPA)|Placebo|Negative control,DRUG|OTHER,4,2,18 Years,,ALL,False,"Amira Bisher,PhD",OTHER,2,2,Egypt,,1,1,0,0,1,1.5,0,0,0,0,2,4.110873864173311,medium,1,0,0,1,0,1,1,0,0,0,1,1,0,1,6,1,1,0,0,3,1,,,,,0,4,1
NCT00629512,Prevention of Gastric Ulcers,A Comparative Efficacy and Safety Study of Nexium (Esomeprazole Magnesium) Delayed-Release Capsules (40mg qd and 20mg qd) Versus Placebo for the Prevention of Gastric Ulcers Associated With Daily NSAID Use in Patients at Risk,COMPLETED,2001-03,2002-12,2009-03-13,INTERVENTIONAL,PHASE3,504.0,ESTIMATED,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,NSAID Associated Gastric Ulcers,Esomeprazole|Esomeprazole|Placebo,DRUG,1,2,18 Years,,ALL,False,AstraZeneca,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.22455842927536,xlarge,0,0,1,0,1,0,0,0,0,0,1,1,0,1,3,1,1,0,0,3,1,2001-03-01,2002-12-01,640.0,2001.0,0,1,0
NCT03334812,"Study on Safety, Tolerability and Prelimenary Efficacy of LNA043 in Patients Undergoing Autologous Chondrocyte Implantation","A Randomized, Placebo-controlled, Patient and Investigator Blinded, Single Dose, Proof of Concept Study Investigating the Safety, Tolerability and Preliminary Efficacy of Intra-articular LNA043 in Regenerating the Articular Cartilage of the Knee at Donor Sites in Patients Undergoing Autologous Chondrocyte Implantation",TERMINATED,2017-10-18,2019-04-05,2021-10-07,INTERVENTIONAL,PHASE2,14.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Knee Cartilage Lesion,LNA043|placebo to LNA043,BIOLOGICAL,2,7,18 Years,50 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,2,Austria,0.0,0,1,0,0,0,2.0,0,0,0,0,1,2.70805020110221,small,1,1,1,0,1,0,1,0,0,0,1,1,1,1,9,1,0,1,0,2,1,,,,,0,2,0
NCT00101712,Efficacy and Safety of Vildagliptin Compared to Placebo in Patients With Type 2 Diabetes and Mild Hyperglycemia,Efficacy and Safety of Vildagliptin Compared to Placebo in Patients With Type 2 Diabetes and Mild Hyperglycemia,COMPLETED,2004-10,2006-05,2012-05-07,INTERVENTIONAL,PHASE3,274.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2",vildagliptin|Vildagliptin Placebo,DRUG,1,5,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,2,Germany|Switzerland,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.616771097666572,large,0,1,1,0,1,0,1,1,0,1,1,1,1,1,6,1,1,0,0,2,1,2004-10-01,2006-05-01,577.0,2004.0,0,3,1
NCT00768612,Study Evaluating Safety and Tolerability of Vabicaserin in Patients With Sudden Worsening of Schizophrenia,"A Randomized, Double-Blind, Risperidone-Reference, Parallel-Group, Safety, and Tolerability Study of Vabicaserin (SCA-136) in Japanese Subjects With Acute Exacerbation of Schizophrenia",WITHDRAWN,2008-11,2009-07,2013-01-29,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Schizophrenia,SCA-136 50mg/day|SCA-136 150 mg/day|SCA-136 300mg/day|Risperidone 4mg/day,DRUG,1,1,20 Years,65 Years,ALL,False,Wyeth is now a wholly owned subsidiary of Pfizer,INDUSTRY,0,0,,0.0,0,1,0,0,0,2.0,0,0,1,0,1,0.0,,1,1,1,0,1,0,0,0,0,0,1,1,1,1,2,1,1,0,0,4,1,2008-11-01,2009-07-01,242.0,2008.0,0,1,0
NCT03369912,A Study to Evaluate CSJ148 in Pregnant Women With Primary HCMV Infection,"A Multicenter, Randomized, Patient, Investigator and Sponsor Blinded, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of CSJ148 in Pregnant Women With Primary HCMV Infection",WITHDRAWN,2018-10-23,2022-11-15,2018-10-09,INTERVENTIONAL,PHASE2,0.0,ACTUAL,,PARALLEL,TREATMENT,TRIPLE,HCMV Infection,CSJ148|Placebo,BIOLOGICAL|OTHER,1,7,18 Years,65 Years,FEMALE,False,Novartis Pharmaceuticals,INDUSTRY,0,0,,0.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,1,1,1,0,1,0,0,0,0,0,0,1,1,1,8,1,0,1,0,2,1,,,,,0,2,0
NCT01034228,Isoleucine Added ORS in Children With Diarrhoea,Exploratory Study to Evaluate the Effect of L-isoleucine Supplemented Oral Rehydration Solution in the Treatment of Acute Diarrhoea in Children and in Inducing Innate Immunity,COMPLETED,2007-07,2008-07,2009-12-17,INTERVENTIONAL,PHASE2,50.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Acute Infectious Diarrhoea in Children,ORS + Isoleucine|ORS without Isoleucine,OTHER,1,1,6 Months,36 Months,MALE,False,"International Centre for Diarrhoeal Disease Research, Bangladesh",OTHER,3,1,Bangladesh,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.9318256327243257,small,1,1,0,1,0,1,0,0,0,0,1,1,1,1,2,1,0,0,0,2,1,2007-07-01,2008-07-01,366.0,2007.0,0,1,0
NCT01260467,Memantine for Recurrent Glioblastoma,A Phase II Study of Memantine in the Treatment of Recurrent Glioblastoma,TERMINATED,2010-11,2014-04,2015-12-10,INTERVENTIONAL,PHASE2,4.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Glioblastoma,memantine,DRUG,2,1,18 Years,,ALL,False,University of Rochester,OTHER,0,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,1.6094379124341003,small,1,1,0,1,1,0,0,0,1,0,0,0,1,0,3,1,1,0,0,1,0,2010-11-01,2014-04-01,1247.0,2010.0,0,0,0
NCT04480567,AAV Gene Therapy Study for Subjects with PKU,"A Phase 1/2 Open-Label, Dose Escalation Study to Determine the Safety and Efficacy of BMN 307, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Phenylalanine Hydroxylase in Subjects with Phenylketonuria",ACTIVE_NOT_RECRUITING,2020-09-24,2027-12,2024-12-12,INTERVENTIONAL,PHASE1|PHASE2,100.0,ESTIMATED,NON_RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,Phenylketonuria (PKU),BMN 307,DRUG,1,3,15 Years,,ALL,False,BioMarin Pharmaceutical,INDUSTRY,0,3,United Kingdom|United States,,1,1,0,0,1,1.5,0,0,0,0,1,4.61512051684126,medium,0,0,1,0,0,0,1,1,1,1,0,0,1,0,4,1,1,0,0,1,0,,2027-12-01,,,0,2,0
NCT00330200,"Effects of ISIS 113715 on Insulin Sensitivity, Glucose, and Lipid Metabolism and Energy Expenditure in Type 2 Diabetics","A Randomized, Double-Blind, Placebo-Controlled Study to Examine the Effects of ISIS 113715 Monotherapy on Insulin Sensitivity, Glucose and Lipid Metabolism and Energy Expenditure in Subjects With Type 2 Diabetes Mellitus",TERMINATED,2005-11-01,2007-03-01,2022-12-05,INTERVENTIONAL,PHASE2,2.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes Mellitus,ISIS 113715,DRUG,4,3,18 Years,70 Years,ALL,False,"Ionis Pharmaceuticals, Inc.",INDUSTRY,0,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,1.0986122886681098,small,1,1,1,0,0,0,0,0,1,0,1,1,1,1,7,1,1,0,0,1,0,,,,,0,1,0
NCT01888900,New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C,Unraveling the Mechanisms of Non-Response in Patients With and Without Cirrhosis Due to Chronic Hepatitis C,COMPLETED,2013-05,2015-11,2017-02-07,INTERVENTIONAL,PHASE2,35.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,"Cirrhosis|Chronic Hepatitis C|Hepatitis C|Hepatitis C, Chronic",DUAL|QUAD,DRUG,1,7,18 Years,,ALL,False,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),NIH,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,4,3.58351893845611,small,1,1,0,1,0,1,0,0,1,0,1,0,1,0,8,1,1,0,0,2,1,2013-05-01,2015-11-01,914.0,2013.0,0,3,1
NCT00005800,Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer,A Phase II Neoadjuvant Trial of Sequential Doxorubicin and Docetaxel for the Treatment of Stage III Breast Cancer Measuring STAT Activation as a Predictor of Response to Therapy,COMPLETED,1999-04,2012-05,2012-09-25,INTERVENTIONAL,PHASE2,45.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Breast Cancer,Filgrastim|Docetaxel|Doxorubicin|Surgery,DRUG|BIOLOGICAL|PROCEDURE,1,0,18 Years,70 Years,FEMALE,False,H. Lee Moffitt Cancer Center and Research Institute,OTHER,2,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.828641396489095,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,1,0,4,1,1999-04-01,2012-05-01,4779.0,1999.0,0,1,0
NCT01510028,Multicenter Study of HGT-1110 Administered Intrathecally in Children With Metachromatic Leukodystrophy (MLD),A Phase I/II Multicenter Open-label Dose Escalation Study of HGT-1110 Administered Intrathecally in Children With Metachromatic Leukodystrophy,COMPLETED,2012-02-02,2017-01-20,2021-06-14,INTERVENTIONAL,PHASE1|PHASE2,24.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Metachromatic Leukodystrophy (MLD),Recombinant human arylsulfatase A,BIOLOGICAL,7,21,,12 Years,ALL,False,Shire,INDUSTRY,0,5,Germany|Australia|Japan|Denmark|France,1.0,1,1,0,0,1,1.5,0,0,0,0,1,3.2188758248682006,small,1,1,1,0,0,0,1,1,0,1,0,0,1,1,28,1,0,1,0,1,0,,,,,0,3,1
NCT01755728,Paracetamol (Acetaminophen) for Closure of PDA in Preterm Infants,Paracetamol (Acetaminophen) for Closure of PDA in Preterm Infants,COMPLETED,2013-01-01,2018-12-31,2019-08-06,INTERVENTIONAL,PHASE3,19.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,PDA,Paracetamol|Ibuprofen|Closure of PDA,DRUG|PROCEDURE,1,1,,4 Months,ALL,False,Hillel Yaffe Medical Center,OTHER_GOV,0,1,Israel,1.0,0,0,1,0,0,3.0,0,0,0,0,1,2.995732273553991,small,1,1,0,1,0,0,0,0,0,0,0,0,1,0,2,1,1,0,0,3,1,,,,,0,1,0
NCT00956007,RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer,A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer,ACTIVE_NOT_RECRUITING,2010-03-31,2029-08,2026-01-06,INTERVENTIONAL,PHASE3,702.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Head and Neck Cancer,cetuximab|intensity-modulated radiation therapy,BIOLOGICAL|RADIATION,1,5,18 Years,,ALL,False,Radiation Therapy Oncology Group,NETWORK,2,264,China|Canada|Saudi Arabia|United States,,0,0,1,0,0,3.0,1,0,0,0,1,6.555356891810665,xlarge,0,1,0,0,0,1,1,1,1,0,1,0,1,1,6,1,0,1,0,2,1,,2029-08-01,,,0,3,1
NCT00973167,Low-magnitude High-frequency Vibration Study on Fracture Rate in Community Elderly,"The Efficacy of Low-magnitude, High-frequency Vibration Treatment on Reducing Fracture Risks and Fracture Incidences in the Community Elderly - a Prospective Randomized Trial",COMPLETED,2009-01,2012-04,2012-04-24,INTERVENTIONAL,PHASE2|PHASE3,704.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Fractures,Low-magnitude high-frequency vibration treatment,DEVICE,1,1,65 Years,85 Years,FEMALE,True,Chinese University of Hong Kong,OTHER,0,1,China,1.0,0,1,1,0,1,2.5,0,0,0,0,1,6.558197802812269,xlarge,0,1,0,1,0,0,0,0,0,0,1,0,1,1,2,1,0,0,1,1,0,2009-01-01,2012-04-01,1186.0,2009.0,0,1,0
NCT01108107,Neoadjuvant Treatment of Colon Cancer,Neoadjuvant Chemotherapy and Biological Treatment for Patients With Locally Advanced Colon Cancer,COMPLETED,2010-04,2015-03,2015-05-21,INTERVENTIONAL,PHASE2,76.0,ACTUAL,NON_RANDOMIZED,FACTORIAL,TREATMENT,NONE,Colon Cancer,Oxaliplatin|Capecitabine|Oxaliplatin|Capecitabine|Panitumumab,DRUG|BIOLOGICAL,1,2,18 Years,,ALL,False,Vejle Hospital,OTHER,1,3,Denmark,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.343805421853684,medium,1,1,0,1,0,1,1,0,0,0,0,0,1,0,3,1,1,1,0,5,1,2010-04-01,2015-03-01,1795.0,2010.0,0,1,0
NCT05957107,Phase II Trial of VDJ001 in Patients With Moderate-to-severe Active Rheumatoid Arthritis,"Randomized, Double-blind, Placebo, Positive-controlled Phase II Trial of VDJ001 in Patients With Moderate-to-severe Active Rheumatoid Arthritis",COMPLETED,2022-05-26,2023-06-02,2025-07-09,INTERVENTIONAL,PHASE2,181.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Rheumatoid Arthritis,Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection,BIOLOGICAL,1,10,18 Years,75 Years,ALL,False,"Beijing VDJBio Co., LTD.",INDUSTRY,0,15,China,1.0,0,1,0,0,0,2.0,0,1,0,0,1,5.204006687076795,medium,0,1,1,0,0,0,1,0,0,0,1,0,1,1,11,1,0,1,0,1,0,,,,,0,1,0
NCT00023907,Paclitaxel in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer,A Phase II Evaluation of Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum and Paclitaxel-Resistant Ovarian or Primary Peritoneal Cancer,TERMINATED,2001-07,,2013-04-11,INTERVENTIONAL,PHASE2,,,,,TREATMENT,NONE,Ovarian Cancer|Primary Peritoneal Cavity Cancer,paclitaxel,DRUG,0,0,,,FEMALE,False,Gynecologic Oncology Group,NETWORK,1,44,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,2,0.0,,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,2001-07-01,,,2001.0,0,1,0
NCT02530307,HT-3951 vs. Placebo in Stroke Rehabilitation,"A Phase 2a, Randomized, Double-Blind, Placebo-Controlled 21-Day Treatment Study, Including an fMRI Sub-Study, to Evaluate the Effect of HT-3951 on Upper Extremity Motor Function Following Ischemic Stroke",TERMINATED,2016-02,2017-12-31,2018-02-01,INTERVENTIONAL,PHASE2,61.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Ischemic Stroke,HT-3951|Placebo,DRUG,7,2,21 Years,85 Years,ALL,False,"Dart NeuroScience, LLC",INDUSTRY,0,18,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,4.127134385045092,medium,1,1,1,0,0,0,1,0,1,0,1,1,1,1,9,1,1,0,0,2,1,2016-02-01,,,2016.0,1,2,0
NCT01232907,The Effects of L-carnitine on Fatigue in Spinal Cord Injury,The Effects of L-carnitine on Fatigue in Spinal Cord Injury,COMPLETED,2010-10,2013-04,2014-10-08,INTERVENTIONAL,PHASE2,2.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Spinal Cord Injury (SCI),L-Carnitine,DRUG,1,3,19 Years,65 Years,ALL,False,University of British Columbia,OTHER,1,1,Canada,1.0,0,1,0,0,0,2.0,0,0,0,0,1,1.0986122886681098,small,1,1,0,1,0,1,0,0,0,0,1,0,1,0,4,1,1,0,0,1,0,2010-10-01,2013-04-01,913.0,2010.0,0,0,0
NCT02042807,To Evaluate the Effect of MCS® in Prostate Cancer Prevention,"A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of MCS® in Prostate Cancer Prevention",ACTIVE_NOT_RECRUITING,2014-10,2024-12,2024-06-13,INTERVENTIONAL,PHASE2,702.0,ESTIMATED,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Prostate Cancer,Placebo|MCS®,DRUG,1,0,50 Years,75 Years,MALE,False,"Health Ever Bio-Tech Co., Ltd.",INDUSTRY,0,1,Taiwan,,0,1,0,0,0,2.0,1,0,0,0,1,6.555356891810665,xlarge,0,0,1,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,0,2,1,2014-10-01,2024-12-01,3714.0,2014.0,0,1,0
NCT02079207,Study Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine,"Multi-center, Randomized, Double Blinded, Phase III Trial to Assess the Immunogenicity and Safety of NBP606 in Adults 50 Years of Age and Older Who Are naïve to Pneumococcal Vaccine",COMPLETED,2013-12,2015-03,2016-01-27,INTERVENTIONAL,PHASE3,767.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Pneumococcal Infections,NBP606|Prodiax-23,BIOLOGICAL,1,1,50 Years,,ALL,True,"SK Chemicals Co., Ltd.",INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.643789733147672,xlarge,0,1,1,0,0,0,0,0,0,0,1,1,0,1,2,1,0,1,0,2,1,2013-12-01,2015-03-01,455.0,2013.0,0,1,0
NCT06045507,Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007),"A Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral MK-8527 Once Monthly in Participants at Low-Risk for HIV-1 Infection",COMPLETED,2023-11-08,2025-02-12,2026-01-07,INTERVENTIONAL,PHASE2,352.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,HIV|HIV Pre-exposure Prophylaxis,MK-8527|Placebo to MK-8527,DRUG,2,2,18 Years,65 Years,ALL,True,Merck Sharp & Dohme LLC,INDUSTRY,0,18,Israel|South Africa|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,5.8664680569332965,large,0,1,1,0,1,0,1,1,1,0,1,1,0,1,4,1,1,0,0,2,1,,,,,0,3,1
NCT03773107,LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma,"LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Phase I/II Study of Carfilzomib, Ruxolitinib, and Low Dose Dexamethasone for Carfilzomib-Refractory Multiple Myeloma",COMPLETED,2019-01-03,2024-02-21,2025-01-13,INTERVENTIONAL,PHASE1|PHASE2,12.0,ACTUAL,NON_RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,Multiple Myeloma,Carfilzomib|Ruxolitinib|Dexamethasone,DRUG,1,8,18 Years,75 Years,ALL,False,Wake Forest University Health Sciences,OTHER,3,2,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,1,2.5649493574615367,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,9,1,1,0,0,3,1,,,,,0,3,1
NCT00139607,Parecoxib In Post Surgery (Hemicolectomy) Pain,"A Multicenter, Open Label, Pilot Study To Evaluate Analgesic Activity And Safety Of Parecoxib 40 Mg IV In Patients Undergoing Hemicolectomy, In The Optimal Management Of Acute Post-Operative Pain Of Surgical Patients",TERMINATED,2002-09,2005-01,2009-08-14,INTERVENTIONAL,PHASE3,60.0,,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Colectomy,Paracoxib,DRUG,1,1,18 Years,80 Years,ALL,False,Pfizer,INDUSTRY,0,3,Italy,0.0,0,0,1,0,0,3.0,0,0,0,0,1,4.110873864173311,medium,1,0,1,0,1,0,1,0,0,1,0,0,1,1,2,1,1,0,0,1,0,2002-09-01,2005-01-01,853.0,2002.0,0,0,0
NCT05703607,A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults,"A PHASE 1/2 RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS",ACTIVE_NOT_RECRUITING,2023-01-25,2030-08-20,2026-01-07,INTERVENTIONAL,PHASE2,900.0,ESTIMATED,RANDOMIZED,SEQUENTIAL,PREVENTION,QUADRUPLE,Shingles|Herpes Zoster Infection|Human,Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection|Candidate 1: PF-07915234: VZV modRNA Suspension for Injection|Candidate 2: PF-07921188: VZV modRNA Suspension for Injection|Candidate 3: PF-07921186: VZV modRNA Suspension for Injection|Shingrix|Candidate 2: PF-07921188: VZV modRNA Powder for Suspension for Injection,BIOLOGICAL,13,6,50 Years,85 Years,ALL,True,Pfizer,INDUSTRY,1,35,United States,,0,1,0,0,0,2.0,0,0,0,0,3,6.803505257608338,xlarge,0,0,1,0,1,1,1,0,1,0,1,1,0,0,19,1,0,1,0,6,1,,,,,0,3,1
NCT01561807,A Study to Investigate VX-787 Given to Adult Volunteers Inoculated With Live Influenza Virus,"A Phase 2a, Randomized, Double-Blind,Placebo-Controlled Study to Investigate the Effects of VX-787 Administered to Adult Volunteers Experimentally Inoculated With Live Influenza Virus",COMPLETED,2012-03,,2016-09-02,INTERVENTIONAL,PHASE2,140.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Influenza Virus,VX-787|Placebo,DRUG,1,12,18 Years,45 Years,ALL,True,Vertex Pharmaceuticals Incorporated,INDUSTRY,0,1,United Kingdom,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.948759890378168,medium,0,1,1,0,0,0,0,0,0,1,1,1,1,1,13,1,1,0,0,2,1,2012-03-01,,,2012.0,0,2,0
NCT04332107,Azithromycin for COVID-19 Treatment in Outpatients Nationwide,Azithromycin for Prevention of Disease Progression in Patients With Mild or Moderate COVID-19,TERMINATED,2020-05-22,2021-03-30,2023-03-02,INTERVENTIONAL,PHASE3,263.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,COVID-19|SARS-CoV-2,Azithromycin|Placebos,DRUG,1,13,18 Years,,ALL,False,Thomas M. Lietman,OTHER,3,1,United States,0.0,0,0,1,0,0,3.0,0,0,0,0,2,5.575949103146316,large,0,1,0,1,0,1,0,0,1,0,1,1,1,1,14,1,1,0,0,2,1,,,,,0,3,1
NCT00167206,Stem Cell Transplantation for Fanconi Anemia,"A Study of Thymic Shielding in Recipients of Total Body Irradiation, Cyclophosphamide, and Fludarabine Followed by Alternate Donor Hematopoietic Stem Cell Transplantation in Patients With Fanconi Anemia",TERMINATED,2004-03,2008-12,2019-08-26,INTERVENTIONAL,PHASE1|PHASE2,16.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Fanconi Anemia,"Hematopoietic Stem Cell Transplant|Thymic Shielding During Radiation|Total Body Irradiation|Cyclophosphamide, Fludarabine",DRUG|PROCEDURE,1,8,1 Day,18 Years,ALL,False,"Masonic Cancer Center, University of Minnesota",OTHER,0,1,United States,0.0,1,1,0,0,1,1.5,0,0,0,0,1,2.833213344056216,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,9,1,1,0,0,4,1,2004-03-01,2008-12-01,1736.0,2004.0,0,3,1
NCT06510504,"Efficacy of BNC210 in Acute, As-needed Treatment of Anxiety in Social Anxiety Disorder - 1","A Phase 3, Randomized, Double-blind, 2-arm, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of BNC210 for the Acute, As-needed Treatment of Anxiety in Adults With Social Anxiety Disorder",COMPLETED,2024-08-06,2025-09-19,2025-10-24,INTERVENTIONAL,PHASE3,370.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Social Anxiety Disorder,225 mg BNC210|Placebo,DRUG,1,3,18 Years,65 Years,ALL,False,Bionomics Limited,INDUSTRY,0,21,United States,1.0,0,0,1,0,0,3.0,0,0,1,0,1,5.916202062607435,large,0,1,1,0,0,0,1,0,1,0,1,1,1,1,4,1,1,0,0,2,1,,,,,0,1,0
NCT03399604,Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil,"A Phase 3 Open-label, Multicenter Study to Evaluate the Long-term Safety and Tolerability of Inhaled LIQ861(Treprostinil) in Pulmonary Arterial Hypertension (WHO Group 1) Patients",COMPLETED,2018-01-02,2019-11-25,2024-07-30,INTERVENTIONAL,PHASE3,121.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Primary Pulmonary Hypertension,LIQ861 Inhaled Treprostinil,DRUG,1,0,18 Years,,ALL,False,"Liquidia Technologies, Inc.",INDUSTRY,1,38,United States,1.0,0,0,1,0,0,3.0,0,0,0,1,1,4.804021044733257,medium,0,1,1,0,0,1,1,0,1,0,0,0,1,0,1,0,1,0,0,1,0,,,,,0,0,0
NCT00332384,Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension,,COMPLETED,2000-01,2001-11,2011-05-30,INTERVENTIONAL,PHASE3,573.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Ocular Hypertension,brimonidine/timolol fixed combination,DRUG,1,0,18 Years,,ALL,False,Allergan,INDUSTRY,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,1,1,6.352629396319567,xlarge,0,1,1,0,0,0,0,0,1,0,1,1,1,1,1,0,1,0,0,1,0,2000-01-01,2001-11-01,670.0,2000.0,0,0,0
NCT02256852,Exploratory Study of QBKPN SSI in Non-Small Cell Lung Cancer,"Open Label,Single Arm,Exploratory Study to Evaluate the Safety,Tolerability,Compliance and MOA,of QBKPN SSI in Subjects With 2 or More Second Primary Pre-invasive/Invasive Adenocarcinoma Following Surgical Resection of Stage I NSCLC",COMPLETED,2014-12,2015-11,2016-02-22,INTERVENTIONAL,PHASE2,6.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Non-Small Cell Lung Cancer,QBKPN SSI,BIOLOGICAL,1,1,18 Years,,ALL,False,Qu Biologics Inc.,INDUSTRY,0,1,Canada,1.0,0,1,0,0,0,2.0,1,0,0,0,1,1.9459101490553132,small,1,1,1,0,0,0,0,0,0,0,0,0,1,0,2,1,0,1,0,1,0,2014-12-01,2015-11-01,335.0,2014.0,0,0,0
NCT01918852,S-1 Versus Capecitabine in the First Line Treatment of MCC Patients.,"S1 Versus Capecitabine in the First Line Treatment of Metastatic Colorectal Cancer Patients, the SALTO Randomised Phase III Study of the Dutch Colorectal Cancer Group. A Safety Evaluation of Oral Fluoropyrimidines",COMPLETED,2013-12,2018-03,2018-03-14,INTERVENTIONAL,PHASE3,161.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Colorectal Cancer|Metastases,Capecitabine|Teysuno|Bevacizumab,DRUG,1,5,18 Years,,ALL,False,Dutch Colorectal Cancer Group,OTHER,1,24,Netherlands,1.0,0,0,1,0,0,3.0,1,0,0,0,2,5.087596335232384,medium,0,1,0,1,0,1,1,0,0,0,1,0,1,1,6,1,1,0,0,3,1,2013-12-01,2018-03-01,1551.0,2013.0,0,3,1
NCT02289352,"Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea","A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel-Design Study to Evaluate the Safety and Therapeutic Equivalence of Brimonidine Topical Gel, 0.33% (Watson Laboratories, Inc., USA) to Reference Product Mirvaso® (Brimonidine) Topical Gel, 0.33% (Galderma Laboratories, L.P., USA) in Patients With Moderate to Severe Facial Erythema Associated With Rosacea",COMPLETED,2014-07,2014-12,2020-01-14,INTERVENTIONAL,PHASE3,462.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Rosacea,Brimonidine|placebo,DRUG,1,1,18 Years,,ALL,False,Actavis Inc.,INDUSTRY,1,16,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.137727054086234,large,0,1,1,0,0,1,1,0,1,0,1,1,1,1,2,1,1,0,0,2,1,2014-07-01,2014-12-01,153.0,2014.0,0,1,0
NCT01267552,Study of Axillary Lymphadenectomy Without Drainage for Breast Cancer,Randomized Clinical Trial of Axillary Lymphadenectomy Without Drainage for Breast Cancer Treatment,COMPLETED,2000-07,2007-12,2010-12-28,INTERVENTIONAL,PHASE2|PHASE3,240.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Breast Cancer|Complications|Seroma,Non drains will be placed during operation|Closed suction drainage,PROCEDURE,1,1,,,FEMALE,False,Universidade Federal de Goias,OTHER,1,2,Brazil,1.0,0,1,1,0,1,2.5,1,0,0,0,3,5.484796933490655,large,0,1,0,1,0,1,1,0,0,0,1,0,1,1,2,1,0,0,0,2,1,2000-07-01,2007-12-01,2709.0,2000.0,0,3,1
NCT03469947,California Prehospital and In Hospital Antifibrinolytic Therapy Via TXA,Tranexamic Acid in Prehospital and In Hospital Civilian Trauma Care in Antifibrinolytic Therapy Study,COMPLETED,2015-03,2024-07-29,2024-07-30,INTERVENTIONAL,PHASE3,200.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Hemorrhagic Shock|Trauma Injury,Tranexamic Acid,DRUG,3,3,18 Years,90 Years,ALL,False,Arrowhead Regional Medical Center,OTHER,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,2,5.303304908059076,medium,0,1,0,1,0,0,0,0,0,0,0,0,1,1,6,1,1,0,0,1,0,2015-03-01,,,2015.0,1,2,0
NCT04286438,Bentracimab in Ticagrelor-treated Patients With Uncontrolled Bleeding or Requiring Urgent Surgery or Invasive Procedure,"A Phase 3, Multicenter, Open-Label, Single-Arm Study of Bentracimab (PB2452) in Ticagrelor-Treated Patients With Uncontrolled Major or Life-Threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure (REVERSE-IT Trial)",COMPLETED,2020-07-15,2024-09-09,2024-10-21,INTERVENTIONAL,PHASE3,226.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Hemorrhage|Urgent Surgery|Invasive Procedure,Bentracimab (PB2452) Infusion,DRUG,3,12,18 Years,,ALL,False,"SFJ Pharmaceuticals, Inc.",INDUSTRY,0,68,China|Belgium|Italy|Netherlands|Sweden|United States|Germany|Austria|Spain|United Kingdom|Switzerland|France|Canada,1.0,0,0,1,0,0,3.0,0,0,0,0,3,5.424950017481403,large,0,1,1,0,0,0,1,1,1,1,0,0,1,0,15,1,1,0,0,1,0,,,,,0,3,1
NCT02337738,A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Participants,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2/3 Study to Evaluate the Efficacy and Safety of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Patients With Wearing Off",COMPLETED,2015-01-27,2016-09-17,2022-03-02,INTERVENTIONAL,PHASE2|PHASE3,404.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Parkinson's Disease,TVP-1012 1mg|TVP-1012 0.5mg|Placebo,DRUG,1,10,30 Years,79 Years,ALL,False,Takeda,INDUSTRY,0,57,Japan,1.0,0,1,1,0,1,2.5,0,0,1,0,1,6.003887067106539,large,0,1,1,0,1,0,1,0,0,0,1,1,1,1,11,1,1,0,0,3,1,,,,,0,3,1
NCT02669849,Study to Assess the Efficacy and Safety of VX-210 in Subjects With Acute Traumatic Cervical Spinal Cord Injury,"A Phase 2b/3, Double-blind, Randomized, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of VX-210 in Subjects With Acute Traumatic Cervical Spinal Cord Injury",TERMINATED,2016-07,2018-11,2020-01-22,INTERVENTIONAL,PHASE2|PHASE3,70.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Cervical Spinal Cord Injury,VX-210|Placebo,DRUG,1,8,14 Years,75 Years,ALL,False,Vertex Pharmaceuticals Incorporated,INDUSTRY,0,39,Canada|United States,0.0,0,1,1,0,1,2.5,0,0,0,0,1,4.2626798770413155,medium,1,1,1,0,0,0,1,1,1,0,1,1,1,1,9,1,1,0,0,2,1,2016-07-01,2018-11-01,853.0,2016.0,1,4,1
NCT04255849,Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men Living With HIV,Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men Living With HIV,ACTIVE_NOT_RECRUITING,2021-02-23,2026-07-01,2026-01-23,INTERVENTIONAL,PHASE3,700.0,ESTIMATED,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,HPV Positive Oropharyngeal Squamous Cell Carcinoma|HIV-1-infection|HPV Infection,"9 valent human papillomavirus vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)|Saline Placebo",BIOLOGICAL|OTHER,1,2,20 Years,50 Years,MALE,False,Weill Medical College of Cornell University,OTHER,7,3,Brazil|Mexico|Puerto Rico,,0,0,1,0,0,3.0,1,0,0,0,3,6.55250788703459,xlarge,0,0,0,1,0,1,1,1,0,0,1,1,0,1,3,1,0,1,0,2,1,,,,,0,3,1
NCT00215358,Study in Patients With Asthma,,COMPLETED,2002-07,2005-12,2010-11-11,INTERVENTIONAL,PHASE2,32.0,,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Asthma,Formoterol Fumarate,DRUG,1,1,12 Years,70 Years,ALL,False,Dey,INDUSTRY,0,2,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.4965075614664802,small,1,0,1,0,0,0,1,0,1,0,1,1,1,0,2,1,1,0,0,1,0,2002-07-01,2005-12-01,1249.0,2002.0,0,0,0
NCT01063348,N-Acetyl Cysteine in Pathologic Skin Picking,"A Double-Blind, Placebo-Controlled Study of N-Acetyl Cysteine in Pathologic Skin Picking",COMPLETED,2012-09,2015-07,2023-02-23,INTERVENTIONAL,PHASE2,66.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Pathologic Skin Picking|Neurotic Excoriation|Psychogenic Excoriation|Dermatillomania,N-Acetyl Cysteine|Placebo,DRUG,1,1,18 Years,64 Years,ALL,False,University of Chicago,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,4,4.204692619390966,medium,1,1,0,1,0,0,0,0,1,0,1,1,1,1,2,1,1,0,0,2,1,2012-09-01,2015-07-01,1033.0,2012.0,0,2,0
NCT03984448,"Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas",Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas,ACTIVE_NOT_RECRUITING,2019-10-22,2028-04-01,2026-02-03,INTERVENTIONAL,PHASE2|PHASE3,363.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diffuse Large B-Cell Lymphoma|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Double-Expressor Lymphoma|EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|High Grade B-Cell Lymphoma, Not Otherwise Specified|Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present|Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma",Biospecimen Collection|Bone Marrow Biopsy|Computed Tomography|Cyclophosphamide|Doxorubicin Hydrochloride|Etoposide|Lumbar Puncture|Positron Emission Tomography|Prednisone|Rituximab|Venetoclax|Vincristine Sulfate,DRUG|BIOLOGICAL|PROCEDURE,2,4,18 Years,80 Years,ALL,False,National Cancer Institute (NCI),NIH,0,636,United States,,0,1,1,0,1,2.5,1,0,0,0,8,5.8971538676367405,large,0,0,0,1,0,0,1,0,1,0,1,0,1,1,6,1,1,1,0,12,1,,,,,0,4,1
NCT05824455,A Clinical Study of IMP4297 Capsule (JS109) Combined With Irinotecan in the Treatment of Advanced Malignant Solid Tumors,"An Open, Multicenter, Phase Ib/II Clinical Study of IMP4297 Capsule (JS109) Combined With Irinotecan in the Treatment of Advanced Malignant Solid Tumors",TERMINATED,2023-03-23,2023-09-28,2024-09-05,INTERVENTIONAL,PHASE1|PHASE2,4.0,ACTUAL,,SEQUENTIAL,TREATMENT,NONE,Advanced Solid Tumors,JS109 combine with irinotecan,COMBINATION_PRODUCT,4,21,18 Years,75 Years,ALL,False,"Shanghai Jun Pai Ying Shi Therapeutics Co., Ltd.",INDUSTRY,1,1,China,0.0,1,1,0,0,1,1.5,1,0,0,0,1,1.6094379124341003,small,1,1,1,0,0,1,0,0,0,0,0,0,1,0,25,1,0,0,0,1,0,,,,,0,2,0
NCT03770455,Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC,PDL-1 Inhibition With Avelumab and Concurrent Second-generation ADT in African Americans With Castrate-resistant Metastatic Prostate Cancer,TERMINATED,2019-01-25,2021-01-07,2024-07-09,INTERVENTIONAL,PHASE2,8.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Metastatic Castration-resistant Prostate Cancer,Avelumab|2nd generation ADT (abiraterone or enzalutamide),DRUG,1,3,18 Years,,MALE,False,"Jodi Layton, MD",OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,2.1972245773362196,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,4,1,1,0,0,2,1,,,,,0,1,0
NCT01982955,Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT),"A Phase Ib/II Multicenter, Randomized, Open Label Trial to Compare Tepotinib (MSC2156119J) Combined With Gefitinib Versus Chemotherapy as Second-Line Treatment in Subjects With MET Positive, Locally Advanced or Metastatic NSCLC Harboring EGFR Mutation and Having Acquired Resistance to Prior EGFR-TKI Therapy (INSIGHT)",COMPLETED,2013-12-23,2021-10-14,2022-11-08,INTERVENTIONAL,PHASE1|PHASE2,88.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Non-small Cell Lung Cancer,Tepotinib|Gefitinib|Pemetrexed|Cisplatin|Carboplatin,DRUG,3,41,18 Years,,ALL,False,"Merck KGaA, Darmstadt, Germany",INDUSTRY,0,44,China|Italy|South Korea|Spain|Malaysia|Taiwan|Singapore,1.0,1,1,0,0,1,1.5,1,0,0,0,1,4.48863636973214,medium,1,1,1,0,1,0,1,1,0,1,1,0,1,1,44,1,1,0,0,5,1,,,,,0,4,1
NCT03559985,Paracetamol and Neuropathic Pain,Analgesic Effect of Paracetamol in Neuropathic Pain Patients,TERMINATED,2018-08-20,2022-08-31,2022-10-10,INTERVENTIONAL,PHASE2,43.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Neuropathic Pain,paracetamol|Placebo comparator,DRUG|OTHER,1,16,18 Years,65 Years,ALL,False,"University Hospital, Clermont-Ferrand",OTHER,0,1,France,0.0,0,1,0,0,0,2.0,0,0,0,0,1,3.784189633918261,small,1,1,0,1,0,0,0,0,0,1,1,1,1,0,17,1,1,0,0,2,1,,,,,0,2,0
NCT02242643,Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age,Immunogenicity and Safety Study of GSK Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age,COMPLETED,2014-10-01,2015-06-23,2018-09-07,INTERVENTIONAL,PHASE3,2432.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Influenza,FluLaval™ Quadrivalent|Fluzone® Quadrivalent,BIOLOGICAL,2,12,6 Months,35 Months,ALL,True,GlaxoSmithKline,INDUSTRY,0,66,Mexico|United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,7.796880342783522,xlarge,0,1,1,0,0,0,1,1,1,0,1,1,0,1,14,1,0,1,0,2,1,,,,,0,3,1
NCT02319135,Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia,"A PHASE III, MULTICENTRE, RANDOMIZED, OPEN LABEL CLINICAL TRIAL OF AZACYTIDINE (VIDAZA®) VERSUS FLUDARABINE AND CYTARABINE (FLUGA SCHEME) IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA.",COMPLETED,2014-10,2019-10-28,2020-04-06,INTERVENTIONAL,PHASE3,289.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Acute Myeloid Leukemia,Azacitadine|Fludarabine|Cytarabine|Lenograstim|Filgastrim,DRUG,1,4,65 Years,,ALL,False,PETHEMA Foundation,OTHER,1,1,Spain,1.0,0,0,1,0,0,3.0,1,0,0,0,1,5.66988092298052,large,0,1,0,1,0,1,0,0,0,1,1,0,1,1,5,1,1,0,0,5,1,2014-10-01,,,2014.0,0,1,0
NCT00317135,"Safety Study of a Vaccine Against Meningitis in Infants ( 2,4 & 6 Months Age) After a Birth Dose of Hepatitis B.","Assess Reactogenicity and Safety of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC Compared to Tritanrix™-HepB/Hiberix™ (Control) in Healthy Infants (2,4,6 Months Age), After a Hepatitis B Birth Dose",COMPLETED,2003-12-11,2004-10-23,2018-08-15,INTERVENTIONAL,PHASE3,500.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,,Diphtheria|Hepatitis B|Whole Cell Pertussis|Haemophilus Influenzae Type b|Tetanus,Tritanrix-HepB/Meningitec conjugate vaccine|Tritanrix/Hiberix vaccine,BIOLOGICAL,3,3,,3 Days,ALL,True,GlaxoSmithKline,INDUSTRY,0,1,Philippines,1.0,0,0,1,0,0,3.0,0,0,0,0,5,6.2166061010848646,large,0,1,1,0,0,0,0,0,0,0,1,0,0,1,6,1,0,1,0,2,1,,,,,0,3,1
NCT02003625,Meloxicam vs Placebo for Mobilization,Non-steroidal Anti-inflammatory Drugs (Meloxicam) to Mobilize Hematopoietic Stem Cells: A Phase II Randomized Trial,COMPLETED,2013-10,2019-04,2020-05-18,INTERVENTIONAL,PHASE2,31.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Non-Hodgkin's Lymphoma|Hodgkin's Lymphoma|Multiple Myeloma|Hematopoietic Stem Cells,GCSF|meloxicam|Placebo,DRUG,4,3,18 Years,75 Years,ALL,False,Massachusetts General Hospital,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,4,3.4657359027997265,small,1,1,0,1,0,1,0,0,1,0,1,0,1,1,7,1,1,0,0,3,1,2013-10-01,2019-04-01,2008.0,2013.0,0,3,1
NCT04235140,Long-term Safety of Lumacaftor/Ivacaftor in Participants With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation,"A Phase 3, Open-label, and Rollover Study to Evaluate the Long-term Safety and Tolerability of Lumacaftor/Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation",COMPLETED,2020-02-24,2023-08-22,2024-09-19,INTERVENTIONAL,PHASE3,52.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Cystic Fibrosis,LUM/IVA,DRUG,1,1,12 Months,,ALL,False,Vertex Pharmaceuticals Incorporated,INDUSTRY,0,23,Canada|United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.970291913552122,medium,1,1,1,0,0,0,1,1,1,0,0,0,1,0,2,1,1,0,0,1,0,,,,,0,1,0
NCT04301089,Immersive Virtual Reality (VR) at the Time of Clinical Evaluation to Improve Psychological Distress and Anxiety in Primary Brain Tumor (PBT) Patients,A Phase II Feasibility Trial Using Immersive Virtual Reality (VR) at the Time of Clinical Evaluation to Improve Psychological Distress and Anxiety in Primary Brain Tumor (PBT) Patients,COMPLETED,2021-03-18,2025-02-04,2025-02-21,INTERVENTIONAL,PHASE2,28.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Anxiety,Pico G2 4K Headset with Applied VR software,DEVICE,1,4,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,1,0,1,3.367295829986474,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,5,1,0,0,1,1,0,,,,,0,0,0
NCT00170989,Valsartan/Hydrochlorothiazide Combination in Hypertensive Patients Not Controlled With Valsartan Alone,Comparison of the Combination of Valsartan 320 mg Plus Hydrochlorothiazide 12.5 mg and Valsartan 320 mg Plus Hydrochlorothiazide 25 mg to Valsartan 320 mg in Mild to Moderate Hypertensive Patients Not Adequately Controlled With Valsartan 320 mg,COMPLETED,2004-09,2005-07,2011-11-08,INTERVENTIONAL,PHASE3,2714.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Hypertension,valsartan plus hydrochlorothiazide,DRUG,1,5,18 Years,80 Years,ALL,,Novartis,INDUSTRY,0,2,Germany|Switzerland,1.0,0,0,1,0,0,3.0,0,0,0,1,1,7.906547232368036,xlarge,0,1,1,0,1,0,1,1,0,1,1,1,1,1,6,1,1,0,0,1,0,2004-09-01,2005-07-01,303.0,2004.0,0,2,0
NCT01983189,Transcranial Magnetic Stimulation for Evaluation and Treatment of Repetetive Behaviors in Autism,Repetetive Transcranial Magnetic Stimulation for Evaluation and Treatment of Repetetive Behavior in Subjects With Autism Spectrum Disorders.,TERMINATED,2008-11,2010-11,2017-03-24,INTERVENTIONAL,PHASE2,10.0,ACTUAL,,SINGLE_GROUP,TREATMENT,DOUBLE,Autism|Asperger Disorder|Other Developmental Pervasive Disorder,transcranial magnetic stimulation,PROCEDURE,1,1,18 Years,55 Years,ALL,False,New York State Psychiatric Institute,OTHER,0,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,3,2.3978952727983707,small,1,1,0,1,0,0,0,0,1,0,0,1,1,0,2,1,0,0,0,1,0,2008-11-01,2010-11-01,730.0,2008.0,0,1,0
NCT03769168,An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA),"An Extension Study of Subcutaneous Secukinumab to Evaluate the Long-term Efficacy, Safety and Tolerability up to 4 Years in Patients With Juvenile Idiopathic Arthritis Subtypes of Juvenile Psoriatic Arthritis and Enthesitis Related Arthritis",COMPLETED,2019-06-07,2024-11-07,2025-10-16,INTERVENTIONAL,PHASE3,55.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Juvenile Psoriatic Arthritis|Enthesitis Related Arthritis,Secukinumab,DRUG,1,17,2 Years,100 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,23,Italy|Belgium|Russia|Turkey (Türkiye)|United States|Germany|Spain|Poland|South Africa,1.0,0,0,1,0,0,3.0,0,1,0,0,2,4.02535169073515,medium,1,1,1,0,1,0,1,1,1,1,0,0,1,0,18,1,1,0,0,1,0,,,,,0,3,1
NCT01693068,Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma,"A Multicenter, Open Label, Randomized Phase II Trial of the MEK Inhibitor Pimasertib or Dacarbazine in Previously Untreated Subjects With N-Ras Mutated Locally Advanced or Metastatic Malignant Cutaneous Melanoma",COMPLETED,2012-12-05,2016-10-24,2018-01-05,INTERVENTIONAL,PHASE2,194.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma,Pimasertib|Dacarbazine,DRUG,1,10,18 Years,,ALL,False,EMD Serono,INDUSTRY,1,101,Italy|Belgium|Netherlands|Sweden|United States|Germany|Spain|Australia|United Kingdom|Switzerland|New Zealand|Israel|South Africa|France,1.0,0,1,0,0,0,2.0,1,0,0,0,1,5.272999558563747,medium,0,1,1,0,0,1,1,1,1,1,1,0,1,1,11,1,1,0,0,2,1,,,,,0,3,1
NCT04035850,Vortioxetine for the Treatment of Hoarding Disorder,Vortioxetine for the Treatment of Hoarding Disorder- an Open Label Study,WITHDRAWN,2019-08-01,2021-08-01,2024-02-02,INTERVENTIONAL,PHASE3,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Hoarding Disorder,Vortioxetine Tablets,DRUG,2,3,25 Years,65 Years,ALL,False,Noam Soreni,OTHER,0,1,Canada,0.0,0,0,1,0,0,3.0,0,0,0,0,1,0.0,,1,1,0,1,0,0,0,0,0,0,0,0,1,0,5,1,1,0,0,1,0,,,,,0,0,0
NCT06004050,"A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczema","A Phase 3 Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Twice-Daily Applications of Delgocitinib Cream 20 mg/g in Chinese Adults and Adolescents (12-17 Years of Age) With Moderate to Severe Chronic Hand Eczema",COMPLETED,2023-09-05,2025-09-12,2025-09-25,INTERVENTIONAL,PHASE3,362.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Chronic Hand Eczema,Delgocitinib|Vehicle cream,DRUG|OTHER,1,18,12 Years,,ALL,False,LEO Pharma,INDUSTRY,0,37,China,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.8944028342648505,large,0,1,1,0,0,0,1,0,0,0,1,1,1,1,19,1,1,0,0,2,1,,,,,0,2,0
NCT01537250,Phase II Clinical Study to Assess the Efficacy and Safety of Nemonoxacin Malate in Treating Adult Patients With Community-acquired Pneumonia (CAP),"A Multi-center, Randomized, Double-blind, Double-dummy Parallel-controlled Phase II Clinical Study to Assess the Efficacy and Safety of Nemonoxacin Malate in Treating Adult Patients With Community-acquired Pneumonia (CAP)",COMPLETED,2009-08,2010-08,2018-01-24,INTERVENTIONAL,PHASE2,192.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Community-acquired Pneumonia,Levofloxacin 500 mg placebol|Levofloxacin 500 mg placebol|Nemonoxacin 3 tablets,DRUG,2,1,18 Years,70 Years,ALL,False,"TaiGen Biotechnology Co., Ltd.",INDUSTRY,0,32,China,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.262690188904886,medium,0,1,1,0,0,0,1,0,0,0,1,1,1,1,3,1,1,0,0,3,1,2009-08-01,2010-08-01,365.0,2009.0,0,1,0
NCT05216250,Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor,"A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Upper Limb Essential Tremor",COMPLETED,2022-04-12,2025-02-03,2026-01-20,INTERVENTIONAL,PHASE2,174.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Upper Limb Essential Tremor (UL ET),BOTOX|Placebo for BOTOX,DRUG|BIOLOGICAL,2,6,18 Years,80 Years,ALL,False,AbbVie,INDUSTRY,0,40,Canada|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.1647859739235145,medium,0,1,1,0,1,0,1,1,1,0,1,1,1,1,8,1,1,1,0,2,1,,,,,0,3,1
NCT00270491,Capecitabine Associated With Weekly Paclitaxel in Metastatic Breast Cancer.,"A Multicenter Randomized Phase II Study Evaluating Tolerance and Efficacy of Capecitabine 5/7 Days With Weekly Paclitaxel Versus the Recommended Treatment Plan of Weekly Paclitaxel-capecitabine, in Patients With Metastatic Breast Cancer.",COMPLETED,2005-12,2010-10,2011-02-25,INTERVENTIONAL,PHASE2,130.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,NONE,Breast Cancer|Neoplasm Metastasis,Paclitaxel|Capecitabine,DRUG,1,4,18 Years,,FEMALE,False,ARCAGY/ GINECO GROUP,OTHER,0,1,France,1.0,0,1,0,0,0,2.0,1,0,0,0,2,4.875197323201151,medium,0,0,0,1,0,0,0,0,0,1,1,0,1,1,5,1,1,0,0,2,1,2005-12-01,2010-10-01,1765.0,2005.0,0,2,0
NCT01614574,Study of Velaglucerase Alfa Enzyme Replacement Therapy in Japanese Patients With Gaucher Disease,"A Multicenter, Open-Label Study of Velaglucerase Alfa Enzyme Replacement Therapy in Japanese Patients With Gaucher Disease",COMPLETED,2012-03-02,2013-05-25,2021-06-28,INTERVENTIONAL,PHASE3,6.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Gaucher Disease,velaglucerase alfa,BIOLOGICAL,5,6,2 Years,,ALL,False,Shire,INDUSTRY,0,3,Japan,1.0,0,0,1,0,0,3.0,0,0,0,0,1,1.9459101490553132,small,1,1,1,0,0,0,1,0,0,0,0,0,1,0,11,1,0,1,0,1,0,,,,,0,1,0
NCT02151474,INCB047986 in Rheumatoid Arthritis,"A Double-Blind, Placebo-Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28-Day Course of INCB047986 in Subjects With Active Rheumatoid Arthritis",TERMINATED,2014-05,2014-08,2015-02-23,INTERVENTIONAL,PHASE2,3.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Rheumatoid Arthritis,INCB047986|Placebo,DRUG,2,9,18 Years,,ALL,False,Incyte Corporation,INDUSTRY,0,9,United States,0.0,0,1,0,0,0,2.0,0,1,0,0,1,1.3862943611198906,small,1,1,1,0,0,0,1,0,1,0,1,1,1,1,11,1,1,0,0,2,1,2014-05-01,2014-08-01,92.0,2014.0,0,2,0
NCT01037218,Treatment of Erectile Dysfunction II,"Randomized, Placebo-controlled, Double-Blind, Parallel Design, Phase 3 Study to Assess the Safety and Efficacy of Udenafil Tablets in Male Subjects With Erectile Dysfunction",COMPLETED,2009-09,2010-04,2015-06-19,INTERVENTIONAL,PHASE3,601.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Erectile Dysfunction,Udenafil|Placebo,DRUG,3,10,19 Years,,MALE,False,Warner Chilcott,INDUSTRY,0,40,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.400257445308821,xlarge,0,1,1,0,0,0,1,0,1,0,1,1,1,1,13,1,1,0,0,2,1,2009-09-01,2010-04-01,212.0,2009.0,0,2,0
NCT01574118,Enhancing Exposure Therapy for Post-traumatic Stress Disorder,Enhancing Exposure Therapy for PTSD: An Investigation of Non-Pharmacological Augmentation Strategies,TERMINATED,2012-04,2020-03,2022-08-29,INTERVENTIONAL,PHASE2,27.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,SINGLE,Chronic Posttraumatic Stress Disorder,Revisiting the Trauma memories|Processing the trauma memories|Psychoeducation|Trauma Memory Retrieval Trial|Exposure to video clips related to the patient's trauma|Breathing retraining|Exposure Homework|Compound extinction,BEHAVIORAL,1,4,18 Years,65 Years,ALL,True,University of Texas at Austin,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,3.332204510175204,small,1,1,0,1,0,1,0,0,1,0,1,0,1,0,5,1,0,0,0,8,1,2012-04-01,2020-03-01,2891.0,2012.0,0,1,0
NCT00058318,"S0312, Gemcitabine and Capecitabine in Treating Patients With Advanced Renal Cell (Kidney) Cancer",A Phase II Study of IV Gemcitabine and Oral Capecitabine in Patients With Advanced Renal Cell Cancer,COMPLETED,2004-12,2008-11,2012-11-02,INTERVENTIONAL,PHASE2,43.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Kidney Cancer,capecitabine|gemcitabine hydrochloride,DRUG,1,2,18 Years,,ALL,False,SWOG Cancer Research Network,NETWORK,1,0,,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.784189633918261,small,1,1,0,0,0,1,0,0,0,0,0,0,1,0,3,1,1,0,0,2,1,2004-12-01,2008-11-01,1431.0,2004.0,0,1,0
NCT02810990,Bosutinib in Elderly Chronic Myeloid Leukemia,"Bosutinib Efficacy, Safety, Tolerability (BEST) Study in Elderly Chronic Myeloid Leukemia Patients Failing Front-line Treatment With Other Tyrosine Kinase Inhibitors",COMPLETED,2016-11-17,2022-06-22,2023-02-03,INTERVENTIONAL,PHASE2,65.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Chronic Myeloid Leukemia,Bosutinib,DRUG,1,7,60 Years,,ALL,False,Gruppo Italiano Malattie EMatologiche dell'Adulto,OTHER,0,45,Italy,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.189654742026425,medium,1,1,0,1,0,0,1,0,0,1,0,0,1,0,8,1,1,0,0,1,0,,,,,0,1,0
NCT02815397,DA-EPOCH-Rituximab/Metformin (RM) for Double Hit Lymphoma,DA-EPOCH-RM: A Phase II Study Evaluating the Efficacy and Safety of Metformin in Combination With Standard Induction Therapy (DA-EPOCH-R) for Previously Untreated C-myc+ Diffuse Large B-Cell Lymphoma,TERMINATED,2016-02,2016-07,2017-11-17,INTERVENTIONAL,PHASE2,2.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Diffuse Large B-Cell Lymphoma,Metformin,DRUG,1,3,18 Years,,ALL,False,Rush University Medical Center,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,1.0986122886681098,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,4,1,1,0,0,1,0,2016-02-01,2016-07-01,151.0,2016.0,1,0,0
NCT07279610,N-Acetylcysteine as Therapy for Transplantation- Associated Thrombotic Microangiopathy,N-Acetylcysteine as Therapy for Transplantation- Associated Thrombotic Microangiopathy,ACTIVE_NOT_RECRUITING,2024-05-01,2026-12-31,2025-12-12,INTERVENTIONAL,PHASE2|PHASE3,44.0,ESTIMATED,,SINGLE_GROUP,TREATMENT,NONE,Thrombotic Microangiopathy,N-Acetylcysteine (NAC) Treatment,DRUG,1,9,18 Years,,ALL,False,The First Affiliated Hospital of Soochow University,OTHER,0,1,China,,0,1,1,0,1,2.5,0,0,0,0,1,3.8066624897703196,small,1,0,0,1,0,0,0,0,0,0,0,0,1,0,10,1,1,0,0,1,0,,,,,0,2,0
NCT00351910,Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder,"A Multi-Centre, Double-Blind, Randomised, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SRTM) in Combination With an Antidepressant in the Treatment of Patients With Major Depressive Disorder With Inadequate Response to an Antidepressant Treatment",COMPLETED,2006-05,2007-04,2011-01-26,INTERVENTIONAL,PHASE3,494.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Major Depressive Disorder,Quetiapine|Amitriptyline|Bupropion|Citalopram|Duloxetine|Escitalopram|Fluoxetine|Paroxetine|Sertraline|Venlafaxine,DRUG,2,1,18 Years,65 Years,ALL,False,AstraZeneca,INDUSTRY,0,72,Belgium|Finland|Sweden|Germany|Australia|Romania|Norway|Poland|Czechia|South Africa|France|Canada,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.20455776256869,large,0,1,1,0,1,0,1,1,0,1,1,1,1,1,3,1,1,0,0,10,1,2006-05-01,2007-04-01,335.0,2006.0,0,2,0
NCT00002413,A Study of MKC-442 in HIV-Positive Patients,An Open Label Study of MKC-442 in at Least Triple Drug Combination in Patients Previously Treated With Nucleoside Reverse Transcriptase and Protease Inhibitors and Who Are Naive to Non-Nucleoside Reverse Transcriptase Inhibitors,COMPLETED,,,2005-06-24,INTERVENTIONAL,PHASE2,,,,,TREATMENT,NONE,HIV Infections,Emivirine,DRUG,0,0,18 Years,,ALL,False,Triangle Pharmaceuticals,INDUSTRY,0,0,,1.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,,,,,0,0,0
NCT01961960,A Study to Evaluate Intramuscular ASP7374,Phase 3 Study of ASP7374 -Open-label Study of Intramuscular ASP7374 in Adults ≥61 Years of Age-,COMPLETED,2013-10,2013-11,2017-09-29,INTERVENTIONAL,PHASE3,55.0,ACTUAL,,SINGLE_GROUP,PREVENTION,NONE,Influenza|Vaccine,ASP7374,BIOLOGICAL,1,2,61 Years,,ALL,True,UMN Pharma Inc.,INDUSTRY,0,1,Japan,1.0,0,0,1,0,0,3.0,0,0,0,0,2,4.02535169073515,medium,1,1,1,0,0,0,0,0,0,0,0,0,0,0,3,1,0,1,0,1,0,2013-10-01,2013-11-01,31.0,2013.0,0,1,0
NCT05149560,Ticagrelor Monotherapy After Stenting,"Ticagrelor Monotherapy After Coronary Stenting in Patients With Acute Myocardial Infarction - A Prospective Single-centre, Single-arm Phase II Study",ACTIVE_NOT_RECRUITING,2021-12-04,2025-12,2025-06-27,INTERVENTIONAL,PHASE2,200.0,ESTIMATED,,SINGLE_GROUP,TREATMENT,NONE,Acute Myocardial Infarction,Ticagrelor 90mg,DRUG,1,7,18 Years,,ALL,False,Vastra Gotaland Region,OTHER_GOV,1,1,Sweden,,0,1,0,0,0,2.0,0,0,0,1,1,5.303304908059076,medium,0,0,0,1,0,1,0,0,0,0,0,0,1,0,8,1,1,0,0,1,0,,2025-12-01,,,0,1,0
NCT03252093,Evaluation of the Safety and Efficacy of Ang-(1-7) to Enhance Cognitive Function in Participants Undergoing CABG,"A Randomized, Placebo-controlled, Double Blind Evaluation of the Safety and Efficacy of Angiotensin 1-7 (Ang-(1-7)) to Enhance Cognitive Function in Participants Undergoing Coronary Artery Bypass Graft (CABG) Surgery.",TERMINATED,2017-07-20,2022-11-15,2025-06-04,INTERVENTIONAL,PHASE2,6.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Coronary Artery Bypass Surgery|Cognitive Impairment,Angiotensin-(1-7)|Placebo for Angiotensin-(1-7),DRUG,1,4,60 Years,80 Years,ALL,False,University of Arizona,OTHER,2,5,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,2,1.9459101490553132,small,1,1,0,1,0,1,1,0,1,0,1,1,1,1,5,1,1,0,0,2,1,,,,,0,2,0
NCT00938587,A Study Of PF-04171327 In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis,"A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, ACTIVE AND PLACEBO-CONTROLLED STUDY OF PF-04171327 IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS",COMPLETED,2009-10-07,2010-07-29,2023-11-22,INTERVENTIONAL,PHASE2,86.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Rheumatoid Arthritis,PF-04171327 10 mg|Prednisone Placebo|PF-04171327 25 mg|Prednisone Placebo|Prednisone 5 mg|Placebo for PF-04171327|Placebo|Placebo for PF-04171327,DRUG|OTHER,1,27,18 Years,,ALL,False,Pfizer,INDUSTRY,0,41,Russia|Turkey (Türkiye)|Hungary|South Korea|United States|Spain|Slovakia|Hong Kong|Serbia|Czechia|Taiwan|Ukraine|Singapore,1.0,0,1,0,0,0,2.0,0,1,0,0,1,4.465908118654584,medium,1,1,1,0,1,0,1,1,1,1,1,1,1,1,28,1,1,0,0,8,1,,,,,0,3,1
NCT03892421,Outpatient Administration of R-DHAP in Relapsed/Refractory Non-Hodgkin Lymphoma,"Safety and Efficacy of an Outpatient Schedule of Rituximab, Cytarabine, Carboplatin, and Dexamethasone in Relapsed/Refractory Non-Hodgkin Lymphoma. Phase I/II Trial.",COMPLETED,2018-04-05,2021-04-30,2021-05-18,INTERVENTIONAL,PHASE1|PHASE2,22.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Relapsed Non Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma,Rituximab|Carboplatin|Cytarabine Injection|Dexamethasone|Filgrastim 0.3 MG/ML,DRUG,2,2,18 Years,65 Years,ALL,False,La Raza Medical Center,OTHER,0,1,Mexico,1.0,1,1,0,0,1,1.5,1,0,0,0,2,3.1354942159291497,small,1,1,0,1,0,0,0,0,0,0,0,0,1,0,4,1,1,0,0,5,1,,,,,0,3,1
NCT04129216,The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer,The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer,COMPLETED,2019-02-20,2022-11-10,2024-05-07,INTERVENTIONAL,PHASE2,30.0,ACTUAL,NON_RANDOMIZED,PARALLEL,BASIC_SCIENCE,NONE,Breast Cancer,Tamoxifen Citrate|Letrozole|Exemestane|Blueprint|Mammaprint,DRUG|DIAGNOSTIC_TEST,1,3,18 Years,90 Years,ALL,False,Johns Hopkins University,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.4339872044851463,small,1,1,0,1,0,1,0,0,1,0,0,0,0,1,4,1,1,0,0,5,1,,,,,0,1,0
NCT01777321,Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A When Administered Subcutaneously Intramuscularly in Adults Aged ≥50 Years,Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A When Administered Subcutaneously Versus Intramuscularly in Adults Aged 50 Years or Older,COMPLETED,2013-06-17,2014-11-11,2018-10-25,INTERVENTIONAL,PHASE3,60.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Herpes Zoster,Herpes zoster vaccine GSK1437173A,BIOLOGICAL,11,5,50 Years,,ALL,True,GlaxoSmithKline,INDUSTRY,0,1,Japan,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.110873864173311,medium,1,1,1,0,0,0,0,0,0,0,1,0,0,1,16,1,0,1,0,1,0,,,,,0,1,0
NCT01500616,Telaprevir Open-Label Study in Co-Infected Patients,"Multicenter, Open-Label, Study of Telaprevir in Combination With Peginterferon Alfa and Ribavirin in Human Immunodeficiency Virus/Genotype 1 Chronic Hepatitis C Coinfected Subjects With Severe Fibrosis or Compensated Cirrhosis",COMPLETED,2012-06,2014-08,2016-08-18,INTERVENTIONAL,PHASE3,122.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Hepatitis C, Chronic",Telaprevir|Telaprevir,DRUG,1,0,18 Years,70 Years,ALL,False,Janssen-Cilag International NV,INDUSTRY,0,29,Belgium|Luxembourg|Russia|Hungary|Germany|United Kingdom|Portugal|Ireland,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.812184355372417,medium,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,0,0,2,1,2012-06-01,2014-08-01,791.0,2012.0,0,2,0
NCT04335006,"A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.","A Multicentre, Open-parallel, Randomized, Controlled Phase Ⅲ Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer.",TERMINATED,2020-07-14,2023-04-14,2023-05-06,INTERVENTIONAL,PHASE3,80.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Breast Cancer|Triple Negative Breast Cancer,Carelizumab|Nab-paclitaxel|Apatinib,DRUG,1,7,18 Years,70 Years,FEMALE,False,"Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,0,1,China,0.0,0,0,1,0,0,3.0,1,0,0,0,2,4.394449154672439,medium,1,1,1,0,0,0,0,0,0,0,1,0,1,1,8,1,1,0,0,3,1,,,,,0,3,1
NCT00323284,A Study of the Trabecular Micro-bypass Stent in Combination With Cataract Surgery in Subjects With Open Angle Glaucoma,A Study of the Glaukos Trabecular Micro-Bypass Stent in Combination With Cataract Surgery in Open Angle Glaucoma Subjects.,COMPLETED,2005-06,2010-03,2018-01-12,INTERVENTIONAL,PHASE3,240.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Open-Angle Glaucoma,iStent plus Cataract Surgery|Cataract surgery only,DEVICE|PROCEDURE,1,1,18 Years,,ALL,False,Glaukos Corporation,INDUSTRY,0,31,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.484796933490655,large,0,1,1,0,0,0,1,0,1,0,1,0,1,1,2,1,0,0,1,2,1,2005-06-01,2010-03-01,1734.0,2005.0,0,1,0
NCT01122784,Randomized Single-Blinded Study to Evaluate Safety and Immunogenicity of Recombinant Plague Vaccine With and Without Adjuvant,"A Phase 2b Randomized, Single-Blinded Study to Evaluate the Safety and Immunogenicity of 80 µg Recombinant Plague Vaccine (rF1V) With and Without Adjuvant at Two Vaccination Schedules in Healthy Adult Volunteers",COMPLETED,2010-07,2012-07,2020-07-30,INTERVENTIONAL,PHASE2,402.0,ACTUAL,RANDOMIZED,PARALLEL,OTHER,SINGLE,Plague Vaccine,rF1V vaccine (with Adjuvant)|rF1V vaccine (without Adjuvant)|rF1V vaccine (with Adjuvant)|rF1V vaccine (without Adjuvant),BIOLOGICAL,1,2,18 Years,55 Years,ALL,True,"DynPort Vaccine Company LLC, A GDIT Company",INDUSTRY,0,11,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.998936561946683,large,0,1,1,0,0,0,1,0,1,0,1,0,0,1,3,1,0,1,0,4,1,2010-07-01,2012-07-01,731.0,2010.0,0,1,0
NCT01726933,LAS41008 in Moderate to Severe Chronic Plaque Psoriasis,"A Multi-center, Randomized, Double-blind, Three-arm, 16 Week, Adaptive Phase III Clinical Study to Investigate the Efficacy and Safety of LAS41008 vs LASW1835 and vs Placebo in Patients With Moderate to Severe Chronic Plaque Psoriasis",COMPLETED,2012-11,2015-11,2015-12-02,INTERVENTIONAL,PHASE3,839.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Plaque Psoriasis,LAS41008|LASW1835|Placebo,DRUG,2,5,18 Years,,ALL,False,"Almirall, S.A.",INDUSTRY,2,4,Germany|Austria|Netherlands|Poland,1.0,0,0,1,0,0,3.0,0,1,0,0,1,6.733401891837359,xlarge,0,1,1,0,0,1,1,1,0,1,1,1,1,1,7,1,1,0,0,3,1,2012-11-01,2015-11-01,1095.0,2012.0,0,3,1
NCT02927847,"Neuroimaging Reward, Behavioral Treatment, and Smoking Cessation",Targeting Reward Dysfunction as a Mechanism to Improve Smoking Cessation,COMPLETED,2017-02-01,2022-05-27,2022-06-28,INTERVENTIONAL,PHASE1|PHASE2,35.0,ACTUAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,SINGLE,Smoking,Nicotine Patch|SPECTRUM Nicotine Research Cigarettes (.03 mg)|Behavioral Activation|Supportive Counseling,BEHAVIORAL|DRUG,3,0,18 Years,55 Years,ALL,True,"Maggie M Sweitzer, PhD",OTHER,1,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,3.58351893845611,small,1,1,0,1,0,1,0,0,1,0,1,0,0,1,3,0,1,0,0,4,1,,,,,0,2,0
NCT03905447,The Effect of Early Treatment of PC945 on Aspergillus Fumigatus Lung Infection in Lung Transplant Patients.,"An Open-label, Pilot Study to Assess Safety, Tolerability, Pharmacokinetics and Effects of Inhaled PC945 in the Pre-emptive Treatment of Aspergillus Fumigatus Colonisation in Lung Transplant Recipients",TERMINATED,2019-09-17,2020-06-01,2021-07-16,INTERVENTIONAL,PHASE2,2.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Aspergillosis|Lung Transplant Infection,PC945|Standard of Care,DRUG,9,9,18 Years,85 Years,ALL,False,Pulmocide Ltd,INDUSTRY,0,3,United Kingdom,0.0,0,1,0,0,0,2.0,0,0,0,0,2,1.0986122886681098,small,1,1,1,0,0,0,1,0,0,1,0,0,1,1,18,1,1,0,0,2,1,,,,,0,3,1
NCT00270049,Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia,The Effect of Subcutaneous r-HuEPO in Patients With Chronic Lymphocytic Leukemia,COMPLETED,1990-11,1994-01,2011-05-18,INTERVENTIONAL,PHASE2,195.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Anemia|Leukemia, Lymphocytic, Chronic|Leukemia, Lymphocytic|Cancer|Neoplasms|Quality of Life",epoetin alfa,DRUG,1,1,18 Years,,ALL,False,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INDUSTRY,0,0,,1.0,0,1,0,0,0,2.0,1,0,0,0,6,5.278114659230517,medium,0,1,1,0,0,0,0,0,0,0,1,1,1,1,2,1,1,0,0,1,0,1990-11-01,1994-01-01,1157.0,1990.0,0,1,0
NCT00273338,DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2]),"A Phase 3, Randomized, Open-Label Study Evaluating DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (ASCENT-2)",TERMINATED,2006-01,2007-11,2007-11-06,INTERVENTIONAL,PHASE3,1200.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,NONE,Prostate Cancer,calcitriol|docetaxel,DRUG,0,0,18 Years,,MALE,False,Novacea,INDUSTRY,0,222,Serbia and Montenegro|Hungary|Puerto Rico|United States|Germany|Slovakia|Romania|Czechia|Canada,0.0,0,0,1,0,0,3.0,1,0,0,0,1,7.0909098220799835,xlarge,0,0,1,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,2,1,2006-01-01,2007-11-01,669.0,2006.0,0,2,0
NCT02717338,"Blood Donor Competence, Autonomy and Relatedness Enhancement","Blood Donor Competence, Autonomy and Relatedness Enhancement (Blood Donor CARE)",COMPLETED,2016-05-27,2020-12-31,2022-03-03,INTERVENTIONAL,PHASE3,2580.0,ACTUAL,RANDOMIZED,FACTORIAL,TREATMENT,NONE,Blood Donors,Competence|Autonomy|Relatedness,BEHAVIORAL,1,14,16 Years,24 Years,ALL,False,Ohio University,OTHER,2,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,7.855932199718614,xlarge,0,1,0,1,0,1,0,0,1,0,1,0,1,0,15,1,0,0,0,3,1,,,,,0,2,0
NCT05170438,Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based Treatment,Phase II Trial of Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based Treatment,ACTIVE_NOT_RECRUITING,2022-07-01,2028-06,2026-01-20,INTERVENTIONAL,PHASE2,51.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Advanced Biliary Tract Cancer,"Lenvatinib Pill,Paclitaxel",DRUG,1,1,20 Years,,ALL,False,"National Health Research Institutes, Taiwan",OTHER,7,8,Taiwan,,0,1,0,0,0,2.0,1,0,0,0,1,3.9512437185814275,medium,1,1,0,1,0,1,1,0,0,0,0,0,1,0,2,1,1,0,0,1,0,,2028-06-01,,,0,0,0
NCT00596258,A Two-Stage Phase 2 Study Of A-007 Topical Gel in High-Grade Squamous Intraepithelial Lesions (HSIL),"A Two-Stage Phase 2 Study Of Dose-Intense 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenyl-Hydrazone (A-007) Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix",COMPLETED,2007-11,2008-08,2009-05-22,INTERVENTIONAL,PHASE2,11.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Cervical Intraepithelial Neoplasia|Uterine Cervical Dysplasia,A-007,DRUG,1,2,18 Years,,FEMALE,False,Tigris Pharmaceuticals,INDUSTRY,0,5,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,2.4849066497880004,small,1,1,1,0,0,0,1,0,1,0,0,0,1,0,3,1,1,0,0,1,0,2007-11-01,2008-08-01,274.0,2007.0,0,1,0
NCT00003058,Troglitazone in Treating Patients With Liposarcoma,"Phase II Clinical Trial of TROGLITAZONE, a Ligand for the Peroxisome Proliferator-Activated Receptor Gamma (PPAR), as Antineoplastic Differentiation Therapy for Patients With Malignant Liposarcoma",COMPLETED,1997-06,2000-01,2017-02-13,INTERVENTIONAL,PHASE2,85.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Sarcoma,troglitazone,DRUG,0,0,18 Years,120 Years,ALL,False,Dana-Farber Cancer Institute,OTHER,1,2,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.454347296253507,medium,1,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1997-06-01,2000-01-01,944.0,1997.0,0,0,0
NCT02274558,A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia",COMPLETED,2014-10,2016-07,2017-07-11,INTERVENTIONAL,PHASE3,234.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Tardive Dyskinesia,NBI-98854|Placebo,DRUG,1,2,18 Years,85 Years,ALL,False,Neurocrine Biosciences,INDUSTRY,0,54,Canada|Puerto Rico|United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.459585514144159,large,0,1,1,0,0,0,1,1,1,0,1,1,1,1,3,1,1,0,0,2,1,2014-10-01,2016-07-01,639.0,2014.0,0,2,0
NCT00807248,Short-term Study of Combination Treatment of Escitalopram and Gaboxadol in Major Depressive Disorder,"Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study of Escitalopram in Combination With Two Fixed Doses of Gaboxadol Compared to Escitalopram in Major Depressive Disorder",COMPLETED,2008-11,2010-02,2012-12-17,INTERVENTIONAL,PHASE2,490.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Major Depressive Disorder,Escitalopram placebo|Gaboxadol placebo|Escitalopram 20 mg|Gaboxadol 5 mg|Gaboxadol 10 mg,DRUG,1,8,18 Years,65 Years,ALL,False,H. Lundbeck A/S,INDUSTRY,0,22,Austria|Russia,1.0,0,1,0,0,0,2.0,0,0,0,0,1,6.19644412779452,large,0,1,1,0,0,0,1,1,0,0,1,1,1,1,9,1,1,0,0,5,1,2008-11-01,2010-02-01,457.0,2008.0,0,3,1
NCT00319085,Preheating of Femur Component in Hybrid Total Hip Arthroplasty,Comparison Between Preheated and Non-preheated Femur Component in Hybrid Total Hip Arthroplasty (THA) A Prospective Randomized Study of the 80 THA Using Radiostereometry.,COMPLETED,2006-05,2010-04,2015-04-10,INTERVENTIONAL,PHASE2,80.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Osteoarthritis, Hip",Total hip replacement (Preheating of femur stem),PROCEDURE,1,3,70 Years,85 Years,ALL,False,"Northern Orthopaedic Division, Denmark",OTHER,0,1,Denmark,1.0,0,1,0,0,0,2.0,0,1,0,0,1,4.394449154672439,medium,1,1,0,1,0,0,0,0,0,0,1,1,1,1,4,1,0,0,0,1,0,2006-05-01,2010-04-01,1431.0,2006.0,0,0,0
NCT00197743,Trial of Vitamins in HIV Progression and Transmission,Trial of Vitamins in HIV Progression and Transmission,COMPLETED,1995-04,2003-08,2010-11-11,INTERVENTIONAL,PHASE3,1085.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,"HIV Infections|Disease Transmission, Vertical",Vitamin A + Beta Carotene|Multivitamins|Placebo,OTHER|DIETARY_SUPPLEMENT,1,1,18 Years,,FEMALE,False,Harvard School of Public Health (HSPH),OTHER,1,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,2,6.990256500493881,xlarge,0,1,0,1,0,1,0,0,1,0,1,1,0,1,2,1,0,0,0,3,1,1995-04-01,2003-08-01,3044.0,1995.0,0,2,0
NCT00002143,Treatment of Psoriasis Using Acitretin in HIV-Positive Patients,Treatment of Psoriasis Using Acitretin in HIV-Positive Patients,COMPLETED,,,2005-06-24,INTERVENTIONAL,PHASE3,30.0,,,,TREATMENT,,HIV Infections|Psoriasis,Acitretin,DRUG,0,0,18 Years,55 Years,ALL,False,Hoffmann-La Roche,INDUSTRY,0,1,United States,1.0,0,0,1,0,0,3.0,0,1,0,0,2,3.4339872044851463,small,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,,,,,0,1,0
NCT07022743,Improving Treatment Outcomes in Chronic Myeloid Leukaemia Patients Using Imatinib and Artesunate Combination Therapy,Improving Treatment Outcomes in Chronic Myeloid Leukaemia Patients Using Imatinib and Artesunate Combination Therapy,ACTIVE_NOT_RECRUITING,2025-07-01,2026-12,2025-09-05,INTERVENTIONAL,PHASE2,75.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,NONE,Chronic Myeloid Leukemia (CML),Imatinib|Artesunate,DRUG,1,3,18 Years,85 Years,ALL,False,Obafemi Awolowo University,OTHER,0,1,Nigeria,,0,1,0,0,0,2.0,1,0,0,0,1,4.330733340286331,medium,1,0,0,1,0,0,0,0,0,0,1,0,1,1,4,1,1,0,0,2,1,,2026-12-01,,,0,1,0
NCT01099215,Study of PVS-10200 for the Treatment of Restenosis in Patients With Peripheral Artery Disease (TRIUMPH),An Open-Label Dose Escalation Safety Study of PVS-10200 for the Treatment of Restenosis in Patients Undergoing Minimally Invasive Peripheral Revascularization (TRIUMPH),COMPLETED,2010-04-30,2012-10-31,2021-06-28,INTERVENTIONAL,PHASE1|PHASE2,21.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Peripheral Artery Disease,PVS-10200,BIOLOGICAL,1,15,18 Years,,ALL,False,Shire,INDUSTRY,0,3,France,1.0,1,1,0,0,1,1.5,0,0,0,0,1,3.091042453358316,small,1,1,1,0,0,0,1,0,0,1,0,0,1,0,16,1,0,1,0,1,0,,,,,0,2,0
NCT04072835,Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303,"The NODE-303 Study: Multi-Centre, Multi-National,Open Label, Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia.",COMPLETED,2019-09-23,2023-01-26,2024-05-23,INTERVENTIONAL,PHASE3,1116.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Paroxysmal Supraventricular Tachycardia,Etripamil NS,DRUG,1,1,18 Years,,ALL,False,Milestone Pharmaceuticals Inc.,OTHER,1,124,Argentina|United States|Brazil|Colombia|Canada,1.0,0,0,1,0,0,3.0,0,0,0,0,1,7.018401799069201,xlarge,0,1,0,1,0,1,1,1,1,0,0,0,1,0,2,1,1,0,0,1,0,,,,,0,1,0
NCT00210808,A Study of the Effectiveness and Safety of Topiramate in the Treatment of Moderate to Severe Binge-eating Disorder Associated With Obesity,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Flexible-dose Study to Assess the Safety and Efficacy of Topiramate in the Treatment of Moderate to Severe Binge-eating Disorder Associated With Obesity",COMPLETED,2003-09,2005-03,2011-06-10,INTERVENTIONAL,PHASE2|PHASE3,407.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Obesity|Binge-Eating Disorder,topiramate,DRUG,1,0,18 Years,65 Years,ALL,False,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INDUSTRY,1,0,,1.0,0,1,1,0,1,2.5,0,0,0,0,2,6.0112671744041615,large,0,1,1,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,1,0,2003-09-01,2005-03-01,547.0,2003.0,0,2,0
NCT05707208,"A Randomized, Controlled Study of Repeat Dose Sustained Release Lidocaine for Treatment of Chronic Scrotal Pain","A Randomized, Controlled Phase II Study of Repeat Dose ST-01 (Lidocaine Polymer Solution) vs Lidocaine for Spermatic Cord Block in Men With Chronic Scrotal Content Pain",ACTIVE_NOT_RECRUITING,2023-03-21,2026-02-02,2025-12-02,INTERVENTIONAL,PHASE2,63.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Chronic Pain,ST-01|1% Lidocaine HCL,DRUG,1,0,19 Years,,MALE,False,Sustained Therapeutics Inc.,INDUSTRY,0,8,Canada,,0,1,0,0,0,2.0,0,0,0,0,1,4.1588830833596715,medium,1,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,2,1,,,,,0,1,0
NCT00035308,Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney Disease,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Safety and Efficacy Trial of LJP 394 in Systemic Lupus Erythematosus (SLE) Patients With a History of Renal Disease",COMPLETED,,2002-12,2006-09-25,INTERVENTIONAL,PHASE3,330.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Immunologic Diseases|Autoimmune Diseases|Systemic Lupus Erythematosus|Lupus Nephritis|Lupus Glomerulonephritis,Abetimus sodium (LJP 394),DRUG,0,0,12 Years,70 Years,ALL,False,La Jolla Pharmaceutical Company,INDUSTRY,0,82,Italy|Sweden|United States|Germany|Austria|Spain|United Kingdom|Mexico|France|Canada,1.0,0,0,1,0,0,3.0,0,1,0,0,5,5.802118375377063,large,0,0,1,0,0,0,1,1,1,1,1,1,1,1,0,0,1,0,0,1,0,,2002-12-01,,,0,2,0
NCT05704725,A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD),"An Open Label, Two-Arm Study in Subjects With Chorioretinal Vascular Disease to Evaluate ABP 938 and Aflibercept (Eylea®) in a Prefilled Syringe",COMPLETED,2023-01-23,2023-03-24,2025-02-14,INTERVENTIONAL,PHASE3,49.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Chorioretinal Vascular Disease,ABP 938|Aflibercept,DRUG,1,3,18 Years,99 Years,ALL,False,Amgen,INDUSTRY,0,4,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.912023005428146,small,1,1,1,0,1,0,1,0,1,0,1,0,1,1,4,1,1,0,0,2,1,,,,,0,1,0
NCT00425217,Rituximab in Membranous Nephropathy,The Use of Rituximab in the Treatment of Idiopathic Membranous Nephropathy,COMPLETED,2004-08,2007-04,2011-02-25,INTERVENTIONAL,PHASE2|PHASE3,15.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Membranous Nephropathy,Rituximab,DRUG,3,4,18 Years,,ALL,False,Mayo Clinic,OTHER,1,1,United States,1.0,0,1,1,0,1,2.5,0,0,0,0,1,2.772588722239781,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,7,1,1,0,0,1,0,2004-08-01,2007-04-01,973.0,2004.0,0,2,0
NCT02397889,Ketamine as a Treatment for Post-Traumatic Stress Disorder (PTSD),Randomized Controlled Trial of Repeated-Dose Intravenous Ketamine for PTSD,COMPLETED,2015-05-18,2020-01-27,2021-03-11,INTERVENTIONAL,PHASE2|PHASE3,30.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Posttraumatic Stress Disorder (PTSD),Ketamine|Midazolam,DRUG,1,5,18 Years,65 Years,ALL,False,Icahn School of Medicine at Mount Sinai,OTHER,0,1,United States,1.0,0,1,1,0,1,2.5,0,0,0,0,1,3.4339872044851463,small,1,1,0,1,0,0,0,0,1,0,1,1,1,1,6,1,1,0,0,2,1,,,,,0,3,1
NCT01572740,Efficacy and Safety of Liraglutide in Combination With Insulin Therapy Compared to Insulin Alone in Japanese Subjects With Type 2 Diabetes,"A 36-week, Randomised, Multi-centre, Double-blind, Parallel Group Trial to Investigate the Efficacy and Safety of Liraglutide in Combination With Insulin Therapy Compared to Insulin Monotherapy in Japanese Subjects With Type 2 Diabetes Mellitus",COMPLETED,2012-04-05,2013-03-27,2018-02-07,INTERVENTIONAL,PHASE3,257.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes|Diabetes Mellitus, Type 2",liraglutide|placebo|insulin,DRUG,1,11,20 Years,,ALL,False,Novo Nordisk A/S,INDUSTRY,0,23,Japan,1.0,0,0,1,0,0,3.0,0,0,0,0,2,5.552959584921617,large,0,1,1,0,0,0,1,0,0,0,1,1,1,1,12,1,1,0,0,3,1,,,,,0,3,1
NCT04770389,Randomized Study of Obicetrapib in Combination With Ezetimibe,"A Placebo-Controlled, Double-Blind, Randomized Phase 2 Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe in Participants With Mild Dyslipidemia",COMPLETED,2021-02-23,2021-06-30,2024-04-24,INTERVENTIONAL,PHASE2,112.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Dyslipidemias|High Cholesterol|Hypercholesterolemia,Obicetrapib 5mg|Ezetimibe 10mg|Placebo,DRUG|OTHER,6,27,18 Years,70 Years,ALL,False,NewAmsterdam Pharma,INDUSTRY,0,9,Netherlands|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,3,4.727387818712341,medium,0,1,1,0,0,0,1,1,1,0,1,1,1,1,33,1,1,0,0,3,1,,,,,0,4,1
NCT00651768,Titratable Dosing in Moderate to Severe Asthmatics,"A 52 wk Randomized, Doubleblind, Single Dummy, Parallel Group Multicenter Phase 3 Study Comparing the Long Term Safety of Symbicort pMDI 4x160/4.5mcg Bid to SymbicortpMDI 2x160/4.5mcg Bid & Budesonide HFA pMDI 4x160mcg Bid in Adult and Adolescent Subjects With Asthma",COMPLETED,2003-08,2005-01,2011-01-24,INTERVENTIONAL,PHASE3,570.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Asthma,budesonide/formoterol|Symbicort pMDI + budesonide HFA pMDI,DRUG,1,2,12 Years,,ALL,False,AstraZeneca,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.3473892096560105,xlarge,0,0,1,0,1,0,0,0,0,0,1,1,1,1,3,1,1,0,0,2,1,2003-08-01,2005-01-01,519.0,2003.0,0,1,0
NCT01306968,Hyperbaric Oxygen Therapy (HBO2) for Persistent Post-concussive Symptoms After Mild Traumatic Brain Injury (mTBI),A Pilot Phase II Study of Hyperbaric Oxygen for Persistent Post-concussive Symptoms After Mild Traumatic Brain Injury (HOPPS),COMPLETED,2011-02,2012-08,2014-09-05,INTERVENTIONAL,PHASE2,79.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Post-concussive Symptoms|Traumatic Brain Injury,hyperbaric oxygen|sham hyperbaric air,DRUG|OTHER,4,0,18 Years,65 Years,ALL,False,U.S. Army Medical Research and Development Command,FED,0,5,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.382026634673881,medium,1,1,0,0,0,0,1,0,1,0,1,1,1,1,4,0,1,0,0,2,1,2011-02-01,2012-08-01,547.0,2011.0,0,2,0
NCT01063374,Low Glycemic Index Diet for Type 2 Diabetics,Low Glycemic Index Diets to Improve Glycemic Control and Cardiovascular Disease in Type 2 Diabetics,COMPLETED,2010-03,2016-08,2016-09-14,INTERVENTIONAL,PHASE2,169.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Type 2 Diabetes,low glycemic diet instruction|high cereal fibre diet instruction,DIETARY_SUPPLEMENT,1,8,21 Years,,ALL,False,University of Toronto,OTHER,1,2,Canada,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.135798437050262,medium,0,1,0,1,0,1,1,0,0,0,1,0,1,1,9,1,0,0,0,2,1,2010-03-01,2016-08-01,2345.0,2010.0,0,2,0
NCT01653574,A Study of Famitinib Malate in HER2-negative Metastatic Breast Cancer,"A Single-Institutional, Phase II, Open-label, Single Arm Trial of Famitinib Malate in in HER2-negative Metastatic Breast Cancer",COMPLETED,2012-05,2013-11,2013-12-03,INTERVENTIONAL,PHASE2,28.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Breast Neoplasms,Famitinib Malate,DRUG,1,5,18 Years,70 Years,FEMALE,False,Fudan University,OTHER,1,1,China,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.367295829986474,small,1,1,0,1,0,1,0,0,0,0,0,0,1,0,6,1,1,0,0,1,0,2012-05-01,2013-11-01,549.0,2012.0,0,1,0
NCT00161018,New Antipsychotic Strategies: Quetiapine and Risperidone vs. Fluphenazine in Treatment Resistant Schizophrenia,,COMPLETED,2003-11,2004-11,2019-08-19,INTERVENTIONAL,PHASE3,150.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Schizophrenia,"Quetiapine, Risperidone, Fluphenazine",DRUG,1,0,18 Years,65 Years,ALL,False,"University of Maryland, Baltimore",OTHER,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,1,0,1,5.017279836814924,medium,0,0,0,1,0,0,0,0,1,0,1,1,1,1,1,0,1,0,0,1,0,2003-11-01,2004-11-01,366.0,2003.0,0,0,0
NCT03370718,Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma,A Phase II Study to Evaluate the Effects of Cabozantinib in Patients With Unresectable/Metastatic Adrenocortical Carcinoma,COMPLETED,2018-02-26,2024-01-12,2024-12-10,INTERVENTIONAL,PHASE2,18.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Metastatic Carcinoma in the Adrenal Cortex|Stage III Adrenal Cortex Carcinoma AJCC v8|Stage IV Adrenal Cortex Carcinoma AJCC v8|Unresectable Adrenal Cortex Carcinoma,Cabozantinib|Pharmacogenomic Study|Pharmacokinetic Study,DRUG|OTHER,1,0,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,4,2.9444389791664403,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,3,1,,,,,0,2,0
NCT00000518,Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM),,COMPLETED,1985-07,1992-12,2016-01-21,INTERVENTIONAL,PHASE3,,,RANDOMIZED,,TREATMENT,,"Arrhythmia|Cardiovascular Diseases|Death, Sudden, Cardiac|Heart Diseases|Tachycardia, Ventricular|Ventricular Arrhythmia|Ventricular Fibrillation","electrophysiology|electrocardiography, ambulatory|imipramine|mexiletine|procainamide|quinidine|sotalol",DRUG|PROCEDURE,0,0,18 Years,75 Years,ALL,False,University of Utah,OTHER,1,0,,1.0,0,0,1,0,0,3.0,0,0,0,1,7,0.0,,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,7,1,1985-07-01,1992-12-01,2710.0,1985.0,0,2,0
NCT04708418,A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma,Phase II Randomized Study of Neoadjuvant Pembrolizumab Alone or in Combination With CMP-001 in Patients With Operable Melanoma: Efficacy and Biomarker Study,ACTIVE_NOT_RECRUITING,2021-10-15,2026-06-30,2025-11-26,INTERVENTIONAL,PHASE2,60.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Clinical Stage III Cutaneous Melanoma AJCC v8|Melanoma of Unknown Primary|Pathologic Stage IIIB Cutaneous Melanoma AJCC v8|Pathologic Stage IIIC Cutaneous Melanoma AJCC v8|Pathologic Stage IIID Cutaneous Melanoma AJCC v8|Recurrent Cutaneous Melanoma,Biopsy Procedure|Biospecimen Collection|Computed Tomography|Pembrolizumab|Positron Emission Tomography|Surgical Procedure|VLP-encapsulated TLR9 Agonist CMP-001,DRUG|BIOLOGICAL|PROCEDURE,1,4,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,188,United States,,0,1,0,0,0,2.0,1,0,0,0,6,4.110873864173311,medium,1,0,0,1,0,0,1,0,1,0,1,0,1,1,5,1,1,1,0,7,1,,,,,0,2,0
NCT02419118,"""Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab ""","""Monoclonal Antibodies for Treatment of Multiple Myeloma. Present Status and Aspects of Effector Mechanisms With Emphasis on the CD38 Antibody Daratumumab """,COMPLETED,2015-01,2015-10-01,2017-11-07,INTERVENTIONAL,PHASE2|PHASE3,4.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Multiple Myeloma,Daratumumab|Lenalidomide|Dexamethasone,DRUG,1,1,18 Years,,ALL,False,Vejle Hospital,OTHER,0,1,Denmark,1.0,0,1,1,0,1,2.5,1,0,0,0,1,1.6094379124341003,small,1,1,0,1,0,0,0,0,0,0,1,0,1,1,2,1,1,0,0,3,1,2015-01-01,,,2015.0,1,2,0
NCT00392574,Safety and Efficacy of Prulifloxacin Versus Placebo in Traveler's Diarrhea,"A Multicenter, Double-Blind, Randomized Study to Compare The Safety and Efficacy of Prulifloxacin Versus Placebo in the Treatment of Acute Gastroenteritis in Adult Travelers",COMPLETED,2006-08,2008-03,2015-05-15,INTERVENTIONAL,PHASE3,282.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Acute Gastroenteritis in Adult Travelers,Prulifloxacin|Placebo,DRUG,1,2,18 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.645446897643238,large,0,1,1,0,1,0,0,0,1,0,1,1,1,1,3,1,1,0,0,2,1,2006-08-01,2008-03-01,578.0,2006.0,0,1,0
NCT02907918,Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer,A Phase II Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab as Neoadjuvant Treatment of Stage II-III ER+ HER2+ Breast Cancer (PALTAN),TERMINATED,2017-06-30,2020-09-23,2021-09-29,INTERVENTIONAL,PHASE2,26.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Breast Cancer|Cancer of Breast|Breast Carcinoma,Palbociclib|Letrozole|Trastuzumab|Goserelin|Breast surgery|Research tumor biopsy|Research bone marrow (OPTIONAL)|Research blood sample|Research blood for germline DNA|Blood for detection of circulating tumor cells,DRUG|BIOLOGICAL|GENETIC|PROCEDURE,1,2,18 Years,,ALL,False,Washington University School of Medicine,OTHER,2,3,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,3,3.295836866004329,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,3,1,1,1,0,10,1,,,,,0,2,0
NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),A Study to Determine the Activity of SCH 717454 in Subjects With Osteosarcoma or Ewing's Sarcoma That Has Relapsed After Standard Systemic Therapy,TERMINATED,2008-02-01,2013-08-31,2018-08-23,INTERVENTIONAL,PHASE2,219.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Osteosarcoma|Sarcoma, Ewing's|Peripheral Neuroectodermal Tumor",robatumumab,BIOLOGICAL,3,8,4 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,0,,0.0,0,1,0,0,0,2.0,1,0,0,0,3,5.393627546352362,large,0,1,1,0,1,0,0,0,0,0,1,1,1,1,11,1,0,1,0,1,0,,,,,0,2,0
NCT01841697,Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026),"A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin",COMPLETED,2013-06-13,2014-11-17,2018-09-10,INTERVENTIONAL,PHASE3,642.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes,Omarigliptin|Sitagliptin|Placebo to omarigliptin|Placebo to Sitagliptin|Open-label Metformin|Open-label Glimepiride,DRUG,3,3,18 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.466144724237619,xlarge,0,1,1,0,1,0,0,0,0,0,1,1,1,1,6,1,1,0,0,6,1,,,,,0,2,0
NCT00555997,"A 12-Week, Placebo Controlled Trial of Ziprasidone as Monotherapy for Major Depressive Disorder","A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Sequential Trial of Ziprasidone as Monotherapy for Major Depressive Disorder",COMPLETED,2008-03,2010-06,2014-07-03,INTERVENTIONAL,PHASE2,120.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Major Depressive Disorder,Ziprasidone|Ziprasidone|Placebo,DRUG,1,2,18 Years,65 Years,ALL,False,Massachusetts General Hospital,OTHER,5,7,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.795790545596741,medium,0,1,0,1,0,1,1,0,1,0,1,1,1,1,3,1,1,0,0,3,1,2008-03-01,2010-06-01,822.0,2008.0,0,1,0
NCT01550510,Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA,Phase I/II Study of Intravenous Ascorbic Acid in Combination With Irinotecan Versus Irinotecan Alone for Advanced Colorectal Cancer,TERMINATED,2011-12,2015-02,2025-05-06,INTERVENTIONAL,PHASE1|PHASE2,4.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Stage IV Colorectal Cancer,Ascorbic Acid|Irinotecan,DRUG,1,1,18 Years,,ALL,False,Thomas Jefferson University,OTHER,0,1,United States,0.0,1,1,0,0,1,1.5,1,0,0,0,1,1.6094379124341003,small,1,1,0,1,0,0,0,0,1,0,1,0,1,1,2,1,1,0,0,2,1,2011-12-01,2015-02-01,1158.0,2011.0,0,2,0
NCT02628613,Neoadjuvant Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin in Breast Cancer With TEKT4 Variations,Phase II Randomized Clinical Trial and Biomarker Analysis of Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin as Neoadjuvant Chemotherapy in Locally Advanced HER2-Negative Breast Cancer With TEKT4 Variations,COMPLETED,2015-12,2019-02,2019-11-01,INTERVENTIONAL,PHASE2,91.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Breast Cancer,Vinorelbine plus Epirubicin|Paclitaxel plus Epirubicin,DRUG,1,1,18 Years,70 Years,FEMALE,False,Fudan University,OTHER,0,1,China,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.5217885770490405,medium,1,1,0,1,0,0,0,0,0,0,1,0,1,1,2,1,1,0,0,2,1,2015-12-01,2019-02-01,1158.0,2015.0,1,1,0
NCT01077713,A Study of Avastin (Bevacizumab) in Combination With Gemcitabine With or Without Cisplatin in First-Line Treatment of Elderly Patients With Non-Small Cell Lung Cancer,Randomised Phase II Trial of Bevacizumab (AVASTIN®) in Combination With Gemcitabine or Attenuated Doses of Cisplatin and Gemcitabine as First-line Treatment of Elderly Patients With Advanced Non-squamous Non-small Cell Lung Cancer - EAGLES,COMPLETED,2010-02,2014-07,2015-10-08,INTERVENTIONAL,PHASE2,86.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Non-Squamous Non-Small Cell Lung Cancer,bevacizumab [Avastin]|cisplatin|gemcitabine|gemcitabine,DRUG,1,9,70 Years,,ALL,False,Hoffmann-La Roche,INDUSTRY,0,26,Italy,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.465908118654584,medium,1,1,1,0,1,0,1,0,0,1,1,0,1,1,10,1,1,0,0,4,1,2010-02-01,2014-07-01,1611.0,2010.0,0,2,0
NCT00448760,Combination Chemotherapy in Treating Patients With Previously Untreated Stage II or Stage III Esophageal Cancer That Can Be Removed By Surgery,"A Nonrandomized Phase II Study: Feasibility and Outcome of Neo Adjuvant Chemotherapy With Oxaliplatin, Fluorodeoxyuridine (FUdR), Taxotere and Leucovorin in the Treatment of Previously Untreated Advanced Esophago-Gastric Carcinoma",COMPLETED,2004-10,2010-04,2017-02-07,INTERVENTIONAL,PHASE2,29.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Esophageal Cancer,Docetaxel|Floxuridine|Leucovorin|Oxaliplatin|Microarray analysis|reverse transcriptase-polymerase chain reaction|Conventional surgery,DRUG|GENETIC|PROCEDURE,1,3,18 Years,120 Years,ALL,False,University of Miami,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.4011973816621555,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,4,1,1,0,0,7,1,2004-10-01,2010-04-01,2008.0,2004.0,0,1,0
NCT00282893,Balloon Prophylaxis of Aneurysmal Vasospasm,Balloon Prophylaxis of Aneurysmal Vasospasm,COMPLETED,2000-10,2006-12,2017-02-15,INTERVENTIONAL,PHASE2,170.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,PREVENTION,SINGLE,Aneurysm|Vasospasm,transluminal ballooning|currently existing therapies for the treatment of vasospasm,OTHER|PROCEDURE,1,1,17 Years,,ALL,False,"University of California, Davis",OTHER,1,5,Netherlands|Canada|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,5.14166355650266,medium,0,1,0,1,0,1,1,1,1,0,1,0,0,0,2,1,0,0,0,2,1,2000-10-01,2006-12-01,2252.0,2000.0,0,3,1
NCT00459121,"Vandetanib, Carboplatin, and Paclitaxel in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed by Surgery","Assessment of Feasibility and Safety of the Addition of ZD6474 (Zactima) to Carboplatin and Paclitaxel Administered Neo-Adjuvantly in Stage IB, II and T3, N1 Non-Small Cell Lung Cancer (NSCLC)",TERMINATED,2007-07,2008-10,2019-03-26,INTERVENTIONAL,PHASE2,2.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Lung Cancer,carboplatin|paclitaxel|Zactima|neoadjuvant therapy,DRUG|PROCEDURE,1,4,18 Years,120 Years,ALL,False,Barbara Ann Karmanos Cancer Institute,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,1.0986122886681098,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,5,1,1,0,0,4,1,2007-07-01,2008-10-01,458.0,2007.0,0,1,0
NCT04669821,A Clinical Study Evaluating Sedation of Intravenous Administration of HSK3486 in ICU Patients Undergoing Long-Term Mechanical Ventilation,"A Multi-Center, Randomized, Open-Label, Propofol-Controlled Exploratory Clinical Study Evaluating Sedation of Intravenous Administration of HSK3486 Injectable Emulsion in ICU Patients Undergoing Long-Term Mechanical Ventilation",COMPLETED,2021-03-09,2021-10-09,2022-05-27,INTERVENTIONAL,PHASE2,20.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Sedation in Intensive Care,HSK3486|Propofol,DRUG,1,2,18 Years,80 Years,ALL,False,"Haisco Pharmaceutical Group Co., Ltd.",INDUSTRY,0,1,China,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.044522437723423,small,1,1,1,0,0,0,0,0,0,0,1,0,1,1,3,1,1,0,0,2,1,,,,,0,1,0
NCT06010693,A Study of Daridorexant in Chinese Patients With Insomnia Disorder,"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Clinical Study to Investigate the Efficacy and Safety of 50 mg Daridorexant in Adult and Elderly Chinese Patients With Insomnia Disorder.",COMPLETED,2023-08-28,2024-05-10,2024-10-30,INTERVENTIONAL,PHASE3,206.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Insomnia Disorder,Daridorexant|Placebo,DRUG,1,2,18 Years,75 Years,ALL,False,"Jiangsu Simcere Pharmaceutical Co., Ltd.",INDUSTRY,0,33,China,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.332718793265369,large,0,1,1,0,0,0,1,0,0,0,1,1,1,1,3,1,1,0,0,2,1,,,,,0,1,0
NCT03864614,A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD),"A Phase 3, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment With SAGE-217 in Adult Subjects With Major Depressive Disorder",COMPLETED,2019-02-27,2023-06-22,2024-08-27,INTERVENTIONAL,PHASE3,1515.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Major Depressive Disorder,SAGE-217,DRUG,4,18,18 Years,75 Years,ALL,False,Biogen,INDUSTRY,0,52,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,7.323830566202317,xlarge,0,1,1,0,1,0,1,0,1,0,0,0,1,0,22,1,1,0,0,1,0,,,,,0,1,0
NCT05050006,ITIL-168 in Advanced Melanoma,"A Phase 2, Open-label, Multicenter Study Evaluating the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes (TILs) in Subjects With Advanced Melanoma (DELTA-1)",TERMINATED,2021-10-07,2023-02-27,2024-04-16,INTERVENTIONAL,PHASE2,29.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Advanced Cutaneous Melanoma,ITIL-168,BIOLOGICAL,1,8,18 Years,,ALL,False,Instil Bio,INDUSTRY,0,22,Canada|United Kingdom|United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,3.4011973816621555,small,1,1,1,0,0,0,1,1,1,1,0,0,1,1,9,1,0,1,0,1,0,,,,,0,2,0
NCT01231906,Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma,A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-Metastatic Ewing Sarcoma,COMPLETED,2010-11-24,2025-12-31,2026-01-23,INTERVENTIONAL,PHASE3,642.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Localized Extraskeletal Ewing Sarcoma|Peripheral Primitive Neuroectodermal Tumor of Bone|Peripheral Primitive Neuroectodermal Tumor of Soft Tissues,Cyclophosphamide|Dexrazoxane|Doxorubicin Hydrochloride|Etoposide|Ifosfamide|Laboratory Biomarker Analysis|Topotecan Hydrochloride|Vincristine Sulfate,DRUG|OTHER,1,0,,50 Years,ALL,False,Children's Oncology Group,NETWORK,1,243,Puerto Rico|United States|Australia|Saudi Arabia|New Zealand|Canada,1.0,0,0,1,0,0,3.0,1,0,0,0,3,6.466144724237619,xlarge,0,1,0,0,0,1,1,1,1,0,1,0,1,1,1,0,1,0,0,8,1,,,,,0,3,1
NCT00787306,Cardiovascular Health And Risk Modification in Family Health Teams,Multidisciplinary Cardiovascular Health And Risk Modification in Family Health Teams,COMPLETED,2008-10,2009-06,2018-04-03,INTERVENTIONAL,PHASE3,229.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Cardiovascular Risk Factors|Hypertension|Hyperlipidemia|Diabetes,Active risk factor surveillance,BEHAVIORAL,1,1,50 Years,80 Years,ALL,True,University of Toronto,OTHER,0,1,Canada,1.0,0,0,1,0,0,3.0,0,0,0,1,4,5.438079308923196,large,0,1,0,1,0,0,0,0,0,0,1,0,0,1,2,1,0,0,0,1,0,2008-10-01,2009-06-01,243.0,2008.0,0,1,0
NCT01278004,Chemotherapy Induced Painful Peripheral Neuropathy Ethosuximide (The CIN-E Study),A Randomised Double-blind Placebo-controlled Trial of the Safety and Efficacy of Ethosuximide 250mg Capsules for the Management of Chemotherapy Induced Painful Peripheral Neuropathy,COMPLETED,2010-05,2014-07,2016-05-26,INTERVENTIONAL,PHASE2,15.0,ACTUAL,RANDOMIZED,PARALLEL,SUPPORTIVE_CARE,DOUBLE,Cancer|Peripheral Neuropathy,Ethosuximide|Placebo,DRUG,1,0,18 Years,,ALL,False,Royal Marsden NHS Foundation Trust,OTHER,1,2,United Kingdom,1.0,0,1,0,0,0,2.0,1,0,0,0,2,2.772588722239781,small,1,1,0,1,0,1,1,0,0,1,1,1,0,1,1,0,1,0,0,2,1,2010-05-01,2014-07-01,1522.0,2010.0,0,2,0
NCT01246752,Haematopoietic Stem Cell Transplantation (HSCT) in Comparison to Conventional Consolidation Therapy for Patients With Acute Myeloid Leukemia (AML) (Intermediate Risk) </= 60y. After First CR,Randomised Trial on Allogeneic Haematopoietic Stem Cell Transplantation in Patients Under the Age of 60 Years With Acute Myeloid Leukemia of Intermediate Risk in First Complete Remission and a Matched Sibling or Unrelated Donor (ETAL-1),TERMINATED,2011-02-10,2020-04-30,2021-10-29,INTERVENTIONAL,PHASE3,143.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Leukemia, Myeloid, Acute","Human Stem Cell Transplantation|Consolidation chemotherapy, i.e. High-dose Cytarabine (HiDAC)",DRUG|BIOLOGICAL,1,4,18 Years,60 Years,ALL,False,University Hospital Carl Gustav Carus,OTHER,1,19,Germany,0.0,0,0,1,0,0,3.0,1,0,0,0,1,4.969813299576001,medium,0,1,0,1,0,1,1,0,0,1,1,0,1,1,5,1,1,1,0,2,1,,,,,0,1,0
NCT03823352,Evaluate Efficacy and Safety/Tolerability Profiles of Antroquinonol in Acute Myeloid Leukemia (AML) Adult Patients,"Open-label, Non-randomized, Phase IIa Study to Evaluate Efficacy and Safety/Tolerability Profiles of Antroquinonol in Adult Patients With Relapsed Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible",COMPLETED,2019-02-20,2020-12-31,2021-02-03,INTERVENTIONAL,PHASE2,12.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Leukemia, Myeloid, Acute",Antroquinonol,DRUG,1,2,18 Years,70 Years,ALL,False,Golden Biotechnology Corporation,INDUSTRY,0,2,Russia,1.0,0,1,0,0,0,2.0,1,0,0,0,1,2.5649493574615367,small,1,1,1,0,0,0,1,0,0,0,0,0,1,0,3,1,1,0,0,1,0,,,,,0,0,0
NCT00053352,Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors,A Phase III Study Of Reduced Therapy In The Treatment Of Children With Low And Intermediate Risk Extracranial Germ Cell Tumors,COMPLETED,2003-11-03,2021-06-30,2021-07-13,INTERVENTIONAL,PHASE3,302.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Childhood Embryonal Tumor|Childhood Extracranial Germ Cell Tumor|Childhood Extragonadal Germ Cell Tumor|Childhood Malignant Ovarian Germ Cell Tumor|Childhood Malignant Testicular Germ Cell Tumor|Childhood Teratoma|Ovarian Embryonal Carcinoma|Ovarian Yolk Sac Tumor|Stage II Malignant Testicular Germ Cell Tumor|Stage IIA Ovarian Germ Cell Tumor|Stage IIB Ovarian Germ Cell Tumor|Stage IIC Ovarian Germ Cell Tumor|Stage III Malignant Testicular Germ Cell Tumor|Stage IIIA Ovarian Germ Cell Tumor|Stage IIIB Ovarian Germ Cell Tumor|Stage IIIC Ovarian Germ Cell Tumor|Testicular Choriocarcinoma and Yolk Sac Tumor|Testicular Embryonal Carcinoma,conventional surgery|cisplatin|etoposide|bleomycin sulfate|laboratory biomarker analysis,DRUG|BIOLOGICAL|OTHER|PROCEDURE,2,2,,21 Years,ALL,False,Children's Oncology Group,NETWORK,1,126,Puerto Rico|United States|Australia|Switzerland|New Zealand|Canada,1.0,0,0,1,0,0,3.0,1,0,0,0,18,5.713732805509369,large,0,1,0,0,0,1,1,1,1,0,0,0,1,0,4,1,1,1,0,5,1,,,,,0,3,1
NCT02075047,Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder,"A PHASE 3, MULTICENTER, FOUR-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY TRIAL OF FLEXIBLE DOSES OF ORAL ZIPRASIDONE IN CHILDREN AND ADOLESCENTS WITH BIPOLAR I DISORDER (CURRENT OR MOST RECENT EPISODE MANIC)",TERMINATED,2014-05-23,2020-05-18,2021-06-16,INTERVENTIONAL,PHASE3,171.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Bipolar Disorder,placebo oral capsules|ziprasidone oral capsules,DRUG,1,3,10 Years,17 Years,ALL,False,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,INDUSTRY,0,50,Ukraine|United States,0.0,0,0,1,0,0,3.0,0,0,0,0,1,5.147494476813453,medium,0,1,1,0,1,0,1,1,1,0,1,1,1,1,4,1,1,0,0,2,1,,,,,0,2,0
NCT02348749,18F-MFBG Imaging for Evaluation of Neuroendocrine Malignancies,A Phase I/IIA Study of 18F-MFBG Imaging for Evaluation of Neuroendocrine Malignancies,COMPLETED,2015-01,2025-03-17,2025-03-19,INTERVENTIONAL,PHASE1|PHASE2,48.0,ACTUAL,,SINGLE_GROUP,DIAGNOSTIC,NONE,Neuroendocrine Tumors,18F-MFBG (meta-fluoro benzylguanidine)|Positron emission tomography (PET) imaging|Blood draws,RADIATION|DEVICE|OTHER,2,1,5 Years,,ALL,False,Memorial Sloan Kettering Cancer Center,OTHER,0,1,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,1,3.8918202981106265,small,1,1,0,1,0,0,0,0,1,0,0,0,0,0,3,1,0,0,1,3,1,2015-01-01,,,2015.0,1,2,0
NCT05899049,"A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study","An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, as First-Line Treatment in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)",ACTIVE_NOT_RECRUITING,2022-07-27,2027-06-07,2025-11-10,INTERVENTIONAL,PHASE3,249.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Carcinoma, Renal Cell",Pembrolizumab|Belzutifan|Pembrolizumab/Quavonlimab|Lenvatinib,DRUG|BIOLOGICAL,2,4,18 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,1,17,China,,0,0,1,0,0,3.0,1,0,0,0,1,5.521460917862246,large,0,0,1,0,1,1,1,0,0,0,1,0,1,1,6,1,1,1,0,4,1,,,,,0,2,0
NCT00739349,NOVA22007 0.05% and 0.1% Cyclosporine Versus Vehicle for the Treatment of Dry Eye,"A Phase II, Multi-Center, Double-Masked, Randomized Study of NOVA22007 0.05% and 0.1% Cyclosporine Ophthalmic Cationic Emulsions Compared to Vehicle for the Treatment of the Signs and Symptoms of Dry Eye",COMPLETED,2008-08,2009-01,2016-06-06,INTERVENTIONAL,PHASE2,132.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Dry Eye,NOVA22007 ''Cyclosporine''|NOVA22007 ''Cyclosporine''|vehicle/placebo,DRUG,1,0,18 Years,,ALL,False,Santen SAS,INDUSTRY,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.890349128221754,medium,0,1,1,0,0,0,0,0,1,0,1,1,1,1,1,0,1,0,0,3,1,2008-08-01,2009-01-01,153.0,2008.0,0,1,0
NCT00085449,"Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer",A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells,WITHDRAWN,2006-05,2007-01,2019-11-27,INTERVENTIONAL,PHASE1|PHASE2,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms,alemtuzumab|cyclosporine|fludarabine phosphate|melphalan|mycophenolate mofetil|peripheral blood stem cell transplantation|radiation therapy,DRUG|BIOLOGICAL|RADIATION|PROCEDURE,3,0,18 Years,60 Years,ALL,False,Alliance for Clinical Trials in Oncology,OTHER,1,24,United States,0.0,1,1,0,0,1,1.5,1,0,0,0,5,0.0,,1,1,0,1,0,1,1,0,1,0,0,0,1,0,3,0,1,1,0,7,1,2006-05-01,2007-01-01,245.0,2006.0,0,3,1
NCT05014438,A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis,"A Phase 2, Randomized, Double-blinded, Placebo-controlled, 5 Parallel-group Study of BMS-986166 or Branebrutinib for the Treatment of Patients With Moderate to Severe Atopic Dermatitis",COMPLETED,2021-08-17,2022-08-22,2023-10-18,INTERVENTIONAL,PHASE2,17.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Dermatitis, Atopic",BMS-986166|Branebrutinib|Placebo,DRUG|OTHER,1,12,18 Years,65 Years,ALL,False,Bristol-Myers Squibb,INDUSTRY,0,42,United States|Germany|Austria|Australia|Spain|Poland|Canada,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.8903717578961645,small,1,1,1,0,1,0,1,1,1,1,1,1,1,1,13,1,1,0,0,3,1,,,,,0,3,1
NCT00333138,Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis,"Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study Evaluating the Safety, Tolerability and Effect on MRI Lesion Parameters of FTY720 vs Placebo in Patients With Relapsing Multiple Sclerosis Including 18 Month Extension Phase",COMPLETED,2003-05,2011-04,2017-09-15,INTERVENTIONAL,PHASE2,281.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Multiple Sclerosis,FTY720|Placebo,DRUG,4,7,18 Years,60 Years,ALL,False,Novartis,INDUSTRY,0,26,Italy|Finland|Spain|Germany|United Kingdom|Poland|Switzerland|Denmark|Portugal|France|Canada,1.0,0,1,0,0,0,2.0,0,1,0,0,1,5.641907070938114,large,0,1,1,0,1,0,1,1,0,1,1,1,1,1,11,1,1,0,0,2,1,2003-05-01,2011-04-01,2892.0,2003.0,0,3,1
NCT00375258,Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage,"A Large Randomised Placebo Controlled Trial Among Trauma Patients With, or at Risk of, Significant Haemorrhage, of the Effects of Antifibrinolytic Treatment on Death and Transfusion Requirement",COMPLETED,2005-05,2010-03,2011-06-30,INTERVENTIONAL,PHASE3,20211.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Hemorrhage,Tranexamic acid|Sodium Chloride 0.9%,DRUG,1,1,16 Years,,ALL,False,London School of Hygiene and Tropical Medicine,OTHER,0,1,United Kingdom,1.0,0,0,1,0,0,3.0,0,0,0,0,1,9.9140317664118,,0,1,0,1,0,0,0,0,0,1,1,1,1,1,2,1,1,0,0,2,1,2005-05-01,2010-03-01,1765.0,2005.0,0,1,0
NCT05585658,"A Randomized, Double-blinded, Active Controlled Crossover Clinical Trial to Investigate PK, PD and Safety of GBPD002","A Randomized, Double-blinded, Active Controlled, Single Dosing, Crossover Clinical Trial to Investigate the Pharmacokinetics, Pharmacodynamics and Safety of GBPD002 and Eprex® After Subcutaneous Administration in Healthy Adult Volunteers.",COMPLETED,2021-10-16,2021-12-16,2022-10-20,INTERVENTIONAL,PHASE1|PHASE2,42.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Natural Blood and Blood Product Toxicity,Erythropoietin alpha,BIOLOGICAL,1,1,18 Years,45 Years,MALE,True,Globe Biotech Limited,INDUSTRY,0,2,Bangladesh,1.0,1,1,0,0,1,1.5,0,0,0,0,1,3.7612001156935624,small,1,1,1,0,0,0,1,0,0,0,1,1,1,0,2,1,0,1,0,1,0,,,,,0,1,0
NCT05122455,Effects of Edoxaban on Platelet Aggregation,Effects of Edoxaban on Platelet Aggregation in Patients With Stable Coronary Artery Disease,COMPLETED,2021-09-14,2024-06-24,2025-04-27,INTERVENTIONAL,PHASE2|PHASE3,61.0,ACTUAL,NON_RANDOMIZED,SEQUENTIAL,BASIC_SCIENCE,NONE,SCAD|AMI,ASA|Clopidogrel|Edoxaban,DRUG,1,5,18 Years,75 Years,ALL,False,University of Sao Paulo,OTHER,1,1,Brazil,1.0,0,1,1,0,1,2.5,0,0,0,0,2,4.127134385045092,medium,1,1,0,1,0,1,0,0,0,0,0,0,0,0,6,1,1,0,0,3,1,,,,,0,4,1
NCT02519855,"Study to Evaluate Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants ≥50 Years of Age (V211-062)","A Phase III, Double-Blind, Randomized, Multicenter Study to Evaluate the Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated)",COMPLETED,2015-09-11,2016-01-26,2018-10-30,INTERVENTIONAL,PHASE3,882.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Herpes Zoster,ZOSTAVAX™|Placebo to ZOSTAVAX™|Influenza Vaccine,BIOLOGICAL,6,0,50 Years,,ALL,True,Merck Sharp & Dohme LLC,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.78332520060396,xlarge,0,1,1,0,1,0,0,0,0,0,1,1,0,1,6,0,0,1,0,3,1,,,,,0,2,0
NCT01305226,A Trial Using Double-Bolus THR-100 Versus Streptokinase,"A Prospective Phase III Parallel, Randomised Controlled Trial Using Double-bolus Recombinant Staphylokinase (THR-100) vs Streptokinase in Patients With Acute Myocardial Infarction",COMPLETED,2010-10,2011-08,2021-02-23,INTERVENTIONAL,PHASE3,120.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Acute Myocardial Infarction,THR-100|Streptokinase,DRUG,1,1,30 Years,75 Years,ALL,False,Bharat Biotech International Limited,INDUSTRY,0,4,India,1.0,0,0,1,0,0,3.0,0,0,0,1,1,4.795790545596741,medium,0,1,1,0,0,0,1,0,0,0,1,0,1,1,2,1,1,0,0,2,1,2010-10-01,2011-08-01,304.0,2010.0,0,1,0
NCT05933278,Homologous Booster Study of COVID-19 Protein Subunit Recombinant Vaccine,Immunogenicity & Safety of IndoVac® as a Homologous Booster Dose Against COVID-19 in Adults Aged 18 Years and Above in Indonesia,COMPLETED,2023-07-25,2024-09-05,2025-06-05,INTERVENTIONAL,PHASE2,150.0,ACTUAL,,SINGLE_GROUP,PREVENTION,NONE,COVID-19,SARS-CoV-2 Subunit Recombinant Protein Vaccine,BIOLOGICAL,1,4,18 Years,,ALL,True,PT Bio Farma,INDUSTRY,0,1,Indonesia,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.017279836814924,medium,0,1,1,0,0,0,0,0,0,0,0,0,0,0,5,1,0,1,0,1,0,,,,,0,0,0
NCT06089278,A Clinical Study of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps.,"A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trials to Assess the Effectiveness, Safety and Pharmacokinetics of TQH2722 Injection in Patients With Chronic Sinusitis With or Without Nasal Polyps.",COMPLETED,2023-12-28,2025-04-30,2025-07-14,INTERVENTIONAL,PHASE2,160.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Sinusitis,300mg of TQH2722 injection|600mg of TQH2722 injection|TQH2722 injection matching placebo,DRUG,2,26,18 Years,75 Years,ALL,False,"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.",INDUSTRY,0,36,China,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.081404364984463,medium,0,1,1,0,0,0,1,0,0,0,1,1,1,1,28,1,1,0,0,3,1,,,,,0,2,0
NCT02328885,Prophylactic Infusion of Donor Lymphocytes in Cord Blood Transplantation,Prophylactic Infusion of Donor Lymphocytes in Cord Blood Transplantation,COMPLETED,2014-07,2017-03-22,2021-12-08,INTERVENTIONAL,PHASE1|PHASE2,17.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Leukemia,DLI of the 20 fraction of the UCBT,DRUG,1,8,,60 Years,ALL,False,Banc de Sang i Teixits,OTHER,5,5,Spain,1.0,1,1,0,0,1,1.5,1,0,0,0,1,2.8903717578961645,small,1,1,0,1,0,1,1,0,0,1,0,0,1,0,9,1,1,0,0,1,0,2014-07-01,,,2014.0,0,2,0
NCT00334685,"[S,S]-Reboxetine Add-On Trial","[S,S]-Reboxetine Add-On Trial: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial Of [S,S]-Reboxetine In Patients With Postherpetic Neuralgia (PHN) Concomitantly Treated With Pregabalin.",TERMINATED,2006-08-22,2007-10-11,2019-12-16,INTERVENTIONAL,PHASE2,136.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Pain,"[S,S]-Reboxetine + Pregabalin|Pregabalin",DRUG,1,4,18 Years,,ALL,False,Pfizer,INDUSTRY,0,83,Italy|Netherlands|Latvia|Russia|Sweden|United States|Germany|Austria|Spain|United Kingdom|Norway|Poland|Switzerland|Czechia|Ukraine|Canada,0.0,0,1,0,0,0,2.0,0,0,0,0,1,4.919980925828125,medium,0,1,1,0,1,0,1,1,1,1,1,1,1,1,5,1,1,0,0,2,1,,,,,0,2,0
NCT00000143,Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT),Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT),COMPLETED,1997-05,2000-06,2016-03-14,INTERVENTIONAL,PHASE3,61.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Cytomegalovirus Retinitis|HIV Infections,Ganciclovir implant and oral ganciclovir|Cidofovir intravenous,DRUG|DEVICE,1,0,13 Years,,ALL,False,Johns Hopkins Bloomberg School of Public Health,OTHER,0,19,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,2,4.127134385045092,medium,1,1,0,1,0,0,1,0,1,0,1,0,1,1,1,0,1,0,1,2,1,1997-05-01,2000-06-01,1127.0,1997.0,0,2,0
NCT06846515,Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301),"A Phase 3 Randomized, Double-blind, Multi-center, Placebo-controlled Study to Evaluate the Efficacy and Safety of AR882 in Participants With Gout",ACTIVE_NOT_RECRUITING,2025-03-11,2026-04,2025-09-17,INTERVENTIONAL,PHASE3,750.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Gout|Arthritis, Gouty|Hyperuricemia|Gout Chronic",AR882 50 mg|AR882 75 mg|Placebo,DRUG,1,4,18 Years,85 Years,ALL,False,Arthrosi Therapeutics,INDUSTRY,0,89,United States,,0,0,1,0,0,3.0,0,1,0,0,4,6.621405651764134,xlarge,0,0,1,0,0,0,1,0,1,0,1,1,1,1,5,1,1,0,0,3,1,,2026-04-01,,,0,2,0
NCT02336815,Selinexor Treatment of Refractory Myeloma,"A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-Dose Dexamethasone (Sd) in Patients With Multiple Myeloma Previously Treated With Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an Anti-CD38 Monoclonal Antibody (mAb) Daratumumab, and Refractory to Prior Treatment With Glucocorticoids, an Immunomodulatory Agent, a Proteasome Inhibitor, and an the Anti-CD38 mAb Daratumumab",COMPLETED,2015-05-26,2019-07-26,2023-01-26,INTERVENTIONAL,PHASE2,202.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Multiple Myeloma,Selinexor|Dexamethasone,DRUG,1,20,18 Years,,ALL,False,Karyopharm Therapeutics Inc,INDUSTRY,0,61,Belgium|United States|Germany|Austria|France|Greece,1.0,0,1,0,0,0,2.0,1,0,0,0,1,5.313205979041787,large,0,1,1,0,0,0,1,1,1,1,0,0,1,1,21,1,1,0,0,2,1,,,,,0,3,1
NCT01754935,"A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor","A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of VX-509 Using Magnetic Resonance Imaging and Arthroscopic Biopsies in Subjects With Active Rheumatoid Arthritis on Stable Disease-Modifying Antirheumatic Drugs",COMPLETED,2013-01,2014-02,2015-05-19,INTERVENTIONAL,PHASE2,43.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Rheumatoid Arthritis,VX-509|VX-509 matching placebo,DRUG,5,9,18 Years,65 Years,ALL,False,Vertex Pharmaceuticals Incorporated,INDUSTRY,0,30,Netherlands|United States|Lithuania|Estonia|Denmark|South Africa,1.0,0,1,0,0,0,2.0,0,1,0,0,1,3.784189633918261,small,1,1,1,0,0,0,1,1,1,0,1,1,1,1,14,1,1,0,0,2,1,2013-01-01,2014-02-01,396.0,2013.0,0,3,1
NCT01288235,Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation,"A Phase II Study of Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation: An Assessment of Long Term Neurocognitive, Neuroendocrine Adn Ototoxicity Outcomes",COMPLETED,2011-02,2016-09,2025-06-03,INTERVENTIONAL,PHASE2,100.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Brain Tumor|Low Grade Glioma|Astrocytoma|Ependymoma|Ganglioglioma,Proton radiotherapy,RADIATION,2,3,1 Year,25 Years,ALL,False,Massachusetts General Hospital,OTHER,2,2,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,5,4.61512051684126,medium,0,1,0,1,0,1,1,0,1,0,0,0,1,0,5,1,0,0,0,1,0,2011-02-01,2016-09-01,2039.0,2011.0,0,1,0
NCT05617508,N-DOSE AD: A Dose Optimization Trial of Nicotinamide Riboside in Alzheimer's Disease,N-DOSE AD: A Dose Optimization Trial of Nicotinamide Riboside in Alzheimer's Disease,COMPLETED,2022-11-22,2025-06-05,2025-12-01,INTERVENTIONAL,PHASE2,80.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Alzheimer Disease|Dementia,Placebo|Nicotinamide Riboside supplementation 1000mg daily in total|Nicotinamide Riboside dose escalation (up to 3000 mg daily in total),DIETARY_SUPPLEMENT|OTHER,1,1,50 Years,85 Years,ALL,False,Haukeland University Hospital,OTHER,1,2,Norway,1.0,0,1,0,0,0,2.0,0,0,1,0,2,4.394449154672439,medium,1,1,0,1,0,1,1,0,0,0,1,1,1,1,2,1,0,0,0,3,1,,,,,0,2,0
NCT03324425,Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer,A Phase II Single Arm Trial of Adding Simvastatin to Dual Anti-HER2 Therapy in Patients With HER2-Positive Metastatic Breast Cancer,ACTIVE_NOT_RECRUITING,2020-03-04,2030-12,2025-02-27,INTERVENTIONAL,PHASE2,5.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Breast Cancer Stage IV,Simvastatin 80mg,DRUG,1,5,18 Years,,FEMALE,False,Baylor Breast Care Center,OTHER,0,2,United States,,0,1,0,0,0,2.0,1,0,0,0,1,1.791759469228055,small,1,1,0,1,0,0,1,0,1,0,0,0,1,0,6,1,1,0,0,1,0,,2030-12-01,,,0,1,0
NCT03274076,Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc),Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc): A Phase I/II Two Center Safety and Tolerability Study,COMPLETED,2017-09-25,2019-11-15,2020-05-08,INTERVENTIONAL,PHASE1|PHASE2,15.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Systemic Sclerosis|Scleroderma,Tofacitinib|Placebo Oral Tablet,DRUG,1,5,18 Years,70 Years,ALL,False,University of Michigan,OTHER,1,2,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,2,2.772588722239781,small,1,1,0,1,0,1,1,0,1,0,1,1,1,1,6,1,1,0,0,2,1,,,,,0,4,1
NCT04072315,Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/,A Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF,COMPLETED,2020-02-13,2022-07-05,2023-12-12,INTERVENTIONAL,PHASE2,9.0,ACTUAL,NON_RANDOMIZED,CROSSOVER,TREATMENT,NONE,Idiopathic Pulmonary Fibrosis,PLN-74809|Knottin tracer,DRUG|RADIATION,1,1,40 Years,,ALL,False,"Pliant Therapeutics, Inc.",INDUSTRY,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.302585092994046,small,1,1,1,0,0,1,0,0,1,0,0,0,1,0,2,1,1,0,0,2,1,,,,,0,1,0
NCT01381315,Axillary Reverse Mapping,ARM: Axillary Reverse Mapping,COMPLETED,2009-09,2016-05,2017-01-10,INTERVENTIONAL,PHASE2,210.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Breast Cancer,Injection of isotope|Axillary lymph node dissection,PROCEDURE,1,4,18 Years,,FEMALE,False,University of Kansas Medical Center,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,5.351858133476067,large,0,1,0,1,0,0,0,0,1,0,0,0,1,0,5,1,0,0,0,2,1,2009-09-01,2016-05-01,2434.0,2009.0,0,1,0
NCT01422317,Effects of High-dose n-3 Fatty Acids on Clinical Outcome and Serum Lipids - Omacor Following Acute Myocardial Infarction,Effects of a High-dose Concentrate of n-3 Fatty Acids or Corn Oil Introduced Early After an Acute Myocardial Infarction on Serum Triacylglycerol and High-density Lipoprotein (HDL)- Cholesterol,COMPLETED,1995-09,2002-12,2012-02-22,INTERVENTIONAL,PHASE3,300.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Coronary Disease|Myocardial Infarction,EPA / DHA / Alpha-Tocopherol|Corn Oil / Alpha-Tocopherol (4 mg),DRUG,1,5,18 Years,,ALL,False,Helse Stavanger HF,OTHER_GOV,4,1,Norway,1.0,0,0,1,0,0,3.0,0,0,0,1,2,5.707110264748875,large,0,1,0,1,0,1,0,0,0,0,1,1,1,1,6,1,1,0,0,2,1,1995-09-01,2002-12-01,2648.0,1995.0,0,3,1
NCT03896217,Simvastatin in Secondary Progressive Multiple Sclerosis,"A Double-blind, Randomised, Placebo-controlled Single-site Study of High Dose Simvastatin Treatment for Secondary Progressive Multiple Sclerosis: Impact on Vascular Perfusion and Oxidative Damage",COMPLETED,2019-05-16,2023-06-15,2025-07-01,INTERVENTIONAL,PHASE2,40.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Secondary Progressive Multiple Sclerosis,Simvastatin,DRUG,2,16,18 Years,65 Years,ALL,False,"University College, London",OTHER,1,1,United Kingdom,1.0,0,1,0,0,0,2.0,0,1,0,0,1,3.713572066704308,small,1,1,0,1,0,1,0,0,0,1,1,0,1,1,18,1,1,0,0,1,0,,,,,0,1,0
NCT00202540,Efficacy and Safety of S18986 in the Treatment of Mild Cognitive Impairment Patients,Efficacy of 15 mg and 50 mg of S18986 on Cognitive Symptoms in Mild Cognitive Impairment Patients Treated Over a 12-month Oral Administration Period,TERMINATED,2005-06,2006-03-29,2024-07-25,INTERVENTIONAL,PHASE2,38.0,ACTUAL,RANDOMIZED,PARALLEL,,DOUBLE,Mild Cognitive Impairment,S18986,DRUG,1,1,55 Years,,ALL,False,Institut de Recherches Internationales Servier,OTHER,0,1,France,0.0,0,1,0,0,0,2.0,0,0,0,0,1,3.6635616461296463,small,1,1,0,1,0,0,0,0,0,1,1,1,0,1,2,1,1,0,0,1,0,2005-06-01,,,2005.0,0,0,0
NCT05493540,Oral Ibuprofen Versus Placebo in Treatment of Patent Ductus Arteriosus (PDA)in Preterm Infants,"Oral Ibuprofen Versus Placebo in Management of Patent Ductus Arteriosus in Preterm Infants: A Double Blind, Randomized Control Trial",COMPLETED,2021-04-15,2022-09-01,2023-02-28,INTERVENTIONAL,PHASE2,80.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Patent Ductus Arteriosus After Premature Birth|Patent Ductus Arteriosus Conservative Management,Ibuprofen oral suspension|Placebo,DRUG,1,5,1 Hour,7 Days,ALL,False,Nada Youssef,OTHER,0,1,Egypt,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.394449154672439,medium,1,1,0,1,0,0,0,0,0,0,1,1,1,1,6,1,1,0,0,2,1,,,,,0,3,1
NCT00619840,Placebo-Controlled Multi-Centre Double-Blind Trial for Adults With Extended-Release Methylphenidate for ADHD,Placebo-Controlled Multi-Centre Double-Blind Trial for Adults With Extended-Release Methylphenidate for ADHD,COMPLETED,2004-11,,2008-02-21,INTERVENTIONAL,PHASE3,363.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Attention Deficit Hyperactivity Disorder,methylphenidate hydrochloride|Placebo,DRUG,1,1,18 Years,,ALL,False,Medice Arzneimittel Pütter GmbH & Co KG,INDUSTRY,0,1,Germany,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.8971538676367405,large,0,1,1,0,0,0,0,0,0,1,1,1,1,1,2,1,1,0,0,2,1,2004-11-01,,,2004.0,0,1,0
NCT00139789,"A Multicenter, Open-label Randomized Crossover Trial to Assess Subject Preference for Kemstro™ Compared to Conventional Baclofen Tablets in Subjects With Stable Multiple Sclerosis","A Multicenter, Open-label Randomized Crossover Trial to Assess Subject Preference for Kemstro™ Compared to Conventional Baclofen Tablets in Subjects With Stable Multiple Sclerosis",COMPLETED,2005-01,2005-04,2013-08-30,INTERVENTIONAL,PHASE3,60.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Multiple Sclerosis,Kemstro,DRUG,0,0,18 Years,65 Years,ALL,,UCB Pharma,INDUSTRY,0,1,United States,1.0,0,0,1,0,0,3.0,0,1,0,0,1,4.110873864173311,medium,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,2005-01-01,2005-04-01,90.0,2005.0,0,0,0
NCT00479089,Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer,Phase II Trial of Weekly Docetaxel (Taxotere) Vs. Weekly Docetaxel in Combination With ZD1839 (Iressa®) As Consolidation Therapy For Metastatic Urothelial Cancer Following Maximal Response To Multi-Agent Chemotherapy,TERMINATED,2004-02,2014-08,2015-11-02,INTERVENTIONAL,PHASE2,50.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Bladder Cancer,Docetaxel|ZD1839|Dexamethasone,DRUG,1,2,,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,3.9318256327243257,small,1,1,0,1,0,1,0,0,1,0,1,0,1,1,3,1,1,0,0,3,1,2004-02-01,2014-08-01,3834.0,2004.0,0,1,0
NCT03574389,A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Infants and Young Children,"A PHASE 3 OPEN-LABEL TRIAL TO ASSESS THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN INFANTS AND YOUNG CHILDREN IN CHINA WHO ARE NAIVE TO PNEUMOCOCCAL VACCINATION",COMPLETED,2018-06-23,2023-10-13,2024-11-05,INTERVENTIONAL,PHASE3,936.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Pneumococcal Infections|Pneumococcal Conjugate Vaccine,13vPnC|Hib,BIOLOGICAL,7,11,42 Days,5 Years,ALL,True,Pfizer,INDUSTRY,0,2,China,1.0,0,0,1,0,0,3.0,0,0,0,0,2,6.842683282238422,xlarge,0,1,1,0,1,0,1,0,0,0,1,0,0,1,18,1,0,1,0,2,1,,,,,0,3,1
NCT04088591,High-dose Intravenous Vitamin C as an Adjunctive Treatment for Sepsis in Rwanda,High-dose Intravenous Vitamin C as an Adjunctive Treatment for Sepsis in Rwanda: a Feasibility Trial,WITHDRAWN,2022-10,2023-12,2022-10-18,INTERVENTIONAL,PHASE3,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Sepsis,Ascorbic Acid 500Mg/Ml Inj|Dextrose in Water,DRUG,2,12,18 Years,80 Years,ALL,False,Virginia Commonwealth University,OTHER,1,1,Rwanda,0.0,0,0,1,0,0,3.0,0,0,0,0,1,0.0,,1,1,0,1,0,1,0,0,0,0,1,1,1,1,14,1,1,0,0,2,1,2022-10-01,2023-12-01,426.0,2022.0,1,2,0
NCT06402591,Results of Extended Versus Single Dose Antibiotic Prophylaxis In Orthopedic Revision Arthroplasty in Nijmegen.,"Multiple Doses Versus Single Dose of Cefazolin to Prevent Periprosthetic Joint Infection After Revision Arthroplasty: a Multicenter Open-label, Randomized Clinical Trial.",ACTIVE_NOT_RECRUITING,2019-01-01,2024-12-01,2024-05-07,INTERVENTIONAL,PHASE3,751.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,PREVENTION,NONE,"Infection Prosthesis Hip and Knee|Infection, Prosthesis Related|Joint Infection|Infection, Surgical Site|Surgical Site Infection|Infection Pro",Cefazolin,DRUG,1,9,18 Years,120 Years,ALL,False,Radboud University Medical Center,OTHER,1,1,Netherlands,,0,0,1,0,0,3.0,0,0,0,0,6,6.62273632394984,xlarge,0,1,0,1,0,1,0,0,0,0,1,0,0,0,10,1,1,0,0,1,0,,,,,0,2,0
NCT01480791,Aliskiren vs Hydrochlorothiazide in Hypertensive Type II Diabetic Patients on Resistance Arteries,"A Double-Blind, Randomized, Parallel Design Study of Aliskiren Versus Hydrochlorothiazide in Mild-to Moderate Hypertensive Type II Diabetes Mellitus Patients on Remodeling of Resistance Arteries",WITHDRAWN,2012-01,2013-12,2015-05-19,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Hypertension|Diabetes,Aliskiren vs. hydrochlorothiazide|Hydrochlorothiazide,DRUG,1,3,30 Years,70 Years,ALL,True,Sir Mortimer B. Davis - Jewish General Hospital,OTHER,1,1,Canada,0.0,0,1,0,0,0,2.0,0,0,0,1,2,0.0,,1,1,0,1,0,1,0,0,0,0,1,1,1,1,4,1,1,0,0,2,1,2012-01-01,2013-12-01,700.0,2012.0,0,2,0
NCT00638274,Comparison of Loss of Resistance Techniques,Comparison of Loss of Resistance Technique With Air Versus Saline to Identify Epidural Space for Combined Spinal Epidural Labor Analgesia,COMPLETED,2005-07,2008-05,2018-11-09,INTERVENTIONAL,PHASE2,356.0,ACTUAL,RANDOMIZED,PARALLEL,OTHER,SINGLE,Pain Relief,Air|Saline,PROCEDURE,1,1,,,FEMALE,False,Wake Forest University Health Sciences,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.877735781779639,large,0,1,0,1,0,0,0,0,1,0,1,0,0,1,2,1,0,0,0,2,1,2005-07-01,2008-05-01,1035.0,2005.0,0,1,0
NCT01925274,A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer,A RANDOMIZED PHASE 2 STUDY OF PF-05212384 PLUS IRINOTECAN VERSUS CETUXIMAB PLUS IRINOTECAN IN PATIENTS WITH KRAS AND NRAS WILD TYPE METASTATIC COLORECTAL CANCER,TERMINATED,2013-11-15,2016-04-06,2019-01-08,INTERVENTIONAL,PHASE2,19.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Metastatic Colorectal Cancer,PF-05212384|irinotecan|Cetuximab|Irinotecan,DRUG,1,30,18 Years,,ALL,False,Pfizer,INDUSTRY,0,32,Japan|Spain|South Korea|United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,2.995732273553991,small,1,1,1,0,1,0,1,1,1,1,1,0,1,1,31,1,1,0,0,4,1,,,,,0,3,1
NCT04504318,Apixaban vs Enoxaparin Following Microsurgical Breast Reconstruction-An RCT,A Randomized Controlled Trial Comparing Apixaban Versus Enoxaparin Following Microsurgical Breast Reconstruction,COMPLETED,2020-08-12,2024-06-19,2025-06-22,INTERVENTIONAL,PHASE1|PHASE2,82.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,SINGLE,Venous Thromboembolism,Apixaban 2.5 MG Oral Tablet|Enoxaparin 40Mg/0.4mL Prefilled Syringe,DRUG,1,1,18 Years,89 Years,FEMALE,False,Stanford University,OTHER,0,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,4.418840607796598,medium,1,1,0,1,0,0,0,0,1,0,1,0,0,1,2,1,1,0,0,2,1,,,,,0,2,0
NCT02272790,"Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","A Multicentre Phase II Study of Adavosertib Plus Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",COMPLETED,2015-01-30,2023-03-08,2023-10-03,INTERVENTIONAL,PHASE2,95.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation",Adavosertib|Paclitaxel|Carboplatin|Gemcitabine|PLD,DRUG,1,22,18 Years,130 Years,FEMALE,False,AstraZeneca,INDUSTRY,0,20,Netherlands|Canada|United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.564348191467836,medium,1,1,1,0,1,0,1,1,1,0,0,0,1,1,23,1,1,0,0,5,1,,,,,0,3,1
NCT04849390,A Study to Investigate the Efficacy and Tolerability of ESO-101 in Patients With Eosinophilic Esophagitis,"A Randomized, Placebo-controlled, Double-blind Trial Evaluating the Efficacy, Tolerability and Safety of ESO-101 in Adult Patients With Active Eosinophilic Esophagitis",COMPLETED,2021-06-29,2023-10-09,2023-11-14,INTERVENTIONAL,PHASE2,43.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Eosinophilic Esophagitis,ESO-101|Placebo,DRUG,1,18,18 Years,70 Years,ALL,False,EsoCap AG,INDUSTRY,2,17,Netherlands|Spain|Germany|Poland|Switzerland,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.784189633918261,small,1,1,1,0,0,1,1,1,0,1,1,1,1,1,19,1,1,0,0,2,1,,,,,0,3,1
NCT01441310,Laparoscopic Sentinel Node Navigation Surgery for Gastric Cancer,Laparoscopic Sentinel Node Navigation Surgery for Gastric Cancer,COMPLETED,2010-07,2016-08,2017-01-09,INTERVENTIONAL,PHASE2,101.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Gastric Cancer,Laparoscopic sentinel node navigation surgery,PROCEDURE,1,1,20 Years,80 Years,ALL,False,Seoul National University Bundang Hospital,OTHER,0,1,South Korea,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.624972813284271,medium,0,1,0,1,0,0,0,0,0,0,0,0,1,0,2,1,0,0,0,1,0,2010-07-01,2016-08-01,2223.0,2010.0,0,0,0
NCT00029510,Magnesium and Asthma - Clinical Trials,Magnesium and Asthma - Clinical Trials,COMPLETED,2002-05,2006-06,2006-08-18,INTERVENTIONAL,PHASE2,240.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Asthma,Magnesium,DRUG,0,0,21 Years,55 Years,ALL,True,National Center for Complementary and Integrative Health (NCCIH),NIH,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.484796933490655,large,0,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,2002-05-01,2006-06-01,1492.0,2002.0,0,0,0
NCT00365313,Preventing Recurrent Ulcer Bleeding in Arthritis Patients Using Esomeprazole Plus Celecoxib,"A Phase 3 Double Blinded, Randomized, Placebo Controlled Trial of Proton Pump Inhibitor for the Prevention of Recurrent Ulcer Bleeding in Patients Receiving a COX-2 Inhibitor",COMPLETED,2002-08,2005-06,2006-10-27,INTERVENTIONAL,PHASE3,273.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Arthritis|Bleeding Ulcer,"celecoxib, esomeprazole",DRUG,1,1,18 Years,95 Years,ALL,False,Chinese University of Hong Kong,OTHER,0,1,China,1.0,0,0,1,0,0,3.0,0,1,0,0,2,5.6131281063880705,large,0,0,0,1,0,0,0,0,0,0,1,1,1,1,2,1,1,0,0,1,0,2002-08-01,2005-06-01,1035.0,2002.0,0,1,0
NCT00566813,Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression,Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression,COMPLETED,2004-11,2020-07-15,2021-04-06,INTERVENTIONAL,PHASE1|PHASE2,10.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 1",Islet Cell Transplant|Islet Cell Transplant plus,DRUG,3,0,18 Years,75 Years,ALL,False,University of Illinois at Chicago,OTHER,0,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,2.3978952727983707,small,1,1,0,1,0,0,0,0,1,0,0,0,1,1,3,0,1,0,0,2,1,2004-11-01,,,2004.0,0,2,0
NCT02726113,Vitamin D and Prostate Cancer: A Clinical Study Enrolling Subjects Undergoing Prostatectomy,Vitamin D and Prostate Cancer: A Randomized Clinical Study,COMPLETED,2011-10,2015-12,2019-12-03,INTERVENTIONAL,PHASE2,50.0,ACTUAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,TRIPLE,Prostate Cancer,cholecalciferol|placebo,DRUG|OTHER,1,1,19 Years,90 Years,MALE,False,Medical University of South Carolina,OTHER,0,2,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.9318256327243257,small,1,1,0,1,0,0,1,0,1,0,1,1,0,1,2,1,1,0,0,2,1,2011-10-01,2015-12-01,1522.0,2011.0,0,1,0
NCT01847313,The Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Diabetic Kidney Disease,Phase 3 Study of the Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Renal Outcomes in Humans With Diabetic Kidney Disease,COMPLETED,2013-04,2015-11,2019-02-08,INTERVENTIONAL,PHASE3,20.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Diabetic Kidney Disease,Liraglutide,DRUG,1,4,30 Years,75 Years,ALL,False,Karl Neff,OTHER,1,1,Ireland,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.044522437723423,small,1,1,0,1,0,1,0,0,0,0,1,0,1,1,5,1,1,0,0,1,0,2013-04-01,2015-11-01,944.0,2013.0,0,0,0
NCT00079040,"Cisplatin, Etoposide, and Bevacizumab in Treating Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer",A Phase II Study of Cisplatin Plus Etoposide (PE) Plus Bevacizumab (NSC #704865) for Previously Untreated Extensive Stage Small Cell Lung Cancer,COMPLETED,2006-01,2009-01,2014-05-14,INTERVENTIONAL,PHASE2,65.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Extensive Stage Small Cell Lung Cancer,cisplatin|etoposide|bevacizumab|laboratory biomarker analysis,DRUG|BIOLOGICAL|OTHER,1,2,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.189654742026425,medium,1,1,0,1,0,0,0,0,1,0,0,0,1,0,3,1,1,1,0,4,1,2006-01-01,2009-01-01,1096.0,2006.0,0,1,0
NCT01086540,Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH),"A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)",COMPLETED,2011-06-24,2019-12-15,2023-02-21,INTERVENTIONAL,PHASE2,57.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Systemic Sclerosis-Associated PAH,Rituximab|Placebo|CMRI|prednisone|methylprednisolone|diphenhydramine|acetaminophen,DRUG|BIOLOGICAL|DIAGNOSTIC_TEST|OTHER,1,18,18 Years,75 Years,ALL,False,National Institute of Allergy and Infectious Diseases (NIAID),NIH,2,17,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.060443010546419,medium,1,1,0,1,0,1,1,0,1,0,1,1,1,1,19,1,1,1,0,7,1,,,,,0,2,0
NCT02222740,"A Safety, Tolerability and Pharmacokinetic Dose Escalation Study of HC-ER in Patients With Osteoarthritis Pain","A Multiple-Dose, Safety, Tolerability, and Pharmacokinetic Dose-Escalation Study of Hydrocodone Bitartrate Extended Release (HC-ER) in Patients With Chronic, Moderate to Severe Osteoarthritis Pain",COMPLETED,2002-09,2002-12,2022-11-10,INTERVENTIONAL,PHASE2,37.0,ACTUAL,NON_RANDOMIZED,PARALLEL,OTHER,NONE,Osteoarthrosis,10 mg of Hydrocodone Bitartrate Extended Release (HC-ER)|20 mg of Hydrocodone Bitartrate Extended Release (HC-ER),DRUG,1,0,18 Years,,ALL,False,"Zogenix, Inc.",INDUSTRY,0,0,,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.6375861597263857,small,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,2,1,2002-09-01,2002-12-01,91.0,2002.0,0,1,0
NCT00032968,Buprenorphine/Naloxone Versus Clonidine for Outpatient Opiate Detoxification - 1,Buprenorphine/Naloxone Versus Clonidine For Out-patient Opiate Detoxification,COMPLETED,2001-01,2002-08,2017-01-12,INTERVENTIONAL,PHASE3,341.0,,RANDOMIZED,,TREATMENT,NONE,Heroin Dependence|Morphine Dependence|Substance Withdrawal Syndrome,Buprenorphine/naloxone,DRUG,7,0,15 Years,,ALL,False,"University of California, Los Angeles",OTHER,0,7,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,3,5.834810737062605,large,0,0,0,1,0,0,1,0,1,0,1,0,1,0,7,0,1,0,0,1,0,2001-01-01,2002-08-01,577.0,2001.0,0,2,0
NCT00026468,Exisulind in Preventing Polyps in Patients With Familial Adenomatous Polyposis,Chemoprevention of Duodenal Polyps in Familial Adenomatous Polyposis,WITHDRAWN,1999-07,1999-07,2013-07-24,INTERVENTIONAL,PHASE2|PHASE3,0.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,PREVENTION,DOUBLE,Colorectal Cancer|Small Intestine Cancer,exisulind,DRUG,0,0,18 Years,80 Years,ALL,False,University of Utah,OTHER,1,0,,0.0,0,1,1,0,1,2.5,1,0,0,0,2,0.0,,1,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1999-07-01,1999-07-01,0.0,1999.0,0,2,0
NCT01157650,Treatment of Fistulous Crohn's Disease by Implant of Autologous Mesenchymal Stem Cells Derived From Adipose Tissue,Treatment of Fistulous Crohn's Disease by Implant of Autologous Mesenchymal Stem Cells Derived From Adipose Tissue,COMPLETED,2010-06,2013-09,2016-11-08,INTERVENTIONAL,PHASE1|PHASE2,15.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Crohn Disease,Autologous mesenchymal stem cells,OTHER,1,1,18 Years,,ALL,False,"Clinica Universidad de Navarra, Universidad de Navarra",OTHER,0,3,Spain,1.0,1,1,0,0,1,1.5,0,1,0,0,1,2.772588722239781,small,1,1,0,1,0,0,1,0,0,1,0,0,1,0,2,1,0,0,0,1,0,2010-06-01,2013-09-01,1188.0,2010.0,0,1,0
NCT01822691,Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS),A Phase II Study to Determine the Safety and Efficacy of INCB024360 in Patients With Myelodysplastic Syndromes,COMPLETED,2013-07,2015-02,2016-01-18,INTERVENTIONAL,PHASE2,15.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Myelodysplastic Syndromes,INCB024360,DRUG,1,4,18 Years,,ALL,False,H. Lee Moffitt Cancer Center and Research Institute,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.772588722239781,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,5,1,1,0,0,1,0,2013-07-01,2015-02-01,580.0,2013.0,0,0,0
NCT00191074,Amendment (g) Unblinded Extension Phase of Somatropin in Patients With Idiopathic Short Stature,Phase III Study of Humatrope in Non-Growth Hormone Deficient Children With Short Stature,COMPLETED,2001-02,2006-01,2007-03-09,INTERVENTIONAL,PHASE3,11.0,,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Growth Disorder,"somatropin, rDNA origin, for injection",DRUG,3,1,9 Years,16 Years,ALL,False,Eli Lilly and Company,INDUSTRY,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,2.4849066497880004,small,1,0,1,0,1,0,0,0,1,0,0,0,1,0,4,1,1,0,0,1,0,2001-02-01,2006-01-01,1795.0,2001.0,0,0,0
NCT03326518,"A Randomized, Controlled Trial to Evaluate CT Image Quality Lumentin® 44","An Open, Randomized, Controlled, Single Centre Trial to Evaluate CT Image Quality and Diagnostic Feasibility of Lumentin® 44, in Comparison With Omnipaque and Movprep.",TERMINATED,2017-11-28,2019-02-15,2020-10-27,INTERVENTIONAL,PHASE2,45.0,ACTUAL,RANDOMIZED,PARALLEL,DIAGNOSTIC,NONE,Subjects Referred to CT-examination of the Abdomen,Lumentin® 44|Diluted Omnipaque®|Movprep®,DIAGNOSTIC_TEST,1,9,18 Years,,ALL,False,Lument AB,INDUSTRY,0,1,Sweden,0.0,0,1,0,0,0,2.0,0,0,0,0,1,3.828641396489095,small,1,1,1,0,0,0,0,0,0,0,1,0,0,1,10,1,0,0,0,3,1,,,,,0,2,0
NCT01057797,Nurse Managed Upper Body Strength Training in Chronic Obstructive Pulmonary Disease (COPD),Nurse Managed Upper Body Strength Training in COPD,COMPLETED,2003-09,2009-01,2010-01-27,INTERVENTIONAL,PHASE2,208.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Chronic Obstructive Pulmonary Disease,Exercise-specific self-efficacy|Gentle chair exercise|upper body strength training,BEHAVIORAL,3,1,45 Years,,ALL,False,University of Illinois at Chicago,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.342334251964811,large,0,1,0,1,0,0,0,0,1,0,1,0,1,1,4,1,0,0,0,3,1,2003-09-01,2009-01-01,1949.0,2003.0,0,1,0
NCT02099110,"Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)","A Phase III, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin Compared With Ertugliflozin Alone and Sitagliptin Alone, in the Treatment of Subjects With T2DM With Inadequate Glycemic Control on Metformin Monotherapy",COMPLETED,2014-04-22,2016-05-26,2018-09-12,INTERVENTIONAL,PHASE3,1233.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,Matching Placebo to Ertugliflozin 5 mg|Matching Placebo to Ertugliflozin 10 mg|Matching Placebo to sitagliptin 100 mg|Ertugliflozin 5 mg|Ertugliflozin 10 mg|Sitagliptin 100 mg|Metformin >= 1500 mg/day|Insulin Glargine Rescue Medication|Glimepiride Rescue Medication,DRUG|BIOLOGICAL,3,5,18 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,1,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,7.1180162044653335,xlarge,0,1,1,0,1,1,0,0,0,0,1,1,1,1,8,1,1,1,0,9,1,,,,,0,2,0
NCT00462813,Diindolylmethane in Treating Patients With Abnormal Cervical Cells,An Investigation Into the Effects of Diidolylmethane (BioResponse DIM®) Supplementation in Women With Low-Grade Cervical Cytological Abnormalities [CRISP-1],COMPLETED,2004-10,2010-01,2013-08-07,INTERVENTIONAL,PHASE3,3000.0,ESTIMATED,RANDOMIZED,,PREVENTION,DOUBLE,Cervical Cancer|Precancerous Condition,oral microencapsulated diindolylmethane|polymerase chain reaction|cervical Papanicolaou test|cytology specimen collection procedure|colposcopic biopsy,DRUG|OTHER|GENETIC|PROCEDURE,1,6,,,FEMALE,False,Barts and the London School of Medicine and Dentistry,OTHER,0,2,United Kingdom,1.0,0,0,1,0,0,3.0,1,0,0,0,2,8.006700845440367,xlarge,0,0,0,1,0,0,1,0,0,1,1,1,0,0,7,1,1,0,0,5,1,2004-10-01,2010-01-01,1918.0,2004.0,0,3,1
NCT02501213,Evaluation of the Efficacy of Diuretics for Symptomatic Malignant Ascites Episodes in Advanced Stage of Cancer (DIASC),A Randomized Cross-over Trial Evaluating the Efficacy of Diuretics for Symptomatic Malignant Ascites Episodes in Advanced Palliative Stage of Cancer,TERMINATED,2016-05-30,2018-12-24,2019-05-16,INTERVENTIONAL,PHASE2,14.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Cancer,Spironolactone (+/- Furosemide),DRUG,1,13,18 Years,,ALL,False,Centre Oscar Lambret,OTHER,1,15,France,0.0,0,1,0,0,0,2.0,1,0,0,0,1,2.70805020110221,small,1,1,0,1,0,1,1,0,0,1,1,0,1,0,14,1,1,0,0,1,0,,,,,0,1,0
NCT01885013,Myocet + Cyclophosphamide + Metformin Vs Myocet + Cyclophosphamide in 1st Line Treatment of HER2 Neg. Metastatic Breast Cancer Patients,Phase II Comparative Study of Myocet Plus Cyclophosphamide in First Line Treatment of HER2 Negative Metastatic Breast Patients,COMPLETED,2010-09,2015-05,2016-01-01,INTERVENTIONAL,PHASE2,126.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Human Epidermal Growth Factor 2 Negative Carcinoma of Breast,Metformin + Myocet + Cyclophosphamide|Myocet + Cyclophosphamide,DRUG,1,6,18 Years,75 Years,FEMALE,False,Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS,OTHER,0,25,Italy,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.844187086458591,medium,0,1,0,1,0,0,1,0,0,1,1,0,1,1,7,1,1,0,0,2,1,2010-09-01,2015-05-01,1703.0,2010.0,0,2,0
NCT00670813,Enhancing the Therapeutic Efficacy of Sleep Deprivation by Modafinil,"Verstärkung Der Therapeutischen Wirkung Von Schlafentzug Durch Modafinil - Eine Doppelblinde, Randomisierte, Placebokontrollierte Monozentrische Studie Der Phase II (Enhancing the Therapeutic Efficacy of Sleep Deprivation by Modafinil - a Double Blind, Placebo-controlled Monocentric Phase II Study)",WITHDRAWN,2008-05,2009-11,2011-07-20,INTERVENTIONAL,PHASE2,30.0,ESTIMATED,RANDOMIZED,PARALLEL,BASIC_SCIENCE,QUADRUPLE,Depression,Modafinil (Vigil)|Placebo,DRUG,1,4,18 Years,70 Years,ALL,False,Technical University of Munich,OTHER,1,1,Germany,0.0,0,1,0,0,0,2.0,0,0,1,0,1,3.4339872044851463,small,1,0,0,1,0,1,0,0,0,1,1,1,0,1,5,1,1,0,0,2,1,2008-05-01,2009-11-01,549.0,2008.0,0,1,0
NCT07002060,"Phase 3 Randomized, Modified Double-blind, Active-controlled Safety Study on vYF in Adults","A Phase 3 Randomized, Modified Double-blind, Active-controlled Study to Assess the Safety of vYF, Yellow Fever Vaccine, in Adults Aged 18 Years up to 60 Years",COMPLETED,2025-05-22,2026-01-20,2026-02-02,INTERVENTIONAL,PHASE3,640.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Yellow Fever Immunization,Yellow fever vaccine (live)|YF vaccine (live),BIOLOGICAL,7,0,18 Years,59 Years,ALL,True,Sanofi,INDUSTRY,0,7,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.46302945692067,xlarge,0,1,1,0,1,0,1,0,1,0,1,1,0,1,7,0,0,1,0,2,1,,,,,0,2,0
NCT06188260,Efficacy of a New Nanoemulsion Artificial Tear Targeting Dry Eye Disease,Efficacy of a New Nanoemulsion Artificial Tear in Dry Eye Disease Management,COMPLETED,2024-01-16,2024-11-04,2024-12-02,INTERVENTIONAL,PHASE2,31.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Dry Eye Syndromes,Systane COMPLETE Lubricant Eye Drops,DRUG,1,2,20 Years,50 Years,ALL,False,The Hong Kong Polytechnic University,OTHER,1,1,Hong Kong,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.4657359027997265,small,1,1,0,1,0,1,0,0,0,0,0,0,1,0,3,1,1,0,0,1,0,,,,,0,0,0
NCT00016913,"Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer","Phase II Study Of Neo-Adjuvant Paclitaxel, Estramustine And Carboplatin (TEC) Plus Androgen Ablation Prior To Radiation Therapy In Patients With Poor Prognosis Localized Prostate Cancer",COMPLETED,2001-05,2008-05,2016-07-06,INTERVENTIONAL,PHASE2,34.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Prostate Cancer,carboplatin|estramustine|paclitaxel|radiation therapy|leuprolide or goserelin acetate,DRUG|RADIATION,1,2,18 Years,,MALE,False,Alliance for Clinical Trials in Oncology,OTHER,1,23,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.5553480614894135,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,3,1,1,0,0,5,1,2001-05-01,2008-05-01,2557.0,2001.0,0,1,0
NCT01305213,"Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer","A Randomized Phase II Evaluation of Single-Agent Bevacizumab (NSC #704865) and Combination Bevacizumab With Fosbretabulin Tromethamine (CA4P) (NSC #752293) in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma",COMPLETED,2011-03-21,2016-11-03,2019-07-30,INTERVENTIONAL,PHASE2,107.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma,Bevacizumab|Fosbretabulin Tromethamine|Laboratory Biomarker Analysis,DRUG|BIOLOGICAL|OTHER,1,5,18 Years,,FEMALE,False,National Cancer Institute (NCI),NIH,1,51,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,3,4.68213122712422,medium,0,1,0,1,0,1,1,0,1,0,1,0,1,1,6,1,1,1,0,3,1,,,,,0,3,1
NCT00413413,Efficacy/Safety of Valsartan Plus Amlodipine and Valsartan Alone in Patients With Hypertension,"A Multi-national, Multicenter, Double-blind, Double-dummy, Randomized, Active-controled, Parallel Study, Comparing Efficacy and Safety of Valsartan/Amlodipine 80/5 mg to Valsartan 80 mg and Valsartan 160 mg Alone Once Daily in Patients With Mild to Moderate Essential Hypertension Not Adequately Controlled With Valsartan 80 mg Monotherapy.",COMPLETED,2007-01,2007-11,2011-04-28,INTERVENTIONAL,PHASE3,1134.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Hypertension,Valsartan/amlodipine 80/5 mg|Valsartan 80 mg|Valsartan 160 mg,DRUG,1,4,18 Years,85 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,19,China,1.0,0,0,1,0,0,3.0,0,0,0,1,1,7.034387929915503,xlarge,0,1,1,0,1,0,1,0,0,0,1,1,1,1,5,1,1,0,0,3,1,2007-01-01,2007-11-01,304.0,2007.0,0,1,0
NCT00664560,Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis,"Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multi-Center Study Evaluating the Efficacy of PN400 (VIMOVO) Twice Daily (Bid) and Celecoxib Once Daily (qd) in Patients With Osteoarthritis of the Knee",COMPLETED,2008-04,2009-01,2012-02-27,INTERVENTIONAL,PHASE3,614.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Osteoarthritis,PN 400 (VIMOVO)|celebrex|Placebo|Rescue Antacid,DRUG,3,9,50 Years,,ALL,False,POZEN,INDUSTRY,0,1,United States,1.0,0,0,1,0,0,3.0,0,1,0,0,1,6.421622267806518,xlarge,0,1,1,0,0,0,0,0,1,0,1,1,1,1,12,1,1,0,0,4,1,2008-04-01,2009-01-01,275.0,2008.0,0,2,0
NCT00983060,Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients,"A Randomized, Adaptive-design, Dose-finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With the Standard of Care (SOC) in Relapsed Patients Infected With HCV Genotype-1",COMPLETED,2009-09,,2020-12-19,INTERVENTIONAL,PHASE2,59.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Chronic Hepatitis C Genotype-1 Relapse,NIM811|Placebo BID + SOC,DRUG,1,4,18 Years,69 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,16,Belgium|Puerto Rico|United States|Germany|Spain|Australia|Taiwan,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.0943445622221,medium,1,1,1,0,1,0,1,1,1,1,1,1,1,1,5,1,1,0,0,2,1,2009-09-01,,,2009.0,0,2,0
NCT00228020,"Study of Safety and Efficacy of a Basiliximab, Mycophenolate Mofetil, Cyclosporine Microemulsion and Prednisone Combination Treatment Regimen in Pediatric Renal Allograft Recipients","A Randomized, Placebo-controlled, Double-blind, Multicenter Study Investigating Basiliximab in Combination With MMF, Cyclosporine Microemulsion and Prednisone in the Prevention of Acute Rejection in Pediatric Renal Allograft Recipients",COMPLETED,2001-05,,2010-08-25,INTERVENTIONAL,PHASE3,212.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Pediatric Kidney Transplantation,"basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent)|MMF, cyclosporine, steroids",DRUG,1,0,1 Year,18 Years,ALL,,Novartis,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.3612921657094255,large,0,1,1,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,2,1,2001-05-01,,,2001.0,0,1,0
NCT00624520,Mental Stress Reduction in Defibrillator Patients,Effectiveness of Mental Stress Reduction in Defibrillator Patients,TERMINATED,2008-09,2014-07,2014-12-22,INTERVENTIONAL,PHASE3,129.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Cardiomyopathy, Dilated|Arrhythmia|Anger|Stress",Cognitive Behavioral Stress Management (CBSM)|Patient Education,BEHAVIORAL|OTHER,3,8,21 Years,85 Years,ALL,False,US Department of Veterans Affairs,FED,0,2,United States,0.0,0,0,1,0,0,3.0,0,0,0,1,4,4.867534450455582,medium,0,1,0,0,0,0,1,0,1,0,1,0,1,1,11,1,0,0,0,2,1,2008-09-01,2014-07-01,2129.0,2008.0,0,3,1
NCT01199120,Cognitive Effects of Omega-3 Supplements in Children With Mild to Moderate Malnutrition,Cognitive Effects of Omega-3 Supplements in Children With Mild to Moderate Malnutrition,COMPLETED,2009-03,2010-09,2010-09-10,INTERVENTIONAL,PHASE2,75.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Malnourishment,Omega 3,DIETARY_SUPPLEMENT,1,1,8 Years,12 Years,ALL,True,Universidad Autonoma de Ciudad Juarez,OTHER,0,1,Mexico,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.330733340286331,medium,1,1,0,1,0,0,0,0,0,0,1,1,1,1,2,1,0,0,0,1,0,2009-03-01,2010-09-01,549.0,2009.0,0,0,0
NCT05633420,Pilot Clinical Trial to Explore Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients,"A Multi-Center Single Arm, Open-label, Pilot Clinical Trial to Explore Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients",COMPLETED,2022-07-24,2022-11-20,2022-12-02,INTERVENTIONAL,PHASE2,20.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,COVID-19,Pyramax,DRUG,1,4,19 Years,,ALL,False,Shin Poong Pharmaceutical Co. Ltd.,INDUSTRY,0,2,South Korea,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.044522437723423,small,1,1,1,0,0,0,1,0,0,0,0,0,1,0,5,1,1,0,0,1,0,,,,,0,0,0
NCT06946420,SENECA: First Line metaStatic pancrEatic caNcer Primary and Distant (if Oligometastatic) lEsion direCted rAdiotherapy,"SENECA: First Line metaStatic pancrEatic caNcer Primary and Distant (if Oligometastatic) lEsion direCted rAdiotherapy, a Phase III Randomized Multicentric Trial",ACTIVE_NOT_RECRUITING,2025-01-10,2031-01-10,2025-04-27,INTERVENTIONAL,PHASE3,108.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Radiation Therapy|SBRT|Pancreatic Cancer Metastatic,SBRT or RT on primary pancreatic and/or metastatic distant lesions before chemotherapy|Standard systemic therapy (chemotherapy) without RT/SBRT,DRUG|RADIATION,1,2,18 Years,,ALL,False,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,OTHER,0,1,Italy,,0,0,1,0,0,3.0,1,0,0,0,3,4.6913478822291435,medium,0,1,0,1,0,0,0,0,0,1,1,0,1,1,3,1,1,0,0,2,1,,,,,0,2,0
NCT02720120,A Study of Ocrelizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA),"A Randomized Placebo-Controlled, Multi-Center, Phase I/II Study of the Safety of Escalating Single Intravenous Doses of Ocrelizumab (rhuMAb 2H7, RO4964913, PRO70769) in Patients With Moderate to Severe Rheumatoid Arthritis Receiving Stable Doses of Concomitant Methotrexate But With Unsatisfactory Clinical Response",TERMINATED,2005-10,2013-02,2016-03-28,INTERVENTIONAL,PHASE1|PHASE2,175.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Rheumatoid Arthritis,Ocrelizumab|Placebo,DRUG,2,14,18 Years,80 Years,ALL,False,Hoffmann-La Roche,INDUSTRY,0,49,Netherlands|Belgium|Russia|Spain|United Kingdom|Australia|New Zealand|Canada,0.0,1,1,0,0,1,1.5,0,1,0,0,1,5.170483995038151,medium,0,1,1,0,1,0,1,1,0,1,1,1,1,1,16,1,1,0,0,2,1,2005-10-01,2013-02-01,2680.0,2005.0,0,4,1
NCT00490620,Study of Combivir for Patients With Primary Biliary Cirrhosis,Randomized Controlled Pilot Study of Combivir for Patients With Primary Biliary Cirrhosis,COMPLETED,2004-01,2007-04,2007-11-01,INTERVENTIONAL,PHASE2|PHASE3,59.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Primary Biliary Cirrhosis,Combination antiviral therapy|Placebo,DRUG,1,1,18 Years,75 Years,ALL,False,University of Alberta,OTHER,2,5,Canada|United Kingdom|United States,1.0,0,1,1,0,1,2.5,0,0,0,0,1,4.0943445622221,medium,1,1,0,1,0,1,1,1,1,1,1,1,1,1,2,1,1,0,0,2,1,2004-01-01,2007-04-01,1186.0,2004.0,0,3,1
NCT04546620,Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL),A Randomised Phase II Evaluation of Molecular Guided Therapy for Diffuse Large B-Cell Lymphoma With Acalabrutinib,ACTIVE_NOT_RECRUITING,2021-10-19,2028-05,2025-08-06,INTERVENTIONAL,PHASE2,453.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,NONE,Diffuse Large B Cell Lymphoma,R-CHOP|R-CHOP + acalabrutinib,DRUG,1,10,16 Years,,ALL,False,University Hospital Southampton NHS Foundation Trust,OTHER,1,33,United Kingdom,,0,1,0,0,0,2.0,1,0,0,0,1,6.118097198041348,large,0,0,0,1,0,1,1,0,0,1,1,0,1,1,11,1,1,0,0,2,1,,2028-05-01,,,0,2,0
NCT07235020,Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria,"A Multi-part, Multi-center PLATform Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Anti-malarial Agents Administered as Monotherapy and/or Combination Therapy IN Participants With Uncomplicated Plasmodium Falciparum Malaria",COMPLETED,2024-01-23,2025-02-21,2025-11-19,INTERVENTIONAL,PHASE2,52.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Uncomplicated Plasmodium Falciparum Malaria,INE963,DRUG,1,9,18 Years,100 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,6,Côte d’Ivoire|Gabon|Ghana|Burkina Faso|Uganda|Kenya,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.970291913552122,medium,1,1,1,0,1,0,1,1,0,0,1,0,1,1,10,1,1,0,0,1,0,,,,,0,2,0
NCT02503020,Arachidonic Acid Supplementation in Very Preterm Infants,"Effects of Different Arachidonic Acid Supplementation on Psychomotor Development in Very Preterm Infants, a Randomized Controlled Trial",COMPLETED,2011-07,2015-03,2015-07-20,INTERVENTIONAL,PHASE2,45.0,ACTUAL,RANDOMIZED,PARALLEL,SCREENING,TRIPLE,Impaired Psychomotor Development,Preterm infants formula A|Preterm infants formula B,DIETARY_SUPPLEMENT,1,5,1 Minute,2 Years,ALL,True,Health Research Institute of Santiago,OTHER,0,0,,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.828641396489095,small,1,1,0,1,0,0,0,0,0,0,1,1,0,1,6,1,0,0,0,2,1,2011-07-01,2015-03-01,1339.0,2011.0,0,2,0
NCT01762020,Barrier Film vs. Standard Skin Care in Preventing Dermatitis in Women With Breast Cancer Receiving Radiation,Phase III Randomized Pair Comparison of a Barrier Film vs. Standard Skin Care in Preventing Radiation Dermatitis in Women With Breast Cancer Receiving Adjuvant Radiation Therapy,COMPLETED,2013-01,2017-02,2017-03-08,INTERVENTIONAL,PHASE3,56.0,ACTUAL,RANDOMIZED,FACTORIAL,TREATMENT,SINGLE,Breast Cancer|Dermatitis,3M Cavilon No Sting Barrier Film|Standard Preparation,DRUG|DEVICE,1,2,18 Years,80 Years,FEMALE,False,London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's,OTHER,0,1,Canada,1.0,0,0,1,0,0,3.0,1,0,0,0,2,4.04305126783455,medium,1,1,0,1,0,0,0,0,0,0,1,0,1,0,3,1,1,0,1,2,1,2013-01-01,2017-02-01,1492.0,2013.0,0,2,0
NCT02600520,Comparison of Rosuvastatin With Atorvastatin in Chronic Periodontitis,1.2% Rosuvastatin Versus 1.2% Atorvastatin Local Drug Delivery in Treatment of Intrabony Defects in Chronic Periodontitis: A Randomized Controlled Clinical Trial,COMPLETED,2014-11,2015-05,2015-11-13,INTERVENTIONAL,PHASE2|PHASE3,45.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Chronic Periodontitis,SRP with RSV gel LDD|SRP with ATV gel LDD|SRP with placebo gel LDD,DRUG,1,4,30 Years,50 Years,ALL,True,"Government Dental College and Research Institute, Bangalore",OTHER,0,0,,1.0,0,1,1,0,1,2.5,0,0,0,0,1,3.828641396489095,small,1,1,0,1,0,0,0,0,0,0,1,1,1,1,5,1,1,0,0,3,1,2014-11-01,2015-05-01,181.0,2014.0,0,2,0
NCT03337620,Efficacy and Safety of Tx360® Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Migraine,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel 20 Week Study of the Efficacy and Safety of the Tx360® Nasal Applicator for Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Migraine",COMPLETED,2017-09-20,2023-12-29,2024-01-05,INTERVENTIONAL,PHASE3,174.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Headache, Migraine",Tx360,DEVICE,1,2,18 Years,65 Years,ALL,False,Tian Medical Inc.,INDUSTRY,3,11,United States,1.0,0,0,1,0,0,3.0,0,0,1,0,1,5.1647859739235145,medium,0,1,1,0,0,1,1,0,1,0,1,1,1,1,3,1,0,0,1,1,0,,,,,0,0,0
NCT01193920,Safety and Immunogenicity of a Group B Streptococcus Vaccine in Non Pregnant and Pregnant Women 18-40 Years of Age,"A Phase Ib/II Randomized, Observer-Blind, Controlled, Single Centre Study of a Trivalent Group B Streptococcus Vaccine in Healthy Non-Pregnant Women Leading Into a Dose-Ranging Study in Pregnant Women in South Africa",COMPLETED,2010-10,2012-12,2014-08-22,INTERVENTIONAL,PHASE1|PHASE2,380.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Streptococcal Infections,Group B Streptococcus Trivalent Vaccine - 20/20/20 μg|Saline solution|Group B Streptococcus Trivalent Vaccine - 0.5/0.5/0.5 μg|Group B Streptococcus Trivalent Vaccine - 2.5/2.5/2.5 μg|Group B Streptococcus Trivalent Vaccine - 5/5/5 μg|saline solution,BIOLOGICAL|OTHER,4,8,18 Years,40 Years,FEMALE,True,Novartis Vaccines,INDUSTRY,0,1,South Africa,1.0,1,1,0,0,1,1.5,0,0,0,0,1,5.942799375126701,large,0,1,1,0,1,0,0,0,0,0,1,1,0,1,12,1,0,1,0,6,1,2010-10-01,2012-12-01,792.0,2010.0,0,3,1
NCT01076582,Comparative Trial in Hormone Withdrawal Associated Symptoms,"A Multi-centre, Randomized, Double-blind, Active Control, Parallel-group, 2-arm Study to Investigate the Effect of Ethinylestradiol / Drospirenone (0.02 mg/3 mg) Oral Contraception in a 24/4 Regimen Compared to Ethinylestradiol / Desogestrel (0.02 mg/0.15 mg) Oral Contraception in a 21/7 Regimen on Hormone Withdrawal Associated Symptoms in Otherwise Healthy Women After 4 Cycles of Treatment",COMPLETED,2010-04,2011-10,2014-10-28,INTERVENTIONAL,PHASE3,592.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Oral Contraceptive,"EE20/DRSP (YAZ, BAY86-5300)|Ethinylestradiol (EE) and desogestrel (DSG) (Mercilon)",DRUG,1,9,18 Years,35 Years,FEMALE,False,Bayer,INDUSTRY,0,44,Italy|Russia|Argentina|Venezuela|South Korea|Germany|United Kingdom|Chile|Switzerland|Czechia|Portugal|Philippines|Colombia|Thailand,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.385194398997726,xlarge,0,1,1,0,0,0,1,1,0,1,1,1,1,1,10,1,1,0,0,2,1,2010-04-01,2011-10-01,548.0,2010.0,0,3,1
NCT05243524,Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer,"Phase 2b Single Arm Study of Maveropepimut-S and Low-Dose Cyclophosphamide in Subjects With Platinum-Resistant, Epithelial Ovarian Cancer.",TERMINATED,2022-08-05,2023-08-31,2023-09-13,INTERVENTIONAL,PHASE2,16.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Platinum-resistant Epithelial Ovarian Cancer,Maveropepimut-S|Cyclophosphamide 50mg,DRUG|OTHER,1,9,18 Years,,FEMALE,False,"ImmunoVaccine Technologies, Inc. (IMV Inc.)",INDUSTRY,0,6,Canada|Puerto Rico|United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,2.833213344056216,small,1,1,1,0,0,0,1,1,1,0,0,0,1,0,10,1,1,0,0,2,1,,,,,0,3,1
NCT04102124,A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC,A Phase II Clinical Study of SHR3680 Combined With SHR3162 in the Treatment of Metastatic Castration-resistant Prostate Cancer Previously Treated With Abiraterone and Docetaxel,TERMINATED,2019-04-08,2021-08-31,2025-06-24,INTERVENTIONAL,PHASE2,20.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Prostate Cancer|Castration-resistant Prostate Cancer,SHR3680|SHR3162|SHR3680(Placebo)|SHR3162(Placebo),DRUG,2,8,18 Years,,MALE,False,"Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,0,1,China,0.0,0,1,0,0,0,2.0,1,0,0,0,2,3.044522437723423,small,1,1,1,0,0,0,0,0,0,0,1,1,1,1,10,1,1,0,0,4,1,,,,,0,3,1
NCT03620123,A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck,A Randomized Phase II Study on the OPTimization of IMmunotherapy in Squamous Carcinoma of the Head and Neck,COMPLETED,2018-07-16,2022-06-19,2022-11-18,INTERVENTIONAL,PHASE2,54.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|Carcinoma, Squamous Cell of Head and Neck",Nivolumab and Ipilimumab|Docetaxel,DRUG,1,8,18 Years,,ALL,False,AIO-Studien-gGmbH,OTHER,1,1,Germany,1.0,0,1,0,0,0,2.0,1,0,0,0,2,4.007333185232471,medium,1,1,0,1,0,1,0,0,0,1,1,0,1,1,9,1,1,0,0,2,1,,,,,0,3,1
NCT01420159,Efficacy and Safety of Methoxyflurane (Penthrox) for the Treatment of Acute Pain in Minor Trauma,"A Randomised, Double Blind, Multi-centre, Placebo Controlled Study to Evaluate the Efficacy and Safety of Methoxyflurane (Penthrox) for the Treatment of Acute Pain in Patients Presenting to an Emergency Department With Minor Trauma",COMPLETED,2011-08,2012-07,2012-10-31,INTERVENTIONAL,PHASE3,300.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Acute Pain Due to Trauma,Methoxyflurane,DRUG,1,4,12 Years,,ALL,False,Medical Developments International Limited,INDUSTRY,1,6,United Kingdom,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.707110264748875,large,0,1,1,0,0,1,1,0,0,1,1,1,1,1,5,1,1,0,0,1,0,2011-08-01,2012-07-01,335.0,2011.0,0,0,0
NCT00155259,"Docetaxel, Cisplatin and Capecitabine as Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer",Docetaxel by 1 Hour Infusion Followed by 24 Hour Infusion of Cisplatin Plus Capecitabine as Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer,COMPLETED,2004-10,2006-12,2007-07-25,INTERVENTIONAL,PHASE2,47.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Breast Cancer,"Docetaxel , Cisplatin , Capecitabine",DRUG,1,1,,65 Years,FEMALE,False,National Taiwan University Hospital,OTHER,0,1,Taiwan,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.871201010907891,small,1,1,0,1,0,0,0,0,0,0,0,0,1,0,2,1,1,0,0,1,0,2004-10-01,2006-12-01,791.0,2004.0,0,0,0
NCT00382759,Nonmyeloablative Stem Cell Transplant in Elderly,Nonmyeloablative Allogeneic Stem Cell Transplantation in Elderly Patients With Hematological Malignancies:Results From the GITMO (Gruppo Italiano Trapianto Midollo Osseo)Multicenter Prospective Clinical Trial,COMPLETED,2000-03,2007-03,2009-08-03,INTERVENTIONAL,PHASE2|PHASE3,50.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Hematological Malignancies,stem cell transplant,PROCEDURE,3,2,60 Years,,ALL,False,Azienda Ospedaliera San Giovanni Battista,OTHER,0,1,Italy,1.0,0,1,1,0,1,2.5,0,0,0,0,1,3.9318256327243257,small,1,1,0,1,0,0,0,0,0,1,0,0,1,0,5,1,0,0,0,1,0,2000-03-01,2007-03-01,2556.0,2000.0,0,1,0
NCT00471159,A Study Of Docetaxel Or Docetaxel Plus PF-3512676 To Treat Patients With Advanced Breast Cancer.,A Randomized Phase 2 Clinical Trial Of Docetaxel With Or Without PF-3512676 As First-Line Treatment Of Patients With Advanced Breast Cancer,WITHDRAWN,2007-08,,2015-05-04,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Breast Neoplasms,docetaxel|PF-3512676,DRUG,2,4,18 Years,,FEMALE,False,Pfizer,INDUSTRY,0,0,,0.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,1,1,1,0,1,0,0,0,0,0,1,0,1,1,6,1,1,0,0,2,1,2007-08-01,,,2007.0,0,2,0
NCT05155059,Non-invasive Intermittent Theta Burst Stimulation of the Dorsolateral Prefrontal Cortex in Functional Movement Disorders,Phase II Trial of Non-Invasive Intermittent Theta Burst Stimulation of the Dorsolateral Prefrontal Cortex in Functional Movement Disorders,ACTIVE_NOT_RECRUITING,2022-05-06,2026-12-01,2025-06-03,INTERVENTIONAL,PHASE2,21.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Functional Movement Disorder,MagStim|Sham Comparator,DEVICE|OTHER,1,3,18 Years,80 Years,ALL,False,National Institute of Neurological Disorders and Stroke (NINDS),NIH,0,1,United States,,0,1,0,0,0,2.0,0,0,0,0,1,3.091042453358316,small,1,1,0,1,0,0,0,0,1,0,1,1,1,1,4,1,0,0,1,2,1,,,,,0,1,0
NCT01268280,Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis,"A Phase II, Double-Blind, Randomized, Three-Way Crossover, Placebo-Controlled, Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis on Standard Therapy",TERMINATED,2010-12,2012-10,2019-09-24,INTERVENTIONAL,PHASE2,32.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Myasthenia Gravis,Placebo|250 mg CK-2017357|500 mg CK-2017357,DRUG,3,7,18 Years,80 Years,ALL,False,Cytokinetics,INDUSTRY,1,15,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,3.4965075614664802,small,1,1,1,0,0,1,1,0,1,0,1,1,1,0,10,1,1,0,0,3,1,2010-12-01,2012-10-01,670.0,2010.0,0,2,0
NCT03293680,Pembrolizumab in Elderly Patients With Advanced Lung Cancer,"Survival, Quality of Life and Self-reported Outcomes of Elderly Patients With Advanced Non-small Cell Lung Cancer Treated With Pembrolizumab (MK-3475) in the First Line Setting",COMPLETED,2017-01-15,2023-07-15,2024-10-23,INTERVENTIONAL,PHASE2,83.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Non Small Cell Lung Cancer,Pembrolizumab,DRUG,1,6,70 Years,,ALL,False,Spanish Lung Cancer Group,OTHER,0,12,Spain,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.430816798843313,medium,1,1,0,1,0,0,1,0,0,1,0,0,1,0,7,1,1,0,0,1,0,,,,,0,1,0
NCT03418480,HARE-40: HPV Anti-CD40 RNA vaccinE,Therapeutic HPV Vaccine (BNT113) Trial in HPV16 Driven Carcinoma,COMPLETED,2017-04-11,2024-01-24,2024-02-07,INTERVENTIONAL,PHASE1|PHASE2,32.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Human Papilloma Virus Related Carcinoma|Head and Neck Neoplasm|Cervical Neoplasm|Penile Neoplasms Malignant|Unknown Primary Tumors,BNT113,DRUG,1,0,18 Years,,ALL,False,University of Southampton,OTHER,1,2,United Kingdom,1.0,1,1,0,0,1,1.5,1,0,0,0,5,3.4965075614664802,small,1,1,0,1,0,1,1,0,0,1,0,0,1,0,1,0,1,0,0,1,0,,,,,0,2,0
NCT04839380,The Purpose of the Study is to Evaluate the Effect of Ruxolitinib Cream on Itch in Participants With Atopic Dermatitis,"An Open-Label, Single-Arm Study to Evaluate the Effect of Ruxolitinib 1.5% Cream on Itch in Adult Participants With Atopic Dermatitis",COMPLETED,2021-10-12,2022-11-18,2023-10-31,INTERVENTIONAL,PHASE2,49.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Atopic Dermatitis,ruxolitinib cream,DRUG,1,12,18 Years,65 Years,ALL,False,Incyte Corporation,INDUSTRY,0,2,Canada,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.912023005428146,small,1,1,1,0,0,0,1,0,0,0,0,0,1,0,13,1,1,0,0,1,0,,,,,0,1,0
NCT03408080,Open Pilot Trial of BHV-4157,An Open Pilot Trial of BHV-4157 in Adult Subjects With Cerebellar Ataxia,ACTIVE_NOT_RECRUITING,2017-12-15,2024-12-15,2024-05-09,INTERVENTIONAL,PHASE3,24.0,ESTIMATED,,SINGLE_GROUP,TREATMENT,NONE,Spinocerebellar Ataxias|Spinocerebellar Ataxia Type 1|Spinocerebellar Ataxia Type 2|Spinocerebellar Ataxia 3|Spinocerebellar Ataxia Type 6|MSA-C,BHV-4157,DRUG,1,4,18 Years,75 Years,ALL,False,"University of California, Los Angeles",OTHER,0,1,United States,,0,0,1,0,0,3.0,0,0,0,0,6,3.2188758248682006,small,1,0,0,1,0,0,0,0,1,0,0,0,1,0,5,1,1,0,0,1,0,,,,,0,1,0
NCT00355680,Green Laser Photocoagulation Study in Proliferative Diabetic Retinopathy,Comparative Study of Indigenous Green Laser With Already Available Green Laser in Proliferative Diabetic Retinopathy,COMPLETED,2005-12,2006-07,2009-02-11,INTERVENTIONAL,PHASE3,24.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Diabetic Retinopathy,"Green Laser (Aurolas, Aurolab)|Green Laser (Iridex)",DEVICE,3,4,18 Years,,ALL,False,Aurolab,OTHER,1,1,India,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.2188758248682006,small,1,1,0,1,0,1,0,0,0,0,1,1,1,1,7,1,0,0,1,2,1,2005-12-01,2006-07-01,212.0,2005.0,0,2,0
NCT04052880,"Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM","A Phase 2 Study of Subcutaneous Daratumumab in Combination With Dose-Attenuated Bortezomib, Lenalidomide, and Dexamethasone in Elderly Newly Diagnosed Multiple Myeloma Patients",ACTIVE_NOT_RECRUITING,2019-10-24,2026-05,2025-07-20,INTERVENTIONAL,PHASE2,17.0,ESTIMATED,,SINGLE_GROUP,TREATMENT,NONE,Newly Diagnosed Multiple Myeloma,Daratumumab|Bortezomib|Lenalidomide|Dexamethasone|Ixazomib,DRUG,1,7,70 Years,,ALL,False,Larysa Sanchez,OTHER,1,1,United States,,0,1,0,0,0,2.0,1,0,0,0,1,2.8903717578961645,small,1,0,0,1,0,1,0,0,1,0,0,0,1,0,8,1,1,0,0,5,1,,2026-05-01,,,0,2,0
NCT03231878,A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN Patients.,"A Randomized, Double-blind, Placebo-controlled, Multinational, Multicenter Study With Open-label Treatment Extension to Assess the Effect of MIN-102 (IMP) on the Progression of Adrenomyeloneuropathy in Male Patients With X-linked Adrenoleukodystrophy",COMPLETED,2017-12-08,2025-03-06,2025-03-18,INTERVENTIONAL,PHASE2|PHASE3,105.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Adrenoleukodystrophy,MIN-102|Placebos,DRUG,1,5,18 Years,65 Years,MALE,False,"Minoryx Therapeutics, S.L.",INDUSTRY,0,10,Italy|Netherlands|Hungary|United States|Germany|Spain|United Kingdom|France,1.0,0,1,1,0,1,2.5,0,0,0,0,1,4.663439094112067,medium,0,1,1,0,0,0,1,1,1,1,1,1,1,1,6,1,1,0,0,2,1,,,,,0,4,1
NCT00280878,Rituximab in Combination With Outpatient Therapy for CD20+ Lymphoma,A Pilot Study of Rituximab in Combination With Out-patient Based VGF/F-GIV Salvage Therapies for Relapsed/Refractory CD20+ Lymphomas,COMPLETED,2006-01,2007-09,2016-01-15,INTERVENTIONAL,PHASE2,12.0,ESTIMATED,NON_RANDOMIZED,CROSSOVER,TREATMENT,NONE,Non-Hodgkin's Lymphoma (CD20+),gemcitabine|vinorelbine|ifosfamide|rituximab,DRUG,1,1,18 Years,,ALL,False,Bayside Health,OTHER_GOV,0,2,Australia,1.0,0,1,0,0,0,2.0,1,0,0,0,1,2.5649493574615367,small,1,0,0,1,0,0,1,0,0,0,0,0,1,0,2,1,1,0,0,4,1,2006-01-01,2007-09-01,608.0,2006.0,0,1,0
NCT03468985,"Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer","A Randomized Phase II Trial of Nivolumab, Cabozantinib Plus Nivolumab, and Cabozantinib Plus Nivolumab Plus Ipilimumab in Patients With Previously Treated Non-Squamous NSCLC",COMPLETED,2018-05-07,2022-12-21,2023-10-17,INTERVENTIONAL,PHASE2,3.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Metastatic Lung Non-Squamous Non-Small Cell Carcinoma|Recurrent Lung Non-Squamous Non-Small Cell Carcinoma|Stage IV Lung Non-Small Cell Cancer AJCC v7,Cabozantinib|Ipilimumab|Nivolumab,DRUG|BIOLOGICAL,1,2,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,468,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,3,1.3862943611198906,small,1,1,0,1,0,0,1,0,1,0,1,0,1,1,3,1,1,1,0,3,1,,,,,0,2,0
NCT03690115,Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (allo-SCT) in FLT3-ITD AML Patients,"Phase 2 Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (allo-SCT) in FLT3-ITD AML Patients: the PONALLO Trial.""",COMPLETED,2019-12-02,2024-12-31,2025-03-25,INTERVENTIONAL,PHASE2,23.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Leukemia, Myeloid, Acute",Ponatinib 30 MG,DRUG,1,7,18 Years,70 Years,ALL,False,Versailles Hospital,OTHER,0,14,France,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.1780538303479458,small,1,1,0,1,0,0,1,0,0,1,0,0,1,0,8,1,1,0,0,1,0,,,,,0,1,0
NCT00037635,A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients,A Phase 3 Study to Assess the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) in Secondary Hyperparathyroidism of End Stage Renal Disease Treated With Hemodialysis,COMPLETED,2001-12,2003-03,2013-05-08,INTERVENTIONAL,PHASE3,400.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Secondary Hyperparathyroidism|End Stage Renal Disease,AMG 073|Placebo,DRUG,1,3,18 Years,,ALL,False,Amgen,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,2,5.993961427306569,large,0,0,1,0,1,0,0,0,0,0,1,1,1,1,4,1,1,0,0,2,1,2001-12-01,2003-03-01,455.0,2001.0,0,2,0
NCT03527108,"Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC","A Phase 2 Study of Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic Non-Small Cell Lung Carcinoma",ACTIVE_NOT_RECRUITING,2020-10-08,2027-04,2026-01-14,INTERVENTIONAL,PHASE2,36.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Non Small Cell Lung Cancer,Nivolumab|Ramucirumab,DRUG,1,4,18 Years,,ALL,False,Fox Chase Cancer Center,OTHER,2,2,United States,,0,1,0,0,0,2.0,1,0,0,0,1,3.6109179126442243,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,5,1,1,0,0,2,1,,2027-04-01,,,0,1,0
NCT00547625,Study to Determine Safety and Effectiveness of Tadalafil on Prostate Related Sex Organ/Urinary Tract Problems,"A Multicenter, Parallel-Arm, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of Tadalafil Administered Once Daily to Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia",COMPLETED,2004-10,2005-07,2007-10-22,INTERVENTIONAL,PHASE2,275.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Prostatic Hyperplasia|Prostate,tadalafil|placebo,DRUG,1,3,45 Years,,MALE,False,Eli Lilly and Company,INDUSTRY,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,5.62040086571715,large,0,1,1,0,1,1,0,0,1,0,1,1,1,1,4,1,1,0,0,2,1,2004-10-01,2005-07-01,273.0,2004.0,0,2,0
NCT02493725,JET-GBS - Japanese Eculizumab Trial for GBS,"A PROSPECTIVE, MULTI-CENTER, PHASE II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ECULIZUMAB IN SUBJECTS WITH GUILLAIN-BARRÉ SYNDROME",COMPLETED,2015-07,2016-10,2017-10-11,INTERVENTIONAL,PHASE2,34.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Gullain Barre Syndrome,Eculizumab|Placebo,DRUG,2,16,18 Years,99 Years,ALL,False,Chiba University,OTHER,1,13,Japan,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.5553480614894135,small,1,1,0,1,0,1,1,0,0,0,1,1,1,1,18,1,1,0,0,2,1,2015-07-01,2016-10-01,458.0,2015.0,1,2,0
NCT06067425,"Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SAR442501 in Pediatric Participants With Achondroplasia","A Phase 2, Open-label, Multi-center, 2-stage Sequential Cohort, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Subcutaneous SAR442501 in Pediatric Participants With Achondroplasia",TERMINATED,2023-10-10,2025-02-12,2025-02-25,INTERVENTIONAL,PHASE2,16.0,ACTUAL,RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,Osteochondrodysplasia,SAR442501,DRUG,1,31,0 Days,12 Years,ALL,False,Sanofi,INDUSTRY,0,9,China|Italy|South Korea|Spain|Australia,0.0,0,1,0,0,0,2.0,0,0,0,0,1,2.833213344056216,small,1,1,1,0,1,0,1,1,0,1,1,0,1,0,32,1,1,0,0,1,0,,,,,0,2,0
NCT00000925,A Study to Evaluate High Protein Supplementation in HIV-Positive Patients With Stable Weight Loss,Evaluation of High Protein Supplementation in HIV-1-Positive Subjects With Stable Weight Loss,COMPLETED,1999-05,,2013-07-29,INTERVENTIONAL,PHASE2,56.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,HIV Infections|HIV Wasting Syndrome,Optimune oral nutritional supplement,DRUG,0,0,18 Years,,ALL,False,National Institute of Allergy and Infectious Diseases (NIAID),NIH,0,19,Puerto Rico|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.04305126783455,medium,1,0,0,1,0,0,1,1,1,0,1,1,1,1,0,0,1,0,0,1,0,1999-05-01,,,1999.0,0,2,0
NCT00092625,Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-803),"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of Ezetimibe 10 mg or Placebo Added to Existing Atorvastatin 10 mg or 20 mg in Attaining Low-Density Lipoprotein Cholesterol Target Levels in Patients With Hypercholesterolemia and Coronary Heart Disease.",COMPLETED,2003-03,2004-08,2024-08-15,INTERVENTIONAL,PHASE3,442.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Hypercholesterolemia|Coronary Disease,"MK0653, ezetimibe|Comparator: ezetimibe, placebo",DRUG,1,1,18 Years,,ALL,False,Organon and Co,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,2,6.093569770045136,large,0,1,1,0,0,0,0,0,0,0,1,1,1,1,2,1,1,0,0,2,1,2003-03-01,2004-08-01,519.0,2003.0,0,2,0
NCT01063517,Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients,"A Randomised, Double Blinded, Multicentre Phase II Study to Assess the Efficacy of Olaparib (AZD2281, KU-0059436) in Combination With Paclitaxel Versus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer Who Progress Following First-line Therapy",COMPLETED,2010-02-02,2023-06-29,2023-07-20,INTERVENTIONAL,PHASE2,124.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Gastric Cancer,olaparib|paclitaxel|Placebo,DRUG,2,15,18 Years,130 Years,ALL,False,AstraZeneca,INDUSTRY,0,7,South Korea,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.8283137373023015,medium,0,1,1,0,1,0,1,0,0,0,1,1,1,1,17,1,1,0,0,3,1,,,,,0,2,0
NCT01982240,12-Week Study of Plecanatide for CIC (The CIC3 Study),"A Randomized, 12-Week, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Plecanatide (3.0 and 6.0 mg) in Patients With Chronic Idiopathic Constipation (The CIC3 Study)",COMPLETED,2013-11,2015-06,2019-12-26,INTERVENTIONAL,PHASE3,1394.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Chronic Idiopathic Constipation,Plecanatide|Placebo|Bisacodyl,DRUG,1,4,18 Years,80 Years,ALL,False,"Bausch Health Americas, Inc.",INDUSTRY,0,189,Canada|United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,7.240649694255466,xlarge,0,1,1,0,0,0,1,1,1,0,1,1,1,1,5,1,1,0,0,3,1,2013-11-01,2015-06-01,577.0,2013.0,0,2,0
NCT04347889,Preventing COVID-19 in Healthcare Workers With HCQ: A RCT,Prophylactic Hydroxychloroquine vs Vitamin C in Healthcare Workers at Risk of COVID-19: A RCT,WITHDRAWN,2020-04-20,2020-12-30,2020-11-02,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,SINGLE,Covid-19,Hydroxychloroquine|Vitamin C,DRUG|OTHER,1,1,18 Years,,ALL,False,Stony Brook University,OTHER,0,0,,0.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,1,1,0,1,0,0,0,0,0,0,1,0,0,1,2,1,1,0,0,2,1,,,,,0,1,0
NCT02335268,Validation of a Predictive Model of Response to Romiplostim in Patients With IPSS Low or Intermediate-1 Risk MDS and Thrombocytopenia,Prospective Validation of a Predictive Model of Response to Romiplostim in Patients With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) and Thrombocytopenia - the EUROPE-trial,COMPLETED,2015-05-21,2021-07-01,2023-08-16,INTERVENTIONAL,PHASE2,77.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Myelodysplastic Syndromes,N-Plate / romiplostim,DRUG,1,6,18 Years,,ALL,False,Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH,OTHER,1,36,Germany|France,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.356708826689592,medium,1,1,0,1,0,1,1,1,0,1,0,0,1,1,7,1,1,0,0,1,0,,,,,0,2,0
NCT03229668,Effect of Pregabalin Administration on Catheter- Related Bladder Discomfort in Urological Surgical Operations,Effect of Pregabalin Administration on Catheter- Related Bladder Discomfort in Urological Surgical Operations,COMPLETED,2017-07-28,2020-02-20,2020-03-31,INTERVENTIONAL,PHASE2|PHASE3,78.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Pregabalin on Catheter Related Bladder Discomfort,Placebo oral capsule|Pregabalin Oral Capsule [Lyrica] 75mg|Pregabalin Oral Capsule [Lyrica] 150 mg,DRUG,1,3,45 Years,85 Years,ALL,False,Saint Savvas Anticancer Hospital,OTHER,1,2,Greece,1.0,0,1,1,0,1,2.5,0,0,0,0,1,4.3694478524670215,medium,1,1,0,1,0,1,1,0,0,0,1,1,0,1,4,1,1,0,0,3,1,,,,,0,2,0
NCT00951574,"Prevention of Venous and Arterial Thromboembolism, in Cancer Patients Undergoing Chemotherapy, With a Low Molecular Weight Heparin (Nadroparin Calcium)","Prevention of Venous and Arterial Thromboembolism, in Cancer Patients Undergoing Chemotherapy, With a Low Molecular Weight Heparin (Nadroparin Calcium). A Randomized, Placebo-controlled, Double-blind, Multicenter Phase III Study.",COMPLETED,2003-10,2008-07,2012-02-01,INTERVENTIONAL,PHASE3,1166.0,ACTUAL,RANDOMIZED,CROSSOVER,PREVENTION,QUADRUPLE,Advanced Cancer|Metastatic Cancer,Nadroparin calcium|saline solution (placebo),DRUG,1,6,18 Years,,ALL,False,Italfarmaco,INDUSTRY,0,46,Italy,1.0,0,0,1,0,0,3.0,1,0,0,0,2,7.062191632286556,xlarge,0,1,1,0,0,0,1,0,0,1,1,1,0,0,7,1,1,0,0,2,1,2003-10-01,2008-07-01,1735.0,2003.0,0,3,1
NCT01159574,"Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma","A Phase II Study of Dexamethasone (DECADRON®), Clarithromycin (BIAXIN®), and Pomalidomide (CC-4047®) for Subjects With Relapsed or Refractory Multiple Myeloma",COMPLETED,2010-08,2015-05-05,2019-06-11,INTERVENTIONAL,PHASE2,121.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Multiple Myeloma,dexamethasone|clarithromycin|Pomalidomide,DRUG,1,2,18 Years,,ALL,False,Weill Medical College of Cornell University,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.804021044733257,medium,0,1,0,1,0,1,0,0,1,0,0,0,1,0,3,1,1,0,0,3,1,2010-08-01,,,2010.0,0,1,0
NCT05413018,An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission,"A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Compare Efficacy and Safety of Oral Azacitidine (CC-486) Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Chinese Patients With Acute Myeloid Leukemia in Complete Remission",ACTIVE_NOT_RECRUITING,2022-08-19,2026-03-01,2025-12-08,INTERVENTIONAL,PHASE2,34.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Leukemia, Myeloid, Acute",CC-486|Placebo,DRUG|OTHER,1,20,55 Years,,ALL,False,Bristol-Myers Squibb,INDUSTRY,0,34,China,,0,1,0,0,0,2.0,1,0,0,0,1,3.5553480614894135,small,1,1,1,0,1,0,1,0,0,0,1,1,1,1,21,1,1,0,0,2,1,,,,,0,2,0
NCT04427618,Tranexamic Acid in the Prevention of Postpartum Hemorrhage in Elective Caesarean Section,Tranexamic Acid in the Prevention of Postpartum Hemorrhage in Elective Caesarean Section: a Randomised Controlled Trial,COMPLETED,2020-06-23,2022-02-01,2022-11-09,INTERVENTIONAL,PHASE3,200.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Postpartum Hemorrhage|Tranexamic Acid,Tranexamic acid|Normal saline,DRUG,1,10,21 Years,,FEMALE,True,KK Women's and Children's Hospital,OTHER_GOV,0,1,Singapore,1.0,0,0,1,0,0,3.0,0,0,0,0,2,5.303304908059076,medium,0,1,0,1,0,0,0,0,0,0,1,1,0,1,11,1,1,0,0,2,1,,,,,0,3,1
NCT04850118,A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP,"A Randomized, Controlled, Masked, Multi-center Study Evaluating the Efficacy, Safety, and Tolerability of Two Doses of AGTC-501 Compared to an Untreated Control Group in Male Participants With X-linked Retinitis Pigmentosa",ACTIVE_NOT_RECRUITING,2024-03-14,2029-10,2025-07-16,INTERVENTIONAL,PHASE2|PHASE3,85.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,X-Linked Retinitis Pigmentosa,rAAV2tYF-GRK1-hRPGRco|Control,DRUG|BIOLOGICAL,1,3,12 Years,50 Years,MALE,False,Beacon Therapeutics,INDUSTRY,0,24,United Kingdom|Australia|United States,,0,1,1,0,1,2.5,0,0,0,0,1,4.454347296253507,medium,1,1,1,0,0,0,1,1,1,1,1,1,1,1,4,1,1,1,0,2,1,,2029-10-01,,,0,3,1
NCT04457297,Initial Attack on Latent Metastasis Using TAS-102 for ct DNA Identified Colorectal Cancer Patients After Curative Resection,"A Randomized, Double-Blind, Phase III Study Comparing FTD/TPI Therapy Versus Placebo in Patients Who Are Positive for Blood Circulating Tumor DNA After Curative Resection of Colorectal Cancer",COMPLETED,2020-07-08,2024-07-18,2026-01-21,INTERVENTIONAL,PHASE3,243.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Colorectal Neoplasms|Trifluridine and Tipiracil|Circulating Tumor DNA,trifluridine and tipiracil|Placebo,DRUG,1,5,20 Years,,ALL,False,National Cancer Center Hospital East,OTHER,1,39,Taiwan|Japan,1.0,0,0,1,0,0,3.0,1,0,0,0,3,5.497168225293202,large,0,1,0,1,0,1,1,1,0,0,1,1,1,1,6,1,1,0,0,2,1,,,,,0,4,1
NCT02612610,A 12-Week Study in Participants With Refractory Chronic Cough (MK-7264-012),A 12-Week Study to Assess the Efficacy and Safety of AF 219 in Subjects With Refractory Chronic Cough,COMPLETED,2015-12-15,2016-11-04,2020-06-30,INTERVENTIONAL,PHASE2,253.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Refractory Chronic Cough,Gefapixant|Placebo (for gefapixant),DRUG,1,58,18 Years,80 Years,ALL,False,"Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",INDUSTRY,0,0,,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.537334267018537,large,0,1,1,0,1,0,0,0,0,0,1,1,1,1,59,1,1,0,0,2,1,,,,,0,2,0
NCT04460560,Terlipressin for HRS-AKI in Liver Transplant Candidates (INFUSE),"A Multi-Center, Open Label, Collaborative Research Study to Treat HRS-AKI Patients With Continuous Terlipressin Infusion",COMPLETED,2020-12-11,2023-12-27,2024-10-09,INTERVENTIONAL,PHASE3,50.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Hepatorenal Syndrome,Terlipressin,DRUG,1,0,18 Years,,ALL,False,University of Pennsylvania,OTHER,0,7,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.9318256327243257,small,1,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,0,1,0,,,,,0,0,0
NCT02840097,Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children: A Pilot and Feasibility Study,Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children (TIC-TOC): A Pilot and Feasibility Study,COMPLETED,2019-03-04,2020-10-03,2021-09-05,INTERVENTIONAL,PHASE2,31.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Brain Injuries|Wounds and Injuries|Hemorrhage,Tranexamic Acid|Placebo,DRUG,2,7,,17 Years,ALL,False,"Daniel Nishijima, MD, MAS",OTHER,1,4,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,3,3.4657359027997265,small,1,1,0,1,0,1,1,0,1,0,1,1,1,1,9,1,1,0,0,2,1,,,,,0,3,1
NCT03287960,Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity,"An Open Label, 1-Year Trial, Including a Double-Blind Placebo-Controlled Withdrawal Period, of Setmelanotide (RM-493), a Melanocortin 4 Receptor (MC4R) Agonist, in Leptin Receptor (LEPR) Deficiency Obesity Due to Bi-Allelic Loss-of-Function LEPR Genetic Mutation",COMPLETED,2018-01-30,2020-09-25,2023-05-23,INTERVENTIONAL,PHASE3,15.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Leptin Receptor Deficiency Obesity,Setmelanotide|Placebo,DRUG,1,9,6 Years,,ALL,False,"Rhythm Pharmaceuticals, Inc.",INDUSTRY,0,6,Netherlands|Germany|Canada|United Kingdom|France|Reunion,1.0,0,0,1,0,0,3.0,0,0,0,0,1,2.772588722239781,small,1,1,1,0,0,0,1,1,0,1,0,0,1,0,10,1,1,0,0,2,1,,,,,0,3,1
NCT00198120,Safety and Effectiveness of D-Cycloserine in Children With Autism,A Randomized Controlled Trial of D-Cycloserine in Autism,COMPLETED,2004-02,2010-08,2016-04-12,INTERVENTIONAL,PHASE3,80.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Autistic Disorder,D-cycloserine|Placebo,DRUG,4,0,3 Years,12 Years,ALL,False,Indiana University,OTHER,3,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.394449154672439,medium,1,1,0,1,0,1,0,0,1,0,1,1,1,1,4,0,1,0,0,2,1,2004-02-01,2010-08-01,2373.0,2004.0,0,1,0
NCT00165620,"A Randomized, Open, Parallel, Optimal Injection Rate-Finding Study for E7337 in Dynamic CT of the Liver in Patients With Liver Disease",,COMPLETED,2004-11,,2010-01-29,INTERVENTIONAL,PHASE2,,,RANDOMIZED,PARALLEL,DIAGNOSTIC,NONE,Lesion,Iomeprole,DRUG,4,4,20 Years,,ALL,,Eisai Limited,INDUSTRY,0,2,Japan,1.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,0,0,1,0,0,0,1,0,0,0,1,0,0,1,8,1,1,0,0,1,0,2004-11-01,,,2004.0,0,1,0
NCT02952820,Long-term Study of Lemborexant in Insomnia Disorder (SUNRISE 2),"A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder (SUNRISE 2)",COMPLETED,2016-11-15,2019-01-08,2020-02-06,INTERVENTIONAL,PHASE3,971.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Insomnia Disorder,lemborexant|Placebo,DRUG,1,22,18 Years,,ALL,False,Eisai Inc.,INDUSTRY,0,114,Italy|Finland|South Korea|United States|Germany|Spain|Romania|Poland|Japan|Mexico|New Zealand|Canada,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.879355804460439,xlarge,0,1,1,0,0,0,1,1,1,1,1,1,1,1,23,1,1,0,0,2,1,,,,,0,3,1
NCT01678820,A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266),"A Phase III, Randomized, Double-blind, Clinical Trial to Study the Efficacy and Safety of MK-0431D (a Fixed-dose Combination [FDC] of Sitagliptin and Simvastatin) for the Treatment of Patients With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy",TERMINATED,2012-10-10,2013-11-01,2018-08-24,INTERVENTIONAL,PHASE3,299.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,Sitagliptin/Simvastatin FDC|Sitagliptin|Simvastatin|Placebo to sitagliptin|Placebo to simvastatin|Placebo to Sitagliptin/Simvastatin FDC|Metformin|Glimepiride,DRUG,3,10,18 Years,79 Years,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,0,,0.0,0,0,1,0,0,3.0,0,0,0,0,1,5.703782474656201,large,0,1,1,0,1,0,0,0,0,0,1,1,1,1,13,1,1,0,0,8,1,,,,,0,2,0
NCT04231682,A Study to Evaluate Efficacy and Safety of Denosumab for Prevention and Treatment of Osteoporosis in 1st Time Liver Transplant Recipients.,"A Prospective Randomized Double-Blind, Placebo-Controlled Phase 2 Study Evaluating the Efficacy and Safety of Early Administration of Denosumab 60mg for Prevention and Treatment of Osteoporosis in First-time Liver Transplant Recipients",WITHDRAWN,2020-07-01,2025-01-01,2020-06-26,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Osteoporosis,Denosumab Injection|Placebos,DRUG,1,6,18 Years,,ALL,False,Albert Einstein Healthcare Network,OTHER,1,0,,0.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,1,1,0,1,0,1,0,0,0,0,1,1,0,1,7,1,1,0,0,2,1,,,,,0,2,0
NCT05909982,Ischemic Post-conditioning in Acute Ischemic Stroke Thrombectomy (PROTECT-1b),Effect of Ischemic Post-conditioning on Infarct Volume in Patients With Acute Ischemic Stroke After Mechanical Thrombectomy,COMPLETED,2023-04-01,2024-01-28,2025-03-18,INTERVENTIONAL,PHASE1|PHASE2,20.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Acute Ischemic Stroke|Reperfusion Injury,Mechanical thrombectomy combined with ischemic post-conditioning,PROCEDURE,1,9,18 Years,,ALL,False,Capital Medical University,OTHER,0,1,China,1.0,1,1,0,0,1,1.5,0,0,0,0,2,3.044522437723423,small,1,1,0,1,0,0,0,0,0,0,0,0,1,0,10,1,0,0,0,1,0,,,,,0,3,1
NCT04683224,"A Study to Evaluate the Safety, Immunogenicity, and Efficacy of UB-612 COVID-19 Vaccine","A Phase 2/3 Randomized, Multicenter, Double-Blind, Placebo Controlled, Dose-Response Study to Evaluate the Safety, Immunogenicity, and Efficacy of UB-612 Vaccine in Adults",WITHDRAWN,2021-02-01,2023-03-22,2022-04-04,INTERVENTIONAL,PHASE2|PHASE3,0.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Covid-19|SARS-CoV-2|Coronavirus,UB-612|Placebo,BIOLOGICAL|OTHER,5,5,18 Years,,ALL,True,"Vaxxinity, Inc.",INDUSTRY,1,0,,0.0,0,1,1,0,1,2.5,0,0,0,0,3,0.0,,1,1,1,0,0,1,0,0,0,0,1,1,0,1,10,1,0,1,0,2,1,,,,,0,4,1
NCT05535023,Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma,Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx,WITHDRAWN,2022-08-24,2023-07-25,2023-09-13,INTERVENTIONAL,PHASE2,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Squamous Cell Carcinoma|Oropharynx Cancer|Head and Neck Cancer,SAR444245|Cemiplimab,DRUG,1,0,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,3,0.0,,1,1,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,2,1,,,,,0,2,0
NCT00855959,Study to Evaluate Efficacy and Safety of Pulmicort Respules in Japanese Adult Asthmatic Patients,"An Evaluation of Efficacy and Safety of Corresponding Doses of Pulmicort Turbuhaler® and Pulmicort Respules® in Japanese Asthmatic Adult Patients (Open, Multicenter, Phase III Study)",COMPLETED,2009-02,2009-08,2011-03-11,INTERVENTIONAL,PHASE3,108.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Asthma,Budesonide|Pulmicort Turbuhaler,DRUG,1,11,16 Years,,ALL,False,AstraZeneca,INDUSTRY,0,6,Japan,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.6913478822291435,medium,0,1,1,0,1,0,1,0,0,0,0,0,1,0,12,1,1,0,0,2,1,2009-02-01,2009-08-01,181.0,2009.0,0,2,0
NCT02354859,A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study),"A Phase 2, Multi-Center, Randomized, Placebo-Controlled Study of IV Gallium Nitrate in Patients With Cystic Fibrosis (IGNITE Study)",COMPLETED,2016-03,2018-02-01,2019-03-21,INTERVENTIONAL,PHASE2,119.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Cystic Fibrosis,Gallium nitrate|Normal Saline,DRUG,1,5,18 Years,,ALL,False,University of Washington,OTHER,1,23,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.787491742782046,medium,0,1,0,1,0,1,1,0,1,0,1,1,1,1,6,1,1,0,0,2,1,2016-03-01,,,2016.0,1,2,0
NCT02308020,"A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain","A Phase 2 Study of Abemaciclib in Patients With Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer, or Melanoma",COMPLETED,2015-04-20,2019-11-08,2020-12-19,INTERVENTIONAL,PHASE2,162.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Breast Cancer|Non-small Cell Lung Cancer|Melanoma|Brain Metastases,Abemaciclib,DRUG,1,10,18 Years,,ALL,False,Eli Lilly and Company,INDUSTRY,0,44,Italy|Belgium|United States|Spain|Austria|Australia|Israel|France|Canada,1.0,0,1,0,0,0,2.0,1,0,0,0,4,5.093750200806762,medium,0,1,1,0,1,0,1,1,1,1,0,0,1,0,11,1,1,0,0,1,0,,,,,0,3,1
NCT00820924,Study of Lapatinib in Breast Cancer Patients With HER-2 Non-amplified Primary Tumors and HER-2 Positive or EGFR Positive Circulating Tumor Cells,"A Phase II Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Daily Dose of Lapatinib in Advanced Breast Cancer Patients With HER-2 Non-amplified Primary Tumours and HER-2 Positive Circulating Tumour Cells or EGFR Positive Circulating Tumor Cells",TERMINATED,2008-06,2011-07,2012-03-28,INTERVENTIONAL,PHASE2,23.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Neoplasms, Breast",LAPATINIB,DRUG,1,3,18 Years,,FEMALE,False,GlaxoSmithKline,INDUSTRY,0,10,Italy|United Kingdom,0.0,0,1,0,0,0,2.0,0,0,0,0,1,3.1780538303479458,small,1,1,1,0,0,0,1,1,0,1,0,0,1,0,4,1,1,0,0,1,0,2008-06-01,2011-07-01,1125.0,2008.0,0,1,0
NCT01096524,Effects of Kneehab 12-week Peri-operative Total Knee Arthroplasty,Phase III Study Investigating the Effects of 6-weeks of Neuromuscular Electrical Stimulation (NMES) Peri-total Knee Arthroplasty (TKA).,COMPLETED,2010-03,2014-06,2014-07-21,INTERVENTIONAL,PHASE3,200.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Knee Osteoarthritis|Disuse Atrophy,Standard Physiotherapy|Kneehab,DEVICE|OTHER,1,1,18 Years,,ALL,False,"Bio-Medical Research, Ltd.",INDUSTRY,1,1,United Kingdom,1.0,0,0,1,0,0,3.0,0,1,0,0,2,5.303304908059076,medium,0,0,1,0,0,1,0,0,0,1,1,0,1,1,2,1,0,0,1,2,1,2010-03-01,2014-06-01,1553.0,2010.0,0,2,0
NCT01110824,Prevention of Left Ventricular Dysfunction During Chemotherapy,Prevention of Left Ventricular Dysfunction With Enalapril and Carvedilol in Patients Submitted to Intensive Chemotherapy for the Treatment of Malignant Hemopathies,COMPLETED,2008-04,2012-03,2013-11-15,INTERVENTIONAL,PHASE3,90.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Acute Myeloid Leukemia|Precursor-cell Lymphoblastic Leukemia-Lymphoma|Lymphoid Neoplasm|Multiple Myeloma|Lymphoma|Autologous Hematopoietic Stem Cell Transplantation,Enalapril and carvedilol,DRUG,1,8,18 Years,70 Years,ALL,False,Hospital Clinic of Barcelona,OTHER,2,2,Spain,1.0,0,0,1,0,0,3.0,1,0,0,0,6,4.51085950651685,medium,1,1,0,1,0,1,1,0,0,1,1,0,0,1,9,1,1,0,0,1,0,2008-04-01,2012-03-01,1430.0,2008.0,0,2,0
NCT02218424,Magnesium vs Placebo for Tonsillectomy,"Systemic Magnesium to Improve Postoperative Pain in Pediatric Patients Undergoing Tonsillectomy: A Randomized, Double Blinded, Placebo Controlled Trial",COMPLETED,2014-10,2015-04,2019-01-03,INTERVENTIONAL,PHASE2|PHASE3,60.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Pain,Magnesium|Normal saline,DRUG,1,7,4 Years,10 Years,ALL,True,Ann & Robert H Lurie Children's Hospital of Chicago,OTHER,0,1,United States,1.0,0,1,1,0,1,2.5,0,0,0,0,1,4.110873864173311,medium,1,1,0,1,0,0,0,0,1,0,1,1,1,1,8,1,1,0,0,2,1,2014-10-01,2015-04-01,182.0,2014.0,0,3,1
NCT01854359,Idebenone for Primary Progressive Multiple Sclerosis,Open Label Extension Trial of Idebenone for Primary Progressive Multiple Sclerosis,COMPLETED,2013-03-12,2018-10-31,2021-05-19,INTERVENTIONAL,PHASE1|PHASE2,61.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Multiple Sclerosis|Primary Progressive Multiple Sclerosis,Idebenone,DRUG,1,4,18 Years,,ALL,False,National Institute of Allergy and Infectious Diseases (NIAID),NIH,0,1,United States,1.0,1,1,0,0,1,1.5,0,1,0,0,2,4.127134385045092,medium,1,1,0,1,0,0,0,0,1,0,0,0,1,0,5,1,1,0,0,1,0,,,,,0,2,0
NCT01487577,Pharmacokinetics-based Mycophenolate Mofetil Dosing for GVHD Prevention,A Pilot Study of Pharmacokinetics-based Mycophenolate Mofetil Dosing for Graft-Versus-Host-Disease Prophylaxis in Pediatric Blood and Marrow Transplantation,COMPLETED,2010-06,2016-01,2016-06-21,INTERVENTIONAL,PHASE2,19.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Allogeneic Blood and Marrow Transplantation (BMT)|Graft Versus Host Disease,Mycophenolate mofetil,DRUG,2,7,6 Months,21 Years,ALL,False,University of Pittsburgh,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,2.995732273553991,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,9,1,1,0,0,1,0,2010-06-01,2016-01-01,2040.0,2010.0,0,2,0
NCT04566601,A Study to Test Different Doses of BI 1358894 and Find Out Whether They Reduce Symptoms in People With Borderline Personality Disorder,"A Phase II Randomized, Double-blinded, Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of 4 Oral Doses of BI 1358894 Once Daily Over 12 Week Treatment Period in Patients With Borderline Personality Disorder",COMPLETED,2020-11-13,2023-01-25,2024-01-30,INTERVENTIONAL,PHASE2,390.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Borderline Personality Disorder,BI 1358894|Placebo,DRUG,1,6,18 Years,65 Years,ALL,False,Boehringer Ingelheim,INDUSTRY,0,67,Italy|Belgium|Argentina|Bulgaria|Sweden|United States|Germany|Spain|Australia|Poland|Japan|Mexico|Czechia|Denmark|France,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.968707559985366,large,0,1,1,0,0,0,1,1,1,1,1,1,1,1,7,1,1,0,0,2,1,,,,,0,3,1
NCT01486277,A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma,"A Phase 2, Single-arm, Open-label, Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) JNJ-26481585 in Subjects With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma",COMPLETED,2011-11,2016-07,2016-11-03,INTERVENTIONAL,PHASE2,26.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Lymphoma, T-Cell, Cutaneous","Quisinostat, 12 mg",DRUG,1,7,18 Years,,ALL,False,"Janssen Research & Development, LLC",INDUSTRY,0,13,Spain|Germany|United States|United Kingdom|Portugal|France,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.295836866004329,small,1,1,1,0,0,0,1,1,1,1,0,0,1,0,8,1,1,0,0,1,0,2011-11-01,2016-07-01,1704.0,2011.0,0,2,0
NCT00000577,Asthma Clinical Research Network (ACRN),Asthma Clinical Research Network (ACRN),WITHDRAWN,1993-09,2008-07,2017-01-16,INTERVENTIONAL,PHASE3,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Asthma|Lung Diseases,Albuterol|Colchicine|Adrenal Cortex Hormones|Adrenergic-Beta Agonists,DRUG,0,0,18 Years,75 Years,ALL,False,Milton S. Hershey Medical Center,OTHER,1,7,United States,0.0,0,0,1,0,0,3.0,0,0,0,0,2,0.0,,1,1,0,1,0,1,1,0,1,0,1,1,1,1,0,0,1,0,0,4,1,1993-09-01,2008-07-01,5417.0,1993.0,0,2,0
NCT01785875,Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis,A Multicenter Single-arm Extension Study to Describe the Long-term Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis,COMPLETED,2013-07-31,2015-07-01,2019-04-10,INTERVENTIONAL,PHASE3,891.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Hyperparathyroidism, Secondary",Etelcalcetide,DRUG,4,12,18 Years,100 Years,ALL,False,Amgen,INDUSTRY,0,208,Italy|Belgium|Netherlands|Russia|Sweden|Hungary|United States|Germany|Austria|Australia|Spain|United Kingdom|Poland|Czechia|Israel|France|Canada,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.79346613258001,xlarge,0,1,1,0,1,0,1,1,1,1,0,0,1,0,16,1,1,0,0,1,0,,,,,0,2,0
NCT00427557,Cellular Therapy With Cord Blood Cells,Use of Umbilical Cord Blood Cell in the Preparative Regimen of Patients With Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation,COMPLETED,2006-10,2010-11,2012-05-28,INTERVENTIONAL,PHASE2,31.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Multiple Myeloma|Leukemia|Lymphoma,Fludarabine|Melphalan|Umbilical Cord Blood|Rituximab|Peripheral Blood Stem Cell Infusion,DRUG|OTHER|PROCEDURE,1,0,,80 Years,ALL,False,M.D. Anderson Cancer Center,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,3,3.4657359027997265,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,5,1,2006-10-01,2010-11-01,1492.0,2006.0,0,2,0
NCT01619657,Preventive Inhalation of Hypertonic Saline in Infants With Cystic Fibrosis,"Randomized, Double-blind, Controlled Pilot Study on Safety of Hypertonic Saline as Preventive Inhalation Therapy in Newborns and Infants With Cystic Fibrosis",COMPLETED,2012-06,2017-10,2017-10-26,INTERVENTIONAL,PHASE2,42.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Cystic Fibrosis Lung Disease,"6% Hypertonic Saline (HS), 4mL|0.9% Isotonic Saline (IS), 4mL",DRUG,1,10,,4 Months,ALL,False,Heidelberg University,OTHER,1,4,Germany,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.7612001156935624,small,1,1,0,1,0,1,1,0,0,1,1,1,0,1,11,1,1,0,0,2,1,2012-06-01,2017-10-01,1948.0,2012.0,0,2,0
NCT03713957,A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment,"A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Tolerability of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment",COMPLETED,2018-11-12,2020-07-20,2022-05-09,INTERVENTIONAL,PHASE2,79.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Parkinson Disease,GRF6021|Placebo,DRUG|OTHER,1,10,40 Years,85 Years,ALL,False,"Alkahest, Inc.",INDUSTRY,1,29,Australia|France|United States,1.0,0,1,0,0,0,2.0,0,0,1,0,1,4.382026634673881,medium,1,1,1,0,0,1,1,1,1,1,1,1,1,1,11,1,1,0,0,2,1,,,,,0,3,1
NCT03696277,SAbR For Oligo-Progressive Renal Cell Cancer.,A Phase II Trial of Stereotactic Ablative Radiation Therapy (SAbR) for Patients With Oligo-progressive Renal Cell Cancer (RCC).,COMPLETED,2018-10-01,2024-01-23,2024-07-17,INTERVENTIONAL,PHASE2,21.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Oligoprogressive Renal Cell Carcinoma,Stereotactic ablative body radiation (SABR),RADIATION,1,8,18 Years,,ALL,False,University of Texas Southwestern Medical Center,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.091042453358316,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,9,1,0,0,0,1,0,,,,,0,1,0
NCT04641975,A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB),"A Phase 3, Double-blind, Randomized, Multicenter, Parallel Group, Placebo-controlled Sequential Dose Titration Study to Evaluate Efficacy, Safety and Pharmacokinetics of Mirabegron in Pediatric Subjects From 5 to < 18 Years of Age With Overactive Bladder",TERMINATED,2021-03-15,2023-07-24,2024-11-14,INTERVENTIONAL,PHASE3,26.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Overactive Bladder (OAB)|Pharmacokinetics of Mirabegron,Mirabegron|Placebo,DRUG,1,16,5 Years,17 Years,ALL,False,"Astellas Pharma Global Development, Inc.",INDUSTRY,0,15,Belgium|Russia|Turkey (Türkiye)|South Korea|United Kingdom|Ukraine|Norway|Malaysia|Philippines|France,0.0,0,0,1,0,0,3.0,0,0,0,0,2,3.295836866004329,small,1,1,1,0,0,0,1,1,0,1,1,1,1,1,17,1,1,0,0,2,1,,,,,0,4,1
NCT00371475,A Study of the TAXUS Liberté Stent for the Treatment of Long De Novo Coronary Artery Lesions,"TAXUS ATLAS LONG LESION: A Multi-center, Single-arm Study of the TAXUS Liberté™-SR Stent for the Treatment of Patients With Long de Novo Coronary Artery Lesions",COMPLETED,2005-03,2011-05,2012-02-02,INTERVENTIONAL,PHASE3,150.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Coronary Artery Disease,TAXUS Liberté-SR|TAXUS™ Express,DEVICE,1,8,18 Years,,ALL,False,Boston Scientific Corporation,INDUSTRY,0,25,Singapore|New Zealand|United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.017279836814924,medium,0,1,1,0,0,0,1,1,1,0,0,0,1,0,9,1,0,0,1,2,1,2005-03-01,2011-05-01,2252.0,2005.0,0,3,1
NCT03605875,A Web Application for Improving Communication on Hemodialysis Rounds,Voicing Individual Concerns for Engagement in Hemodialysis (VOICE-HD): a Web Application for Rounds,COMPLETED,2018-11-28,2019-12-13,2020-03-25,INTERVENTIONAL,PHASE3,77.0,ACTUAL,RANDOMIZED,PARALLEL,HEALTH_SERVICES_RESEARCH,NONE,Hemodialysis,Web-App|Paper,BEHAVIORAL,4,1,18 Years,,ALL,False,University of Alberta,OTHER,0,4,Canada,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.356708826689592,medium,1,1,0,1,0,0,1,0,0,0,1,0,0,1,5,1,0,0,0,2,1,,,,,0,1,0
NCT00691301,"Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer","A Limited Access Phase II Trial of Pemetrexed (Alimta, LY231514) (NSC #698037) in Combination With Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix",COMPLETED,2008-09,2014-07,2018-01-09,INTERVENTIONAL,PHASE2,55.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Cervical Cancer,cisplatin|pemetrexed disodium,DRUG,2,2,,120 Years,FEMALE,False,Gynecologic Oncology Group,NETWORK,1,12,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.02535169073515,medium,1,1,0,0,0,1,1,0,1,0,0,0,1,0,4,1,1,0,0,2,1,2008-09-01,2014-07-01,2129.0,2008.0,0,1,0
NCT01791101,Eltrombopag in Patients With Delayed Post Transplant Thrombocytopenia.,Eltrombopag in Patients With Delayed Post Transplant Thrombocytopenia.,COMPLETED,2013-09-16,2020-06-26,2021-06-11,INTERVENTIONAL,PHASE2,10.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Thrombocytopenia,Eltrombopag,DRUG,1,5,18 Years,,ALL,False,Gruppo Italiano Malattie EMatologiche dell'Adulto,OTHER,0,16,Italy,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.3978952727983707,small,1,1,0,1,0,0,1,0,0,1,0,0,1,0,6,1,1,0,0,1,0,,,,,0,1,0
NCT03793712,Study With Lu AF11167 for the Treatment of Negative Symptoms in Patients With Schizophrenia,"Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-flexible-dose Study of Lu AF11167 for the Treatment of Persistent Prominent Negative Symptoms in Patients With Schizophrenia",TERMINATED,2018-12-27,2020-09-03,2020-09-23,INTERVENTIONAL,PHASE2,168.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Schizophrenia,Lu AF11167 (1-2 mg/day)|Lu AF11167 (3-4 mg/day)|Placebo,DRUG,1,12,18 Years,55 Years,ALL,False,H. Lundbeck A/S,INDUSTRY,0,53,Bulgaria|Latvia|Hungary|Germany|Poland|Estonia|Czechia|Ukraine,0.0,0,1,0,0,0,2.0,0,0,1,0,1,5.1298987149230735,medium,0,1,1,0,0,0,1,1,0,1,1,1,1,1,13,1,1,0,0,3,1,,,,,0,3,1
NCT05215977,Efficacy and Safety of MW031 in PMO Subjects,"A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study, Evaluating the Efficacy and Safety of Recombinant Fully Human Anti-RANKL Monoclonal Antibody in Postmenopausal Osteoporosis Subjects With Increased Bone Fracture Risk",COMPLETED,2019-12-27,2021-09-27,2023-10-11,INTERVENTIONAL,PHASE3,448.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Osteoporosis, Postmenopausal",MW031|Placebo,DRUG,1,3,55 Years,80 Years,FEMALE,False,"Mabwell (Shanghai) Bioscience Co., Ltd.",INDUSTRY,0,1,China,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.1070228877422545,large,0,1,1,0,0,0,0,0,0,0,1,1,1,1,4,1,1,0,0,2,1,,,,,0,1,0
NCT01510912,Open-Label Study of Diclofenac Capsules to Treat Osteoarthritis Pain,"A Multicenter, Open-Label, Safety Study of Diclofenac [Test] Capsules in Subjects With Osteoarthritis of the Knee or Hip",COMPLETED,2012-01,2013-03,2014-05-09,INTERVENTIONAL,PHASE3,602.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Osteoarthritis,Diclofenac,DRUG,1,0,40 Years,,ALL,False,"Iroko Pharmaceuticals, LLC",INDUSTRY,0,40,United States,1.0,0,0,1,0,0,3.0,0,1,0,0,1,6.401917196727186,xlarge,0,1,1,0,0,0,1,0,1,0,0,0,1,0,1,0,1,0,0,1,0,2012-01-01,2013-03-01,425.0,2012.0,0,0,0
NCT01553357,Lenalidomide and Dexamethasone in Primary Plasma Cell Leukemia,A Pilot Study of Lenalidomide and Dexamethasone in Patients With Primary Plasma Cell Leukemia,COMPLETED,2009-03,2011-09,2012-03-14,INTERVENTIONAL,PHASE2,23.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Primary Plasma Cell Leukemia,"Lenalidomide, dexamethasone",DRUG,3,4,18 Years,,ALL,False,IRCCS Centro di Riferimento Oncologico della Basilicata,OTHER,1,1,Italy,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.1780538303479458,small,1,1,0,1,0,1,0,0,0,1,0,0,1,0,7,1,1,0,0,1,0,2009-03-01,2011-09-01,914.0,2009.0,0,1,0
NCT00120757,Efficacy of Alendronate Versus Placebo in the Treatment of HIV-associated Osteoporosis (ANRS120),"Efficacy of Alendronate Versus Placebo in the Treatment of HIV-1 Associated Osteoporosis, a Multicenter, Randomized, Controlled Trial. ANRS 120 Fosivir",COMPLETED,2004-10,2008-11,2011-12-22,INTERVENTIONAL,PHASE3,140.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Osteoporosis|HIV Infections,Alendronate,DRUG,1,7,18 Years,,ALL,False,French National Agency for Research on AIDS and Viral Hepatitis,OTHER_GOV,0,3,France,1.0,0,0,1,0,0,3.0,0,0,0,0,2,4.948759890378168,medium,0,0,0,1,0,0,1,0,0,1,1,1,1,1,8,1,1,0,0,1,0,2004-10-01,2008-11-01,1492.0,2004.0,0,2,0
NCT06510257,Safety and Efficacy Reconyl for Cough With/Without Sore Throat,Safety and Efficacy of Reconyl for Cough With/Without Sore Throat: A Preliminary Study,COMPLETED,2024-07-23,2024-10-03,2025-02-07,INTERVENTIONAL,PHASE2,60.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Cough,Reconyl|Placebo tablet of Reconyl,DRUG,3,0,18 Years,60 Years,ALL,False,Dexa Medica Group,INDUSTRY,1,2,Indonesia,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.110873864173311,medium,1,1,1,0,0,1,1,0,0,0,1,1,1,1,3,0,1,0,0,2,1,,,,,0,1,0
NCT02556801,Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy,"A Single-center, Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Investigate the Relative Efficacy and Safety of Immunotherapy With SUBLIVAC FIX Phleum Pratense in Grass Pollen-Allergic Subjects With IgE-Mediated Seasonal ARC",COMPLETED,2015-09,2016-10,2019-09-13,INTERVENTIONAL,PHASE2,168.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Allergic Rhinitis|Allergic Rhinoconjunctivitis,SUBLIVAC FIX Phleum Prat.,BIOLOGICAL,1,8,18 Years,65 Years,ALL,False,HAL Allergy,INDUSTRY,0,1,Canada,1.0,0,1,0,0,0,2.0,0,0,0,0,2,5.1298987149230735,medium,0,1,1,0,0,0,0,0,0,0,1,1,1,1,9,1,0,1,0,1,0,2015-09-01,2016-10-01,396.0,2015.0,1,2,0
NCT04207801,A Phase II Study to Evaluate Efficacy & Safety of AUR101 in Patients of Moderate-to-Severe Psoriasis,"A Phase II, Multicenter, Double-blind, Double-dummy, Placebo Controlled, Randomized, Study to Evaluate the Efficacy and Safety of Two Doses of AUR101 in Patients With Moderate-to-Severe Psoriasis",COMPLETED,2020-01-21,2021-04-15,2023-08-14,INTERVENTIONAL,PHASE2,90.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Chronic Plaque-type Psoriasis,AUR101|Matching Placebo,DRUG,1,7,18 Years,65 Years,ALL,False,Aurigene Discovery Technologies Limited,INDUSTRY,0,9,India,1.0,0,1,0,0,0,2.0,0,1,0,0,1,4.51085950651685,medium,1,1,1,0,0,0,1,0,0,0,1,1,1,1,8,1,1,0,0,2,1,,,,,0,2,0
NCT00568477,Value of Rituximab in Humoral Chronic Rejection After Renal Transplantation,"Prospective, Randomized, Open, 2-arm National Multi-center Study to Evaluate the Value of Rituximab in Humoral Chronic Rejection After Renal Transplantation.",TERMINATED,2007-12,2010-12,2009-10-01,INTERVENTIONAL,PHASE2,200.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Grafting|Renal Transplantation|Transplantation, Kidney|Chronic Allograft Nephropathy",MabThera,DRUG,1,1,18 Years,,ALL,False,Technical University of Munich,OTHER,10,1,Germany,0.0,0,1,0,0,0,2.0,0,0,0,0,4,5.303304908059076,medium,0,0,0,1,0,1,0,0,0,1,1,0,1,1,2,1,1,0,0,1,0,2007-12-01,2010-12-01,1096.0,2007.0,0,1,0
NCT00379977,"Study to Assess the Safety & Reactogenicity of GSK Biologicals' DTPa/Hib Vaccine When Given at 3, 4 and 5 Months of Age","Open, Primary Vaccination Study to Assess Safety and Reactogenicity of GSK Biologicals' DTPa/Hib Vaccine When Administered to Healthy Chinese Infants at 3, 4 and 5 Months of Age.",COMPLETED,2006-09,2006-12,2016-10-12,INTERVENTIONAL,PHASE3,30.0,,NON_RANDOMIZED,SINGLE_GROUP,PREVENTION,NONE,Tetanus|Haemophilus Influenzae Type b|Acellular Pertussis|Diphtheria,"diphtheria, tetanus, pertussis & Hib vaccine",BIOLOGICAL,1,0,90 Days,120 Days,ALL,True,GlaxoSmithKline,INDUSTRY,0,1,China,1.0,0,0,1,0,0,3.0,0,0,0,0,4,3.4339872044851463,small,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,2006-09-01,2006-12-01,91.0,2006.0,0,1,0
NCT01194375,A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris,,COMPLETED,2010-09,2011-12,2012-07-02,INTERVENTIONAL,PHASE2,180.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Acne Vulgaris,Low Strength IDP-107|High Strength IDP-107|Placebo,DRUG,2,1,12 Years,,ALL,False,Dow Pharmaceutical Sciences,INDUSTRY,0,20,Canada|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.198497031265826,medium,0,1,1,0,0,0,1,1,1,0,1,1,1,1,3,1,1,0,0,3,1,2010-09-01,2011-12-01,456.0,2010.0,0,2,0
NCT00056875,Recombinant Human Keratinocyte Growth Factor in Unrelated and Related Transplants,Safety and Efficacy of Recombinant Human Keratinocyte Growth Factor in Unrelated and Related Transplants,COMPLETED,2002-09,2005-06,2015-03-25,INTERVENTIONAL,PHASE1|PHASE2,50.0,,NON_RANDOMIZED,,PREVENTION,NONE,Graft Versus Host Disease,recombinant human keratinocyte growth factor,DRUG,0,0,3 Years,65 Years,ALL,False,University of Michigan,OTHER,0,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,3.9318256327243257,small,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,2002-09-01,2005-06-01,1004.0,2002.0,0,1,0
NCT02514577,Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis,"A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis",COMPLETED,2015-11-07,2017-05-01,2020-01-27,INTERVENTIONAL,PHASE3,217.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Plaque Psoriasis,IDP-122 Lotion|IDP-122 Vehicle Lotion,DRUG,1,1,18 Years,,ALL,False,"Bausch Health Americas, Inc.",INDUSTRY,0,15,United States,1.0,0,0,1,0,0,3.0,0,1,0,0,1,5.384495062789089,large,0,1,1,0,0,0,1,0,1,0,1,1,1,1,2,1,1,0,0,2,1,,,,,0,1,0
NCT01697501,A Study Evaluating IL28B Polymorphism in Patients With HBeAg-Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a) in Study ML18253,Cross-sectional Multicenter Study Evaluating the IL28B Polymorphism in Patients With HBeAg-negative Chronic Hepatitis B Treated With Pegylated Interferon Alfa-2a in the Course of Peg.Be.Liver Study,COMPLETED,2012-11-08,2013-06-21,2017-04-10,INTERVENTIONAL,PHASE3,88.0,ACTUAL,,SINGLE_GROUP,OTHER,NONE,"Hepatitis B, Chronic",Interleukin 28B testing,OTHER,2,6,18 Years,,ALL,False,Hoffmann-La Roche,INDUSTRY,0,12,Italy,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.48863636973214,medium,1,1,1,0,1,0,1,0,0,1,0,0,0,0,8,1,0,0,0,1,0,,,,,0,1,0
NCT04604275,Functional Sucrase Deficiency in Short Bowel Syndrome Patients With Intestinal Failure,Functional Sucrase Deficiency in Short Bowel Syndrome Patients With Intestinal Failure,TERMINATED,2022-01-31,2024-09-01,2025-10-01,INTERVENTIONAL,PHASE2,3.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Short Gut Syndrome,Sucrase|Placebo,DRUG|OTHER,4,3,,,ALL,False,University of Miami,OTHER,1,2,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,1.3862943611198906,small,1,1,0,1,0,1,1,0,1,0,1,1,1,0,7,1,1,0,0,2,1,,,,,0,2,0
NCT03808675,Aerobic Exercise in Parkinson's Disease,Long Term Aerobic Exercise to Slow Progression in Parkinson's Disease,COMPLETED,2019-07-01,2024-09-30,2024-10-09,INTERVENTIONAL,PHASE2|PHASE3,57.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Parkinson's Disease,Aerobic walking|Usual care with PD specific health education,BEHAVIORAL,6,19,40 Years,,ALL,False,VA Office of Research and Development,FED,1,2,United States,1.0,0,1,1,0,1,2.5,0,0,1,0,1,4.060443010546419,medium,1,1,0,0,0,1,1,0,1,0,1,0,1,1,25,1,0,0,0,2,1,,,,,0,3,1
NCT00076375,Preliminary Study of Safety and Efficacy of Nanocrystalline Silver Cream in Atopic Dermatitis (Eczema),"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Two Concentrations of Nanocrystalline Silver Cream (NPI) Applied Twice Daily in Adults With Mild to Moderate Atopic Dermatitis",COMPLETED,2003-11,2004-04,2005-06-24,INTERVENTIONAL,PHASE2,180.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Atopic Dermatitis|Eczema,Nanocrystalline silver cream (NPI),DRUG,0,0,18 Years,65 Years,ALL,False,Nucryst Pharmaceuticals,INDUSTRY,0,19,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,5.198497031265826,medium,0,0,1,0,0,0,1,0,1,0,1,1,1,1,0,0,1,0,0,1,0,2003-11-01,2004-04-01,152.0,2003.0,0,1,0
NCT04334512,A Study of Quintuple Therapy to Treat COVID-19 Infection,"A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Quintuple Therapy to Treat COVID-19 Infection",COMPLETED,2020-06-22,2024-02-27,2024-02-29,INTERVENTIONAL,PHASE2,118.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,COVID-19|Corona Virus Infection|Coronavirus-19|Sars-CoV2,Hydroxychloroquine|Azithromycin|Vitamin C|Vitamin D|Zinc,DRUG|DIETARY_SUPPLEMENT,7,0,18 Years,,ALL,False,ProgenaBiome,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,4,4.77912349311153,medium,0,1,0,1,0,1,0,0,1,0,1,1,1,1,7,0,1,0,0,5,1,,,,,0,3,1
NCT05876312,"Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients","A Phase 1, Randomized, Double Blind, Placebo-Controlled, Single Ascending Dose Study in Healthy Participants Followed by a Phase 2a Open Label Study in Participants With PNH and Residual Anemia to Evaluate the Safety, Tolerability, PK and PD of ADX-038",ACTIVE_NOT_RECRUITING,2023-08-07,2026-09-30,2026-01-22,INTERVENTIONAL,PHASE1|PHASE2,50.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Paroxysmal Nocturnal Hemoglobinuria (PNH),ADX-038|Placebo,DRUG,2,5,18 Years,,ALL,True,"ADARx Pharmaceuticals, Inc.",INDUSTRY,2,4,United Kingdom|Australia,,1,1,0,0,1,1.5,0,0,0,0,1,3.9318256327243257,small,1,0,1,0,0,1,1,1,0,1,1,1,1,1,7,1,1,0,0,2,1,,,,,0,4,1
NCT01854775,"Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children","A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children",COMPLETED,2013-05-06,2025-06-18,2026-01-09,INTERVENTIONAL,PHASE2|PHASE3,129.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Acquired Immune Deficiency Syndrome (AIDS)|HIV Infections,E/C/F/TAF|E/C/F/TAF (Low Dose),DRUG,9,57,2 Years,17 Years,ALL,False,Gilead Sciences,INDUSTRY,0,16,Zimbabwe|United States|South Africa|Uganda|Thailand,1.0,0,1,1,0,1,2.5,0,0,0,0,2,4.867534450455582,medium,0,1,1,0,1,0,1,1,1,0,0,0,1,1,66,1,1,0,0,2,1,,,,,0,5,1
NCT03803475,Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients,Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients,COMPLETED,2018-10-11,2020-08-25,2021-08-24,INTERVENTIONAL,PHASE3,485.0,ACTUAL,,SINGLE_GROUP,DIAGNOSTIC,NONE,Prostate Cancer,Ga-68 labeled PSMA-11|Positron emission tomography-computed tomography (PET/CT)|Positron emission tomography-magnetic resonance imaging (PET/MRI),DRUG|DEVICE,5,0,18 Years,,MALE,False,Thomas Hope,OTHER,0,1,United States,1.0,0,0,1,0,0,3.0,1,0,0,0,1,6.186208623900494,large,0,1,0,1,0,0,0,0,1,0,0,0,0,0,5,0,1,0,1,3,1,,,,,0,1,0
NCT00837577,MK0431/ONO-5435 Phase III Clinical Trial -Add-on to Voglibose Study for Patients With Type 2 Diabetes Mellitus (MK0431-104),"A Phase III, Randomized, Placebo-controlled, Double-blind Clinical Trial and Subsequent Open-label, Extension Clinical Trial to Study the Efficacy and Safety of Addition of Sitagliptin in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy and Voglibose Monotherapy",COMPLETED,2009-02-05,2010-08-11,2017-05-15,INTERVENTIONAL,PHASE3,133.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Non-Insulin-Dependent",Comparator: Placebo|Sitagliptin|Voglibose,DRUG,1,2,20 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.897839799950911,medium,0,1,1,0,1,0,0,0,0,0,1,1,1,1,3,1,1,0,0,3,1,,,,,0,1,0
NCT02495077,Effects of Inhibiting Early Inflammation in Kidney Transplant Patients,Randomized Controlled Trial of Infliximab (Remicade®) Induction Therapy for Deceased Donor Kidney Transplant Recipients (CTOT-19),COMPLETED,2015-11-02,2021-07-23,2022-08-16,INTERVENTIONAL,PHASE2,290.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Kidney Transplant,Infliximab|Methylprednisolone|Mycophenolate Mofetil|Tacrolimus|Thymoglobulin®|Acetaminophen|Loratadine|Placebo for Infliximab|Prednisone|Diphenhydramine,DRUG|BIOLOGICAL,1,45,18 Years,,ALL,False,National Institute of Allergy and Infectious Diseases (NIAID),NIH,2,15,Canada|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.673323267171493,large,0,1,0,1,0,1,1,1,1,0,1,1,1,1,46,1,1,1,0,10,1,,,,,0,3,1
NCT06060457,"A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age","A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults ≥65 Years of Age",COMPLETED,2023-09-25,2024-06-07,2025-07-30,INTERVENTIONAL,PHASE3,1900.0,ACTUAL,RANDOMIZED,SEQUENTIAL,PREVENTION,QUADRUPLE,Respiratory Syncytial Virus,Placebo|mRNA-1345|Fluzone HD,BIOLOGICAL,7,5,65 Years,,ALL,True,"ModernaTX, Inc.",INDUSTRY,0,34,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,7.550135342488429,xlarge,0,1,1,0,0,0,1,0,1,0,1,1,0,0,12,1,0,1,0,3,1,,,,,0,2,0
NCT02487277,"PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma",Perioperative Stromal Depletion Strategies in Pancreatic Ductal Adenocarcinoma,TERMINATED,2015-07-14,2018-05-18,2020-01-02,INTERVENTIONAL,PHASE2,3.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Adenocarcinoma,PEGPH20|Gemcitabine|Nab-paclitaxel,DRUG,2,4,18 Years,,ALL,False,Andrew Ko,OTHER,0,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,1.3862943611198906,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,6,1,1,0,0,3,1,,,,,0,2,0
NCT03339401,The AdAPT Trial; Adenovirus After Allogeneic Pediatric Transplantation,"Study to Assess the Safety, Overall Tolerability, and Antiviral Activity of Brincidofovir Versus Standard of Care for Treatment of Adenovirus in High-risk Pediatric Allogeneic Hematopoietic Transplant Recipients",TERMINATED,2017-12-22,2019-05-10,2021-01-25,INTERVENTIONAL,PHASE2,29.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Adenovirus,Standard of Care|Brincidofovir,DRUG|OTHER,1,0,2 Months,25 Years,ALL,False,Jazz Pharmaceuticals,INDUSTRY,0,36,Italy|Netherlands|United States|Germany|Spain|United Kingdom|Poland|France|Ireland,0.0,0,1,0,0,0,2.0,0,0,0,0,1,3.4011973816621555,small,1,1,1,0,0,0,1,1,1,1,1,0,1,1,1,0,1,0,0,2,1,,,,,0,2,0
NCT02144077,Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy,"A Randomized, Observer Blind, Multinational Phase III Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) in Comparison to Metvix® in the Treatment of Non-aggressive Basal Cell Carcinoma (BCC) With Photodynamic Therapy (PDT)",COMPLETED,2014-01-28,2020-09-09,2022-11-03,INTERVENTIONAL,PHASE3,281.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Basal Cell Carcinoma (BCC),BF-200 ALA|methyl-aminolevulinate,DRUG,1,5,18 Years,,ALL,False,Biofrontera Bioscience GmbH,INDUSTRY,1,1,Germany,1.0,0,0,1,0,0,3.0,1,0,0,0,1,5.641907070938114,large,0,1,1,0,0,1,0,0,0,1,1,1,1,1,6,1,1,0,0,2,1,,,,,0,2,0
NCT01464177,Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Multiforme,Prospective Randomized Phase II Trial of Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Multiforme,COMPLETED,2011-10,2024-08,2024-12-09,INTERVENTIONAL,PHASE2,40.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Recurrent Glioblastoma Multiforme,Stereotactic hypofractionated RT 5x5Gy|Stereotactic hypofractionated RT 5x7Gy,RADIATION,1,4,18 Years,,ALL,False,Andre Tsin Chih Chen,OTHER,0,1,Brazil,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.713572066704308,small,1,0,0,1,0,0,0,0,0,0,1,1,1,1,5,1,0,0,0,2,1,2011-10-01,2024-08-01,4688.0,2011.0,0,1,0
NCT01676701,Evaluation of Tabalumab Using Auto-Injector or Prefilled Syringe in Participants With Rheumatoid Arthritis (RA),Pharmacokinetic Evaluations of Tabalumab Following Subcutaneous Administration by Prefilled Syringe or Auto Injector in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate,TERMINATED,2012-09,2013-08,2018-04-26,INTERVENTIONAL,PHASE3,8.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Rheumatoid Arthritis,Tabalumab Auto-Injector|Tabalumab Prefilled Syringe,DRUG,2,8,18 Years,,ALL,False,Eli Lilly and Company,INDUSTRY,0,37,Russia|Argentina|Puerto Rico|United States|Poland|Czechia,0.0,0,0,1,0,0,3.0,0,1,0,0,1,2.1972245773362196,small,1,1,1,0,1,0,1,1,1,0,1,0,1,1,10,1,1,0,0,2,1,2012-09-01,2013-08-01,334.0,2012.0,0,3,1
NCT00396877,Efficacy And Safety Of Clopidogrel In Neonates /Infants With Systemic To Pulmonary Artery Shunt Palliation,International Randomized Double Blind Study Evaluating the Efficacy and the Safety of Clopidogrel 0.2 mg/kg Once Daily Versus Placebo in Neonates and Infants With Cyanotic Congenital Heart Disease Palliated With Systemic to Pulmonary Artery Shunt,COMPLETED,2006-11,2010-02,2014-10-24,INTERVENTIONAL,PHASE3,906.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,"Heart Defects, Congenital",Clopidogrel (SR25990)|placebo,DRUG,1,2,,92 Days,ALL,False,Sanofi,INDUSTRY,1,31,China|Germany|Norway|Taiwan|Singapore|Thailand|Italy|Netherlands|Finland|South Korea|Spain|Portugal|Canada|Russia|Argentina|Sweden|India|United States|United Kingdom|Poland|Mexico|Denmark|Israel|South Africa|France|Belgium|Hungary|Brazil|Hong Kong|Malaysia|Egypt,1.0,0,0,1,0,0,3.0,0,0,0,1,1,6.810142450115136,xlarge,0,1,1,0,1,1,1,1,1,1,1,1,1,1,3,1,1,0,0,2,1,2006-11-01,2010-02-01,1188.0,2006.0,0,2,0
NCT01930175,Study of Efficacy and Safety of VAY736 in Patients With Pemphigus Vulgaris,"A Randomized, Partial-blind, Placebo-controlled Trial Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of VAY736 in the Treatment of Patients With Pemphigus Vulgaris",TERMINATED,2013-12-18,2019-09-25,2021-10-08,INTERVENTIONAL,PHASE2,13.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Pemphigus Vulgaris,VAY736|Placebo,DRUG,1,7,20 Years,70 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,5,Taiwan|Austria|Bulgaria|United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,2.6390573296152584,small,1,1,1,0,1,0,1,1,1,0,1,1,1,1,8,1,1,0,0,2,1,,,,,0,3,1
NCT01986075,A Sequenced Behavioral and Medication Intervention for Cocaine Dependence,A Sequenced Behavioral and Medication Intervention for Cocaine Dependence,COMPLETED,2014-01,2021-01,2022-01-25,INTERVENTIONAL,PHASE1|PHASE2,145.0,ACTUAL,RANDOMIZED,SEQUENTIAL,TREATMENT,QUADRUPLE,Cocaine Dependence,Computer-assisted behavior therapy|Mixed-Amphetamine Salts- Extended Release (MAS-ER)|Placebo,BEHAVIORAL|DRUG,1,0,18 Years,60 Years,ALL,False,New York State Psychiatric Institute,OTHER,1,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,4.983606621708336,medium,0,1,0,1,0,1,0,0,1,0,1,1,1,0,1,0,1,0,0,3,1,2014-01-01,2021-01-01,2557.0,2014.0,0,2,0
NCT01649557,"Multicenter, Open-label, Safety and Tolerability Study","A Phase 2, Multicenter, Open-label Study to Assess the Safety and Tolerability of Oral OPC-34712 as Monotherapy in Adult Patients With Schizophrenia",COMPLETED,2009-08,2011-09,2015-10-29,INTERVENTIONAL,PHASE2,244.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Schizophrenia,OPC-34712,DRUG,2,8,18 Years,67 Years,ALL,False,"Otsuka Pharmaceutical Development & Commercialization, Inc.",INDUSTRY,0,68,Bulgaria|Russia|India|South Korea|United States|Croatia|Slovakia|Romania|Ukraine|Serbia|Taiwan|Philippines,1.0,0,1,0,0,0,2.0,0,0,1,0,1,5.501258210544727,large,0,1,1,0,0,0,1,1,1,0,0,0,1,0,10,1,1,0,0,1,0,2009-08-01,2011-09-01,761.0,2009.0,0,2,0
NCT00081601,Study of CEP-701 in Treatment of Prostate Cancer,An Open-Label Phase 2 Study of Oral CEP-701 in Patients With Asymptomatic Hormone-Refractory Cancer With Rising Prostate Specific Antigen,COMPLETED,2004-03,2005-06,2012-08-24,INTERVENTIONAL,PHASE2,30.0,,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Prostate Cancer,CEP-701,DRUG,0,0,18 Years,,MALE,False,Cephalon,INDUSTRY,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.4339872044851463,small,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,2004-03-01,2005-06-01,457.0,2004.0,0,0,0
NCT05126901,"Evaluate the Safety and Efficacy of Ferric Maltol Oral Suspension vs. Ferrous Sulfate Oral Liquid in Children and Adolescents Aged 2 to 17 Years With Iron-deficiency Anaemia, With a Single Arm Study in Infants Aged 1 Month to Less Than 2 Years","Randomised, Open-label, Active-controlled, Multicentre, Comparative Study to Evaluate the Safety and Efficacy of Ferric Maltol (Iron (III)-Maltol Complex) (ST10) Oral Suspension Compared to Ferrous Sulfate Oral Liquid in Children and Adolescents Aged 2 to 17 Years With Iron-deficiency Anaemia, Incorporating a Single Arm Study in Infants Aged 1 Month to Less Than 2 Years",COMPLETED,2021-11-03,2024-06-09,2025-11-10,INTERVENTIONAL,PHASE3,65.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Anemia|Iron-deficiency,Ferric Maltol|Ferrous sulfate,DRUG,1,9,1 Month,17 Years,ALL,False,Shield Therapeutics,INDUSTRY,0,23,United Kingdom|Puerto Rico|United States,1.0,0,0,1,0,0,3.0,0,0,0,0,2,4.189654742026425,medium,1,1,1,0,0,0,1,1,1,1,1,0,1,1,10,1,1,0,0,2,1,,,,,0,4,1
NCT01294475,Preventing Child Maltreatment Through A Cellular-Phone Technology-Based Parenting Program,Preventing Child Maltreatment Through A Cellular-Phone Technology-Based Parenting Program,COMPLETED,2007-05,2011-08,2013-05-09,INTERVENTIONAL,PHASE1|PHASE2,371.0,ACTUAL,,SINGLE_GROUP,PREVENTION,NONE,Child Maltreatment,Planned Activities Training,BEHAVIORAL,1,0,18 Years,,FEMALE,True,Centers for Disease Control and Prevention,FED,0,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,5.918893854273146,large,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,2007-05-01,2011-08-01,1553.0,2007.0,0,1,0
NCT00470457,A Randomized Study to Evaluate a Novel Method of Specific Allergen Immunotherapy,A Randomized Study to Evaluate a Novel Method of Specific Allergen Immunotherapy in Grass and/or Tree Pollen Allergic Subjects by Intralymphatic Allergen Administration,COMPLETED,2001-06,2005-03,2015-12-03,INTERVENTIONAL,PHASE2,156.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Rhinoconjunctivitis Due to Grass Pollen Allergy,Allergen specific immunotherapy,BIOLOGICAL,1,0,18 Years,65 Years,ALL,False,University of Zurich,OTHER,1,1,Switzerland,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.056245805348308,medium,0,1,0,1,0,1,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,2001-06-01,2005-03-01,1369.0,2001.0,0,0,0
NCT01869257,Impact of Triclosan-coated Suture on Surgical Site Infection After Colorectal Surgery,Impact of Triclosan-coated Suture on Surgical Site Infection After Colorectal Surgery,COMPLETED,2009-05,2013-05,2013-06-05,INTERVENTIONAL,PHASE3,279.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Colorectal Resection,Triclosan coated suture|regular suture,DEVICE,1,1,18 Years,85 Years,ALL,False,University of Milano Bicocca,OTHER,0,1,Italy,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.634789603169249,large,0,1,0,1,0,0,0,0,0,1,1,0,1,1,2,1,0,0,1,2,1,2009-05-01,2013-05-01,1461.0,2009.0,0,1,0
NCT00602901,Elderly Back Pain: Comparing Chiropractic to Medical Care,Elderly Back Pain: Comparing Chiropractic to Medical Care,COMPLETED,2004-07,2007-03,2017-04-06,INTERVENTIONAL,PHASE2,240.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Subacute Low Back Pain|Chronic Low Back Pain,HVLA-SM|LVVA-SM|Usual medical care,DRUG|OTHER,1,7,55 Years,,ALL,False,Palmer College of Chiropractic,OTHER,1,2,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,5.484796933490655,large,0,1,0,1,0,1,1,0,1,0,1,0,1,1,8,1,1,0,0,3,1,2004-07-01,2007-03-01,973.0,2004.0,0,3,1
NCT01819701,"L-carnitine and Coenzyme Q10 in Relation to the Oxidative Stress, Antioxidant Enzymes Activities, Inflammation, and the Risk of Coronary Artery Disease",,COMPLETED,2013-01,2014-02,2014-03-13,INTERVENTIONAL,PHASE2|PHASE3,47.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,SINGLE,Coronary Artery Disease,LC-1000|LC-2000|Q10-150|Q10-300|Placebo,OTHER|DIETARY_SUPPLEMENT,2,0,20 Years,90 Years,ALL,True,Taichung Veterans General Hospital,OTHER,0,1,Taiwan,1.0,0,1,1,0,1,2.5,0,0,0,0,1,3.871201010907891,small,1,1,0,1,0,0,0,0,0,0,1,0,0,1,2,0,0,0,0,5,1,2013-01-01,2014-02-01,396.0,2013.0,0,2,0
NCT00378001,Clinical Efficacy and Tolerability of Two FSH Preparations (Human FSH Versus rFSH - Follitropin Alpha) in Women Undergoing IVF,"A Prospective, Multicenter, Investigator Blinded, Randomized, Concurrent Control Study of Efficacy and Tolerability of Two FSH Preparations (Fostimon® Versus Gonal-F®) in Women Undergoing IVF",COMPLETED,2005-03,2006-05,2015-02-16,INTERVENTIONAL,PHASE3,152.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Infertility,FSH-IBSA|GONAL-F,DRUG,1,4,18 Years,40 Years,FEMALE,False,IBSA Institut Biochimique SA,INDUSTRY,0,4,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.030437921392435,medium,0,0,1,0,0,0,1,0,1,0,1,1,1,1,5,1,1,0,0,2,1,2005-03-01,2006-05-01,426.0,2005.0,0,1,0
NCT00836277,Phase II Study of Irinotecan and Panitumumab,Phase II Study of Irinotecan and Panitumumab as Second-Line Therapy for Patients With Advanced Esophageal Adenocarcinoma,COMPLETED,2009-05,2015-08,2016-11-15,INTERVENTIONAL,PHASE2,24.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Esophageal Cancer,Panitumumab|Irinotecan,DRUG,2,3,18 Years,,ALL,False,"Weijing Sun, MD, FACP",OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.2188758248682006,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,5,1,1,0,0,2,1,2009-05-01,2015-08-01,2283.0,2009.0,0,1,0
NCT05962957,Role of Pentoxifylline and Celecoxib in Parkinsonism,Clinical Study to Compare the Possible Safety and Efficacy of Pentoxifylline and Celecoxib in Patients With Parkinson's Disease Treated With Conventional Treatment,COMPLETED,2023-08-07,2024-09-20,2025-08-12,INTERVENTIONAL,PHASE2,80.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Parkinson Disease,carbidopa-levodopa|Pentoxifylline 400 MG|Celecoxib 200mg,DRUG,1,0,18 Years,60 Years,ALL,False,Mostafa Bahaa,OTHER,2,1,Egypt,1.0,0,1,0,0,0,2.0,0,0,1,0,1,4.394449154672439,medium,1,1,0,1,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,3,1,,,,,0,1,0
NCT00496457,Efficacy Study With 500 mg QD of TRO19622 vs Placebo in Patients With Painful Peripheral Diabetic Neuropathy,"A Double-Blind, Randomized, Multicenter Study With 500 mg QD of TRO19622 Versus Placebo in Patients With Painful Peripheral Diabetic Neuropathy",COMPLETED,2007-05,2008-12,2016-11-22,INTERVENTIONAL,PHASE2,159.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Diabetic Neuropathy,Experimental|Placebo comparator,DRUG,1,3,18 Years,,ALL,False,Hoffmann-La Roche,INDUSTRY,1,31,Latvia|Croatia|Germany|Poland|Serbia,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.075173815233827,medium,0,1,1,0,1,1,1,1,0,1,1,1,1,1,4,1,1,0,0,2,1,2007-05-01,2008-12-01,580.0,2007.0,0,2,0
NCT05283057,Empagliflozin in Patients With Glomerulonephritis,Effect of Sodium Glucose Transporter 2 Inhibitor Empagliflozin on Proteinuria and Kidney Disease Progression in Patients With Non-diabetic Glomerulonephritis- A Randomized Controlled Trial,COMPLETED,2020-02-20,2021-09-30,2022-03-16,INTERVENTIONAL,PHASE3,50.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Glomerulonephritis|Proteinuria,Empagliflozin 25 MG|placebo,DRUG,1,1,18 Years,75 Years,ALL,False,Kasr El Aini Hospital,OTHER,0,1,Egypt,1.0,0,0,1,0,0,3.0,0,0,0,0,2,3.9318256327243257,small,1,1,0,1,0,0,0,0,0,0,1,1,1,1,2,1,1,0,0,2,1,,,,,0,2,0
NCT01268332,Safety and Adherence of a Non-medicated Intravaginal Ring (IVR),Expanded Safety and Adherence Study of a Non-medicated Intravaginal Ring,COMPLETED,2011-05,2013-03-07,2017-08-15,INTERVENTIONAL,PHASE2,195.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Healthy,Non-medicated Intravaginal Ring,DRUG,2,0,18 Years,45 Years,FEMALE,True,Population Council,OTHER,3,3,India|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.278114659230517,medium,0,1,0,1,0,1,1,1,1,0,1,0,0,1,2,0,1,0,0,1,0,2011-05-01,,,2011.0,0,1,0
NCT02084732,Safety and Efficacy of Sorafenib in Patients With Advanced Thyroid Cancer: a Phase II Clinical Study,Safety and Efficacy of Sorafenib in Patients With Advanced Thyroid Cancer: a Phase II Clinical Study,COMPLETED,2013-10-01,2019-11-01,2019-11-13,INTERVENTIONAL,PHASE2,35.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Thyroid Cancer,Sorafenib,DRUG,1,2,18 Years,,ALL,False,"Instituto Nacional de Cancerologia, Columbia",OTHER_GOV,0,1,Colombia,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.58351893845611,small,1,1,0,1,0,0,0,0,0,0,0,0,1,0,3,1,1,0,0,1,0,,,,,0,0,0
NCT04899232,Antithrombin III in Infectious Disease Caused by COVID-19,Antithrombin III (AT3) in Infectious Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)/ Coronavirus Disease of 2019 (COVID-19),TERMINATED,2021-07-06,2022-03-31,2022-09-07,INTERVENTIONAL,PHASE2,52.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Antithrombin III Deficiency|Covid19,Antithrombin III,DRUG,1,10,18 Years,,ALL,False,Enrique Ginzburg,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,2,3.970291913552122,medium,1,1,0,1,0,1,0,0,1,0,1,0,1,1,11,1,1,0,0,1,0,,,,,0,2,0
NCT00869232,UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission,"UARK 2008-02, A Phase II Trial for High-risk Myeloma Evaluation Accelerating and Sustaining Complete Remission (AS-CR) by Applying Non-host-exhausting and Timely Dose-reduced MEL-80-VRD-PACE Tandem Transplants",ACTIVE_NOT_RECRUITING,2008-10,2027-10,2025-06-29,INTERVENTIONAL,PHASE2,90.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Multiple Myeloma,Velcade|Melphalan|Thalidomide|Dexamethasone|Cisplatin|Adriamycin|Cyclophosphamide|Etoposide,DRUG,1,1,18 Years,75 Years,ALL,False,University of Arkansas,OTHER,0,1,United States,,0,1,0,0,0,2.0,1,0,0,0,1,4.51085950651685,medium,1,1,0,1,0,0,0,0,1,0,0,0,1,0,2,1,1,0,0,8,1,2008-10-01,2027-10-01,6939.0,2008.0,0,1,0
NCT01004198,Phase IIa Study of MP4OX in Traumatic Hemorrhagic Shock Patients,"A Multi-center, Randomized, Double-blind, Controlled Dose-finding Study to Evaluate the Safety and Efficacy of MP4OX Treatment Plus Standard of Care in Severely Injured Trauma Patients With Lactic Acidosis Due to Hemorrhagic Shock",COMPLETED,2009-12,2010-06,2013-08-19,INTERVENTIONAL,PHASE2,51.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Shock, Hemorrhagic|Shock, Traumatic|Acidosis, Lactic",MP4OX|MP4OX|Ringers Lactate solution,DRUG,1,7,18 Years,80 Years,ALL,False,Sangart,INDUSTRY,0,13,Germany|United Kingdom|South Africa|France,1.0,0,1,0,0,0,2.0,0,0,0,0,3,3.9512437185814275,medium,1,1,1,0,0,0,1,1,0,1,1,1,1,1,8,1,1,0,0,3,1,2009-12-01,2010-06-01,182.0,2009.0,0,4,1
NCT04486963,A Phase Ⅱ Clinical Study of Sanhuangjingshimingwan in Wet( Neovascular)Age-related Macular Degeneration(wAMD) Subjects,"A Randomized, Double-blind, Placebo-controlled, Ranibizumab Injected, Multicenter Phase II Clinical Study on the Efficacy and Safety of Sanhuangjingshimingwan in the Wet AMD(Qi and Yin Deficiency, Phlegm-blood Stasis Syndrome )Subjects",COMPLETED,2020-07-24,2022-11-15,2022-11-25,INTERVENTIONAL,PHASE2,78.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Age-related Macular Degeneration,Sanhuangjingshimingwan|Sanhuangjingshimingwan Placebo,DRUG,1,12,50 Years,80 Years,ALL,False,"Tasly Pharmaceutical Group Co., Ltd",INDUSTRY,0,6,China,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.3694478524670215,medium,1,1,1,0,0,0,1,0,0,0,1,1,1,1,13,1,1,0,0,2,1,,,,,0,2,0
NCT01010672,Phase II Study of Ridaforolimus (MK-8669) With Metastatic Bone or Soft-tissue Sarcoma Patients (MK-8669-030 AM1),A Phase II Study of MK-8669 When Administered as Maintenance Therapy to Japanese Patients With Metastatic Bone or Soft-tissue Sarcomas,COMPLETED,2009-11,2013-01,2015-04-30,INTERVENTIONAL,PHASE2,50.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Sarcoma,Ridaforolimus,DRUG,1,0,13 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,1,0,,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.9318256327243257,small,1,1,1,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,2009-11-01,2013-01-01,1157.0,2009.0,0,0,0
NCT00191672,A Trial Of Gemcitabine Plus Paclitaxel And Gemcitabine Plus Docetaxel In Metastatic Breast Cancer,A Phase II Randomized Trial Of Gemcitabine Plus Paclitaxel And Gemcitabine Plus Docetaxel In Patients With Metastatic Breast Cancer,COMPLETED,2003-12,2006-11,2007-01-26,INTERVENTIONAL,PHASE2,120.0,,RANDOMIZED,PARALLEL,TREATMENT,NONE,Breast Neoplasms,Gemcitabine|Paclitaxel|Docetaxel,DRUG,1,2,18 Years,,ALL,False,Eli Lilly and Company,INDUSTRY,0,2,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.795790545596741,medium,0,0,1,0,1,0,1,0,1,0,1,0,1,1,3,1,1,0,0,3,1,2003-12-01,2006-11-01,1066.0,2003.0,0,1,0
NCT03644472,Postmenopausal Women and Their Endothelium,Postmenopausal Women and Their Endothelium: Is Dietary Nitrate Supplementation Protective,COMPLETED,2018-11-07,2023-02-20,2023-02-27,INTERVENTIONAL,PHASE2,37.0,ACTUAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,DOUBLE,Postmenopausal Women,nitrate rich beetroot juice|nitrate depleted beetroot juice,DRUG,2,4,,70 Years,FEMALE,True,Penn State University,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.6375861597263857,small,1,1,0,1,0,0,0,0,1,0,1,1,0,0,6,1,1,0,0,2,1,,,,,0,2,0
NCT00144339,Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients,"A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial Assessing the Rate of Decline of Lung Function With Tiotropium 18 mcg Inhalation Capsule Once Daily in Patients With Chronic Obstructive Pulmonary Disease (COPD).",COMPLETED,2002-12,,2014-05-20,INTERVENTIONAL,PHASE3,5993.0,ACTUAL,,PARALLEL,TREATMENT,,"Pulmonary Disease, Chronic Obstructive",tiotropium|placebo,DRUG,2,85,40 Years,,ALL,False,Boehringer Ingelheim,INDUSTRY,0,490,Germany|Norway|Japan|Switzerland|Taiwan|Singapore|Greece|Thailand|Italy|Netherlands|Finland|Spain|Czechia|Portugal|Ireland|Russia|Argentina|Turkey (Türkiye)|United States|Austria|Australia|United Kingdom|Lithuania|Poland|Mexico|New Zealand|Denmark|Slovenia|Philippines|South Africa|France|Belgium|Hungary|Brazil|Slovakia|Hong Kong|Malaysia,1.0,0,0,1,0,0,3.0,0,0,0,0,1,8.69851424787661,xlarge,0,1,1,0,0,0,1,1,1,1,0,0,1,1,87,1,1,0,0,2,1,2002-12-01,,,2002.0,0,3,1
NCT01137968,Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC),A Randomized Phase II Study of Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy for Advance Non-small Cell Lung Cancer(NSCLC),COMPLETED,2010-05,2013-09,2016-01-26,INTERVENTIONAL,PHASE2,116.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Non-small Cell Lung Cancer,imetelstat|Bevacizumab,DRUG,1,3,18 Years,,ALL,False,Geron Corporation,INDUSTRY,0,33,Germany|Canada|United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.762173934797756,medium,0,1,1,0,0,0,1,1,1,1,1,0,1,1,4,1,1,0,0,2,1,2010-05-01,2013-09-01,1219.0,2010.0,0,2,0
NCT01466868,Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma,A Phase II Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma,TERMINATED,2011-11,2014-06,2014-07-10,INTERVENTIONAL,PHASE2,22.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Diffuse Large B Cell Lymphoma,MK2206,DRUG,1,5,18 Years,90 Years,ALL,False,Centre Leon Berard,OTHER,1,13,France,0.0,0,1,0,0,0,2.0,1,0,0,0,1,3.1354942159291497,small,1,1,0,1,0,1,1,0,0,1,0,0,1,0,6,1,1,0,0,1,0,2011-11-01,2014-06-01,943.0,2011.0,0,1,0
NCT02106468,The Efficacy of Omega-3 in Treatment of Atrophic/Erosive Lichen Planus,"The Efficacy of Omega-3 in Treatment of Atrophic/Erosive Lichen Planus and Improvement of Quality of Life: A Randomized, Double Blind, Controlled Study",COMPLETED,2013-05,2015-02,2015-04-28,INTERVENTIONAL,PHASE2,30.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Oral Lichen Planus,Prednisone tablet 5mg|Omega-3 soft capsules 1000 mg,DRUG,1,3,30 Years,60 Years,ALL,True,October 6 University,OTHER,0,1,Egypt,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.4339872044851463,small,1,1,0,1,0,0,0,0,0,0,1,1,1,1,4,1,1,0,0,2,1,2013-05-01,2015-02-01,641.0,2013.0,0,1,0
NCT01665768,Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma,"A Trial of Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in CD20+, B-cell Lymphomas, Gray Zone Lymphoma, and Hodgkin's Lymphoma",COMPLETED,2012-09,2020-08,2021-10-26,INTERVENTIONAL,PHASE2,56.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"CD20+, B-cell Lymphomas|Mantle Cell Lymphoma|Non-Mantle Cell Low Grade B Cell Lymphomas (SLL/CLL)|Transformed Lymphoma/DLBCL/PMBCL|Hodgkin's Disease|Gray Zone Lymphoma",Everolimus|Rituximab,DRUG|BIOLOGICAL,1,3,18 Years,100 Years,ALL,False,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,6,4.04305126783455,medium,1,1,0,1,0,1,0,0,1,0,0,0,1,0,4,1,1,1,0,2,1,2012-09-01,2020-08-01,2891.0,2012.0,0,2,0
NCT03177668,Clinical Study of YS110 in Patients With Malignant Pleural Mesothelioma,Phase I/II Clinical Study of YS110 in Patients With Malignant Pleural Mesothelioma,COMPLETED,2017-08-08,2020-02-05,2020-09-25,INTERVENTIONAL,PHASE1|PHASE2,40.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Malignant Pleural Mesothelioma,YS110,DRUG,7,0,20 Years,,ALL,False,"Kissei Pharmaceutical Co., Ltd.",INDUSTRY,0,1,Japan,1.0,1,1,0,0,1,1.5,0,0,0,0,1,3.713572066704308,small,1,1,1,0,0,0,0,0,0,0,0,0,1,0,7,0,1,0,0,1,0,,,,,0,2,0
NCT02310568,POC Study in Partially Responsive Generalized Anxiety Disorder,"An 8-week, Randomized, Phase 2, Double-blind, Sequential Parallel-group Comparison Study Of Two Dose Levels Of Pf 06372865 Compared To Placebo As An Adjunctive Treatment In Outpatients With Inadequate Response To Standard Of Care For Generalized Anxiety Disorder",TERMINATED,2014-11,2015-10,2017-01-09,INTERVENTIONAL,PHASE2,90.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Generalized Anxiety Disorder,PF-06372865.,DRUG,3,12,18 Years,65 Years,ALL,False,Pfizer,INDUSTRY,0,47,United States,0.0,0,1,0,0,0,2.0,0,0,1,0,1,4.51085950651685,medium,1,1,1,0,1,0,1,0,1,0,1,1,1,1,15,1,1,0,0,1,0,2014-11-01,2015-10-01,334.0,2014.0,0,1,0
NCT00606450,"Double-Blind, Randomized, Placebo-controlled Comparison of CC-10004 in Subjects With Moderate to Severe Plaque Type Psoriasis","A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Comparison Study of CC-10004 in Subjects With Moderate-to-Severe Plaque-Type Psoriasis",COMPLETED,2006-04-01,2007-05-01,2020-04-24,INTERVENTIONAL,PHASE2,260.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Psoriasis,CC-10004|CC-10004|Placebo,DRUG,1,2,18 Years,,ALL,False,Amgen,INDUSTRY,0,31,Germany|Czechia|Canada,1.0,0,1,0,0,0,2.0,0,1,0,0,1,5.564520407322694,large,0,1,1,0,1,0,1,1,0,1,1,1,1,1,3,1,1,0,0,3,1,,,,,0,2,0
NCT01192191,A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 in Japanese Subjects With COPD,A Long-term Study to Evaluate the Safety and Tolerability of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Japanese Subjects With Chronic Obstructive Pulmonary Disease (COPD),COMPLETED,2010-08,2012-01,2017-01-11,INTERVENTIONAL,PHASE3,187.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Pulmonary Disease, Chronic Obstructive",Fluticasone Furoate/GW642444 Inhalation Powder 100/25mcg|Fluticasone Furoate/GW642444 Inhalation Powder 200/25mcg,DRUG,2,8,40 Years,,ALL,False,GlaxoSmithKline,INDUSTRY,0,35,Japan,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.236441962829949,medium,0,1,1,0,0,0,1,0,0,0,1,1,1,1,10,1,1,0,0,2,1,2010-08-01,2012-01-01,518.0,2010.0,0,2,0
NCT00143091,"Multicentre Trial to Evaluate the Safety and Efficacy of CP-316,311 in Major Depressive Disorder","A Six-Week, Fixed Dose, Double-Blind, Double-Dummy, Placebo and Sertraline Controlled, Multicentre Trial to Evaluate the Safety and Efficacy of CP-316,311 in Outpatients With Major Depressive Disorder",TERMINATED,2005-04,2006-04,2008-03-24,INTERVENTIONAL,PHASE2,200.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Depressive Disorder, Major","CP-316,311|Placebo|Sertraline",DRUG,1,1,18 Years,,ALL,False,Pfizer,INDUSTRY,0,10,Russia|Serbia and Montenegro|United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,5.303304908059076,medium,0,0,1,0,1,0,1,1,1,0,1,1,1,1,2,1,1,0,0,3,1,2005-04-01,2006-04-01,365.0,2005.0,0,2,0
NCT00679991,A Phase 1-2 Study of PRT-201 Administered in Chronic Kidney Disease (CKD) Patients,"A Phase 1-2, Multi-Center, Dose Escalation Study of a Single Dose of PRT-201 Administered Immediately After Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease",COMPLETED,2008-11,2011-07,2015-04-30,INTERVENTIONAL,PHASE1|PHASE2,66.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Chronic Kidney Disease,PRT-201|PRT-201,DRUG,1,1,18 Years,,ALL,False,Proteon Therapeutics,INDUSTRY,0,11,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,4.204692619390966,medium,1,1,1,0,0,0,1,0,1,0,1,1,1,1,2,1,1,0,0,2,1,2008-11-01,2011-07-01,972.0,2008.0,0,2,0
NCT02841774,High Intensity Lipid Lowering Following Acute Coronary Syndromes for Persons Living With HIV,High Intensity Lipid Lowering Following Acute Coronary Syndromes for Persons Living With Human Immunodeficiency Virus (HILLCLIMBER),COMPLETED,2016-11,2021-06,2022-10-18,INTERVENTIONAL,PHASE2,10.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,HIV Infection|Coronary Heart Disease,Pravastatin|Rosuvastatin,DRUG,2,0,18 Years,75 Years,ALL,False,Matthew Feinstein,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,1,2,2.3978952727983707,small,1,1,0,1,0,0,0,0,1,0,1,0,1,1,2,0,1,0,0,2,1,2016-11-01,2021-06-01,1673.0,2016.0,1,2,0
NCT03129074,Study of Varlitinib Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer,"A Phase 2, Single Arm Study of Varlitinib Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer as First-line Systemic Therapy",WITHDRAWN,2018-05,2020-09,2018-05-23,INTERVENTIONAL,PHASE2,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Advanced or Metastatic Biliary Tract Cancer,Varlitinib|Capecitabine,DRUG,2,6,18 Years,,ALL,False,ASLAN Pharmaceuticals,OTHER,0,0,,0.0,0,1,0,0,0,2.0,1,0,0,0,1,0.0,,1,1,0,1,0,0,0,0,0,0,0,0,1,0,8,1,1,0,0,2,1,2018-05-01,2020-09-01,854.0,2018.0,1,2,0
NCT03911674,Effects of Oral Stimulation in Preterm Infants,"Effects of Oral Stimulation on Feeding Performance, Length of Hospital Stay and Anthropometric Variables of Preterm Infants",COMPLETED,2017-09-01,2018-04-01,2019-04-11,INTERVENTIONAL,PHASE3,48.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Premature Infant|Eating Disorder,Oral manual stimulation of feeding in preterm infants,OTHER,7,0,,7 Days,ALL,False,CEU San Pablo University,OTHER,0,1,Spain,1.0,0,0,1,0,0,3.0,0,0,0,0,2,3.8918202981106265,small,1,1,0,1,0,0,0,0,0,1,0,0,1,1,7,0,0,0,0,1,0,,,,,0,2,0
NCT02716974,A Study of Definitive Therapy to Treat Prostate Cancer,A Phase II Study of Definitive Therapy for Newly Diagnosed Men With Oligometastatic Prostate Cancer,COMPLETED,2016-06,2022-04,2022-08-04,INTERVENTIONAL,PHASE2,26.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Prostate Cancer,Leuprolide Acetate|Bicalutamide|Docetaxel|Prostatectomy|Radiation,DRUG|RADIATION|PROCEDURE,1,2,18 Years,80 Years,MALE,False,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,OTHER,0,3,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.295836866004329,small,1,1,0,1,0,0,1,0,1,0,0,0,1,0,3,1,1,0,0,5,1,2016-06-01,2022-04-01,2130.0,2016.0,1,1,0
NCT03568318,A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis,"A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis",ACTIVE_NOT_RECRUITING,2018-08-09,2030-10-23,2025-12-23,INTERVENTIONAL,PHASE3,1533.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Atopic Dermatitis,Placebo|Upadacitinib|Topical corticosteroids (TCS),DRUG,2,22,12 Years,75 Years,ALL,False,AbbVie,INDUSTRY,0,193,China|Germany|Norway|Japan|Greece|Italy|Netherlands|Spain|Czechia|Ireland|Canada|Sweden|Puerto Rico|United States|Austria|Australia|United Kingdom|New Zealand|Israel|France|Belgium|Hungary|Slovakia|Hong Kong,,0,0,1,0,0,3.0,0,0,0,0,1,7.335633981927201,xlarge,0,1,1,0,1,0,1,1,1,1,1,1,1,1,24,1,1,0,0,3,1,,,,,0,3,1
NCT01060618,Double-method Comparative Study in Order to Predict the Use of Co-receptors From Type 1 HIV: Phenotypic Study (Trofile ESTA®) and Virologic Response to a CCR5 Antagonist in the Short Term,Estudio Comparativo de Dos métodos Para Predecir el Uso de Co-receptores Por el Virus de la Inmunodeficiencia 1 (HIV-1): el Ensayo fenotípico (Trofile ESTA®) y la Respuesta virológica a Corto Plazo a un Antagonista de CCR5,COMPLETED,2009-05,2011-12,2013-02-28,INTERVENTIONAL,PHASE2|PHASE3,58.0,ACTUAL,NON_RANDOMIZED,PARALLEL,DIAGNOSTIC,NONE,HIV Infections,Maraviroc + Trofile ESTA® (diagnose test),OTHER,1,5,18 Years,,ALL,False,Asociacion para el Estudio de las Enfermedades Infecciosas,NETWORK,0,4,Spain,1.0,0,1,1,0,1,2.5,0,0,0,0,1,4.07753744390572,medium,1,1,0,0,0,0,1,0,0,1,0,0,0,1,6,1,0,0,0,1,0,2009-05-01,2011-12-01,944.0,2009.0,0,2,0
NCT03576313,Mass Drug Administration of Ivermectin and Dihydroartemisinin-piperaquine as an Additional Intervention for Malaria Elimination,Mass Drug Administration of Ivermectin and Dihydroartemisinin-piperaquine as an Additional Intervention for Malaria Elimination,COMPLETED,2018-08-11,2021-07-31,2022-03-14,INTERVENTIONAL,PHASE3,4939.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,SINGLE,Malaria,dihydroartemisinin-piperaquine (DP)|ivermectin (IVM)|standard malaria control interventions only,DRUG|OTHER,2,7,6 Months,,ALL,True,London School of Hygiene and Tropical Medicine,OTHER,6,1,The Gambia,1.0,0,0,1,0,0,3.0,0,0,0,0,1,8.505120610181969,xlarge,0,1,0,1,0,1,0,0,0,0,1,0,0,1,9,1,1,0,0,3,1,,,,,0,2,0
NCT01253460,"Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)","A Phase II Clinical Trial of Sapacitabine, Cyclophosphamide, and Rituximab (SCR) for Relapsed Patients With Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL) and Deletion 11q22-23 by FISH",TERMINATED,2011-08-22,2019-02-13,2019-09-06,INTERVENTIONAL,PHASE2,18.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Leukemia,Cyclophosphamide|Rituximab|Sapacitabine,DRUG,1,1,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,2,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,2.9444389791664403,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,2,1,1,0,0,3,1,,,,,0,1,0
NCT01298960,Growth Hormone (GH) in in Vitro Fertilization (IVF) Poor-responder Patients,Phase II Randomized Study of Cotreatment With Growth Hormone in a Long GnRH Agonist Protocol in Women With Previous Poor Ovarian Response,TERMINATED,2011-02,2013-06,2020-02-12,INTERVENTIONAL,PHASE2,52.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Complications; Artificial Fertilization, Introduction of Embryo in Embryo Transfer",Somatropin,DRUG,1,2,18 Years,39 Years,FEMALE,False,Fundacion Dexeus,OTHER,0,1,Spain,0.0,0,1,0,0,0,2.0,0,0,0,0,1,3.970291913552122,medium,1,1,0,1,0,0,0,0,0,1,1,0,1,1,3,1,1,0,0,1,0,2011-02-01,2013-06-01,851.0,2011.0,0,0,0
NCT00092560,Two Investigational Drugs in Patients With Mixed Hyperlipidemia (0653-036),Evaluation of the Efficacy and Safety of Fenofibrate and Ezetimibe Coadministration in Patients With Mixed Hyperlipidemia,COMPLETED,2002-12,2003-12,2024-08-15,INTERVENTIONAL,PHASE3,587.0,ACTUAL,,,TREATMENT,,Hypercholesterolemia|Hypertriglyceridemia,"MK0653, ezetimibe|Comparator: fenofibrate monotherapy",DRUG,1,1,18 Years,75 Years,ALL,False,Organon and Co,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,2,6.376726947898627,xlarge,0,1,1,0,0,0,0,0,0,0,0,0,1,0,2,1,1,0,0,2,1,2002-12-01,2003-12-01,365.0,2002.0,0,2,0
NCT02370160,HM2014-26 DT2219 for Relapsed or Refractory B-Lineage Leukemia or Lymphoma,HM2014-26 DT2219 Immunotoxin for the Treatment of Relapsed or Refractory CD19 (+) and/or CD 22 (+) B-lineage Leukemia or Lymphoma,COMPLETED,2015-12-21,2018-04-08,2020-01-13,INTERVENTIONAL,PHASE1|PHASE2,18.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Refractory B-Lineage Leukemia|Relapsed B-Lineage Leukemia|Refractory B-Lineage Lymphoma|Relapsed B-Lineage Lymphoma,DT2219ARL,BIOLOGICAL,2,5,12 Years,,ALL,False,"Masonic Cancer Center, University of Minnesota",OTHER,0,1,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,4,2.9444389791664403,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,7,1,0,1,0,1,0,,,,,0,3,1
NCT00147160,Phase II Cisplatin + Temozolomide in Malignant Glial Tumours in Children and Adolescents,Phase II Study of the Combination of Cisplatin + Temozolomide in Malignant Glial Tumours in Children and Adolescents at Diagnosis or in Relapse,COMPLETED,2003-10,2007-12,2012-04-11,INTERVENTIONAL,PHASE2,87.0,ESTIMATED,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Glioma,"Temozolomide, Cisplatinum",DRUG,1,3,4 Years,21 Years,ALL,False,"Gustave Roussy, Cancer Campus, Grand Paris",OTHER,0,2,United Kingdom|France,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.477336814478207,medium,1,0,0,1,0,0,1,1,0,1,0,0,1,0,4,1,1,0,0,1,0,2003-10-01,2007-12-01,1522.0,2003.0,0,1,0
NCT05316220,A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis,"A Randomized, Double-blind Study to Assess the Safety and Efficacy of Mesalamine Delayed-release Capsules in Children Aged 5 to 17 Years for the Maintenance of Remission of Ulcerative Colitis",WITHDRAWN,2025-09-15,2026-07-19,2025-08-12,INTERVENTIONAL,PHASE3,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Ulcerative Colitis (UC),Mesalamine|Placebo,DRUG,1,2,5 Years,17 Years,ALL,False,AbbVie,INDUSTRY,0,10,Puerto Rico|United States,0.0,0,0,1,0,0,3.0,0,1,0,0,1,0.0,,1,1,1,0,1,0,1,1,1,0,1,1,1,1,3,1,1,0,0,2,1,,,,,0,2,0
NCT03926624,Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage,"Phase 3 Randomized Trial of DFP-10917 vs Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High & Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage",TERMINATED,2019-11-22,2026-01-07,2026-01-22,INTERVENTIONAL,PHASE3,167.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Leukemia, Myeloid, Acute",DFP-10917|Cytarabine|Azacitidine|Decitabine|Mitoxantrone|Etoposide|Fludarabine|Idarubicin|Venetoclax|Cladribine,DRUG,2,8,18 Years,,ALL,False,"Delta-Fly Pharma, Inc.",INDUSTRY,0,39,United States,0.0,0,0,1,0,0,3.0,1,0,0,0,1,5.123963979403259,medium,0,1,1,0,0,0,1,0,1,0,1,0,1,1,10,1,1,0,0,10,1,,,,,0,2,0
NCT00623324,The Effects of Aplindore on the Treatment of Signs and Symptoms of Parkinson's Disease,"A Phase II, Dose Ranging, Randomized, Double Blind, Placebo-controlled, Multi-center, Pilot Study to Assess the Safety, Tolerability, Efficacy and Pharmacokinetics of Aplindore in Patients With Early Stage Parkinson's Disease",COMPLETED,2008-01,,2011-10-03,INTERVENTIONAL,PHASE2,40.0,ESTIMATED,RANDOMIZED,SINGLE_GROUP,TREATMENT,DOUBLE,Early Stage Parkinson's Disease,Aplindore|Placebo,DRUG,1,1,30 Years,,ALL,False,Ligand Pharmaceuticals,INDUSTRY,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,1,0,1,3.713572066704308,small,1,0,1,0,0,0,0,0,1,0,1,1,1,0,2,1,1,0,0,2,1,2008-01-01,,,2008.0,0,1,0
NCT03727724,Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer,Phase II Single Arm Study of Afatinib in Combination With Cetuximab in EGFR Exon 20 Insertion Positive Non-small-cell Lung Cancer,COMPLETED,2018-12-04,2022-09-06,2023-10-18,INTERVENTIONAL,PHASE2,37.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Carcinoma, Non-Small-Cell Lung",Afatinib|Cetuximab,DRUG,1,5,18 Years,,ALL,False,The Netherlands Cancer Institute,OTHER,2,4,Netherlands,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.6375861597263857,small,1,1,0,1,0,1,1,0,0,0,0,0,1,0,6,1,1,0,0,2,1,,,,,0,2,0
NCT01281124,Azacitidine in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer,Pilot Phase II Study of 5-Azacytidine in Previously Treated Patients With Advanced NSCLC,COMPLETED,2011-01-12,2012-09-12,2019-09-24,INTERVENTIONAL,PHASE2,1.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Recurrent Lung Non-Small Cell Carcinoma|Stage IV Lung Non-Small Cell Cancer AJCC v7,Azacitidine|Diagnostic Laboratory Biomarker Analysis|Pharmacological Study,DRUG|OTHER,1,2,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,2,0.6931471805599453,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,3,1,1,0,0,3,1,,,,,0,2,0
NCT00567424,GW273225 Therapy Added To Current Seizure Treatments In Patients With Partial Seizures,"An Open-label Evaluation of Drug Interactions, Safety, Tolerability and Efficacy of GW273225 Add-on Treatment of Partial Seizures, Whether or Not Secondarily Generalized",WITHDRAWN,2006-07,2008-03,2013-04-04,INTERVENTIONAL,PHASE2,0.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Epilepsy,GW273225,DRUG,1,1,18 Years,,ALL,False,GlaxoSmithKline,INDUSTRY,0,30,United States,0.0,0,1,0,0,0,2.0,0,0,1,0,1,0.0,,1,1,1,0,0,0,1,0,1,0,0,0,1,0,2,1,1,0,0,1,0,2006-07-01,2008-03-01,609.0,2006.0,0,0,0
NCT06603623,Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine,"Phase 2 Double-Blind, Randomized, Placebo Controlled, Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine",COMPLETED,2024-10-10,2025-03-28,2025-07-08,INTERVENTIONAL,PHASE2,647.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Migraine,BHV-2100|BHV-2100|Placebo,DRUG,2,14,18 Years,64 Years,ALL,False,Biohaven Therapeutics Ltd.,INDUSTRY,0,60,United States,1.0,0,1,0,0,0,2.0,0,0,1,0,1,6.473890696352274,xlarge,0,1,1,0,0,0,1,0,1,0,1,1,1,1,16,1,1,0,0,3,1,,,,,0,2,0
NCT03967223,Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors,"Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)",ACTIVE_NOT_RECRUITING,2019-12-31,2026-07-31,2025-07-16,INTERVENTIONAL,PHASE2,103.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Neoplasms,"Letetresgene autoleucel (lete-cel, GSK3377794)|Fludarabine|Cyclophosphamide",DRUG,2,14,10 Years,,ALL,False,Adaptimmune,INDUSTRY,0,38,Italy|Netherlands|United States|Spain|United Kingdom|France|Canada,,0,1,0,0,0,2.0,0,0,0,0,1,4.6443908991413725,medium,0,1,1,0,0,0,1,1,1,1,0,0,1,1,16,1,1,0,0,3,1,,,,,0,3,1
NCT00554723,CHInese Medicine NeuroAid Efficacy on Stroke Recovery,"A Double Blind, Placebo Controlled, Randomized, Multicenter Study to Investigate CHInese Medicine NeuroAid Efficacy on Stroke Recovery",COMPLETED,2007-05,2012-08,2014-05-01,INTERVENTIONAL,PHASE3,1100.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Cerebral Infarction|Stroke,NeuroAid|NeuroAid matched Placebo,DRUG,1,1,18 Years,,ALL,False,CHIMES Society,OTHER,1,24,Hong Kong|Malaysia|Philippines|Singapore|Sri Lanka|Thailand,1.0,0,0,1,0,0,3.0,0,0,0,0,2,7.00397413672268,xlarge,0,1,0,1,0,1,1,1,0,0,1,1,1,1,2,1,1,0,0,2,1,2007-05-01,2012-08-01,1919.0,2007.0,0,3,1
NCT04804423,Fluoride Therapies on Hypersensitive Carious Lesions in Primary Teeth,Evaluation of the Efficacy of Fluoride Therapies on Hypersensitive Carious Lesions in Primary Teeth,COMPLETED,2020-01-13,2021-04-01,2021-05-06,INTERVENTIONAL,PHASE2|PHASE3,30.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Dentin Hypersensitivity|Active Dental Caries,38% Silver Fluoride and Potassium Iodide solution (generic name; Riva Star®)|Sodium fluoride varnish (generic name; Duraphat®),DRUG,1,3,2 Years,5 Years,ALL,False,University Medicine Greifswald,OTHER,1,1,Germany,1.0,0,1,1,0,1,2.5,0,0,0,0,2,3.4339872044851463,small,1,1,0,1,0,1,0,0,0,1,0,0,1,1,4,1,1,0,0,2,1,,,,,0,3,1
NCT02849223,Transcranial Direct Current Stimulation (TDCS) as an Intervention for Patients With Traumatic Brain Injury,Transcranial Direct Current Stimulation (TDCS) as an Intervention for Patients With Traumatic Brain Injury,ACTIVE_NOT_RECRUITING,2016-07,2026-09,2025-10-09,INTERVENTIONAL,PHASE2,41.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Traumatic Brain Injury,Anodal Transcranial Direct Current Stimulation|Sham stimulation,DEVICE,1,1,18 Years,65 Years,ALL,False,Minneapolis Veterans Affairs Medical Center,FED,2,1,United States,,0,1,0,0,0,2.0,0,0,0,0,1,3.7376696182833684,small,1,1,0,0,0,1,0,0,1,0,1,1,1,1,2,1,0,0,1,2,1,2016-07-01,2026-09-01,3714.0,2016.0,1,1,0
NCT00754559,A Study to Assess Efficacy With Respect to Clinical Improvement in Disease Activity and Safety of Tocilizumab in Patients Wtih Active Rheumatoid Arthritis.,"""Effectiveness After Four and Twentyfour Weeks and Safety of Tocilizumab in Patients With Active RA""",COMPLETED,2008-08,2009-11,2016-02-08,INTERVENTIONAL,PHASE3,286.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Rheumatoid Arthritis,Tocilizumab,DRUG,1,20,18 Years,,ALL,False,Hoffmann-La Roche,INDUSTRY,0,81,Germany,1.0,0,0,1,0,0,3.0,0,1,0,0,1,5.659482215759621,large,0,1,1,0,1,0,1,0,0,1,0,0,1,0,21,1,1,0,0,1,0,2008-08-01,2009-11-01,457.0,2008.0,0,1,0
NCT01433159,Comparison of HP011-101 to Standard Care for Stage I-II Pressure Ulcers in Subjects With Spinal Cord Injury,Comparison of HP011-101 to Standard Care in the Management of Stage I-II Pressure Ulcers in Subjects With Spinal Cord Injury,TERMINATED,2011-09,2013-01,2014-02-10,INTERVENTIONAL,PHASE2,19.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Pressure Ulcers|Spinal Cord Injury,HP011-101 (Xenaderm Ointment)|Standard Care,DRUG,1,0,12 Years,,ALL,False,Healthpoint,INDUSTRY,0,5,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,2,2.995732273553991,small,1,1,1,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,0,2,1,2011-09-01,2013-01-01,488.0,2011.0,0,2,0
NCT05688280,"Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS","Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors. A Multicenter Phase 1b/2a Trial in Colorectal Cancer, Non-small Cell Lung Cancer, and Soft Tissue Sarcoma Patients",ACTIVE_NOT_RECRUITING,2022-11-29,2025-02,2025-01-08,INTERVENTIONAL,PHASE1|PHASE2,42.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Metastatic Solid Tumor|Colon Cancer|Nonsmall Cell Lung Cancer|Soft Tissue Sarcoma,1.0% IP-001 for Injection,DRUG,1,16,18 Years,,ALL,False,"Immunophotonics, Inc.",INDUSTRY,0,16,United States|Germany|United Kingdom|Switzerland|France,,1,1,0,0,1,1.5,1,0,0,0,4,3.7612001156935624,small,1,1,1,0,0,0,1,1,1,1,0,0,1,1,17,1,1,0,0,1,0,,2025-02-01,,,0,4,1
NCT01127880,Role of Antibiotics to Reduce Infectious Complications in Tube Thoracotomy Management of Traumatic Hemopneumothorax,"The Role of Antibiotics in the Reduction of Infectious Complications in Tube Thoracotomy Management of Traumatic Hemopneumothorax: A Prospective, Double-Blinded Study",COMPLETED,2005-07,2009-12,2010-05-21,INTERVENTIONAL,PHASE2|PHASE3,50.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Hemopneumothorax|Pneumothorax,Ancef or Clindamycin|Placebo,DRUG,1,1,16 Years,,ALL,True,"St. Luke's Hospital, Pennsylvania",OTHER,0,1,United States,1.0,0,1,1,0,1,2.5,0,0,0,0,2,3.9318256327243257,small,1,1,0,1,0,0,0,0,1,0,1,1,0,1,2,1,1,0,0,2,1,2005-07-01,2009-12-01,1614.0,2005.0,0,3,1
NCT00978380,Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725,"A Multi-Centre, Open-Label, Single-Arm, and Multiple Dosing Trial on Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency",COMPLETED,2009-09-21,2015-10-20,2018-01-24,INTERVENTIONAL,PHASE3,63.0,ACTUAL,,SINGLE_GROUP,PREVENTION,NONE,Congenital Bleeding Disorder|Congenital FXIII Deficiency,catridecacog,DRUG,1,1,6 Years,,ALL,False,Novo Nordisk A/S,INDUSTRY,0,34,Italy|Finland|United States|Germany|Austria|Spain|United Kingdom|Japan|Switzerland|Israel|France|Canada,1.0,0,0,1,0,0,3.0,0,0,0,0,2,4.1588830833596715,medium,1,1,1,0,0,0,1,1,1,1,0,0,0,0,2,1,1,0,0,1,0,,,,,0,2,0
NCT00366379,A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.,"An Open Label Study to Determine the Effect on Fasting Glucose Levels, and Safety, of Increasing Doses of GK Activator (2) in Patients With Type 2 Diabetes Not Optimally Controlled With One Previous Oral Antihyperglycemic Agent.",COMPLETED,2006-07,2007-06,2016-11-02,INTERVENTIONAL,PHASE2,127.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Diabetes Mellitus Type 2,GK Activator (2),DRUG,1,2,18 Years,75 Years,ALL,False,Hoffmann-La Roche,INDUSTRY,0,21,Mexico|Estonia|Latvia|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.852030263919617,medium,0,1,1,0,1,0,1,1,1,0,0,0,1,0,3,1,1,0,0,1,0,2006-07-01,2007-06-01,335.0,2006.0,0,1,0
NCT00241579,Analgesic Efficacy of Smoked Cannabis,Analgesic Efficacy of Smoked Cannabis,COMPLETED,2002-02,2004-01,2006-06-23,INTERVENTIONAL,PHASE1|PHASE2,15.0,,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Pain|Hyperalgesia,Smoked Cannabis,DRUG,3,2,18 Years,90 Years,ALL,True,Center for Medicinal Cannabis Research,OTHER,0,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,2,2.772588722239781,small,1,0,0,1,0,0,0,0,1,0,1,1,1,0,5,1,1,0,0,1,0,2002-02-01,2004-01-01,699.0,2002.0,0,2,0
NCT01303679,1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer,Phase III Randomized Multicenter Trial Comparing Continued Maintenance Therapy With the Bevacizumab + Taxane Versus Bevacizumab + Substituting Exemestane in Patients With Metastatic Breast Cancer or Locally Advanced With Estrogen Receptor Positive and Having at Least a Stable Disease After 16 to 18 Weeks of Treatment With Bevacizumab + Taxane.,TERMINATED,2010-06,2018-05,2023-09-06,INTERVENTIONAL,PHASE3,117.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,First Line Metastatic Breast Cancer,Paclitaxel|Bevacizumab|Exemestane,DRUG,1,0,18 Years,,FEMALE,False,ARCAGY/ GINECO GROUP,OTHER,0,1,France,0.0,0,0,1,0,0,3.0,1,0,0,0,1,4.770684624465665,medium,0,1,0,1,0,0,0,0,0,1,1,0,1,1,1,0,1,0,0,3,1,2010-06-01,2018-05-01,2891.0,2010.0,0,1,0
NCT01342796,Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects,"A Phase II, Randomized, Controlled, Observer-Blind, Clinical Study to Evaluate the Humoral and Cell Mediated Immunity and Safety of Two Intramuscular Doses of MF59C.1-adjuvanted Subunit Influenza Vaccine or Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects Aged 6 to <36 Months",COMPLETED,2011-05,2012-02,2021-04-19,INTERVENTIONAL,PHASE2,84.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,SINGLE,Seasonal Influenza|Influenza|Influenza Due to Unspecified Influenza Virus|Human Influenza,"MF59C.1-adjuvanted subunit influenza vaccine|Sub unit, Inactivated, Influenza vaccine",BIOLOGICAL,2,3,6 Months,36 Months,ALL,True,Novartis Vaccines,INDUSTRY,0,2,Belgium,1.0,0,1,0,0,0,2.0,0,0,0,0,4,4.442651256490317,medium,1,1,1,0,1,0,1,0,0,0,1,0,0,1,5,1,0,1,0,2,1,2011-05-01,2012-02-01,276.0,2011.0,0,2,0
NCT00683696,Echocardiography Guided Cardiac Resynchronization Therapy (EchoCRT),Echocardiography Guided Cardiac Resynchronization Therapy (EchoCRT),TERMINATED,2008-08,2013-03,2018-01-17,INTERVENTIONAL,PHASE2|PHASE3,1680.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Heart Failure|Ventricular Dyssynchrony,Implantable Cardioverter Defibrillator with Cardiac Resynchronization Therapy (BIOTRONIK Lumax HF-T CRT-D),DEVICE,2,5,18 Years,,ALL,False,"Biotronik, Inc.",INDUSTRY,1,122,Italy|Belgium|Netherlands|United States|Germany|Austria|Australia|Spain|United Kingdom|Poland|Switzerland|Czechia|Denmark|Israel|Portugal|France|Canada,0.0,0,1,1,0,1,2.5,0,0,0,1,2,7.427144133408616,xlarge,0,1,1,0,0,1,1,1,1,1,1,1,1,1,7,1,0,0,1,1,0,2008-08-01,2013-03-01,1673.0,2008.0,0,4,1
NCT04737096,DAOIB Combined With tDCS for Early-phase Dementia,"DAOIB Combined With tDCS for Early-phase Dementia - a Randomized, Double-blinded and Placebo Controlled Clinical Trial",COMPLETED,2020-01-01,2023-01-02,2023-01-06,INTERVENTIONAL,PHASE2,97.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Transcranial Direct Current Stimulation|Dementia,DAOIB|Placebo|tDCS,DRUG|DEVICE,1,5,50 Years,100 Years,ALL,False,Chang Gung Memorial Hospital,OTHER,0,1,Taiwan,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.584967478670572,medium,1,1,0,1,0,0,0,0,0,0,1,1,1,1,6,1,1,0,1,3,1,,,,,0,3,1
NCT05052996,Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV,"A Phase 2 Randomized, Open-Label, Active-Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV",ACTIVE_NOT_RECRUITING,2021-10-05,2027-11,2025-07-17,INTERVENTIONAL,PHASE2,142.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,HIV-1 Infection,ISL|LEN|B/F/TAF|ISL/LEN FDC,DRUG,1,19,18 Years,,ALL,False,Gilead Sciences,INDUSTRY,1,44,United States,,0,1,0,0,0,2.0,0,0,0,0,1,4.962844630259907,medium,0,1,1,0,1,1,1,0,1,0,1,0,1,1,20,1,1,0,0,4,1,,2027-11-01,,,0,2,0
NCT04159896,ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer,Phase II Multi-Center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Castrate Resistant Prostate Cancer,TERMINATED,2019-11-13,2022-03-01,2024-07-16,INTERVENTIONAL,PHASE2,10.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Castration Levels of Testosterone|Castration-Resistant Prostate Carcinoma|Metastatic Prostate Carcinoma|Prostate Carcinoma Metastatic in the Bone|Stage IVB Prostate Cancer AJCC v8,Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981|Nivolumab,DRUG|BIOLOGICAL,1,3,18 Years,,MALE,False,Barbara Ann Karmanos Cancer Institute,OTHER,1,2,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,5,2.3978952727983707,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,4,1,1,1,0,2,1,,,,,0,2,0
NCT00196196,A Precision and Accuracy Study of the Codman Valve Position Verification (VPV) System.,A Precision and Accuracy Study of the Codman Valve Position Verification (VPV) System.,COMPLETED,2004-09,2006-10,2012-05-28,INTERVENTIONAL,PHASE3,274.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Hydrocephalus|Normal Pressure Hydrocephalus,Codman VPV System,DEVICE,1,1,,,ALL,False,Codman & Shurtleff,INDUSTRY,0,8,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,2,5.616771097666572,large,0,1,1,0,0,0,1,0,1,0,0,0,1,0,2,1,0,0,1,1,0,2004-09-01,2006-10-01,760.0,2004.0,0,1,0
NCT01064024,"Evaluate the Safety and Efficacy of Phenazopyridine Hydrochloride Tablets, USP 200 mg vs. Placebo","A Double Blind, Randomized, Parallel Controlled Study to Evaluate the Safety and Efficacy of Phenazopyridine Hydrochloride Tablets, USP 200 mg vs. Placebo as a Urinary Analgesic for Short Term Treatment in Female Subjects Suffering From Pain or Burning When Passing Urine Associated With Uncomplicated Urinary Tract Infections (uUTI)",COMPLETED,2009-12,2010-12,2013-01-29,INTERVENTIONAL,PHASE3,233.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Pain|Urinary Tract Infections,Phenazopyridine Hydrochloride|Placebo,DRUG,1,0,18 Years,,FEMALE,False,"Amneal Pharmaceuticals, LLC",INDUSTRY,3,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,2,5.455321115357702,large,0,1,1,0,0,1,0,0,1,0,1,1,1,1,1,0,1,0,0,2,1,2009-12-01,2010-12-01,365.0,2009.0,0,2,0
NCT00525824,"12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe","A 12-week Open-label, Randomised, Parallel-group, Multicentre, Phase IIIb Study to Compare the Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe and Simvastatin in Patients With Hypercholesterolaemia and CHD",COMPLETED,2007-08,2008-09,2011-05-13,INTERVENTIONAL,PHASE3,1743.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Hypercholesterolemia|Coronary Heart Disease|Atherosclerosis,Rosuvastatin (Crestor)|Ezetimibe|Simvastatin,DRUG,1,12,18 Years,,ALL,False,AstraZeneca,INDUSTRY,0,9,Netherlands|Argentina|Venezuela|United States|Brazil|Lithuania|Chile|Peru|Colombia,1.0,0,0,1,0,0,3.0,0,0,0,1,3,7.463936604468925,xlarge,0,1,1,0,1,0,1,1,1,0,1,0,1,1,13,1,1,0,0,3,1,2007-08-01,2008-09-01,397.0,2007.0,0,4,1
NCT00201123,Effects of Interferon-Gamma on Cavitary Pulmonary Tuberculosis in the Lungs,Host Response to Tuberculosis and Acquired Immune Deficiency Syndrome,COMPLETED,2005-04,2007-08,2016-12-16,INTERVENTIONAL,PHASE2,89.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Tuberculosis|AIDS-related Complex,Aerosol Interferon-Gamma|Subcutaneous interferon-gamma|Placebo,DRUG|OTHER,1,2,18 Years,75 Years,ALL,False,NYU Langone Health,OTHER,1,2,South Africa|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.499809670330265,medium,1,1,0,1,0,1,1,1,1,0,1,0,1,1,3,1,1,0,0,3,1,2005-04-01,2007-08-01,852.0,2005.0,0,3,1
NCT00780962,N-Acetylcysteine to Prevent Radiocontrast Nephropathy in Emergency Department Patients,N-Acetylcysteine to Prevent Radiocontrast Nephropathy in Emergency Department Patients,COMPLETED,2007-10-16,2010-08-09,2024-10-29,INTERVENTIONAL,PHASE2,399.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Radiocontrast Nephropathy,N-Acetylcysteine (NAC)|0.9% Sodium-chloride,DRUG,1,0,18 Years,120 Years,ALL,False,Beth Israel Deaconess Medical Center,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.991464547107982,large,0,1,0,1,0,1,0,0,1,0,1,1,0,1,1,0,1,0,0,2,1,,,,,0,1,0
NCT01591746,Botulinum Toxin A (Botox) in Tissue Expander Breast Reconstruction,Botulinum Toxin A in Tissue Expander Breast Reconstruction: A Double-Blinded Randomized Controlled Trial,COMPLETED,2012-08,2017-07-18,2019-10-10,INTERVENTIONAL,PHASE3,131.0,ACTUAL,RANDOMIZED,PARALLEL,SUPPORTIVE_CARE,QUADRUPLE,"Breast Cancer|Pain, Postoperative|BRCA1 Mutation|BRCA2 Mutation|Breast Diseases|Neoplasms",Botulinum Toxin Type A|Placebo,DRUG,2,4,18 Years,,FEMALE,True,Mayo Clinic,OTHER,1,1,United States,1.0,0,0,1,0,0,3.0,1,0,0,0,6,4.882801922586371,medium,0,1,0,1,0,1,0,0,1,0,1,1,0,1,6,1,1,0,0,2,1,2012-08-01,,,2012.0,0,3,1
NCT00956046,A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy Europeans Children Aged 6 to 35 Months,"Immunogenicity and Safety of Multiple Formulations of an Intramuscular Inactivated, Split Virion Swine-origin A/H1N1 Influenza Vaccine With and Without Adjuvant in Healthy European Subjects Aged 6 to 35 Months",COMPLETED,2009-09,2011-06,2014-01-14,INTERVENTIONAL,PHASE2,401.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Influenza|Swine-origin A/H1N1 Influenza,"Swine A/H1N1 influenza vaccine (split virion, inactivated)|Swine A/H1N1 influenza vaccine (split virion, inactivated + Adjuvant)|Swine A/H1N1 influenza vaccine (split virion, inactivated + adjuvant)",BIOLOGICAL,2,0,6 Months,35 Months,ALL,True,"Sanofi Pasteur, a Sanofi Company",INDUSTRY,0,15,Finland,1.0,0,1,0,0,0,2.0,0,0,0,0,2,5.996452088619021,large,0,1,1,0,1,0,1,0,0,0,1,0,0,1,2,0,0,1,0,3,1,2009-09-01,2011-06-01,638.0,2009.0,0,2,0
NCT03306888,Feasibility and Acceptability of Implementing a Clinic-based Physical Activity Coaching Intervention in People With Premanifest and Early Stage HD,Feasibility and Acceptability of Implementing a Clinic-based Physical Activity Coaching Intervention in People With Premanifest and Early Stage Huntington's Disease,COMPLETED,2017-10-10,2019-04-01,2019-05-30,INTERVENTIONAL,PHASE1|PHASE2,14.0,ACTUAL,,SINGLE_GROUP,OTHER,NONE,Huntington's Disease,Physical Activity Coaching,OTHER,1,8,18 Years,65 Years,ALL,False,"Teachers College, Columbia University",OTHER,0,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,2.70805020110221,small,1,1,0,1,0,0,0,0,1,0,0,0,0,0,9,1,0,0,0,1,0,,,,,0,2,0
NCT06972888,A Phase II Clinical Study of AC-201 Tablets in Subjects With Plaque Psoriasis,"A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profile of AC-201 Tablets in Subjects With Moderate-to-severe Plaque Psoriasis",COMPLETED,2024-04-23,2025-04-28,2025-05-22,INTERVENTIONAL,PHASE2,145.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Plaque Psoriasis,AC-201|Placebo,DRUG,1,5,18 Years,75 Years,ALL,False,Accro Bioscience (Suzhou) Limited,INDUSTRY,0,1,China,1.0,0,1,0,0,0,2.0,0,1,0,0,1,4.983606621708336,medium,0,1,1,0,0,0,0,0,0,0,1,1,1,1,6,1,1,0,0,2,1,,,,,0,2,0
NCT06194188,A Phase 2 Clinical Study of CU-20401,A Phase 2 Clinical Study to Evaluate the Efficacy and Safety of CU-20401 for Injection in Moderate to Severe Contour Protuberance or Excessive Enrichment Due to Submental Fat (SMF) Accumulation,COMPLETED,2023-12-20,2024-09-02,2025-01-22,INTERVENTIONAL,PHASE2,108.0,ACTUAL,RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,Efficacy and Safety,Subcutaneous injection of CU-20401,DRUG,1,9,18 Years,65 Years,ALL,True,"Cutia Therapeutics（Wuxi）Co.,Ltd",INDUSTRY,0,1,China,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.6913478822291435,medium,0,1,1,0,0,0,0,0,0,0,1,0,1,0,10,1,1,0,0,1,0,,,,,0,1,0
NCT00004103,Combination Chemotherapy Followed by Surgery in Treating Patients With Stomach Cancer,A Phase II Study of Systemic Therapy With CPT-11 (Camptosar HCl) and Cisplatin in Patients With Advanced Gastric Cancer to be Followed by Surgical Resection and Postoperative Intraperitoneal Chemotherapy,COMPLETED,1998-07,2009-06,2011-04-06,INTERVENTIONAL,PHASE2,,,,,TREATMENT,,Gastric Cancer,cisplatin|floxuridine|irinotecan hydrochloride|adjuvant therapy|conventional surgery|neoadjuvant therapy,DRUG|PROCEDURE,0,0,18 Years,,ALL,False,NYU Langone Health,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,0.0,,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,6,1,1998-07-01,2009-06-01,3988.0,1998.0,0,1,0
NCT00297427,Acupuncture for Urinary Incontinence,Efficacy of Acupuncture in Treating Urinary Incontinence,COMPLETED,2005-10,2011-07,2016-10-24,INTERVENTIONAL,PHASE2,127.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,TRIPLE,Urinary Incontinence,Acupuncture|Sham acupuncture,OTHER|PROCEDURE,9,11,25 Years,,FEMALE,False,University of Pittsburgh,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.852030263919617,medium,0,1,0,1,0,1,0,0,1,0,1,1,1,0,20,1,0,0,0,2,1,2005-10-01,2011-07-01,2099.0,2005.0,0,2,0
NCT00306527,"Comparison of Safety, Tolerability and Immunogenicity of Influenza Vaccines in Adults and Elderly","A Phase III, Observer-Blind, Randomized, Multi-Center Study to Evaluate Safety, Tolerability and Immunogenicity (in a Subset) Following a Single Intramuscular Dose of a Trivalent Subunit Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs, in Healthy Adult and Elderly Subjects Who Received Either One or the Other Vaccine One Year Before in the V58P4 Study.",COMPLETED,2005-09,2006-04,2019-08-14,INTERVENTIONAL,PHASE3,2235.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,PREVENTION,SINGLE,Influenza,Cell culture derived influenza vaccine|egg-derived influenza subunit vaccine,BIOLOGICAL,1,5,18 Years,,ALL,True,Novartis Vaccines,INDUSTRY,1,5,Poland,1.0,0,0,1,0,0,3.0,0,0,0,0,1,7.71244383427499,xlarge,0,1,1,0,1,1,1,0,0,0,1,0,0,0,6,1,0,1,0,2,1,2005-09-01,2006-04-01,212.0,2005.0,0,2,0
NCT00448227,"Pharmacokinetics, Acceptability and Safety of Famciclovir in Infants (1 Month to Less Than 12 Months) With Herpes Simplex Infection","A Multicenter, Open-label, Single-arm Study to Evaluate the Single-dose Pharmacokinetics, Acceptability and Safety of Famciclovir Oral Pediatric Formulation in Infants 1 Month to Less Than 1 Year of Age With Herpes Simplex Virus Infections",COMPLETED,2007-10,,2011-02-11,INTERVENTIONAL,PHASE2,18.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Herpes Simplex,famciclovir,DRUG,4,5,1 Month,1 Year,ALL,False,Novartis,INDUSTRY,0,6,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.9444389791664403,small,1,1,1,0,1,0,1,0,1,0,0,0,1,0,9,1,1,0,0,1,0,2007-10-01,,,2007.0,0,1,0
NCT03136861,SKIPPAIN - Speed of Onset of SecuKinumab-Induced Relief From Pain in Patients With AxIal SpoNdyloarthritis,"A 24-week, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Secukinumab in Controlling Spinal Pain in Patients With Axial Spondyloarthritis",COMPLETED,2017-06-30,2019-02-15,2021-09-05,INTERVENTIONAL,PHASE3,383.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Spondyloarthritis,AIN457|AIN457 Placebo,DRUG|BIOLOGICAL,1,1,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,66,Italy|Belgium|Bulgaria|Finland|Latvia|Russia|Sweden|Spain|Croatia|United Kingdom|Lithuania|Poland|Estonia|Switzerland|Czechia|Ireland|Greece,1.0,0,0,1,0,0,3.0,0,1,0,0,1,5.950642552587727,large,0,1,1,0,1,0,1,1,0,1,1,1,1,1,2,1,1,1,0,2,1,,,,,0,2,0
NCT01311661,A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the Respimat® Inhaler in Patients With Moderate to Severe Asthma,"Phase II, Randomised, Double-Blind, Cross-over Study to Compare the 24-hour FEV1-time Profile of Orally Inhaled Olodaterol, Delivered With the Respimat® Inhaler, After 3 Weeks of Olodaterol Once Daily Medium Dose, Twice Daily Low Dose and Placebo or After 3 Weeks of Once Daily High Dose, Twice Daily Medium Dose and Placebo Administration in Patients With Moderate to Severe Persistent Asthma",COMPLETED,2011-03,,2014-05-01,INTERVENTIONAL,PHASE2,206.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Asthma,Placebo twice daily|Olodaterol low daily dose twice daily|Olodaterol medium daily dose twice daily|Placebo twice daily|Olodaterol high daily dose once daily and placebo|Olodaterol medium daily dose once daily and placebo,DRUG,1,26,18 Years,70 Years,ALL,False,Boehringer Ingelheim,INDUSTRY,0,36,Hungary|United States|Germany|Austria|Slovakia|Slovenia,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.332718793265369,large,0,1,1,0,0,0,1,1,1,1,1,1,1,0,27,1,1,0,0,6,1,2011-03-01,,,2011.0,0,3,1
NCT01201161,Ranibizumab for Diabetic Traction Retinal Detachment,The Effect of Intravitreous Ranibizumab on Intra-Operative Bleeding During Pars Plana Vitrectomy for Diabetic Traction Retinal Detachment,COMPLETED,2008-12,2010-01,2010-09-14,INTERVENTIONAL,PHASE2,19.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Diabetic Retinopathy|Retinal Detachment,Ranibizumab|Sham injection,DRUG|OTHER,1,1,18 Years,80 Years,ALL,False,University of Sao Paulo,OTHER,0,1,Brazil,1.0,0,1,0,0,0,2.0,0,0,0,0,2,2.995732273553991,small,1,1,0,1,0,0,0,0,0,0,1,1,1,1,2,1,1,0,0,2,1,2008-12-01,2010-01-01,396.0,2008.0,0,2,0
NCT03274661,Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient Tumors,Evaluating Immune Checkpoint Inhibition In Solid Tumor Patients With Homologous Recombination Repair Deficiency,COMPLETED,2017-11-03,2022-03-19,2023-10-19,INTERVENTIONAL,PHASE2,52.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Solid Tumor, Adult",Pembrolizumab 200 mg Q3W,DRUG,1,2,18 Years,99 Years,ALL,False,Baptist Health South Florida,OTHER,2,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.970291913552122,medium,1,1,0,1,0,1,0,0,1,0,0,0,1,0,3,1,1,0,0,1,0,,,,,0,0,0
NCT01680861,Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate Sodium,"Randomized, Open-Label Trial of Tacrolimus/Everolimus vs. Tacrolimus/Enteric-Coated Mycophenolate Sodium to Prevent Biopsy-Proven Acute Rejection and Chronic Allograft Injury in Adult, Primary Kidney Transplantation",COMPLETED,2012-11,2014-12,2016-12-15,INTERVENTIONAL,PHASE3,32.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Transplant; Failure, Kidney",Tacrolimus|Everolimus|Enteric Coated Mycophenolate Sodium (EC-MPS)|Corticosteroids,DRUG,1,6,18 Years,75 Years,ALL,False,Gaetano Ciancio,OTHER,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.4965075614664802,small,1,1,0,1,0,0,0,0,1,0,1,0,1,1,7,1,1,0,0,4,1,2012-11-01,2014-12-01,760.0,2012.0,0,2,0
NCT00536042,Open-Label Trial of the Use of Minocycline in the Treatment of Asthma,Open-Label Trial of the Use of Minocycline as an Anti-Inflammatory Agent in the Treatment of Asthma,COMPLETED,1997-10,2009-06,2020-03-10,INTERVENTIONAL,PHASE2,14.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Asthma,Minocycline,DRUG,1,3,18 Years,75 Years,ALL,False,State University of New York - Downstate Medical Center,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.70805020110221,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,4,1,1,0,0,1,0,1997-10-01,2009-06-01,4261.0,1997.0,0,0,0
NCT05390970,Platelet-Rich Plasma for Stress Urinary Incontinence,Platelet-Rich Plasma Injection for the Treatment of Female Stress Urinary Incontinence: A Randomized Placebo-Controlled Study,COMPLETED,2022-05-23,2023-12-13,2024-08-29,INTERVENTIONAL,PHASE3,50.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Urinary Incontinence,Stress|Urinary Incontinence",Platelet-rich plasma injection,PROCEDURE,2,6,18 Years,99 Years,FEMALE,True,Annah J. Vollstedt,OTHER,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,2,3.9318256327243257,small,1,1,0,1,0,0,0,0,1,0,1,1,1,1,8,1,0,0,0,1,0,,,,,0,2,0
NCT00384670,A Phase I/II Trial of a Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naïve Children,A Phase I/II Trial of a Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naïve Children,COMPLETED,2003-08,2004-05,2014-02-24,INTERVENTIONAL,PHASE1|PHASE2,7.0,ACTUAL,,SINGLE_GROUP,PREVENTION,NONE,Dengue Fever,Dengue Vaccine Formulation 17|Licensed Japanese Encephalitis (JE) Vaccine,BIOLOGICAL,1,6,6 Years,10 Years,ALL,True,U.S. Army Medical Research and Development Command,FED,1,1,Thailand,1.0,1,1,0,0,1,1.5,0,0,0,0,1,2.0794415416798357,small,1,1,0,0,0,1,0,0,0,0,0,0,0,0,7,1,0,1,0,2,1,2003-08-01,2004-05-01,274.0,2003.0,0,3,1
NCT01319370,Effectiveness and Safety of Minoxidil Foam Versus Placebo Foam for Androgenetic Alopecia,"Investigator-Initiated, Double Blind, Two-Armed, Placebo-Controlled, Randomized Clinical Trial With an Open-Label Extension Phase, to Investigate Efficacy of 5% Minoxidil Topical Foam Twice Daily in Men With Androgenetic Alopecia in the Temple and Vertex Region Concerning Hair Volume Over 24 / 104 Weeks",COMPLETED,2010-11,2013-03,2013-11-07,INTERVENTIONAL,PHASE2,70.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Androgenetic Alopecia,Minoxidil|vehicle of 5% Minoxidil topical foam,DRUG,1,4,18 Years,70 Years,MALE,False,Natalie GARCIA BARTELS,OTHER,1,1,Germany,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.2626798770413155,medium,1,1,0,1,0,1,0,0,0,1,1,1,1,1,5,1,1,0,0,2,1,2010-11-01,2013-03-01,851.0,2010.0,0,1,0
NCT00006470,Vaccine Therapy Plus Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer That Has Been Completely Removed in Surgery,Phase II Study of Postoperative Adjuvant Immunotherapy and Radiation in Patients With Completely Resected Stage II and Stage IIIA Non-Small Cell Lung Cancer,COMPLETED,2001-03,,2013-08-13,INTERVENTIONAL,PHASE2,,,,,TREATMENT,,Lung Cancer,monoclonal antibody 11D10 anti-idiotype vaccine|monoclonal antibody 3H1 anti-idiotype vaccine|radiation therapy,BIOLOGICAL|RADIATION,0,0,18 Years,,ALL,False,Radiation Therapy Oncology Group,NETWORK,1,237,Canada|United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,0.0,,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,0,1,0,3,1,2001-03-01,,,2001.0,0,2,0
NCT00005970,"Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer",Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel With or Without Trastuzumab as Adjuvant Treatment for Women With HER-2 Over-Expressing or Amplified Node Positive or High-Risk Node Negative Breast Cancer,COMPLETED,2000-05-19,2010-01-27,2020-08-14,INTERVENTIONAL,PHASE3,3436.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Breast Adenocarcinoma|HER2 Positive Breast Carcinoma|Stage IA Breast Cancer AJCC v7|Stage IB Breast Cancer AJCC v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage IIIA Breast Cancer AJCC v7,Aromatase Inhibition Therapy|Cyclophosphamide|Doxorubicin Hydrochloride|Laboratory Biomarker Analysis|Paclitaxel|Tamoxifen Citrate|Trastuzumab,DRUG|BIOLOGICAL|OTHER,1,1,18 Years,,FEMALE,False,National Cancer Institute (NCI),NIH,4,157,Canada|South Africa|Peru|United States,1.0,0,0,1,0,0,3.0,1,0,0,0,7,8.142354276849835,xlarge,0,1,0,1,0,1,1,1,1,0,1,0,1,1,2,1,1,1,0,7,1,,,,,0,3,1
NCT01902173,"Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer",Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer,COMPLETED,2013-10-08,2023-12-23,2025-01-14,INTERVENTIONAL,PHASE1|PHASE2,27.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Hematopoietic and Lymphoid Cell Neoplasm|Locally Advanced Malignant Solid Neoplasm|Locally Advanced Melanoma|Metastatic Malignant Solid Neoplasm|Metastatic Melanoma|Stage IIIC Cutaneous Melanoma AJCC v7|Stage IV Cutaneous Melanoma AJCC v6 and v7|Unresectable Malignant Solid Neoplasm|Unresectable Melanoma,Biopsy|Biospecimen Collection|Computed Tomography|Dabrafenib Mesylate|Magnetic Resonance Imaging|Trametinib Dimethyl Sulfoxide|Uprosertib,DRUG|PROCEDURE,4,5,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,2,16,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,9,3.332204510175204,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,9,1,1,0,0,7,1,,,,,0,4,1
NCT03647423,QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.,QUILT-3.091 NANT Chordoma Vaccine: A Randomized Phase 1b/2 Trial of the NANT Chordoma Vaccine vs. Radiation in Subjects With Unresectable Chordoma.,WITHDRAWN,2018-08-31,2021-12-28,2025-02-21,INTERVENTIONAL,PHASE1|PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Chordoma|Unresectable Malignant Neoplasm,Aldoxorubicin Hydrochloride|ALT-803|ETBX-051|ETBX-061|GI-6301|haNK|Avelumab|Cetuximab|Cyclophosphamide|SBRT,DRUG|BIOLOGICAL|RADIATION,2,16,18 Years,,ALL,False,"ImmunityBio, Inc.",INDUSTRY,0,1,United States,0.0,1,1,0,0,1,1.5,0,0,0,0,2,0.0,,1,1,1,0,0,0,0,0,1,0,1,0,1,1,18,1,1,1,0,10,1,,,,,0,4,1
NCT03629080,A Study of CMV Vaccine (HB-101) in Kidney Transplant Patients,"A Randomized, Placebo-Controlled, Phase 2 Study of HB-101, a Bivalent Cytomegalovirus (CMV) Vaccine, in CMV-Seronegative Recipient (R-) Patients Awaiting Kidney Transplantation From Living CMV-Seropositive Donors (D+).",COMPLETED,2018-12-12,2022-06-22,2023-10-26,INTERVENTIONAL,PHASE2,83.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Cytomegalovirus (CMV) Infection|Kidney Transplantation,HB-101 vaccine|placebo,BIOLOGICAL,7,7,18 Years,99 Years,ALL,False,Hookipa Biotech GmbH,INDUSTRY,0,25,United States|Germany|United Kingdom|Norway|Denmark|France,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.430816798843313,medium,1,1,1,0,0,0,1,1,1,1,1,1,0,1,14,1,0,1,0,2,1,,,,,0,4,1
NCT02405780,"A Study to Compare FKB327 Long-term Safety, Efficacy and Immunogenicity With Humira® in Rheumatoid Arthritis Patients","An Open-label Extension Study to Compare the Long-term Efficacy, Safety, Immunogenicity and Pharmacokinetics of FKB327 and Humira® in Patients With Rheumatoid Arthritis on Concomitant Methotrexate",COMPLETED,2015-06-10,2018-01-18,2019-03-26,INTERVENTIONAL,PHASE3,645.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Arthritis, Rheumatoid",FKB327|Humira®,DRUG,9,4,18 Years,,ALL,False,"Fujifilm Kyowa Kirin Biologics Co., Ltd.",INDUSTRY,0,92,Russia|United States|Germany|Spain|Romania|Chile|Poland|Peru|Czechia|Ukraine|Canada,1.0,0,0,1,0,0,3.0,0,1,0,0,1,6.470799503782602,xlarge,0,1,1,0,0,0,1,1,1,1,1,0,1,1,13,1,1,0,0,2,1,,,,,0,3,1
NCT00593580,Bone Health in Gynecologic Cancers-does FOSAVANCE Help?,The Impact of Bisphosphonates on Bone Loss in Patients Undergoing Surgery and Postoperative Chemotherapy for Gynecologic Malignancies.,COMPLETED,2008-02,2011-06,2011-06-29,INTERVENTIONAL,PHASE2,60.0,ESTIMATED,RANDOMIZED,PARALLEL,PREVENTION,SINGLE,Ovarian Cancer,placebo|alendronate/cholecalciferol,DRUG,1,0,18 Years,,FEMALE,True,British Columbia Cancer Agency,OTHER,0,1,Canada,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.110873864173311,medium,1,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,2,1,2008-02-01,2011-06-01,1216.0,2008.0,0,1,0
NCT03037580,Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction,"A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)",TERMINATED,2017-08-15,2019-12-03,2020-11-10,INTERVENTIONAL,PHASE3,84.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Pulmonary Hypertension|Heart Failure With Preserved Ejection Fraction,Oral treprostinil|Placebo,DRUG,1,3,18 Years,85 Years,ALL,False,United Therapeutics,INDUSTRY,0,82,United States,0.0,0,0,1,0,0,3.0,0,0,0,1,2,4.442651256490317,medium,1,1,1,0,0,0,1,0,1,0,1,1,1,1,4,1,1,0,0,2,1,,,,,0,2,0
NCT00210379,Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma,"A Phase II Study of CHOP + Rituximab, With Intrathecal Methotrexate Followed by Radiotherapy in Patients With Primary Testicular Non-Hodgkin's Lymphoma",COMPLETED,2000-11,2007-03,2009-07-22,INTERVENTIONAL,PHASE2,64.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,"Lymphoma, B Cell",rituximab|CHOP|intrathecal methotrexate|radiotherapy,DRUG|PROCEDURE,3,1,18 Years,,MALE,False,International Extranodal Lymphoma Study Group (IELSG),OTHER,0,1,Switzerland,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.174387269895637,medium,1,1,0,1,0,0,0,0,0,0,0,0,1,0,4,1,1,0,0,4,1,2000-11-01,2007-03-01,2311.0,2000.0,0,1,0
NCT00135096,Insulin Glulisine Administered Pre-meal Versus Post-meal in Adult Subjects With Type 2 Diabetes Mellitus Receiving Insulin Glargine as Basal Insulin,"APIDRA® (Insulin Glulisine) Administered Premeal vs Postmeal in Adult Subjects With Type 2 Diabetes Mellitus Receiving LANTUS® (Insulin Glargine) as Basal Insulin: a Multicenter, Randomized, Parallel, Open Label Clinical Study",COMPLETED,2004-08,2007-07,2011-01-11,INTERVENTIONAL,PHASE3,345.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2",insulin glulisine|insulin glargine,DRUG,1,0,18 Years,70 Years,ALL,False,Sanofi,INDUSTRY,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.846438775057725,large,0,1,1,0,1,0,0,0,1,0,1,0,1,1,1,0,1,0,0,2,1,2004-08-01,2007-07-01,1064.0,2004.0,0,1,0
NCT00480896,Treatment and Control of Atopic Dermatitis With 0.03% Tacrolimus Ointment,"Clinical Study on Tacrolimus Ointment Over the Long-term. ""CONTROL Study - Children""",COMPLETED,2004-06,2005-11,2014-09-18,INTERVENTIONAL,PHASE3,250.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Dermatitis, Atopic",tacrolimus ointment|Placebo ointment,DRUG,1,1,2 Years,15 Years,ALL,False,Astellas Pharma Inc,INDUSTRY,0,22,Italy|Belgium|Finland|Netherlands|Hungary|Spain|Germany|United Kingdom|Czechia|Portugal|France,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.5254529391317835,large,0,1,1,0,0,0,1,1,0,1,1,1,1,1,2,1,1,0,0,2,1,2004-06-01,2005-11-01,518.0,2004.0,0,2,0
NCT00148096,Mechanical Heat Recovery Ventilation on House Dust Mite Sensitive Asthma,Randomised Controlled Trial of Mechanical Heat Recovery Ventilation on Asthma Control of Patients Allergic to the House Dust Mite,COMPLETED,2003-02,2007-04,2009-12-24,INTERVENTIONAL,PHASE2,119.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Asthma,Mechanical Heat Recovery Ventilation,DEVICE,1,4,16 Years,60 Years,ALL,True,University of Glasgow,OTHER,8,1,United Kingdom,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.787491742782046,medium,0,1,0,1,0,1,0,0,0,1,1,1,1,1,5,1,0,0,1,1,0,2003-02-01,2007-04-01,1520.0,2003.0,0,0,0
NCT00391196,"A 1-Year Study On The Effects Of CP-945,598 For The Treatment Of Obesity In Overweight Type 2 Diabetic Patients","A 1-Year, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study To Evaluate The Efficacy And Safety Of CP-945,598 In The Treatment Of Overweight, Oral Agent-Treated Subjects With Type 2 Diabetes Mellitus",TERMINATED,2006-11,2009-01,2012-11-07,INTERVENTIONAL,PHASE3,975.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Obesity,"Placebo|CP-945,598|CP-945,598 Treatment B",DRUG,1,24,18 Years,70 Years,ALL,False,Pfizer,INDUSTRY,0,91,Argentina|Sweden|United States|Germany|Brazil|Australia|Slovakia|United Kingdom|Mexico|Czechia|Canada,0.0,0,0,1,0,0,3.0,0,0,0,0,1,6.883462586413092,xlarge,0,1,1,0,1,0,1,1,1,1,1,1,1,1,25,1,1,0,0,3,1,2006-11-01,2009-01-01,792.0,2006.0,0,3,1
NCT01043796,Evaluation of Insecticide Treated Nets and Wall Liners for the Prevention of Malaria,"Malaria Transmission Consortium: The Added Effects of Insecticide Treated Materials, Artemisinin-containing Combination Treatments, and Larviciding on Malaria Transmission and Illness",COMPLETED,2010-05,2014-12,2015-02-03,INTERVENTIONAL,PHASE3,1730.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Malaria,Insecticide treated nets and wall liners|Insecticide treated nets alone,OTHER,1,0,6 Months,11 Years,ALL,True,Centers for Disease Control and Prevention,FED,2,1,Kenya,1.0,0,0,1,0,0,3.0,0,0,0,0,1,7.456454555176209,xlarge,0,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,2,1,2010-05-01,2014-12-01,1675.0,2010.0,0,1,0
NCT02366962,A Study to Assess the Safety of ASP7374 in Adult Subjects Aged 20 or Older,Phase III Study of ASP7374-Open-label Study of Subcutaneous Vaccination of Quadrivalent ASP7374 in Adult Subjects Aged 20 or Older,COMPLETED,2015-02,2015-04,2017-09-29,INTERVENTIONAL,PHASE3,55.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,PREVENTION,NONE,Influenza|Vaccine,ASP7374,BIOLOGICAL,1,1,20 Years,,ALL,True,UMN Pharma Inc.,INDUSTRY,0,1,Japan,1.0,0,0,1,0,0,3.0,0,0,0,0,2,4.02535169073515,medium,1,1,1,0,0,0,0,0,0,0,0,0,0,0,2,1,0,1,0,1,0,2015-02-01,2015-04-01,59.0,2015.0,1,1,0
NCT00322062,MOVIPREP® Versus NaP Pivotal Phase III Study,"A Prospective Randomised Single-Blinded Multicentric and Pivotal Phase III Study Comparing the Efficacy, Safety and Acceptability of a New 2 Litres Gut Lavage Solution NRL994 Versus a Sodium Phosphate Solution for Colonoscopy Preparation",COMPLETED,2002-04,2003-03,2008-04-16,INTERVENTIONAL,PHASE3,340.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Colonoscopy,macrogol3350 NA sulphate NACL KCL ascorbic acid NA ascorbate|Sodium Phosphate Solution,DRUG,2,3,18 Years,75 Years,ALL,False,Norgine,INDUSTRY,0,18,France,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.831882477283517,large,0,1,1,0,0,0,1,0,0,1,1,0,1,1,5,1,1,0,0,2,1,2002-04-01,2003-03-01,334.0,2002.0,0,1,0
NCT06705062,Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination with Post-engraftment Anti-thymoglobin As Graft Versus Host Disease Prophylaxis in Alternative Donor Peripheral Stem Cell Transplantation,A Multi-center Randomized Clinical Study Comparing Reduced-dose (35mg/kg) Versus Standard Dose (50mg/kg) Post-transplantation Cyclophosphamide in Combination with Post-engraftment Anti-thymoglobin (ATG) and Tacrolimus and Post-engraftment Anti-thymoglobin As Graft Versus Host Disease (GVHD) Prophylaxis in Patients Undergo Alternative Donor Peripheral Hematopoietic Stem Cell Transplantation,ACTIVE_NOT_RECRUITING,2024-11-01,2028-07-01,2024-11-29,INTERVENTIONAL,PHASE3,316.0,ESTIMATED,RANDOMIZED,PARALLEL,PREVENTION,NONE,Allogeneic Hematopoietic Cell Transplant|Graft Versus Host Disease,reduced-dose PTCy|Standard dose PTCY,DRUG,1,8,18 Years,55 Years,ALL,False,Shanghai Jiao Tong University School of Medicine,OTHER,1,1,China,,0,0,1,0,0,3.0,0,0,0,0,2,5.75890177387728,large,0,0,0,1,0,1,0,0,0,0,1,0,0,1,9,1,1,0,0,2,1,,,,,0,3,1
NCT00111462,Evaluating Treatment of Anemia in Subjects With Non-Myeloid MalignanciesReceiving Multicycle Chemotherapy,"A Randomized, Open-Label Study of Darbepoetin Alfa (Novel Erythropoiesis Stimulating Protein, NESP) Using Fixed and Weight-Based Dosing for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies Receiving Multicycle Chemotherapy",COMPLETED,,,2013-05-08,INTERVENTIONAL,PHASE2,,,RANDOMIZED,FACTORIAL,TREATMENT,NONE,Anemia|Non-Myeloid Malignancies|Cancer,Darbepoetin alfa,DRUG,1,4,,,,False,Amgen,INDUSTRY,0,0,,1.0,0,1,0,0,0,2.0,1,0,0,0,3,0.0,,0,0,1,0,1,0,0,0,0,0,1,0,1,0,5,1,1,0,0,1,0,,,,,0,1,0
NCT00209846,A Study of Gaboxadol in Primary Insomnia,A Prospective Randomised Double-Blind Parallel-Group Placebo-Controlled Study of Gaboxadol in Primary Insomnia,COMPLETED,2004-06,2006-11,2007-03-30,INTERVENTIONAL,PHASE3,320.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Primary Insomnia,Gaboxadol,DRUG,2,0,66 Years,,ALL,False,H. Lundbeck A/S,INDUSTRY,0,1,Sweden,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.771441123130016,large,0,0,1,0,0,0,0,0,0,0,1,1,1,1,2,0,1,0,0,1,0,2004-06-01,2006-11-01,883.0,2004.0,0,0,0
NCT03053388,Evaluation of the Efficacy Safety and Tolerability of Nitric Oxide Given Intermittently Via Inhalation to Subjects With Bronchiolitis,Evaluation of the Efficacy Safety and Tolerability of Nitric Oxide Given Intermittently Via Inhalation to Subjects With Bronchiolitis,COMPLETED,2017-03-05,2018-04-28,2019-07-09,INTERVENTIONAL,PHASE3,69.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Bronchiolitis,Nitric Oxide|Supportive treatment,DRUG|OTHER,1,3,,12 Months,ALL,False,Beyond Air Inc.,INDUSTRY,0,10,Israel,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.248495242049359,medium,1,1,1,0,0,0,1,0,0,0,1,1,1,1,4,1,1,0,0,2,1,,,,,0,1,0
NCT02535988,Abscopal Effect for Metastatic Colorectal Cancer,"A Phase II Study of Radiotherapy and ZADAXIN's® (Thymalfasin) Induced Abscopal Effect in Patients With Heavily Pretreated, Metastatic Colorectal Cancer",WITHDRAWN,2015-09,2017-12,2023-09-21,INTERVENTIONAL,PHASE2,0.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Colorectal Cancer|Metastatic Colorectal Cancer|Thymalfasin,Radiation therapy|Thymalfasin,DRUG|RADIATION,1,2,19 Years,,ALL,False,Zhejiang Provincial People's Hospital,OTHER,0,0,,0.0,0,1,0,0,0,2.0,1,0,0,0,3,0.0,,1,1,0,1,0,0,0,0,0,0,0,0,1,0,3,1,1,0,0,2,1,2015-09-01,2017-12-01,822.0,2015.0,1,2,0
NCT02532088,Modulating Effects of Oil Palm Phenolics in Subjects With Pre-diabetes,Modulating Effects of Oil Palm Phenolics in Subjects With Pre-diabetes,WITHDRAWN,2020-05,2021-09,2021-10-06,INTERVENTIONAL,PHASE1|PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Prediabetes,Oil Palm Phenolics|Placebo,DIETARY_SUPPLEMENT,1,4,18 Years,70 Years,ALL,False,Universiti Sains Malaysia,OTHER,2,1,Malaysia,0.0,1,1,0,0,1,1.5,0,0,0,0,1,0.0,,1,1,0,1,0,1,0,0,0,0,1,1,1,1,5,1,0,0,0,2,1,2020-05-01,2021-09-01,488.0,2020.0,1,2,0
NCT00228488,Effect of Iressa With/Without Concurrent Chemoradiotherapy on Tumor Gene Expression Profiles in Patients With Advanced Non-Nasopharyngeal Head and Neck Carcinoma,Phase II Study of Iressa With/Without Concurrent Chemoradiotherapy in Patients With Advanced Non-Nasopharyngeal Head and Neck Carcinoma and to Study the Effect of Iressa™ (ZD1839) on Tumour Gene Expression Profiles ®,COMPLETED,2004-06,2005-12,2007-12-19,INTERVENTIONAL,PHASE2,60.0,,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Head and Neck Cancer,Gefitinib,DRUG,1,1,18 Years,,ALL,False,AstraZeneca,INDUSTRY,0,2,Singapore|Hong Kong,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.110873864173311,medium,1,0,1,0,1,0,1,1,0,0,0,0,1,0,2,1,1,0,0,1,0,2004-06-01,2005-12-01,548.0,2004.0,0,1,0
NCT06354803,Effect of Pezzi Ball on Balance in Pregnant Women,Amelioration of Kinaesthesia in Pregnant Women Using Pezzi Ball Exercises: Randomized Controlled Trial,COMPLETED,2023-03-02,2024-03-03,2024-04-09,INTERVENTIONAL,PHASE2|PHASE3,45.0,ACTUAL,RANDOMIZED,PARALLEL,SUPPORTIVE_CARE,QUADRUPLE,Postural Stability,proprioceptive training,OTHER,1,0,25 Years,30 Years,FEMALE,True,Kafrelsheikh University,OTHER,0,1,Egypt,1.0,0,1,1,0,1,2.5,0,0,0,0,1,3.828641396489095,small,1,1,0,1,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,,,,,0,1,0
NCT00060203,Brostallicin in Treating Patients With Recurrent or Refractory Multiple Myeloma,A Phase I/II Study of the Safety and Efficacy of Brostallicin (PNU-166196A) in Adult Patients With Multiple Myeloma That Has Progressed on Prior Chemotherapy,COMPLETED,2002-12,2004-04,2014-01-16,INTERVENTIONAL,PHASE1|PHASE2,3.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Multiple Myeloma and Plasma Cell Neoplasm,brostallicin,DRUG,1,6,18 Years,,ALL,False,Case Comprehensive Cancer Center,OTHER,1,1,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,1,1.3862943611198906,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,7,1,1,0,0,1,0,2002-12-01,2004-04-01,487.0,2002.0,0,2,0
NCT02218203,Clinical Neuropharmacology of Pain in Spinal Cord Injury- Dextromethorphan/Lidocaine Combination Clinical Trial,Clinical Neuropharmacology of Pain in Spinal Cord Injury- Dextromethorphan/Lidocaine Combination (Factorial Design) Clinical Trial,COMPLETED,2003-04,2008-01,2025-12-08,INTERVENTIONAL,PHASE2,26.0,ACTUAL,RANDOMIZED,FACTORIAL,TREATMENT,QUADRUPLE,Central Neuropathic Pain|Allodynia|Spinal Cord Injury,Dextromethorphan|Lidocaine|Placebo (Dextromethorphan)|Placebo (Lidocaine),DRUG,1,0,18 Years,70 Years,ALL,False,Brigham and Women's Hospital,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,3,3.295836866004329,small,1,1,0,1,0,1,0,0,1,0,1,1,1,0,1,0,1,0,0,4,1,2003-04-01,2008-01-01,1736.0,2003.0,0,2,0
NCT04088227,Effects of Platelet Rich Plasma Injections on Biomarkers After Anterior Cruciate Ligament Tears,Effect of Platelet Rich Plasma Injections on Inflammatory and Chondrodegenerative Biomarkers in Patients With Acute Anterior Cruciate Ligament Tears,COMPLETED,2019-09-12,2023-04-21,2025-02-17,INTERVENTIONAL,PHASE2,24.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Anterior Cruciate Ligament Tear|Anterior Cruciate Ligament Rupture,Experimental Group|Control Group,DRUG|OTHER,1,0,14 Years,40 Years,ALL,False,Andrews Research & Education Foundation,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,3.2188758248682006,small,1,1,0,1,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,2,1,,,,,0,2,0
NCT02424461,Antibiotic Treatment for 7 Days Versus 14 Days in Patients With Acute Male Urinary Tract Infection,"Antibiotic Treatment for 7 Days Versus 14 Days in Patients With Acute Male Urinary Tract Infection Due to Fluoroquinolones Susceptible Bacteria: a Multicentre, Non-inferiority, Double Blind, Randomized Placebo-controlled Trial",COMPLETED,2015-01-25,2019-07-25,2024-05-01,INTERVENTIONAL,PHASE3,274.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Acute Male Urinary Tract Infection,Ceftriaxone|Ofloxacine|Ofloxacine|Placebo of ofloxacine,DRUG,1,3,18 Years,,MALE,False,Assistance Publique - Hôpitaux de Paris,OTHER,0,1,France,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.616771097666572,large,0,1,0,1,0,0,0,0,0,1,1,0,1,1,4,1,1,0,0,4,1,,,,,0,1,0
NCT01186861,"Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy","A Randomized, Double-Blind, Placebo-controlled Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Erlotinib Plus Placebo in Patients With Nonprogression Following Four Cycles of 1st-line Platinum-based Chemotherapy for Advanced NSCLC",COMPLETED,2011-03-04,2015-03-11,2025-11-18,INTERVENTIONAL,PHASE2,205.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy,OSI-906|erlotinib|placebo,DRUG,1,6,18 Years,,ALL,False,Astellas Pharma Inc,INDUSTRY,0,69,Russia|South Korea|United States|Germany|Brazil|Romania|United Kingdom|Poland|Canada,1.0,0,1,0,0,0,2.0,1,0,0,0,1,5.327876168789581,large,0,1,1,0,0,0,1,1,1,1,1,1,1,1,7,1,1,0,0,3,1,,,,,0,3,1
NCT01871142,Evaluation of the Attenuation by Aes-103 of Hypoxia Mediated Decrements in Endurance Exercise Performance,"Double-Blind, Placebo Controlled Evaluation of the Attenuation by Aes-103 of Hypoxia Mediated Decrements in Endurance Exercise Performance in Healthy Adult Humans",COMPLETED,2013-03,2014-06,2014-10-24,INTERVENTIONAL,PHASE1|PHASE2,12.0,ACTUAL,RANDOMIZED,CROSSOVER,PREVENTION,TRIPLE,Hypoxia,Placebo|Aes-103|Aes-103,DRUG,1,1,18 Years,40 Years,MALE,True,Colorado State University,OTHER,1,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,2.5649493574615367,small,1,1,0,1,0,1,0,0,1,0,1,1,0,0,2,1,1,0,0,3,1,2013-03-01,2014-06-01,457.0,2013.0,0,2,0
NCT04148742,"Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3)","A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients With Non-Hodgkin B-cell Lymphoma",WITHDRAWN,2021-08,2023-07,2025-02-25,INTERVENTIONAL,PHASE1|PHASE2,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Non-Hodgkin's B-cell Lymphoma,DZD9008,DRUG,2,2,18 Years,,ALL,False,Dizal Pharmaceuticals,INDUSTRY,0,2,China,0.0,1,1,0,0,1,1.5,1,0,0,0,1,0.0,,1,1,1,0,0,0,1,0,0,0,0,0,1,0,4,1,1,0,0,1,0,2021-08-01,2023-07-01,699.0,2021.0,1,1,0
NCT01309542,Long-Term Safety Of DVS-233 SR In Patients With Major Depressive Disorder,A 10 Month Open-Label Evaluation Of The Long-Term Safety Of DVS-233 SR In Outpatients With Major Depressive Disorder.,COMPLETED,2003-08,2006-03,2011-04-26,INTERVENTIONAL,PHASE3,1403.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Major Depressive Disorder,Desvenlafaxine Succinate,DRUG,4,3,18 Years,75 Years,ALL,False,Pfizer,INDUSTRY,0,117,Finland|Latvia|Serbia and Montenegro|United States|Germany|Slovakia|Lithuania|Poland|Estonia|South Africa|France,1.0,0,0,1,0,0,3.0,0,0,0,0,1,7.247080584585756,xlarge,0,1,1,0,1,0,1,1,1,1,0,0,1,0,7,1,1,0,0,1,0,2003-08-01,2006-03-01,943.0,2003.0,0,2,0
NCT04142242,Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49,Safety and Immunogenicity of a Single Dose of MenACYW Conjugate Vaccine at Least 3 Years Following Initial Vaccination With Either Menomune® Vaccine or MenACYW Conjugate Vaccine in Older Adults,COMPLETED,2019-10-04,2022-05-25,2025-09-11,INTERVENTIONAL,PHASE3,471.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Meningococcal Infection (Healthy Volunteers),"Meningococcal Polysaccharide (serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|Blood sample",BIOLOGICAL|OTHER,1,9,59 Years,,ALL,True,"Sanofi Pasteur, a Sanofi Company",INDUSTRY,0,34,Puerto Rico|United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.156978985585555,large,0,1,1,0,1,0,1,1,1,0,1,0,0,1,10,1,0,1,0,2,1,,,,,0,3,1
NCT01033942,Pre-Exposure Prophylaxis in YMSM,Acceptability and Feasibility of a Pre-Exposure Prophylaxis (PrEP) Trial With Young Men Who Have Sex With Men (YMSM),COMPLETED,2009-08,2011-09,2017-04-17,INTERVENTIONAL,PHASE2,68.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,HIV,"coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP|Placebo|Many Men, Many Voices (3MV)",BEHAVIORAL|DRUG,89,7,18 Years,22 Years,MALE,True,"University of North Carolina, Chapel Hill",OTHER,2,2,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.23410650459726,medium,1,1,0,1,0,1,1,0,1,0,1,1,0,1,96,1,1,0,0,3,1,2009-08-01,2011-09-01,761.0,2009.0,0,2,0
NCT00092573,Study of Ezetimibe and Fenofibrate in Patients With Mixed Hyperlipidemia (0653-036)(COMPLETED),Evaluation of the Efficacy and Safety of Fenofibrate and Ezetimibe Coadministration in Patients With Mixed Hyperlipidemia,COMPLETED,2003-04,2004-11,2024-08-15,INTERVENTIONAL,PHASE3,576.0,ACTUAL,,,TREATMENT,,Hypercholesterolemia|Hypertriglyceridemia,"MK0653, ezetimibe|Comparator: fenofibrate monotherapy",DRUG,1,1,18 Years,75 Years,ALL,False,Organon and Co,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,2,6.3578422665081,xlarge,0,1,1,0,0,0,0,0,0,0,0,0,1,0,2,1,1,0,0,2,1,2003-04-01,2004-11-01,580.0,2003.0,0,2,0
NCT03506373,"Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia",Phase II Study of Ibrutinib in Combination With Ixazomib in Patients With Waldenström Macroglobulinemia,TERMINATED,2018-08-14,2025-06-23,2025-09-18,INTERVENTIONAL,PHASE2,21.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Recurrent Waldenstrom Macroglobulinemia|Refractory Waldenstrom Macroglobulinemia|Waldenstrom Macroglobulinemia,Ibrutinib|Ixazomib Citrate|Laboratory Biomarker Analysis|Pharmacodynamic Study|Pharmacokinetic Study,DRUG|OTHER,1,4,18 Years,,ALL,False,Mayo Clinic,OTHER,0,2,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,3,3.091042453358316,small,1,1,0,1,0,0,1,0,1,0,0,0,1,0,5,1,1,0,0,5,1,,,,,0,2,0
NCT01311869,Green Tea Extract: a Non-Surgical Alternative for Treatment of Uterine Fibroids,Green Tea Extract: a Non-Surgical Alternative for Treatment of Uterine Fibroids,TERMINATED,2010-12,2011-09,2013-10-24,INTERVENTIONAL,PHASE2,43.0,ACTUAL,RANDOMIZED,PARALLEL,HEALTH_SERVICES_RESEARCH,TRIPLE,Leiomyoma,EGCG ( Green Tea extract)|Brown rice pills,DIETARY_SUPPLEMENT,1,1,18 Years,,FEMALE,False,Meharry Medical College,OTHER,0,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,3.784189633918261,small,1,1,0,1,0,0,0,0,1,0,1,1,0,1,2,1,0,0,0,2,1,2010-12-01,2011-09-01,274.0,2010.0,0,1,0
NCT02656069,Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics,"G-Pen (Glucagon Injection) Compared to Lilly Glucagon (Glucagon for Injection [RDNA Origin]) for Induced Hypoglycemia Rescue in Adult Patients With T1DM: A Phase 3, Multi-center, Randomized, Blinded, 2-Way Crossover Study to Evaluate Efficacy and Safety",COMPLETED,2017-03-15,2017-09-25,2018-10-30,INTERVENTIONAL,PHASE3,80.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,TRIPLE,"Hypoglycemia|Diabetes Mellitus, Type 1",G-Pen (glucagon injection)|Lilly Glucagon (glucagon injection [rDNA origin]),DRUG,3,6,18 Years,75 Years,ALL,False,Xeris Pharmaceuticals,INDUSTRY,0,7,Canada|United States,1.0,0,0,1,0,0,3.0,0,0,0,0,2,4.394449154672439,medium,1,1,1,0,0,0,1,1,1,0,1,1,1,0,9,1,1,0,0,2,1,,,,,0,4,1
NCT03391869,Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer,Randomized Phase III Trial of Local Consolidation Therapy (LCT) After Nivolumab and Ipilimumab for Immunotherapy-Naive Patients With Metastatic Non-Small Cell Lung Cancer (LONESTAR),ACTIVE_NOT_RECRUITING,2017-12-29,2026-03-31,2025-12-17,INTERVENTIONAL,PHASE3,339.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Lung Adenocarcinoma|Lung Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8,Ipilimumab|Local Consolidation Therapy|Nivolumab|Quality-of-Life Assessment|Radiation Therapy|Therapeutic Conventional Surgery,BIOLOGICAL|RADIATION|OTHER|PROCEDURE,2,0,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,0,5,United States,,0,0,1,0,0,3.0,1,0,0,0,3,5.8289456176102075,large,0,1,0,1,0,0,1,0,1,0,1,0,1,1,2,0,0,1,0,6,1,,,,,0,2,0
NCT04141969,A Novel Nutraceutical to Combat Post-Lyme Disease Syndrome,A Novel Nutraceutical to Combat Post-Lyme Disease Syndrome,COMPLETED,2019-11-29,2021-03-28,2021-04-12,INTERVENTIONAL,PHASE2|PHASE3,100.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Post-Lyme Disease Syndrome (PLDS),RLP|Placebo,OTHER|DIETARY_SUPPLEMENT,2,0,12 Years,75 Years,ALL,False,Optimal Health Research,OTHER,0,1,United States,1.0,0,1,1,0,1,2.5,0,0,0,0,1,4.61512051684126,medium,0,1,0,1,0,0,0,0,1,0,1,1,1,1,2,0,0,0,0,2,1,,,,,0,2,0
NCT05157269,Trial to Evaluate Nitazoxanide for Treatment of Mild COVID-19 in Subjects Not at High Risk of Severe Illness,"Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild COVID-19 in Subjects Not at High Risk of Severe Illness",WITHDRAWN,2024-08,2025-03,2024-09-24,INTERVENTIONAL,PHASE3,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,COVID-19,Nitazoxanide|Placebo|Vitamin Super-B Complex,DRUG|DIETARY_SUPPLEMENT,1,0,12 Years,,ALL,False,Romark Laboratories L.C.,INDUSTRY,0,0,,0.0,0,0,1,0,0,3.0,0,0,0,0,1,0.0,,1,1,1,0,0,0,0,0,0,0,1,1,1,1,1,0,1,0,0,3,1,2024-08-01,2025-03-01,212.0,2024.0,1,1,0
NCT05250583,Use of a Biological Lens of Amniotic Membrane (LV-Visio-AMTRIX) in the Treatment of Treatment-Resistant Keratitis,"Use of a Double Amniotic Membrane Inserted in a Ring of Umbilical Vessels with Wharton's Jelly, Tissues Treated by the AMTRIX Process, in the Treatment of Keratitis Resisting Healing Medical Treatment",TERMINATED,2020-06-29,2021-01-07,2024-11-14,INTERVENTIONAL,PHASE2,5.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Keratitis,LV-Visio-AMTRIX,BIOLOGICAL,1,4,18 Years,65 Years,ALL,False,TBF Genie Tissulaire,INDUSTRY,0,1,France,0.0,0,1,0,0,0,2.0,0,0,0,0,1,1.791759469228055,small,1,1,1,0,0,0,0,0,0,1,0,0,1,0,5,1,0,1,0,1,0,,,,,0,0,0
NCT01066741,"Prevention of Radiation-induced Severe Oral Mucositis in Oral Cavity, Oropharynx, Hypopharynx, and Cavum Cancer","Randomized Evaluation of a Phytopharmaceutical in Prevention of Severe Oral Mucositis in Patients Receiving Radiotherapy for Oral Cavity, Oropharynx, Hypopharynx, or Cavum Cancer",TERMINATED,2009-05,2011-08,2012-11-01,INTERVENTIONAL,PHASE3,78.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,SINGLE,Oropharynx Cancer|Hypopharynx Cancer,Homeodent®|1.4% Sodium Bicarbonate solution,DRUG,1,9,18 Years,85 Years,ALL,False,Centre Leon Berard,OTHER,1,1,France,0.0,0,0,1,0,0,3.0,1,0,0,0,2,4.3694478524670215,medium,1,1,0,1,0,1,0,0,0,1,1,0,0,1,10,1,1,0,0,2,1,2009-05-01,2011-08-01,822.0,2009.0,0,3,1
NCT03288454,Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT,"Phase 2 Placebo-Controlled, Single-Site, Single-Blind Study of Apixaban Reversal by Ciraparantag as Measured by WBCT",COMPLETED,2017-08-30,2019-08-05,2025-09-02,INTERVENTIONAL,PHASE2,60.0,ACTUAL,RANDOMIZED,SEQUENTIAL,TREATMENT,SINGLE,Healthy,Ciraparantag|Placebo|Apixaban,DRUG,2,0,50 Years,75 Years,ALL,True,"Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.",INDUSTRY,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.110873864173311,medium,1,1,1,0,0,0,0,0,1,0,1,0,1,0,2,0,1,0,0,3,1,,,,,0,1,0
NCT00000405,Effects of Jumping on Growing Bones,The Effects of Jumping on Growing Bones,COMPLETED,1998-09,2008-11,2016-06-09,INTERVENTIONAL,PHASE2,200.0,,RANDOMIZED,FACTORIAL,PREVENTION,NONE,Osteoporosis,Exercise intervention,PROCEDURE,0,0,5 Years,10 Years,ALL,True,Oregon State University,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.303304908059076,medium,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1998-09-01,2008-11-01,3714.0,1998.0,0,0,0
NCT02421094,Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis,Phase 2 Study to Evaluate Non-Invasive Imaging Methods in Efficacy Assessment of GR-MD-02 for the Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis,COMPLETED,2015-09,2016-09-27,2020-10-08,INTERVENTIONAL,PHASE2,30.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Nonalcoholic Steatohepatitis,GR-MD-02|Placebo,DRUG,1,2,18 Years,75 Years,ALL,False,Galectin Therapeutics Inc.,INDUSTRY,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.4339872044851463,small,1,1,1,0,0,0,0,0,1,0,1,1,1,1,3,1,1,0,0,2,1,2015-09-01,,,2015.0,1,1,0
NCT03276494,Safety & Tolerability of Hypertonic Saline Administration Via Intraosseous Access,Intraosseous Administration of Hypertonic Saline in Acute Brain-injured Patients: A Prospective Case Series and Literature Review,COMPLETED,2017-04-21,2018-04-21,2019-07-09,INTERVENTIONAL,PHASE2,6.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Stroke|Intracranial Hypotension|Cerebral Edema,Intraosseous|Hypertonic saline,DRUG|DEVICE,1,1,18 Years,,ALL,False,Ohio State University,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,3,1.9459101490553132,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,2,1,1,0,1,2,1,,,,,0,2,0
NCT03591094,"Study Assessing PTI-428 Safety, Tolerability, Pharmacokinetics and Effect in Subjects With Cystic Fibrosis","A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect of PTI-428 in Subjects With Cystic Fibrosis",COMPLETED,2018-08-21,2019-02-18,2020-02-27,INTERVENTIONAL,PHASE2,40.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Cystic Fibrosis,PTI-428|Placebo,DRUG,1,5,18 Years,,ALL,False,"Proteostasis Therapeutics, Inc.",INDUSTRY,0,26,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.713572066704308,small,1,1,1,0,0,0,1,0,1,0,1,1,1,1,6,1,1,0,0,2,1,,,,,0,2,0
NCT00205894,Occipital Nerve Stimulation to Treat Chronic Headaches,Multicenter Feasibility Study of the Bion for Occipital Nerve Stimulation for Treatment of Chronic Headaches,COMPLETED,2004-01,2007-09,2008-09-05,INTERVENTIONAL,PHASE1|PHASE2,20.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Headache Disorders,bion microstimulator,DEVICE,2,0,18 Years,,ALL,False,Boston Scientific Corporation,INDUSTRY,0,2,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,3.044522437723423,small,1,1,1,0,0,0,1,0,1,0,0,0,1,0,2,0,0,0,1,1,0,2004-01-01,2007-09-01,1339.0,2004.0,0,1,0
NCT00797394,Efficacy of Natural Extract 2007RD01 Combined With Saw Palmetto in Benign Prostatic Hyperplasia Patients Compared to Saw Palmetto,,COMPLETED,2008-11,,2011-04-13,INTERVENTIONAL,PHASE2,110.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Benign Prostatic Hyperplasia,Combination of 2007RD01 and saw palmetto lipidic extract|Saw palmetto lipidic extract,DIETARY_SUPPLEMENT,1,5,50 Years,75 Years,MALE,False,innoVactiv Inc.,INDUSTRY,0,4,Canada,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.709530201312334,medium,0,0,1,0,0,0,1,0,0,0,1,1,1,1,6,1,0,0,0,2,1,2008-11-01,,,2008.0,0,2,0
NCT04751994,Iron Babies Pilot Supplementation Trial,Enhancing Brain Development by Early Iron Supplementation of African Infants: An Enabling Pilot Study,COMPLETED,2021-08-03,2022-03-09,2022-05-26,INTERVENTIONAL,PHASE3,100.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Iron-deficiency|Anaemia in Early Infancy,Iron drops/Ferrous sulphate|Placebo drops,DIETARY_SUPPLEMENT,1,13,6 Weeks,10 Weeks,ALL,True,London School of Hygiene and Tropical Medicine,OTHER,0,1,The Gambia,1.0,0,0,1,0,0,3.0,0,0,0,0,2,4.61512051684126,medium,0,1,0,1,0,0,0,0,0,0,1,1,0,1,14,1,0,0,0,2,1,,,,,0,3,1
NCT00679666,Corneal Crosslinking in Keratoconus and Corneal Ectasia,Corneal Collagen Cross-Linking for the Treatment of Progressive Keratoconus and Corneal Ectasia,WITHDRAWN,2008-04,2010-10,2017-04-20,INTERVENTIONAL,PHASE2|PHASE3,0.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Progressive Keratoconus|Corneal Ectasia,Riboflavin|Placebo,DRUG,1,1,18 Years,,ALL,True,Ohio State University,OTHER,0,2,United States,0.0,0,1,1,0,1,2.5,0,0,0,0,2,0.0,,1,1,0,1,0,0,1,0,1,0,1,0,1,0,2,1,1,0,0,2,1,2008-04-01,2010-10-01,913.0,2008.0,0,3,1
NCT05233566,Ketamine for Postoperative Avoidance of Depressive Symptoms: The K-PASS Feasibility Trial,Ketamine for Postoperative Avoidance of Depressive Symptoms: The K-PASS Feasibility Trial,COMPLETED,2022-04-25,2023-03-08,2024-04-10,INTERVENTIONAL,PHASE3,32.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Postoperative Depression,Ketamine|Normal saline,DRUG,3,2,18 Years,,ALL,False,Washington University School of Medicine,OTHER,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,1,0,1,3.4965075614664802,small,1,1,0,1,0,0,0,0,1,0,1,1,0,1,5,1,1,0,0,2,1,,,,,0,1,0
NCT02274766,Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia,ADS-5102 (Amantadine HCl) Extended Release Efficacy and Safety Study in Parkinson's Disease Patients With Levodopa-Induced Dyskinesia (EASE LID 3 Study),COMPLETED,2014-10,2016-03-10,2018-01-10,INTERVENTIONAL,PHASE3,77.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Dyskinesia|Levodopa-Induced Dyskinesia (LID)|Parkinson's Disease (PD),ADS-5102|Placebo,DRUG|OTHER,1,1,30 Years,85 Years,ALL,False,"Adamas Pharmaceuticals, Inc.",INDUSTRY,0,51,Spain|Germany|Austria|United States|France,1.0,0,0,1,0,0,3.0,0,0,1,0,3,4.356708826689592,medium,1,1,1,0,0,0,1,1,1,1,1,1,1,1,2,1,1,0,0,2,1,2014-10-01,,,2014.0,0,3,1
NCT03347266,Evaluate the Analgesic Efficacy and Safety of VVZ-149 Injection for Postoperative Pain Following Total Hip Arthroplasty.,"A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Analgesic Efficacy and Safety of VVZ-149 Injection for Post-operative Pain Following Total Hip Arthroplasty",COMPLETED,2017-12-20,2018-07-19,2019-03-13,INTERVENTIONAL,PHASE2,12.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Post-Operative Pain,VVZ-149 injections|Placebo,DRUG,1,8,25 Years,65 Years,ALL,False,"Vivozon, Inc.",INDUSTRY,0,1,South Korea,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.5649493574615367,small,1,1,1,0,0,0,0,0,0,0,1,1,1,1,9,1,1,0,0,2,1,,,,,0,2,0
NCT00003466,Temozolomide in Treating Patients With Progressive Low-Grade Glioma,Phase II Treatment of Adults and Children With Progressive Low Grade Gliomas With Temodal,COMPLETED,1998-03,2005-07,2014-07-09,INTERVENTIONAL,PHASE2,100.0,ESTIMATED,,,TREATMENT,,Brain and Central Nervous System Tumors,temozolomide,DRUG,2,0,4 Years,,ALL,False,Duke University,OTHER,1,2,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.61512051684126,medium,0,0,0,1,0,1,1,0,1,0,0,0,1,0,2,0,1,0,0,1,0,1998-03-01,2005-07-01,2679.0,1998.0,0,0,0
NCT03073356,Ketones in Heart Failure - Effects on Cardiac Efficiency,Effects of Ketones on Cardiac Function and Oxygen Consumption in Heart Failure Patients With Reduced Ejection Fraction and Healthy Test Subjects,COMPLETED,2017-03-17,2017-11-16,2017-12-11,INTERVENTIONAL,PHASE2,44.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,TRIPLE,"Heart Failure, Systolic|Ketonemia",Infusion of 3-OHB|Infusion of placebo,BIOLOGICAL,2,4,18 Years,90 Years,ALL,True,University of Aarhus,OTHER,0,1,Denmark,1.0,0,1,0,0,0,2.0,0,0,0,1,2,3.8066624897703196,small,1,1,0,1,0,0,0,0,0,0,1,1,1,0,6,1,0,1,0,2,1,,,,,0,3,1
NCT01907256,Comparing the Aesthetic Results of Two Common Incisions in External Rhinoplasty,Comparing the Aesthetic Results of Two Common Incisions in External Rhinoplasty A Randomized Trial,COMPLETED,2012-12,2013-11,2014-01-20,INTERVENTIONAL,PHASE3,56.0,ESTIMATED,RANDOMIZED,FACTORIAL,TREATMENT,SINGLE,Cosmetic Outcome,inverted V incision|stair step incisions,PROCEDURE,3,3,18 Years,65 Years,ALL,False,Tehran University of Medical Sciences,OTHER,0,1,Iran,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.04305126783455,medium,1,0,0,1,0,0,0,0,0,0,1,0,1,0,6,1,0,0,0,2,1,2012-12-01,2013-11-01,335.0,2012.0,0,2,0
NCT00885456,Program of Rehabilitative Exercise and Education to Avert Vascular Events After Non-disabling Stroke or Transient Ischemic Attack: A Multi-site RCT,Effectiveness of a Program of Rehabilitative Exercise and Education to Avert Vascular Events After Non-disabling Stroke: A Multi-site RCT,COMPLETED,2011-10-30,2017-06-30,2018-03-23,INTERVENTIONAL,PHASE2,187.0,ACTUAL,RANDOMIZED,PARALLEL,HEALTH_SERVICES_RESEARCH,SINGLE,Transient Ischemic Attack|Non-disabling Stroke,PREVENT program|Usual Care,BEHAVIORAL,5,12,17 Years,,ALL,False,Marilyn MacKay-Lyons,OTHER,3,2,Canada,1.0,0,1,0,0,0,2.0,0,0,0,0,2,5.236441962829949,medium,0,1,0,1,0,1,1,0,0,0,1,0,0,1,17,1,0,0,0,2,1,,,,,0,3,1
NCT01156922,B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Very Severe Chronic Fatigue Syndrome,B-lymphocyte Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Severely Affected Chronic Fatigue Syndrome Patients. An Open Label Phase II Study With Rituximab Induction and Maintenance Treatment for Patients in WHO Performance Status III-IV,TERMINATED,2010-06,2016-04,2024-03-04,INTERVENTIONAL,PHASE2,8.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Chronic Fatigue Syndrome|Myalgic Encephalomyelitis,Rituximab,DRUG,1,1,18 Years,66 Years,ALL,False,Haukeland University Hospital,OTHER,0,1,Norway,0.0,0,1,0,0,0,2.0,0,0,0,0,2,2.1972245773362196,small,1,1,0,1,0,0,0,0,0,0,0,0,1,0,2,1,1,0,0,1,0,2010-06-01,2016-04-01,2131.0,2010.0,0,1,0
NCT00387322,Pemetrexed Disodium and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors,"Phase I/II Study of Two Different Schedules of Pemetrexed (ALIMTA) and Erlotinib (TARCEVA) in Advanced Solid Tumors, With Emphasis on Non-Small Cell Lung Cancer (NSCLC)",COMPLETED,2005-03,2009-05,2010-03-29,INTERVENTIONAL,PHASE1|PHASE2,42.0,ACTUAL,NON_RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Lung Cancer|Unspecified Adult Solid Tumor, Protocol Specific",erlotinib hydrochloride|pemetrexed disodium,DRUG,2,6,18 Years,,ALL,False,"University of California, Davis",OTHER,1,1,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,2,3.7612001156935624,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,8,1,1,0,0,2,1,2005-03-01,2009-05-01,1522.0,2005.0,0,4,1
NCT04193722,The Effect of Hyperbaric OxygeN Therapy on brEast Cancer Patients With Late Radiation toxicitY - UMBRELLA HONEY Trial,The Effect of Hyperbaric Oxygen Therapy on Breast Cancer Patients With Late Radiation Toxicity,COMPLETED,2019-08-28,2023-05-08,2025-04-03,INTERVENTIONAL,PHASE3,189.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Breast Cancer|Radiation Toxicity,Hyperbaric oxygen therapy,DRUG,1,7,18 Years,,FEMALE,False,UMC Utrecht,OTHER,0,1,Netherlands,1.0,0,0,1,0,0,3.0,1,0,0,0,2,5.247024072160486,medium,0,1,0,1,0,0,0,0,0,0,1,0,1,1,8,1,1,0,0,1,0,,,,,0,2,0
NCT03921151,5HT2CR Balance in Brain Connectivity in Cocaine Dependence,5-HT2AR: 5HT2CR Balance in Brain Connectivity in Cocaine Dependence,COMPLETED,2014-05-13,2019-01-24,2021-11-22,INTERVENTIONAL,PHASE1|PHASE2,90.0,ACTUAL,NON_RANDOMIZED,PARALLEL,BASIC_SCIENCE,TRIPLE,Cocaine Dependence,Mirtazapine 15 MG Oral Tablet,DRUG,1,1,18 Years,60 Years,ALL,True,Virginia Commonwealth University,OTHER,2,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,4.51085950651685,medium,1,1,0,1,0,1,0,0,1,0,0,1,0,1,2,1,1,0,0,1,0,,,,,0,1,0
NCT02678351,68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery,68Ga-PSMA-11 PET/MRI for Detection of Regional Nodal and Distant Metastases in Patients With Intermediate and High-Risk Prostate Cancer,COMPLETED,2016-04-18,2021-12,2022-03-04,INTERVENTIONAL,PHASE2|PHASE3,74.0,ACTUAL,,SINGLE_GROUP,DIAGNOSTIC,NONE,Stage II Prostate Adenocarcinoma|Stage III Prostate Adenocarcinoma,68Ga-PSMA-11|Magnetic resonance imaging (MRI)|Positron Emission Tomography (PET),DRUG|PROCEDURE,1,3,18 Years,,MALE,False,Andrei Iagaru,OTHER,1,1,United States,1.0,0,1,1,0,1,2.5,1,0,0,0,2,4.31748811353631,medium,1,1,0,1,0,1,0,0,1,0,0,0,0,0,4,1,1,0,0,3,1,,2021-12-01,,,0,3,1
NCT00265551,Study Evaluating SCA-136 in Subjects With Acute Exacerbations of Schizophrenia,"A Randomized, Double-Blind, Placebo-Controlled, Olanzapine-Referenced, Parallel Group Safety, Efficacy, and Tolerability Study of SCA-136 in Subjects With Acute Exacerbations of Schizophrenia",COMPLETED,2006-01,2007-01,2007-12-10,INTERVENTIONAL,PHASE2,300.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Schizophrenia,SCA-136 (200 mg)|SCA-136 (400 mg)|olanzapine (15 mg)|placebo,DRUG,1,9,18 Years,65 Years,ALL,False,Wyeth is now a wholly owned subsidiary of Pfizer,INDUSTRY,0,35,United States,1.0,0,1,0,0,0,2.0,0,0,1,0,1,5.707110264748875,large,0,0,1,0,1,0,1,0,1,0,1,1,1,1,10,1,1,0,0,4,1,2006-01-01,2007-01-01,365.0,2006.0,0,2,0
NCT00303251,Safety of TKI258 in Advanced/Metastatic Melanoma Subjects,"A Phase I/II Dose Escalating Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of TKI258 (CHIR-258) in Patients With Locally Advanced or Metastatic Melanoma",COMPLETED,2006-04,,2021-03-11,INTERVENTIONAL,PHASE1|PHASE2,47.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Melanoma,TKI258,DRUG,3,5,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,3,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,1,3.871201010907891,small,1,1,1,0,1,0,1,0,1,0,0,0,1,0,8,1,1,0,0,1,0,2006-04-01,,,2006.0,0,2,0
NCT01455051,Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation,Ofatumumab as Part of the Reduced Intensity Conditioning Regimen for Patients With High Risk Chronic Lymphocytic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation: a Pilot Study by GETH and GELLC,COMPLETED,2011-10,2017-10,2022-05-06,INTERVENTIONAL,PHASE2,25.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Chronic Lymphocytic Leukemia,Ofatumumab,DRUG,1,6,18 Years,70 Years,ALL,False,Grupo Espanol de trasplantes hematopoyeticos y terapia celular,OTHER,1,9,Spain,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.258096538021482,small,1,1,0,1,0,1,1,0,0,1,0,0,1,0,7,1,1,0,0,1,0,2011-10-01,2017-10-01,2192.0,2011.0,0,1,0
NCT05496231,A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age,"A Phase 1/2 Randomized, Observer-blinded, Multi-country Study to Evaluate Safety and Immunogenicity of Investigational Adjuvanted Human Papillomavirus Vaccine in Females (16 to 26 Years of Age)",COMPLETED,2022-08-22,2024-02-25,2025-02-03,INTERVENTIONAL,PHASE1|PHASE2,1080.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Cervical Intraepithelial Neoplasia,HPV9 High formulation|HPV9 Medium formulation|HPV9 Low formulation|Gardasil 9,BIOLOGICAL,14,12,16 Years,26 Years,FEMALE,True,GlaxoSmithKline,INDUSTRY,0,68,Bulgaria|United States|Germany|Lithuania|Poland|Estonia|Czechia|France,1.0,1,1,0,0,1,1.5,0,0,0,0,1,6.985641817639208,xlarge,0,1,1,0,0,0,1,1,1,1,1,1,0,1,26,1,0,1,0,4,1,,,,,0,4,1
NCT02287831,Umbilical Cord Mesenchymal Stem Cells Injection for Peripheral Arterial Disease,Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Injection for Peripheral Arterial Disease,COMPLETED,2014-02,2022-12-26,2023-02-08,INTERVENTIONAL,PHASE1|PHASE2,28.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Peripheral Arterial Disease,umbilical cord mesenchymal stem cells,BIOLOGICAL,1,1,18 Years,75 Years,ALL,False,"Institute of Hematology & Blood Diseases Hospital, China",OTHER,0,0,,1.0,1,1,0,0,1,1.5,0,0,0,0,1,3.367295829986474,small,1,1,0,1,0,0,0,0,0,0,0,0,1,0,2,1,0,1,0,1,0,2014-02-01,,,2014.0,0,1,0
NCT00878631,Feasibility Trial of Traumatic Brain Injured Patients Randomized in the Prehospital Setting to Either Hypertonic Saline and Dextran Versus Normal Saline,The Toronto Prehospital Hypertonic Resuscitation Head Injury and Multi Organ Dysfunction Trial,COMPLETED,2004-09,2008-12,2009-04-09,INTERVENTIONAL,PHASE2|PHASE3,113.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Brain Injuries,hypertonic saline mixed with dextran|Normal Saline,DRUG,4,4,16 Years,,ALL,False,Unity Health Toronto,OTHER,2,2,Canada,1.0,0,1,1,0,1,2.5,0,0,0,0,1,4.736198448394496,medium,0,1,0,1,0,1,1,0,0,0,1,1,1,1,8,1,1,0,0,2,1,2004-09-01,2008-12-01,1552.0,2004.0,0,3,1
NCT02586831,Diabetes Islet Preservation Immune Treatment,"A Pilot, Safety and Feasibility Trial of Anti-Thymocyte Globulin (ATG), Low Dose Interleukin-2 (IL-2), Adalimumab and Exenatide in the Treatment of New-Onset Type 1 Diabetes",WITHDRAWN,2024-06-01,2024-06-01,2026-01-15,INTERVENTIONAL,PHASE1|PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,"Diabetes Mellitus, Type 1|Hypoglycemia|Autoimmune Diseases|Diabetes Mellitus",Anti-Thymocyte Globulin (ATG)|Interleukin 2|Exenatide|Adalimumab|ATG Placebo|IL-2 Placebo|Adalimumab Placebo|Exenatide Placebo,DRUG|OTHER,2,4,18 Years,35 Years,ALL,False,Camillo Ricordi and Jay Skyler,OTHER,1,0,,0.0,1,1,0,0,1,1.5,0,1,0,0,4,0.0,,1,1,0,1,0,1,0,0,0,0,1,1,1,1,6,1,1,0,0,8,1,,,,,0,4,1
NCT01626131,Exercise: A Novel Treatment for Combat Post Traumatic Stress Disorder,Exercise: A Novel Treatment for Combat PTSD,TERMINATED,2011-10,2013-01,2013-04-26,INTERVENTIONAL,PHASE2,11.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Post-Traumatic Stress Disorder,exercise training|Stretching training,BEHAVIORAL,1,2,18 Years,65 Years,ALL,False,"INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium",OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,2.4849066497880004,small,1,1,0,1,0,1,0,0,1,0,1,0,1,1,3,1,0,0,0,2,1,2011-10-01,2013-01-01,458.0,2011.0,0,1,0
NCT03742531,Does Induction Dosage in Latent Phase Affect Active Phase of Labor?,Does Induction Dosage in Latent Phase Affect Active Phase of Labor?A Randomized Study,COMPLETED,2018-12-15,2019-12-01,2021-01-20,INTERVENTIONAL,PHASE2,300.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Oxytocin|Induction of Labor,oxytocin,DRUG,1,4,18 Years,40 Years,FEMALE,True,Zeynep Kamil Maternity and Pediatric Research and Training Hospital,OTHER,0,1,Turkey (Türkiye),1.0,0,1,0,0,0,2.0,0,0,0,0,2,5.707110264748875,large,0,1,0,1,0,0,0,0,0,0,1,0,1,1,5,1,1,0,0,1,0,,,,,0,1,0
NCT01385202,THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation,THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation,COMPLETED,2011-06,2013-05,2025-02-04,INTERVENTIONAL,PHASE3,172.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Heart Diseases|Arrhythmia|Atrial Fibrillation,THERMOCOOL® SMARTTOUCH™ Catheter,DEVICE,2,1,18 Years,,ALL,False,"Biosense Webster, Inc.",INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,1,3,5.153291594497779,medium,0,1,1,0,0,0,0,0,0,0,0,0,1,0,3,1,0,0,1,1,0,2011-06-01,2013-05-01,700.0,2011.0,0,1,0
NCT01138202,Pharmacokinetics (PK) and Safety of 2 Different Doses of Lopinavir/Ritonavir in in HIV/Tuberculosis (TB) Co-infected Patients Receiving Rifampicin Containing Anti-tuberculosis Therapy,A Pilot Study of the Pharmacokinetics and Safety of Lopinavir/Ritonavir 400/100mg Bid Versus Lopinavir/Ritonavir 600/150 mg BID Combined With Nucleoside Analogue Reverse Transcriptase Inhibitors in HIV/TB Co-infected Patients Receiving Rifampicin Containing Anti-tuberculosis Therapy,COMPLETED,2010-11,2015-12,2020-07-17,INTERVENTIONAL,PHASE2,40.0,ACTUAL,NON_RANDOMIZED,FACTORIAL,OTHER,NONE,HIV Infections|Tuberculosis,LPV/r,DRUG,1,4,18 Years,60 Years,ALL,False,The HIV Netherlands Australia Thailand Research Collaboration,OTHER,1,1,Thailand,1.0,0,1,0,0,0,2.0,0,0,0,0,2,3.713572066704308,small,1,1,0,1,0,1,0,0,0,0,0,0,0,0,5,1,1,0,0,1,0,2010-11-01,2015-12-01,1856.0,2010.0,0,1,0
NCT02773368,A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus,A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus. DUALTM IX - Add-on to SGLT2i,COMPLETED,2016-05-23,2017-10-23,2020-08-11,INTERVENTIONAL,PHASE3,420.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes|Diabetes Mellitus, Type 2",insulin degludec/liraglutide|insulin glargine,DRUG,1,32,18 Years,,ALL,False,Novo Nordisk A/S,INDUSTRY,0,88,Russia|Argentina|Finland|Hungary|India|United States|Spain|Slovakia|Switzerland|Slovenia|Canada,1.0,0,0,1,0,0,3.0,0,0,0,0,2,6.042632833682381,large,0,1,1,0,0,0,1,1,1,1,1,0,1,1,33,1,1,0,0,2,1,,,,,0,4,1
NCT03760068,Mylan Insulin Aspart Study,"A Randomized, Multicenter, Open-Label, Parallel-Group Clinical Study Comparing the Safety and Efficacy of MYL-1601D With NovoLog® in Type 1 Diabetes Mellitus Patients",COMPLETED,2018-11-07,2020-01-17,2022-02-25,INTERVENTIONAL,PHASE3,478.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 1",MYL-1601D Product|FlexPen NovoLog®,DRUG,1,6,18 Years,65 Years,ALL,False,Mylan Inc.,INDUSTRY,1,158,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.171700597410915,large,0,1,1,0,0,1,1,0,1,0,1,0,1,1,7,1,1,0,0,2,1,,,,,0,2,0
NCT00824850,Study Evaluating Prevnar Infant Long-term Immune Response Versus Prevnar Naive Cohort,Characterization of the Prevnar Infant Long-term Immune Response vs a Prevnar Naive Cohort,COMPLETED,2010-01,2010-09,2011-11-11,INTERVENTIONAL,PHASE2,75.0,ACTUAL,NON_RANDOMIZED,PARALLEL,BASIC_SCIENCE,NONE,Pneumococcal Conjugate Vaccine,13-valent Pneumococcal Conjugate Vaccine|13-valent Pneumococcal Conjugate Vaccine,BIOLOGICAL,6,12,8 Years,16 Years,ALL,True,Pfizer,INDUSTRY,0,2,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.330733340286331,medium,1,1,1,0,1,0,1,0,1,0,0,0,0,1,18,1,0,1,0,2,1,2010-01-01,2010-09-01,243.0,2010.0,0,2,0
NCT01149174,Preoperative Intravesical Electromotive Mitomycin-c for Primary Non-muscle Invasive Bladder Cancer,Single Preoperative Intravesical Instillation of Electromotive Mitomycin-c for Primary Non-muscle Invasive Bladder Cancer: a Prospective Randomized Trial.,COMPLETED,1994-01,2009-06,2011-10-04,INTERVENTIONAL,PHASE3,352.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,SINGLE,Superficial Bladder Cancer,Mitomycin-C 40 mg,DRUG,1,1,18 Years,90 Years,ALL,False,University of Rome Tor Vergata,OTHER,0,1,Italy,1.0,0,0,1,0,0,3.0,1,0,0,0,1,5.8664680569332965,large,0,1,0,1,0,0,0,0,0,1,1,0,0,1,2,1,1,0,0,1,0,1994-01-01,2009-06-01,5630.0,1994.0,0,0,0
NCT05900674,Endovascular Stroke Treatment And Reteplase Protocol,Endovascular Stroke Treatment And Reteplase Protocol,WITHDRAWN,2023-07,2024-07,2024-04-09,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Ischemic Stroke,Reteplase Injection,DRUG,3,1,18 Years,90 Years,ALL,False,Zeenat Qureshi Stroke Institute,OTHER,0,0,,0.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,1,1,0,1,0,0,0,0,0,0,1,0,1,1,4,1,1,0,0,1,0,2023-07-01,2024-07-01,366.0,2023.0,1,0,0
NCT01705574,"Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women","A Randomized, Double-blind Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Women",COMPLETED,2012-10-24,2018-09-06,2019-09-20,INTERVENTIONAL,PHASE3,583.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Acquired Immunodeficiency Syndrome|HIV Infections,E/C/F/TDF|ATV|RTV|FTC/TDF|E/C/F/TDF Placebo|ATV Placebo|RTV Placebo|FTC/TDF Placebo|E/C/F/TAF,DRUG,1,4,18 Years,,FEMALE,False,Gilead Sciences,INDUSTRY,0,99,Italy|Belgium|Russia|Puerto Rico|United States|United Kingdom|Dominican Republic|Mexico|Portugal|France|Uganda|Thailand,1.0,0,0,1,0,0,3.0,0,0,0,0,2,6.369900982828227,xlarge,0,1,1,0,1,0,1,1,1,1,1,1,1,1,5,1,1,0,0,9,1,,,,,0,3,1
NCT00619918,Nebulized Hypertonic Saline for Bronchiolitis,Nebulized Hypertonic Saline for Treatment of Viral Bronchiolitis,COMPLETED,2008-02,2011-05,2024-11-05,INTERVENTIONAL,PHASE2|PHASE3,447.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Bronchiolitis,Nebulized 3% saline|Nebulized 0.9% saline,DRUG,3,3,,24 Months,ALL,False,Children's Hospital Los Angeles,OTHER,2,2,United States,1.0,0,1,1,0,1,2.5,0,0,0,0,1,6.104793232414985,large,0,1,0,1,0,1,1,0,1,0,1,1,1,1,6,1,1,0,0,2,1,2008-02-01,2011-05-01,1185.0,2008.0,0,3,1
NCT02644018,Efficacy and Safety Study of Ingavirin® to Treat Influenza and Other Acute Respiratory Viral Infections in Patients 3-6 y.o.,"Double Blind Randomized Placebo-controlled Multicenter Study to Evaluate Clinical Efficacy and Safety of Ingavirin®, Capsules 30 mg, in 3-6 Years Old Patients With Influenza and Other Acute Respiratory Viral Infections in the Course of Standard Therapy",COMPLETED,2016-01,2016-05,2016-06-09,INTERVENTIONAL,PHASE3,190.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Common Cold|Influenza,Imidazolyl ethanamide pentandioic acid|placebo,DRUG,1,11,3 Years,6 Years,ALL,False,Valenta Pharm JSC,INDUSTRY,1,13,Russia,1.0,0,0,1,0,0,3.0,0,0,0,0,2,5.25227342804663,medium,0,1,1,0,0,1,1,0,0,0,1,1,1,1,12,1,1,0,0,2,1,2016-01-01,2016-05-01,121.0,2016.0,1,3,1
NCT00921518,Prevention of Acute Kidney Injury in Cardiac Surgery Patients,Prevention of Acute Kidney Injury in Cardiac Surgery Patients,COMPLETED,2009-01,2012-01,2014-04-15,INTERVENTIONAL,PHASE2,92.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Kidney Injury,0.9% Sodium Chloride (Placebo)|Sodium Bicarbonate,DRUG,1,0,18 Years,,ALL,False,"Community Medical Center, Scranton, PA",OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.532599493153256,medium,1,1,0,1,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,2,1,2009-01-01,2012-01-01,1095.0,2009.0,0,1,0
NCT00709618,"Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects","A Phase II, Single-Arm, Multi-Center Study Evaluating the Combination of Vinorelbine and Lapatinib in Women With ErbB2 Overexpressing Metastatic Breast Cancer",TERMINATED,2008-06,2012-05,2014-07-14,INTERVENTIONAL,PHASE2,44.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,"Neoplasms, Breast","Lapatinib, Vinorelbine",DRUG,1,6,18 Years,,FEMALE,False,GlaxoSmithKline,INDUSTRY,0,22,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,3.8066624897703196,small,1,1,1,0,0,0,1,0,1,0,0,0,1,0,7,1,1,0,0,1,0,2008-06-01,2012-05-01,1430.0,2008.0,0,1,0
NCT04407390,Effects of Nicotinamide Riboside on the Clinical Outcome of Covid-19 in the Elderly,"Effects of Nicotinamide Riboside on the Clinical Outcome of Covid-19 in the Elderly. A Randomized Double-blind, Placebo-controlled Trial of Nicotinamide Riboside NR-COVID19",WITHDRAWN,2020-06-01,2022-05-01,2022-09-22,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,COVID,Nicotinamide riboside|Placebo,DIETARY_SUPPLEMENT,4,20,70 Years,,ALL,False,University of Copenhagen,OTHER,2,1,Denmark,0.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,1,1,0,1,0,1,0,0,0,0,1,1,1,1,24,1,0,0,0,2,1,,,,,0,2,0
NCT03401190,CM4620 Injectable Emulsion Versus Supportive Care in Patients With Acute Pancreatitis and SIRS,"An Open-Label, Dose-Response Study of CM4620 Injectable Emulsion (CM4620-IE) in Patients With Acute Pancreatitis and Accompanying Systemic Inflammatory Response Syndrome (SIRS)",COMPLETED,2018-03-12,2019-04-30,2021-12-07,INTERVENTIONAL,PHASE2,21.0,ACTUAL,RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,Acute Pancreatitis|Systemic Inflammatory Response Syndrome,CM4620 Injectable Emulsion (Low Dose)|CM4620 Injectable Emulsion (High Dose),DRUG,1,6,18 Years,,ALL,False,"CalciMedica, Inc.",INDUSTRY,0,9,United States,1.0,0,1,0,0,0,2.0,0,1,0,0,2,3.091042453358316,small,1,1,1,0,0,0,1,0,1,0,1,0,1,0,7,1,1,0,0,2,1,,,,,0,3,1
NCT05865990,HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease,"Multicenter, Single-arm, 3 Cohort, Phase II Trial of HER3-DXd in Patients With Active Brain Metastases From Metastatic Breast Cancer and Non-small Cell Lung Cancer, and in Patients With Leptomeningeal Disease From Advanced Solid Tumors",ACTIVE_NOT_RECRUITING,2023-11-24,2026-10,2024-09-19,INTERVENTIONAL,PHASE2,63.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Metastatic Breast Cancer|Advanced Non-Small Cell Squamous Lung Cancer|Solid Tumor, Adult",Patritumab deruxtecan,DRUG,2,13,18 Years,,ALL,False,MedSIR,OTHER,1,8,Austria|Spain,,0,1,0,0,0,2.0,1,0,0,0,3,4.1588830833596715,medium,1,1,0,1,0,1,1,1,0,1,0,0,1,0,15,1,1,0,0,1,0,,2026-10-01,,,0,3,1
NCT01879410,A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD),"DB2114951: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy Umeclidinium/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With COPD",COMPLETED,2013-06-13,2014-01-09,2017-11-08,INTERVENTIONAL,PHASE3,700.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Pulmonary Disease, Chronic Obstructive",UMEC/VI Inhalation Powder 62.5/25 mcg via NDPI|FSC Inhalation Powder 250/50 mcg via ACCUHALER/DISKUS|Placebo DISKUS|Placebo NDPI,DRUG,1,1,40 Years,,ALL,False,GlaxoSmithKline,INDUSTRY,0,72,Russia|United States|Romania|Norway|Chile|Mexico|South Africa,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.55250788703459,xlarge,0,1,1,0,0,0,1,1,1,0,1,1,1,1,2,1,1,0,0,4,1,,,,,0,2,0
NCT01069510,Spironolactone in Adult Congenital Heart Disease,Heart Failure in Congenital Heart Disease: the Role of Myocardial Fibrosis. Treatment Sub-Study: Spironolactone vs. Placebo,COMPLETED,2010-02,2017-03,2019-08-21,INTERVENTIONAL,PHASE2,40.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Congenital Heart Disease|Heart Failure|Endomyocardial Fibrosis,Spironolactone 25mg|Placebo,DRUG|OTHER,1,2,18 Years,80 Years,ALL,False,Oregon Health and Science University,OTHER,2,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,1,3,3.713572066704308,small,1,1,0,1,0,1,0,0,1,0,1,1,1,1,3,1,1,0,0,2,1,2010-02-01,2017-03-01,2585.0,2010.0,0,2,0
NCT00730210,Treatment of Hypoparathyroidism With Subcutaneous PTH (1-84) Injections: Effects on Muscle Function and Quality of Life,Treatment of Hypoparathyroidism With Subcutaneous PTH (1-84) Injections: Effects on Muscle Function and Quality of Life,COMPLETED,2008-06,2010-08,2012-10-24,INTERVENTIONAL,PHASE2,62.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Hypoparathyroidism,a: PTH (1-84)|b:placebo,DRUG,1,8,25 Years,80 Years,ALL,False,University of Aarhus,OTHER,0,1,Denmark,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.143134726391533,medium,1,1,0,1,0,0,0,0,0,0,1,1,1,1,9,1,1,0,0,2,1,2008-06-01,2010-08-01,791.0,2008.0,0,2,0
NCT00640510,A Study Comparing Rapid Acting Intramuscular Olanzapine and Placebo in Agitated Patients With Schizophrenia,"A Placebo-Controlled, Double-Blind Confirmatory Study of Rapid-Acting Intramuscular Olanzapine in Agitated Patients With Schizophrenia",COMPLETED,2008-03,2008-07,2009-09-02,INTERVENTIONAL,PHASE3,34.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Schizophrenia,Rapid Acting Intramuscular Olanzapine|Isotonic sodium chloride solution,DRUG,1,3,20 Years,64 Years,ALL,False,Eli Lilly and Company,INDUSTRY,0,11,Japan,1.0,0,0,1,0,0,3.0,0,0,1,0,1,3.5553480614894135,small,1,1,1,0,1,0,1,0,0,0,1,1,1,1,4,1,1,0,0,2,1,2008-03-01,2008-07-01,122.0,2008.0,0,1,0
NCT00600210,"Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer","AVF3963s Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer",WITHDRAWN,2008-01,2011-04,2017-08-23,INTERVENTIONAL,PHASE2,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Cervical Cancer,Bevacizumab|Carboplatin|Radiation Therapy,DRUG|RADIATION,1,1,18 Years,,ALL,False,Leo W. Jenkins Cancer Center,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,0.0,,1,1,0,1,0,1,0,0,1,0,0,0,1,0,2,1,1,0,0,3,1,2008-01-01,2011-04-01,1186.0,2008.0,0,1,0
NCT05611710,Anakinra in Dengue With Hyperinflammation ( AnaDen ),Anakinra for Dengue Patients With Hyperinflammation - a Randomized Double-blind Placebo-controlled Trial,ACTIVE_NOT_RECRUITING,2023-01-02,2027-12-31,2026-01-06,INTERVENTIONAL,PHASE2,160.0,ESTIMATED,RANDOMIZED,SEQUENTIAL,TREATMENT,DOUBLE,Dengue|Dengue With Warning Signs|Severe Dengue|Anakinra|Immuno-modulation|Anti-inflammatory Agents|Macrophage Activation Syndrome|Hyperinflammatory Syndrome|Cytokine Storm,Placebo|Anakinra,DRUG,1,17,12 Years,,ALL,False,"Oxford University Clinical Research Unit, Vietnam",OTHER,2,1,Vietnam,,0,1,0,0,0,2.0,0,1,0,0,9,5.081404364984463,medium,0,0,0,1,0,1,0,0,0,0,1,1,1,0,18,1,1,0,0,2,1,,,,,0,3,1
NCT04383210,Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors,CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients With Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors,TERMINATED,2020-09-29,2024-02-28,2025-04-03,INTERVENTIONAL,PHASE2,54.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Locally Advanced Solid Tumor|Metastatic Solid Tumor|Pancreatic Cancer|Lung Cancer|Head and Neck Cancer|Breast Cancer|Kidney Cancer|Colorectal Cancer|Bladder Cancer|Ovarian Cancer|Sarcoma|Gallbladder Cancer|Bile Duct Cancer|Esophageal Cancer|Uterine Cancer|Cholangiocarcinoma|Prostate Cancer,Seribantumab,DRUG,1,0,18 Years,,ALL,False,Elevation Oncology,INDUSTRY,0,42,Canada|Australia|South Korea|United States,0.0,0,1,0,0,0,2.0,1,0,0,0,17,4.007333185232471,medium,1,1,1,0,0,0,1,1,1,0,0,0,1,1,1,0,1,0,0,1,0,,,,,0,2,0
NCT04517110,Perioperative Pregabalin for Reducing Opioid Consumption After Cardiac Surgery,Peri-Operative Pregabalin for Reducing opIoid Consumption AfTer Cardiac surgEry: A Randomized Trial,TERMINATED,2021-04-09,2022-09-07,2022-09-10,INTERVENTIONAL,PHASE3,17.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Opioid Use,Pregabalin 300 mg|Pregabalin 75 mg|Pregabalin 300 mg Placebo|Pregabalin 75 mg Placebo|Usual Care,DRUG|OTHER,2,11,18 Years,,ALL,False,Hamilton Health Sciences Corporation,OTHER,1,1,Canada,0.0,0,0,1,0,0,3.0,0,0,0,0,1,2.8903717578961645,small,1,1,0,1,0,1,0,0,0,0,1,1,1,1,13,1,1,0,0,5,1,,,,,0,2,0
NCT02150213,Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492,A Multicenter Medical Safety Follow-up Study for Patients With Partial Onset Seizures Who Received More Than 28 Days of Total Exposure to BGG492 in Studies CBGG492A2207 and/or CBGG492A2212,COMPLETED,2014-08,2015-09,2016-12-05,INTERVENTIONAL,PHASE2,59.0,ACTUAL,,SINGLE_GROUP,,NONE,Adrenocortical Adenoma|Endometrial Stromal Sarcomas,"MRI, CT or ultrasound was permitted if MRI was contraindicated|Dexamethasone Supression Test|Sonogram|Biopsy|BGG492",DRUG|PROCEDURE,2,0,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,20,Italy|Hungary|South Korea|United States|Germany|Slovakia,1.0,0,1,0,0,0,2.0,1,0,0,0,2,4.0943445622221,medium,1,1,1,0,1,0,1,1,1,1,0,0,0,0,2,0,1,0,0,5,1,2014-08-01,2015-09-01,396.0,2014.0,0,3,1
NCT01753713,Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma,Phase II Study of TKI258 (Dovitinib) in Patients With Recurrent or Progressive Glioblastoma Who Have Progressed With or Without Anti-Angiogenic Therapy (Including Anti-VEGF Therapy),COMPLETED,2012-12-20,2017-09-20,2017-12-12,INTERVENTIONAL,PHASE2,33.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor,dovitinib|laboratory biomarker analysis,DRUG|OTHER,2,4,18 Years,,ALL,False,"Manmeet Ahluwalia, MD",OTHER,2,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,4,3.5263605246161616,small,1,1,0,1,0,1,0,0,1,0,0,0,1,1,6,1,1,0,0,2,1,,,,,0,3,1
NCT00490113,A Trial of Pyridoxamine to Lower Urine Oxalate in Subjects With Stone Disease or Hyperoxaluria,Effects of Pyridoxamine on Oxalate Excretion in Stone Disease and Hyperoxaluria,WITHDRAWN,2007-01,,2017-01-05,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,TRIPLE,Kidney Stones,Pyridoxamine,DRUG,1,1,18 Years,,ALL,False,University of Kansas Medical Center,OTHER,1,0,,0.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,1,1,0,1,0,1,0,0,0,0,1,1,1,0,2,1,1,0,0,1,0,2007-01-01,,,2007.0,0,0,0
NCT05760313,A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide,A Phase 2 Dose Finding Study Evaluating the Safety and Efficacy of Linaclotide in Pediatric Subjects 6 Months to Less Than 2 Years of Age With Functional Constipation (FC).,COMPLETED,2023-04-27,2025-06-09,2026-01-06,INTERVENTIONAL,PHASE2,19.0,ACTUAL,RANDOMIZED,SEQUENTIAL,TREATMENT,QUADRUPLE,Functional Constipation,Linaclotide|Placebo,DRUG,4,0,6 Months,23 Months,ALL,False,AbbVie,INDUSTRY,1,38,Bulgaria|Hungary|United States|Croatia|Germany|United Kingdom|Serbia,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.995732273553991,small,1,1,1,0,1,1,1,1,1,1,1,1,1,0,4,0,1,0,0,2,1,,,,,0,2,0
NCT02513160,Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 6-Week Clinical Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) at 320 or 640 mcg/Day in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma",COMPLETED,2015-09-30,2016-03-31,2021-11-09,INTERVENTIONAL,PHASE3,713.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Persistent Asthma,Beclomethasone Dipropionate 640|Placebo|Beclomethasone dipropionate via 320 mcg BAI|albuterol/salbutamol|Beclomethasone dipropionate via 320 mcg MDI,DRUG,1,6,12 Years,,ALL,False,"Teva Branded Pharmaceutical Products R&D, Inc.",INDUSTRY,0,75,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.570882962339584,xlarge,0,1,1,0,0,0,1,0,1,0,1,1,1,1,7,1,1,0,0,5,1,,,,,0,2,0
NCT00821860,Video-Assisted Surgery or Talc Pleurodesis in Treating Patients With Malignant Mesothelioma,Prospective Randomised Controlled Trial of Video-Assisted Thoracoscopic (VAT) Cytoreductive Pleurectomy Compared to Talc Pleurodesis in Patients With Suspected or Proven Malignant Mesothelioma,COMPLETED,2003-09,2013-05,2013-06-28,INTERVENTIONAL,PHASE3,196.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Malignant Mesothelioma|Metastatic Cancer,talc|therapeutic thoracoscopy|therapeutic videothoracoscopy,OTHER|PROCEDURE,1,6,18 Years,,ALL,False,Papworth Hospital NHS Foundation Trust,OTHER_GOV,0,5,United Kingdom,1.0,0,0,1,0,0,3.0,1,0,0,0,2,5.2832037287379885,medium,0,1,0,1,0,0,1,0,0,1,1,0,1,1,7,1,0,0,0,3,1,2003-09-01,2013-05-01,3530.0,2003.0,0,3,1
NCT00978120,Safety and Efficacy of an H1N1 Influenza Vaccine in People With Asthma,A Phase II Study in Patients With Asthma to Assess the Safety and Immunogenicity of an Unadjuvanted Novartis H1N1 Influenza Vaccine Administered at Two Dose Levels,COMPLETED,2009-10,2010-09,2012-08-10,INTERVENTIONAL,PHASE2,390.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,H1N1 Influenza Virus,H1N1 vaccine high dose|H1N1 vaccine low dose,BIOLOGICAL,13,4,12 Years,,ALL,False,National Institute of Allergy and Infectious Diseases (NIAID),NIH,1,7,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.968707559985366,large,0,1,0,1,0,1,1,0,1,0,1,0,0,1,17,1,0,1,0,2,1,2009-10-01,2010-09-01,335.0,2009.0,0,2,0
NCT00678782,Evaluation of The Efficacy And Safety of Intra-Articular Etanercept in Patients With Refractory Knee Joint Synovitis,"Evaluation of The Efficacy And Safety of Intra-Articular Etanercept in Patients With Refractory Knee Joint Synovitis: a Placebo Controlled, Single-Blind, Crossover-Trial, With Randomisation of Treatment Sequence",COMPLETED,2005-04,2007-12,2008-05-16,INTERVENTIONAL,PHASE2,31.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,SINGLE,Persistent Knee Joint Synovitis,etanercept|placebo,DRUG,1,1,18 Years,,ALL,False,University of Padova,OTHER,2,1,Italy,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.4657359027997265,small,1,1,0,1,0,1,0,0,0,1,1,0,1,0,2,1,1,0,0,2,1,2005-04-01,2007-12-01,974.0,2005.0,0,1,0
NCT03208582,Do Bisphosphonates Alter the Skeletal Response to Mechanical Stimulation in Children With Osteogenesis Imperfecta?,Do Bisphosphonates Alter the Skeletal Response to Mechanical Stimulation in Children With Osteogenesis Imperfecta?,COMPLETED,2017-04-01,2017-11-02,2018-09-07,INTERVENTIONAL,PHASE2,13.0,ACTUAL,,SINGLE_GROUP,BASIC_SCIENCE,NONE,Osteogenesis Imperfecta,Risedronate Sodium|Calcichew tablets,DRUG|DIETARY_SUPPLEMENT,1,0,4 Years,16 Years,ALL,False,Sheffield Children's NHS Foundation Trust,OTHER,0,1,United Kingdom,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.6390573296152584,small,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,2,1,,,,,0,1,0
NCT04526782,ENCOrafenib With Binimetinib in bRAF NSCLC,A Phase II Study of the BRAF Inhibitor Encorafenib in Combination With the MEK Inhibitor Binimetinib in Patients With BRAFV600E-mutant Metastatic Non-small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,2021-01-19,2026-03,2025-11-18,INTERVENTIONAL,PHASE2,119.0,ESTIMATED,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Non Small Cell Lung Cancer|BRAF V600E,Encorafenib 75 MG|Binimetinib 15 MG,DRUG,1,4,18 Years,,ALL,False,Intergroupe Francophone de Cancerologie Thoracique,OTHER,0,36,France,,0,1,0,0,0,2.0,1,0,0,0,2,4.787491742782046,medium,0,0,0,1,0,0,1,0,0,1,0,0,1,1,5,1,1,0,0,2,1,,2026-03-01,,,0,2,0
NCT00211224,Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS),Phase 3 Study of Riluzole in Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP) (Parkinson's Plus Syndromes),TERMINATED,2000-04,2004-11,2005-12-15,INTERVENTIONAL,PHASE3,800.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Multiple System Atrophy|Progressive Supranuclear Palsy,Riluzole,DRUG,1,3,30 Years,80 Years,ALL,False,King's College London,OTHER,3,1,United Kingdom,0.0,0,0,1,0,0,3.0,0,0,0,0,2,6.68586094706836,xlarge,0,0,0,1,0,1,0,0,0,1,1,1,1,1,4,1,1,0,0,1,0,2000-04-01,2004-11-01,1675.0,2000.0,0,1,0
NCT04602624,A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD),An Open-Label Evaluation of the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease,COMPLETED,2020-12-07,2021-09-28,2025-09-15,INTERVENTIONAL,PHASE2,26.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Alzheimer Disease|Cognitive Dysfunction|Mild Dementia,SAGE-718,DRUG,1,4,50 Years,80 Years,ALL,False,"Supernus Pharmaceuticals, Inc.",INDUSTRY,0,10,United States,1.0,0,1,0,0,0,2.0,0,0,1,0,3,3.295836866004329,small,1,1,1,0,0,0,1,0,1,0,0,0,1,0,5,1,1,0,0,1,0,,,,,0,1,0
NCT02235324,"Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer",Phase II Study of Ziv-Aflibercept Followed by the Addition of 5-FU in the Third Line Setting of Metastatic Colorectal Cancer,WITHDRAWN,2015-03,2018-03,2015-05-06,INTERVENTIONAL,PHASE2,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Mucinous Adenocarcinoma of the Colon|Mucinous Adenocarcinoma of the Rectum|Recurrent Colon Cancer|Recurrent Rectal Cancer|Signet Ring Adenocarcinoma of the Colon|Signet Ring Adenocarcinoma of the Rectum|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer,ziv-aflibercept|leucovorin calcium|fluorouracil|laboratory biomarker analysis,DRUG|BIOLOGICAL|OTHER,2,3,18 Years,,ALL,False,University of Southern California,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,10,0.0,,1,1,0,1,0,1,0,0,1,0,0,0,1,0,5,1,1,1,0,4,1,2015-03-01,2018-03-01,1096.0,2015.0,1,2,0
NCT06251024,Study of a Respiratory Syncytial Virus Candidate Formulation in Adults Aged 60 Years and Older,"A Phase IIb, Randomized, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of an RSV Vaccine Candidate in Adult Participants 60 Years and Older",COMPLETED,2024-04-02,2025-03-11,2025-04-04,INTERVENTIONAL,PHASE2,4541.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Respiratory Syncytial Virus Infection|Healthy Volunteers,RSV vaccine candidate|Placebo,BIOLOGICAL,1,23,60 Years,,ALL,True,"Sanofi Pasteur, a Sanofi Company",INDUSTRY,0,25,Australia|Dominican Republic|Chile|Honduras|Mexico|Colombia,1.0,0,1,0,0,0,2.0,0,0,0,0,2,8.421122722665503,xlarge,0,1,1,0,1,0,1,1,0,0,1,1,0,1,24,1,0,1,0,2,1,,,,,0,4,1
NCT01520324,Neoplasia Detection With Methylene Blue MMX Tablets in Patients With UC Undergoing Colonoscopy,Intraepithelial Neoplasia Detection Rate After Single Oral Dose of Methylene Blue MMX Modified Release Tablets Administered to Patients With Long Standing Ulcerative Colitis Undergoing Colonoscopy.,COMPLETED,2012-01,2012-07,2019-02-08,INTERVENTIONAL,PHASE2,53.0,ACTUAL,,SINGLE_GROUP,DIAGNOSTIC,NONE,Ulcerative Colitis,oral delivery mucosal stain,DEVICE,5,3,18 Years,,ALL,False,Cosmo Technologies Ltd,INDUSTRY,0,1,Italy,1.0,0,1,0,0,0,2.0,0,1,0,0,1,3.9889840465642745,medium,1,1,1,0,0,0,0,0,0,1,0,0,0,0,8,1,0,0,1,1,0,2012-01-01,2012-07-01,182.0,2012.0,0,1,0
NCT04635423,"Efficacy, Immunogenicity, and Safety Study of the 9vHPV Vaccine in Japanese Males (V503-064)","A Phase 3, Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9vHPV Vaccine in Japanese Males, 16 to 26 Years of Age.",COMPLETED,2020-11-30,2025-07-23,2025-08-11,INTERVENTIONAL,PHASE3,1059.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,"Warts, Genital|Neoplasms, Anal",V503|Placebo,BIOLOGICAL|OTHER,5,7,16 Years,26 Years,MALE,True,Merck Sharp & Dohme LLC,INDUSTRY,0,22,Japan,1.0,0,0,1,0,0,3.0,0,0,0,0,2,6.966024187106113,xlarge,0,1,1,0,1,0,1,0,0,0,1,1,0,1,12,1,0,1,0,2,1,,,,,0,3,1
NCT05211323,"A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer",A Randomized Phase II Trial Evaluating Chemotherapy Plus Atezolizumab vs Chemotherapy Plus Bevacizumab and Atezolizumab in Advanced Combined Hepatocellular Carcinoma-Cholangiocarcinoma,ACTIVE_NOT_RECRUITING,2022-12-07,2026-03-31,2025-09-10,INTERVENTIONAL,PHASE2,88.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,NONE,Combined Hepatocellular Carcinoma and Cholangiocarcinoma|Stage III Liver Cancer|Stage IV Liver Cancer,Atezolizumab|Bevacizumab|Biospecimen Collection|Cisplatin|Computed Tomography|Conventional Magnetic Resonance Imaging|Gemcitabine Hydrochloride,DRUG|BIOLOGICAL|PROCEDURE,1,2,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,37,United States,,0,1,0,0,0,2.0,1,0,0,0,3,4.48863636973214,medium,1,0,0,1,0,0,1,0,1,0,1,0,1,1,3,1,1,1,0,7,1,,,,,0,2,0
NCT00125359,Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer,A Phase II Clinical Study of Erlotinib (Tarceva) and Bexarotene (Targretin) Oral Capsules in Patients With Advanced Non-small Cell Lung Cancer,COMPLETED,2005-08,2014-03,2019-01-08,INTERVENTIONAL,PHASE2,42.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Carcinoma, Non-small-cell Lung",erlotinib and bexarotene,DRUG,1,3,18 Years,,ALL,False,Konstantin Dragnev,OTHER,2,2,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.7612001156935624,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,4,1,1,0,0,1,0,2005-08-01,2014-03-01,3134.0,2005.0,0,0,0
NCT04793659,Fasudil fOr redUcing elopemeNt and Spatial Disorientation,"A Phase 2a Combined Open-Label and Double-Blind, Placebo-Controlled Crossover Study Assessing the Effectiveness, Safety, and Tolerability of Oral Fasudil in Subjects With Dementia and Wandering Behaviors of Elopement and/or Getting Lost",COMPLETED,2020-12-15,2022-02-11,2022-07-11,INTERVENTIONAL,PHASE2,24.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Dementia,Oral Fasudil 90 mg/day|Oral Fasudil 180 mg/day|Oral Placebo,DRUG,1,19,50 Years,90 Years,ALL,False,Woolsey Pharmaceuticals,INDUSTRY,0,11,Australia|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.2188758248682006,small,1,1,1,0,0,0,1,1,1,0,1,1,1,0,20,1,1,0,0,3,1,,,,,0,3,1
NCT01559259,Evaluation of the Efficacy of Novel Ibuprofen Acetaminophen Combination Formulations in the Treatment of Post-surgical Dental Pain,EVALUATION OF THE EFFICACY OF NOVEL IBUPROFEN ACETAMINOPHEN COMBINATION FORMULATIONS IN THE TREATMENT OF POST-SURGICAL DENTAL PAIN,COMPLETED,2012-04-10,2012-09-13,2020-05-19,INTERVENTIONAL,PHASE2,394.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Pain,Ibuprofen/acetaminophen|Ibuprofen/acetaminophen|Ibuprofen/acetaminophen|Ibuprofen|Placebo,DRUG,1,15,16 Years,40 Years,ALL,False,Pfizer,INDUSTRY,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.978885764901122,large,0,1,1,0,1,0,0,0,1,0,1,1,1,1,16,1,1,0,0,5,1,,,,,0,2,0
NCT01794182,Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals,"A Randomized, Multi-Center, Prospective, Double Blind, Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema",COMPLETED,2013-06-13,2016-04-04,2024-11-12,INTERVENTIONAL,PHASE2,86.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Ischemic Stroke|Malignant Edema,Glyburide for Injection|Placebo,DRUG,2,3,18 Years,80 Years,ALL,False,"Remedy Pharmaceuticals, Inc.",INDUSTRY,0,17,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.465908118654584,medium,1,1,1,0,0,0,1,0,1,0,1,1,0,1,5,1,1,0,0,2,1,,,,,0,2,0
NCT00165880,"An Open-label, Randomized, Phase II Study of the Efficacy and Safety of Indisulam (E7070) in Combination With Capecitabine","An Open-label, Randomized, Phase II Study of the Efficacy and Safety of Indisulam (E7070) in Combination With Capecitabine Versus Capecitabine Monotherapy for the Treatment of Metastatic Breast Cancer Patients Following Prior Anthracycline and Taxane Therapy",TERMINATED,2004-12,2007-09,2014-07-01,INTERVENTIONAL,PHASE2,62.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,DIAGNOSTIC,NONE,Metastatic Breast Cancer,E7070,DRUG,1,1,18 Years,,FEMALE,False,Eisai Limited,INDUSTRY,0,33,Italy|Russia|Spain|Germany|United Kingdom,0.0,0,1,0,0,0,2.0,1,0,0,0,1,4.143134726391533,medium,1,1,1,0,0,0,1,1,0,1,1,0,0,0,2,1,1,0,0,1,0,2004-12-01,2007-09-01,1004.0,2004.0,0,1,0
NCT02040779,A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week Clinical Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma",COMPLETED,2013-12-26,2014-12-24,2021-11-09,INTERVENTIONAL,PHASE3,273.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Persistent Asthma,Beclomethasone dipropionate breath-actuated inhaler|Placebo breath-actuated inhaler|albuterol/salbutamol,DRUG,1,9,12 Years,,ALL,False,"Teva Branded Pharmaceutical Products R&D, Inc.",INDUSTRY,0,47,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.6131281063880705,large,0,1,1,0,0,0,1,0,1,0,1,1,1,1,10,1,1,0,0,3,1,,,,,0,2,0
NCT00108979,Study of Escitalopram in Adult Patients With Major Depressive Disorder,Double-Blind Study of Escitalopram in Adult Patients With Major Depressive Disorder,COMPLETED,2005-03,2006-07,2012-03-05,INTERVENTIONAL,PHASE3,240.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Major Depressive Disorder,Escitalopram,DRUG,1,1,18 Years,80 Years,ALL,False,Forest Laboratories,INDUSTRY,0,9,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.484796933490655,large,0,0,1,0,0,0,1,0,1,0,1,1,1,1,2,1,1,0,0,1,0,2005-03-01,2006-07-01,487.0,2005.0,0,0,0
NCT00852579,Effects of Macrolides on Asthma Control,"Effects of Macrolides on Asthma Control, Airway Inflammation and Bacterial Colonisation in Smokers With Asthma.",COMPLETED,2009-03,2011-08,2011-10-19,INTERVENTIONAL,PHASE3,77.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Asthma,Azithromycin|Placebo,DRUG,1,9,18 Years,70 Years,ALL,True,Euan J Cameron,OTHER,2,2,United Kingdom,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.356708826689592,medium,1,1,0,1,0,1,1,0,0,1,1,1,1,1,10,1,1,0,0,2,1,2009-03-01,2011-08-01,883.0,2009.0,0,2,0
NCT00093496,Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer,A Phase II Trial Of Gemcitabine in Combination With 17-Allylaminogeldamycin (17-AAG) In Advanced Epithelial Ovarian And Primary Peritoneal Carcinoma,COMPLETED,2007-10,2012-03,2014-05-20,INTERVENTIONAL,PHASE2,29.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Primary Peritoneal Cavity Cancer|Recurrent Ovarian Epithelial Cancer|Stage III Ovarian Epithelial Cancer|Stage IV Ovarian Epithelial Cancer,gemcitabine hydrochloride|tanespimycin,DRUG,1,3,18 Years,,FEMALE,False,National Cancer Institute (NCI),NIH,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,4,3.4011973816621555,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,4,1,1,0,0,2,1,2007-10-01,2012-03-01,1613.0,2007.0,0,2,0
NCT05587296,"A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer","A Double-blind, Randomized, Placebo-controlled Multicenter Study to Investigate Efficacy and Safety of Elinzanetant for the Treatment of Vasomotor Symptoms Induced by Adjuvant Endocrine Therapy, Over 52 Weeks and Optionally for an Additional up to 2.5 Years in Women With Hormone-receptor Positive Breast Cancer:",ACTIVE_NOT_RECRUITING,2022-10-14,2028-06-05,2026-02-03,INTERVENTIONAL,PHASE3,474.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer|Hot Flashes",Elinzanetant (BAY3427080)|Placebo,DRUG,2,6,18 Years,70 Years,FEMALE,False,Bayer,INDUSTRY,0,102,Italy|Belgium|Finland|Hungary|Kazakhstan|Spain|Germany|Austria|Romania|United Kingdom|Poland|Israel|Portugal|France|Ireland|Canada,,0,0,1,0,0,3.0,1,0,0,0,2,6.163314804034641,large,0,1,1,0,0,0,1,1,0,1,1,1,1,1,8,1,1,0,0,2,1,,,,,0,4,1
NCT05561062,Atorvastatin in Patients With Ulcerative Colitis,Combination of Atorvastatin and Mesalazine to Enhance Anti-inflammatory Effects and Attenuates Progression of Ulcerative Colitis,COMPLETED,2022-12-01,2024-11-01,2025-08-11,INTERVENTIONAL,PHASE2,50.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Inflammatory Bowel Diseases,Atorvastatin 80mg,DRUG,1,1,18 Years,75 Years,ALL,False,Tanta University,OTHER,0,1,Egypt,1.0,0,1,0,0,0,2.0,0,1,0,0,1,3.9318256327243257,small,1,1,0,1,0,0,0,0,0,0,1,1,1,1,2,1,1,0,0,1,0,,,,,0,0,0
NCT05116462,Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer,"A Randomized, Double-blind, Phase 3 Study of the Efficacy and Safety of Sindilizumab Combined With Chemotherapy or Placebo Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer (ORIENT-99)",ACTIVE_NOT_RECRUITING,2024-03-15,2028-10-14,2025-06-26,INTERVENTIONAL,PHASE3,506.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Non-Small Cell Lung Cancer,Pemetrexed|Carboplatin|Paclitaxel|Sintilimab|Cisplatin|Nab paclitaxel|Placebo,DRUG,2,4,18 Years,,ALL,False,Innovent Biologics (Suzhou) Co. Ltd.,INDUSTRY,0,1,China,,0,0,1,0,0,3.0,1,0,0,0,1,6.2285110035911835,xlarge,0,1,1,0,0,0,0,0,0,0,1,1,1,1,6,1,1,0,0,7,1,,,,,0,2,0
NCT03341962,Phase 2 Dose-finding IMU-838 for Ulcerative Colitis,"A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of IMU-838 for Induction and Maintenance Therapy in Moderate-to-severe Ulcerative Colitis",TERMINATED,2018-03-15,2022-11-16,2024-03-05,INTERVENTIONAL,PHASE2,263.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Ulcerative Colitis,IMU-838|Placebo,DRUG,1,41,18 Years,80 Years,ALL,False,Immunic AG,INDUSTRY,0,131,Bulgaria|Serbia|Belarus|Georgia|Netherlands|Spain|Czechia|Portugal|Russia|Turkey (Türkiye)|North Macedonia|United States|United Kingdom|Romania|Poland|Ukraine|Bosnia and Herzegovina|Croatia|Albania,0.0,0,1,0,0,0,2.0,0,1,0,0,1,5.575949103146316,large,0,1,1,0,0,0,1,1,1,1,1,1,1,1,42,1,1,0,0,2,1,,,,,0,3,1
NCT02323646,Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine Fibroids,"A Phase 2, Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids",COMPLETED,2015-02-12,2017-04-06,2019-06-25,INTERVENTIONAL,PHASE2,42.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Uterine Fibroids,Placebo|Telapristone Acetate,DRUG,1,12,18 Years,47 Years,FEMALE,False,Repros Therapeutics Inc.,INDUSTRY,0,8,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.7612001156935624,small,1,1,1,0,0,0,1,0,1,0,1,1,1,1,13,1,1,0,0,2,1,,,,,0,2,0
NCT01638546,Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer,"A Multi-Center, Randomized, Double-Blind Phase II Study Comparing ABT-888, a PARP Inhibitor, Versus Placebo With Temozolomide in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer",ACTIVE_NOT_RECRUITING,2012-07-27,2026-03-25,2025-10-29,INTERVENTIONAL,PHASE2,97.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Recurrent Lung Small Cell Carcinoma,Laboratory Biomarker Analysis|Placebo Administration|Temozolomide|Veliparib,DRUG|OTHER,1,3,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,14,United States,,0,1,0,0,0,2.0,1,0,0,0,1,4.584967478670572,medium,1,1,0,1,0,0,1,0,1,0,1,1,1,1,4,1,1,0,0,4,1,,,,,0,1,0
NCT01157988,90Y-ibritumomab Tiuxetan Consolidation After 6th R-CHOP Chemotherapy in Patients With Bulky Diffuse Large B Cell Lymphoma,"Phase II Study of 90Y-ibritumomab Tiuxetan Treatment as a Consolidation After 6th R-CHOP Chemotherapy in Patients With Limited-stage, Bulky Diffuse Large B Cell Lymphoma",COMPLETED,2007-01,,2010-07-08,INTERVENTIONAL,PHASE2,20.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Lymphoma, Large B-Cell, Diffuse",ibritumomab tiuxetan (Zevalin),DRUG,2,1,18 Years,,ALL,False,Chonnam National University Hospital,OTHER,6,1,South Korea,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.044522437723423,small,1,1,0,1,0,1,0,0,0,0,0,0,1,0,3,1,1,0,0,1,0,2007-01-01,,,2007.0,0,0,0
NCT04060888,A Study of Ustekinumab in Chinese Participants With Active Systemic Lupus Erythematosus,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Chinese Subjects With Active Systemic Lupus Erythematosus",WITHDRAWN,2020-07-14,2026-03-31,2025-02-03,INTERVENTIONAL,PHASE3,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Lupus Erythematosus, Systemic",Ustekinumab (approximately 6 mg/kg)|Ustekinumab 90 milligram (mg)|Placebo,DRUG,1,6,18 Years,75 Years,ALL,False,"Janssen Research & Development, LLC",INDUSTRY,0,0,,0.0,0,0,1,0,0,3.0,0,1,0,0,1,0.0,,1,1,1,0,0,0,0,0,0,0,1,1,1,1,7,1,1,0,0,3,1,,,,,0,2,0
NCT00314288,Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia,"A Multicenter, Multinational, Randomised, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Study to Investigate the Anti-dyskinetic Efficacy and Safety of Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia",COMPLETED,2002-07,2003-07,2017-01-23,INTERVENTIONAL,PHASE2,360.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Parkinson's Disease|Dyskinesia,Sarizotan HCl,DRUG,0,0,30 Years,,ALL,False,EMD Serono,INDUSTRY,0,51,Belgium|Bulgaria|South Africa|Hungary|United States|Germany|United Kingdom|Romania|Portugal|France|Canada,1.0,0,1,0,0,0,2.0,0,0,1,0,2,5.8888779583328805,large,0,0,1,0,0,0,1,1,1,1,1,1,1,1,0,0,1,0,0,1,0,2002-07-01,2003-07-01,365.0,2002.0,0,2,0
NCT04224688,"A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)","A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)",TERMINATED,2020-06-03,2022-05-05,2023-08-08,INTERVENTIONAL,PHASE3,30.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Primary Immune Thrombocytopenia,Rozanolixizumab|Placebo,DRUG|OTHER,1,8,18 Years,,ALL,False,UCB Biopharma SRL,INDUSTRY,0,29,China|Bulgaria|Russia|United States|Germany|Spain|United Kingdom|Poland|Taiwan|Ukraine|France,0.0,0,0,1,0,0,3.0,0,0,0,0,1,3.4339872044851463,small,1,1,1,0,0,0,1,1,1,1,1,1,1,1,9,1,1,0,0,2,1,,,,,0,3,1
NCT01932788,Preventing Health Disparities During Pregnancy Through Vitamin D Supplementation,Preventing Health Disparities During Pregnancy Through Vitamin D Supplementation,COMPLETED,2013-01,2018-04-30,2018-11-21,INTERVENTIONAL,PHASE3,342.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Vitamin D3 Deficiency,Vitamin D3 4000 IU in gummy form|Placebo gummy vitamin,DRUG,1,0,18 Years,45 Years,FEMALE,True,Medical University of South Carolina,OTHER,1,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.8377304471659395,large,0,1,0,1,0,1,0,0,1,0,1,1,0,1,1,0,1,0,0,2,1,2013-01-01,,,2013.0,0,1,0
NCT00272103,Itopride in Functional Dyspepsia:a Dose Finding Study,"A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Dose Finding Study in 4 Parallel Groups to Establish the Efficacy and Safety of an Eight Week Treatment With Itopride Three Times Daily Compared to Placebo in Patients Suffering From Functional Dyspepsia",COMPLETED,2000-12,2002-01,2006-05-04,INTERVENTIONAL,PHASE2|PHASE3,500.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Functional Dyspepsia,Itopride (drug),DRUG,4,1,18 Years,95 Years,ALL,False,Royal Adelaide Hospital,OTHER,2,1,Germany,1.0,0,1,1,0,1,2.5,0,0,0,0,1,6.2166061010848646,large,0,0,0,1,0,1,0,0,0,1,1,1,1,1,5,1,1,0,0,1,0,2000-12-01,2002-01-01,396.0,2000.0,0,1,0
NCT00230503,Dose-Ranging Study of Pradefovir in Patients With Compensated Hepatitis B,Dose-Ranging Study of Pradefovir in Patients With Compensated Hepatitis B,COMPLETED,2004-06,2006-12,2012-06-22,INTERVENTIONAL,PHASE2,220.0,,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Hepatitis B, Chronic",pradefovir mesylate|adefovir dipivoxyl,DRUG,2,1,18 Years,60 Years,ALL,False,"Bausch Health Americas, Inc.",INDUSTRY,0,0,,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.3981627015177525,large,0,0,1,0,0,0,0,0,0,0,1,0,1,1,3,1,1,0,0,2,1,2004-06-01,2006-12-01,913.0,2004.0,0,1,0
NCT06047080,"An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma","A Phase III, Multicenter, Randomized, Open-Label Study Comparing the Efficacy and Safety of Glofitamab (RO7082859) in Combination With Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma",ACTIVE_NOT_RECRUITING,2023-09-18,2030-12-31,2025-12-18,INTERVENTIONAL,PHASE3,1130.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Large B-Cell Lymphoma,Glofitamab|Polatuzumab vedotin|Rituximab|Cyclophosphamide|Doxorubicin|Prednisone,DRUG,1,14,18 Years,80 Years,ALL,False,Hoffmann-La Roche,INDUSTRY,0,231,China|Germany|Japan|Switzerland|Taiwan|Italy|South Korea|Spain|Canada|Argentina|Turkey (Türkiye)|Puerto Rico|United States|United Kingdom|Australia|Poland|Mexico|Denmark|France|Belgium|Brazil,,0,0,1,0,0,3.0,1,0,0,0,1,7.030857476116121,xlarge,0,1,1,0,1,0,1,1,1,1,1,0,1,1,15,1,1,0,0,6,1,,,,,0,3,1
NCT03793361,Phase II Study of Regorafenib as Maintenance Therapy,Efficacy of Regorafenib as Maintenance Therapy in Non-adipocytic Soft Tissue Sarcoma Having Received First-line Doxorubicin-based Chemotherapy,COMPLETED,2019-05-15,2024-09-26,2024-12-10,INTERVENTIONAL,PHASE2,127.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Metastatic Soft Tissue Sarcoma,Regorafenib|Placebo,DRUG,1,5,18 Years,,ALL,False,Centre Oscar Lambret,OTHER,0,20,France,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.852030263919617,medium,0,1,0,1,0,0,1,0,0,1,1,1,1,1,6,1,1,0,0,2,1,,,,,0,2,0
NCT01739361,Acetaminophen for the Reduction of Oxidative Injury in Severe Sepsis,Phase IIa Randomized Controlled Trial of Acetaminophen for the Reduction of Oxidative Stress in Severe Sepsis,COMPLETED,2013-04,2013-12,2017-12-26,INTERVENTIONAL,PHASE2,44.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Severe Sepsis,Acetaminophen|placebo,DRUG,1,2,18 Years,,ALL,False,Vanderbilt University,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.8066624897703196,small,1,1,0,1,0,0,0,0,1,0,1,1,1,1,3,1,1,0,0,2,1,2013-04-01,2013-12-01,244.0,2013.0,0,1,0
NCT06041061,"A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial Evaluating the Efficacy, Safety, and Immunogenicity of a 14- Valent Recombinant Human Papillomavirus Vaccine (SCT1000) in Healthy Women Aged 18-45 Years",ACTIVE_NOT_RECRUITING,2023-08-13,2028-08,2023-09-18,INTERVENTIONAL,PHASE3,18000.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,HPV InfectioN|HPV-Related Carcinoma,Recombinant 14-Valent Human Papillomavirus Vaccine（Insect Cell）|placebo,BIOLOGICAL,3,20,18 Years,45 Years,FEMALE,True,Sinocelltech Ltd.,INDUSTRY,5,5,China,,0,0,1,0,0,3.0,1,0,0,0,2,9.798182590890704,,0,1,1,0,0,1,1,0,0,0,1,1,0,1,23,1,0,1,0,2,1,,2028-08-01,,,0,3,1
NCT01553786,Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL),STUDY OF THE EFFICACY AND SAFETY OF FIRST LINE TREATMENT WITH CHOP AND LENALIDOMIDE (Rev-CHOP) IN PATIENTS AGED FROM 60 TO 80 YEARS WITH PREVIOUSLY UNTREATED ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL),COMPLETED,2011-11,2019-03-21,2021-07-26,INTERVENTIONAL,PHASE2,80.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,T-cell Lymphoma,Lenalidomide,DRUG,1,0,60 Years,80 Years,ALL,False,The Lymphoma Academic Research Organisation,OTHER,0,30,Belgium|France,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.394449154672439,medium,1,1,0,1,0,0,1,1,0,1,0,0,1,0,1,0,1,0,0,1,0,2011-11-01,,,2011.0,0,1,0
NCT00369642,A Controlled Trial of Daily Cognitive-Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder,A Controlled Trial of Daily Cognitive-Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder,COMPLETED,2004-10,2006-12,2010-08-09,INTERVENTIONAL,PHASE3,60.0,,RANDOMIZED,PARALLEL,TREATMENT,NONE,Obsessive-Compulsive Disorder,Cognitive-behavioral therapy,BEHAVIORAL,3,3,7 Years,17 Years,ALL,True,University of South Florida,OTHER,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.110873864173311,medium,1,0,0,1,0,0,0,0,1,0,1,0,1,1,6,1,0,0,0,1,0,2004-10-01,2006-12-01,791.0,2004.0,0,1,0
NCT05041842,Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer,Treatment With Tucatinib in Addition to Pertuzumab and Trastuzumab in Patients With HER2-positive Metastatic Breast Cancer After Local Therapy of Isolated Brain Progression,ACTIVE_NOT_RECRUITING,2021-12-17,2026-04-30,2025-11-17,INTERVENTIONAL,PHASE2,53.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Metastatic Breast Cancer With a Isolated Brain Progression,Tucatinib|Pertuzumab|Trastuzumab|Hormone therapy|Pertuzumab/ Trastuzumab,DRUG,1,4,18 Years,,ALL,False,UNICANCER,OTHER,2,16,France,,0,1,0,0,0,2.0,1,0,0,0,1,3.9889840465642745,medium,1,1,0,1,0,1,1,0,0,1,0,0,1,0,5,1,1,0,0,5,1,,,,,0,1,0
NCT01685242,"A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle","A Single-Center, Double-Masked, Randomization, Vehicle-Controlled, Evaluation of the Onset and Duration of Action of AC-170 0.24% Ophthalmic Solution (Formula AFH-002) Compared to Vehicle (Formula AFH-001) in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis",COMPLETED,2012-09,2012-11,2017-10-10,INTERVENTIONAL,PHASE3,100.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Allergic Conjunctivitis,AC-170 0.24%|AC-170 0%,DRUG,4,21,10 Years,,ALL,False,"Aciex Therapeutics, Inc.",INDUSTRY,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.61512051684126,medium,0,1,1,0,0,0,0,0,1,0,1,1,1,1,25,1,1,0,0,2,1,2012-09-01,2012-11-01,61.0,2012.0,0,2,0
NCT01733186,"Evaluation of Safety and Exploratory Efficacy of CARTISTEM®, a Cell Therapy Product for Articular Cartilage Defects","Evaluation of Safety and Exploratory Efficacy of CARTISTEM®, a Cell Therapy Product for Articular Cartilage Defects: A Phase I/IIa Clinical Trial in Patients With Focal, Full-thickness Grade 3-4 Articular Cartilage Defects of the Knee",COMPLETED,2013-01-07,2017-08-29,2026-01-29,INTERVENTIONAL,PHASE1|PHASE2,12.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Degeneration Articular Cartilage Knee,CARTISTEM®,BIOLOGICAL,1,4,18 Years,,ALL,False,"Medipost, Inc.",INDUSTRY,0,2,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,2.5649493574615367,small,1,1,1,0,0,0,1,0,1,0,0,0,1,0,5,1,0,1,0,1,0,,,,,0,1,0
NCT01449786,Sublingual Immunotherapy of Birch Pollen Associated Apple Allergy,Sublingual Immunotherapy of Birch Pollen Associated Apple Allergy,COMPLETED,2012-03-14,2016-12-20,2017-04-13,INTERVENTIONAL,PHASE2,60.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Birch Pollen Related Apple Allergy|Birch Pollen Allergy,rMal d 1|rBet v 1|placebo drops,DRUG|OTHER,1,2,18 Years,65 Years,ALL,False,Medical University of Vienna,OTHER,1,1,Austria,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.110873864173311,medium,1,1,0,1,0,1,0,0,0,0,1,1,1,1,3,1,1,0,0,3,1,,,,,0,2,0
NCT01576718,A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications,A 12-Week Dose-ranging Study to Evaluate the Efficacy and Safety of Fp Spiromax® (Fluticasone Propionate Inhalation Powder) Administered Twice Daily Compared With Placebo in Adolescent and Adult Subjects With Severe Persistent Asthma Uncontrolled on High Dose Inhaled Corticosteroid Therapy,COMPLETED,2012-04,2013-10,2018-05-08,INTERVENTIONAL,PHASE2,889.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Asthma,Fp MDPI|Placebo MDPI|Flovent Diskus|albuterol/salbutamol,DRUG|OTHER,1,10,12 Years,,ALL,False,"Teva Branded Pharmaceutical Products R&D, Inc.",INDUSTRY,0,300,Bulgaria|Germany|Serbia|Greece|Spain|Ireland|Canada|Russia|United States|United Kingdom|Australia|Romania|Poland|New Zealand|Israel|Ukraine|South Africa|Hungary|Croatia,1.0,0,1,0,0,0,2.0,0,0,0,0,1,6.7912214627261855,xlarge,0,1,1,0,0,0,1,1,1,1,1,1,1,1,11,1,1,0,0,4,1,2012-04-01,2013-10-01,548.0,2012.0,0,3,1
NCT00603590,Phase II Study of Heart Polypill Safety and Efficacy in Primary Prevention of Cardiovascular Disease,Phase II Study of Heart Polypill in Primary Prevention of Cardiovascular Disease - Safety and Efficacy,COMPLETED,2006-11,2008-07,2009-10-02,INTERVENTIONAL,PHASE2,475.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Cardiovascular Disease|Hypertension|Hyperlipidemia|Heart Disease,Polypill|Placebo drug,DRUG,1,2,50 Years,80 Years,ALL,True,Tehran University of Medical Sciences,OTHER,1,1,Iran,1.0,0,1,0,0,0,2.0,0,0,0,1,4,6.16541785423142,large,0,1,0,1,0,1,0,0,0,0,1,1,0,1,3,1,1,0,0,2,1,2006-11-01,2008-07-01,608.0,2006.0,0,2,0
NCT00002790,Prevention of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Receiving a Bone Marrow Transplant,A PHASE I/II STUDY OF RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH METHOTREXATE (MTX) AND CYCLOSPORINE (CPS) IN PATIENTS UNDERGOING MARROW TRANSPLANTATION FROM RELATED DONORS MISMATCHED FOR ONE HLA ANTIGEN IN THE DIRECTION OF GRAFT-VERSUS-HOST DISEASE (GVHD),WITHDRAWN,1996-03,,2015-03-06,INTERVENTIONAL,PHASE1|PHASE2,0.0,ACTUAL,,,SUPPORTIVE_CARE,,Graft Versus Host Disease|Leukemia|Myelodysplastic Syndromes,cyclosporine|methotrexate|sirolimus,DRUG,0,0,13 Years,,ALL,False,Fred Hutchinson Cancer Center,OTHER,1,0,,0.0,1,1,0,0,1,1.5,1,0,0,0,3,0.0,,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,3,1,1996-03-01,,,1996.0,0,3,1
NCT04359290,Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS,"Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS A Single-arm, Open-label, Proof of Concept Study",COMPLETED,2020-07-01,2021-07-30,2021-08-24,INTERVENTIONAL,PHASE2,15.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"ARDS, Human|COVID",Ruxolitinib administration,DRUG,1,11,18 Years,,ALL,False,Philipps University Marburg,OTHER,0,1,Germany,1.0,0,1,0,0,0,2.0,0,0,0,0,2,2.772588722239781,small,1,1,0,1,0,0,0,0,0,1,0,0,1,0,12,1,1,0,0,1,0,,,,,0,2,0
NCT00225797,Efficacy and Safety of Oxmorphone Extended Release in Chronic Non-malignant Pain,"An Open-Label Titration Followed by a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Tolerability, and Safety of Oxymorphone Extended Release Tablets in Opioid-Naïve Patients With Chronic Low Back Pain",COMPLETED,2004-11,2005-07,2024-01-02,INTERVENTIONAL,PHASE3,160.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Chronic Pain,Oxymorphone Extended Release,DRUG,1,4,18 Years,,ALL,False,Endo Pharmaceuticals,INDUSTRY,0,33,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.081404364984463,medium,0,0,1,0,0,0,1,0,1,0,1,1,1,1,5,1,1,0,0,1,0,2004-11-01,2005-07-01,242.0,2004.0,0,0,0
NCT00633997,Assessment of the Skin-concentration of Vildagliptin 50 mg Every 12 Hours for 10 Days in Healthy Subjects and Patients With Type 2 Diabetes,"An Open-label, Multiple Dose Study to Assess the Steady-state Skin Concentrations and Pharmacokinetics of Vildagliptin 50 mg BID for 10 Days in Healthy Subjects and Patients With Type 2 Diabetes",TERMINATED,2008-02,,2020-12-17,INTERVENTIONAL,PHASE1|PHASE2,22.0,ACTUAL,NON_RANDOMIZED,PARALLEL,BASIC_SCIENCE,NONE,"Diabetes Mellitus, Type 2",Vildagliptin|Vildagliptin,DRUG,1,1,30 Years,65 Years,ALL,True,Novartis,INDUSTRY,0,1,United States,0.0,1,1,0,0,1,1.5,0,0,0,0,1,3.1354942159291497,small,1,1,1,0,1,0,0,0,1,0,0,0,0,1,2,1,1,0,0,2,1,2008-02-01,,,2008.0,0,2,0
NCT02581397,Transpulmin Suppository and Guaiacol Compared to Transpulmin Syrup in Pediatric Participants With Productive Cough,Randomized Clinical Trial Evaluating the Non-clinical Inferiority of Suppository Transpulmin and Suppository Guaiacol Compared to Transpulmin Syrup in Frames of Productive Cough of Infectious Origin in Pediatric Participants.,TERMINATED,2015-05-05,2016-12-06,2018-04-13,INTERVENTIONAL,PHASE3,270.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,NONE,Cough,Transpulmin suppository|Guaiacol suppository|Transpulmin syrup,DRUG,1,1,2 Years,6 Years,ALL,False,Ache Laboratorios Farmaceuticos S.A.,INDUSTRY,0,1,Brazil,0.0,0,0,1,0,0,3.0,0,0,0,0,1,5.602118820879701,large,0,0,1,0,0,0,0,0,0,0,1,0,1,1,2,1,1,0,0,3,1,,,,,0,1,0
NCT01146197,Input of the Use of Indometacin in Gitelman Syndrome as Compared to Potassium Sparing Diuretics,Evaluation of Safety and Efficacity of Indometacin and Two Potassium Sparing Diuretics in Adult Patients Affected by Gitelman Syndrome,COMPLETED,2010-02,2013-01,2013-12-10,INTERVENTIONAL,PHASE1|PHASE2,33.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Gitelman Syndrome,TREATMENT,DRUG,1,3,18 Years,60 Years,ALL,False,Assistance Publique - Hôpitaux de Paris,OTHER,0,1,France,1.0,1,1,0,0,1,1.5,0,0,0,0,1,3.5263605246161616,small,1,1,0,1,0,0,0,0,0,1,1,0,1,0,4,1,1,0,0,1,0,2010-02-01,2013-01-01,1065.0,2010.0,0,1,0
NCT00882310,"A Study of Gemzar, Taxotere, and Xeloda for Adjuvant Pancreatic Cancer","A Phase II Study of Gemzar, Taxotere, and Xeloda (GTX) for Adjuvant Pancreatic Cancer",COMPLETED,2006-09,2014-10,2016-07-25,INTERVENTIONAL,PHASE2,37.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Pancreatic Cancer,Gemcitabine|Docetaxel|Capecitabine,DRUG,1,2,18 Years,75 Years,ALL,False,Columbia University,OTHER,0,0,,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.6375861597263857,small,1,1,0,1,0,0,0,0,0,0,0,0,1,0,3,1,1,0,0,3,1,2006-09-01,2014-10-01,2952.0,2006.0,0,1,0
NCT00240110,Valproate Efficacy in Cocaine-Bipolar Comorbidity,Valproate Efficacy in Cocaine-Bipolar Comorbidity,COMPLETED,2006-03,2014-03,2016-10-17,INTERVENTIONAL,PHASE1|PHASE2,152.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Bipolar Disorder|Cocaine Dependence,Valproate|Placebo|Lithium Carbonate,DRUG,1,1,18 Years,65 Years,ALL,True,University of Miami,OTHER,1,2,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,2,5.030437921392435,medium,0,1,0,1,0,1,1,0,1,0,1,1,1,1,2,1,1,0,0,3,1,2006-03-01,2014-03-01,2922.0,2006.0,0,3,1
NCT00526110,"Docetaxel, 5-Fluorouracil and Oxaliplatin in Adenocarcinoma of the Stomach or Gastroesophageal Junction Patients","A Phase I/II Study of Docetaxel, 5-Fluorouracil and Oxaliplatin (D-FOX) in Patients With Untreated Locally Unresectable or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction",COMPLETED,2004-08,2015-06,2016-10-31,INTERVENTIONAL,PHASE1|PHASE2,98.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Gastrointestinal Diseases,5-Fluorouracil|Docetaxel|Oxaliplatin,DRUG,2,1,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,4.59511985013459,medium,1,1,0,1,0,1,0,0,1,0,0,0,1,0,3,1,1,0,0,3,1,2004-08-01,2015-06-01,3956.0,2004.0,0,2,0
NCT02527213,Double-blind Trial of Sodium Thiosulfate for the Treatment of Pain Associated With Calcific Uremic Arteriolopathy,Randomized Double Blind Placebo Controlled Trial of Sodium Thiosulfate for the Treatment of Pain Associated With Calcific Uremic Arteriolopathy Followed by a Single Armed Extension Phase to Prospectively Observe Lesion Progression,WITHDRAWN,2015-01-30,2016-08-29,2025-05-07,INTERVENTIONAL,PHASE3,0.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,DOUBLE,Calciphylaxis|Calcific Uremic Arteriolopathy,Sodium thiosulfate|Placebo,DRUG,1,0,18 Years,,ALL,False,"American Regent, Inc.",INDUSTRY,0,3,United States,0.0,0,0,1,0,0,3.0,0,0,0,0,2,0.0,,1,1,1,0,0,0,1,0,1,0,1,1,1,0,1,0,1,0,0,2,1,,,,,0,2,0
NCT03064113,Effects of TD-4208 on FEV1 in Subjects With Chronic Obstructive Pulmonary Disease (COPD),"A Phase 2, Randomized, Double-Blind, Crossover Study to Examine the Pharmacodynamics, Safety and Tolerability, and Pharmacokinetics of Single Doses of TD-4208 in Subjects Diagnosed With Chronic Obstructive Pulmonary Disease",COMPLETED,2011-05,2011-10,2022-02-24,INTERVENTIONAL,PHASE2,32.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,"Chronic Obstructive Pulmonary Disease, COPD",Placebo|TD-4208 700 μg|TD-4208 350 μg|Ipratropium 500 μg,DRUG,1,6,40 Years,75 Years,ALL,False,Mylan Inc.,INDUSTRY,1,1,New Zealand,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.4965075614664802,small,1,1,1,0,0,1,0,0,0,0,1,1,1,0,7,1,1,0,0,4,1,2011-05-01,2011-10-01,153.0,2011.0,0,2,0
NCT04348513,Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection,Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection (Thy-Support),TERMINATED,2020-05-29,2021-04-19,2021-09-23,INTERVENTIONAL,PHASE2,5.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Pulmonary Infection|Covid-19,T3 solution for injection|Placebo,DRUG,1,26,18 Years,,ALL,False,Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.,INDUSTRY,1,1,Greece,0.0,0,1,0,0,0,2.0,0,0,0,0,2,1.791759469228055,small,1,1,1,0,0,1,0,0,0,0,1,1,1,1,27,1,1,0,0,2,1,,,,,0,3,1
NCT00422513,A Study Comparing Mircera and Epoetin Alfa for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.,"A Randomized, Open-label Study Comparing the Pharmacoeconomic (Time and Motion) Benefit of Mircera and Epoetin Alfa in Patients With Chronic Kidney Disease (Stage V) on Dialysis.",TERMINATED,2007-03,2007-12,2011-12-14,INTERVENTIONAL,PHASE3,260.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Anemia,methoxy polyethylene glycol-epoetin beta|Epoetin alfa,DRUG,2,2,18 Years,,ALL,False,Hoffmann-La Roche,INDUSTRY,0,44,United States,0.0,0,0,1,0,0,3.0,0,0,0,0,1,5.564520407322694,large,0,1,1,0,1,0,1,0,1,0,1,0,1,1,4,1,1,0,0,2,1,2007-03-01,2007-12-01,275.0,2007.0,0,1,0
NCT00786513,Use of a Biofilm Antimicrobial Susceptibility Assay to Guide Antibiotic Therapy,Randomized Double Blind Controlled Trial of the Use of a Biofilm Antimicrobial Susceptibility Assay to Guide Antibiotic Therapy in Chronic Pseudomonas Aeruginosa Infected Cystic Fibrosis Patients,COMPLETED,2008-11,2014-03,2014-04-04,INTERVENTIONAL,PHASE2,134.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Cystic Fibrosis,Conventional antimicrobial susceptibility testing|Biofilm antimicrobial susceptibility testing,OTHER,1,4,,,ALL,False,The Hospital for Sick Children,OTHER,0,5,Canada,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.90527477843843,medium,0,1,0,1,0,0,1,0,0,0,1,1,1,1,5,1,0,0,0,2,1,2008-11-01,2014-03-01,1946.0,2008.0,0,1,0
NCT02635360,Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer,A Randomized Phase II Study of Chemoradiation and Pembrolizumab for Locally Advanced Cancer,COMPLETED,2017-02-09,2022-12-14,2025-07-03,INTERVENTIONAL,PHASE2,94.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Cervical Cancer,Pembrolizumab|Brachytherapy|Cisplatin,DRUG|RADIATION,2,4,18 Years,,FEMALE,False,Linda R Duska,OTHER,1,8,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.553876891600541,medium,1,1,0,1,0,1,1,0,1,0,1,0,1,1,6,1,1,0,0,3,1,,,,,0,2,0
NCT01534260,"Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype","Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype",COMPLETED,2012-02-10,2017-02-13,2018-08-17,INTERVENTIONAL,PHASE1|PHASE2,37.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Acute Myeloid Leukemia,"sorafenib, vorinostat and bortezomib",DRUG,2,2,18 Years,,ALL,False,Hamid Sayar,OTHER,3,1,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,1,3.6375861597263857,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,4,1,1,0,0,1,0,,,,,0,1,0
NCT05240560,Proof of Concept Study Evaluating BP1.3656 in Patients With Fatigue Following Ischemic Stroke,A Multisite Randomized Clinical Trial Evaluating Efficacy and Safety of BP1.3656 vs Placebo in Patients With Fatigue Following Ischemic Stroke,TERMINATED,2023-01-20,2024-02-08,2024-08-09,INTERVENTIONAL,PHASE2,5.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Fatigue,BP1.3656,DRUG,1,0,18 Years,,ALL,False,Bioprojet,OTHER,0,2,Switzerland|France,0.0,0,1,0,0,0,2.0,0,0,0,0,1,1.791759469228055,small,1,1,0,1,0,0,1,1,0,1,1,1,1,1,1,0,1,0,0,1,0,,,,,0,1,0
NCT00141960,Famotidine in Subjects With Non-erosive Gastroesophageal Reflux Disease,"YM1170 Phase 2/3 Study: A Double Blind, Placebo Controlled, Group-comparison Study in Patients With Non-erosive Gastroesophageal Reflux Disease",COMPLETED,2005-09,,2011-11-21,INTERVENTIONAL,PHASE2|PHASE3,480.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Gastroesophageal Reflux,Famotidine,DRUG,1,5,20 Years,,ALL,False,Astellas Pharma Inc,INDUSTRY,0,7,Japan,1.0,0,1,1,0,1,2.5,0,0,0,0,1,6.175867270105761,large,0,0,1,0,0,0,1,0,0,0,1,1,1,1,6,1,1,0,0,1,0,2005-09-01,,,2005.0,0,2,0
NCT00380120,Ultrasound Findings to Adjust the Duration of Anticoagulation,The AESOPUS Study: Ultrasound Findings to Adjust the Duration of Anticoagulation in Patients With Deep Vein Thrombosis,COMPLETED,1999-01,2006-06,2008-03-18,INTERVENTIONAL,PHASE3,538.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Deep Vein Thrombosis,sodium warfarin|Sodium warfarin,DRUG,1,1,18 Years,,ALL,False,University of Padova,OTHER,0,1,Italy,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.289715570908998,xlarge,0,1,0,1,0,0,0,0,0,1,1,0,0,1,2,1,1,0,0,2,1,1999-01-01,2006-06-01,2708.0,1999.0,0,1,0
NCT00312520,Pulse Steroids Versus Oral Steroids in Problematic Hemangiomas of Infancy,The Efficacy and Safety of Intravenous Pulse Steroids Compared to Standard Oral Steroids in the Treatment of Problematic Hemangiomas in Infants: A Randomized Controlled Trial,COMPLETED,2002-07,2005-06,2018-04-19,INTERVENTIONAL,PHASE3,20.0,,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Hemangiomas,prednisolone|methylprednisolone,DRUG,1,2,1 Month,4 Months,ALL,False,The Hospital for Sick Children,OTHER,1,1,Canada,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.044522437723423,small,1,0,0,1,0,1,0,0,0,0,1,0,1,1,3,1,1,0,0,2,1,2002-07-01,2005-06-01,1066.0,2002.0,0,1,0
NCT05712720,Study to Evaluate the Efficacy and Safety of RZ402 in Diabetic Macular Edema (DME),"A Randomized, Double-Masked, Placebo-Controlled, Parallel-Arm Study to Evaluate the Efficacy and Safety of RZ402 in Participants With Diabetic Macular Edema (DME)",COMPLETED,2023-02-06,2024-04-11,2025-10-03,INTERVENTIONAL,PHASE2,94.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Diabetic Macular Edema,Experimental: Group 1 - 50mg RZ402|Experimental: Group 2 - 200mg RZ402|Experimental: Group 3 - 400mg RZ402|Placebo: Group 4 - Placebo,DRUG|OTHER,2,5,18 Years,75 Years,ALL,False,Rezolute,OTHER,0,32,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.553876891600541,medium,1,1,0,1,0,0,1,0,1,0,1,1,1,1,7,1,1,0,0,4,1,,,,,0,2,0
NCT04492020,Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine When Administered During the Prodrome",COMPLETED,2020-08-21,2022-04-19,2023-05-31,INTERVENTIONAL,PHASE3,518.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Migraine,Ubrogepant 100 mg|Placebo,DRUG,1,3,18 Years,75 Years,ALL,False,AbbVie,INDUSTRY,0,73,United States,1.0,0,0,1,0,0,3.0,0,0,1,0,1,6.251903883165888,xlarge,0,1,1,0,1,0,1,0,1,0,1,1,1,0,4,1,1,0,0,2,1,,,,,0,1,0
NCT04364620,AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002),A Phase II Study of AB-16B5 Combined With Docetaxel in Previously Treated Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002),COMPLETED,2021-02-23,2023-12-31,2025-04-06,INTERVENTIONAL,PHASE2,35.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,NSCLC Stage IV,AB-16B5|Docetaxel,DRUG,1,6,18 Years,,ALL,False,Alethia Biotherapeutics,INDUSTRY,0,5,Canada|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.58351893845611,small,1,1,1,0,0,0,1,1,1,0,0,0,1,0,7,1,1,0,0,2,1,,,,,0,3,1
NCT00672620,Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder,"A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder",COMPLETED,2008-04,2008-12,2013-12-18,INTERVENTIONAL,PHASE3,611.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Major Depressive Disorder,Vortioxetine|Duloxetine|Placebo,DRUG,1,11,18 Years,75 Years,ALL,False,Takeda,INDUSTRY,1,38,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.416732282512326,xlarge,0,1,1,0,1,1,1,0,1,0,1,1,1,1,12,1,1,0,0,3,1,2008-04-01,2008-12-01,244.0,2008.0,0,2,0
NCT00114582,Optimizing the Ambiance During Mealtimes in Dutch Nursing Homes,Optimizing the Ambiance During Mealtimes in Dutch Nursing Homes,COMPLETED,2002-04,2003-12,2009-02-13,INTERVENTIONAL,PHASE2,120.0,,RANDOMIZED,PARALLEL,PREVENTION,NONE,Malnutrition,family style dinner,PROCEDURE,3,0,40 Years,,ALL,,Wageningen University,OTHER,1,1,Netherlands,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.795790545596741,medium,0,0,0,1,0,1,0,0,0,0,1,0,0,1,3,0,0,0,0,1,0,2002-04-01,2003-12-01,609.0,2002.0,0,0,0
NCT01692782,Adult Attention Deficit Hyperactivity Disorder,"A Randomized, Double Blind, Parallel Group, Multicenter Efficacy and Safety Study of SEP-225289 Versus Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)",COMPLETED,2012-12,2013-12,2015-01-12,INTERVENTIONAL,PHASE2,341.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Adult Attention Deficit Hyperactivity Disorder,SEP-225289|SEP-225289|Placebo,DRUG,1,5,18 Years,55 Years,ALL,False,"Sumitomo Pharma America, Inc.",INDUSTRY,0,31,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.834810737062605,large,0,1,1,0,0,0,1,0,1,0,1,1,1,1,6,1,1,0,0,3,1,2012-12-01,2013-12-01,365.0,2012.0,0,2,0
NCT03278782,Study of Pembrolizumab (MK-3475) in Combination With Romidepsin,A Phase I/II Study of Pembrolizumab (MK-3475) in Combination With Romidepsin in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma,ACTIVE_NOT_RECRUITING,2017-11-14,2027-07-31,2026-01-09,INTERVENTIONAL,PHASE1|PHASE2,39.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Recurrent Anaplastic Large Cell Lymphoma|Recurrent Angioimmunoblastic T-Cell Lymphoma|Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma|Recurrent Mycosis Fungoides|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Refractory Anaplastic Large Cell Lymphoma|Refractory Angioimmunoblastic T-Cell Lymphoma|Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Refractory Mycosis Fungoides|Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified|Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma",Pembrolizumab|Romidepsin,DRUG|BIOLOGICAL,2,4,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,1,United States,,1,1,0,0,1,1.5,1,0,0,0,11,3.6888794541139363,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,6,1,1,1,0,2,1,,,,,0,4,1
NCT00843024,Migraine Study in Adolescent Patients,"TXA107979: A Randomized, Multicenter, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of a Combination Product Containing Sumatriptan and Naproxen Sodium for the Acute Treatment of Migraine in Adolescents",COMPLETED,2008-12,2010-06,2017-01-18,INTERVENTIONAL,PHASE3,589.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Migraine Disorders,Sumatriptan and Naproxen Sodium|Placebo,DRUG,1,10,12 Years,17 Years,ALL,False,GlaxoSmithKline,INDUSTRY,0,79,United States,1.0,0,0,1,0,0,3.0,0,0,1,0,1,6.380122536899765,xlarge,0,1,1,0,0,0,1,0,1,0,1,1,1,1,11,1,1,0,0,2,1,2008-12-01,2010-06-01,547.0,2008.0,0,2,0
NCT06127524,Skin Change Actions by Nursing,Biophysical Detection of Skin Changes to Cue Pressure Injury Prevention in Nursing Homes,ACTIVE_NOT_RECRUITING,2023-12-04,2026-06-30,2026-01-12,INTERVENTIONAL,PHASE2,4733.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,PREVENTION,NONE,Pressure Injury,SEM Scanner,DEVICE,1,1,18 Years,,ALL,True,"University of California, Los Angeles",OTHER,4,7,United States,,0,1,0,0,0,2.0,0,0,0,0,1,8.46252579007393,xlarge,0,1,0,1,0,1,1,0,1,0,0,0,0,0,2,1,0,0,1,1,0,,,,,0,0,0
NCT05653024,INhaled Salbutamol vs Placebo for the Treatment of Acute IgE-mediated Abdominal Pain From Allergic Food REactions,A Double-blind Randomized Controlled Trial of Inhaled Salbutamol vs Placebo for the Treatment of Acute Abdominal Pain From Food-induced IgE-mediated Reactions,TERMINATED,2023-07-01,2025-05-05,2025-05-21,INTERVENTIONAL,PHASE3,24.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,IgE-mediated Abdominal Pain,Salbutamol|Placebo,DRUG,1,4,6 Years,55 Years,ALL,False,Philippe Bégin,OTHER,0,1,Canada,0.0,0,0,1,0,0,3.0,0,0,0,0,1,3.2188758248682006,small,1,1,0,1,0,0,0,0,0,0,1,1,1,1,5,1,1,0,0,2,1,,,,,0,1,0
NCT01001624,Melanil in the Treatment of Melasma,Efficacy of Melanil in the Treatment of Melasma,COMPLETED,2009-10,2010-11,2012-05-04,INTERVENTIONAL,PHASE3,150.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Melasma,Melanil facial cream|Hydroquinone 2% cream,OTHER,1,2,18 Years,75 Years,ALL,False,Catalysis SL,INDUSTRY,0,1,Cuba,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.017279836814924,medium,0,1,1,0,0,0,0,0,0,0,1,0,1,1,3,1,0,0,0,2,1,2009-10-01,2010-11-01,396.0,2009.0,0,1,0
NCT03312023,Ledipasvir/Sofosbuvir for Hepatitis B Virus Infection,A Phase II Open-Label Study of Ledipasvir/Sofosbuvir for 12 Weeks in Subjects With Hepatitis B Virus Infection,COMPLETED,2018-02-01,2021-06-30,2021-09-20,INTERVENTIONAL,PHASE2,21.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Hepatitis B,Ledipasvir 90 MG / Sofosbuvir 400 MG Oral Tablet [Harvoni]|Sofosbuvir 400 MG [Sovaldi]|Ledipasvir 90 MG,DRUG,2,1,18 Years,,ALL,False,"University of Maryland, Baltimore",OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.091042453358316,small,1,1,0,1,0,1,0,0,1,0,1,0,1,1,3,1,1,0,0,3,1,,,,,0,1,0
NCT00006123,Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer,Autotransplantation and Her 2 Neu Antibody Immunotherapy in Advanced Breast Cancer,WITHDRAWN,2000-07,2000-07,2018-05-16,INTERVENTIONAL,PHASE1|PHASE2,0.0,ACTUAL,,,TREATMENT,,Breast Cancer,trastuzumab|carboplatin|carmustine|cisplatin|cyclophosphamide|thiotepa|peripheral blood stem cell transplantation,DRUG|BIOLOGICAL|PROCEDURE,0,0,18 Years,65 Years,FEMALE,False,Beth Israel Deaconess Medical Center,OTHER,0,2,United States,0.0,1,1,0,0,1,1.5,1,0,0,0,1,0.0,,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,1,0,7,1,2000-07-01,2000-07-01,0.0,2000.0,0,2,0
NCT03020823,To Evaluate the Efficacy and Safety of SCB01A in Subjects With r/m Squamous Cell Head and Neck Cancer,"An Open-Label, Phase II Study to Evaluate the Efficacy and Safety of SCB01A in Subjects With Recurrent or Metastatic Squamous Cell Head and Neck Cancer Who Have Failed Platinum-Based Treatment",TERMINATED,2017-04-30,2018-11-20,2023-06-05,INTERVENTIONAL,PHASE2,10.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Head and Neck Neoplasms,SCB01A,DRUG,1,3,20 Years,,ALL,False,"SynCore Biotechnology Co., Ltd.",INDUSTRY,0,4,Taiwan,0.0,0,1,0,0,0,2.0,0,0,0,0,1,2.3978952727983707,small,1,1,1,0,0,0,1,0,0,0,0,0,1,0,4,1,1,0,0,1,0,,,,,0,0,0
NCT02277223,Curcumin in Pediatric Ulcerative Colitis,Curcumin for Induction and Maintenance Therapy in Pediatric Ulcerative Colitis,WITHDRAWN,2020-03-01,2022-12-31,2021-10-01,INTERVENTIONAL,PHASE3,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Ulcerative Colitis,Curcumin|Placebo,DRUG|DIETARY_SUPPLEMENT,1,4,6 Years,18 Years,ALL,False,"Schneider Children's Medical Center, Israel",OTHER,0,1,Israel,0.0,0,0,1,0,0,3.0,0,1,0,0,1,0.0,,1,1,0,1,0,0,0,0,0,0,1,1,1,1,5,1,1,0,0,2,1,,,,,0,1,0
NCT01872260,"Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer","A Phase Ib/II, Multicenter Study of the Combination of LEE011 and BYL719 With Letrozole in Adult Patients With Advanced ER+ Breast Cancer",ACTIVE_NOT_RECRUITING,2013-10-22,2027-02-26,2026-01-30,INTERVENTIONAL,PHASE1|PHASE2,255.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Breast Cancer,LEE011|Letrozole|BYL719,DRUG,3,7,18 Years,100 Years,FEMALE,False,Novartis Pharmaceuticals,INDUSTRY,0,25,Italy|South Korea|United States|Spain|United Kingdom|Australia|Switzerland|France,,1,1,0,0,1,1.5,1,0,0,0,1,5.545177444479562,large,0,1,1,0,1,0,1,1,1,1,1,0,1,1,10,1,1,0,0,3,1,,,,,0,4,1
NCT00156923,ALK21-010: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol-dependent Adults,A Multi-Center Extension of Alkermes' Study ALK21-003-EXT (NCT01218971) to Evaluate the Long-Term Safety of Medisorb® Naltrexone,COMPLETED,2003-10,2007-01,2017-07-11,INTERVENTIONAL,PHASE3,108.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Alcoholism,Medisorb naltrexone 380 mg|Medisorb naltrexone 190 mg,DRUG,1,0,18 Years,,ALL,False,"Alkermes, Inc.",INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.6913478822291435,medium,0,1,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,2,1,2003-10-01,2007-01-01,1188.0,2003.0,0,1,0
NCT02819323,A Safety and Efficacy Study of a Bowel Cleansing Preparation (BLI800) in Pediatric Subjects Undergoing Colonoscopy,A Safety and Efficacy Study of a Bowel Cleansing Preparation (BLI800) in Pediatric Subjects Undergoing Colonoscopy,COMPLETED,2016-06,2018-03-27,2021-05-03,INTERVENTIONAL,PHASE3,91.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Colonoscopy,PEG-ELS|BLI800,DRUG,1,0,12 Years,16 Years,ALL,False,Braintree Laboratories,INDUSTRY,0,27,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.5217885770490405,medium,1,1,1,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,0,2,1,2016-06-01,,,2016.0,1,1,0
NCT00399659,Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.,A 52-week Extension to Study CHTF919N2201 to Evaluate the Safety and Efficacy of Tegaserod (6 mg b.i.d. and 12 mg o.d.) Given Orally for the Treatment of Opioid-induced Constipation (OIC) in Patients With Chronic Non-cancer Pain,TERMINATED,2006-11,2007-04,2012-05-01,INTERVENTIONAL,PHASE3,360.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Opioid-induced Constipation,Tegaserod,DRUG,1,3,18 Years,,ALL,,Novartis,INDUSTRY,0,57,United States,0.0,0,0,1,0,0,3.0,0,0,0,0,1,5.8888779583328805,large,0,1,1,0,1,0,1,0,1,0,0,0,1,1,4,1,1,0,0,1,0,2006-11-01,2007-04-01,151.0,2006.0,0,0,0
NCT00781859,Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-006) Trial.,"A Randomized, Placebo Controlled, Double-masked, Multicenter Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion",COMPLETED,2008-12,2010-04,2014-12-17,INTERVENTIONAL,PHASE3,326.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Vitreomacular Adhesion,125 µg Ocriplasmin|Placebo,DRUG,1,1,18 Years,,ALL,False,ThromboGenics,INDUSTRY,0,41,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.7899601708972535,large,0,1,1,0,0,0,1,0,1,0,1,1,1,1,2,1,1,0,0,2,1,2008-12-01,2010-04-01,486.0,2008.0,0,1,0
NCT02855359,Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma,"An Open Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) in Combination With RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) Compared With RCHOP Alone as Frontline Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Grade 3b",TERMINATED,2016-08,2018-05-15,2019-03-11,INTERVENTIONAL,PHASE2,24.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diffuse, Large B-Cell, Lymphoma|Follicular Lymphoma, Grade 3b|Transformed Lymphoma / DLBCL",denintuzumab mafodotin|rituximab|cyclophosphamide|doxorubicin|vincristine|prednisone,DRUG,3,5,18 Years,,ALL,False,Seagen Inc.,INDUSTRY,0,35,Puerto Rico|United States,0.0,0,1,0,0,0,2.0,1,0,0,0,3,3.2188758248682006,small,1,1,1,0,0,0,1,1,1,0,1,0,1,1,8,1,1,0,0,6,1,2016-08-01,,,2016.0,1,4,1
NCT02488759,"An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors","Non-Comparative, Open-Label, Multiple Cohort, Phase 1/2 Study of Nivolumab Monotherapy and Nivolumab Combination Therapy in Subjects With Virus-Positive and Virus-Negative Solid Tumors",COMPLETED,2015-10-13,2022-10-24,2023-11-13,INTERVENTIONAL,PHASE1|PHASE2,578.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Various Advanced Cancer,Nivolumab|Ipilimumab|Relatlimab|Daratumumab,DRUG,4,3,18 Years,,ALL,False,Bristol-Myers Squibb,INDUSTRY,1,40,Netherlands|Belgium|South Korea|United States|Germany|Spain|United Kingdom|Japan|Mexico|Taiwan|France,1.0,1,1,0,0,1,1.5,1,0,0,0,1,6.361302477572996,xlarge,0,1,1,0,1,1,1,1,1,1,1,0,1,1,7,1,1,0,0,4,1,,,,,0,4,1
NCT03698279,Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age,Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age,COMPLETED,2018-10-09,2019-10-16,2022-04-04,INTERVENTIONAL,PHASE2,665.0,ACTUAL,RANDOMIZED,SEQUENTIAL,PREVENTION,TRIPLE,Influenza,"High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 30 μg (split-virion, inactivated)|High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 45 μg, (split-virion, inactivated)|High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 60 µg (split-virion, inactivated)|Fluarix Quadrivalent Influenza vaccine (Unadjuvanted QIV-SD) (Inactivated)|FLUAD Pediatric (adjuvanted TIV) (Surface Antigen, Inactivated)",BIOLOGICAL,14,0,6 Months,17 Years,ALL,True,"Sanofi Pasteur, a Sanofi Company",INDUSTRY,0,16,Canada|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,6.501289670540389,xlarge,0,1,1,0,1,0,1,1,1,0,1,1,0,0,14,0,0,1,0,5,1,,,,,0,3,1
NCT01190696,Titanium Elastic Nailing Versus Hip Spica Cast in Treatment of Femoral Fractures in Children,Study of Surgical Method Versus Casting for Treatment of Femoral Fracture in Children,COMPLETED,2009-02,2010-01,2010-08-30,INTERVENTIONAL,PHASE2,46.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Femoral Shaft Fracture,titanium elastic nailing|Hip spica casting,DEVICE|PROCEDURE,1,3,6 Years,12 Years,ALL,True,Isfahan University of Medical Sciences,OTHER,0,1,Iran,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.8501476017100584,small,1,1,0,1,0,0,0,0,0,0,0,0,1,1,4,1,0,0,1,2,1,2009-02-01,2010-01-01,334.0,2009.0,0,1,0
NCT06280196,"A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC","A Phase I/III, Multi-center, Randomized, Double-blind Study of BAT3306 Plus Chemotherapy Versus Keytruda® Plus Chemotherapy to Evaluate Pharmacokinetics, Efficacy, and Safety in Participants With Stage IV Non-squamous Non-small Cell Lung Cancer.",TERMINATED,2024-07-19,2025-07-30,2025-12-02,INTERVENTIONAL,PHASE3,162.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,"Carcinoma, Non-Small-Cell Lung",BAT3306|EU-Keytruda®|US-Keytruda®|Pemetrexed|Carboplatin,DRUG,1,1,18 Years,,ALL,False,Bio-Thera Solutions,INDUSTRY,0,1,China,0.0,0,0,1,0,0,3.0,1,0,0,0,1,5.093750200806762,medium,0,1,1,0,0,0,0,0,0,0,1,1,1,1,2,1,1,0,0,5,1,,,,,0,1,0
NCT00374296,MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease,A Phase II Study of MGCD0103 (MG-0103) in Patients With Acute Myelogenous Leukemia/High Risk MDS Who Are Elderly and Have Previously Untreated Disease or Who Are Adult and Have Relapsed/Refractory Disease,TERMINATED,2006-09,2008-09,2015-07-01,INTERVENTIONAL,PHASE2,35.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,"Myelogenous Leukemia, Acute|Myelodysplastic Syndromes",MGCD0103,DRUG,2,4,18 Years,,ALL,False,Mirati Therapeutics Inc.,INDUSTRY,0,13,Canada|United States,0.0,0,1,0,0,0,2.0,1,0,0,0,2,3.58351893845611,small,1,1,1,0,0,0,1,1,1,0,0,0,1,0,6,1,1,0,0,1,0,2006-09-01,2008-09-01,731.0,2006.0,0,3,1
NCT01087762,Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis,"Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis",COMPLETED,2010-03,2015-08,2018-08-01,INTERVENTIONAL,PHASE3,325.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Spondyloarthropathies,CZP 200 mg Q2W|CZP 400 mg Q4W|Placebo,BIOLOGICAL|OTHER,1,9,18 Years,,ALL,False,UCB BIOSCIENCES GmbH,INDUSTRY,0,104,Italy|Belgium|Argentina|Netherlands|Hungary|United States|Germany|Brazil|Spain|United Kingdom|Poland|Mexico|Czechia|France|Canada,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.786897381366708,large,0,1,1,0,0,0,1,1,1,1,1,1,1,1,10,1,0,1,0,3,1,2010-03-01,2015-08-01,1979.0,2010.0,0,3,1
NCT03331562,A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer,A SU2C Catalyst ® Randomized Phase II Trial of the PD1 Inhibitor Pembrolizumab With or Without a Vitamin D Receptor Agonist Paricalcitol in Patients With Stage IV Pancreatic Cancer Who Have Been Placed in Best Possible Response,COMPLETED,2017-12-27,2020-07-10,2022-12-27,INTERVENTIONAL,PHASE2,24.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Pancreatic Cancer|Pancreas Adenocarcinoma|Advanced Pancreatic Cancer|Metastatic Pancreatic Cancer|Metastatic Pancreatic Adenocarcinoma,Pembrolizumab|paricalcitol|placebo,DRUG,1,4,18 Years,,ALL,False,Translational Genomics Research Institute,OTHER,2,6,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,5,3.2188758248682006,small,1,1,0,1,0,1,1,0,1,0,1,1,1,1,5,1,1,0,0,3,1,,,,,0,2,0
NCT03354962,Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA),Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA),TERMINATED,2018-10-15,2020-10-27,2020-12-04,INTERVENTIONAL,PHASE1|PHASE2,6.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Melanoma,Nivolumab + Ipilimumab|Combined treatment schema,COMBINATION_PRODUCT,3,4,18 Years,,ALL,False,Institut Claudius Regaud,OTHER,0,6,France,0.0,1,1,0,0,1,1.5,1,0,0,0,1,1.9459101490553132,small,1,1,0,1,0,0,1,0,0,1,1,0,1,1,7,1,0,0,0,2,1,,,,,0,3,1
NCT03867162,FY15-14: Tularemia Vaccine Protocol (NDBR Lot 4),"Phase 2 Open-Label Safety and Immunogenicity Study of Tularemia Vaccine, Live, Attenuated (NDBR 101, Lot 4) in Adult Subjects at Risk of Exposure to Tularemia Bacteria",WITHDRAWN,2021-06-09,2021-12-17,2023-08-21,INTERVENTIONAL,PHASE2,0.0,ACTUAL,,SINGLE_GROUP,PREVENTION,NONE,Tularemia,Live Attenuated Tularemia Vaccine,BIOLOGICAL,2,1,18 Years,65 Years,ALL,True,U.S. Army Medical Research and Development Command,FED,1,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,1,1,0,0,0,1,0,0,1,0,0,0,0,0,3,1,0,1,0,1,0,,,,,0,0,0
NCT00242346,High Doses of Candesartan Cilexetil on the Reduction of Proteinuria,"A Double-Blind, Randomised, Dose Ranging, Multi-Centre, Phase IIIb Study to Evaluate the Efficacy and Safety of High Doses of Candesartan Cilexetil (Atacand®) on the Reduction of Proteinuria in the Treatment of Subjects With Hypertension and Moderate to Severe Proteinuria",COMPLETED,2003-04,2006-12,2007-12-19,INTERVENTIONAL,PHASE3,270.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Proteinuria,candesartan cilexetil,DRUG,1,2,18 Years,80 Years,ALL,False,AstraZeneca,INDUSTRY,0,26,Canada,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.602118820879701,large,0,0,1,0,1,0,1,0,0,0,1,1,1,1,3,1,1,0,0,1,0,2003-04-01,2006-12-01,1340.0,2003.0,0,0,0
NCT03504046,Safety and Feasibility Evaluation of the APS APP,Inpatient Safety and Feasibility Evaluation of the Zone-MPC Control Algorithm Integrated Into the APS APP,COMPLETED,2018-02-28,2018-09-04,2018-09-05,INTERVENTIONAL,PHASE2|PHASE3,6.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Type 1 Diabetes Mellitus,Artificial Pancreas App,DEVICE,1,7,18 Years,75 Years,ALL,False,Sansum Diabetes Research Institute,OTHER,1,1,United States,1.0,0,1,1,0,1,2.5,0,0,0,0,1,1.9459101490553132,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,8,1,0,0,1,1,0,,,,,0,2,0
NCT02784288,Phase II Treatment Stratification Trial Using Neck Dissection-Driven Selection to Improve Quality of Life for Low Risk Patients With HPV+ Oropharyngeal Squamous Cell Cancer,Phase II Treatment Stratification Trial Using Neck Dissection-Driven Selection to Improve Quality of Life for Low Risk Patients With HPV+ Oropharyngeal Squamous Cell Cancer,COMPLETED,2016-10-31,2022-07-12,2023-06-27,INTERVENTIONAL,PHASE2,40.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Oropharyngeal Squamous Cell Cancer,Neck Dissection|Standard-of-Care (SOC) Transoral Surgery of Primary Site|SOC Radiation|SOC Carboplatin|SOC Paclitaxel|Videofluoroscopy,DRUG|RADIATION|PROCEDURE,1,5,18 Years,,ALL,False,University of Michigan Rogel Cancer Center,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.713572066704308,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,6,1,1,0,0,6,1,,,,,0,2,0
NCT05212688,Randomised Study to Investigate the Effectiveness of Acupuncture for the Relief of Long COVID-19 Related Fatigue,A Randomised Phase II Study to Investigate the Effectiveness of ACUpuncture for the Relief of Long COVID Related Fatigue.,COMPLETED,2022-07-19,2024-09-25,2024-10-18,INTERVENTIONAL,PHASE2,119.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,COVID-19,Acupuncture|Active Control,OTHER,1,0,18 Years,,ALL,False,Royal Marsden NHS Foundation Trust,OTHER,0,1,United Kingdom,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.787491742782046,medium,0,1,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,2,1,,,,,0,1,0
NCT06889688,Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer,"A Multicenter, Phase III, Randomized Controlled Trial Comparing Camrelizumab Plus Apatinib and Eribulin Versus Physician's Choice Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer",ACTIVE_NOT_RECRUITING,2025-04-01,2031-03-31,2025-05-15,INTERVENTIONAL,PHASE3,246.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,NONE,Breast Cancer Stage IV,Camrelizumab+Apatinib+Eribulin|Physician's choice chemotherapy,DRUG,2,7,18 Years,70 Years,FEMALE,False,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,OTHER,0,6,China,,0,0,1,0,0,3.0,1,0,0,0,1,5.5093883366279774,large,0,0,0,1,0,0,1,0,0,0,1,0,1,1,9,1,1,0,0,2,1,,,,,0,2,0
NCT00247988,Weekly Carboplatin and Taxotere in Platinum Sensitive Relapsed Ovarian or Tubal or Primary Peritoneal Cancers,Phase II Study of Weekly Carboplatin and Taxotere in Platinum Sensitive Relapsed Ovarian or Tubal or Primary Peritoneal Cancers,TERMINATED,2003-10,2007-04,2007-04-24,INTERVENTIONAL,PHASE2,38.0,,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Platinum Sensitive Relapsed Ovarian Cancer,Weekly Taxotere with weekly carboplatin,DRUG,1,1,,,FEMALE,False,University of Saskatchewan,OTHER,1,1,Canada,0.0,0,1,0,0,0,2.0,1,0,0,0,1,3.6635616461296463,small,1,0,0,1,0,1,0,0,0,0,0,0,1,0,2,1,1,0,0,1,0,2003-10-01,2007-04-01,1278.0,2003.0,0,0,0
NCT01000688,Vildagliptin and Endothelium-dependent Vasodilatation,The Effect of Vildagliptin on Endothelium-dependent Vasodilatation. A Double Blind Cross-over Study in Type 2 Diabetes Mellitus.,COMPLETED,2010-01,2010-10,2010-11-05,INTERVENTIONAL,PHASE3,16.0,ESTIMATED,RANDOMIZED,CROSSOVER,PREVENTION,TRIPLE,Type 2 Diabetes|Endothelial Dysfunction,vildagliptin + acarbose|acarbose + vildagliptin,DRUG,1,3,35 Years,75 Years,ALL,False,Radboud University Medical Center,OTHER,0,1,Netherlands,1.0,0,0,1,0,0,3.0,0,0,0,0,2,2.833213344056216,small,1,0,0,1,0,0,0,0,0,0,1,1,0,0,4,1,1,0,0,2,1,2010-01-01,2010-10-01,273.0,2010.0,0,2,0
NCT00034788,A Study on the Efficacy and Safety of Long-Term Treatment and Re-Treatment of Lower Extremity Diabetic Ulcers With REGRANEX,A Multicenter Clinical Evaluation of the Efficacy and Safety of REGRANEX Gel in the Long-Term Treatment and Re-Treatment of Lower Extremity Diabetic Ulcers,TERMINATED,2000-12,2004-02,2011-06-08,INTERVENTIONAL,PHASE3,84.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Foot Ulcer|Diabetic Foot|Skin Ulcer|Diabetic Neuropathies,Becaplermin,DRUG,1,1,18 Years,80 Years,ALL,False,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INDUSTRY,0,0,,0.0,0,0,1,0,0,3.0,0,0,0,0,4,4.442651256490317,medium,1,1,1,0,0,0,0,0,0,0,1,1,1,1,2,1,1,0,0,1,0,2000-12-01,2004-02-01,1157.0,2000.0,0,1,0
NCT01274403,"A Randomized Study With Oral Melphalan + Prednisone (MP) Versus Melphalan, + Prednisone + Thalidomide (MPT) for Newly Diagnosesd Elderly Patients With Multiple Myeloma",,COMPLETED,,,2011-01-11,INTERVENTIONAL,PHASE2,130.0,ACTUAL,RANDOMIZED,,,NONE,Multiple Myeloma,"Melphalan, Prednisone and Thalidomide",DRUG,2,2,65 Years,,ALL,False,Gruppo Italiano Studio Linfomi,OTHER,0,1,Italy,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.875197323201151,medium,0,1,0,1,0,0,0,0,0,1,1,0,0,0,4,1,1,0,0,1,0,,,,,0,0,0
NCT02705703,Consolidation Therapy in Patients With Metastatic Solid Malignancies,"Phase I/II Study of Low-Dose Cyclophosphamide, Tumor Associated Peptide Antigen (TAPA)-Pulsed Dendritic Cell (DC) Therapy and Low Dose GM-CSF, as Consolidation Therapy in Patients With Metastatic Solid Malignancies",WITHDRAWN,2017-07-28,2019-01-31,2018-08-28,INTERVENTIONAL,PHASE1|PHASE2,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Cancer|Metastatic Solid Malignancies,TAPA-pulsed DC vaccine,BIOLOGICAL,1,2,18 Years,,ALL,False,Kiromic BioPharma Inc.,INDUSTRY,0,0,,0.0,1,1,0,0,1,1.5,1,0,0,0,2,0.0,,1,1,1,0,0,0,0,0,0,0,0,0,1,0,3,1,0,1,0,1,0,,,,,0,2,0
NCT05123703,A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS),"A Phase III Multicenter, Randomized, Double-blind, Double-dummy Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis",ACTIVE_NOT_RECRUITING,2022-05-19,2029-09-17,2026-01-30,INTERVENTIONAL,PHASE3,188.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Relapsing-Remitting Multiple Sclerosis,Ocrelizumab|Ocrelizumab Placebo|Fingolimod|Fingolimod Placebo,DRUG|OTHER,1,6,10 Years,17 Years,ALL,False,Hoffmann-La Roche,INDUSTRY,1,102,Latvia|Germany|Serbia|Switzerland|Greece|Italy|Spain|Estonia|Portugal|Canada|Argentina|India|United States|Austria|Australia|Romania|United Kingdom|Poland|Mexico|Ukraine|France|Belgium|Hungary|Brazil|Morocco,,0,0,1,0,0,3.0,0,1,0,0,1,5.241747015059643,medium,0,1,1,0,1,1,1,1,1,1,1,1,1,1,7,1,1,0,0,4,1,,,,,0,3,1
NCT03997903,Imatinib for Pain in Sickle Cell Anemia,IMatinib for PAin in Chronic Treatment of Sickle Cell Anemia (IMPACT SCA): A Pilot Study of Imatinib in Patients With Sickle Cell Anemia and Recurrent Vaso-occlusive Pain,TERMINATED,2020-02-26,2024-08-06,2026-01-29,INTERVENTIONAL,PHASE1|PHASE2,7.0,ACTUAL,,SINGLE_GROUP,BASIC_SCIENCE,NONE,Sickle Cell Disease,Imatinib Mesylate,DRUG,4,5,18 Years,25 Years,ALL,True,Indiana University,OTHER,2,2,United States,0.0,1,1,0,0,1,1.5,0,0,0,0,1,2.0794415416798357,small,1,1,0,1,0,1,1,0,1,0,0,0,0,0,9,1,1,0,0,1,0,,,,,0,2,0
NCT00004203,Oxaliplatin in Treating Patients With Metastatic Bladder Cancer,A Phase II Study of Oxaliplatin in Urothelial Cancer,COMPLETED,2000-02,2005-04,2013-09-05,INTERVENTIONAL,PHASE2,20.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter,oxaliplatin,DRUG,1,0,18 Years,,ALL,False,University of Chicago,OTHER,1,14,Canada|United States,1.0,0,1,0,0,0,2.0,1,0,0,0,2,3.044522437723423,small,1,1,0,1,0,1,1,1,1,0,0,0,1,0,1,0,1,0,0,1,0,2000-02-01,2005-04-01,1886.0,2000.0,0,2,0
NCT00489203,Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer,A Phase II Study to Evaluate the Efficacy of Oral Beclomethasone Dipropionate for Prevention of Acute GVHD After Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens,COMPLETED,2007-04,,2021-02-03,INTERVENTIONAL,PHASE2,140.0,ACTUAL,RANDOMIZED,PARALLEL,SUPPORTIVE_CARE,QUADRUPLE,"Hematopoietic/Lymphoid Cancer|Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Atypical Chronic Myeloid Leukemia|Blastic Phase Chronic Myelogenous Leukemia|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Chronic Myelogenous Leukemia|Childhood Myelodysplastic Syndromes|Chronic Eosinophilic Leukemia|Chronic Myelomonocytic Leukemia|Chronic Neutrophilic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|de Novo Myelodysplastic Syndromes|Essential Thrombocythemia|Extramedullary Plasmacytoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Graft Versus Host Disease|Isolated Plasmacytoma of Bone|Juvenile Myelomonocytic Leukemia|Meningeal Chronic Myelogenous Leukemia|Myelodysplastic/Myeloproliferative Disease, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Previously Treated Myelodysplastic Syndromes|Primary Myelofibrosis|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Myelodysplastic Syndromes|Stage I Adult Burkitt Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Diffuse Small Cleaved Cell Lymphoma|Stage I Adult Hodgkin Lymphoma|Stage I Adult Immunoblastic Large Cell Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage I Adult T-cell Leukemia/Lymphoma|Stage I Childhood Hodgkin Lymphoma|Stage I Chronic Lymphocytic Leukemia|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Multiple Myeloma|Stage I Mycosis Fungoides/Sezary Syndrome|Stage I Small Lymphocytic Lymphoma|Stage II Adult Hodgkin Lymphoma|Stage II Adult T-cell Leukemia/Lymphoma|Stage II Chronic Lymphocytic Leukemia|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma|Stage II Multiple Myeloma|Stage II Mycosis Fungoides/Sezary Syndrome|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Multiple Myeloma|Stage III Mycosis Fungoides/Sezary Syndrome|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|Stage IV Small Lymphocytic Lymphoma",beclomethasone dipropionate|placebo|tacrolimus|methotrexate|allogeneic hematopoietic stem cell transplantation,DRUG|PROCEDURE,1,16,,,ALL,False,Fred Hutchinson Cancer Center,OTHER,0,2,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,136,4.948759890378168,medium,0,1,0,1,0,0,1,0,1,0,1,1,0,1,17,1,1,0,0,5,1,2007-04-01,,,2007.0,0,3,1
NCT04329403,Clinical Endpoint Bioequivalence Study of Adapalene Gel 0.1%,"Randomized, Double Blind, Placebo Controlled, Parallel Group Design, Three Arm, Multicentric Study to Evaluate the Efficacy and Safety of Topical Adapalene Gel, 0.1 % in Healthy Males and Nonpregnant Female Subjects With Acne Vulgaris",WITHDRAWN,2020-07,2021-05,2020-06-26,INTERVENTIONAL,PHASE3,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Acne Vulgaris,Adapalene 0.1% Gel|Differin 0.1% Topical Gel|Placebo,DRUG|OTHER,2,2,12 Years,40 Years,ALL,False,Aurobindo Pharma Ltd,INDUSTRY,0,0,,0.0,0,0,1,0,0,3.0,0,0,0,0,1,0.0,,1,1,1,0,0,0,0,0,0,0,1,1,1,1,4,1,1,0,0,3,1,2020-07-01,2021-05-01,304.0,2020.0,1,1,0
NCT03134703,Methadone Demonstration Project With Neonatal Intensive Care Unit Infants Diagnosed With Neonatal Abstinence Syndrome,Methadone Demonstration Project With Neonatal Intensive Care Unit Infants Diagnosed With Neonatal Abstinence Syndrome,TERMINATED,2017-02-27,2019-03-27,2023-07-03,INTERVENTIONAL,PHASE2,11.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Neonatal Abstinence Syndrome,Methadone|Morphine,DRUG,1,10,,72 Hours,ALL,False,Johns Hopkins All Children's Hospital,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,2.4849066497880004,small,1,1,0,1,0,1,0,0,1,0,0,0,1,1,11,1,1,0,0,2,1,,,,,0,2,0
NCT00151827,Olmesartan Medoxomil in Hypertension and Renal Impairment,Efficacy and Safety of Olmesartan Medoxomil Compared With Losartan in Patients With Hypertension and Mild to Moderate Renal Impairment,COMPLETED,2003-08,2005-07,2010-10-14,INTERVENTIONAL,PHASE3,393.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Essential Hypertension|Renal Impairment,Olmesartan medoxomil|Losartan|Furosemide oral tablets,DRUG,1,7,18 Years,75 Years,ALL,False,Sankyo Pharma Gmbh,INDUSTRY,0,1,Germany,1.0,0,0,1,0,0,3.0,0,0,0,1,2,5.976350909297934,large,0,1,1,0,0,0,0,0,0,1,1,1,1,1,8,1,1,0,0,3,1,2003-08-01,2005-07-01,700.0,2003.0,0,3,1
NCT00825227,Safety and Efficacy of Armodafinil for Fatigue Associated With Taxanes Alone or in Combination With Other Agents,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Armodafinil Treatment (150 mg/Day) for Patients With Fatigue Associated With Taxane Chemotherapy Alone or in Combination With Other Agents",TERMINATED,2008-12,2010-02,2017-11-17,INTERVENTIONAL,PHASE2,10.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Fatigue|Chemotherapy Side Effects,"Armodafinil 150 mg/day|Placebo,",DRUG,1,2,18 Years,,ALL,False,Cephalon,INDUSTRY,0,29,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,2,2.3978952727983707,small,1,1,1,0,0,0,1,0,1,0,1,1,1,1,3,1,1,0,0,2,1,2008-12-01,2010-02-01,427.0,2008.0,0,2,0
NCT05195827,Effect of PRM-125 on Ambulatory Blood Pressure,Evaluation of Once-Daily PRM125 On Ambulatory Blood Pressure in Adults With Hypertension,WITHDRAWN,2021-12-20,2022-11-30,2023-03-20,INTERVENTIONAL,PHASE3,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Hypertension,PRM-125,DRUG,1,1,30 Years,80 Years,ALL,False,"PRM Pharma, LLC",INDUSTRY,0,1,United States,0.0,0,0,1,0,0,3.0,0,0,0,1,1,0.0,,1,1,1,0,0,0,0,0,1,0,0,0,1,0,2,1,1,0,0,1,0,,,,,0,0,0
NCT02770261,Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R208 and Each Monotherapy,"A Multi-center, Randomized, Double-blind, Parellel Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R208 and Each Monotherapy in Patients With Hypertension and Primary Hypercholesterolemia.",COMPLETED,2015-12,2016-10,2016-12-26,INTERVENTIONAL,PHASE3,219.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Hypertension|Cholesterolemia,DP-R208|Candesartan32mg|Rosuvastatin 20mg|DP-R208 Placebo|Candesartan32mg Placebo|Rosuvastatin 20mg Placebo,DRUG,1,0,19 Years,,ALL,False,Alvogen Korea,INDUSTRY,0,1,South Korea,1.0,0,0,1,0,0,3.0,0,0,0,1,2,5.393627546352362,large,0,1,1,0,0,0,0,0,0,0,1,1,1,1,1,0,1,0,0,6,1,2015-12-01,2016-10-01,305.0,2015.0,1,2,0
NCT05684861,Serum TWEAK Levels in Acne Vulgaris,Serum TWEAK Levels in Acne Vulgaris Patients Treated With Oral Isotretinoin,COMPLETED,2022-01-01,2023-01-01,2023-01-13,INTERVENTIONAL,PHASE2,150.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,DIAGNOSTIC,SINGLE,Acne Vulgaris,Isotretinoin|ELISA Assays of Serum TWEAK.,DRUG|DIAGNOSTIC_TEST,1,1,10 Years,60 Years,ALL,True,South Valley University,OTHER,0,1,Egypt,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.017279836814924,medium,0,1,0,1,0,0,0,0,0,0,1,0,0,0,2,1,1,0,0,2,1,,,,,0,1,0
NCT00081861,Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma,A Phase II Study of Avastin Plus Rituximab for Patients With Relapsed and Chemotherapy- or Rituxan-Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma,COMPLETED,2004-03,2007-09,2012-04-05,INTERVENTIONAL,PHASE2,13.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Lymphoma,Avastin|Rituximab,DRUG,1,0,18 Years,,ALL,True,M.D. Anderson Cancer Center,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,2.6390573296152584,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,2,1,2004-03-01,2007-09-01,1279.0,2004.0,0,1,0
NCT03490942,Glucagon Infusion in T1D Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses,Fixed Rate Continuous Subcutaneous Glucagon Infusion (CSGI) vs Placebo in Type 1 Diabetes Mellitus Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses to Insulin-Induced Hypoglycemia,TERMINATED,2018-03-15,2020-02-10,2021-02-21,INTERVENTIONAL,PHASE2,49.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Hypoglycemia Unawareness|Diabetes Mellitus, Type 1",Glucagon|Placebo,DRUG,1,0,21 Years,64 Years,ALL,False,Xeris Pharmaceuticals,INDUSTRY,1,5,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,2,3.912023005428146,small,1,1,1,0,0,1,1,0,1,0,1,1,1,1,1,0,1,0,0,2,1,,,,,0,2,0
NCT00138242,"Docetaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer",Phase II Trial of Weekly Docetaxel (Taxotere®) and Carboplatin as Initial Chemotherapy for Women With Ovarian Cancer and Similar Malignancies,COMPLETED,2004-12,2006-10,2013-06-26,INTERVENTIONAL,PHASE2,30.0,ESTIMATED,,,TREATMENT,NONE,Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer,carboplatin|docetaxel|adjuvant therapy,DRUG|PROCEDURE,1,5,18 Years,,FEMALE,False,Floyd & Delores Jones Cancer Institute at Virginia Mason Medical Center,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,3,3.4339872044851463,small,1,0,0,1,0,0,0,0,1,0,0,0,1,0,6,1,1,0,0,3,1,2004-12-01,2006-10-01,669.0,2004.0,0,3,1
NCT02258542,A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA,"A Multicentre, Double-blind, Randomized, Parallel Group, Phase 3 Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus Long-acting β2 Agonist (BORA)",COMPLETED,2014-11-19,2018-07-02,2019-08-21,INTERVENTIONAL,PHASE3,2133.0,ACTUAL,RANDOMIZED,PARALLEL,OTHER,DOUBLE,Asthma,Benralizumab|Benralizumab,BIOLOGICAL,16,26,12 Years,75 Years,ALL,False,AstraZeneca,INDUSTRY,0,429,Bulgaria|Germany|Japan|Vietnam|South Korea|Spain|Chile|Peru|Czechia|Canada|Russia|Argentina|Sweden|Turkey (Türkiye)|United States|United Kingdom|Australia|Romania|Poland|Philippines|South Africa|Ukraine|France|Brazil,1.0,0,0,1,0,0,3.0,0,0,0,0,1,7.665753431861699,xlarge,0,1,1,0,1,0,1,1,1,1,1,1,0,1,42,1,0,1,0,2,1,,,,,0,3,1
NCT04259086,Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Upper Facial Lines,"A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA for Injection (DAXI for Injection) for the Combined Treatment of Upper Facial Lines (Glabellar Lines, Dynamic Forehead Lines and Lateral Canthal Lines)",COMPLETED,2019-12-06,2020-11-02,2023-06-27,INTERVENTIONAL,PHASE2,48.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines)",DaxibotulinumtoxinA for injection,DRUG,3,0,18 Years,,ALL,False,"Revance Therapeutics, Inc.",INDUSTRY,0,8,Canada|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.8918202981106265,small,1,1,1,0,0,0,1,1,1,0,0,0,1,0,3,0,1,0,0,1,0,,,,,0,1,0
NCT00062374,Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction,"An Evaluation of Preoperative Chemotherapy With Irinotecan and Cisplatin for Advanced, But Resectable Gastric Cancer: A Coordinated Multidisciplinary, Multicenter Study Linking Functional Imaging, Genomic Expression Profiles and Histopathology",COMPLETED,2003-06,2011-06,2017-07-06,INTERVENTIONAL,PHASE2,55.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Gastric Adenocarcinoma|Stage II Gastric Cancer|Stage III Gastric Cancer|Stage IV Gastric Cancer,Cisplatin|Computed Tomography|Fludeoxyglucose F-18|Fluorothymidine F-18|Irinotecan Hydrochloride|Positron Emission Tomography|Therapeutic Conventional Surgery,DRUG|RADIATION|OTHER|PROCEDURE,1,0,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,4,4.02535169073515,medium,1,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,7,1,2003-06-01,2011-06-01,2922.0,2003.0,0,2,0
NCT03662074,Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer,Phase II Pilot Study of Subsequent Line Gemcitabine and Nivolumab for Advanced SCLC,TERMINATED,2018-11-07,2022-02-03,2023-08-02,INTERVENTIONAL,PHASE2,14.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Small Cell Lung Carcinoma|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8,Gemcitabine|Nivolumab,DRUG|BIOLOGICAL,1,5,18 Years,,ALL,False,Wake Forest University Health Sciences,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,4,2.70805020110221,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,6,1,1,1,0,2,1,,,,,0,3,1
NCT00263718,Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Psoriasis Vulgaris,"Calcipotriol Plus Betamethasone Dipropionate Gel Compared to Betamethasone Dipropionate in the Gel Vehicle, Calcipotriol in the Gel Vehicle and the Gel Vehicle Alone in Psoriasis Vulgaris",COMPLETED,2005-12,2006-05,2025-02-24,INTERVENTIONAL,PHASE2,360.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Psoriasis Vulgaris,Calcipotriol plus betamethasone dipropionate (LEO 80185) gel,DRUG,1,3,18 Years,,ALL,False,LEO Pharma,INDUSTRY,0,5,Sweden|Germany|United Kingdom|Ireland|Canada,1.0,0,1,0,0,0,2.0,0,1,0,0,1,5.8888779583328805,large,0,0,1,0,0,0,1,1,0,1,1,1,1,1,4,1,1,0,0,1,0,2005-12-01,2006-05-01,151.0,2005.0,0,1,0
NCT00010218,Karenitecin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer,Phase II Trial Of Karenitecin (IND 57250) In Patients With Relapsed or Refractory Non-small Cell Lung Cancer,COMPLETED,2001-04,2006-01,2016-07-19,INTERVENTIONAL,PHASE2,55.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Lung Cancer,karenitecin,DRUG,0,0,18 Years,,ALL,False,Alliance for Clinical Trials in Oncology,OTHER,1,44,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.02535169073515,medium,1,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,2001-04-01,2006-01-01,1736.0,2001.0,0,0,0
NCT02607618,Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-2,"A Phase 3, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Versus Vancomycin in the Treatment of ABSSSI: REVIVE-2",COMPLETED,2015-11,2017-08-08,2018-08-07,INTERVENTIONAL,PHASE3,613.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Skin Structures and Soft Tissue Infections,Iclaprim|Vancomycin,DRUG,1,1,18 Years,,ALL,False,Motif Bio,INDUSTRY,0,54,Belgium|Argentina|Turkey (Türkiye)|Hungary|United States|Croatia|Romania|Estonia|Czechia|Portugal,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.419994928147142,xlarge,0,1,1,0,0,0,1,1,1,0,1,1,1,1,2,1,1,0,0,2,1,2015-11-01,,,2015.0,1,2,0
NCT01312818,"Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)","A Therapeutic Trial of Bortezomib (Velcade), Vorinostat (SAHA) and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)",TERMINATED,2011-06,2013-01,2017-12-28,INTERVENTIONAL,PHASE2,2.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Acute Lymphoblastic Leukemia,Bortezomib|Vorinostat|Dexamethasone|Methotrexate|Imatinib mesylate,DRUG,1,2,2 Years,30 Years,ALL,False,"Masonic Cancer Center, University of Minnesota",OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,1.0986122886681098,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,3,1,1,0,0,5,1,2011-06-01,2013-01-01,580.0,2011.0,0,1,0
NCT04426890,To Compare Efficacy and Safety of CT-P39 and EU-approved Xolair in Patients With Chronic Spontaneous Urticaria,"A Double-blind, Randomized, Active-controlled, Parallel Group, Phase 3 Study to Compare Efficacy and Safety of CT-P39 and Xolair in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment",COMPLETED,2020-12-09,2023-04-27,2025-07-29,INTERVENTIONAL,PHASE3,634.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Chronic Spontaneous Urticaria,CT-P39|EU-approved Xolair,BIOLOGICAL,2,21,12 Years,75 Years,ALL,False,Celltrion,INDUSTRY,0,1,Poland,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.453624998892692,xlarge,0,1,1,0,0,0,0,0,0,0,1,1,1,1,23,1,0,1,0,2,1,,,,,0,2,0
NCT01482910,VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration),"A Randomized, Double-masked, Photodynamic Therapy-controlled Phase-3 Study of the Efficacy, Safety, and Tolerability of Intravitreal VEGF Trap-Eye in Chinese Subjects With Neovascular Age-Related Macular Degeneration",COMPLETED,2011-12,2014-08,2016-11-04,INTERVENTIONAL,PHASE3,304.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Macular Degeneration,"Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Visudyne",DRUG|BIOLOGICAL,1,1,50 Years,,ALL,False,Bayer,INDUSTRY,1,14,China,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.720311776607412,large,0,1,1,0,0,1,1,0,0,0,1,1,1,1,2,1,1,1,0,2,1,2011-12-01,2014-08-01,974.0,2011.0,0,1,0
NCT04989413,Cannabidiol 133mg + Cannabigerol 66mg + Tetrahydrocannabinol 4mg Vs Placebo As Adjuvant Treatment in Chronic Migraine -,"Randomized, Double Blind Clinical Trial to Study the Effect of Cannabidiol (CBD) 133mg + Cannabigerol (CBG) 66mg + Tetrahydrocannabinol (THC) 4mg a Day As Adjunctive Therapy in the Treatment of Chronic Migraine - CAMTREA TRIAL",TERMINATED,2022-10-18,2025-02-20,2025-02-24,INTERVENTIONAL,PHASE2|PHASE3,110.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Chronic Migraine, Headache|Overuse Headache Medication",Placebo oral drops|Cannabidiol + Cannabigerol + Tetrahydrocannabinol 133/66/4mg,DRUG,1,12,25 Years,65 Years,ALL,False,Hospital Israelita Albert Einstein,OTHER,1,1,Brazil,0.0,0,1,1,0,1,2.5,0,0,1,0,2,4.709530201312334,medium,0,1,0,1,0,1,0,0,0,0,1,1,1,1,13,1,1,0,0,2,1,,,,,0,4,1
NCT00023413,TBTC Study 23C: Pharmacokinetics of Intermittent Rifabutin and Isoniazid With Daily Efavirenz,TBTC Study 23C: Intensive Pharmacokinetic Study of Intermittent Rifabutin and Isoniazid With Daily Efavirenz in Combination With Two Nucleoside Analogs for Treatment of HIV and Tuberculosis Co-infections,COMPLETED,1999-11,2004-02,2012-06-05,INTERVENTIONAL,PHASE2,20.0,,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,HIV Infections|Tuberculosis,Rifabutin|Efavirenz,DRUG,1,3,18 Years,,ALL,False,Centers for Disease Control and Prevention,FED,1,23,Canada|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,3.044522437723423,small,1,0,0,0,0,1,1,1,1,0,0,0,1,0,4,1,1,0,0,2,1,1999-11-01,2004-02-01,1553.0,1999.0,0,3,1
NCT01869413,Tranexamic Acid During Cystectomy Trial (TACT),Tranexamic Acid During Cystectomy Trial (TACT),COMPLETED,2013-06,2021-06,2022-10-04,INTERVENTIONAL,PHASE2|PHASE3,354.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Bladder Cancer,Tranexamic Acid|Placebo,DRUG,1,8,18 Years,,ALL,False,Ottawa Hospital Research Institute,OTHER,7,10,Canada,1.0,0,1,1,0,1,2.5,1,0,0,0,1,5.872117789475416,large,0,1,0,1,0,1,1,0,0,0,1,1,0,1,9,1,1,0,0,2,1,2013-06-01,2021-06-01,2922.0,2013.0,0,3,1
NCT00808860,Anti-Diabetic Effect of Gynostemma Pentaphyllum Tea as add-on Therapy With Sulfonylureas in Type 2 Diabetic Patients,Anti-Diabetic Effect of Gynostemma Pentaphyllum Tea as add-on Therapy With Sulfonylureas in Type 2 Diabetic Patients,COMPLETED,2008-02,2008-12,2010-12-06,INTERVENTIONAL,PHASE1|PHASE2,25.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes,GP group|Placebo group,DIETARY_SUPPLEMENT,2,5,40 Years,70 Years,ALL,False,Hanoi Medical University,OTHER,2,1,Vietnam,1.0,1,1,0,0,1,1.5,0,0,0,0,1,3.258096538021482,small,1,1,0,1,0,1,0,0,0,0,1,1,1,1,7,1,0,0,0,2,1,2008-02-01,2008-12-01,304.0,2008.0,0,3,1
NCT01271660,A Study Evaluating the Efficacy and Safety of Pregabalin Against Frequent Muscle Cramp in Patients With Liver Cirrhosis,"A Randomized, Double-blinded, Placebo-controlled Study Evaluating the Efficacy and Safety of 6-week Treatment of Pregabalin Against Frequent Muscle Cramp in Patients With Liver Cirrhosis",COMPLETED,2011-07,2018-03,2020-03-20,INTERVENTIONAL,PHASE3,60.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Muscle Cramp|Liver Cirrhosis,Pregabalin|Placebo,DRUG,1,1,,75 Years,ALL,False,Seoul National University Boramae Hospital,OTHER,1,1,South Korea,1.0,0,0,1,0,0,3.0,0,0,0,0,2,4.110873864173311,medium,1,1,0,1,0,1,0,0,0,0,1,1,1,1,2,1,1,0,0,2,1,2011-07-01,2018-03-01,2435.0,2011.0,0,2,0
NCT00323960,Five-year Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis,"Five-year Single-blind, Phase III Effectiveness Randomised Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis: Prednisone Versus Prednisone Plus Cyclosporine a Versus Prednisone Plus Methotrexate",COMPLETED,2006-05-31,2015-11-29,2023-03-28,INTERVENTIONAL,PHASE3,139.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Juvenile Dermatomyositis,3 MPDN pulse + PDN|3 MPDN pulse + PDN + CSA|3 MPDN pulse + PDN + MTX,DRUG,2,2,1 Year,18 Years,ALL,False,Istituto Giannina Gaslini,OTHER,1,1,Italy,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.941642422609304,medium,0,1,0,1,0,1,0,0,0,1,1,0,1,1,4,1,1,0,0,3,1,,,,,0,1,0
NCT02004860,Tacrolimus Ointment Interest (PROTOPIC ®) in the Maintenance Treatment of Severe Seborrheic Dermatitis,Phase 3 : Tacrolimus Ointment Interest (PROTOPIC ®) in the Maintenance Treatment of Severe Seborrheic Dermatitis on Adult Face,COMPLETED,2014-01,2017-10,2018-05-29,INTERVENTIONAL,PHASE3,120.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Severe Seborrheic Dermatitis,Protopic (R)|Mycoster (R),DRUG,1,4,18 Years,,ALL,False,"University Hospital, Rouen",OTHER,0,1,France,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.795790545596741,medium,0,1,0,1,0,0,0,0,0,1,1,1,1,1,5,1,1,0,0,2,1,2014-01-01,2017-10-01,1369.0,2014.0,0,1,0
NCT04344860,Prevent Postpartum Hemorrhage in Women With Von Willebrand Disease: The VWD-WOMAN Trial,"Prospective, Randomized Trial Comparing Recombinant Von Willebrand Factor (rVWF) Plus Tranexamic Acid vs. rVWF Alone to Reduce Postpartum Hemorrhage in Women With Von Willebrand Disease: The VWD-WOMAN Trial",COMPLETED,2021-06-04,2024-09-01,2025-10-31,INTERVENTIONAL,PHASE3,20.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Von Willebrand Diseases|Postpartum Hemorrhage,Recombinant Von Willebrand factor|Tranexamic Acid Injection [Cyklokapron],DRUG,1,3,18 Years,,FEMALE,False,Nicoletta C Machin,OTHER,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,2,3.044522437723423,small,1,1,0,1,0,0,0,0,1,0,1,0,0,1,4,1,1,0,0,2,1,,,,,0,2,0
NCT04845620,Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED),"A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects With Atopic Dermatitis",COMPLETED,2021-04-07,2023-06-01,2025-12-23,INTERVENTIONAL,PHASE3,652.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Atopic Dermatitis Eczema,Roflumilast Cream 0.05%|Vehicle Cream,DRUG,1,7,2 Years,5 Years,ALL,False,"Arcutis Biotherapeutics, Inc.",INDUSTRY,0,76,Canada|United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.481577129276431,xlarge,0,1,1,0,0,0,1,1,1,0,1,1,1,1,8,1,1,0,0,2,1,,,,,0,3,1
NCT05249920,Treatment of Acute Ischemic STroke With Edaravone Dexborneol II (TASTE-2),Treatment of Acute Ischemic STroke With Edaravone Dexborneol Ⅱ (TASTE-2),COMPLETED,2022-03-18,2023-05-19,2023-08-22,INTERVENTIONAL,PHASE3,1362.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Acute Ischemic Stroke|Mechanical Thrombectomy|Edaravone Dexborneol|Phase III,Edaravone Dexborneol Concentrated Solution for injection|Edaravone Dexborneol placebo,DRUG,2,8,18 Years,80 Years,ALL,False,Beijing Tiantan Hospital,OTHER,0,1,China,1.0,0,0,1,0,0,3.0,0,0,0,0,4,7.217443431696533,xlarge,0,1,0,1,0,0,0,0,0,0,1,1,1,1,10,1,1,0,0,2,1,,,,,0,3,1
NCT03661320,"A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer","A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy Alone Versus Neoadjuvant Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post- Surgery Therapy With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle- Invasive Bladder Cancer",ACTIVE_NOT_RECRUITING,2018-11-06,2027-12-30,2026-02-03,INTERVENTIONAL,PHASE3,855.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Urinary Bladder Neoplasms|Muscle-Invasive Bladder Cancer,Nivolumab|Gemcitabine|Cisplatin,DRUG|BIOLOGICAL,2,8,18 Years,,ALL,False,Bristol-Myers Squibb,INDUSTRY,1,172,Germany|Norway|Japan|Taiwan|Singapore|Greece|Italy|Netherlands|Finland|South Korea|Spain|Chile|Portugal|Canada|Russia|Argentina|United States|Austria|Australia|Romania|United Kingdom|Mexico|New Zealand|Israel|France|Belgium|Brazil|Colombia,,0,0,1,0,0,3.0,1,0,0,0,2,6.752270376141742,xlarge,0,1,1,0,1,1,1,1,1,1,1,0,1,1,10,1,1,1,0,3,1,,,,,0,4,1
NCT03096782,Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma,Cord Blood Ex-Vivo MSC Expansion Plus Fucosylation to Enhance Homing and Engraftment,COMPLETED,2017-10-13,2022-09-20,2023-10-11,INTERVENTIONAL,PHASE2,6.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Acute Biphenotypic Leukemia|Acute Leukemia|Acute Lymphoblastic Leukemia|Acute Lymphoblastic Leukemia in Remission|Acute Myeloid Leukemia|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Chemotherapy-Related Leukemia|Chronic Lymphocytic Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Myelomonocytic Leukemia|Hodgkin Lymphoma|Langerhans Cell Histiocytosis|Minimal Residual Disease|Myelodysplastic Syndrome|Myelodysplastic Syndrome With Excess Blasts|Non-Hodgkin Lymphoma|Recurrent Hodgkin Lymphoma|Refractory Acute Lymphoblastic Leukemia|Refractory Myelodysplastic Syndrome|Small Lymphocytic Lymphoma|Therapy-Related Myelodysplastic Syndrome",Anti-Thymocyte Globulin|Busulfan|Clofarabine|Cyclophosphamide|Filgrastim-sndz|Fludarabine|Melphalan|Mycophenolate Mofetil|Rituximab|Tacrolimus|Total-Body Irradiation|Umbilical Cord Blood Transplantation,DRUG|BIOLOGICAL|RADIATION|PROCEDURE,1,2,12 Years,65 Years,ALL,False,M.D. Anderson Cancer Center,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,22,1.9459101490553132,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,3,1,1,1,0,12,1,,,,,0,2,0
NCT00651482,Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus),Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus),TERMINATED,2008-08,2012-03,2017-04-11,INTERVENTIONAL,PHASE2,10.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Kidney Neoplasms|Kidney (Renal Cell) Cancer,Everolimus|Bevacizumab,DRUG,1,8,18 Years,,ALL,False,Sandy Srinivas,OTHER,2,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,2,2.3978952727983707,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,9,1,1,0,0,2,1,2008-08-01,2012-03-01,1308.0,2008.0,0,3,1
NCT00017082,Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer,"A Multicenter, Phase II Study Of Oxaliplatin Single Agent As Third-Line Treatment Of Metastatic Colorectal Carcinoma",COMPLETED,2001-04,2010-12,2013-06-26,INTERVENTIONAL,PHASE2,,,,,TREATMENT,,Colorectal Cancer,oxaliplatin,DRUG,0,0,18 Years,,ALL,False,Prologue Research International,INDUSTRY,0,10,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,0.0,,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,2001-04-01,2010-12-01,3531.0,2001.0,0,0,0
NCT03185182,Diagnostic Imaging for Clear Cell Renal Cell Carcinoma,"""An Exploratory Study Regarding the Use of the Biomarker Dopamine Transporter (DAT) for Image Diagnosis of Clear Cell Renal Cell Carcinoma""",TERMINATED,2017-07-14,2018-09-12,2019-06-21,INTERVENTIONAL,PHASE2,5.0,ACTUAL,,SINGLE_GROUP,DIAGNOSTIC,NONE,Clear Cell Renal Cell Carcinoma,Ioflupane I123,DRUG,1,1,18 Years,,ALL,False,Region Skane,OTHER,1,1,Sweden,0.0,0,1,0,0,0,2.0,1,0,0,0,1,1.791759469228055,small,1,1,0,1,0,1,0,0,0,0,0,0,0,0,2,1,1,0,0,1,0,,,,,0,0,0
NCT00152282,A Study to Evaluate the Safety and Effectiveness of Asoprisnil and Estrogen Administration to Postmenopausal Women,A Phase II Pilot Study to Evaluate the Safety and Efficacy of J867 Administered With Estrogen to Postmenopausal Women,COMPLETED,2000-09,2001-08,2008-05-29,INTERVENTIONAL,PHASE2,105.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Amenorrhea|Postmenopause,Asoprisnil/Premarin|Asoprisnil/Premarin|Asoprisnil/Premarin|Placebo and Premarin,DRUG,2,4,48 Years,65 Years,FEMALE,False,Abbott,INDUSTRY,0,0,,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.663439094112067,medium,0,1,1,0,0,0,0,0,0,0,1,1,1,1,6,1,1,0,0,4,1,2000-09-01,2001-08-01,334.0,2000.0,0,3,1
NCT01402882,Clinical Randomisation of an Antifibrinolytic in Significant Head Injury,"Tranexamic Acid for the Treatment of Significant Traumatic Brain Injury: an International Randomised, Double Blind Placebo Controlled Trial",COMPLETED,2012-07,2019-10,2020-02-17,INTERVENTIONAL,PHASE3,12737.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Traumatic Brain Injury,Tranexamic Acid,DRUG,1,6,16 Years,,ALL,False,London School of Hygiene and Tropical Medicine,OTHER,0,1,Georgia,1.0,0,0,1,0,0,3.0,0,0,0,0,1,9.45234493093131,,0,1,0,1,0,0,0,0,0,0,1,1,1,1,7,1,1,0,0,1,0,2012-07-01,2019-10-01,2648.0,2012.0,0,1,0
NCT00249782,"A Phase II, Randomized Study of ACZONE™ (Dapsone) Gel, 5% for Papulopustular Rosacea.","A Phase II, Randomized, Partial-Blind, Parallel-Group, Active- and Vehicle-Controlled, Multicenter Study of the Safety and Efficacy of ACZONE™ (Dapsone) Gel, 5% in Subjects With Papulopustular Rosacea",COMPLETED,2005-11,2006-05,2011-05-30,INTERVENTIONAL,PHASE2,400.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Rosacea,"Vehicle control, 2x/day|ACZONE (dapsone) Gel, 5%, 2x/day|ACZONE (dapsone) Gel, 5%, 1x/day|MetroGel® (metronidazole gel), 1.0% 1x/day|ACZONE (dapsone) Gel, 5%, 1x/day (AM) + MetroGel (metronidazole gel), 1.0%, 1x/day (PM)",DRUG,4,2,18 Years,,ALL,False,Allergan,INDUSTRY,0,26,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.993961427306569,large,0,1,1,0,0,0,1,0,1,0,1,0,1,1,6,1,1,0,0,5,1,2005-11-01,2006-05-01,181.0,2005.0,0,2,0
NCT01309659,Trial To Evaluate the Efficacy of Intravenous Iron in Older Adults With Unexplained Anemia,"A Randomized, Open-Label, Wait-list Control Trial To Evaluate the Efficacy of Intravenous Iron in Older Adults With Unexplained Anemia and a Serum Ferritin Between 20 and 200 ng/mL",TERMINATED,2011-05,2014-09,2016-02-05,INTERVENTIONAL,PHASE2,19.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Anemia|Unexplained Anemia (UAE),iron sucrose|iron sucrose,DRUG,1,17,65 Years,,ALL,False,Duke University,OTHER,1,5,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,2,2.995732273553991,small,1,1,0,1,0,1,1,0,1,0,1,0,1,1,18,1,1,0,0,2,1,2011-05-01,2014-09-01,1219.0,2011.0,0,3,1
NCT01465659,Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery,A Phase I/II Study of the Combination of Temozolomide and Pazopanib in Advanced Pancreatic Neuroendocrine Tumors (PNET),COMPLETED,2011-12-12,2021-01-27,2021-08-05,INTERVENTIONAL,PHASE1|PHASE2,29.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Pancreatic Alpha Cell Carcinoma|Pancreatic Beta Islet Cell Carcinoma|Pancreatic Delta Cell Carcinoma|Pancreatic G-cell Carcinoma|Recurrent Islet Cell Carcinoma,temozolomide|pazopanib hydrochloride,DRUG,2,6,18 Years,,ALL,False,Northwestern University,OTHER,3,5,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,5,3.4011973816621555,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,8,1,1,0,0,2,1,,,,,0,4,1
NCT00410059,BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC,"A Phase II, Open Label Study of Erlotinib (Tarceva) in Previously Treated Subjects With Advanced Non-Small Cell Lung Cancer",COMPLETED,2006-11,2016-07,2017-08-02,INTERVENTIONAL,PHASE2,59.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Lung Cancer,Erlotinib,DRUG,1,0,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.0943445622221,medium,1,1,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,2006-11-01,2016-07-01,3530.0,2006.0,0,0,0
NCT02923180,Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer,A Phase II Trial of Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate- and High-Risk Prostate Cancer,ACTIVE_NOT_RECRUITING,2017-02-14,2026-07,2025-07-22,INTERVENTIONAL,PHASE2,33.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Prostate Cancer,Enoblituzumab,DRUG,2,13,18 Years,,MALE,False,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,OTHER,1,1,United States,,0,1,0,0,0,2.0,1,0,0,0,1,3.5263605246161616,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,15,1,1,0,0,1,0,,2026-07-01,,,0,1,0
NCT04795180,Pilot Randomized Evaluation of Butyrate Irrigation Before Ileostomy Closure on the Colonic Mucosa in Rectal Cancer Patients (BUTYCLO),Pilot Randomized Evaluation of Butyrate Irrigation Before Ileostomy Closure on the Colonic Mucosa in Rectal Cancer Patients: Short-term Outcomes and Microbiota (BUTYCLO),COMPLETED,2013-12-10,2016-06-21,2021-03-12,INTERVENTIONAL,PHASE2,45.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Rectal Cancer,Irrigations trough the efferent limb of loop ileostomy,DRUG,2,4,18 Years,,ALL,False,Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta,OTHER,0,1,Spain,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.828641396489095,small,1,1,0,1,0,0,0,0,0,1,1,1,0,1,6,1,1,0,0,1,0,,,,,0,1,0
NCT02044380,Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations,An Open Label Trial of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s),COMPLETED,2014-03,2016-02,2017-03-31,INTERVENTIONAL,PHASE3,14.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Carcinoma, Non-Small-Cell Lung",Afatinib,DRUG,1,0,18 Years,,ALL,False,Boehringer Ingelheim,INDUSTRY,0,5,Canada,1.0,0,0,1,0,0,3.0,1,0,0,0,1,2.70805020110221,small,1,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,2014-03-01,2016-02-01,702.0,2014.0,0,0,0
NCT00116779,A Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate Cancer,"An Open-label, Randomized, Multi-center, Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate Cancer Dosed for Thirteen 28-day Cycles",COMPLETED,2004-02,2005-08,2011-12-19,INTERVENTIONAL,PHASE2,127.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Prostate Cancer,Degarelix,DRUG,2,11,18 Years,,MALE,False,Ferring Pharmaceuticals,INDUSTRY,0,35,Canada|United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.852030263919617,medium,0,1,1,0,0,0,1,1,1,0,1,0,1,1,13,1,1,0,0,1,0,2004-02-01,2005-08-01,547.0,2004.0,0,2,0
NCT00006079,Eflornithine To Prevent Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia,A Randomized Double-Blind Study of Alpha-Difluromethylornithine (DFMO) Versus Placebo in Patients With Cervical Intraepithelial Neoplasia (CIN) Grade 2-3,COMPLETED,1998-06-19,2004-04-27,2018-10-25,INTERVENTIONAL,PHASE2,150.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,PREVENTION,TRIPLE,Cervical Cancer|Precancerous Condition,Eflornithine|Placebo,DRUG|OTHER,1,0,18 Years,,FEMALE,False,M.D. Anderson Cancer Center,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,2,5.017279836814924,medium,0,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,2,1,,,,,0,2,0
NCT01276379,Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab,"Single-Arm, Multicenter, Prospective, Phase 2 Study for the Evaluation of Biomarkers in Patients With Advanced &/or Metastatic Colorectal Cancer With Wild Type KRAS Treated Biweekly With Chemotherapy and Cetuximab as First-Line Treatment",COMPLETED,2011-01,2017-12-21,2021-07-02,INTERVENTIONAL,PHASE2,221.0,ACTUAL,,SINGLE_GROUP,SCREENING,NONE,Colorectal Cancer,FOLFIRI (m)|FOLFOX-6 (m)|Cetuximab,DRUG,1,5,18 Years,,ALL,False,Grupo Espanol Multidisciplinario del Cancer Digestivo,OTHER,0,27,Spain,1.0,0,1,0,0,0,2.0,1,0,0,0,1,5.402677381872279,large,0,1,0,1,0,0,1,0,0,1,0,0,0,0,6,1,1,0,0,3,1,2011-01-01,,,2011.0,0,2,0
NCT00158379,Taxol Carboplatin and Erythropoetin,Carboplatin With Following Taxol® Therapy Under Additional Application of Epoetin Alfa (ERYPO ®) With Female Patients With Advanced Ovarian Cancer FIGO IA/G3 - IV,COMPLETED,2003-07,2008-06,2017-02-06,INTERVENTIONAL,PHASE2,105.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Ovarian Cancer,Paclitaxel,DRUG,1,1,18 Years,,FEMALE,False,North Eastern German Society of Gynaecological Oncology,OTHER,0,0,,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.663439094112067,medium,0,1,0,1,0,0,0,0,0,0,0,0,1,0,2,1,1,0,0,1,0,2003-07-01,2008-06-01,1797.0,2003.0,0,0,0
NCT02667496,Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease,A Study Examining the Safety and Activity of Innate Immune System Stimulation With Leukine® (Sargramostim) to Reduce Brain Amyloid Load in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease,WITHDRAWN,2016-11,2017-03-31,2017-04-07,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Dementia Alzheimer's Type,Sargramostim GZ402664|Placebo|Florbetapir F18,DRUG,1,4,40 Years,80 Years,ALL,False,Sanofi,INDUSTRY,1,1,United States,0.0,0,1,0,0,0,2.0,0,0,1,0,1,0.0,,1,1,1,0,1,1,0,0,1,0,1,1,1,1,5,1,1,0,0,3,1,2016-11-01,,,2016.0,1,1,0
NCT02525796,Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism,Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism,COMPLETED,2016-01,2021-10-02,2023-05-03,INTERVENTIONAL,PHASE2|PHASE3,69.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Primary Hyperparathyroidism,eplerenone|amiloride|Placebo|Cinacalcet,DRUG,1,1,18 Years,80 Years,ALL,False,Brigham and Women's Hospital,OTHER,0,1,United States,1.0,0,1,1,0,1,2.5,0,0,0,0,1,4.248495242049359,medium,1,1,0,1,0,0,0,0,1,0,1,1,1,1,2,1,1,0,0,4,1,2016-01-01,,,2016.0,1,2,0
NCT00261196,Collagenase in the Treatment of Adhesive Capsulitis (Frozen Shoulder),Collagenase in the Treatment of Adhesive Capsulitis (Frozen Shoulder),WITHDRAWN,2006-01,2009-01,2019-10-03,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,TRIPLE,Adhesive Capsulitis|Frozen Shoulder,Collagenase,DRUG,1,1,18 Years,80 Years,ALL,False,Stony Brook University,OTHER,0,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,2,0.0,,1,1,0,1,0,0,0,0,1,0,1,1,1,0,2,1,1,0,0,1,0,2006-01-01,2009-01-01,1096.0,2006.0,0,1,0
NCT00501696,"A Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose Naltrexone","A Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose Naltrexone on Quality of Life as Measured by the Multiple Sclerosis Quality of Life Inventory (MSQLI54)",COMPLETED,2007-02,2007-11,2008-05-19,INTERVENTIONAL,PHASE3,80.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,TRIPLE,Multiple Sclerosis,4.5 mg Naltrexone|Naltrexone,DRUG,1,0,18 Years,86 Years,ALL,False,"University of California, San Francisco",OTHER,0,1,United States,1.0,0,0,1,0,0,3.0,0,1,0,0,1,4.394449154672439,medium,1,1,0,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,2,1,2007-02-01,2007-11-01,273.0,2007.0,0,1,0
NCT00401362,A a Single Dose Efficacy Study in Inducing Laxation in Advance Illness Patients,A Double-Blind Placebo-Controlled Study of Methylnaltrexone (MNTX) for the Relief of Constipation Due to Chronic Opioid Therapy in Patients With Advanced Medical Illness,COMPLETED,2003-02,2005-02,2019-11-25,INTERVENTIONAL,PHASE3,154.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Advanced Illness Patients With Opioid Induced Constipation,SC Methylnaltrexone|SC Placebo|SC Methylnaltrexone,DRUG,1,0,18 Years,,ALL,False,"Bausch Health Americas, Inc.",INDUSTRY,1,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.043425116919247,medium,0,1,1,0,0,1,0,0,1,0,1,1,1,1,1,0,1,0,0,3,1,2003-02-01,2005-02-01,731.0,2003.0,0,1,0
NCT01882062,Proof of Concept of an Anaplerotic Study Using Brain Phosphorus Magnetic Resonance Spectroscopy in Huntington Disease,,COMPLETED,2013-05,2013-07,2016-03-24,INTERVENTIONAL,PHASE2,10.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Huntington Disease,Triheptanoin 1g/kg/day,DRUG,1,1,18 Years,,ALL,False,"Institut National de la Santé Et de la Recherche Médicale, France",OTHER_GOV,0,1,France,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.3978952727983707,small,1,1,0,1,0,0,0,0,0,1,0,0,1,0,2,1,1,0,0,1,0,2013-05-01,2013-07-01,61.0,2013.0,0,0,0
NCT00459862,Pazopanib in Treating Patients With Malignant Pleural Mesothelioma,Phase II Study of GW786034 in Patients With Malignant Pleural Mesothelioma,COMPLETED,2007-03,2013-05,2015-02-24,INTERVENTIONAL,PHASE2,34.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Advanced Malignant Mesothelioma|Localized Malignant Mesothelioma|Recurrent Malignant Mesothelioma,laboratory biomarker analysis|pazopanib hydrochloride,DRUG|OTHER,1,5,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,3,3.5553480614894135,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,6,1,1,0,0,2,1,2007-03-01,2013-05-01,2253.0,2007.0,0,3,1
NCT01110746,"To Evaluate the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin During Subcutaneous Insulin Pump Therapy","A Double-blind Study of the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin During Subcutaneous Insulin Pump Therapy",COMPLETED,2010-02,2010-06,2015-08-03,INTERVENTIONAL,PHASE3,20.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Type 1 Diabetes Mellitus,Viaject 7|LISPRO,DRUG,1,1,18 Years,75 Years,ALL,False,Biodel,INDUSTRY,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.044522437723423,small,1,1,1,0,0,0,0,0,1,0,1,1,1,0,2,1,1,0,0,2,1,2010-02-01,2010-06-01,120.0,2010.0,0,1,0
NCT01117246,Pilot Study for Palliation of Pain in Bone Metastases by MR-HIFU,Pilot Study for the Treatment of Bone Metastases by High Intensity Focused Ultrasound Guided by MRI to Perform Pain Palliation,COMPLETED,2010-05,2011-10,2012-02-20,INTERVENTIONAL,PHASE1|PHASE2,2.0,ACTUAL,,SINGLE_GROUP,SUPPORTIVE_CARE,NONE,Secondary Malignant Neoplasm of Bone,High Intensity Focused Ultrasound,DEVICE,3,4,18 Years,80 Years,ALL,False,Philips Healthcare,INDUSTRY,0,1,France,1.0,1,1,0,0,1,1.5,0,0,0,0,1,1.0986122886681098,small,1,1,1,0,0,0,0,0,0,1,0,0,0,0,7,1,0,0,1,1,0,2010-05-01,2011-10-01,518.0,2010.0,0,2,0
NCT00533546,Activated Protein C in Acute Stroke Trial,Activated Protein C in Acute Stroke Trial,TERMINATED,2007-09,2010-10,2016-10-24,INTERVENTIONAL,PHASE2,12.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Stroke,Activated Protein C,DRUG,1,3,18 Years,,ALL,False,University of Rochester,OTHER,1,9,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,2.5649493574615367,small,1,1,0,1,1,1,1,0,1,0,0,0,1,0,4,1,1,0,0,1,0,2007-09-01,2010-10-01,1126.0,2007.0,0,0,0
NCT00754988,A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin.,"A Multicenter, Randomized, Double-dummy, Placebo and Active-controlled Study to Assess the Safety, Tolerability and Effect of Taspoglutide on Glycemic Control Compared to Sitagliptin and Placebo in Patients With Type II Diabetes Mellitus Inadequately Controlled With Metformin.",COMPLETED,2008-10,2011-03,2016-11-04,INTERVENTIONAL,PHASE3,666.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Diabetes Mellitus Type 2,Metformin|Placebo (matching sitagliptin)|Placebo (matching taspoglutide)|Sitagliptin|Taspoglutide,DRUG,1,2,18 Years,75 Years,ALL,False,Hoffmann-La Roche,INDUSTRY,0,148,Germany|Norway|Switzerland|Taiwan|Greece|Thailand|South Korea|Spain|Peru|Canada|Argentina|Sweden|Turkey (Türkiye)|Puerto Rico|United States|United Kingdom|Australia|Romania|Poland|Mexico|South Africa|France|Slovakia,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.502790045915623,xlarge,0,1,1,0,1,0,1,1,1,1,1,1,1,1,3,1,1,0,0,5,1,2008-10-01,2011-03-01,881.0,2008.0,0,2,0
NCT01902303,Evaluation of Cold Sore Treatments on Ultra Violet (UV) Induced Cold Sores,Evaluation of Cold Sore Treatments on UV Induced Cold Sores,COMPLETED,2013-07,2015-02,2016-04-28,INTERVENTIONAL,PHASE2,303.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Oral Herpes Simplex,Matching Placebo|BTL-TML-HSV,DRUG,1,1,18 Years,,ALL,False,"Beech Tree Labs, Inc.",INDUSTRY,2,3,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.717027701406222,large,0,1,1,0,0,1,1,0,1,0,1,1,1,1,2,1,1,0,0,2,1,2013-07-01,2015-02-01,580.0,2013.0,0,1,0
NCT00002703,Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer,A PHASE III TRIAL EMPLOYING CONFORMAL PHOTONS WITH PROTON BOOST IN EARLY STAGE PROSTATE CANCER: CONVENTIONAL DOSE COMPARED TO HIGH DOSE IRRADIATION,COMPLETED,1996-01,2005-09,2013-11-06,INTERVENTIONAL,PHASE3,390.0,ESTIMATED,RANDOMIZED,,TREATMENT,,Prostate Cancer,high-LET heavy ion therapy|low-LET photon therapy,RADIATION,0,0,,,MALE,False,Proton Radiation Oncology Group,OTHER,1,2,United States,1.0,0,0,1,0,0,3.0,1,0,0,0,1,5.968707559985366,large,0,0,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,2,1,1996-01-01,2005-09-01,3531.0,1996.0,0,1,0
NCT00931203,Trial of Celecoxib With Preoperative Chemo- Radiation for Locally Advanced Rectal Cancer,A Phase II Trial of Celecoxib With Preoperative Chemo- Radiation for Locally Advanced Rectal Cancer,COMPLETED,2008-07,2013-04,2016-05-04,INTERVENTIONAL,PHASE2,55.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Locally Advanced Rectal Cancer,Celecoxib,DRUG,1,4,18 Years,80 Years,ALL,False,"National Health Research Institutes, Taiwan",OTHER,7,1,Taiwan,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.02535169073515,medium,1,1,0,1,0,1,0,0,0,0,0,0,1,0,5,1,1,0,0,1,0,2008-07-01,2013-04-01,1735.0,2008.0,0,0,0
NCT01256203,Efficacy and Safety of a Sunscreen Against Porfimer Sodium-induced Phototoxicity to Visible Light,"Prospective, Randomized, Controlled, Partially Blinded, Skin Photobiological Clinical Study of the Efficacy and Safety of a Sunscreen Product as Skin Protector Against Porfimer Sodium-induced Phototoxicity to Visible Light",WITHDRAWN,2013-05,2014-03,2014-03-04,INTERVENTIONAL,PHASE2,0.0,ACTUAL,,SINGLE_GROUP,PREVENTION,SINGLE,High-grade Dysplasia in Barrett Esophagus|Non Small Cell Lung Cancer|Esophageal Cancer,Solar Protection Formula SPF® 60|Photobiological testing,DRUG|PROCEDURE,1,4,18 Years,,ALL,False,Pinnacle Biologics Inc.,INDUSTRY,0,0,,0.0,0,1,0,0,0,2.0,1,0,0,0,3,0.0,,1,1,1,0,0,0,0,0,0,0,0,0,0,0,5,1,1,0,0,2,1,2013-05-01,2014-03-01,304.0,2013.0,0,2,0
NCT03565003,A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China,"A Phase 1/2a, Multi-Center, Dose Escalation/Dose Expansion, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3068 in Adult Patients With Advanced Solid Tumors",COMPLETED,2018-11-20,2023-01-31,2024-09-25,INTERVENTIONAL,PHASE1|PHASE2,126.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Non-small Cell Lung Cancer|Head and Neck Cancer|Esophageal Cancer|Other Metastatic Solid Tumors,JAB-3068,DRUG,3,7,18 Years,,ALL,False,"Jacobio Pharmaceuticals Co., Ltd.",INDUSTRY,0,4,China,1.0,1,1,0,0,1,1.5,1,0,0,0,4,4.844187086458591,medium,0,1,1,0,0,0,1,0,0,0,0,0,1,0,10,1,1,0,0,1,0,,,,,0,3,1
NCT00248703,Secondary Adjuvant Treatment for Patients With Isolated Tumor Cells in Bone Marrow,Secondary Adjuvant (Rescue) Treatment With Docetaxel (Taxotere) and Detection of Isolated Tumor Cells in Bone Marrow as a Surrogate Marker for Effect in Node Positive and High Risk Node Negative Breast Cancer After Standard Adjuvant Epirubicin-containing Treatment,COMPLETED,2003-10,2022-04,2022-04-22,INTERVENTIONAL,PHASE2,1128.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Breast Cancer,Docetaxel,DRUG,1,2,18 Years,70 Years,ALL,False,Oslo University Hospital,OTHER,8,1,Norway,1.0,0,1,0,0,0,2.0,1,0,0,0,1,7.029087564149662,xlarge,0,1,0,1,0,1,0,0,0,0,0,0,1,0,3,1,1,0,0,1,0,2003-10-01,2022-04-01,6757.0,2003.0,0,0,0
NCT03483103,Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006),A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL (017006),COMPLETED,2018-07-27,2022-12-01,2023-12-20,INTERVENTIONAL,PHASE2,74.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Lymphoma, Non-Hodgkin|Lymphoma, Nonhodgkin|Lymphoma, B-Cell|Lymphoma, Large B-Cell, Diffuse",lisocabtagene maraleucel,BIOLOGICAL,1,36,18 Years,,ALL,False,"Juno Therapeutics, a Subsidiary of Celgene",INDUSTRY,0,59,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,4,4.31748811353631,medium,1,1,1,0,0,0,1,0,1,0,0,0,1,0,37,1,0,1,0,1,0,,,,,0,2,0
NCT00000303,Rapid Evaluation of Baclofen for Treatment of Cocaine Abuse/Dependence - 6,Rapid Evaluation of Cocaine Pharmacotherapies (Baclofen),COMPLETED,1997-10,,2016-07-11,INTERVENTIONAL,PHASE2,0.0,,RANDOMIZED,,TREATMENT,DOUBLE,Cocaine-Related Disorders,Baclofen,DRUG,4,0,18 Years,65 Years,ALL,False,"University of California, Los Angeles",OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,1,0,0,1,0,1,0,0,1,0,1,1,1,0,4,0,1,0,0,1,0,1997-10-01,,,1997.0,0,0,0
NCT03422627,Safety and Efficacy of Efavaleukin Alfa in Subjects With Steroid Refractory Chronic Graft Versus Host Disease,"A Phase 1b/2 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Efavaleukin Alfa in Adult Subjects With Steroid Refractory Chronic Graft Versus Host Disease",TERMINATED,2018-04-27,2022-10-13,2023-11-22,INTERVENTIONAL,PHASE1|PHASE2,32.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Chronic Graft Versus Host Disease cGVHD,Efavaleukin Alfa,DRUG,4,0,18 Years,100 Years,ALL,False,Amgen,INDUSTRY,0,14,Belgium|Japan|France|United States,0.0,1,1,0,0,1,1.5,0,0,0,0,1,3.4965075614664802,small,1,1,1,0,1,0,1,1,1,1,0,0,1,0,4,0,1,0,0,1,0,,,,,0,2,0
NCT02305927,"Trial of Vitamin D in HIV Progression, Birth Outcomes, and Child Health","Trial of Vitamin D in HIV Progression, Birth Outcomes, and Child Health",COMPLETED,2015-06-15,2019-09-18,2020-04-24,INTERVENTIONAL,PHASE3,2300.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,HIV,Vitamin D3 (cholecalciferol)|Placebo,OTHER|DIETARY_SUPPLEMENT,3,0,18 Years,,FEMALE,False,Wafaie Fawzi,OTHER,1,1,Tanzania,1.0,0,0,1,0,0,3.0,0,0,0,0,1,7.741099090035366,xlarge,0,1,0,1,0,1,0,0,0,0,1,1,0,1,3,0,0,0,0,2,1,,,,,0,1,0
NCT00301327,Efficacy and Safety of Summers Non-Pesticide Lice Asphyxiator (L.A.)for the Treatment of Head Lice.,"A Multi-Center, Randomized, Vehicle Controlled, Double Blind Clinical Trial to Evaluate the Efficacy and Safety of Summers Non-Pesticide Lice Asphyxiator (L.A.) for the Treatment of Head Lice.",COMPLETED,2006-01,,2007-05-30,INTERVENTIONAL,PHASE3,120.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Head Lice,Summers 5% L.A.,DRUG,1,1,6 Months,,ALL,False,Summers Laboratories,INDUSTRY,0,5,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.795790545596741,medium,0,0,1,0,0,0,1,0,1,0,1,1,1,1,2,1,1,0,0,1,0,2006-01-01,,,2006.0,0,0,0
NCT04603027,A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis,"A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Cohort, Dose-Ranging Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis",COMPLETED,2020-09-21,2021-12-06,2022-12-19,INTERVENTIONAL,PHASE2,249.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Psoriasis|Plaque Psoriasis,EDP1815|Placebo,DRUG,1,20,18 Years,70 Years,ALL,False,"Evelo Biosciences, Inc.",INDUSTRY,0,29,Poland|United Kingdom|Hungary|United States,1.0,0,1,0,0,0,2.0,0,1,0,0,2,5.521460917862246,large,0,1,1,0,0,0,1,1,1,1,1,1,1,1,21,1,1,0,0,2,1,,,,,0,4,1
NCT03236727,SSEP Fluctuations Due to Dexmedetomidine During Posterior Spine Fusion,SSEP Fluctuations Due to Dexmedetomidine During Posterior Spine Fusion,COMPLETED,2014-03,2016-06,2017-08-03,INTERVENTIONAL,PHASE3,25.0,ACTUAL,NON_RANDOMIZED,CROSSOVER,SUPPORTIVE_CARE,NONE,Spinal Fusion,Dexmedetomidine,DRUG,1,0,18 Years,75 Years,ALL,False,George Papanicolaou Hospital,OTHER,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.258096538021482,small,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,2014-03-01,2016-06-01,823.0,2014.0,0,0,0
NCT00163761,Efficacy Study of Outpatient Therapy for Lymphoma,A Multicentre Phase II Study of Risk-adjusted Outpatient-based Salvage Therapy for Patients With Relapsed and Refractory Lymphoma,COMPLETED,2002-12,2008-02,2016-01-08,INTERVENTIONAL,PHASE2,90.0,ACTUAL,NON_RANDOMIZED,CROSSOVER,TREATMENT,NONE,Non-Hodgkin's Lymphoma|Hodgkin's Disease,"gemcitabine, vinorelbine, ifosfamide, filgastrim|gemcitabine, vinorelbine, filgastrim",DRUG,1,4,18 Years,,ALL,False,Bayside Health,OTHER_GOV,0,10,Australia,1.0,0,1,0,0,0,2.0,1,0,0,0,2,4.51085950651685,medium,1,1,0,1,0,0,1,0,0,0,0,0,1,0,5,1,1,0,0,2,1,2002-12-01,2008-02-01,1888.0,2002.0,0,2,0
NCT02326142,A Phase 2 Study of OBE001 Versus Placebo in the Delay of Preterm Birth,"A Phase 2, Double-blind, Parallel Group, Randomised, Placebo Controlled, Proof of Concept Study to Assess the Safety and Efficacy of OBE001 After Oral Administration in Pregnant Women With Threatened Preterm Labour.",TERMINATED,2015-03,2017-10,2017-11-06,INTERVENTIONAL,PHASE2,10.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Preterm Labor,OBE001|Placebo,DRUG,1,4,18 Years,,FEMALE,False,ObsEva SA,INDUSTRY,0,23,Belgium|Spain|Germany|United Kingdom|Poland|Switzerland,0.0,0,1,0,0,0,2.0,0,0,0,0,1,2.3978952727983707,small,1,1,1,0,0,0,1,1,0,1,1,1,1,1,5,1,1,0,0,2,1,2015-03-01,2017-10-01,945.0,2015.0,1,2,0
NCT03348670,Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms,Explore the Relationship Between Single Nucleotide Polymorphisms and Abiraterone Response and Toxicity in Patients With Prostate Cancer.,ACTIVE_NOT_RECRUITING,2023-08-18,2026-05-28,2025-08-17,INTERVENTIONAL,PHASE2|PHASE3,600.0,ESTIMATED,RANDOMIZED,PARALLEL,HEALTH_SERVICES_RESEARCH,QUADRUPLE,Prostate Cancer,Abiraterone - Usual|Abiraterone - Study,DRUG,1,0,22 Years,75 Years,MALE,False,"Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair",INDUSTRY,0,1,United States,,0,1,1,0,1,2.5,1,0,0,0,1,6.398594934535208,xlarge,0,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,2,1,,,,,0,2,0
NCT00872170,Sildenafil to Improve Exercise Capacity in People With Thalassemia and Pulmonary Hypertension,Pilot of Oral Sildenafil for the Treatment of Pulmonary Hypertension in Thalassemia With Comparison to Controls,COMPLETED,2009-03,2010-11,2014-02-21,INTERVENTIONAL,PHASE2|PHASE3,27.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Thalassemia|Hypertension, Pulmonary",Sildenafil,DRUG,1,10,7 Years,,ALL,False,Carelon Research,OTHER,1,1,United States,1.0,0,1,1,0,1,2.5,0,0,0,1,2,3.332204510175204,small,1,1,0,1,0,1,0,0,1,0,0,0,1,1,11,1,1,0,0,1,0,2009-03-01,2010-11-01,610.0,2009.0,0,3,1
NCT02182570,WAL 801 CL Dry Syrup in Pediatric Atopic Dermatitis Patients,Phase III Open-labeled Study of WAL 801 CL Dry Syrup in Pediatric Atopic Dermatitis Patients,COMPLETED,2001-06,,2014-07-14,INTERVENTIONAL,PHASE3,62.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Dermatitis, Atopic",WAL 801 CL dry syrup,DRUG,2,5,,15 Years,ALL,False,Boehringer Ingelheim,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.143134726391533,medium,1,1,1,0,0,0,0,0,0,0,0,0,1,0,7,1,1,0,0,1,0,2001-06-01,,,2001.0,0,1,0
NCT00689273,"Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study In Subjects With Osteoarthritic Pain Of The Knee","A 2-WEEK, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP, PHASE 2, MULTICENTER STUDY OF PF-04136309 IN SUBJECTS WITH OSTEOARTHRITIC PAIN OF THE KNEE",COMPLETED,2008-08-05,2008-11-27,2021-07-13,INTERVENTIONAL,PHASE2,159.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,"Osteoarthritis, Knee",PF-04136309|Placebo,DRUG,1,9,18 Years,75 Years,ALL,False,Pfizer,INDUSTRY,0,22,South Korea|United States,1.0,0,1,0,0,0,2.0,0,1,0,0,1,5.075173815233827,medium,0,1,1,0,1,0,1,1,1,0,1,1,1,1,10,1,1,0,0,2,1,,,,,0,3,1
NCT01220973,Atorvastatin Calcium and Celecoxib in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer,Phase II Trial of Atorvastatin and Celecoxib in Patients With Hormone-Dependent Prostate-Specific Antigen Progression After Local Therapy for Prostate Cancer.,COMPLETED,2009-02,2014-11-18,2018-06-08,INTERVENTIONAL,PHASE2,27.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Prostate Cancer,atorvastatin calcium|celecoxib|laboratory biomarker analysis,DRUG|OTHER,1,0,18 Years,120 Years,MALE,False,"Rutgers, The State University of New Jersey",OTHER,2,4,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.332204510175204,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,1,0,1,0,0,3,1,2009-02-01,,,2009.0,0,1,0
NCT05038618,"A Study o Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901, CT-COV-21 Sub-study","A Phase II, Prospective, Open-Label, Single-Center Study to Evaluate the Safety, Tolerability, and Immunogenicity of COVID-19 Vaccine Candidate MVC-COV1901, CT-COV-21 Sub-study",COMPLETED,2021-08-02,2022-03-11,2022-06-13,INTERVENTIONAL,PHASE2,399.0,ACTUAL,,SINGLE_GROUP,PREVENTION,NONE,Covid19 Vaccine,MVC-COV1901(S protein with adjuvant),BIOLOGICAL,2,2,20 Years,64 Years,ALL,True,Medigen Vaccine Biologics Corp.,INDUSTRY,0,1,Taiwan,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.991464547107982,large,0,1,1,0,0,0,0,0,0,0,0,0,0,0,4,1,0,1,0,1,0,,,,,0,0,0
NCT00778518,"Safety, Tolerability and PK/PD Study in Young Adult Patients With Childhood Onset Growth Hormone Deficiency (GHD).","Phase IIb Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of ARX201 Following Repeated Dosing to Young Adult Patients With Childhood Onset Growth Hormone Deficiency (GHD).",COMPLETED,2008-07,2009-10,2009-10-12,INTERVENTIONAL,PHASE2,36.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Growth Hormone Deficiency,ARX201|ARX201|ARX201,DRUG,1,1,18 Years,30 Years,MALE,False,"Ambrx, Inc.",INDUSTRY,1,1,Hungary,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.6109179126442243,small,1,0,1,0,0,1,0,0,0,0,1,0,1,1,2,1,1,0,0,3,1,2008-07-01,2009-10-01,457.0,2008.0,0,1,0
NCT00370318,Prophylactic Antipyretic Treatment in Children Receiving Pneumococcal Conjugate and Standard Infant Vaccines,"Multicentre Study to Assess the Effect of Prophylactic Antipyretic Treatment on the Rate of Febrile Reactions Following Concomitant Administration of GSK Biologicals' 10-valent Pneumococcal Conjugate, Infanrix Hexa and Rotarix Vaccines",COMPLETED,2006-09,2007-04,2017-03-23,INTERVENTIONAL,PHASE3,400.0,,RANDOMIZED,PARALLEL,PREVENTION,NONE,"Infections, Rotavirus",10 valent pneumococcal conjugate vaccine|Infanrix Hexa|Rotarix|Paracetamol,DRUG|BIOLOGICAL,1,1,9 Weeks,16 Weeks,ALL,True,GlaxoSmithKline,INDUSTRY,0,10,Czechia,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.993961427306569,large,0,0,1,0,0,0,1,0,0,0,1,0,0,1,2,1,1,1,0,4,1,2006-09-01,2007-04-01,212.0,2006.0,0,1,0
NCT00620490,Paravertebral Analgesia Associated With Intravenous Morphine PCA After Thoracotomy,Postoperative Analgesia After Thoracotomy Without Thoracic Epidural Analgesia : Paravertebral Analgesia With a Catheter Associated With Intravenous Morphine Patient-controlled-analgesia (Pca),COMPLETED,2008-03,2009-03,2025-12-17,INTERVENTIONAL,PHASE3,60.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Pain,"ropivacaine|nacl 0,9%",DRUG|OTHER,1,1,18 Years,80 Years,ALL,False,"University Hospital, Strasbourg, France",OTHER,0,1,France,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.110873864173311,medium,1,1,0,1,0,0,0,0,0,1,1,1,0,1,2,1,1,0,0,2,1,2008-03-01,2009-03-01,365.0,2008.0,0,1,0
NCT04432090,GPR119 Agonist for Hypoglycemia in Type 1 Diabetes,"A Randomized, Placebo-controlled, Double-blinded Cross-over Study of the Pharmacologic Action of a GPR119 Agonist on Glucagon Counter-regulation During Insulin-induced Hypoglycemia in Type 1 Diabetes Mellitus",COMPLETED,2021-04-21,2023-08-12,2024-10-17,INTERVENTIONAL,PHASE2,110.0,ACTUAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 1",Placebo|Study Medication (MBX-2982)|No medication for this group,DRUG|OTHER,3,0,20 Years,60 Years,ALL,True,AdventHealth Translational Research Institute,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.709530201312334,medium,0,1,0,1,0,0,0,0,1,0,1,1,0,0,3,0,1,0,0,3,1,,,,,0,1,0
NCT03110510,FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study,SAMSUNG MEDICAL CENTER,WITHDRAWN,2019-09-06,2019-09-06,2022-06-15,INTERVENTIONAL,PHASE2,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Biliary Tract Cancer,Fluorouracil|Irinotecan Hydrochloride|leucovorin calcium,DRUG,1,2,20 Years,,ALL,False,Samsung Medical Center,OTHER,0,1,South Korea,0.0,0,1,0,0,0,2.0,1,0,0,0,1,0.0,,1,1,0,1,0,0,0,0,0,0,0,0,1,0,3,1,1,0,0,3,1,,,,,0,1,0
NCT04830813,Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung Cancer,"A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 3 Clinical Study of Chiauranib Capsule in Patients With Progressed or Relapsed Small-cell Lung Cancer After 2 Lines Chemotherapy (CHIS)",COMPLETED,2021-03-05,2024-04-01,2024-12-09,INTERVENTIONAL,PHASE3,184.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Small Cell Lung Cancer,Chiauranib|Placebo,DRUG,2,4,18 Years,75 Years,ALL,False,"Chipscreen Biosciences, Ltd.",INDUSTRY,0,1,China,1.0,0,0,1,0,0,3.0,1,0,0,0,1,5.220355825078324,medium,0,1,1,0,0,0,0,0,0,0,1,1,1,1,6,1,1,0,0,2,1,,,,,0,2,0
NCT00197613,The Adult Antiretroviral Treatment and Resistance Study (Tshepo),The Adult Antiretroviral Treatment and Resistance Study (Tshepo),COMPLETED,2002-12,2007-12,2012-09-17,INTERVENTIONAL,PHASE3,650.0,,RANDOMIZED,PARALLEL,,NONE,AIDS|HIV Infection,"(A) zidovudine, lamivudine and nevirapine|(B) zidovudine, lamivudine and efavirenz|(C) zidovudine, didanosine, and nevirapine|(D) zidovudine, didanosine, and efavirenz|(E) stavudine, lamivudine, and nevirapine|(F) stavudine, lamivudine and efavirenz|Adherence Strategy Standard of Care (SOC)|Adherence Strategy Community-Based DOT",DRUG|PROCEDURE,1,1,18 Years,,ALL,False,Harvard School of Public Health (HSPH),OTHER,4,1,Botswana,1.0,0,0,1,0,0,3.0,0,0,0,0,2,6.478509642208569,xlarge,0,0,0,1,0,1,0,0,0,0,1,0,0,1,2,1,1,0,0,8,1,2002-12-01,2007-12-01,1826.0,2002.0,0,2,0
NCT04771013,Safety and Efficacy of Thymic Peptides in the Treatment of Hospitalized COVID-19 Patients in Honduras,"A Single-arm, Open-Label, Phase II Clinical Study to Evaluate the Safety and Efficacy of Thymic Peptides in the Treatment of Hospitalized COVID-19 Patients in Honduras",COMPLETED,2021-02-10,2021-05-14,2022-02-04,INTERVENTIONAL,PHASE2,22.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,COVID-19,Thymic peptides,BIOLOGICAL,3,1,21 Years,,ALL,False,Universidad Católica de Honduras,OTHER,1,1,Honduras,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.1354942159291497,small,1,1,0,1,0,1,0,0,0,0,0,0,1,0,4,1,0,1,0,1,0,,,,,0,0,0
NCT00015860,STI571 Plus Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphocytic Leukemia,A Phase I/II Trial of STI-571 and Chemotherapy in Lymphoid Blast Crisis of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoid Leukemia,COMPLETED,2001-05,2003-10,2013-06-24,INTERVENTIONAL,PHASE1|PHASE2,,,,,TREATMENT,,Leukemia,daunorubicin hydrochloride|imatinib mesylate|prednisone|vincristine sulfate,DRUG,0,0,18 Years,,ALL,False,Jonsson Comprehensive Cancer Center,OTHER,1,5,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,1,0.0,,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,4,1,2001-05-01,2003-10-01,883.0,2001.0,0,2,0
NCT01622660,Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy,Phase II Study of Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy,TERMINATED,2012-06,2016-02,2017-08-22,INTERVENTIONAL,PHASE2,2.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Bladder Cancer,Gemcitabine|Pazopanib,DRUG,1,0,18 Years,,ALL,False,Memorial Sloan Kettering Cancer Center,OTHER,1,5,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,1.0986122886681098,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,1,0,1,0,0,2,1,2012-06-01,2016-02-01,1340.0,2012.0,0,1,0
NCT00049660,Capecitabine Compared With Vinorelbine in Treating Women With Metastatic Breast Cancer,A Randomized Phase II-III Trial Evaluating the Efficacy of Capecitabine and Vinorelbine in Anthracycline and Taxane Pre-Treated Metastatic Breast Cancer,TERMINATED,2002-09,,2012-07-18,INTERVENTIONAL,PHASE2|PHASE3,47.0,ACTUAL,RANDOMIZED,,TREATMENT,,Breast Cancer,capecitabine|vinorelbine tartrate,DRUG,0,0,18 Years,,FEMALE,False,European Organisation for Research and Treatment of Cancer - EORTC,NETWORK,0,12,Belgium|Germany|United Kingdom|Slovenia|France,0.0,0,1,1,0,1,2.5,1,0,0,0,1,3.871201010907891,small,1,1,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,0,2,1,2002-09-01,,,2002.0,0,3,1
NCT03865082,Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206),Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors,ACTIVE_NOT_RECRUITING,2019-10-29,2022-04,2022-02-17,INTERVENTIONAL,PHASE2,30.0,ESTIMATED,,SINGLE_GROUP,TREATMENT,NONE,Solid Tumor,Tilsotolimod|Nivolumab|Ipilimumab,DRUG,2,1,18 Years,,ALL,False,"Idera Pharmaceuticals, Inc.",INDUSTRY,1,3,United States,,0,1,0,0,0,2.0,1,0,0,0,1,3.4339872044851463,small,1,0,1,0,0,1,1,0,1,0,0,0,1,0,3,1,1,0,0,3,1,,2022-04-01,,,0,1,0
NCT03045523,A Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic Fibrosis,"A Phase IIa, Randomized, Double-blind, Placebo-controlled Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic Fibrosis Harbouring One F508del CFTR Mutation and a Second Gating (Class III) Mutation",COMPLETED,2017-01,2017-08-11,2017-11-21,INTERVENTIONAL,PHASE2,37.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Cystic Fibrosis,GLPG2222 150 mg q.d.|GLPG2222 300 mg q.d.|Placebo,DRUG,3,3,18 Years,99 Years,ALL,False,Galapagos NV,INDUSTRY,0,22,Belgium|Germany|United Kingdom|Australia|Czechia|Ireland,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.6375861597263857,small,1,1,1,0,0,0,1,1,0,1,1,1,1,1,6,1,1,0,0,3,1,2017-01-01,,,2017.0,1,3,1
NCT02927080,Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD),"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy",TERMINATED,2016-11,2019-10-09,2022-09-26,INTERVENTIONAL,PHASE2,95.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Facioscapulohumeral Muscular Dystrophy,ACE-083|ACE-083 or placebo,DRUG,5,14,18 Years,,ALL,False,"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA",INDUSTRY,0,24,Canada|Spain|United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,4.564348191467836,medium,1,1,1,0,1,0,1,1,1,1,1,1,1,1,19,1,1,0,0,2,1,2016-11-01,,,2016.0,1,3,1
NCT00009659,Use of the Synthetic Hormone CDB-2914 in Treating Symptoms of Menopause,"Biologic Activity of a Selective Progesterone Receptor Modulator, CDB-2914, in Post-Menopausal Women",COMPLETED,2001-01,2001-12,2008-03-04,INTERVENTIONAL,PHASE2,58.0,,,,TREATMENT,,Postmenopause,CDB 2914,DRUG,0,0,,,FEMALE,True,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),NIH,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.07753744390572,medium,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,2001-01-01,2001-12-01,334.0,2001.0,0,0,0
NCT00598559,Safety and Efficacy of Intravenous Acetaminophen (IV APAP) in Adult Inpatients,"A Phase III, Multi-Center, Open-Label, Prospective, Repeated Dose, Randomized, Controlled, Multi-Day Study of the Safety and Efficacy of Intravenous Acetaminophen in Adult Inpatients",COMPLETED,2008-01,2008-11,2016-10-21,INTERVENTIONAL,PHASE3,213.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Acute Pain|Fever,IV Acetaminophen,DRUG,2,2,18 Years,85 Years,ALL,False,Mallinckrodt,INDUSTRY,0,14,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,2,5.365976015021851,large,0,1,1,0,0,0,1,0,1,0,1,0,1,1,4,1,1,0,0,1,0,2008-01-01,2008-11-01,305.0,2008.0,0,1,0
NCT00574080,UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide,UARK 2006-15: A Phase III Randomized Study of Tandem Transplants With or Without Bortezomib (Velcade) and Thalidomide (Thalomid) to Evaluate Its Effect on Response Rate and Durability of Response in Multiple Myeloma Patients,TERMINATED,2006-07,2011-03,2017-11-20,INTERVENTIONAL,PHASE3,20.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Multiple Myeloma,Interim/Maintenance Dexamethasone|Induction/Consolidation Dexamethasone|Induction/Consolidation Cisplatin|Induction/Consolidation Adriamycin|InductionConsolidation Cyclophosphamide|Induction/Consolidation Etoposide|Induction Pegfilgrastim|Transplant 1 Dexamethasone|Transplant 1 Cisplatin|Transplant 1 Adriamycin|Transplant 1 Cyclophosphamide|Transplant 1 Etoposide|Transplant 1 Melphalan|Transplant 1 and 2 Pegfilgrastim|Autologous Peripheral Blood Stem Cell Transplant (ASCT)|Transplant 2 Carmustine|Transplant 2 Etoposide|Transplant 2 Cytarabine|Transplant 2 Melphalan|Transplant 2 Dexamethasone|Transplant 1 and 2 Bortezomib|Transplant 1 and 2 Thalidomide,DRUG|PROCEDURE,1,0,18 Years,,ALL,False,University of Arkansas,OTHER,0,1,United States,0.0,0,0,1,0,0,3.0,1,0,0,0,1,3.044522437723423,small,1,1,0,1,0,0,0,0,1,0,1,0,1,1,1,0,1,0,0,22,1,2006-07-01,2011-03-01,1704.0,2006.0,0,1,0
NCT04848480,"A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6)","Efficacy and Safety of Once Weekly Insulin Icodec Compared to Once Daily Insulin Degludec 100 Units/mL, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes. A 26-week, Randomised, Multicentre, Open-label, Active-controlled, Parallel Group, Two Armed, Treat-to-target Trial Investigating the Effect on Glycaemic Control and Safety of Treatment With Once Weekly Insulin Icodec Compared to Once Daily Insulin Degludec, Both in Combination With Insulin Aspart in Adults With Type 1 Diabetes, With a 26-week Extension Investigating Long Term Safety",COMPLETED,2021-04-30,2022-12-02,2025-12-04,INTERVENTIONAL,PHASE3,582.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 1",insulin icodec|insulin degludec|insulin aspart,DRUG,1,17,18 Years,,ALL,False,Novo Nordisk A/S,INDUSTRY,0,130,Italy|Netherlands|Russia|Turkey (Türkiye)|India|United States|Germany|Austria|Spain|United Kingdom|Japan|Canada,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.368187186350492,xlarge,0,1,1,0,0,0,1,1,1,1,1,0,1,1,18,1,1,0,0,3,1,,,,,0,3,1
NCT00957580,Trial of Pimasertib in Hematological Malignancies,Phase II Trial With Safety-Run-In of MEK Inhibitor MSC1936369B in Subjects With Poor Prognosis Acute Myeloid Leukemia and Other Hematological Malignancies,TERMINATED,2009-09-30,2012-12-31,2017-08-21,INTERVENTIONAL,PHASE2,81.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Leukemia, Myeloid, Acute|Hematologic Neoplasms",Pimasertib|Pimasertib|Pimasertib|Pimasertib|Pimasertib,DRUG,2,19,18 Years,,ALL,False,EMD Serono,INDUSTRY,0,9,France|United States,0.0,0,1,0,0,0,2.0,1,0,0,0,2,4.406719247264253,medium,1,1,1,0,0,0,1,1,1,1,1,0,1,1,21,1,1,0,0,5,1,,,,,0,4,1
NCT00061880,BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma,Phase 1-2 Multi-Center Study of Intravenous BCX-1777 in Patients With Refractory Cutaneous T-Cell Lymphoma (CTCL),COMPLETED,2003-02,2008-01,2013-05-30,INTERVENTIONAL,PHASE1|PHASE2,,,,,TREATMENT,NONE,Lymphoma,forodesine hydrochloride,DRUG,0,0,18 Years,,ALL,False,BioCryst Pharmaceuticals,INDUSTRY,0,3,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,1,0.0,,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,2003-02-01,2008-01-01,1795.0,2003.0,0,1,0
NCT04934579,"Rituximab,Methotrexate and Lenalidomide in Newly Diagnosed Primary Central Nervous System Lymphoma","Efficacy and Safety Study of Rituximab, Methotrexate and Lenalidomide Chemotherapy（R2-MTX） in Newly Diagnosed Primary Central Nervous System Lymphoma：a Single Arm, Multicenter, Phase 2 Study",COMPLETED,2020-01-01,2022-11-15,2022-11-23,INTERVENTIONAL,PHASE2,17.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Primary Central Nervous System Lymphoma,Rituximab|Lenalidomide|Methotrexate,DRUG,1,3,18 Years,75 Years,ALL,False,"Second Affiliated Hospital, School of Medicine, Zhejiang University",OTHER,0,1,China,1.0,0,1,0,0,0,2.0,1,0,0,0,1,2.8903717578961645,small,1,1,0,1,0,0,0,0,0,0,0,0,1,0,4,1,1,0,0,3,1,,,,,0,1,0
NCT00592579,A Phase 2 Study With Panzem in Patients With Relapsed or Plateau Phase Multiple Myeloma,"Phase 2, Open-Label, Safety, and Efficacy Study of 2-Methoxyestradiol Administered to Patients With Plateau Phase or Relapsed Multiple Myeloma",COMPLETED,2001-03,2008-09,2009-02-26,INTERVENTIONAL,PHASE2,60.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Relapsed Multiple Myeloma|Plateau Phase Multiple Myeloma,2-methoxyestradiol,DRUG,1,2,18 Years,,ALL,False,"CASI Pharmaceuticals, Inc.",INDUSTRY,0,2,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,2,4.110873864173311,medium,1,1,1,0,0,0,1,0,1,0,0,0,1,0,3,1,1,0,0,1,0,2001-03-01,2008-09-01,2741.0,2001.0,0,1,0
NCT02975479,"Intralymphatic Immunotherapy in Increasing Doses, Substudy",Intralymphatic Immunotherapy in Increasing Doses up to 10 000 SQ-U - a Human Randomized Clinical Trial. Substudy.,COMPLETED,2016-05,2022-06-20,2022-06-24,INTERVENTIONAL,PHASE2|PHASE3,40.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Rhinitis, Allergic, Seasonal",ALK Diluent|ALK Alutard SQ 5-grasses or ALK Alutard Birch,DRUG,1,8,18 Years,55 Years,ALL,False,Karolinska Institutet,OTHER,2,2,Sweden,1.0,0,1,1,0,1,2.5,0,0,0,0,1,3.713572066704308,small,1,0,0,1,0,1,1,0,0,0,1,1,1,1,9,1,1,0,0,2,1,2016-05-01,,,2016.0,1,3,1
NCT02209779,Efficacy and Safety of Different Doses of BIRB 796 BS in Patients With Active Rheumatoid Arthritis,"A Randomised, Parallel, Double-blind, Placebo-controlled Study to Investigate Efficacy and Safety of Different Doses (5, 10, 20 and 30 mg) of BIRB 796 BS Administered Twice a Day Orally Over 4 Weeks in Patients With Active Rheumatoid Arthritis Who Have Failed at Least One DMARD",COMPLETED,2001-05,,2014-08-06,INTERVENTIONAL,PHASE2,167.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Arthritis, Rheumatoid",BIBR 796 BS|Placebo,DRUG,1,16,18 Years,75 Years,ALL,False,Boehringer Ingelheim,INDUSTRY,0,0,,1.0,0,1,0,0,0,2.0,0,1,0,0,1,5.123963979403259,medium,0,1,1,0,0,0,0,0,0,0,1,1,1,1,17,1,1,0,0,2,1,2001-05-01,,,2001.0,0,2,0
NCT00406679,"Analgesic Efficacy, Safety and Tolerability of Two Paracetamol-containing Solutions in Post-Surgical Dental Pain","Single-Dose Comparison of the Analgesic Efficacy, Safety and Tolerability of Two Paracetamol 1%-Containing Solutions and Placebo in a Post-Surgical Dental Pain Model",COMPLETED,2006-11,2007-10,2011-08-11,INTERVENTIONAL,PHASE3,135.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Pain, Postoperative",Paracetamol (acetaminophen) solution experimental|paracetamol (acetaminophen) solution commercial|placebo,DRUG,0,0,18 Years,65 Years,ALL,False,Baxter Healthcare Corporation,INDUSTRY,0,2,United Kingdom,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.912654885736052,medium,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,0,1,0,0,3,1,2006-11-01,2007-10-01,334.0,2006.0,0,1,0
NCT01069796,Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer,A Multi Phase II Clinical Trials Evaluating the Association of Bevacizumab With Weekly Paclitaxel and Capecitabine in First Line Treatment for Patients With Triple Negative Metastatic or Locally Advanced Cancer,TERMINATED,2010-04,2014-06,2016-03-17,INTERVENTIONAL,PHASE2,64.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Triple Negative Metastatic Breast Cancer,Paclitaxel|Bevacizumab|Capecitabine,DRUG,1,0,18 Years,,FEMALE,False,ARCAGY/ GINECO GROUP,OTHER,0,17,France,0.0,0,1,0,0,0,2.0,1,0,0,0,1,4.174387269895637,medium,1,1,0,1,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,3,1,2010-04-01,2014-06-01,1522.0,2010.0,0,1,0
NCT01778062,Indacaterol EfectIveness In COPD Patients With Tuberculosis History,"A Phase Ⅲb, Multicenter, Double-blind, Randomized, Controlled Trial, to Assess the Efficacy and Safety of Indacaterol (150㎍ o.d.) vs. Placebo, in Patients With Moderate-to-severe COPD With Destroyed Lung by Tuberculosis",COMPLETED,2013-02,2014-09,2015-10-23,INTERVENTIONAL,PHASE3,136.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Patients With Moderate-to-severe COPD With Destroyed Lung by Tuberculosis,Indacaterol|Control,DRUG,1,3,19 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,13,South Korea,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.919980925828125,medium,0,1,1,0,1,0,1,0,0,0,1,1,1,1,4,1,1,0,0,2,1,2013-02-01,2014-09-01,577.0,2013.0,0,1,0
NCT02880462,A 6-month Study to Evaluate Sulforaphane add-on Effects in Treatment of Schizophrenia,Phase 2 Study of the Effect of add-on Sulforaphane in Treatment of Schizophrenia,COMPLETED,2016-12-26,2019-05-20,2020-03-24,INTERVENTIONAL,PHASE2,172.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Schizophrenia,sulforaphane|placebo,OTHER|DIETARY_SUPPLEMENT,1,6,18 Years,50 Years,ALL,False,Central South University,OTHER,1,0,,1.0,0,1,0,0,0,2.0,0,0,1,0,1,5.153291594497779,medium,0,1,0,1,0,1,0,0,0,0,1,1,1,1,7,1,0,0,0,2,1,,,,,0,2,0
NCT02321462,"Efficacy, Safety and Tolerability of Eziclen in Adult Subjects Undergoing Colonoscopy","Efficacy, Safety and Tolerability of a Split-dose of a New Bowel Cleansing Preparation (Eziclen) in Adult Subjects Undergoing Colonoscopy: A Phase III, Multicentre, Randomised, 2 Parallel Group, Comparative Versus Fortrans®, Non-inferiority, Investigator-blinded Study",COMPLETED,2015-03,2015-12,2019-03-04,INTERVENTIONAL,PHASE3,296.0,ACTUAL,RANDOMIZED,PARALLEL,DIAGNOSTIC,SINGLE,Bowel Cleansing,Eziclen|Fortrans®,DRUG,1,7,18 Years,,ALL,False,Ipsen,INDUSTRY,0,3,Russia,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.6937321388027,large,0,1,1,0,0,0,1,0,0,0,1,0,0,1,8,1,1,0,0,2,1,2015-03-01,2015-12-01,275.0,2015.0,1,2,0
NCT00734162,Evaluation of Tenofovir Disoproxil Fumarate in Adolescents With Chronic Hepatitis B Infection,"A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Adolescents With Chronic Hepatitis B Infection",COMPLETED,2008-12,2015-12,2016-09-01,INTERVENTIONAL,PHASE3,106.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Hepatitis B Virus (HBV),Tenofovir disoproxil fumarate (TDF)|Placebo,DRUG,2,35,12 Years,17 Years,ALL,False,Gilead Sciences,INDUSTRY,0,21,Bulgaria|Turkey (Türkiye)|United States|Spain|Romania|Poland|France,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.672828834461906,medium,0,1,1,0,1,0,1,1,1,1,1,1,1,1,37,1,1,0,0,2,1,2008-12-01,2015-12-01,2556.0,2008.0,0,3,1
NCT00282646,Safety and Feasibility Study of Autologous Bone Marrow Cell Transplantation in Patients With Peripheral Arterial Occlusive Disease (PAOD),(Intraarterial Progenitor Cell Transplantation of Bone Marrow Mononuclear Cells for Induction of Neovascularization in Patients With Peripheral Arterial Occlusive Disease),COMPLETED,2005-10,2011-03,2021-10-26,INTERVENTIONAL,PHASE2,40.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Arterial Occlusive Diseases,intraarterial stem cell therapy|Stem cells,OTHER|PROCEDURE,1,4,18 Years,80 Years,ALL,False,Johann Wolfgang Goethe University Hospital,OTHER,0,1,Germany,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.713572066704308,small,1,1,0,1,0,0,0,0,0,1,1,1,1,1,5,1,0,0,0,2,1,2005-10-01,2011-03-01,1977.0,2005.0,0,1,0
NCT02131662,"Bay1002670, Fibroids, Safety and Efficacy EU,US,Can, Jap","A Randomized, Parallel-group, Double-blind, Placebo Controlled, Multi-center Study to Assess the Efficacy and Safety of Different Doses of BAY1002670 in Subjects With Uterine Fibroids Over 3 Months",COMPLETED,2014-05-15,2016-05-04,2017-12-08,INTERVENTIONAL,PHASE2,309.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Leiomyoma,BAY1002670|BAY1002670|BAY1002670|BAY1002670|Placebo,DRUG,1,3,18 Years,50 Years,FEMALE,False,Bayer,INDUSTRY,0,105,Belgium|Bulgaria|Finland|Sweden|Hungary|United States|Germany|Spain|Norway|Japan|Switzerland|Czechia|Canada,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.736572297479192,large,0,1,1,0,0,0,1,1,1,1,1,1,1,1,4,1,1,0,0,5,1,,,,,0,2,0
NCT00208546,"Cetuximab, Capecitabine, Oxaliplatin and Bevacizumab in Advanced Colorectal Cancer","Cetuximab Added to Capecitabine, Oxaliplatin and Bevacizumab in Patients With Previously Untreated Advanced Colorectal Carcinoma, a Randomised Phase III Study",COMPLETED,2005-06,2009-12,2012-02-02,INTERVENTIONAL,PHASE3,750.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Colorectal Cancer,21Capecitabine + bevacizumab + oxaliplatin|1Capecitabine + oxaliplatin + bevacizumab + cetuximab,DRUG,2,5,18 Years,,ALL,False,Dutch Colorectal Cancer Group,OTHER,4,1,Netherlands,1.0,0,0,1,0,0,3.0,1,0,0,0,1,6.621405651764134,xlarge,0,1,0,1,0,1,0,0,0,0,1,0,1,1,7,1,1,0,0,2,1,2005-06-01,2009-12-01,1644.0,2005.0,0,2,0
NCT03992846,Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain.,"A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled, Clinical Study to Assess the Efficacy and Safety of Linzagolix in Subjects With Moderate to Severe Endometriosis-associated Pain.",COMPLETED,2019-06-13,2022-04-01,2025-04-02,INTERVENTIONAL,PHASE3,486.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Endometriosis,75 mg linzagolix tablet|200 mg linzagolix tablet|Add-back capsule (E2 1 mg / NETA 0.5 mg)|Placebo tablet to match 75 mg linzagolix tablet|Placebo tablet to match 200 mg linzagolix tablet|Placebo capsule to match Add-back capsule,DRUG,2,0,18 Years,49 Years,FEMALE,False,"Kissei Pharmaceutical Co., Ltd.",INDUSTRY,0,71,Bulgaria|Hungary|United States|Spain|Austria|Romania|Poland|Czechia|Ukraine|France,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.18826412308259,large,0,1,1,0,0,0,1,1,1,1,1,1,1,1,2,0,1,0,0,6,1,,,,,0,2,0
NCT01391546,Immunogenicity and Safety Study of ZOSTAVAX Administered by Intramuscular or Subcutaneous Route to Participants Aged From 50 Years Old (V211-045),"An Open-label, Randomised, Comparative, Multicentre Study of the Immunogenicity and Safety of ZOSTAVAX When Administered by Intramuscular Route or Subcutaneous Route to Subjects of 50 Years of Age and Older",COMPLETED,2011-06-20,2012-10-15,2019-01-09,INTERVENTIONAL,PHASE3,354.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Herpes Zoster,ZOSTAVAX,BIOLOGICAL,2,6,50 Years,,ALL,True,Merck Sharp & Dohme LLC,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.872117789475416,large,0,1,1,0,1,0,0,0,0,0,1,0,0,1,8,1,0,1,0,1,0,,,,,0,1,0
NCT00274846,Donor Peripheral Stem Cell Transplant in Treating Patients With Relapsed Acute Myeloid Leukemia,Allogeneic Natural Killer Cells in Patients With Relapsed Acute Myelogenous Leukemia,COMPLETED,2005-03,2008-06,2017-12-28,INTERVENTIONAL,PHASE2,21.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Leukemia,aldesleukin|therapeutic allogeneic lymphocytes|cyclophosphamide|fludarabine phosphate|in vitro treated peripheral blood stem cell transplantation,DRUG|BIOLOGICAL|PROCEDURE,1,4,2 Years,,ALL,False,"Masonic Cancer Center, University of Minnesota",OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.091042453358316,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,5,1,1,1,0,5,1,2005-03-01,2008-06-01,1188.0,2005.0,0,1,0
NCT01342627,Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma,Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma (SERCC Study) Impact of Adverse Events Management in Elderly mRCC Patients Treated With Sorafenib,TERMINATED,2010-10,2015-09,2015-10-06,INTERVENTIONAL,PHASE2,4.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Metastatic Renal Cell Carcinoma,Sorafenib,DRUG,1,4,65 Years,,ALL,False,Centro di Riferimento Oncologico - Aviano,OTHER,0,1,Italy,0.0,0,1,0,0,0,2.0,1,0,0,0,1,1.6094379124341003,small,1,1,0,1,0,0,0,0,0,1,0,0,1,0,5,1,1,0,0,1,0,2010-10-01,2015-09-01,1796.0,2010.0,0,0,0
NCT03079427,Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma,Randomized Phase 2 Study of Capecitabine vs Gemcistabine Plus Cisplatin in Patients With Resected Extrahepatic Cholangiocarcinoma With Regional Lymph Node Metastasis,COMPLETED,2017-05-15,2022-11-15,2022-12-06,INTERVENTIONAL,PHASE2,101.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Cholangiocarcinoma|Biliary Tract Cancer|Adjuvant Chemotherapy|Capecitabine|Gemcitabine|Cisplatin,Gemcitabine plus cisplatin|Capecitabine,DRUG,1,3,19 Years,,ALL,False,Asan Medical Center,OTHER,3,1,South Korea,1.0,0,1,0,0,0,2.0,1,0,0,0,6,4.624972813284271,medium,0,1,0,1,0,1,0,0,0,0,1,0,1,1,4,1,1,0,0,2,1,,,,,0,2,0
NCT03485027,Rechallenge of Prior Regimen in Third or Later-line Chemotherapy in Metastatic Colorectal Cancer,A Phase II Clinical Trial of Prior Regimen Rechallenge in Third or Later-line Chemotherapy for Patients With Metastatic Colorectal Cancer,COMPLETED,2018-01-24,2023-07-01,2023-12-08,INTERVENTIONAL,PHASE2,43.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Metastatic Colorectal Cancer|Chemotherapy Effect,the rechallenge regimen,DRUG,1,1,18 Years,80 Years,ALL,False,Fudan University,OTHER,1,1,China,1.0,0,1,0,0,0,2.0,1,0,0,0,2,3.784189633918261,small,1,1,0,1,0,1,0,0,0,0,0,0,1,0,2,1,1,0,0,1,0,,,,,0,1,0
NCT00114127,Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome,Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome,COMPLETED,2004-06,2010-07,2014-06-10,INTERVENTIONAL,PHASE3,28.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Anxiety Disorder,Duloxetine|Duloxetine|Placebo,DRUG,1,1,18 Years,,ALL,False,Massachusetts General Hospital,OTHER,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,1,0,1,3.367295829986474,small,1,1,0,1,0,0,0,0,1,0,1,1,1,1,2,1,1,0,0,3,1,2004-06-01,2010-07-01,2221.0,2004.0,0,1,0
NCT03186261,Antibacterial Effect of Nano Silver Fluoride vs Chlorhexidine on Occlusal Carious Molars Treated With Partial Caries Removal Technique,Evaluation of the Antibacterial Effect of Nano Silver Fluoride Versus Chlorhexidine on Occlusal Carious Molars Treated With Partial Caries Removal Technique: A Randomized Clinical Trial,COMPLETED,2018-04-01,2018-12-28,2021-09-16,INTERVENTIONAL,PHASE3,44.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Dental Caries,Nano silver fluoride solution|Cavity Cleanser,DRUG,1,0,18 Years,40 Years,ALL,True,Cairo University,OTHER,0,1,Egypt,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.8066624897703196,small,1,1,0,1,0,0,0,0,0,0,1,1,1,1,1,0,1,0,0,2,1,,,,,0,1,0
NCT00903786,A Long-term Extension Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-Epileptic Drugs (AEDs),A Long-term Extension Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-Epileptic Drugs (AEDs),COMPLETED,2009-06-17,2016-10-31,2018-08-29,INTERVENTIONAL,PHASE2,21.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Refractory Partial Seizures,perampanel,DRUG,1,4,20 Years,64 Years,ALL,False,"Eisai Co., Ltd.",INDUSTRY,0,9,Japan,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.091042453358316,small,1,1,1,0,0,0,1,0,0,0,0,0,1,0,5,1,1,0,0,1,0,,,,,0,0,0
NCT04772742,Eptinezumab in Adults With Migraine and Medication Overuse Headache,"Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Eptinezumab for the Preventive Treatment of Migraine in Patients With a Dual Diagnosis of Migraine and Medication Overuse Headache",COMPLETED,2021-02-17,2022-09-30,2022-10-31,INTERVENTIONAL,PHASE3,193.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Migraine|Medication Overuse Headache,Placebo|Eptinezumab,DRUG,1,18,18 Years,75 Years,ALL,False,H. Lundbeck A/S,INDUSTRY,0,40,China|South Korea|Spain|Georgia|Taiwan,1.0,0,0,1,0,0,3.0,0,0,1,0,2,5.267858159063328,medium,0,1,1,0,0,0,1,1,0,1,1,1,1,1,19,1,1,0,0,2,1,,,,,0,4,1
NCT00192842,Gemcitabine With Curcumin for Pancreatic Cancer,Phase II Trial of Gemcitabine and Curcumin in Patients With Advanced Pancreatic Cancer,COMPLETED,2004-07,2010-09,2010-09-22,INTERVENTIONAL,PHASE2,17.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Pancreatic Cancer,curcumin (+ gemcitabine),DRUG,1,4,18 Years,,ALL,False,Rambam Health Care Campus,OTHER,0,0,,1.0,0,1,0,0,0,2.0,1,0,0,0,1,2.8903717578961645,small,1,1,0,1,0,0,0,0,0,0,0,0,1,0,5,1,1,0,0,1,0,2004-07-01,2010-09-01,2253.0,2004.0,0,0,0
NCT03443973,Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD),"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of Gantenerumab in Patients With Early (Prodromal to Mild) Alzheimer's Disease",TERMINATED,2018-08-22,2022-11-28,2024-01-17,INTERVENTIONAL,PHASE3,975.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Alzheimer Disease,Gantenerumab|Placebo,DRUG,6,20,50 Years,90 Years,ALL,False,Hoffmann-La Roche,INDUSTRY,0,155,Japan|Singapore|Netherlands|Finland|South Korea|Spain|Chile|Portugal|Argentina|Sweden|Turkey (Türkiye)|Puerto Rico|United States|United Kingdom|Poland|Mexico|Denmark|Belgium|Croatia,0.0,0,0,1,0,0,3.0,0,0,1,0,1,6.883462586413092,xlarge,0,1,1,0,1,0,1,1,1,1,1,1,1,1,26,1,1,0,0,2,1,,,,,0,3,1
NCT00067860,Diet/Growth Factor Mechanisms of Gut Adaptation,Diet/Growth Factor Mechanisms of Gut Adaptation,COMPLETED,1996-10,2006-12,2016-05-16,INTERVENTIONAL,PHASE2,27.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Short Bowel Syndrome,recombinant human growth hormone|diet modification,BEHAVIORAL|DRUG,0,0,18 Years,80 Years,ALL,False,Emory University,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.332204510175204,small,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0,1,0,0,2,1,1996-10-01,2006-12-01,3713.0,1996.0,0,1,0
NCT06199960,Dual Ovarian Stimulation (Duostim) and Shanghai Protocols in Poor Ovarian Responders,Comparison of Two Types of Dual Ovarian Stimulation: Duostim Versus Shanghai Protocols in Patients With Poor Ovarian Reserve: A Randomized Controlled Trial,COMPLETED,2019-08-02,2023-11-20,2024-01-10,INTERVENTIONAL,PHASE3,116.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Assisted Reproductive Techniques,Doustim protocol,OTHER,1,5,35 Years,45 Years,FEMALE,False,Royan Institute,OTHER_GOV,0,1,Iran,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.762173934797756,medium,0,1,0,1,0,0,0,0,0,0,1,0,1,1,6,1,0,0,0,1,0,,,,,0,1,0
NCT06254482,An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD),"A Phase 2b, Double-Blind, Randomized Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease",ACTIVE_NOT_RECRUITING,2023-08-25,2029-07-16,2025-11-21,INTERVENTIONAL,PHASE2,144.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Huntington Disease,Votoplam,DRUG,2,4,25 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,24,Italy|Netherlands|Spain|Germany|Austria|Australia|United Kingdom|New Zealand|France|Canada,,0,1,0,0,0,2.0,0,0,0,0,1,4.976733742420574,medium,0,1,1,0,1,0,1,1,0,1,1,1,1,1,6,1,1,0,0,1,0,,,,,0,2,0
NCT00196924,Human Papilloma Virus Vaccine Safety and Immunogenicity Trial in Young Adolescent Women With GSK Bio HPV-16/18.,"Evaluate the Safety and Immunogenicity of GSK Biologicals' HPV-16/18 Vaccine Administered Intramuscularly According to a 0,1,6 Month Schedule in Healthy Female Subjects (10 - 14 Years)",COMPLETED,2004-06,2006-03,2017-03-23,INTERVENTIONAL,PHASE3,2067.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,"Infections, Papillomavirus",HPV-16/18 L1/AS04,BIOLOGICAL,1,1,10 Years,14 Years,FEMALE,True,GlaxoSmithKline,INDUSTRY,0,61,Sweden|South Korea|Spain|Germany|Australia|Panama|Norway|Honduras|Czechia|Taiwan|Colombia|France,1.0,0,0,1,0,0,3.0,0,0,0,0,1,7.63433723562832,xlarge,0,1,1,0,0,0,1,1,0,1,1,1,0,1,2,1,0,1,0,1,0,2004-06-01,2006-03-01,638.0,2004.0,0,1,0
NCT00005824,Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory AIDS-Related Lymphoma,Pilot Study of the Safety and Feasibility of Autologous Peripheral Blood Stem Cell Transplantation for Patients With Relapsed AIDS-Related Lymphoma,COMPLETED,2000-11,2006-04,2016-02-03,INTERVENTIONAL,PHASE2,,,,,TREATMENT,NONE,Lymphoma,filgrastim|busulfan|cyclophosphamide|peripheral blood stem cell transplantation,DRUG|BIOLOGICAL|PROCEDURE,0,0,18 Years,120 Years,ALL,False,AIDS Malignancy Consortium,NETWORK,1,2,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,0.0,,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,1,1,0,4,1,2000-11-01,2006-04-01,1977.0,2000.0,0,1,0
NCT02003924,Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer,"PROSPER: A MULTINATIONAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER",COMPLETED,2013-10-31,2025-11-28,2026-01-27,INTERVENTIONAL,PHASE3,1401.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Nonmetastatic Castration-Resistant Prostate Cancer|Prostate Cancer|Cancer of the Prostate,Enzalutamide|Placebo,DRUG,1,46,18 Years,,MALE,False,Pfizer,INDUSTRY,2,397,China|Germany|Serbia|Taiwan|Singapore|Greece|Thailand|Italy|Netherlands|Finland|South Korea|Spain|Chile|Canada|Russia|Argentina|Sweden|Turkey (Türkiye)|United States|Austria|Australia|United Kingdom|Poland|New Zealand|Denmark|Ukraine|France|Belgium|Brazil|Slovakia|Hong Kong|Malaysia,1.0,0,0,1,0,0,3.0,1,0,0,0,3,7.2456550675945355,xlarge,0,1,1,0,1,1,1,1,1,1,1,1,1,1,47,1,1,0,0,2,1,,,,,0,4,1
NCT05763823,A Study of Letermovir (MK-8228) to Evaluate Efficacy and Safety for Prevention of Cytomegalovirus Infection in Chinese Hematopoietic Stem Cell Transplant Recipients (MK-8228-045),"A Phase 3, Open Label, Single-Arm Clinical Trial to Evaluate the Efficacy and Safety of MK-8228 (Letermovir) for the Prevention of Clinically Significant Cytomegalovirus (CMV) Infection in Chinese Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients",COMPLETED,2023-03-24,2024-04-18,2025-03-25,INTERVENTIONAL,PHASE3,120.0,ACTUAL,,SINGLE_GROUP,PREVENTION,NONE,Cytomegalovirus Infection,Letermovir,DRUG,1,9,18 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,21,China,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.795790545596741,medium,0,1,1,0,1,0,1,0,0,0,0,0,0,0,10,1,1,0,0,1,0,,,,,0,1,0
NCT02352259,Treatment of Liver Metastases With Electrochemotherapy (ECTJ) Phase II,Treatment of Liver Metastases With Electrochemotherapy (ECTJ) Phase II,COMPLETED,2013-09,2018-10,2021-03-24,INTERVENTIONAL,PHASE2,23.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Liver Metastases,Electrochemotherapy|Cliniporator Vitae®|Bleomycin PHC 15 e. (United States Pharmacopeia - USP),DRUG|DEVICE|PROCEDURE,1,1,18 Years,,ALL,False,Institute of Oncology Ljubljana,OTHER,3,4,Slovenia,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.1780538303479458,small,1,1,0,1,0,1,1,0,0,0,0,0,1,0,2,1,1,0,1,3,1,2013-09-01,2018-10-01,1856.0,2013.0,0,1,0
NCT04440059,A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia,"A Multicenter, Open Clinical Trial to Evaluate the Safety and Efficacy of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia (WM)",COMPLETED,2019-08-10,2024-01-09,2024-04-18,INTERVENTIONAL,PHASE2,47.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Waldenstrom's Macroglobulinemia Recurrent|Waldenstrom's Macroglobulinemia Refractory,ICP-022,DRUG,1,3,18 Years,,ALL,False,"Beijing InnoCare Pharma Tech Co., Ltd.",INDUSTRY,0,16,China,1.0,0,1,0,0,0,2.0,0,0,0,0,2,3.871201010907891,small,1,1,1,0,0,0,1,0,0,0,0,0,1,0,4,1,1,0,0,1,0,,,,,0,1,0
NCT03214380,A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes,"A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro, Both in Combination With Insulin Glargine or Insulin Degludec in Adults With Type 2 Diabetes PRONTO-T2D",COMPLETED,2017-07-14,2019-03-13,2020-03-27,INTERVENTIONAL,PHASE3,933.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,LY900014|Insulin Lispro|Insulin Glargine|Insulin Degludec|Metformin|SGLT2 inhibitor,DRUG,1,10,18 Years,,ALL,False,Eli Lilly and Company,INDUSTRY,0,141,Italy|Russia|Argentina|Hungary|India|United States|Germany|Puerto Rico|Australia|Slovakia|South Korea|Spain|Japan|Mexico|Czechia|Taiwan,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.839476438228843,xlarge,0,1,1,0,1,0,1,1,1,1,1,1,1,1,11,1,1,0,0,6,1,,,,,0,3,1
NCT01416480,"Clinical Trial to Evaluate the Safety and Efficacy of ""Theobromine Capsule"" as an Antitussive in Acute Cougher","Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of ""Theobromine Capsule 300mg"" as an Antitussive Agent in Acute Cough Patients.",COMPLETED,2010-05,2011-05,2011-08-15,INTERVENTIONAL,PHASE3,332.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Acute Bronchitis,Theobromine 300mg|Levodropropizine 10mg,DRUG,1,3,18 Years,,ALL,False,"Ahn-Gook Pharmaceuticals Co.,Ltd",INDUSTRY,0,1,South Korea,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.808142489980444,large,0,1,1,0,0,0,0,0,0,0,1,1,1,1,4,1,1,0,0,2,1,2010-05-01,2011-05-01,365.0,2010.0,0,1,0
NCT03655080,Pulsed Abraxane and Radiotherapy for Improving and Maintaining Ambulation After Cancer-Related Cord Compression,Novel Approach of Pulsed Abraxane and Radiotherapy for Improving and Maintaining Ambulation After Cancer-Related Cord Compression,TERMINATED,2019-01-09,2021-06-15,2025-02-04,INTERVENTIONAL,PHASE2,2.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Cord Compression,Radiation therapy|nab-Paclitaxel,DRUG|RADIATION,1,10,18 Years,,ALL,False,Washington University School of Medicine,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,1.0986122886681098,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,11,1,1,0,0,2,1,,,,,0,2,0
NCT00256880,Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma,"A Phase II, Open-Label Study of Pazopanib (GW786034) in Patients With Relapsed or Refractory Multiple Myeloma",COMPLETED,2005-01,2005-12,2017-01-18,INTERVENTIONAL,PHASE2,100.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,"Carcinoma, Renal Cell",GW786034,DRUG,1,1,21 Years,,ALL,False,GlaxoSmithKline,INDUSTRY,0,8,Australia|United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.61512051684126,medium,0,1,1,0,0,0,1,1,1,0,0,0,1,0,2,1,1,0,0,1,0,2005-01-01,2005-12-01,334.0,2005.0,0,1,0
NCT04583280,A Study of Rilematovir in Infants and Children and Subsequently in Neonates Hospitalized With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus (RSV),"A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rilematovir in Infants and Children (≥28 Days to ≤5 Years of Age) and Subsequently in Neonates (<28 Days of Age), Hospitalized With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus (RSV)",TERMINATED,2021-09-06,2022-03-18,2025-02-04,INTERVENTIONAL,PHASE3,28.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Respiratory Tract Infections,Rilematovir|Rilematovir X mg/kg|Placebo,DRUG,1,20,1 Day,5 Years,ALL,False,"Janssen Research & Development, LLC",INDUSTRY,0,142,China|Bulgaria|Latvia|Germany|Japan|Taiwan|Thailand|Italy|South Korea|Spain|Estonia|Czechia|Argentina|Sweden|Turkey (Türkiye)|United States|Panama|Poland|Mexico|Israel|Ukraine|Belgium|Hungary|Brazil|Slovakia|Malaysia,0.0,0,0,1,0,0,3.0,0,0,0,0,1,3.367295829986474,small,1,1,1,0,0,0,1,1,1,1,1,1,1,1,21,1,1,0,0,3,1,,,,,0,3,1
NCT04287179,SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes,Effect and Safety of Two Different Dose-escalation Regimens for Once-weekly Semaglutide s.c. in Subjects With Type 2 Diabetes Mellitus Previously Treated With GLP-1 RAs,WITHDRAWN,2020-03-09,2021-01-25,2022-02-03,INTERVENTIONAL,PHASE3,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2",Semaglutide,DRUG,1,7,18 Years,,ALL,False,Novo Nordisk A/S,INDUSTRY,0,25,Austria|Finland|Sweden|United States,0.0,0,0,1,0,0,3.0,0,0,0,0,1,0.0,,1,1,1,0,0,0,1,1,1,0,1,0,1,1,8,1,1,0,0,1,0,,,,,0,2,0
NCT04684979,Transplantation of Hematopoietic Stem Cells From HLA-compatible Donors in Patients With B-Cell Lymphoid Malignancies,A Non-Myeloablative Conditioning Regimen With Peri-Transplant Rituximab and the Transplantation of Hematopoietic Stem Cells From HLA-compatible Related or Unrelated Donors in Patients With B-Cell Lymphoid Malignancies,WITHDRAWN,2022-03-28,2027-03,2023-11-01,INTERVENTIONAL,PHASE2,0.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,B-Cell Lymphoid Malignancies|Hematologic Malignancy|Non-Hodgkin Lymphoma,Hematopoietic Stem Cells from HLA-compatible Related|Hematopoietic Stem Cells from HLA Unrelated,BIOLOGICAL,1,9,18 Years,74 Years,ALL,False,Baptist Health South Florida,OTHER,0,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,3,0.0,,1,1,0,1,0,0,0,0,1,0,0,0,1,1,10,1,0,1,0,2,1,,2027-03-01,,,0,3,1
NCT05302596,Semaglutide Use in Elderly Obese Patients,Preserving Lean Body Mass During Weight Loss In Elderly Obese Patients With GLP-1 Receptor Agonist Treatment,COMPLETED,2022-09-01,2024-10-30,2025-04-17,INTERVENTIONAL,PHASE2,16.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Obesity|Aging,Semaglutide Pen Injector,DRUG,2,2,65 Years,,ALL,True,State University of New York at Buffalo,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,2.833213344056216,small,1,1,0,1,0,1,0,0,1,0,1,0,1,1,4,1,1,0,0,1,0,,,,,0,1,0
NCT05147662,"A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A, a Genetic Bleeding Disorder That is Caused by the Lack of a Protein Called Clotting Factor 8 (FVIII) in the Blood","A Phase 3, Single Group Treatment, Open-label, Study to Evaluate the Safety of BAY 94-9027 Infusions for Prophylaxis and Treatment of Bleeding in Previously Treated Children Aged 7 to <12 Years With Severe Hemophilia A",COMPLETED,2022-03-23,2025-06-25,2026-01-21,INTERVENTIONAL,PHASE3,36.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Treatment of Bleeding|Prophylaxis of Bleeding|Hemophilia A|Children,"Damoctocog alfa pegol (Jivi, BAY94-9027)",BIOLOGICAL,1,6,7 Years,11 Years,MALE,False,Bayer,INDUSTRY,0,17,Italy|Argentina|Turkey (Türkiye)|United States|Brazil|Norway|Canada,1.0,0,0,1,0,0,3.0,0,0,0,0,4,3.6109179126442243,small,1,1,1,0,0,0,1,1,1,1,0,0,1,0,7,1,0,1,0,1,0,,,,,0,3,1
NCT02970162,Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),"A Phase 3, Double-Blind, Placebo-controlled, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome",COMPLETED,2016-11,2017-10,2018-12-24,INTERVENTIONAL,PHASE3,26.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Lambert-Eaton Myasthenic Syndrome,Amifampridine Phosphate|Placebo Oral Tablet,DRUG,2,1,18 Years,,ALL,False,"Catalyst Pharmaceuticals, Inc.",INDUSTRY,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.295836866004329,small,1,1,1,0,0,0,0,0,1,0,1,1,1,1,3,1,1,0,0,2,1,2016-11-01,2017-10-01,334.0,2016.0,1,1,0
NCT04443062,Lutetium-177-PSMA-617 in Oligo-metastatic Hormone Sensitive Prostate Cancer,Lutetium-177-PSMA-617 Radioligand Therapy in Oligo-metastatic Hormone Sensitive Prostate Cancer.,ACTIVE_NOT_RECRUITING,2020-07-20,2026-01-01,2024-10-30,INTERVENTIONAL,PHASE2,58.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,NONE,Prostate Cancer,177Lu-PSMA-617,DRUG,2,7,18 Years,,MALE,False,Radboud University Medical Center,OTHER,2,4,Netherlands|Cyprus,,0,1,0,0,0,2.0,1,0,0,0,1,4.07753744390572,medium,1,0,0,1,0,1,1,1,0,0,1,0,1,1,9,1,1,0,0,1,0,,,,,0,2,0
NCT01122862,Effect of a Commercial Cosmetic Mouth Rinse on Plaque Re-growth,A Clinical Study to Evaluate the Effect of a Commercial Cosmetic Mouth Rinse on Plaque Re-growth,COMPLETED,2010-04,2010-05,2013-09-09,INTERVENTIONAL,PHASE2,23.0,ACTUAL,RANDOMIZED,CROSSOVER,PREVENTION,SINGLE,Healthy Subjects,0.12% chlorhexidine mouthrinse|Cosmetic mouthrinse|Sterile water,DRUG|OTHER,1,4,18 Years,,ALL,True,GlaxoSmithKline,INDUSTRY,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.1780538303479458,small,1,1,1,0,0,0,0,0,1,0,1,0,0,0,5,1,1,0,0,3,1,2010-04-01,2010-05-01,30.0,2010.0,0,1,0
NCT00412646,"TMC125-C203: Phase II Randomized (Patients Are Assigned Different Treatments Based on Chance), Placebo Controlled Dose Escalating Trial of TMC125 in HIV-1 Infected Patients","A Randomized, Placebo-controlled Phase II Trial in HIV-1-infected, NRTI-, PI and NNRTI-experienced Subjects to Evaluate the Safety, Tolerability and Efficacy of Different Doses of TMC125 b.i.d. on Top of an Individually Optimized Antiretroviral Therapy by Means of a 2-stage Dose-escalating Design",COMPLETED,2002-06,2006-11,2010-04-28,INTERVENTIONAL,PHASE2,260.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Anti-Retroviral Agents|HIV-1,TMC125,DRUG,1,1,18 Years,,ALL,False,"Tibotec Pharmaceuticals, Ireland",INDUSTRY,0,0,,1.0,0,1,0,0,0,2.0,0,0,0,0,2,5.564520407322694,large,0,1,1,0,0,0,0,0,0,0,1,1,1,1,2,1,1,0,0,1,0,2002-06-01,2006-11-01,1614.0,2002.0,0,1,0
NCT05568888,Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( TAP Study ),"A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE1116 (4-Factor Prothrombin Complex Concentrate [Kcentra® / Beriplex®]) to Improve Survival in Patients With Traumatic Injury and Acute Major Bleeding",TERMINATED,2023-03-28,2024-10-29,2025-12-10,INTERVENTIONAL,PHASE3,1366.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Traumatic Injury,BE1116|Placebo,DRUG,1,8,15 Years,,ALL,False,CSL Behring,INDUSTRY,0,113,United Kingdom|Australia|United States,0.0,0,0,1,0,0,3.0,0,0,0,0,1,7.220373836723949,xlarge,0,1,1,0,0,0,1,1,1,1,1,1,1,1,9,1,1,0,0,2,1,,,,,0,3,1
NCT04157088,"Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC)","A Randomized, Open-label, Multicenter, Phase 2b Study to Evaluate Physical Function, Including Balance and Daily Activity, in Participants With Castration-resistant Prostate Cancer Treated With Darolutamide or Enzalutamide",TERMINATED,2019-12-17,2022-07-08,2023-08-04,INTERVENTIONAL,PHASE2,30.0,ACTUAL,RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,"Prostatic Cancer, Castration-Resistant","Darolutamide (Nubeqa, BAY1841788)|Enzalutamide",DRUG,1,19,18 Years,,MALE,False,Bayer,INDUSTRY,0,7,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,3.4339872044851463,small,1,1,1,0,0,0,1,0,1,0,1,0,1,0,20,1,1,0,0,2,1,,,,,0,2,0
NCT02899988,A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Plaque Psoriasis,"A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo- Controlled Study of LY3074828 in Subjects With Moderate-to- Severe Plaque Psoriasis",COMPLETED,2016-09-14,2019-05-08,2020-06-18,INTERVENTIONAL,PHASE2,205.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Plaque Psoriasis,Mirikizumab|Placebo,DRUG,1,8,18 Years,75 Years,ALL,False,Eli Lilly and Company,INDUSTRY,0,40,Puerto Rico|United States|Germany|Poland|Japan|Canada,1.0,0,1,0,0,0,2.0,0,1,0,0,1,5.327876168789581,large,0,1,1,0,1,0,1,1,1,1,1,1,1,1,9,1,1,0,0,2,1,,,,,0,3,1
NCT00552188,Phase 2 Study in Vascular Inflammation on Patients After an Acute Coronary Syndrome Event,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Effect of VIA-2291, a 5-Lipoxygenase Inhibitor, on Vascular Inflammation in Patients After an Acute Coronary Syndrome Event",COMPLETED,2007-10,2009-11,2013-08-09,INTERVENTIONAL,PHASE2,52.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Acute Coronary Syndrome,VIA-2291|Placebo,DRUG,1,1,18 Years,80 Years,ALL,False,"Tallikut Pharmaceuticals, Inc.",INDUSTRY,5,2,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.970291913552122,medium,1,1,1,0,0,1,1,0,1,0,1,1,1,1,2,1,1,0,0,2,1,2007-10-01,2009-11-01,762.0,2007.0,0,1,0
NCT02876003,Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma,"An Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy, Safety and CNS Exposure of G-202 in Patients With PSMA Positive Recurrent or Progressive Glioblastoma",WITHDRAWN,2016-09,2020-10,2017-02-24,INTERVENTIONAL,PHASE2,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Glioblastoma,G-202,DRUG,1,4,18 Years,,ALL,False,"GenSpera, Inc.",INDUSTRY,1,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,1,1,1,0,0,1,0,0,1,0,0,0,1,0,5,1,1,0,0,1,0,2016-09-01,2020-10-01,1491.0,2016.0,1,0,0
NCT01039103,Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS),"A Randomized, International, Multi Centre Study to Assess the Efficacy and Safety of Intravenous PEG-liposomal Prednisolone Sodium Phosphate (Nanocort®) vs Intravenous Methylprednisolone (Solu-Medrol®) Treatment in Patients With Acute Exacerbation of Relapsing-remitting Multiple Sclerosis or in Patients With Clinically Isolated Syndrome (CIS)",TERMINATED,2009-12,2011-11,2016-10-06,INTERVENTIONAL,PHASE2,15.0,ACTUAL,RANDOMIZED,PARALLEL,,SINGLE,Acute Exacerbation of Remitting Relapsing Multiple Sclerosis|Clinically Isolated Syndrome,PEG-liposomal prednisolone sodium phosphate|Methylprednisolone,DRUG,1,5,18 Years,65 Years,ALL,False,Galapagos NV,INDUSTRY,0,8,Germany|Belgium|Poland,0.0,0,1,0,0,0,2.0,0,1,0,0,2,2.772588722239781,small,1,1,1,0,0,0,1,1,0,1,1,0,0,1,6,1,1,0,0,2,1,2009-12-01,2011-11-01,700.0,2009.0,0,4,1
NCT01401361,Atrial Flutter Ablation With Contact Therapy Cool Path Ablation System Along With EnSite Velocity Contact System,Clinical Evaluation of Contact™ Therapy™ Cool Path™ Cardiac Ablation System in Conjunction With EnSite Velocity Contact™ Technology for the Treatment of Typical Atrial Flutter,COMPLETED,2011-10,2012-09,2019-02-15,INTERVENTIONAL,PHASE3,150.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Typical Atrial Flutter,Treatment Arm,DEVICE,2,1,18 Years,,ALL,False,Abbott Medical Devices,INDUSTRY,0,20,Canada|United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.017279836814924,medium,0,1,1,0,0,0,1,1,1,0,0,0,1,0,3,1,0,0,1,1,0,2011-10-01,2012-09-01,336.0,2011.0,0,1,0
NCT02402842,Clinical and Biological Interest of Taxanes in Advanced Squamous Cell Anal Carcinoma,"Assessment of the Clinical Value of a Docetaxel, Cisplatin and 5-fluorouracil (DCF) Strategy Adapted to Patients for the Management of Metastatic or Locally Advanced Anal Resistant Radiochemotherapy Squamous Cell Anal Carcinoma.",COMPLETED,2014-09,2020-06-30,2022-05-16,INTERVENTIONAL,PHASE2,70.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Anal Canal Carcinoma,"Docetaxel, Cisplatin and 5-Fluorouracil",DRUG,1,6,18 Years,,ALL,False,Centre Hospitalier Universitaire de Besancon,OTHER,0,16,France,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.2626798770413155,medium,1,1,0,1,0,0,1,0,0,1,0,0,1,0,7,1,1,0,0,1,0,2014-09-01,,,2014.0,0,1,0
NCT01406561,Safety and Efficacy of OMS103HP-S Administered in Joint Irrigation Solution to Subjects Undergoing Arthroscopic Meniscectomy,"A Randomized, Double-Blind, Parallel Group, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of OMS103HP-S Administered in Joint Irrigation Solution to Subjects Undergoing Arthroscopic Meniscectomy",COMPLETED,2011-08,2012-12,2018-10-26,INTERVENTIONAL,PHASE3,344.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Meniscal Tear,OMS103HP-S|Vehicle,DRUG,2,6,18 Years,75 Years,ALL,False,Omeros Corporation,INDUSTRY,0,18,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.84354441703136,large,0,1,1,0,0,0,1,0,1,0,1,1,1,1,8,1,1,0,0,2,1,2011-08-01,2012-12-01,488.0,2011.0,0,2,0
NCT05130970,"Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis","A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Garadacimab in Subjects With Idiopathic Pulmonary Fibrosis",COMPLETED,2022-02-03,2024-01-02,2024-12-13,INTERVENTIONAL,PHASE2,81.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Idiopathic Pulmonary Fibrosis,Garadacimab|Placebo,DRUG,8,9,40 Years,,ALL,False,CSL Behring,INDUSTRY,0,47,Italy|Belgium|United States|Germany|Austria|Australia|Spain|United Kingdom|Poland|Denmark|Canada,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.406719247264253,medium,1,1,1,0,0,0,1,1,1,1,1,1,1,1,17,1,1,0,0,2,1,,,,,0,3,1
NCT01484470,Umbilical Cord Transplantation for the Elderly Population,Umbilical Cord Transplantation for the Elderly Population,COMPLETED,2010-01,2018-11-21,2019-08-21,INTERVENTIONAL,PHASE2,18.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Hematologic Malignancies,StemEx,BIOLOGICAL,1,1,55 Years,73 Years,ALL,False,Loyola University,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.9444389791664403,small,1,1,0,1,0,1,0,0,1,0,0,0,1,1,2,1,0,1,0,1,0,2010-01-01,,,2010.0,0,0,0
NCT01962870,The Role of Vasopressin in the Social Deficits of Autism,Randomized Placebo-controlled Trial of Vasopressin Treatment for Social Deficits in Children With Autism,COMPLETED,2013-12,2017-05-30,2019-05-24,INTERVENTIONAL,PHASE2,68.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Autism Spectrum Disorders,Vasopressin|Placebo,DRUG,1,20,6 Years,12 Years,ALL,False,Stanford University,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.23410650459726,medium,1,1,0,1,0,1,0,0,1,0,1,1,1,1,21,1,1,0,0,2,1,2013-12-01,,,2013.0,0,2,0
NCT02770170,"Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis","A Double-blind, Randomised, Placebo-controlled Trial Evaluating the Effect of BI 655064 Administered as Sub-cutaneous Injections, on Renal Response After One Year of Treatment, in Patients With Active Lupus Nephritis",COMPLETED,2016-05-16,2020-08-18,2025-10-16,INTERVENTIONAL,PHASE2,121.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Lupus Nephritis,BI 655064 dose 1|BI 655064 dose 2|BI 655064 dose 3|Placebo,DRUG,1,5,18 Years,70 Years,ALL,False,Boehringer Ingelheim,INDUSTRY,0,74,Germany|Japan|Serbia|Greece|Thailand|Italy|South Korea|Spain|Czechia|Portugal|Canada|United States|United Kingdom|Australia|Poland|Mexico|Philippines|France|Hong Kong|Malaysia,1.0,0,1,0,0,0,2.0,0,1,0,0,1,4.804021044733257,medium,0,1,1,0,0,0,1,1,1,1,1,1,1,1,6,1,1,0,0,4,1,,,,,0,3,1
NCT03031470,Pilot Study of Reparixin for Early Allograft Dysfunction Prevention in Liver Transplantation,"A Multicenter, Open-label, Randomized Pilot Clinical Study of Efficacy and Safety of Reparixin for Prevention of Early Allograft Dysfunction in Patients Undergoing Orthotopic Liver Transplantation",TERMINATED,2015-03-10,2017-03-31,2025-01-07,INTERVENTIONAL,PHASE2,40.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Ischemia-reperfusion Injury in Liver Transplant|Early Allograft Dysfunction,Reparixin|Control,DRUG|OTHER,2,20,18 Years,,ALL,False,Dompé Farmaceutici S.p.A,INDUSTRY,0,7,Russia|Belarus,0.0,0,1,0,0,0,2.0,0,0,0,0,2,3.713572066704308,small,1,1,1,0,0,0,1,1,0,0,1,0,1,1,22,1,1,0,0,2,1,,,,,0,4,1
NCT00978718,Selenium in Preventing Prostate Cancer,Phase III Trial of Selenium for Prostate Cancer Prevention,COMPLETED,2001-08,2004-06,2012-08-15,INTERVENTIONAL,PHASE3,700.0,ESTIMATED,RANDOMIZED,,PREVENTION,DOUBLE,Prostate Cancer,high-selenium baker's yeast|selenium|placebo,OTHER|DIETARY_SUPPLEMENT,1,2,,79 Years,MALE,False,University of Arizona,OTHER,1,0,,1.0,0,0,1,0,0,3.0,1,0,0,0,1,6.55250788703459,xlarge,0,0,0,1,0,1,0,0,0,0,1,1,0,0,3,1,0,0,0,3,1,2001-08-01,2004-06-01,1035.0,2001.0,0,1,0
NCT00246090,"A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine","A Phase II Open Label Single-Arm Study of E7389 in Patients With Locally Advanced or Metastatic Breast Cancer, Previously Treated With Anthracycline, Taxane, and Capecitabine Therapy, Refractory to the Last Prior Therapy for Their Disease",COMPLETED,2005-10,2007-09,2014-07-14,INTERVENTIONAL,PHASE2,298.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Breast Cancer,E7389,DRUG,1,1,18 Years,,FEMALE,False,Eisai Inc.,INDUSTRY,1,65,Canada|United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,5.700443573390687,large,0,1,1,0,0,1,1,1,1,0,0,0,1,0,2,1,1,0,0,1,0,2005-10-01,2007-09-01,700.0,2005.0,0,1,0
NCT00301574,An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease.,"Placebo-Controlled, Double-Blind Study of Galantamine (R113675) in the Treatment of Alzheimer's Disease.",COMPLETED,2001-04,2004-02,2011-05-17,INTERVENTIONAL,PHASE3,398.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Alzheimer Disease,galantamine,DRUG,1,1,45 Years,,ALL,False,Janssen Pharmaceutical K.K.,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,1,0,1,5.988961416889864,large,0,1,1,0,0,0,0,0,0,0,1,1,1,1,2,1,1,0,0,1,0,2001-04-01,2004-02-01,1036.0,2001.0,0,0,0
NCT01093118,A Study to Evaluate TMI-358 in the Treatment of Distal Subungual Onychomycosis,"A Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TMI-358 in the Treatment of Distal Subungual Onychomycosis of the Toenail",TERMINATED,2009-09,,2011-01-17,INTERVENTIONAL,PHASE2,120.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Distal Subungual Onychomycosis,TMI-358|MMI-467,DRUG,1,0,18 Years,75 Years,ALL,False,"Talima Therapeutics, Inc.",INDUSTRY,0,7,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,4.795790545596741,medium,0,0,1,0,0,0,1,0,1,0,1,1,1,1,1,0,1,0,0,2,1,2009-09-01,,,2009.0,0,1,0
NCT00038090,Thalidomide-Dexamethasone for Multiple Myeloma,Thalidomide-Dexamethasone for Multiple Myeloma,COMPLETED,2000-06,2005-05,2018-10-31,INTERVENTIONAL,PHASE2|PHASE3,83.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Multiple Myeloma,Thalidomide|Dexamethasone,DRUG,1,0,,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,1,United States,1.0,0,1,1,0,1,2.5,1,0,0,0,1,4.430816798843313,medium,1,1,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,2,1,2000-06-01,2005-05-01,1795.0,2000.0,0,2,0
NCT03507790,A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.",COMPLETED,2018-10-10,2024-05-29,2025-08-11,INTERVENTIONAL,PHASE2,153.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Mild to Moderate Alzheimer's Disease,CT1812|Placebo,DRUG,2,2,50 Years,85 Years,ALL,False,Cognition Therapeutics,INDUSTRY,1,32,Netherlands|Spain|United States|Australia|Czechia,1.0,0,1,0,0,0,2.0,0,0,1,0,1,5.0369526024136295,medium,0,1,1,0,0,1,1,1,1,1,1,1,1,1,4,1,1,0,0,2,1,,,,,0,2,0
NCT02582190,COlchicine for the Prevention of Post Electrical Cardioversion Recurrence of AF,Colchicine for the Prevention of Atrial Fibrillation Recurrence After Electrical Cardioversion of Persistent Atrial Fibrillation.,WITHDRAWN,2017-12-02,2018-09-02,2018-01-25,INTERVENTIONAL,PHASE3,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Atrial Fibrillation,Colchicine group,DRUG,1,1,18 Years,80 Years,ALL,False,Elpen Pharmaceutical Co. Inc.,INDUSTRY,0,0,,0.0,0,0,1,0,0,3.0,0,0,0,0,1,0.0,,1,1,1,0,0,0,0,0,0,0,0,0,1,0,2,1,1,0,0,1,0,,,,,0,0,0
NCT00318890,Cisplatin and Docetaxel Plus Docetaxel and Radiotherapy With Amifostine for Squamous Cell Carcinoma of the Head and Neck,A Phase I/II Trial of Induction Cisplatin and Docetaxel Followed by Concomitant Docetaxel/Radiotherapy With Subcutaneous Amifostine for Locally Advanced Squamous Cell Carcinoma of the Head and Neck,COMPLETED,2002-10,2007-12,2019-02-05,INTERVENTIONAL,PHASE1|PHASE2,48.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Cancer of Head and Neck|Head Cancer|Head and Neck Cancer|Neck Cancer|Neck Neoplasms,Cisplatin|Docetaxel|Radiotherapy|Amifostine,DRUG|PROCEDURE,1,3,19 Years,,ALL,False,University of Alabama at Birmingham,OTHER,1,1,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,5,3.8918202981106265,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,4,1,1,0,0,4,1,2002-10-01,2007-12-01,1887.0,2002.0,0,3,1
NCT01704690,Combination Treatment of S-1 With Paclitaxel in Advanced Esophageal Cancer,Combination Treatment of S-1 With Paclitaxel Versus Paclitaxel+Cisplatin and 5-Fu+Cisplatin as First-line Treatment in Advanced Esophageal Cancer,TERMINATED,2012-08,2017-03,2017-04-07,INTERVENTIONAL,PHASE2|PHASE3,4.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Esophageal Cancer,S-1 and Paclitaxel|Paclitaxel and Cisplatin|5-FU and Cisplatin,DRUG,1,3,18 Years,75 Years,ALL,False,Peking University,OTHER,0,1,China,0.0,0,1,1,0,1,2.5,1,0,0,0,1,1.6094379124341003,small,1,1,0,1,0,0,0,0,0,0,1,0,1,1,4,1,1,0,0,3,1,2012-08-01,2017-03-01,1673.0,2012.0,0,2,0
NCT00436618,Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment,Phase II Trial of Everolimus (RAD001) in Relapsed/Refractory Lymphoma,COMPLETED,2005-08,2019-10-09,2019-10-22,INTERVENTIONAL,PHASE2,277.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Leukemia|Lymphoma|Lymphoproliferative Disorder,Everolimus,DRUG,1,3,18 Years,120 Years,ALL,False,Mayo Clinic,OTHER,1,3,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,3,5.627621113690637,large,0,1,0,1,0,1,1,0,1,0,0,0,1,1,4,1,1,0,0,1,0,2005-08-01,,,2005.0,0,1,0
NCT04608318,Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL),"A Phase 3 Multicentre, Randomized, Prospective, Open-label Trial of Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)",ACTIVE_NOT_RECRUITING,2021-03-01,2027-09,2024-12-31,INTERVENTIONAL,PHASE3,897.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,NONE,Chronic Lymphoid Leukemia,Ibrutinib|Venetoclax|Obinutuzumab,BIOLOGICAL,1,9,18 Years,,ALL,False,German CLL Study Group,OTHER,10,181,Italy|Belgium|Finland|Netherlands|Sweden|Spain|Germany|Austria|Norway|Switzerland|Denmark|Israel|Ireland,,0,0,1,0,0,3.0,1,0,0,0,1,6.8001700683022,xlarge,0,0,0,1,0,1,1,1,0,1,1,0,1,1,10,1,0,1,0,3,1,,2027-09-01,,,0,3,1
NCT03291418,To Compare the Gastrointestinal Safety of a 14-Day Oral Dosing Regimen of ATB-346 to Sodium Naproxen in Healthy Subjects,"A Double-Blind, Controlled Study to Compare the Gastrointestinal Safety of a 14-Day Oral Dosing Regimen of ATB-346 to Sodium Naproxen in Healthy Subjects",COMPLETED,2017-09-08,2018-04-30,2018-06-06,INTERVENTIONAL,PHASE1|PHASE2,258.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Gastric Ulcer,ATB-346 OR Placebo|Naproxen sodium,DRUG,1,5,18 Years,65 Years,ALL,True,Antibe Therapeutics Inc.,INDUSTRY,0,1,Canada,1.0,1,1,0,0,1,1.5,0,0,0,0,1,5.556828061699537,large,0,1,1,0,0,0,0,0,0,0,1,1,0,1,6,1,1,0,0,2,1,,,,,0,3,1
NCT03230318,"Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma",A Pivotal Study of Derazantinib in Patients With Inoperable or Advanced Intrahepatic Cholangiocarcinoma and FGFR2 Gene Fusions or FGFR2 Gene Mutations or Amplifications,COMPLETED,2017-09-28,2022-10-25,2023-12-19,INTERVENTIONAL,PHASE2,148.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Intrahepatic Cholangiocarcinoma|Combined Hepatocellular and Cholangiocarcinoma,derazantinib,DRUG,2,5,18 Years,,ALL,False,Basilea Pharmaceutica,INDUSTRY,0,41,Italy|Belgium|South Korea|United States|Germany|Spain|United Kingdom|Switzerland|France|Ireland|Canada,1.0,0,1,0,0,0,2.0,1,0,0,0,2,5.003946305945459,medium,0,1,1,0,0,0,1,1,1,1,0,0,1,0,7,1,1,0,0,1,0,,,,,0,3,1
NCT02446418,A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma,"A 6-month, Open Label, Randomised, Efficacy Study to Evaluate Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) Inhalation Powder Delivered Once Daily Via the Dry Powder Inhaler ELLIPTA™ Compared With Usual ICS/LABA Maintenance Therapy Delivered by Dry Powder Inhaler in Subjects With Persistent Asthma",COMPLETED,2015-07-09,2017-07-20,2019-01-14,INTERVENTIONAL,PHASE3,423.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Asthma,Fluticasone Furoate|Vilanterol|Fluticasone propionate|Salmeterol|Budesonide|Formoterol Fumarate,DRUG,1,2,18 Years,75 Years,ALL,False,GlaxoSmithKline,INDUSTRY,0,93,Germany|France,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.049733455231958,large,0,1,1,0,0,0,1,1,0,1,1,0,1,1,3,1,1,0,0,6,1,,,,,0,2,0
NCT00004197,Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma,A Phase II Trial to Evaluate the Rate of Immune Response Using Idiotype Immunotherapies Produced by Molecular Biological Means for Treatment of Aggressive B Cell Lymphoma,COMPLETED,1999-06-25,2003-11-20,2023-09-07,INTERVENTIONAL,PHASE2,,,,,TREATMENT,,Lymphoma,keyhole limpet hemocyanin|sargramostim|tumor cell-based vaccine therapy|cyclophosphamide|doxorubicin hydrochloride|mitoxantrone hydrochloride|prednisone|vincristine sulfate,DRUG|BIOLOGICAL,0,0,18 Years,120 Years,ALL,False,University of Nebraska,OTHER,1,2,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,0.0,,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,1,1,0,8,1,,,,,0,1,0
NCT00546897,Lenalidomide in Older Patients With Acute Myeloid Leukemia Without Chromosome 5q Abnormalities,Phase II Trial of Lenalidomide in Older Patients (>/= 60 Years) With Untreated Acute Myeloid Leukemia Without Chromosome 5q Abnormalities,COMPLETED,2007-02,2012-03,2014-09-29,INTERVENTIONAL,PHASE2,48.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Leukemia, Myeloid, Acute",Lenalidomide,DRUG,1,15,60 Years,,ALL,False,Washington University School of Medicine,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.8918202981106265,small,1,1,0,1,0,0,0,0,1,0,0,0,1,1,16,1,1,0,0,1,0,2007-02-01,2012-03-01,1855.0,2007.0,0,1,0
NCT00588913,"Adoptive Immunotherapy, Aldesleukin, and Zoledronate in Treating Patients With Stage IV Kidney Cancer and Lung Metastases","Phase I/II Study of Adoptive Immunotherapy Comprising Pyrophosphomonoester Antigen-stimulated T Cells, IL-2, and Nitrogen-containing Bisphosphonates in Patients With Stage IV Renal Cell Carcinoma",COMPLETED,2006-01,2009-08,2013-07-10,INTERVENTIONAL,PHASE1|PHASE2,20.0,ESTIMATED,NON_RANDOMIZED,,TREATMENT,NONE,Kidney Cancer|Metastatic Cancer,aldesleukin|therapeutic autologous lymphocytes|zoledronic acid,DRUG|BIOLOGICAL,2,2,20 Years,80 Years,ALL,False,Tokyo Women's Medical University,OTHER,0,2,Japan,1.0,1,1,0,0,1,1.5,1,0,0,0,2,3.044522437723423,small,1,0,0,1,0,0,1,0,0,0,0,0,1,0,4,1,1,1,0,3,1,2006-01-01,2009-08-01,1308.0,2006.0,0,3,1
NCT04545060,VIR-7831 for the Early Treatment of COVID-19 in Outpatients,"A Phase II/III Randomized, Multi-center, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Monoclonal Antibody VIR-7831 for the Early Treatment of Coronavirus Disease 2019 (COVID-19) in Non-hospitalized Patients",COMPLETED,2020-08-27,2021-09-02,2022-11-07,INTERVENTIONAL,PHASE2|PHASE3,1057.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Covid19,VIR-7831 (sotrovimab)|Placebo,DRUG|BIOLOGICAL,1,28,18 Years,,ALL,False,"Vir Biotechnology, Inc.",INDUSTRY,1,91,United States|Spain|Austria|Brazil|United Kingdom|Peru|Canada,1.0,0,1,1,0,1,2.5,0,0,0,0,1,6.964135612418245,xlarge,0,1,1,0,0,1,1,1,1,1,1,1,1,1,29,1,1,1,0,2,1,,,,,0,4,1
NCT04368520,Clinical Trial to Optimise Levels of Vitamin D for Rhinovirus Protection,Clinical Trial to Optimise Levels of Vitamin D for Rhinovirus Protection (COLD),WITHDRAWN,2020-03-01,2022-05-01,2024-07-05,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,SINGLE,Common Cold,Vitamin D3|Vitamin D3|Placebo,OTHER|DIETARY_SUPPLEMENT,1,3,18 Years,70 Years,ALL,True,Queen Mary University of London,OTHER,1,1,United Kingdom,0.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,1,1,0,1,0,1,0,0,0,1,1,0,0,1,4,1,0,0,0,3,1,,,,,0,1,0
NCT06439420,CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial,Cognitive Behavioral Therapy for Insomnia in Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial,COMPLETED,2024-07-08,2025-09-25,2025-10-01,INTERVENTIONAL,PHASE2,70.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Primary Brain Tumor|Glioblastoma|Astrocytoma|Oligodendroglioma|Meningioma|Primary Central Nervous System (CNS) Lymphoma,Cognitive Behavioral Therapy for Insomnia,BEHAVIORAL,9,0,18 Years,,ALL,False,Virginia Commonwealth University,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,6,4.2626798770413155,medium,1,1,0,1,0,0,0,0,1,0,1,0,1,1,9,0,0,0,0,1,0,,,,,0,2,0
NCT04036682,A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer,"A Phase 1/2, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients With Locally-Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Previously Received Platinum-Based Systemic Chemotherapy",ACTIVE_NOT_RECRUITING,2019-10-31,2026-03-31,2025-03-13,INTERVENTIONAL,PHASE1|PHASE2,284.0,ESTIMATED,NON_RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,Non Small Cell Lung Cancer|EGFR Exon 20 Mutation,CLN-081,DRUG,6,9,18 Years,,ALL,False,Cullinan Therapeutics Inc.,INDUSTRY,0,64,Italy|Netherlands|South Korea|United States|Spain|Hong Kong|Japan|Taiwan|Singapore,,1,1,0,0,1,1.5,1,0,0,0,2,5.652489180268651,large,0,0,1,0,0,0,1,1,1,1,0,0,1,0,15,1,1,0,0,1,0,,,,,0,4,1
NCT03412682,To Evaluate the Efficacy and Safety of FE 999315 in Japanese Subjects With Mild to Moderate Active Ulcerative Colitis,"A Phase 3, Multi-centre, Randomised, Double-blind, Active-controlled, Parallel-group Trial Investigating the Efficacy and Safety of FE 999315 Following 8 Weeks of Treatment for Mild to Moderate Active Ulcerative Colitis in Japanese Subjects",COMPLETED,2018-03-02,2020-05-26,2020-06-18,INTERVENTIONAL,PHASE3,274.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Colitis, Ulcerative","Budesonide (6 mg)|Budesonide (9 mg)|Mesalazine (3,600 mg)",DRUG,1,11,16 Years,75 Years,ALL,False,Ferring Pharmaceuticals,INDUSTRY,0,72,Japan,1.0,0,0,1,0,0,3.0,0,1,0,0,1,5.616771097666572,large,0,1,1,0,0,0,1,0,0,0,1,1,1,1,12,1,1,0,0,3,1,,,,,0,2,0
NCT00111982,Trial of Extended Treatment With Liatermin (r-metHuGDNF) Administered by Continuous Intraputaminal (IPu)Infusion to Subjects With Idiopathic Parkinson's Disease Who Have Completed a Previous Trial of Liatermin,"Multi-Center, Open-Label Trial of Extended Treatment With Liatermin (r-metHuGDNF) Administered by Continuous Intraputaminal (IPu) Infusion to Subjects With Idiopathic Parkinson's Disease Who Have Completed a Previous Trial of Liatermin (Protocol 20020168)",COMPLETED,2003-12,2006-02,2010-02-26,INTERVENTIONAL,PHASE1|PHASE2,34.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Parkinson's Disease,Liatermin,BIOLOGICAL,1,1,35 Years,70 Years,ALL,False,Amgen,INDUSTRY,1,0,,1.0,1,1,0,0,1,1.5,0,0,1,0,1,3.5553480614894135,small,1,1,1,0,1,1,0,0,0,0,0,0,1,0,2,1,0,1,0,1,0,2003-12-01,2006-02-01,793.0,2003.0,0,1,0
NCT01560182,Gene Therapy for Metachromatic Leukodystrophy (MLD),A Phase I/II Clinical Trial of Hematopoietic Stem Cell Gene Therapy for the Treatment of Metachromatic Leukodystrophy,COMPLETED,2010-04-09,2025-09-19,2025-12-05,INTERVENTIONAL,PHASE1|PHASE2,20.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Lysosomal Storage Disease|Metachromatic Leukodystrophy,OTL-200 Gene Therapy,GENETIC,8,4,,7 Years,ALL,False,Orchard Therapeutics,INDUSTRY,1,1,Italy,1.0,1,1,0,0,1,1.5,0,0,0,0,2,3.044522437723423,small,1,1,1,0,0,1,0,0,0,1,0,0,1,0,12,1,0,0,0,1,0,,,,,0,3,1
NCT01561482,Study of Metformin With Simvastatin for Men With Prostate Carcinoma,Open-Label Study Of Metformin In Combination With Simvastatin For Men With Prostate Carcinoma And A Rising Serum Prostate-Specific Antigen Level After Radical Prostatectomy And/Or Radiation Therapy,WITHDRAWN,2012-01,2014-07,2015-07-22,INTERVENTIONAL,PHASE2,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Prostate Carcinoma,Metformin|Simvastatin,DRUG,1,3,18 Years,,MALE,False,Nicholas Mitsiades,OTHER,0,3,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,0.0,,1,1,0,1,0,0,1,0,1,0,0,0,1,0,4,1,1,0,0,2,1,2012-01-01,2014-07-01,912.0,2012.0,0,1,0
NCT04684524,Dupilumab in Allergic Fungal Rhinosinusitis (AFRS) (LIBERTY-AFRS-AI),A Randomized Double-blind Placebo-controlled Parallel Group Study Assessing the Efficacy and Safety of Dupilumab in Patients With Allergic Fungal Rhinosinusitis (AFRS),COMPLETED,2020-12-01,2025-03-07,2025-12-22,INTERVENTIONAL,PHASE3,62.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Allergic Fungal Rhinosinusitis,Dupilumab SAR231893|Placebo,DRUG,1,22,6 Years,,ALL,True,Sanofi,INDUSTRY,1,47,China|Argentina|Turkey (Türkiye)|India|United States|Saudi Arabia|Japan|Israel|Canada,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.143134726391533,medium,1,1,1,0,1,1,1,1,1,0,1,1,1,1,23,1,1,0,0,2,1,,,,,0,3,1
NCT07177196,Personalized Antisense Oligonucleotide Therapy for a Single Participant With PRPH2 Mutation Associated With Retinal Dystrophy,An Open-label Single Center Study of an Individualized Antisense Oligonucleotide Treatment for Retinal Dystrophy Associated With a Pathogenic PRPH2 Variant,ACTIVE_NOT_RECRUITING,2025-08-28,2027-08,2025-09-16,INTERVENTIONAL,PHASE1|PHASE2,1.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Retinal Dystrophy,nL-PRPH2-001,DRUG,8,6,,,FEMALE,False,n-Lorem Foundation,OTHER,1,1,United States,,1,1,0,0,1,1.5,0,0,0,0,1,0.6931471805599453,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,14,1,1,0,0,1,0,,2027-08-01,,,0,2,0
NCT03820596,Sintilimab in Combination With Chidamide in Refractory and Relapsed ENKTCL,"Safety and Efficacy of Sintilimab(S) in Combination With Histone Deacetylase Inhibitor (Chidamide, C) in Refractory and Relapsed Extranodal Natural Killer Cell/T-cell Lymphoma(EN): A Single-arm, Multicenter Phase I b/II Study(SCENT)",COMPLETED,2019-03-29,2021-11-30,2022-04-14,INTERVENTIONAL,PHASE1|PHASE2,40.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Safety and Efficacy,Sintilimab|Chidamide,DRUG,5,3,18 Years,75 Years,ALL,False,Huiqiang Huang,OTHER,0,4,China,1.0,1,1,0,0,1,1.5,0,0,0,0,1,3.713572066704308,small,1,1,0,1,0,0,1,0,0,0,0,0,1,0,8,1,1,0,0,2,1,,,,,0,3,1
NCT00761462,BAY 0 9867 Cipro Pediatric Use Study (QUIP),"A Prospective, Open-label, Non-randomized, Naturalistic, Long-term Safety Surveillance, Observational Study of Either Ciprofloxacin (Either as Oral Suspension, Oral Tablets or Sequential IV Followed by Oral Therapy or Purely IV Therapy) or a Non-quinolone Antibiotic (Either as Oral Suspension, Oral Tablets or Sequential IV Followed by Oral Therapy or Purely IV Therapy) in the Treatment of Pediatric Patients With Infectious Diagnoses",COMPLETED,1999-10,2008-01,2015-07-31,INTERVENTIONAL,PHASE3,1029.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Infectious Diseases,Ciprofloxacin|Non-quinolone antibiotic,DRUG,2,0,2 Months,16 Years,ALL,False,Bayer,INDUSTRY,0,67,Canada|United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.937314081223682,xlarge,0,1,1,0,0,0,1,1,1,0,0,0,1,1,2,0,1,0,0,2,1,1999-10-01,2008-01-01,3014.0,1999.0,0,2,0
NCT03613662,A Research Study to Characterize the Pharmacodynamics and Safety of Repeat Dose SP-102,"An Open-label, Single-arm Study to Characterize the Pharmacodynamics and Safety of Repeat Dose SP-102 Administered by Epidural Injection in Subjects With Lumbosacral Radiculopathy",COMPLETED,2018-07-13,2019-03-15,2022-01-13,INTERVENTIONAL,PHASE2,19.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Lumbosacral Radicular Pain,SP-102,DRUG,3,3,18 Years,70 Years,ALL,False,"Semnur Pharmaceuticals, Inc.",INDUSTRY,2,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.995732273553991,small,1,1,1,0,0,1,0,0,1,0,0,0,1,0,6,1,1,0,0,1,0,,,,,0,1,0
NCT02082262,AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic Conjunctivitis,,COMPLETED,2014-03,2014-07,2016-03-14,INTERVENTIONAL,PHASE3,140.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Conjunctivitis, Allergic",AGN-229666,DRUG,1,0,10 Years,,ALL,False,Allergan,INDUSTRY,0,1,Japan,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.948759890378168,medium,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,2014-03-01,2014-07-01,122.0,2014.0,0,0,0
NCT01369862,Study of Single Dose GHB16L2 Trivalent Influenza Vaccine in Healthy Adults,"Randomised, Double-blind, Placebo-controlled, Phase I/II Study of Single Dose GHB16L2 Trivalent Influenza Vaccine in Healthy Adults",COMPLETED,2011-01,2011-08,2014-01-10,INTERVENTIONAL,PHASE1|PHASE2,80.0,ESTIMATED,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,"Influenza, Human",GHB16L2|Placebo,BIOLOGICAL,1,3,18 Years,60 Years,ALL,True,AVIR Green Hills Biotechnology AG,INDUSTRY,0,1,Austria,1.0,1,1,0,0,1,1.5,0,0,0,0,1,4.394449154672439,medium,1,0,1,0,0,0,0,0,0,0,1,1,0,1,4,1,0,1,0,2,1,2011-01-01,2011-08-01,212.0,2011.0,0,2,0
NCT00093262,Study of Clevidipine Assessing Its Postoperative Antihypertensive Effect in Cardiac Surgery (ESCAPE-2),Efficacy Study of Clevidipine Assessing Its Postoperative Antihypertensive Effect in Cardiac Surgery (ESCAPE-2),COMPLETED,2003-12,2004-10,2014-05-08,INTERVENTIONAL,PHASE3,206.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Hypertension,clevidipine|placebo,DRUG,1,4,18 Years,,ALL,False,The Medicines Company,INDUSTRY,0,15,United States,1.0,0,0,1,0,0,3.0,0,0,0,1,1,5.332718793265369,large,0,1,1,0,0,0,1,0,1,0,1,1,1,1,5,1,1,0,0,2,1,2003-12-01,2004-10-01,305.0,2003.0,0,1,0
NCT06594146,Study of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia (ITP),"A Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Initial Efficacy of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia",ACTIVE_NOT_RECRUITING,2024-11-11,2025-12-30,2025-04-23,INTERVENTIONAL,PHASE2,62.0,ACTUAL,RANDOMIZED,SEQUENTIAL,TREATMENT,QUADRUPLE,Primary Immune Thrombocytopenia,CM313 injection|placebo,BIOLOGICAL|OTHER,1,0,18 Years,65 Years,ALL,False,Keymed Biosciences Co.Ltd,INDUSTRY,0,1,China,,0,1,0,0,0,2.0,0,0,0,0,1,4.143134726391533,medium,1,1,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,2,1,,,,,0,1,0
NCT01745588,Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma,Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma: A Phase 2 Open-Label Randomized Study by Tristate Consortium,COMPLETED,2012-12,2025-09-03,2025-09-11,INTERVENTIONAL,PHASE2,23.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Multiple Myeloma,Pomalidomide|stem cell|Dexamethasone|Clarithromycin,DRUG|PROCEDURE,1,4,18 Years,,ALL,False,Memorial Sloan Kettering Cancer Center,OTHER,5,10,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.1780538303479458,small,1,1,0,1,0,1,1,0,1,0,1,0,1,1,5,1,1,0,0,4,1,2012-12-01,,,2012.0,0,1,0
NCT00081588,"An Open Label Trial of TMC114/RTV in HIV-1 Infected, Treatment-experienced Subjects.","An Open Label Trial of TMC114/RTV in HIV-1 Infected, Treatment-experienced Subjects.",COMPLETED,2003-11,2008-12,2014-06-20,INTERVENTIONAL,PHASE2,555.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,HIV Infection,TMC114,DRUG,1,1,18 Years,,ALL,False,"Tibotec Pharmaceuticals, Ireland",INDUSTRY,0,64,Belgium|Argentina|Hungary|United States|Germany|Austria|Australia|Brazil|Spain|United Kingdom|Portugal|France|Canada,1.0,0,1,0,0,0,2.0,0,0,0,0,1,6.320768294250582,xlarge,0,1,1,0,0,0,1,1,1,1,0,0,1,0,2,1,1,0,0,1,0,2003-11-01,2008-12-01,1857.0,2003.0,0,1,0
NCT02356588,A Trial Evaluating the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for Post-Operative Pain After Abdominal Surgery,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for the Treatment of Post-Operative Pain in Patients After Abdominal Surgery",COMPLETED,2015-02,2015-08,2017-02-13,INTERVENTIONAL,PHASE3,161.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Post-Operative Pain,Sufentanil Tablet 30 mcg|Placebo Tablet,DRUG,1,13,18 Years,,ALL,False,"Talphera, Inc",INDUSTRY,0,4,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.087596335232384,medium,0,1,1,0,0,0,1,0,1,0,1,1,1,1,14,1,1,0,0,2,1,2015-02-01,2015-08-01,181.0,2015.0,1,2,0
NCT00190788,Extended Therapy of Drotrecogin Alfa (Activated) 4 vs 7 Days Infusion,A Phase IIIb Study to Determine Efficacy and Safety of Extended Drotrecogin Alfa (Activated) Therapy in Patients With Persistent Requirement for Vasopressor Support After 96 Hour Infusion With Commercial Drotrecogin Alfa (Activated),COMPLETED,2004-06,2007-05,2007-10-12,INTERVENTIONAL,PHASE3,200.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Sepsis|Hypotension,Drotrecogin Alfa (Activated)|placebo,DRUG,1,4,18 Years,,ALL,False,Eli Lilly and Company,INDUSTRY,0,2,France|United States,1.0,0,0,1,0,0,3.0,0,0,0,0,2,5.303304908059076,medium,0,0,1,0,1,0,1,1,1,1,1,1,1,1,5,1,1,0,0,2,1,2004-06-01,2007-05-01,1064.0,2004.0,0,3,1
NCT01009788,ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer,A Phase 2 Study of ABT-888 and Temozolomide for Metastatic Breast Cancer and an Expansion Cohort in BRCA1/2 Mutation Carriers,COMPLETED,2009-11,2015-09,2025-03-14,INTERVENTIONAL,PHASE2,63.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Breast Cancer|Metastatic Breast Cancer|BRCA1 Gene Mutation|brca2 Gene Mutation,ABT-888|temozolomide,DRUG,1,2,18 Years,,ALL,False,"Steven J Isakoff, MD, PhD",OTHER,3,3,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,4,4.1588830833596715,medium,1,1,0,1,0,1,1,0,1,0,0,0,1,0,3,1,1,0,0,2,1,2009-11-01,2015-09-01,2130.0,2009.0,0,2,0
NCT01520103,Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer,Randomized Phase II Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer,COMPLETED,2012-01,2016-10-31,2017-08-09,INTERVENTIONAL,PHASE2,139.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Her2-negative Metastatic Breast Cancer|Her2-negative Locally Advanced Breast Cancer,"Vinorebine, Everolimus|Vinorelbine",DRUG,1,4,18 Years,,FEMALE,False,AIO-Studien-gGmbH,OTHER,2,1,Germany,1.0,0,1,0,0,0,2.0,1,0,0,0,2,4.941642422609304,medium,0,1,0,1,0,1,0,0,0,1,1,0,1,1,5,1,1,0,0,2,1,2012-01-01,,,2012.0,0,2,0
NCT02239003,NMDA-enhancing Agent for the Treatment of Mild Cognitive Impairment,,COMPLETED,2012-01,2017-12,2018-01-24,INTERVENTIONAL,PHASE2,24.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Mild Cognitive Impairment,DAOIB|Placebo,DRUG,1,4,50 Years,90 Years,ALL,False,Chang Gung Memorial Hospital,OTHER,0,1,Taiwan,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.2188758248682006,small,1,1,0,1,0,0,0,0,0,0,1,1,1,1,5,1,1,0,0,2,1,2012-01-01,2017-12-01,2161.0,2012.0,0,1,0
NCT04498403,"A Study of the Long-Term Safety of Crisaborole Ointment, 2% in Japanese Pediatric and Adult Participants With Mild to Moderate Atopic Dermatitis","A PHASE 3, MULTICENTER, OPEN-LABEL STUDY OF THE LONG-TERM SAFETY OF CRISABOROLE OINTMENT, 2% IN JAPANESE PEDIATRIC AND ADULT PARTICIPANTS WITH MILD TO MODERATE ATOPIC DERMATITIS",TERMINATED,2020-09-14,2020-12-18,2021-08-12,INTERVENTIONAL,PHASE3,40.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Atopic Dermatitis,Crisaborole 2%,DRUG,1,0,7 Months,,ALL,False,Pfizer,INDUSTRY,0,11,Japan,0.0,0,0,1,0,0,3.0,0,0,0,0,1,3.713572066704308,small,1,1,1,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,,,,,0,0,0
NCT00381303,"GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV) Positive Women and Men.","GRACE: An Open-label, Multicenter Trial to Compare the Efficacy, Safety, and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race, When Administered in Combination With an Individually Optimized Background Regimen Over a 48-week Treatment Period.",COMPLETED,2006-11,2008-12,2014-04-21,INTERVENTIONAL,PHASE3,429.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,HIV|Infectious,darunavir|ritonavir,DRUG,2,8,18 Years,,ALL,False,"Tibotec, Inc",INDUSTRY,1,46,Canada|Puerto Rico|United States,1.0,0,0,1,0,0,3.0,0,0,0,0,2,6.063785208687608,large,0,1,1,0,0,1,1,1,1,0,0,0,1,0,10,1,1,0,0,2,1,2006-11-01,2008-12-01,761.0,2006.0,0,4,1
NCT05861427,Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult Japanese Participants With Episodic Migraine,"A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study With An Active Treatment Extension to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prevention of Migraine in Japanese Subjects With Episodic Migraine",COMPLETED,2023-07-12,2025-03-01,2025-03-17,INTERVENTIONAL,PHASE3,523.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Migraine,Atogepant|Placebo for Atogepant,DRUG,2,6,18 Years,80 Years,ALL,False,AbbVie,INDUSTRY,0,48,Japan,1.0,0,0,1,0,0,3.0,0,0,1,0,1,6.261491684321042,xlarge,0,1,1,0,1,0,1,0,0,0,1,1,1,1,8,1,1,0,0,2,1,,,,,0,2,0
NCT02877927,Oral Omadacycline vs. Oral Linezolid for the Treatment of ABSSSI,"A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Oral Omadacycline to Oral Linezolid for Treating Adult Subjects With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)",COMPLETED,2016-08,2017-06-06,2018-11-30,INTERVENTIONAL,PHASE3,735.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Bacterial Infections|Skin Structures and Soft Tissue Infections,Omadacycline|Linezolid,DRUG,1,2,18 Years,,ALL,False,Paratek Pharmaceuticals Inc,INDUSTRY,0,50,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,2,6.601230118728877,xlarge,0,1,1,0,0,0,1,0,1,0,1,1,1,1,3,1,1,0,0,2,1,2016-08-01,,,2016.0,1,2,0
NCT00146627,Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African Trypanosomiasis,Clinical Study Comparing the Nifurtimox-Eflornithine Combination With the Standard Eflornithine Regimen for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis in the Meningoencephalitic Phase,COMPLETED,,2008-06,2016-09-29,INTERVENTIONAL,PHASE3,280.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Trypanosomiasis, African",Eflornithine|Nifurtimox,DRUG,0,0,15 Years,70 Years,ALL,False,Drugs for Neglected Diseases,OTHER,6,4,Democratic Republic of the Congo|Republic of the Congo,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.638354669333745,large,0,0,0,1,0,1,1,1,0,0,1,0,1,1,0,0,1,0,0,2,1,,2008-06-01,,,0,2,0
NCT03462927,A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream,"A Randomised, Open-label, Maximal Use Trial, Evaluating the Pharmacokinetic Profile of Active Ingredients and Their Metabolites After Application of MC2-01 Cream Compared With Active Comparator in Subjects With Extensive Psoriasis Vulgaris",COMPLETED,2018-02-08,2018-08-04,2019-12-24,INTERVENTIONAL,PHASE2,63.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Psoriasis Vulgaris,MC2-01 Cream|CAL/BDP combination,DRUG,8,8,18 Years,,ALL,False,MC2 Therapeutics,INDUSTRY,0,1,United States,1.0,0,1,0,0,0,2.0,0,1,0,0,1,4.1588830833596715,medium,1,1,1,0,0,0,0,0,1,0,1,0,1,1,16,1,1,0,0,2,1,,,,,0,2,0
NCT01329627,Feasibility Study of Metronomic Chemotherapy for Locally Advanced HER2-Negative Breast Cancer,Phase II Feasibility Study of Weekly Paclitaxel Followed by Weekly Doxorubicin Plus Daily Oral Cyclophosphamide for Locally Advanced HER2-Negative Breast Cancer,TERMINATED,2010-08,2012-08,2014-05-21,INTERVENTIONAL,PHASE2,12.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Locally Advanced HER2-negative Breast Cancer,Paclitaxel/doxorubicin/cyclophosphamide|Paclitaxel/doxorubicin/cyclophosphamide,DRUG,1,1,18 Years,,FEMALE,False,Instituto do Cancer do Estado de São Paulo,OTHER,1,1,Brazil,0.0,0,1,0,0,0,2.0,1,0,0,0,1,2.5649493574615367,small,1,1,0,1,0,1,0,0,0,0,0,0,1,0,2,1,1,0,0,2,1,2010-08-01,2012-08-01,731.0,2010.0,0,1,0
NCT02720627,An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris,An Open Label Evaluation of the Adrenal Suppression Potential and Trough Plasma Concentrations of Cortexolone 17α-Propionate (CB-03-01) Cream Applied Every 12 Hours for Two Weeks in Subjects 9 to <12 Years of Age With Acne Vulgaris,COMPLETED,2016-10-28,2018-03-21,2020-11-20,INTERVENTIONAL,PHASE2,27.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Acne Vulgaris,cortexolone 17α-propionate,DRUG,1,1,9 Years,11 Years,ALL,False,Cassiopea SpA,INDUSTRY,0,10,Poland|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.332204510175204,small,1,1,1,0,0,0,1,1,1,0,0,0,1,0,2,1,1,0,0,1,0,,,,,0,1,0
NCT01861496,Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours,Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis (Liposomal Cisplatin Formulation) in Patients With Advanced or Refractory Tumours,COMPLETED,2013-04,2021-10,2022-02-24,INTERVENTIONAL,PHASE1|PHASE2,50.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Phase 1: Advanced or Refractory Solid Tumours|Phase 2 Part: Metastatic Breast Cancer, Prostate Cancer and Skin Cancer",LiPlaCis,DRUG,1,8,18 Years,,ALL,False,Allarity Therapeutics,INDUSTRY,0,4,Denmark,1.0,1,1,0,0,1,1.5,1,0,0,0,2,3.9318256327243257,small,1,1,1,0,0,0,1,0,0,0,0,0,1,0,9,1,1,0,0,1,0,2013-04-01,2021-10-01,3105.0,2013.0,0,3,1
NCT00449696,Gel-200 Versus Placebo in Osteoarthritis of the Knee,"A Multi-Center, Randomized, Double-Blind, Controlled, Parallel-Group Study of a Single Intra-Articular Injection of Gel-200 With a Single Intra-Articular Injection of Phosphate Buffered Saline (PBS) in Osteoarthritis of the Knee.",COMPLETED,2006-09,2007-12,2011-10-07,INTERVENTIONAL,PHASE3,379.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Osteoarthritis of the Knee,Gel-200|Placebo,DEVICE,1,8,40 Years,80 Years,ALL,False,Seikagaku Corporation,INDUSTRY,0,1,United States,1.0,0,0,1,0,0,3.0,0,1,0,0,1,5.940171252720432,large,0,1,1,0,0,0,0,0,1,0,1,1,1,1,9,1,0,0,1,2,1,2006-09-01,2007-12-01,456.0,2006.0,0,2,0
NCT01447927,Metformin Hydrochloride in Preventing Esophageal Cancer in Patients With Barrett Esophagus,Randomized Double Blind Placebo Controlled Trial of Barrett's Esophagus Chemoprevention With Metformin,COMPLETED,2012-06,2013-09,2014-07-21,INTERVENTIONAL,PHASE2,93.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Barrett Esophagus|Esophageal Cancer,metformin hydrochloride|placebo,DRUG|OTHER,1,1,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,7,Canada|Puerto Rico|United States,1.0,0,1,0,0,0,2.0,1,0,0,0,2,4.543294782270004,medium,1,1,0,1,0,0,1,1,1,0,1,1,0,1,2,1,1,0,0,2,1,2012-06-01,2013-09-01,457.0,2012.0,0,3,1
NCT03568461,Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma,"A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Efficacy and Safety of Tisagenlecleucel (CTL019) in Adult Patients With Refractory or Relapsed Follicular Lymphoma",COMPLETED,2018-11-12,2025-05-28,2025-10-07,INTERVENTIONAL,PHASE2,98.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Follicular Lymphoma,tisagenlecleucel,BIOLOGICAL,1,17,18 Years,100 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,31,Italy|Belgium|Netherlands|United States|Germany|Austria|Australia|Spain|United Kingdom|Norway|Japan|France,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.59511985013459,medium,1,1,1,0,1,0,1,1,1,1,0,0,1,0,18,1,0,1,0,1,0,,,,,0,2,0
NCT02837042,Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma,Phase II Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma Following Previous Chemotherapy,TERMINATED,2016-10,2019-10,2022-06-21,INTERVENTIONAL,PHASE2,6.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Penile Squamous Cell Carcinoma,Pembrolizumab,DRUG,1,3,18 Years,,MALE,False,University of Alabama at Birmingham,OTHER,1,3,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,1.9459101490553132,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,4,1,1,0,0,1,0,2016-10-01,2019-10-01,1095.0,2016.0,1,0,0
NCT03581942,Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL),Phase IB/II Study Combining the PI3K Inhibitor Copanlisib With the BTK Inhibitor Ibrutinib in Patients With Recurrent/Refractory Primary CNS Lymphoma,ACTIVE_NOT_RECRUITING,2018-08-23,2026-07,2025-08-06,INTERVENTIONAL,PHASE1|PHASE2,18.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL),Ibrutinib|Copanlisib,DRUG,2,5,18 Years,,ALL,False,Memorial Sloan Kettering Cancer Center,OTHER,0,7,United States,,1,1,0,0,1,1.5,1,0,0,0,1,2.9444389791664403,small,1,1,0,1,0,0,1,0,1,0,0,0,1,0,7,1,1,0,0,2,1,,2026-07-01,,,0,3,1
NCT03308942,Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants,"Phase 2, Multi-Arm Study of Niraparib Administered Alone and in Combination With a PD-1 Inhibitor in Patients With Non-Small Cell Lung Cancer",COMPLETED,2017-09-29,2021-08-31,2023-10-16,INTERVENTIONAL,PHASE2,53.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Neoplasms,Niraparib|Pembrolizumab|TSR-042 (Dostarlimab),DRUG|BIOLOGICAL,4,24,18 Years,,ALL,False,"Tesaro, Inc.",INDUSTRY,0,16,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.9889840465642745,medium,1,1,1,0,0,0,1,0,1,0,0,0,1,1,28,1,1,1,0,3,1,,,,,0,2,0
NCT00288392,"Efficacy of Soluble Beta-1,3/1,6-Glucan Compared to Placebo on Chronic Leg Ulcers in Diabetes Patients","A Double-Blind Therapeutic Exploratory Clinical Study to Evaluate the Efficacy of Soluble Beta-1,3/1,6-Glucan Compared to Placebo on Chronic Leg Ulcers in Diabetes Patients",COMPLETED,2005-06,2006-09,2006-10-18,INTERVENTIONAL,PHASE2,60.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Foot Ulcer,"Soluble beta-1,3/1,6-glucan",DRUG,1,4,18 Years,,ALL,False,Biotec Pharmacon ASA,INDUSTRY,0,2,Russia,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.110873864173311,medium,1,0,1,0,0,0,1,0,0,0,1,1,1,1,5,1,1,0,0,1,0,2005-06-01,2006-09-01,457.0,2005.0,0,0,0
NCT00387192,A Study With OPTIVATE® in People With Von Willebrand Disease,"An Open Multi-centre Study in Patients With Von Willebrand Disease to Investigate the Pharmacokinetics, Efficacy and Safety of OPTIVATE®, a High Purity, Dual Inactivated Factor VIII and Von Willebrand Factor Concentrate",TERMINATED,2006-11,2008-09,2010-03-03,INTERVENTIONAL,PHASE3,26.0,ESTIMATED,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Von Willebrand Disease,Optivate,DRUG,1,0,12 Years,,ALL,False,Bio Products Laboratory,OTHER,0,4,Israel|United Kingdom,0.0,0,0,1,0,0,3.0,0,0,0,0,1,3.295836866004329,small,1,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,1,0,0,1,0,2006-11-01,2008-09-01,670.0,2006.0,0,1,0
NCT03553836,Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716),"Adjuvant Therapy With Pembrolizumab Versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE-716)",ACTIVE_NOT_RECRUITING,2018-09-12,2033-10-12,2024-11-29,INTERVENTIONAL,PHASE3,976.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Melanoma,Pembrolizumab|Placebo,BIOLOGICAL|OTHER,1,4,12 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,159,Italy|Belgium|United States|Germany|Brazil|Australia|Spain|United Kingdom|Chile|Poland|Japan|Switzerland|Israel|South Africa|France|Canada,,0,0,1,0,0,3.0,1,0,0,0,1,6.884486652042782,xlarge,0,1,1,0,1,0,1,1,1,1,1,1,1,1,5,1,0,1,0,2,1,,,,,0,2,0
NCT04454411,Brain Mechanisms of Pharmacotherapy in Opioid Use Disorder,Brain Mechanisms of Cognitive Response to Pharmacotherapy in Opioid Use Disorder,TERMINATED,2022-08-01,2024-08-31,2025-08-06,INTERVENTIONAL,PHASE2,3.0,ACTUAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,NONE,Opioid Dependence,Brixadi|Vivitrol,DRUG,2,3,18 Years,65 Years,ALL,True,University of Pennsylvania,OTHER,0,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,1.3862943611198906,small,1,1,0,1,0,0,0,0,1,0,1,0,0,1,5,1,1,0,0,2,1,,,,,0,1,0
NCT04459871,Safety and Efficacy of Topical Recombinant Human Thrombin(rhThrombin) for Surgical Hemostasis,"A Phase 3, Stratified Randomized, Double-blind, Placebo-controlled Study of Topical Recombinant Human Thrombin (rhThrombin) in Surgical Hemostasis",COMPLETED,2019-11-11,2021-10-20,2022-11-29,INTERVENTIONAL,PHASE3,348.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Surgical Hemostasis,recombinant human Thrombin(CHO cell)|placebo,BIOLOGICAL,1,3,18 Years,70 Years,ALL,False,"Suzhou Zelgen Biopharmaceuticals Co.,Ltd",INDUSTRY,0,1,China,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.855071922202427,large,0,1,1,0,0,0,0,0,0,0,1,1,1,1,4,1,0,1,0,2,1,,,,,0,1,0
NCT02308644,Intravitreous Bevacizumab and Standard Metabolic Control for Diabetic Macular Edema - A Contrast Sensitivity Study,Phase 3 Intravitreous Bevacizumab and Standard Metabolic Control for Diabetic Macular Edema - A Contrast Sensitivity Pilot Study.,COMPLETED,2009-02,2013-02,2014-12-04,INTERVENTIONAL,PHASE3,41.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,SINGLE,Diabetic Macular Edema,intravitreal bevacizumab injection(1.25mg),DRUG,1,1,18 Years,,ALL,False,University of Sao Paulo,OTHER,0,1,Brazil,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.7376696182833684,small,1,1,0,1,0,0,0,0,0,0,1,0,1,0,2,1,1,0,0,1,0,2009-02-01,2013-02-01,1461.0,2009.0,0,0,0
NCT04305444,"Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas","Phase II Expansion Cohorts Studies of a Novel Triple Combination Therapy, DTRM-555, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Relapsed/Refractory Non-Hodgkin's Lymphomas",TERMINATED,2020-04-24,2024-12-31,2025-01-08,INTERVENTIONAL,PHASE2,55.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Relapsed Chronic Lymphocytic Leukemia|Refractory Chronic Lymphocytic Leukemia|Diffuse Large B Cell Lymphoma|Follicular Lymphoma|Richter's Transformation,DTRM-555,DRUG,1,6,18 Years,,ALL,False,Zhejiang DTRM Biopharma,INDUSTRY,0,8,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,5,4.02535169073515,medium,1,1,1,0,0,0,1,0,1,0,0,0,1,0,7,1,1,0,0,1,0,,,,,0,2,0
NCT00141544,"The Efficacy of ESTRATEST® Tablets in Relieving Menopausal Symptoms in Estrogenized, Non-Hysterectomized Postmenopausal Women","A Multi-Center, Double-Blind Study to Determine the Efficacy of ESTRATEST® Tablets in Relieving Menopausal Symptoms in Estrogenized, Non-Hysterectomized Postmenopausal Women",TERMINATED,2004-07,2008-03,2008-04-11,INTERVENTIONAL,PHASE2,28.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Menopause,esterified estrogens 1.25 mg and methyltestosterone 2.5 mg|Esterified estrogens 1.25 mg,DRUG,1,3,35 Years,65 Years,FEMALE,False,Solvay Pharmaceuticals,INDUSTRY,0,78,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,3.367295829986474,small,1,1,1,0,0,0,1,0,1,0,1,1,1,1,4,1,1,0,0,2,1,2004-07-01,2008-03-01,1339.0,2004.0,0,1,0
NCT01052844,Gabapentin in the Prevention of Nausea and Vomiting Induced by Chemotherapy,"Clinical Trial of Gabapentin in the Prevention of Nausea Ond Vomiting Induced by Chemotherapy, a Randomized, Double-blind, Placebo Controled Study",COMPLETED,2009-01,2010-07,2014-03-07,INTERVENTIONAL,PHASE3,80.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Vomiting|Cisplatin Adverse Reaction,Placebo|Gabapentin,DRUG,2,0,18 Years,,ALL,False,Faculdade de Medicina do ABC,OTHER,0,1,Brazil,1.0,0,0,1,0,0,3.0,0,0,0,0,2,4.394449154672439,medium,1,1,0,1,0,0,0,0,0,0,1,1,1,1,2,0,1,0,0,2,1,2009-01-01,2010-07-01,546.0,2009.0,0,2,0
NCT00536744,Effectiveness of dermaPACE™ Device and Standard Treatment Compared to Standard Treatment Alone for Diabetic Foot Ulcers,Use of the dermaPACE™ (Pulsed Acoustic Cellular Expression) Device in Conjunction With Standard of Care in the Treatment of Diabetic Foot Ulcers,COMPLETED,2007-10,2010-09,2014-04-14,INTERVENTIONAL,PHASE3,206.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Diabetic Foot Ulcers,acoustical pulse energy (extracorporeal shockwave)|Sham,DEVICE|OTHER,1,1,18 Years,,ALL,False,"SANUWAVE, Inc.",INDUSTRY,0,23,Germany|United Kingdom|United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.332718793265369,large,0,1,1,0,0,0,1,1,1,1,1,1,1,1,2,1,0,0,1,2,1,2007-10-01,2010-09-01,1066.0,2007.0,0,2,0
NCT00123734,Clinical Trial to Evaluate the Accuracy of [99mTc] ThromboView in the Detection of Deep Vein Thrombosis,Phase II Clinical Trial to Evaluate the Accuracy of Anti-Fibrin Humanized Monoclonal Antibody (DI-DD3B6/22-80B3) Fab' Protein Fragment (ThromboView) Conjugated With Technetium-99m in the Detection of Deep Vein Thrombosis,COMPLETED,2005-03,2006-05,2009-08-24,INTERVENTIONAL,PHASE2,94.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,DIAGNOSTIC,NONE,Deep Vein Thrombosis,ThromboView,DRUG,2,6,18 Years,,ALL,False,Agen Biomedical,INDUSTRY,0,12,Canada|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.553876891600541,medium,1,1,1,0,0,0,1,1,1,0,0,0,0,0,8,1,1,0,0,1,0,2005-03-01,2006-05-01,426.0,2005.0,0,2,0
NCT00502034,Low-dose IL-2 Plus IFN-alpha Immunotherapy as Adjuvant Treatment of Renal Carcinoma.,"Adjuvant Low-dose Interleukin-2 (IL2) Plus Interferone-alpha (IFN) in Operable Renal Cell Cancer (RCC). Phase III, Randomized, Multicenter Trial of the Italian Oncology Group for Clinical Research (GOIRC).",COMPLETED,1994-07,2012-06,2013-07-10,INTERVENTIONAL,PHASE3,310.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Carcinoma, Renal Cell",Interferon Alfa-2a|Interleukin-2,DRUG,1,1,18 Years,75 Years,ALL,False,Gruppo Oncologico Italiano di Ricerca Clinica,OTHER,0,8,Italy,1.0,0,0,1,0,0,3.0,1,0,0,0,1,5.739792912179234,large,0,1,0,1,0,0,1,0,0,1,1,0,1,1,2,1,1,0,0,2,1,1994-07-01,2012-06-01,6545.0,1994.0,0,1,0
NCT02737709,Paclitaxel Detection in NSCLC Treated With TC Regimen,"A Clinical Experience Trial to Detect the Plasma Paclitaxel Drug Concentration in Chinese Non -Small Cell Lung Cancer (NSCLC) Patients Treated With a Paclitaxel Plus Carboplatin (TC) Regimens, and Explore Individualized Treatment Using Pharmacokinetically-guided Dosing Strategy",TERMINATED,2016-03,2018-10-25,2018-10-29,INTERVENTIONAL,PHASE2,51.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Non-small Cell Lung Cancer,Paclitaxel and Carboplatin regimen,DRUG,1,5,18 Years,75 Years,ALL,False,Sun Yat-sen University,OTHER,0,1,China,0.0,0,1,0,0,0,2.0,1,0,0,0,1,3.9512437185814275,medium,1,1,0,1,0,0,0,0,0,0,0,0,1,0,6,1,1,0,0,1,0,2016-03-01,,,2016.0,1,1,0
NCT03035409,"Anamorelin Hydrochloride, Physical Activity, and Nutritional Counseling in Decreasing Cancer-Related Fatigue in Patients With Incurable Metastatic or Recurrent Solid Tumors",Effects of Anamorelin on Cancer-Related-Fatigue in Patients With Advanced Cancer,ACTIVE_NOT_RECRUITING,2017-02-08,2026-02-28,2025-11-10,INTERVENTIONAL,PHASE2,129.0,ACTUAL,,SINGLE_GROUP,SUPPORTIVE_CARE,NONE,Advanced Malignant Solid Neoplasm|C-Reactive Protein Measurement|Cancer Fatigue|Metastatic Malignant Solid Neoplasm|Recurrent Malignant Solid Neoplasm|Weight Loss,Anamorelin Hydrochloride|Exercise Intervention|Laboratory Biomarker Analysis|Nutritional Assessment|Quality-of-Life Assessment|Questionnaire Administration,BEHAVIORAL|DRUG|OTHER,1,3,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,1,United States,,0,1,0,0,0,2.0,1,0,0,0,6,4.867534450455582,medium,0,1,0,1,0,1,0,0,1,0,0,0,0,0,4,1,1,0,0,6,1,,,,,0,2,0
NCT05405309,RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia,A Phase Ib/II Trial of Combination RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia,TERMINATED,2022-09-23,2025-01-10,2025-06-03,INTERVENTIONAL,PHASE1|PHASE2,5.0,ACTUAL,NON_RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,Chronic Lymphocytic Leukemia,RP-3500|Olaparib,DRUG,2,4,18 Years,,ALL,False,University of Utah,OTHER,1,1,United States,0.0,1,1,0,0,1,1.5,1,0,0,0,1,1.791759469228055,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,6,1,1,0,0,2,1,,,,,0,3,1
NCT03054909,IP ALT-803 Followed by SQ ALT-803 for Ovarian Cancer,"QUILT-2.021: Randomized Study of Single Course of Intraperitoneal (IP) ALT-803 Followed by Subcutaneous (SQ) Maintenance ALT-803 Versus Subcutaneous (SQ) Maintenance ALT-803 Only After 1st Line Chemotherapy for Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer",COMPLETED,2017-09-19,2022-02-16,2023-10-13,INTERVENTIONAL,PHASE2,7.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,FIGO Stage III and IV Ovarian Cancer|FIGO Stage III and IV Fallopian Tube Cancer|FIGO Stage III Primary Peritoneal Cancer,ALT-803 Subcutaneous|ALT-803 Intraperitoneal,BIOLOGICAL,1,6,18 Years,,FEMALE,False,"Masonic Cancer Center, University of Minnesota",OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,3,2.0794415416798357,small,1,1,0,1,0,0,0,0,1,0,1,0,1,1,7,1,0,1,0,2,1,,,,,0,3,1
NCT01233609,Trial of Oral Valproic Acid for Retinitis Pigmentosa,"A Phase II Multiple Site, Randomized, Placebo-Controlled Trial of Oral Valproic Acid for Autosomal Dominant Retinitis Pigmentosa",COMPLETED,2010-11,2015-12,2017-12-02,INTERVENTIONAL,PHASE2,90.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Retinitis Pigmentosa,Valproic Acid|Placebo,DRUG,1,4,18 Years,,ALL,False,Foundation Fighting Blindness,OTHER,1,6,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.51085950651685,medium,1,1,0,1,0,1,1,0,1,0,1,1,1,1,5,1,1,0,0,2,1,2010-11-01,2015-12-01,1856.0,2010.0,0,1,0
NCT00656409,Conjugate Pneumococcal Vaccine in Ataxia Telangiectasia (AT),Conjugate Pneumococcal Vaccine in Ataxia Telangiectasia (AT),COMPLETED,2006-06,2008-03,2008-04-11,INTERVENTIONAL,PHASE3,30.0,ACTUAL,,,BASIC_SCIENCE,,Ataxia Telangiectasia (AT),Conjugated pneumococcal vaccine (Prevenar),DRUG,1,1,2 Years,,ALL,False,Institute of Child Health,OTHER,1,1,United Kingdom,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.4339872044851463,small,1,1,0,1,0,1,0,0,0,1,0,0,0,0,2,1,1,0,0,1,0,2006-06-01,2008-03-01,639.0,2006.0,0,0,0
NCT05696509,Influence of Anesthetics on Clinical Outcome in Mitral and Aortic Valve Replacement in Adults,Influence of Anesthetics on Clinical Outcome in Mitral and Aortic Valve Replacement in Adults: a Randomized Clinical Trial,COMPLETED,2020-01-03,2022-10-16,2023-01-25,INTERVENTIONAL,PHASE3,75.0,ACTUAL,RANDOMIZED,PARALLEL,OTHER,SINGLE,Mitral Valve Insufficiency|Aortic Valve Insufficiency,Propofol|Isoflurane|Sevoflurane,DRUG,3,0,40 Years,60 Years,ALL,False,Astana Medical University,OTHER,0,1,Kazakhstan,1.0,0,0,1,0,0,3.0,0,0,0,0,2,4.330733340286331,medium,1,1,0,1,0,0,0,0,0,0,1,0,0,1,3,0,1,0,0,3,1,,,,,0,2,0
NCT00422032,2 Arm Study of Clofarabine IV in MDS Patients,Phase II Randomized Study of Two Different Schedules of Intravenous Clofarabine in Myelodysplastic Syndrome (MDS),COMPLETED,2006-01,2011-11,2012-07-27,INTERVENTIONAL,PHASE2,60.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Myelodysplastic Syndrome|Leukemia,Clofarabine,DRUG,1,0,,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,2,4.110873864173311,medium,1,1,0,1,0,1,0,0,1,0,1,0,1,1,1,0,1,0,0,1,0,2006-01-01,2011-11-01,2130.0,2006.0,0,1,0
NCT03054363,"Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer",Phase IB/II Open-label Single Arm Study to Evaluate Safety and Efficacy of Tucatinib in Combination With Palbociclib and Letrozole in Subjects With Hormone Receptor Positive and HER2-positive Metastatic Breast Cancer,COMPLETED,2017-11-27,2023-02-07,2023-11-13,INTERVENTIONAL,PHASE1|PHASE2,42.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Breast Cancer,Tucatinib in Combination with Palbociclib and Letrozole|Tucatinib in Combination with Palbociclib and Letrozole,DRUG,2,5,18 Years,100 Years,FEMALE,False,"University of Colorado, Denver",OTHER,3,6,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,1,3.7612001156935624,small,1,1,0,1,0,1,1,0,1,0,1,0,1,0,7,1,1,0,0,2,1,,,,,0,3,1
NCT06409663,A Strain Change Study for SARS-CoV-2 rS Vaccines,"A Phase 3 Open-Label, Single-Arm Study to Evaluate the Safety and Immunogenicity of a JN.1 Subvariant SARS CoV-2 rS Vaccine",COMPLETED,2024-10-14,2025-04-17,2025-07-18,INTERVENTIONAL,PHASE3,60.0,ACTUAL,,SINGLE_GROUP,PREVENTION,NONE,Severe Acute Respiratory Syndrome Coronavirus 2 Infection,NVX-CoV2705 Vaccine,BIOLOGICAL,3,6,18 Years,90 Years,ALL,True,Novavax,INDUSTRY,0,2,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.110873864173311,medium,1,1,1,0,0,0,1,0,1,0,0,0,0,0,9,1,0,1,0,1,0,,,,,0,1,0
NCT01745263,DO-HEALTH / Vitamin D3 - Omega3 - Home Exercise - Healthy Ageing and Longevity Trial,Vitamin D3 - Omega3 - Home Exercise - Healthy Ageing and Longevity Trial (Acronym: DO-HEALTH),COMPLETED,2012-12-20,2018-01-19,2018-08-09,INTERVENTIONAL,PHASE3,2157.0,ACTUAL,RANDOMIZED,FACTORIAL,PREVENTION,QUADRUPLE,Improve Healthy Ageing in Seniors; Prevent Disease at Older Age,Vitamin D3|Omega 3 fatty acids|Strength Home Exercise|Flexibility Home Exercise,DRUG|PROCEDURE,5,28,70 Years,,ALL,True,University of Zurich,OTHER,25,7,Germany|Austria|Switzerland|Portugal|France,1.0,0,0,1,0,0,3.0,0,0,0,0,1,7.67693714581808,xlarge,0,1,0,1,0,1,1,1,0,1,1,1,0,0,33,1,1,0,0,4,1,,,,,0,3,1
NCT01488487,Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma,Phase II Single Arm Study of Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma (HCC),COMPLETED,2011-12,2015-03,2016-04-07,INTERVENTIONAL,PHASE2,24.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Advanced Adult Hepatocellular Carcinoma,Everolimus|Pasireotide,DRUG,1,3,18 Years,,ALL,False,UNC Lineberger Comprehensive Cancer Center,OTHER,1,3,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.2188758248682006,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,4,1,1,0,0,2,1,2011-12-01,2015-03-01,1186.0,2011.0,0,1,0
NCT05638087,Dexamethasone Treatment for OSA in Children,Dexamethasone as a Novel Treatment for Obstructive Sleep Apnea in Children,ACTIVE_NOT_RECRUITING,2022-10-26,2025-08-30,2025-05-16,INTERVENTIONAL,PHASE3,10.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Obstructive Sleep Apnea,Dexamethasone|Placebo Control,DRUG,1,10,2 Years,10 Years,ALL,False,The Hospital for Sick Children,OTHER,0,1,Canada,,0,0,1,0,0,3.0,0,0,0,0,1,2.3978952727983707,small,1,1,0,1,0,0,0,0,0,0,1,1,1,1,11,1,1,0,0,2,1,,,,,0,2,0
NCT06217393,Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia,Randomized Multicentre Open-label Study to Investigate the Non-inferiority of Itopride Hydrochloride 150mg Once Daily Versus Itopride Hydrochloride 50 mg Thrice Daily in Subjects With Functional (Non-ulcer) Dyspepsia or Chronic Gastritis,ACTIVE_NOT_RECRUITING,2024-02-28,2025-02-28,2025-01-29,INTERVENTIONAL,PHASE3,564.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Functional Dyspepsia,Itopride Hydrochloride 150 mg extended release tablets|Itopride Hydrochloride 50 mg film coated tablets,DRUG,1,4,18 Years,99 Years,ALL,False,Abbott,INDUSTRY,0,19,Armenia|Malaysia|Vietnam|Philippines|Thailand,,0,0,1,0,0,3.0,0,0,0,0,1,6.336825731146441,xlarge,0,1,1,0,0,0,1,1,0,0,1,0,1,1,5,1,1,0,0,2,1,,,,,0,2,0
NCT00388193,Rituximab Combined With Chemotherapy in Burkitt's Lymphoma,Burkimab:Study Multicenter of Optimization of the Treatment of LLA-B and the Burkitt's Lymphoma in Adult Patients (From 15 Years Old),COMPLETED,2006-08,2013-12,2014-10-28,INTERVENTIONAL,PHASE2,20.0,ESTIMATED,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Acute Lymphoblastic Leukemia|Burkitt's Lymphoma,RITUXIMAB,DRUG,1,3,15 Years,,ALL,False,PETHEMA Foundation,OTHER,0,15,Spain,1.0,0,1,0,0,0,2.0,1,0,0,0,2,3.044522437723423,small,1,0,0,1,0,0,1,0,0,1,0,0,1,0,4,1,1,0,0,1,0,2006-08-01,2013-12-01,2679.0,2006.0,0,1,0
NCT06190093,A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects with Neovascular Age-related Macular Degeneration (AMD),Safety and Effectiveness of ONS-5010 Compared to Lucentis® in Subjects with Neovascular Age-related Macular Degeneration; NORSE EIGHT,COMPLETED,2024-01-24,2024-12-05,2025-02-25,INTERVENTIONAL,PHASE3,400.0,ACTUAL,,PARALLEL,TREATMENT,TRIPLE,Neovascular Age-related Macular Degeneration|Age-Related Macular Degeneration|Wet Macular Degeneration,bevacizumab|ranibizumab,BIOLOGICAL,1,0,50 Years,,ALL,False,"Outlook Therapeutics, Inc.",INDUSTRY,0,61,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,3,5.993961427306569,large,0,1,1,0,0,0,1,0,1,0,0,1,1,1,1,0,0,1,0,2,1,,,,,0,2,0
NCT00229021,Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis,"A Multicenter, Double-Blind, Randomized, Phase 3 Study of Doripenem Verus a Comparator Antibiotic in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis",COMPLETED,2003-12,2006-03,2011-06-10,INTERVENTIONAL,PHASE3,741.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Urinary Tract Infections|Pyelonephritis,doripenum,DRUG,1,1,18 Years,,ALL,False,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INDUSTRY,1,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,2,6.60934924316738,xlarge,0,1,1,0,0,1,0,0,0,0,1,1,1,1,2,1,1,0,0,1,0,2003-12-01,2006-03-01,821.0,2003.0,0,1,0
NCT01474421,Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease,"A Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Oral Dose Study to Assess the Efficacy, Safety and Tolerability of AQW051 in Reducing L-dopa Induced Dyskinesias in Parkinson's Patients With Moderate to Severe L-dopa Induced Dyskinesias",COMPLETED,2011-09-15,2013-02-21,2020-12-24,INTERVENTIONAL,PHASE2,71.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Dyskinesias|Drug-induced,AQW051|AQW051|Placebo,DRUG,3,5,30 Years,85 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,24,Germany|France|Italy|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.276666119016055,medium,1,1,1,0,1,0,1,1,1,1,1,1,1,1,8,1,1,0,0,3,1,,,,,0,4,1
NCT00064714,Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I Diabetes,Effect of AC 2993 (Synthetic Exendin-4) - Administered Alone or in Combination With Daclizumab - on Islet Function in Patients With Type I Diabetes,COMPLETED,2003-07,2008-03,2015-03-11,INTERVENTIONAL,PHASE2,47.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Diabetes Mellitus,AC2993 (exenatide)|daclizumab (immunosuppressive),DRUG,1,0,18 Years,60 Years,ALL,False,AstraZeneca,INDUSTRY,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.871201010907891,small,1,1,1,0,1,1,0,0,1,0,1,0,1,0,1,0,1,0,0,2,1,2003-07-01,2008-03-01,1705.0,2003.0,0,1,0
NCT01780987,AStudy To Evaluate Safety And Eficacy Of Apixaban In Japanese Acute Deep Vein Thrombosis (DVT) And Pulmonary Embolism (PE) Patients,"Active-control, Multicenter, Randomized, Open-label, Safety And Efficacy Study Evaluating The Use Of Apixaban In The Treatment Of Symptomatic Deep Vein Thrombosis And Pulmonary Embolism In Japanese",COMPLETED,2013-01,2014-09,2016-06-23,INTERVENTIONAL,PHASE3,80.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Deep Vein Thrombosis|Pulmonary Embolism,Apixaban|Unfractionated Heparin (UFH)|Warfarin,DRUG,1,5,20 Years,,ALL,False,Pfizer,INDUSTRY,1,20,Japan,1.0,0,0,1,0,0,3.0,0,0,0,0,2,4.394449154672439,medium,1,1,1,0,1,1,1,0,0,0,1,0,1,1,6,1,1,0,0,3,1,2013-01-01,2014-09-01,608.0,2013.0,0,3,1
NCT00684593,A Study to Assess the Clinical Effects of Navarixin in Participants With Psoriasis (MK-7123-009),A Study to Assess the Clinical Effects of SCH 527123 in Psoriasis,COMPLETED,2007-06-01,2007-10-01,2019-02-05,INTERVENTIONAL,PHASE2,31.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Psoriasis,Navarixin 10 mg|Placebo,DRUG|OTHER,1,5,18 Years,70 Years,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,0,,1.0,0,1,0,0,0,2.0,0,1,0,0,1,3.4657359027997265,small,1,1,1,0,1,0,0,0,0,0,1,1,1,1,6,1,1,0,0,2,1,,,,,0,2,0
NCT01464593,Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC),Phase II Open Label Trial of Thermal Ablation and Lyso-Thermosensitive Liposomal Doxorubicin (Thermodox) for Metastatic Colorectal Cancer (mCRC) Liver Lesions,TERMINATED,2011-09,2013-06,2022-10-13,INTERVENTIONAL,PHASE2,2.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Colon Cancer Liver Metastasis,Lyso-Thermosensitive Liposomal Doxorubicin|5% Dextrose Solution|ThermoDox,DRUG|OTHER,1,3,18 Years,,ALL,False,Imunon,INDUSTRY,0,4,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,1.0986122886681098,small,1,1,1,0,0,0,1,0,1,0,0,0,1,0,4,1,1,0,0,3,1,2011-09-01,2013-06-01,639.0,2011.0,0,1,0
NCT06671821,Long-term Efficacy and Safety of HRS-7535 Tablets in Obese Subjects,"HRS-7535-202 Follow-up Study: A Long-term Evaluation of Safety, Tolerability, and Efficacy in Obese Subjects (Open-label, Extension Trial)",COMPLETED,2024-11-20,2025-09-28,2025-11-17,INTERVENTIONAL,PHASE2,81.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Chronic Weight Management,HRS-7535,DRUG,1,5,18 Years,65 Years,ALL,False,"Shandong Suncadia Medicine Co., Ltd.",INDUSTRY,0,1,China,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.406719247264253,medium,1,1,1,0,0,0,0,0,0,0,0,0,1,1,6,1,1,0,0,1,0,,,,,0,1,0
NCT00309621,Safety and Efficacy of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis,Safety and Efficacy of Alitretinoin in the Treatment of Severe Refractory Chronic Hand Dermatitis,COMPLETED,2006-04,2007-05,2023-05-10,INTERVENTIONAL,PHASE3,250.0,,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Hand Dermatoses,alitretinoin,DRUG,4,4,18 Years,75 Years,ALL,False,Basilea Pharmaceutica,INDUSTRY,0,33,Germany|Poland|Canada,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.5254529391317835,large,0,0,1,0,0,0,1,1,0,1,0,0,1,0,8,1,1,0,0,1,0,2006-04-01,2007-05-01,395.0,2006.0,0,2,0
NCT02480114,Gabapentin Compared to Standard of Care in Preventing Mucositis in Patients With Stage III-IV Head and Neck Cancer Undergoing Primary or Adjuvant Chemoradiation Therapy,A Randomized Phase III Trial of Gabapentin Versus Standard of Care for Prevention and Treatment of Mucositis in Locally Advanced Head and Neck Cancer Patients Undergoing Primary or Adjuvant Chemoradiation,COMPLETED,2015-07,2020-01,2021-02-18,INTERVENTIONAL,PHASE3,79.0,ACTUAL,RANDOMIZED,PARALLEL,SUPPORTIVE_CARE,NONE,Malignant Head and Neck Neoplasm|Mucositis|Radiation-Induced Disorder,Educational Intervention|Gabapentin|Pain Therapy|Quality-of-Life Assessment|Questionnaire Administration|Oxycodone/Acetaminophen|Hydrocodone/Acetaminophen|Fentanyl|Ibuprofen|Magic Mouthwash,DRUG|OTHER,1,2,21 Years,,ALL,False,Vanderbilt-Ingram Cancer Center,OTHER,1,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,3,4.382026634673881,medium,1,1,0,1,0,1,0,0,1,0,1,0,0,1,3,1,1,0,0,10,1,2015-07-01,2020-01-01,1645.0,2015.0,1,2,0
NCT00505414,A Study to Evaluate the Effectiveness and Safety of CG5503 (Tapentadol) in the Treatment of Chronic Tumor Related Pain Compared With Placebo and Morphine,"A Randomized Withdrawal, Active- and Placebo-controlled, Double-blind, Multi-center Phase III Trial Assessing Safety and Efficacy of Oral CG5503 (Tapentadol) Prolonged Release (PR*) in Subjects With Moderate to Severe Chronic Malignant Tumor-related Pain. *Prolonged Release and is the Recommended Nomenclature for Use in the European Union (EU). ER Means Extended Release and is the Recommended Nomenclature for Use in the United States of America (USA). ""PR"" is Synonymous With ""ER"" and is Interchangeable.",TERMINATED,2007-06,2009-05,2019-11-01,INTERVENTIONAL,PHASE3,136.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Pain|Neoplasm|Cancer,Tapentadol in the Titration Phase|Morphine in the Maintenance Phase|Matching Placebo in the Maintenance Phase after Tapentadol in the Titration Phase|Tapentadol in the Maintenance Phase|Morphine in the Titration Phase,DRUG,1,1,18 Years,,ALL,False,Grünenthal GmbH,INDUSTRY,1,37,Argentina|Latvia|United States|Chile|Ukraine|France,0.0,0,0,1,0,0,3.0,1,0,0,0,3,4.919980925828125,medium,0,1,1,0,0,1,1,1,1,1,1,1,1,1,2,1,1,0,0,5,1,2007-06-01,2009-05-01,700.0,2007.0,0,3,1
NCT03305614,TDCS and Aphasia Therapy in the Chronic Phase After Stroke,The Neuromodulatory Effect of Combined Transcranial Direct Current Stimulation with Intensive Aphasia Therapy in the Chronic Phase After Stroke,TERMINATED,2017-11-24,2018-04-18,2024-09-19,INTERVENTIONAL,PHASE2,25.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Aphasia Following Cerebral Infarction|Aphasia Following Nontraumatic Intracerebral Hemorrhage,tDCS|Aphasia therapy,PROCEDURE,1,4,18 Years,85 Years,ALL,False,"University Hospital, Ghent",OTHER,0,1,Belgium,0.0,0,1,0,0,0,2.0,0,0,0,0,2,3.258096538021482,small,1,1,0,1,0,0,0,0,0,0,1,1,1,1,5,1,0,0,0,2,1,,,,,0,2,0
NCT02806414,Evaluation of the Inhibitory Effects of Topical Ivermectin on Markers of Rosacea Specific Inflammation.,"A Single Site Evaluation of the Inhibitory Effects of Topical Ivermectin on Serine Protease Activity and Production of LL-37 Cathelicidin Peptide, Biochemical Markers of Rosacea-specific Inflammation and on the Skin Microbiome in Rosacea.",COMPLETED,2016-07,2021-05,2021-10-05,INTERVENTIONAL,PHASE1|PHASE2,25.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Rosacea,Ivermectin,DRUG,1,1,18 Years,70 Years,ALL,False,"University of California, San Diego",OTHER,1,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,3.258096538021482,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,2,1,1,0,0,1,0,2016-07-01,2021-05-01,1765.0,2016.0,1,1,0
NCT00893516,CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma,A Multicentre Open-label Dose Escalation Tiral of Zanolimumab in Combination With CHOP Chemotherapy in Patients With CD4 Positive Non-cutaneous Peripheral T-cell Lymphoma With Nodal Involvement.,TERMINATED,2007-05,2008-12,2024-04-09,INTERVENTIONAL,PHASE2,5.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,T-cell Lymphoma,CHOP + CD4|CHOP,DRUG|BIOLOGICAL,1,0,18 Years,,ALL,False,Emergent BioSolutions,INDUSTRY,0,0,,0.0,0,1,0,0,0,2.0,1,0,0,0,1,1.791759469228055,small,1,1,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,1,0,2,1,2007-05-01,2008-12-01,580.0,2007.0,0,1,0
NCT04424316,A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.,"A PHASE 3, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY",COMPLETED,2020-06-17,2023-10-27,2025-02-11,INTERVENTIONAL,PHASE3,14727.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Respiratory Tract Infection,RSVpreF|Placebo,BIOLOGICAL,23,3,0 Years,49 Years,FEMALE,True,Pfizer,INDUSTRY,0,464,Netherlands|The Gambia|Argentina|Finland|South Korea|United States|Spain|Brazil|Australia|Chile|Japan|Mexico|New Zealand|Denmark|Taiwan|Philippines|South Africa|Canada,1.0,0,0,1,0,0,3.0,0,0,0,0,1,9.597505722912913,,0,1,1,0,1,0,1,1,1,1,1,1,0,1,26,1,0,1,0,2,1,,,,,0,3,1
NCT00598104,Safety and Efficacy of QAX576 in Adults With Moderate Persistent Allergic Asthma,"A Randomized, Double-blinded, Placebo Controlled, Parallel Group, Multi-center Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Intravenous Doses of QAX576 in Moderate Persistent Allergic Asthmatics Following Inhaled Corticosteroid Withdrawal",WITHDRAWN,2008-01,,2016-03-04,INTERVENTIONAL,PHASE1|PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Asthma,QAX576|Placebo,DRUG,1,1,18 Years,55 Years,ALL,False,Novartis,INDUSTRY,0,0,,0.0,1,1,0,0,1,1.5,0,0,0,0,1,0.0,,1,1,1,0,1,0,0,0,0,0,1,1,1,1,2,1,1,0,0,2,1,2008-01-01,,,2008.0,0,2,0
NCT04199104,A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010),"A Phase 3, Randomized, Placebo-controlled, Double-blind Clinical Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib as 1L Intervention in a PD-L1 Selected Population of Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010).",COMPLETED,2020-02-05,2025-03-31,2025-04-23,INTERVENTIONAL,PHASE3,511.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Head and Neck Squamous Cell Carcinoma,Lenvatinib|Pembrolizumab|Placebo,DRUG|BIOLOGICAL,3,3,18 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,1,152,China|Germany|Japan|Taiwan|Italy|South Korea|Spain|Peru|Canada|Russia|Turkey (Türkiye)|United States|United Kingdom|Australia|Poland|Mexico|France|Hungary|Brazil,1.0,0,0,1,0,0,3.0,1,0,0,0,1,6.238324625039508,xlarge,0,1,1,0,1,1,1,1,1,1,1,1,1,1,6,1,1,1,0,3,1,,,,,0,3,1
NCT06597084,Anti-epileptogenic Effects of Eslicarbazepine Acetate,Prevention of Epilepsy in Stroke Patients at High Risk of Developing Unprovoked Seizures: Anti-epileptogenic Effects of Eslicarbazepine Acetate,COMPLETED,2019-05-29,2023-09-11,2025-05-02,INTERVENTIONAL,PHASE2,129.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Post Stroke Epilepsy,ESL 800 mg|Placebo,DRUG,1,19,18 Years,,ALL,False,Bial - Portela C S.A.,INDUSTRY,0,22,Italy|Sweden|Spain|Germany|Austria|United Kingdom|Israel|Portugal|France,1.0,0,1,0,0,0,2.0,0,0,1,0,1,4.867534450455582,medium,0,1,1,0,0,0,1,1,0,1,1,1,1,1,20,1,1,0,0,2,1,,,,,0,3,1
NCT01336933,Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma,"A Phase II Study of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin Lymphoma",COMPLETED,2011-07-06,2016-12-28,2023-09-22,INTERVENTIONAL,PHASE2,34.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Hepatosplenic T-cell Lymphoma|Peripheral T-cell Lymphoma,prednisone|cyclophosphamide|etoposide|Vincristine|pralatrexate|laboratory biomarker analysis|comparative genomic hybridization|gene expression analysis|nucleic acid sequencing|mutation analysis|immunohistochemistry staining method|microarray analysis|RNA analysis,DRUG|GENETIC|OTHER,1,5,18 Years,,ALL,False,University of Nebraska,OTHER,2,9,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,4,3.5553480614894135,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,6,1,1,0,0,13,1,,,,,0,3,1
NCT03622216,A Dose Escalation Study of Bradanicline in Refractory Chronic Cough,A Dose Escalation Study to Assess the Efficacy and Safety of Bradanicline in Subjects With Refractory Chronic Cough,COMPLETED,2018-11-05,2019-05-22,2019-06-20,INTERVENTIONAL,PHASE2,46.0,ACTUAL,RANDOMIZED,SEQUENTIAL,TREATMENT,DOUBLE,Chronic Cough,Bradanicline|Placebo,DRUG,1,2,18 Years,80 Years,ALL,False,"Attenua, Inc.",INDUSTRY,0,17,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.8501476017100584,small,1,1,1,0,0,0,1,0,1,0,1,1,1,0,3,1,1,0,0,2,1,,,,,0,1,0
NCT01004406,"Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase I",Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER),COMPLETED,2011-09,2013-03,2019-07-30,INTERVENTIONAL,PHASE3,59.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,SINGLE,Acute Coronary Syndrome,intensive LDL-lowering therapy|standard statin monotherapy,DRUG|DEVICE,1,3,31 Years,,ALL,False,VA Office of Research and Development,FED,0,2,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.0943445622221,medium,1,1,0,0,0,0,1,0,1,0,1,0,0,1,4,1,1,0,1,2,1,2011-09-01,2013-03-01,547.0,2011.0,0,1,0
NCT06351306,DEC-C and Thioguanine for R/R AML,"A Phase II Open-Label, Single Center Trial of Oral Decitabine-Cedazuridine (DEC-C) (Inqovi®) in Combination With Thioguanine (Tabloid®) in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)",WITHDRAWN,2024-04-01,2024-04-01,2025-03-24,INTERVENTIONAL,PHASE2,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Acute Myeloid Leukemia,Thioguanine (Tabloid ®)|DecitabineCedazuridine (Inqovi ®),DRUG,1,3,18 Years,,ALL,False,Columbia University,OTHER,0,0,,0.0,0,1,0,0,0,2.0,1,0,0,0,1,0.0,,1,1,0,1,0,0,0,0,0,0,0,0,1,0,4,1,1,0,0,2,1,,,,,0,1,0
NCT00003906,Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women,Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer,COMPLETED,1999-05,2012-08,2015-10-06,INTERVENTIONAL,PHASE3,19747.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Breast Cancer,Raloxifene|Tamoxifen,DRUG,1,6,35 Years,,FEMALE,False,NSABP Foundation Inc,NETWORK,3,516,Canada|Puerto Rico|United States,1.0,0,0,1,0,0,3.0,1,0,0,0,1,9.890807499378754,,0,1,0,0,0,1,1,1,1,0,1,1,0,1,7,1,1,0,0,2,1,1999-05-01,2012-08-01,4841.0,1999.0,0,3,1
NCT03075904,A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus),"A Phase 1B/2, Multicenter, Open-Label, Safety, and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus)",TERMINATED,2017-07-18,2019-01-16,2020-02-05,INTERVENTIONAL,PHASE1|PHASE2,8.0,ACTUAL,NON_RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,Pemphigus|Pemphigus Vulgaris|Pemphigus Foliaceus,ALXN1830,DRUG,1,4,18 Years,,ALL,False,"Alexion Pharmaceuticals, Inc.",INDUSTRY,0,3,United States,0.0,1,1,0,0,1,1.5,0,0,0,0,3,2.1972245773362196,small,1,1,1,0,0,0,1,0,1,0,0,0,1,0,5,1,1,0,0,1,0,,,,,0,2,0
NCT07145333,Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms,Explore the Relationship Between Single Nucleotide Polymorphisms and Topotecan Response and Toxicity in Patients With Small Cell Lung Cancer.,ACTIVE_NOT_RECRUITING,2025-08-12,2026-10-28,2025-09-08,INTERVENTIONAL,PHASE2|PHASE3,600.0,ESTIMATED,RANDOMIZED,PARALLEL,HEALTH_SERVICES_RESEARCH,QUADRUPLE,SCLC,Topotecan - usual|Topotecan - study,DRUG,1,0,24 Years,64 Years,ALL,False,"Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair",INDUSTRY,1,1,United States,,0,1,1,0,1,2.5,0,0,0,0,1,6.398594934535208,xlarge,0,0,1,0,0,1,0,0,1,0,1,1,0,1,1,0,1,0,0,2,1,,,,,0,2,0
NCT01413100,Scleroderma Treatment With Autologous Transplant (STAT) Study,A Phase II Multi-center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation With Post Transplant Maintenance for the Treatment of Systemic Sclerosis,COMPLETED,2011-09-15,2024-09-11,2025-01-07,INTERVENTIONAL,PHASE2,21.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Systemic Scleroderma,Anti-Thymocyte Globulin|Autologous Hematopoietic Stem Cell Transplantation|Cyclophosphamide|Filgrastim|Laboratory Biomarker Analysis|Mycophenolate Mofetil|Peripheral Blood Stem Cell Transplantation|Plerixafor|Quality-of-Life Assessment|Questionnaire Administration,DRUG|BIOLOGICAL|OTHER|PROCEDURE,1,15,,70 Years,ALL,False,Fred Hutchinson Cancer Center,OTHER,1,12,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.091042453358316,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,16,1,1,1,0,10,1,,,,,0,2,0
NCT02092207,Phase 2 Study to Evaluation the Safety and Efficacy of Orally Administered KL7016 in Patients With Dry Eye Syndrome,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, 12 Weeks, Phase II Clinical Study to Evaluate the Safety and Efficacy of Orally Administered KL7016 in Patients With Dry Eye Syndrome",COMPLETED,2012-10,2014-07,2017-12-21,INTERVENTIONAL,PHASE2,147.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Dry Eye Syndrome,KL7016 900mg|KL7016 600mg|Placebo,DRUG,1,5,18 Years,,ALL,False,"Yungjin Pharm. Co., Ltd.",INDUSTRY,0,9,South Korea,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.997212273764115,medium,0,1,1,0,0,0,1,0,0,0,1,1,1,1,6,1,1,0,0,3,1,2012-10-01,2014-07-01,638.0,2012.0,0,2,0
NCT00553267,Telmisartan/Amlodipine (80/10) vs. Telmisartan/Amlodipine (40/10) vs. amlodipine10 in Resistant Hypertension,"An Eight-week Randomised, Double-blind Study to Compare the Fixed-dose Combination of Telmisartan 40mg + Amlodipine 10mg Versus Telmisartan 80mg + Amlodipine 10mg Versus Amlodipine 10mg Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Amlodipine 10mg Monotherapy",COMPLETED,2007-11,,2014-02-13,INTERVENTIONAL,PHASE3,947.0,ACTUAL,,PARALLEL,TREATMENT,,Hypertension,fixed dose combination of telmisartan+amlodipine|amlodipine,DRUG,1,9,18 Years,,ALL,False,Boehringer Ingelheim,INDUSTRY,0,97,Italy|Bulgaria|Russia|Turkey (Türkiye)|Spain|Austria|Australia|Slovakia|United Kingdom|Switzerland|Czechia|New Zealand|Ukraine|Ireland,1.0,0,0,1,0,0,3.0,0,0,0,1,1,6.854354502255021,xlarge,0,1,1,0,0,0,1,1,0,1,0,0,1,1,10,1,1,0,0,2,1,2007-11-01,,,2007.0,0,3,1
NCT01408407,Alkagin Paste in the Prevention of Radiation Dermatitis,A Phase II Study Designed to Evaluate the Value of Alkagin Paste in the Prevention of Radiation Dermatitis for Patients Undergoing External Radiation Therapy,TERMINATED,2011-12,,2015-05-25,INTERVENTIONAL,PHASE2,2.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Anus Neoplasms|Rectal Neoplasms|Urogenital Neoplasms,Aveeno cream|Alkagin paste,OTHER,1,0,18 Years,,ALL,False,Dr. Te Vuong,OTHER,1,1,Canada,0.0,0,1,0,0,0,2.0,0,0,0,0,3,1.0986122886681098,small,1,1,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,2,1,2011-12-01,,,2011.0,0,2,0
NCT00653107,Palliation Dysphagia Cancer Oesophagus Stent+Brachytherapy Versus Brachytherapy Only,Palliation of Dysphagia in Patients With Advanced Cancer of the Oesophagus by Comparing Stent Followed by 3 Courses of Brachytherapy With 3 Courses of Brachytherapy Only. A Randomised Phase III Study (PACO),TERMINATED,2008-06,2012-04,2019-05-14,INTERVENTIONAL,PHASE3,41.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Esophageal Neoplasm,Stent insertion|Brachytherapy|Brachytherapy,RADIATION|PROCEDURE,1,1,18 Years,,ALL,False,Oslo University Hospital,OTHER,2,1,Norway,0.0,0,0,1,0,0,3.0,0,0,0,0,1,3.7376696182833684,small,1,1,0,1,0,1,0,0,0,0,1,0,1,1,2,1,0,0,0,3,1,2008-06-01,2012-04-01,1400.0,2008.0,0,1,0
NCT01917136,11C-acetate/18Fluorodeoxyglucose-FDG PET/CT and Cardiac MRI in Pulmonary Hypertension,"Evaluation of Regional Myocardial Perfusion, Glucose Utilization and Oxidative Metabolism in Patients With Pulmonary Hypertension Using Combined [11C]Acetate and [18F]Fluorodeoxyglucose (FDG) PET/CT and Cardiovascular MRI",COMPLETED,2013-08,2018-10,2019-02-05,INTERVENTIONAL,PHASE2,21.0,ACTUAL,,SINGLE_GROUP,DIAGNOSTIC,NONE,Pulmonary Hypertension,11C-acetate|[18F]Fluoro-2-deoxy-2-D-glucose|Cardiac MRI,DRUG|OTHER,1,0,18 Years,80 Years,ALL,False,University of Pennsylvania,OTHER,5,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,1,1,3.091042453358316,small,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,3,1,2013-08-01,2018-10-01,1887.0,2013.0,0,1,0
NCT00161811,Comparison of the Safety and Immune Response of Three Different Lots of an Influenza Vaccine Made by a New Manufacturing Process With a Vaccine Made by the Traditional Manufacturing Process for Season 2004/2005,"Single-blind Randomized Controlled Phase II/III Study to Investigate the Immunogenicity and Safety After a Single Vaccination With Three Different Lots of an Inactivated Influenza Vaccine (Whole Virion, Vero Cell-derived) in Comparison to a Licensed Egg Derived Influenza Vaccine for Season 2004/2005.",COMPLETED,2004-11,2005-07,2015-10-09,INTERVENTIONAL,PHASE2|PHASE3,1400.0,,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Influenza,Vero Cell-derived Influenza Vaccine|Egg cell-derived Influenza Vaccine,BIOLOGICAL,0,0,18 Years,,ALL,True,"Alachua Government Services, Inc.",INDUSTRY,0,4,Germany|Austria,1.0,0,1,1,0,1,2.5,0,0,0,0,1,7.244941546337007,xlarge,0,0,1,0,0,0,1,1,0,1,1,1,0,1,0,0,0,1,0,2,1,2004-11-01,2005-07-01,242.0,2004.0,0,3,1
NCT01802411,Intercostal Nerve Block With Liposome Bupivacaine in Subjects Undergoing Posterolateral Thoracotomy,"A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study to Assess the Efficacy and Safety of Intercostal Nerve Block With Liposome Bupivacaine in Subjects Undergoing Posterolateral Thoracotomy",COMPLETED,2012-12,2013-06,2021-07-12,INTERVENTIONAL,PHASE3,191.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Posterolateral Thoracotomy|Postoperative Pain,EXPAREL 266 mg|Placebo,DRUG,1,2,18 Years,,ALL,False,"Pacira Pharmaceuticals, Inc",INDUSTRY,0,21,Bulgaria|United States|Poland|Czechia|Georgia,1.0,0,0,1,0,0,3.0,0,0,0,0,2,5.2574953720277815,medium,0,1,1,0,0,0,1,1,1,0,1,1,1,1,3,1,1,0,0,2,1,2012-12-01,2013-06-01,182.0,2012.0,0,3,1
NCT04801771,Effects of Hypoglossal Nerve Stimulation on Cognition and Language in Down Syndrome and Obstructive Sleep Apnea,Effects of Hypoglossal Nerve Stimulation on Cognition and Language in Down Syndrome and Obstructive Sleep Apnea,ACTIVE_NOT_RECRUITING,2021-06-24,2027-09-30,2025-09-18,INTERVENTIONAL,PHASE3,57.0,ESTIMATED,,SINGLE_GROUP,TREATMENT,NONE,Down Syndrome|Obstructive Sleep Apnea,Inspire Upper Airway Stimulation (UAS) System,DEVICE,6,3,10 Years,21 Years,ALL,False,"Inspire Medical Systems, Inc.",INDUSTRY,2,8,United States,,0,0,1,0,0,3.0,0,0,0,0,2,4.060443010546419,medium,1,0,1,0,0,1,1,0,1,0,0,0,1,0,9,1,0,0,1,1,0,,,,,0,2,0
NCT01204034,Study to Assess the Effect of Formoterol and Beclomethasone Dipropionate in Patients With Chronic Obstructive Pulmonary Disease (COPD),"Open-label, Prospective Exploratory Study to Assess the Effects of Formoterol and Beclometasone Dipropionate Combination Therapy on Central and Peripheral Airway Dimensions in COPD Patients",COMPLETED,2010-09,2012-06,2012-07-03,INTERVENTIONAL,PHASE3,29.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Chronic Obstructive Pulmonary Disease,Inuvair,DRUG,6,15,40 Years,,ALL,False,"University Hospital, Antwerp",OTHER,1,1,Belgium,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.4011973816621555,small,1,1,0,1,0,1,0,0,0,0,0,0,1,0,21,1,1,0,0,1,0,2010-09-01,2012-06-01,639.0,2010.0,0,1,0
NCT00713934,Autologous Bone Marrow Stem Cells in Cirrhosis Patients,Autologous Transplantation of Bone Marrow Derived CD 133 Positive Stem Cell and Mono Nuclear Cell (MNC) Transplantation in Patients With Decompensate Cirrhosis: Randomized Clinical Trial,COMPLETED,2008-01,2009-02,2011-10-04,INTERVENTIONAL,PHASE1|PHASE2,7.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Stem Cell Transplantation|Cirrhosis,CD133|BM-MNC,BIOLOGICAL,2,1,18 Years,75 Years,ALL,False,Royan Institute,OTHER_GOV,2,2,Iran,1.0,1,1,0,0,1,1.5,0,0,0,0,2,2.0794415416798357,small,1,1,0,1,0,1,1,0,0,0,1,0,1,1,3,1,0,1,0,2,1,2008-01-01,2009-02-01,397.0,2008.0,0,3,1
NCT02775734,NAC in CC Resistant PCOS After LOD,N-acetyl-cysteine in Clomiphene Citrate Resistant Polycystic Ovary Syndrome After Laparoscopic Ovarian Drilling: A Randomized Controlled Trial,COMPLETED,2016-05,2017-03,2017-05-02,INTERVENTIONAL,PHASE2|PHASE3,144.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Clomiphene Citrate Resistant Polycystic Ovary Syndrome,N-acetyl-cysteine|Clomiphene citrate,DRUG,1,7,18 Years,35 Years,FEMALE,False,Ain Shams University,OTHER,0,1,Egypt,1.0,0,1,1,0,1,2.5,0,0,0,0,1,4.976733742420574,medium,0,1,0,1,0,0,0,0,0,0,1,1,1,1,8,1,1,0,0,2,1,2016-05-01,2017-03-01,304.0,2016.0,1,3,1
NCT03432364,"A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)","A Phase 1/2, Open-label, Single-arm Study to Assess the Safety, Tolerability, and Efficacy of ST-400 Autologous Hematopoietic Stem Cell Transplant for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)",COMPLETED,2018-03-29,2022-11-17,2023-12-14,INTERVENTIONAL,PHASE1|PHASE2,5.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Transfusion Dependent Beta-thalassemia,ST-400 Investigational product,GENETIC,1,4,18 Years,40 Years,ALL,False,Sangamo Therapeutics,INDUSTRY,0,6,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,1.791759469228055,small,1,1,1,0,0,0,1,0,1,0,0,0,1,0,5,1,0,0,0,1,0,,,,,0,1,0
NCT02629809,"Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia","First-Line Therapy With Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (iFCG) for Patients With Chronic Lymphocytic Leukemia (CLL) With Mutated IGHV Gene and Non-Del(17p)",ACTIVE_NOT_RECRUITING,2016-03-18,2026-03-31,2025-09-05,INTERVENTIONAL,PHASE2,81.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,Cyclophosphamide|Fludarabine Phosphate|Ibrutinib|Obinutuzumab,DRUG|BIOLOGICAL,1,7,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,0,1,United States,,0,1,0,0,0,2.0,1,0,0,0,2,4.406719247264253,medium,1,1,0,1,0,0,0,0,1,0,0,0,1,0,8,1,1,1,0,4,1,,,,,0,3,1
NCT04650399,A Multicenter Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Vaccine in Adolescents,"A Multicenter, Randomized, Controlled, Double Blinded Pivotal Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Virus Vaccine Candidate (VLA1553) in Adolescents Aged 12 Years to <18 Years",COMPLETED,2022-01-31,2024-02-15,2024-05-03,INTERVENTIONAL,PHASE3,750.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Chikungunya,Active|Placebo,BIOLOGICAL,1,11,12 Years,17 Years,ALL,True,Butantan Institute,OTHER_GOV,1,10,Brazil,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.621405651764134,xlarge,0,1,0,1,0,1,1,0,0,0,1,1,0,1,12,1,0,1,0,2,1,,,,,0,2,0
NCT00357799,VeinViewer for Peripheral IV Placement in Children With Difficult Intravenous (IV) Access,VeinViewer for Peripheral IV Placement in Children With Difficult IV Access,COMPLETED,2006-10,2010-10,2011-08-24,INTERVENTIONAL,PHASE2|PHASE3,170.0,ESTIMATED,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Catheterization, Peripheral|Phlebotomy",VeinViewer,DEVICE,1,1,,19 Years,ALL,False,"Children's Hospital and Health System Foundation, Wisconsin",OTHER,1,1,United States,1.0,0,1,1,0,1,2.5,0,0,0,0,2,5.14166355650266,medium,0,0,0,1,0,1,0,0,1,0,1,0,1,0,2,1,0,0,1,1,0,2006-10-01,2010-10-01,1461.0,2006.0,0,2,0
NCT02979899,Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma,A Randomized Phase 3 Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma (TAPPAS),COMPLETED,2017-02-13,2019-08-31,2020-05-12,INTERVENTIONAL,PHASE3,128.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Advanced Angiosarcoma,TRC105|Votrient,DRUG|BIOLOGICAL,1,3,12 Years,,ALL,False,Tracon Pharmaceuticals Inc.,INDUSTRY,0,39,Italy|United States|Germany|Austria|Spain|United Kingdom|Poland|France,1.0,0,0,1,0,0,3.0,1,0,0,0,1,4.859812404361672,medium,0,1,1,0,0,0,1,1,1,1,1,0,1,1,4,1,1,1,0,2,1,,,,,0,2,0
NCT00046332,A Study Comparing 4 Doses Of GW810781 Versus Placebo In HIV-Infected Patients,"A Phase II, Randomized, Placebo-controlled Study to Compare Antiviral Effect, Safety, Tolerability and Pharmacokinetics of Four Oral Doses of S-1360 Versus Placebo Over 10 Days in ART-naive HIV-1 Infected Adults.",COMPLETED,2002-06,2003-01,2013-02-21,INTERVENTIONAL,PHASE2,100.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,HIV Infections,GW810781,DRUG,1,1,18 Years,,ALL,False,GlaxoSmithKline,INDUSTRY,1,23,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.61512051684126,medium,0,0,1,0,0,1,1,0,1,0,1,1,1,1,2,1,1,0,0,1,0,2002-06-01,2003-01-01,214.0,2002.0,0,0,0
NCT01670032,Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo,"A Multicenter, Double Blind, Randomized, Vehicle Controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of CD 07223 1.5% Topical Gel in Impetigo",COMPLETED,2012-08,2013-08,2014-08-12,INTERVENTIONAL,PHASE2|PHASE3,328.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Impetigo,Experimental: CD07223 1.5 % Topical Gel BID|Experimental: CD07223 1.5% Topical Gel TID|Placebo Comparator: CD07223 vehicle gel BID|Placebo Comparator: CD07223 vehicle gel TID,DRUG,1,0,2 Years,,ALL,False,"NovaBay Pharmaceuticals, Inc.",INDUSTRY,0,13,South Africa|United States,1.0,0,1,1,0,1,2.5,0,0,0,0,1,5.796057750765372,large,0,1,1,0,0,0,1,1,1,0,1,1,1,1,1,0,1,0,0,4,1,2012-08-01,2013-08-01,365.0,2012.0,0,3,1
NCT02468232,Study of Efficacy and Safety of LCZ696 in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction,"A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction.",COMPLETED,2015-06-15,2021-02-18,2023-12-08,INTERVENTIONAL,PHASE3,225.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Heart Failure With Reduced Ejection Fraction (HF-rEF),LCZ696|Enalapril|Placebo to LCZ696|Placebo to Enalapril,DRUG,2,25,20 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,49,Japan,1.0,0,0,1,0,0,3.0,0,0,0,1,1,5.420534999272286,large,0,1,1,0,1,0,1,0,0,0,1,1,1,1,27,1,1,0,0,4,1,,,,,0,2,0
NCT05355298,ACCENT: AMP945 in Combination with Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer,"A Phase 1b/2a, Multicentre, Open Label Study of the Pharmacokinetics, Safety and Efficacy of AMP945 in Combination with Nab-paclitaxel and Gemcitabine in Pancreatic Cancer Patients",ACTIVE_NOT_RECRUITING,2022-05-31,2026-05-01,2025-02-05,INTERVENTIONAL,PHASE1|PHASE2,62.0,ESTIMATED,,SINGLE_GROUP,TREATMENT,NONE,Pancreatic Cancer|PDAC|Pancreatic Ductal Adenocarcinoma,AMP945 ascending doses|AMP945 RP2D,DRUG,3,4,18 Years,,ALL,False,Amplia Therapeutics Limited,INDUSTRY,0,13,Australia|South Korea,,1,1,0,0,1,1.5,1,0,0,0,3,4.143134726391533,medium,1,0,1,0,0,0,1,1,0,0,0,0,1,0,7,1,1,0,0,2,1,,,,,0,5,1
NCT01450163,"Evaluate The Efficacy and Safety Of Pregabalin In Prevention, Reduction of Oxaliplatin-Induced Painful Neuropathy","PHASE III, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Pregabalin in Prevention and Reduction of Oxaliplatin-induced Painful Neuropathy",COMPLETED,2011-08,2014-12,2017-05-09,INTERVENTIONAL,PHASE3,200.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Pain|Neuropathic Pain|Polyneuropathy,"Pregabalin, Oxaliplatin|Placebo , Oxaliplatin",DRUG,1,4,18 Years,,ALL,False,University of Sao Paulo,OTHER,1,1,Brazil,1.0,0,0,1,0,0,3.0,0,0,0,0,3,5.303304908059076,medium,0,1,0,1,0,1,0,0,0,0,1,1,0,1,5,1,1,0,0,2,1,2011-08-01,2014-12-01,1218.0,2011.0,0,2,0
NCT00254163,"Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients","A Prospective, Randomized, Open Label, Phase III Trial of Fludarabine, Cyclophosphamide, and Rituximab vs. Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-cell Chronic Lymphocytic Leukemia",COMPLETED,2003-12,2011-09,2016-11-03,INTERVENTIONAL,PHASE3,184.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,B-Cell Chronic Lymphocytic Leukemia,Fludarabine|Cyclophosphamide|Rituximab|Pentostatin,DRUG,1,8,18 Years,,ALL,False,US Oncology Research,INDUSTRY,1,11,United States,1.0,0,0,1,0,0,3.0,1,0,0,0,1,5.220355825078324,medium,0,1,1,0,0,1,1,0,1,0,1,0,1,1,9,1,1,0,0,4,1,2003-12-01,2011-09-01,2831.0,2003.0,0,2,0
NCT02633293,An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE,An Open-Label Extension Study of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease,TERMINATED,2016-09-15,2021-08-01,2022-12-02,INTERVENTIONAL,PHASE2|PHASE3,243.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Pulmonary Hypertension|Interstitial Lung Disease|Combined Pulmonary Fibrosis and Emphysema,Inhaled Treprostinil,DRUG,1,2,18 Years,,ALL,False,United Therapeutics,INDUSTRY,0,92,Puerto Rico|United States,0.0,0,1,1,0,1,2.5,0,0,0,1,3,5.497168225293202,large,0,1,1,0,0,0,1,1,1,0,0,0,1,0,3,1,1,0,0,1,0,,,,,0,3,1
NCT05356793,The Efficacy Of SCH1 In The Treatment Of Acute Infectious Conjunctivitis,"A Double-Masked, Placebo-Controlled, Randomized, Phase II Clinical Trial To Assess The Efficacy Of SCH1 In The Treatment Of Acute Infectious Conjunctivitis",COMPLETED,2021-09-01,2022-08-13,2023-04-11,INTERVENTIONAL,PHASE2,30.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Acute Infectious Conjunctivitis (Disorder),SCH-1|Placebo,DRUG,1,0,18 Years,,ALL,False,Sacsh,INDUSTRY,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.4339872044851463,small,1,1,1,0,0,0,0,0,1,0,1,1,1,1,1,0,1,0,0,2,1,,,,,0,1,0
NCT02260193,16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis,"Phase 2 Open-Label Study to Assess the Efficacy, Safety, and Tolerability of AKB-6548 in Subjects With Anemia Secondary to End Stage Renal Disease (ESRD), Undergoing Chronic Hemodialysis.",COMPLETED,2014-09-10,2015-07-22,2022-07-01,INTERVENTIONAL,PHASE2,94.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Anemia|End Stage Renal Disease,AKB-6548|AKB-6548|AKB-6548,DRUG,3,20,18 Years,79 Years,ALL,False,Akebia Therapeutics,INDUSTRY,0,16,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.553876891600541,medium,1,1,1,0,0,0,1,0,1,0,0,0,1,1,23,1,1,0,0,3,1,,,,,0,3,1
NCT00003516,Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer,"Phase II Study of Antineoplaston A10 and AS2-1 Capsules In Patients With Incurable, Stage C or D Adenocarcinoma of the Prostate",TERMINATED,1996-03-27,2004-03-18,2018-02-05,INTERVENTIONAL,PHASE2,16.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Prostate Cancer,Antineoplaston therapy (Atengenal + Astugenal),DRUG,0,0,18 Years,99 Years,MALE,False,Burzynski Research Institute,OTHER,0,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,2.833213344056216,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,,,,,0,0,0
NCT00125606,Phase 3 Trial for AML Patients in CR2 Comparing 8Gy TBI /Fludarabine to Conditioning With TBI 12Gy/Cyclophosphamide,Randomized Phase 3 Trial for Patients With AML in CR2 Comparing Total Body Irradiation (TBI) With 8Gy/Fludarabine to Conditioning With TBI 12Gy/Cyclophosphamide,TERMINATED,2004-10,2011-07,2012-12-18,INTERVENTIONAL,PHASE3,30.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Acute Myeloid Leukemia,conditioning for allogeneic HSCT,PROCEDURE,1,5,18 Years,60 Years,ALL,False,University Hospital Muenster,OTHER,9,1,Germany,0.0,0,0,1,0,0,3.0,1,0,0,0,1,3.4339872044851463,small,1,1,0,1,0,1,0,0,0,1,1,0,1,1,6,1,0,0,0,1,0,2004-10-01,2011-07-01,2464.0,2004.0,0,1,0
NCT03790033,"Efficacy and Safety of Ucha-Shinki-Hwan on Korean Patients With Cold Hypersensitivity in the Hands and Feet-Double Blinded, Randomized, Multicenter, Placebo Controlled Clinical Trial","Efficacy and Safety of Ucha-Shinki-Hwan on Korean Patients With Cold Hypersensitivity in the Hands and Feet-Double Blinded, Randomized, Multicenter, Placebo Controlled Clinical Trial",COMPLETED,2018-12-11,2019-09-14,2021-09-01,INTERVENTIONAL,PHASE2|PHASE3,164.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Cold Hypersensitivity,Ucha-Shinki-Hwan|Placebo,DRUG,1,10,19 Years,59 Years,FEMALE,False,Gachon University Gil Oriental Medical Hospital,OTHER,4,1,South Korea,1.0,0,1,1,0,1,2.5,0,0,0,0,1,5.10594547390058,medium,0,1,0,1,0,1,0,0,0,0,1,1,1,1,11,1,1,0,0,2,1,,,,,0,3,1
NCT02394652,The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer: A Phase II Randomized Trial,The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer: A Phase II Randomized Trial,COMPLETED,2015-05-21,2021-01-12,2021-04-21,INTERVENTIONAL,PHASE2,16.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Uterine Cervical Neoplasms|Squamous Cell Carcinoma|Adenocarcinoma|Carcinoma, Adenosquamous",Metformin|Cisplatin|FAZA,DRUG,1,4,18 Years,,FEMALE,False,"University Health Network, Toronto",OTHER,0,5,Canada,1.0,0,1,0,0,0,2.0,1,0,0,0,4,2.833213344056216,small,1,1,0,1,0,0,1,0,0,0,1,0,1,1,5,1,1,0,0,3,1,,,,,0,2,0
NCT01551147,A Placebo and Active Controlled Study of ONO-6950 Following Allergen Challenge in Patients With Asthma,"A Double-blind, Placebo-controlled, Three-way Crossover Study to Compare the Safety and Efficacy of 8 Days of Therapy With ONO-6950 Versus Placebo and Montelukast (Singulair®) on Asthmatic Responses and Airway Hypersensitivity Following Allergen Challenge in Patients With Asthma",COMPLETED,2012-06,,2013-04-30,INTERVENTIONAL,PHASE2,25.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Asthma,ONO-6950|Placebo|Montelukast,DRUG,4,2,18 Years,60 Years,ALL,False,Ono Pharma USA Inc,INDUSTRY,1,5,Canada,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.258096538021482,small,1,1,1,0,0,1,1,0,0,0,1,1,1,0,6,1,1,0,0,3,1,2012-06-01,,,2012.0,0,2,0
NCT02435849,Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients,"A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia",COMPLETED,2015-04-08,2022-11-17,2024-02-13,INTERVENTIONAL,PHASE2,80.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,B-cell Acute Lymphoblastic Leukemia,CTL019,BIOLOGICAL,1,33,,25 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,23,Italy|Belgium|United States|Germany|Austria|Australia|Spain|Norway|Japan|France|Canada,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.394449154672439,medium,1,1,1,0,1,0,1,1,1,1,0,0,1,0,34,1,0,1,0,1,0,,,,,0,2,0
NCT00003049,Surgery Followed by Radiation Therapy and Chemotherapy in Treating Patients With Cancer of the Pancreas,"A Prospective, Randomized Trial of Extended Lymphadenectomy in the Management of Resectable Pancreatic Cancer",COMPLETED,1997-05,2007-07,2016-12-22,INTERVENTIONAL,PHASE3,100.0,ESTIMATED,RANDOMIZED,,TREATMENT,,Pancreatic Cancer,fluorouracil|leucovorin calcium|conventional surgery|radiation therapy,DRUG|RADIATION|PROCEDURE,0,0,18 Years,120 Years,ALL,False,Mayo Clinic,OTHER,1,1,United States,1.0,0,0,1,0,0,3.0,1,0,0,0,1,4.61512051684126,medium,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,4,1,1997-05-01,2007-07-01,3713.0,1997.0,0,1,0
NCT00052949,Imatinib Mesylate in Treating Patients With Recurrent Small Cell Lung Cancer,Phase II Trial of STI571 in Patients With Relapsed Small Cell Lung Cancer,COMPLETED,2003-05,,2013-10-08,INTERVENTIONAL,PHASE2,91.0,ESTIMATED,,SINGLE_GROUP,TREATMENT,NONE,Recurrent Small Cell Lung Cancer,imatinib mesylate|laboratory biomarker analysis,DRUG|OTHER,1,5,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.5217885770490405,medium,1,0,0,1,0,1,0,0,1,0,0,0,1,0,6,1,1,0,0,2,1,2003-05-01,,,2003.0,0,2,0
NCT00486538,Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Sunitinib,"An Open-Label, Phase 2 Study to Evaluate the Efficacy and Tolerability of ABT-869 in Subjects With Advanced Renal Cell Carcinoma (RCC) Who Have Previously Received Treatment With Sunitinib",COMPLETED,2007-06,2012-06,2013-01-04,INTERVENTIONAL,PHASE2,53.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Advanced Renal Cell Carcinoma,ABT-869,DRUG,1,5,18 Years,,ALL,False,"AbbVie (prior sponsor, Abbott)",INDUSTRY,1,13,Canada|United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.9889840465642745,medium,1,1,1,0,1,1,1,1,1,0,0,0,1,0,6,1,1,0,0,1,0,2007-06-01,2012-06-01,1827.0,2007.0,0,2,0
NCT02183038,Efficacy and Safety of Meloxicam vs. Naproxen Sodium in Patients With Acute Non Bacterial Pharyngitis or Pharyngo-tonsillitis,Double-blind Study to Compare Efficacy and Safety of Meloxicam 7.5 mg and 15 mg vs. Naproxen Sodium 1100 mg in the Symptomatic Treatment of Acute Non Bacterial Pharyngitis or Pharyngo-tonsillitis Over a Period of 5 Days,COMPLETED,1998-07,,2014-07-08,INTERVENTIONAL,PHASE2,390.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Pharyngitis,Meloxicam low|Meloxicam high|Naproxen sodium|Meloxicam placebo low|Meloxicam placebo high|Naproxen sodium placebo,DRUG,2,17,18 Years,,ALL,False,Boehringer Ingelheim,INDUSTRY,0,0,,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.968707559985366,large,0,1,1,0,0,0,0,0,0,0,1,1,1,1,19,1,1,0,0,6,1,1998-07-01,,,1998.0,0,2,0
NCT00141258,Pregabalin Epilepsy Add-On Trial,"Pregabalin Add-On Titration Trial: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Pregabalin (150 mg - 600 mg/Day) Using a Flexible, Optimized Dose Schedule in Subjects With Partial Seizures",COMPLETED,2005-10,2006-08,2021-01-22,INTERVENTIONAL,PHASE3,178.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Partial Seizures,pregabalin,DRUG,1,1,18 Years,,ALL,False,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,INDUSTRY,0,5,South Korea,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.187385805840755,medium,0,1,1,0,1,0,1,0,0,0,1,1,1,1,2,1,1,0,0,1,0,2005-10-01,2006-08-01,304.0,2005.0,0,0,0
NCT02782858,Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MS,"An International, Double-blind, Randomised, Placebo-controlled Phase IIb Trial to Assess the Efficacy, Safety, and Pharmacokinetics of GNbAC1 in Patients With Relapsing Remitting Multiple Sclerosis",COMPLETED,2016-04,2017-12,2020-10-20,INTERVENTIONAL,PHASE2,270.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Multiple Sclerosis, Relapsing-Remitting",GNbAC1|Placebo,DRUG,1,0,18 Years,55 Years,ALL,False,GeNeuro SA,INDUSTRY,3,12,Italy|Bulgaria|Russia|Hungary|Spain|Croatia|Germany|Poland|Serbia|Estonia|Czechia|Ukraine,1.0,0,1,0,0,0,2.0,0,1,0,0,1,5.602118820879701,large,0,1,1,0,0,1,1,1,0,1,1,1,1,1,1,0,1,0,0,2,1,2016-04-01,2017-12-01,609.0,2016.0,1,2,0
NCT00643448,Explorative Study of AZD1305 in Atrial Fibrillation Patients,"A Randomised, Placebo-controlled, Double-blind, Parallel-group, Multicentre, Phase IIa Study to Explore the Relationship Between QTcF Interval at First Dose (Loading Dose) and at Steady State After Treatment With AZD1305 Extended-release Tablets or Placebo When Given to Patients With Documented AF",COMPLETED,2008-03,2008-08,2012-01-26,INTERVENTIONAL,PHASE2,65.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Atrial Fibrillation,AZD1305|AZD1305|Placebo,DRUG,1,3,20 Years,80 Years,ALL,False,AstraZeneca,INDUSTRY,0,18,Russia|Sweden|Slovakia|Norway|Poland|Denmark,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.189654742026425,medium,1,1,1,0,1,0,1,1,0,0,1,1,1,1,4,1,1,0,0,3,1,2008-03-01,2008-08-01,153.0,2008.0,0,2,0
NCT00053248,Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia,"A Phase I/II Study To Determine The Safety, Tolerability, And Anti-Leukemic Effects of Trisenox (Arsenic Trioxide) In Combination With Gleevec (STI571) In Patients With Resistant Chronic Myelogenous Leukemia In Chronic Phase",COMPLETED,2002-10,2005-06,2012-05-28,INTERVENTIONAL,PHASE1|PHASE2,16.0,ACTUAL,,,TREATMENT,NONE,Leukemia,arsenic trioxide|imatinib mesylate,DRUG,3,0,18 Years,,ALL,False,OHSU Knight Cancer Institute,OTHER,1,3,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,1,2.833213344056216,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,3,0,1,0,0,2,1,2002-10-01,2005-06-01,974.0,2002.0,0,2,0
NCT00382148,A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g,"A Phase IIb, Open-Label Study of Xolair (Omalizumab) in Peanut-Allergic Subjects Randomized to Study Drug in Study Q2788g (TOPS)",COMPLETED,2006-11,,2009-12-15,INTERVENTIONAL,PHASE2,10.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Peanut Hypersensitivity,omalizumab,DRUG,1,3,6 Years,75 Years,ALL,False,"Genentech, Inc.",INDUSTRY,0,0,,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.3978952727983707,small,1,1,1,0,0,0,0,0,0,0,0,0,1,0,4,1,1,0,0,1,0,2006-11-01,,,2006.0,0,0,0
NCT03149055,Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT),"A Single Center, Open-label Trial of Isavuconazole Prophylaxis Against Invasive Fungal Infection in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT)",COMPLETED,2017-05-04,2021-11-08,2025-05-16,INTERVENTIONAL,PHASE2,99.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Hematologic Malignancy|Myeloproliferative Disorder,Isavuconazole,DRUG,2,0,18 Years,,ALL,False,Memorial Sloan Kettering Cancer Center,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.605170185988092,medium,1,1,0,1,0,1,0,0,1,0,0,0,1,0,2,0,1,0,0,1,0,,,,,0,1,0
NCT00123526,Workplace-Sponsored Diet and Exercise Program to Reduce Obesity,Active Living and Healthy Diet at the Workplace,COMPLETED,2004-09,2008-06,2013-09-24,INTERVENTIONAL,PHASE3,899.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Obesity|Cardiovascular Diseases|Heart Diseases,Diet|Physical Activity,BEHAVIORAL,1,0,18 Years,65 Years,ALL,False,"University of Massachusetts, Worcester",OTHER,1,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,1,3,6.802394763324311,xlarge,0,1,0,1,0,1,0,0,1,0,1,0,0,1,1,0,0,0,0,2,1,2004-09-01,2008-06-01,1369.0,2004.0,0,2,0
NCT01331655,Clinical Study of a Conventional and Flexible Extended Oral Contraceptive of EE/DRSP With or Without Metafolin in Latin America,"A Multicenter, Open-label, 3-arm, Active-controlled, Parallel-group, 1-year Study to Investigate the Efficacy and Safety of a Flexible Regimen of the Combined Oral Contraceptive, With and Without 0.451 mg Levomefolate Calcium (BAY98-7071 and BAY86-5300, Respectively) Versus the Standard 24 + 4 Regimen With Levomefolate (BAY98-7071 + BAY86-7660) and to Assess Compliance With a Device (CADDY) in Healthy Women Who Desire Contraception",WITHDRAWN,2013-04,2014-11,2014-07-15,INTERVENTIONAL,PHASE3,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Contraception,EE20/DRSP (BAY86-5300)|EE20/DRSP/L-5-MTHF (BAY98-7071)|EE20/DRSP/L-5-MTHF (BAY98-7071) + L-5-MTHF (BAY86-7660),DRUG,1,3,18 Years,35 Years,FEMALE,True,Bayer,INDUSTRY,0,0,,0.0,0,0,1,0,0,3.0,0,0,0,0,1,0.0,,1,1,1,0,0,0,0,0,0,0,1,0,1,1,4,1,1,0,0,3,1,2013-04-01,2014-11-01,579.0,2013.0,0,1,0
NCT01393678,Study to Evaluate Efficacy and Safety of PENNEL Capsule in the Patients With Chronic Liver Disease,"A Multicenter, Randomized, Double-blind, 2 Parallel Group, Phase 3 Study of PENNEL Capsule in Chronic Liver Disease",COMPLETED,1997-11,1998-05,2011-07-13,INTERVENTIONAL,PHASE3,220.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Chronic Liver Disease,NISSEL|PENNEL,DRUG,1,5,20 Years,65 Years,ALL,False,PharmaKing,INDUSTRY,0,1,South Korea,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.3981627015177525,large,0,1,1,0,0,0,0,0,0,0,1,1,1,1,6,1,1,0,0,2,1,1997-11-01,1998-05-01,181.0,1997.0,0,2,0
NCT00361478,Effect of the 'Mother and Baby' Program on Well-Being,Effect of the 'Mother and Baby' Program on New Mothers' Psychological and Physical Well-Being.,COMPLETED,2005-07,2006-08,2008-08-13,INTERVENTIONAL,PHASE3,160.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,SINGLE,Postnatal Depression,Exercise and education|Education,BEHAVIORAL,1,2,18 Years,45 Years,FEMALE,True,University of Melbourne,OTHER,0,1,Australia,1.0,0,0,1,0,0,3.0,0,0,1,0,1,5.081404364984463,medium,0,1,0,1,0,0,0,0,0,0,1,0,0,1,3,1,0,0,0,2,1,2005-07-01,2006-08-01,396.0,2005.0,0,1,0
NCT01433978,"A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)","A Phase 3, Multicenter, Randomized, Double-blind, Active-controlled, Parallel-group Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Oral E5501 Versus Eltrombopag, in Adults With Chronic Immune Thrombocytopenia (Idiopathic Thrombocytopenic Purpura)",TERMINATED,2012-03-26,2013-09,2018-02-06,INTERVENTIONAL,PHASE3,24.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Idiopathic Thrombocytopenic Purpura,Eltrombopag|Avatrombopag|Standard of care,DRUG,1,0,18 Years,99 Years,ALL,False,Eisai Inc.,INDUSTRY,0,1,United States,0.0,0,0,1,0,0,3.0,0,0,0,0,1,3.2188758248682006,small,1,1,1,0,0,0,0,0,1,0,1,1,1,1,1,0,1,0,0,3,1,,2013-09-01,,,0,1,0
NCT00320385,Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer,"A Randomized, Multicenter, Open-Label, Phase III Study of Lapatinib in Combination With Trastuzumab Versus Lapatinib Monotherapy in Subjects With HER2-positive Metastatic Breast Cancer Whose Disease Has Progressed on Trastuzumab-Containing Regimens",COMPLETED,2005-11,2010-10,2016-02-26,INTERVENTIONAL,PHASE3,296.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Neoplasms, Breast",Lapatinib|Trastuzumab,DRUG|BIOLOGICAL,1,7,18 Years,,FEMALE,False,GlaxoSmithKline,INDUSTRY,0,145,Italy|Bulgaria|Finland|United States|Croatia|Austria|Germany|Spain|United Kingdom|Poland|Czechia|Greece|Canada,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.6937321388027,large,0,1,1,0,0,0,1,1,1,1,1,0,1,1,8,1,1,1,0,2,1,2005-11-01,2010-10-01,1795.0,2005.0,0,3,1
NCT03029585,Phase II Study of Intraperitoneal NanoPac® in Patients With Ovarian Cancer,Phase II Study of Four Dose Levels of Intraperitoneal NanoPac® Plus IV Carboplatin and Paclitaxel in Patients With Epithelial Ovarian Cancer Undergoing Cytoreductive Surgery,TERMINATED,2017-04-19,2019-11-04,2021-04-27,INTERVENTIONAL,PHASE2,10.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Ovarian Carcinoma,NanoPac® 100 mg/m2|NanoPac® 200 mg/m2|NanoPac® 300 mg/m2|NanoPac® 400 mg/m2|Standard of Care Intravenous Chemotherapy,DRUG,1,2,18 Years,,FEMALE,False,"NanOlogy, LLC",INDUSTRY,1,7,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,2.3978952727983707,small,1,1,1,0,0,1,1,0,1,0,1,0,1,1,3,1,1,0,0,5,1,,,,,0,1,0
NCT03345407,Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD),"A Phase IIb, Randomized (Stratified), Double-Blind (Sponsor Open), Parallel-Group, Placebo-Controlled, Dose-Finding Study of Nemiralisib (GSK2269557) Added to Standard of Care (SoC) Versus SoC Alone in Participants Diagnosed With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",TERMINATED,2017-11-28,2019-01-10,2021-07-14,INTERVENTIONAL,PHASE2,943.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Pulmonary Disease, Chronic Obstructive",Placebo ELLIPTA|Nemiralisib ELLIPTA 50 µg|Nemiralisib ELLIPTA 100 µg|Nemiralisib ELLIPTA 250 µg|Nemiralisib ELLIPTA 500 µg|Nemiralisib ELLIPTA 750 µg|Albuterol (Salbutamol) MDI or nebules|Standard of care therapy,DRUG,1,20,40 Years,80 Years,ALL,False,GlaxoSmithKline,INDUSTRY,0,161,Italy|Netherlands|Argentina|Russia|Sweden|South Korea|United States|Germany|Spain|Australia|Romania|United Kingdom|Poland|Mexico|France|Canada,0.0,0,1,0,0,0,2.0,0,0,0,0,1,6.8501261661455,xlarge,0,1,1,0,0,0,1,1,1,1,1,1,1,1,21,1,1,0,0,8,1,,,,,0,3,1
NCT03023111,Miltefosine and GM-CSF in Cutaneous Leishmaniasis,Miltefosine and GM-CSF in Cutaneous Leishmaniasis: a Randomized and Controlled Trial,COMPLETED,2017-06-30,2020-02-14,2020-04-07,INTERVENTIONAL,PHASE3,300.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Cutaneous Leishmaniasis,Sbv|Miltefosine plus placebo|Miltefosine plus GM-CSF,DRUG,1,3,18 Years,65 Years,ALL,False,Hospital Universitário Professor Edgard Santos,OTHER,1,2,Brazil,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.707110264748875,large,0,1,0,1,0,1,1,0,0,0,1,1,1,1,4,1,1,0,0,3,1,,,,,0,1,0
NCT00232011,Extension Study to Assess Safety and Efficacy of Pimecrolimus in Adult Patients With Atopic Dermatitis,A Clinical Study Continued From the Confirmatory Study to Assess the Efficacy and Safety of ASM981 Cream in Adult Atopic Dermatitis Patients,COMPLETED,2004-05,2005-05,2007-12-17,INTERVENTIONAL,PHASE3,160.0,,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Atopic Dermatitis,Pimecrolimus Cream 1%,DRUG,1,1,16 Years,65 Years,ALL,,Novartis,INDUSTRY,0,1,Japan,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.081404364984463,medium,0,0,1,0,1,0,0,0,0,0,0,0,1,0,2,1,1,0,0,1,0,2004-05-01,2005-05-01,365.0,2004.0,0,0,0
NCT01422811,"Unnecessary, Avoidable Lengths of Stay: a Strategy for Clinician Empowerment and Effectiveness Evaluation","Unnecessary, Avoidable Lengths of Stay: a Strategy for Clinician Empowerment and Effectiveness Evaluation",COMPLETED,2008-02,2010-02,2018-07-03,INTERVENTIONAL,PHASE3,3862.0,ACTUAL,RANDOMIZED,PARALLEL,HEALTH_SERVICES_RESEARCH,DOUBLE,Hospitalization|Length of Stay,Multicomponent strategy to reduce avoidable length of stay|No intervention,BEHAVIORAL|OTHER,1,1,,,ALL,False,Azienda Ospedaliero-Universitaria di Parma,OTHER,1,1,Italy,1.0,0,0,1,0,0,3.0,0,0,0,0,2,8.259199362666282,xlarge,0,1,0,1,0,1,0,0,0,1,1,1,0,1,2,1,0,0,0,2,1,2008-02-01,2010-02-01,731.0,2008.0,0,2,0
NCT03608371,BTRX-246040 Study in Participants With Parkinson's Disease With Motor Fluctuations,"Phase 2A, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BTRX-246040 in Parkinson's Disease Subjects With Motor Fluctuations",COMPLETED,2018-08-31,2019-04-23,2025-06-24,INTERVENTIONAL,PHASE2,24.0,ACTUAL,RANDOMIZED,SEQUENTIAL,TREATMENT,QUADRUPLE,Parkinson Disease|Motor Disorder,BTRX-246040|Placebo,DRUG,1,5,30 Years,76 Years,ALL,False,"BlackThorn Therapeutics, Inc.",INDUSTRY,0,4,United States,1.0,0,1,0,0,0,2.0,0,0,1,0,2,3.2188758248682006,small,1,1,1,0,0,0,1,0,1,0,1,1,1,0,6,1,1,0,0,2,1,,,,,0,3,1
NCT02719171,BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis,"A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumab in Patients With Active Psoriatic Arthritis",COMPLETED,2016-04,2017-08,2019-05-30,INTERVENTIONAL,PHASE2,185.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Arthritis, Psoriatic",risankizumab|placebo for risankizumab,DRUG,1,11,18 Years,,ALL,False,AbbVie,INDUSTRY,1,0,,1.0,0,1,0,0,0,2.0,0,1,0,0,1,5.225746673713202,medium,0,1,1,0,1,1,0,0,0,0,1,1,1,1,12,1,1,0,0,2,1,2016-04-01,2017-08-01,487.0,2016.0,1,2,0
NCT03633344,Efficacy of the Administration of Colloidal Silicon Dioxide in Tablet Dosage Form in Patients With Acute Diarrhea,Efficacy of the Administration of Colloidal Silicon Dioxide in Tablet Dosage Form (Carbowhite) in Patients With Acute Diarrhea.,COMPLETED,2016-03-29,2016-10-07,2019-06-06,INTERVENTIONAL,PHASE2,145.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Diarrhoea;Acute,Carbowhite|Carbowhite placebo,DRUG,1,3,18 Years,55 Years,ALL,False,Omnifarma Kiev LLC,INDUSTRY,0,0,,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.983606621708336,medium,0,1,1,0,0,0,0,0,0,0,1,1,1,1,4,1,1,0,0,2,1,,,,,0,1,0
NCT00113334,Study of ABT-510 (Thrombospondin Analogue) in Patients With Advanced Head and Neck Cancer,A Phase 1b/2 Study of ABT-510 (Thrombospondin Analogue) in Patients With Advanced Head and Neck Cancer,COMPLETED,2005-04,2008-03,2014-08-07,INTERVENTIONAL,PHASE1|PHASE2,6.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Head and Neck Cancer,ABT-510,DRUG,1,0,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,1,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,1,1.9459101490553132,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,2005-04-01,2008-03-01,1065.0,2005.0,0,1,0
NCT02947334,Efficacy And Safety Of Bococizumab For Lipid Lowering In Asian Hypercholesterolemia Subjects,"A Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Bococizumab (Pf-04950615) In Asian Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events",WITHDRAWN,2016-10-31,2019-05-03,2017-12-02,INTERVENTIONAL,PHASE3,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Primary Hyperlipidemia or Mixed Dyslipidemia,Bococizumab|Placebo,DRUG|BIOLOGICAL,1,0,18 Years,,ALL,False,Pfizer,INDUSTRY,0,1,China,0.0,0,0,1,0,0,3.0,0,0,0,0,1,0.0,,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,0,1,1,0,2,1,,,,,0,1,0
NCT03547999,A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC,A Phase II Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Resectable Hepatic-Limited Metastatic Colorectal Cancer HCRN: GI16-288,TERMINATED,2018-06-26,2024-03-13,2025-07-22,INTERVENTIONAL,PHASE2,17.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Metastatic Colorectal Cancer,mFOLFOX6|MVA-BN-CV301|FPV-CV301|Nivolumab,DRUG|BIOLOGICAL,1,6,18 Years,,ALL,False,Patrick Boland,OTHER,3,7,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,2.8903717578961645,small,1,1,0,1,0,1,1,0,1,0,1,0,1,1,7,1,1,1,0,4,1,,,,,0,2,0
NCT02603432,A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100),"A PHASE 3, MULTICENTER, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB (MSB0010718C) PLUS BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE ALONE AS A MAINTENANCE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER WHOSE DISEASE DID NOT PROGRESS AFTER COMPLETION OF FIRST-LINE PLATINUM-CONTAINING CHEMOTHERAPY",COMPLETED,2016-04-25,2023-03-28,2024-03-27,INTERVENTIONAL,PHASE3,700.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Urothelial Cancer,Avelumab|Best Supportive Care|Following the planned interim analysis for this study: Avelumab,BIOLOGICAL|OTHER,1,25,18 Years,,ALL,False,Pfizer,INDUSTRY,0,382,Norway|Japan|Serbia|Taiwan|Greece|Italy|Netherlands|South Korea|Spain|Czechia|Portugal|Canada|Russia|Argentina|Sweden|India|United States|United Kingdom|Australia|Poland|Mexico|New Zealand|Denmark|Israel|France|Belgium|Hungary|Brazil|Hong Kong,1.0,0,0,1,0,0,3.0,1,0,0,0,1,6.55250788703459,xlarge,0,1,1,0,1,0,1,1,1,1,1,0,1,1,26,1,0,1,0,3,1,,,,,0,3,1
NCT01431963,Clinical Study of Lamotrigine to Treat Newly Diagnosed Epilepsy,"A Multi-center, Uncontrolled, Open-label, Evaluation of Lamotrigine Monotherapy in Newly Diagnosed Epilepsy or Recurrent Epilepsy (Currently Untreated)",COMPLETED,2011-09,2014-10,2016-10-20,INTERVENTIONAL,PHASE3,70.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Epilepsy,Lamictal,DRUG,1,2,16 Years,,ALL,False,GlaxoSmithKline,INDUSTRY,0,13,Japan|South Korea,1.0,0,0,1,0,0,3.0,0,0,1,0,1,4.2626798770413155,medium,1,1,1,0,0,0,1,1,0,0,0,0,1,0,3,1,1,0,0,1,0,2011-09-01,2014-10-01,1126.0,2011.0,0,1,0
NCT00733863,Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Mild Alzheimer's Patients.,"A 52-week,Multi-center,Randomized,Double-blind,Placebo-controlled,Parallel Group Study in Patients With Mild Alzheimer's Disease to Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106",COMPLETED,2008-07,,2020-02-11,INTERVENTIONAL,PHASE2,27.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Alzheimer Disease,Placebo|CAD106,BIOLOGICAL,1,1,40 Years,85 Years,ALL,False,Novartis,INDUSTRY,0,4,United Kingdom|Sweden|France|Switzerland,1.0,0,1,0,0,0,2.0,0,0,1,0,1,3.332204510175204,small,1,1,1,0,1,0,1,1,0,1,1,1,1,1,2,1,0,1,0,2,1,2008-07-01,,,2008.0,0,2,0
NCT05673993,A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome,"A Phase Ⅲ, Multi-center, Randomized, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Subcutaneous Telitacicept in Subjects With Active Primary Sjogren's Syndrome",COMPLETED,2023-04-06,2025-05-06,2025-10-01,INTERVENTIONAL,PHASE3,381.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Primary Sjogren's Syndrome,Telitacicept 80 mg|Telitacicept 160 mg|Placebo,DRUG|BIOLOGICAL,1,6,18 Years,70 Years,ALL,False,"RemeGen Co., Ltd.",INDUSTRY,0,78,China,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.945420608606575,large,0,1,1,0,0,0,1,0,0,0,1,1,1,1,7,1,1,1,0,3,1,,,,,0,2,0
NCT03096093,Investigation of a Therapeutic Vaccine (ACIT-1) in Cancer,A Phase I Clinical Study to Determine the Optimal Dose for the Safe Immune Restoration and Immune Response of Allogeneic Cell Immunotherapy (ACIT-1) in Adult Cancer Patients,ACTIVE_NOT_RECRUITING,2017-04-25,2027-07,2026-01-20,INTERVENTIONAL,PHASE1|PHASE2,34.0,ESTIMATED,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Cancer|Neoplasms,ACIT-1,BIOLOGICAL,1,1,18 Years,,ALL,False,Cancer Vaccines Limited,INDUSTRY,6,2,United Kingdom,,1,1,0,0,1,1.5,1,0,0,0,2,3.5553480614894135,small,1,0,1,0,0,1,1,0,0,1,0,0,1,1,2,1,0,1,0,1,0,,2027-07-01,,,0,2,0
NCT02254421,Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract,"A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT) Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract",COMPLETED,2015-01-31,2017-04-17,2018-09-24,INTERVENTIONAL,PHASE2,60.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Respiratory Syncytial Virus Infection,Presatovir|Placebo,DRUG,1,3,18 Years,75 Years,ALL,False,Gilead Sciences,INDUSTRY,0,17,Sweden|South Korea|United States|Switzerland|France,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.110873864173311,medium,1,1,1,0,1,0,1,1,1,1,1,1,1,1,4,1,1,0,0,2,1,,,,,0,2,0
NCT04086121,A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032,An Open Label Extension Study to Assess the Long Term Safety of Treatment With BI 655130 Administered Subcutaneously in Adult Patients With Moderate to Severe Atopic Dermatitis,TERMINATED,2019-09-24,2022-02-23,2025-02-24,INTERVENTIONAL,PHASE2,14.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Dermatitis, Atopic",Spesolimab,DRUG,1,5,18 Years,75 Years,ALL,False,Boehringer Ingelheim,INDUSTRY,0,10,Canada|Japan|United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,2.70805020110221,small,1,1,1,0,0,0,1,1,1,0,0,0,1,0,6,1,1,0,0,1,0,,,,,0,2,0
NCT00791921,Efficacy Confirmation Trial of CDP870 Without Coadministration of Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA),"A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Trial to Assess the Efficacy, Pharmacokinetics, and Safety of CDP870 Without Coadministration of MTX in Japanese Active RA Patients in Whom MTX Cannot be Administrated.",COMPLETED,2008-11,2010-01,2012-08-07,INTERVENTIONAL,PHASE3,230.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Rheumatoid Arthritis,CDP870|Placebo of CDP870,DRUG,1,1,20 Years,74 Years,ALL,False,"Otsuka Pharmaceutical Co., Ltd.",INDUSTRY,1,7,Japan,1.0,0,0,1,0,0,3.0,0,1,0,0,1,5.442417710521793,large,0,1,1,0,0,1,1,0,0,0,1,1,1,1,2,1,1,0,0,2,1,2008-11-01,2010-01-01,426.0,2008.0,0,1,0
NCT01371721,"A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD","A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder",COMPLETED,2012-02,2015-10,2017-02-08,INTERVENTIONAL,PHASE3,269.0,ACTUAL,,,TREATMENT,NONE,Major Depressive Disorder,DVS SR,DRUG,1,5,7 Years,17 Years,ALL,False,Pfizer,INDUSTRY,0,35,Mexico|United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.598421958998375,large,0,1,1,0,1,0,1,1,1,0,0,0,1,0,6,1,1,0,0,1,0,2012-02-01,2015-10-01,1338.0,2012.0,0,2,0
NCT05054621,Immunogenicity of COVID-19 Vaccine on Heterologous Schedule,"A Single-blind, Randomized Study to Evaluate the Immunogenicity of Heterologous Prime-boost COVID-19 Vaccine Schedule",COMPLETED,2021-09-15,2022-08-31,2024-08-22,INTERVENTIONAL,PHASE2,100.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,SINGLE,Covid-19|Vaccine|Immunogenicity|Reactogenicity|Healthy,Heterologous prime-boost schedule with AZD1222 and MVC-COV1901|Homologous prime-boost schedule with two doses of AZD1222,BIOLOGICAL,1,4,20 Years,70 Years,ALL,True,Chang Gung Memorial Hospital,OTHER,0,1,Taiwan,1.0,0,1,0,0,0,2.0,0,0,0,0,5,4.61512051684126,medium,0,1,0,1,0,0,0,0,0,0,1,0,0,1,5,1,0,1,0,2,1,,,,,0,2,0
NCT03671616,Immunogenicity and Safety of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given as a Booster at Age 15-18 Months,"Immunogenicity and Safety of Adjuvanted Reduced Dose Inactivated Polio Vaccine, IPV-Al SSI Given as a Booster Vaccination at the Age of 15-18 Months to Infants Previously Immunised With IPV-Al SSI or IPV SSI",COMPLETED,2018-05-15,2018-10-03,2018-11-14,INTERVENTIONAL,PHASE3,666.0,ACTUAL,,SINGLE_GROUP,OTHER,NONE,Poliomyelitis,IPV-Al SSI,BIOLOGICAL,1,6,15 Months,18 Months,ALL,True,Statens Serum Institut,OTHER,4,1,Panama,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.502790045915623,xlarge,0,1,0,1,0,1,0,0,0,0,0,0,0,0,7,1,0,1,0,1,0,,,,,0,1,0
NCT04562116,A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis,An Open-label Drug-Drug Interaction Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Subjects With Moderate-to-Severe Atopic Dermatitis,COMPLETED,2021-12-08,2023-06-07,2024-12-05,INTERVENTIONAL,PHASE2,17.0,ACTUAL,,SINGLE_GROUP,BASIC_SCIENCE,NONE,Atopic Dermatitis,Nemolizumab|CYP 450 Substrates,DRUG,3,1,18 Years,,ALL,False,Galderma R&D,INDUSTRY,0,6,Bulgaria|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.8903717578961645,small,1,1,1,0,0,0,1,1,1,0,0,0,0,0,4,1,1,0,0,2,1,,,,,0,2,0
NCT00378716,Combination Chemotherapy in Treating Patients With Resected Colon Cancer,A Clinical Trial Comparing Oral Uracil/Ftorafur (UFT) Plus Leucovorin (LV) With 5-Fluorouracil (5-FU) Plus LV in the Treatment of Patients With Stages II And III Carcinoma of the Colon,COMPLETED,1997-02,2009-04,2010-01-11,INTERVENTIONAL,PHASE3,1608.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Colorectal Cancer,5-fluorouracil|leucovorin calcium|tegafur|uracil,DRUG,1,3,,,ALL,False,NSABP Foundation Inc,NETWORK,1,0,,1.0,0,0,1,0,0,3.0,1,0,0,0,1,7.3833681469923835,xlarge,0,1,0,0,0,1,0,0,0,0,1,0,1,1,4,1,1,0,0,4,1,1997-02-01,2009-04-01,4442.0,1997.0,0,1,0
NCT03815916,31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Parkinson's Disease,"A Phase 2, Pilot Open Label, Sequential Group, Investigator Blinded Study of Magnetic Resonance Spectroscopy (31P-MRS) to Assess the Effects of CNM-Au8 for the Bioenergetic Improvement of Impaired Neuronal Redox State in Parkinson's Disease",COMPLETED,2019-12-19,2021-06-07,2024-05-16,INTERVENTIONAL,PHASE2,13.0,ACTUAL,NON_RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,Parkinson's Disease,Gold Nanocrystals,DRUG,1,0,30 Years,80 Years,ALL,False,Clene Nanomedicine,INDUSTRY,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,1,0,1,2.6390573296152584,small,1,1,1,0,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,,,,,0,0,0
NCT01065506,Smoking Termination Enhancement Project (STEP),Smoking Termination Enhancement Project (STEP),COMPLETED,2009-09,2013-08,2016-02-04,INTERVENTIONAL,PHASE3,150.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Smoking,Cognitive Behavioral Treatment|Nicotine Patch|Wellness Program|Aerobic Exercise,BEHAVIORAL|DRUG,1,0,18 Years,65 Years,ALL,True,Southern Methodist University,OTHER,1,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.017279836814924,medium,0,1,0,1,0,1,0,0,1,0,1,0,1,1,1,0,1,0,0,4,1,2009-09-01,2013-08-01,1430.0,2009.0,0,1,0
NCT04098406,Therapeutic Nanocatalysis to Slow Disease Progression of Amyotrophic Lateral Sclerosis (ALS),"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS.",COMPLETED,2019-12-19,2021-07-13,2024-07-03,INTERVENTIONAL,PHASE2,45.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Amyotrophic Lateral Sclerosis,CNM-Au8|Placebo,DRUG,1,2,30 Years,80 Years,ALL,False,Clene Nanomedicine,INDUSTRY,1,2,Australia,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.828641396489095,small,1,1,1,0,0,1,1,0,0,0,1,1,1,1,3,1,1,0,0,2,1,,,,,0,1,0
NCT04996004,A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma,A Phase I/II Study of TTI-621 in Combination With Doxorubicin in Patients With Unresectable or Metastatic High-Grade Leiomyosarcoma,TERMINATED,2021-06-22,2023-12-07,2024-12-11,INTERVENTIONAL,PHASE2,76.0,ACTUAL,NON_RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,Leiomyosarcoma,Ontorpacept (TTI-621)|Doxorubicin,DRUG,20,17,18 Years,,ALL,False,Pfizer,INDUSTRY,0,23,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,4.343805421853684,medium,1,1,1,0,1,0,1,0,1,0,0,0,1,0,37,1,1,0,0,2,1,,,,,0,2,0
NCT01194804,E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients,Phase II Clinical Study of Eculizumab (h5G1.1-mAb) in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients: Extension Study to C07-001 Protocol,COMPLETED,2008-04,2011-03,2019-09-17,INTERVENTIONAL,PHASE2,27.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Paroxysmal Nocturnal Hemoglobinuria,Eculizumab,DRUG,1,4,12 Years,,ALL,False,"Alexion Pharmaceuticals, Inc.",INDUSTRY,1,0,,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.332204510175204,small,1,1,1,0,0,1,0,0,0,0,0,0,1,0,5,1,1,0,0,1,0,2008-04-01,2011-03-01,1064.0,2008.0,0,0,0
NCT03610633,Oxytocin and Stress Response in Alcohol Use Disorder,Impact of Oxytocin on Neurobiologic Substrates of Social Stress in Individuals With Alcohol Use Disorder,COMPLETED,2016-03,2018-09,2019-10-23,INTERVENTIONAL,PHASE2,11.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Alcohol Use Disorder,Oxytocin|Placebo,DRUG,1,0,21 Years,40 Years,ALL,False,Medical University of South Carolina,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.4849066497880004,small,1,1,0,1,0,0,0,0,1,0,1,1,1,1,1,0,1,0,0,2,1,2016-03-01,2018-09-01,914.0,2016.0,1,1,0
NCT01398033,Paclitaxel-Coated Versus Uncoated Balloon for Treatment of Below-the-Knee In-Stent-Restenosis,Paclitaxel-Coated Versus Uncoated Balloon for Treatment of Below-the-Knee In-Stent-Restenosis,WITHDRAWN,2012-04,2014-09,2015-08-05,INTERVENTIONAL,PHASE3,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,In-stent Stenosis of Infrapopliteal Arteries,paclitaxel-coated balloon|non-coated balloon,DEVICE,1,1,50 Years,90 Years,ALL,False,Herz-Zentrums Bad Krozingen,OTHER,1,1,Germany,0.0,0,0,1,0,0,3.0,0,0,0,0,1,0.0,,1,1,0,1,0,1,0,0,0,1,1,1,1,1,2,1,0,0,1,2,1,2012-04-01,2014-09-01,883.0,2012.0,0,1,0
NCT00523133,Research on Individualized Treatment for Alcoholism,Posttreatment Effects of Naltrexone,COMPLETED,2000-09,2005-07,2007-08-31,INTERVENTIONAL,PHASE2,185.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Alcohol Dependence,naltrexone|naltrexone|Broad Spectrum Treatment|Motivational Enhancement Treatment,BEHAVIORAL|DRUG,1,1,21 Years,65 Years,ALL,False,Indiana University School of Medicine,OTHER,3,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.225746673713202,medium,0,1,0,1,0,1,0,0,1,0,1,1,1,0,2,1,1,0,0,4,1,2000-09-01,2005-07-01,1764.0,2000.0,0,1,0
NCT01655433,Evaluation of Ultrafast Hypothermia Before Reperfusion in STEMI Patients,VELOCITY: Pilot Study to Evaluate Ultrafast Hypothermia Before Reperfusion in Patients With Acute ST-Elevation Myocardial Infarction,TERMINATED,2012-11,2014-03,2014-07-25,INTERVENTIONAL,PHASE2,54.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,ST-elevation MI|Hypothermia,Velomedix APLS device|No Hypothermia Treatment,DEVICE|OTHER,1,3,18 Years,85 Years,ALL,False,"Velomedix, Inc.",INDUSTRY,0,7,Canada|United States,0.0,0,1,0,0,0,2.0,0,0,0,0,2,4.007333185232471,medium,1,1,1,0,0,0,1,1,1,0,1,0,1,1,4,1,0,0,1,2,1,2012-11-01,2014-03-01,485.0,2012.0,0,3,1
NCT05822752,"Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)","A Phase 2, Randomized Study to Evaluate the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab for Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Patients Who Have Progressed After an Immune Checkpoint Inhibitor Containing Regimen in First-Line HCC",ACTIVE_NOT_RECRUITING,2023-09-21,2026-11,2025-08-14,INTERVENTIONAL,PHASE2,130.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Hepatocellular Carcinoma,Budigalimab|Livmoniplimab|Lenvatinib|Sorafenib,DRUG,1,3,18 Years,,ALL,False,AbbVie,INDUSTRY,0,59,Italy|South Korea|United States|Spain|Japan|Taiwan|France,,0,1,0,0,0,2.0,1,0,0,0,1,4.875197323201151,medium,0,1,1,0,1,0,1,1,1,1,1,0,1,1,4,1,1,0,0,4,1,,2026-11-01,,,0,2,0
NCT01787552,A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF,"A Phase Ib/II, Open-label, Multi-center, Dose-finding Study to Assess the Safety and Efficacy of the Oral Combination of LDE225 and INC424 (Ruxolitinib) in Patients With Myelofibrosis",COMPLETED,2013-05-08,2018-04-10,2020-04-15,INTERVENTIONAL,PHASE1|PHASE2,50.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Primary Myelofibrosis|Thrombocytosis|Essential Thrombocythemia|Polycythemia Vera|Myeloproliferative Disorders|Bone Marrow Diseases|Hematologic Diseases|Blood Coagulation Disorders|Blood Platelet Disorders|Hemorrhagic Disorders,LDE225|INC424,DRUG,2,14,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,18,Italy|Belgium|Netherlands|Spain|Germany|United Kingdom|Australia|Denmark|France|Ireland|Canada,1.0,1,1,0,0,1,1.5,0,0,0,0,10,3.9318256327243257,small,1,1,1,0,1,0,1,1,0,1,0,0,1,0,16,1,1,0,0,2,1,,,,,0,5,1
NCT05048849,"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of COVID-19 Vaccine, CT-COV-21 Extension Study","A Phase II, Prospective, Open-Label, Multi-Center Study to Evaluate the Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidate MVC-COV1901, CT-COV-21 Extension Study",COMPLETED,2021-07-19,2022-04-12,2022-08-24,INTERVENTIONAL,PHASE2,274.0,ACTUAL,,SINGLE_GROUP,PREVENTION,NONE,Covid19 Vaccine,MVC-COV1901(S protein with adjuvant),BIOLOGICAL,3,3,20 Years,,ALL,True,Medigen Vaccine Biologics Corp.,INDUSTRY,0,11,Taiwan,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.616771097666572,large,0,1,1,0,0,0,1,0,0,0,0,0,0,0,6,1,0,1,0,1,0,,,,,0,1,0
NCT00074438,Study to Assess the Efficacy and Safety of Rituximab in Patients With Rheumatoid Arthritis,"Randomized, Multifactorial, Double-blind, Parallel-group, Dose-ranging Study of the Efficacy and Safety of Rituximab (MabThera®/Rituxan®) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis",COMPLETED,2003-06,2011-07,2013-05-09,INTERVENTIONAL,PHASE2,465.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Rheumatoid Arthritis,methotrexate|rituximab|corticosteroids|placebo,DRUG,1,2,18 Years,80 Years,ALL,False,"Genentech, Inc.",INDUSTRY,1,0,,1.0,0,1,0,0,0,2.0,0,1,0,0,1,6.144185634125646,large,0,1,1,0,0,1,0,0,0,0,1,1,1,1,3,1,1,0,0,4,1,2003-06-01,2011-07-01,2952.0,2003.0,0,1,0
NCT03756038,Benzodiazepines for the Reduction of Distress and Pain During and After Emergency Department Care,"Single Dose Administration of Benzodiazepines to Reduce Distress, Pain Severity, and the Need for Opiates Both During and After Emergency Department Care",TERMINATED,2019-01-25,2019-03-27,2020-03-09,INTERVENTIONAL,PHASE2,1.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Acute Pain,Placebos|Lorazepam,DRUG,1,1,18 Years,65 Years,ALL,False,Maria Pacella,OTHER,2,2,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,0.6931471805599453,small,1,1,0,1,0,1,1,0,1,0,1,1,1,1,2,1,1,0,0,2,1,,,,,0,1,0
NCT00931749,Effects of Ultrasound Therapy on Cartilage Healing in Patients With Knee Osteoarthritis,"The Effects of Low Intensity Ultrasound on Medial Tibial Cartilage Morphology in Patients With Mild or Moderate Knee Osteoarthritis: A Double Blind, Randomized Placebo-controlled Study.",COMPLETED,2009-09,2010-06,2010-06-09,INTERVENTIONAL,PHASE2,27.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Knee Osteoarthritis,Low intensity pulsed ultrasound therapy|Sham Low intensity pulsed ultrasound therapy,DEVICE,1,6,45 Years,,ALL,False,McMaster University,OTHER,0,1,Canada,1.0,0,1,0,0,0,2.0,0,1,0,0,1,3.332204510175204,small,1,1,0,1,0,0,0,0,0,0,1,1,1,1,7,1,0,0,1,2,1,2009-09-01,2010-06-01,273.0,2009.0,0,2,0
NCT00098748,"Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects","A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced, Non CCR5-Tropic HIV-1 Infected Subjects",COMPLETED,2004-11,2009-04,2010-12-07,INTERVENTIONAL,PHASE2|PHASE3,190.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,HIV Infections,"Optimized Background Therapy (OBT)|maraviroc (UK-427,857)|Optimized Background Therapy (OBT)|maraviroc (UK-427,857)|Optimized Background Therapy (OBT)",DRUG,1,15,16 Years,,ALL,False,ViiV Healthcare,INDUSTRY,1,77,Netherlands|Belgium|United States|Germany|Spain|Australia|United Kingdom|Switzerland|Canada,1.0,0,1,1,0,1,2.5,0,0,0,0,1,5.25227342804663,medium,0,1,1,0,0,1,1,1,1,1,1,1,1,1,16,1,1,0,0,5,1,2004-11-01,2009-04-01,1612.0,2004.0,0,4,1
NCT01284348,To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer,"An Open-Label Randomized, Phase 2A, Dose-Ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens",TERMINATED,2011-03-25,2012-09-21,2024-08-29,INTERVENTIONAL,PHASE2,26.0,ACTUAL,RANDOMIZED,PARALLEL,SUPPORTIVE_CARE,TRIPLE,"Anemia|Carcinoma, Non-Small-Cell Lung|Carcinoma, Small-Cell Lung|Bladder Cancer|Cancer of Head and Neck|Uterine Cervical Cancer",Sotatercept 15 mg|Sotatercept 30 mg,DRUG,1,13,18 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,0,,0.0,0,1,0,0,0,2.0,1,0,0,0,6,3.295836866004329,small,1,1,1,0,1,0,0,0,0,0,1,1,0,1,14,1,1,0,0,2,1,,,,,0,3,1
NCT00918255,Study of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa,A Phase 2 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa,COMPLETED,2009-04,2010-11,2011-05-09,INTERVENTIONAL,PHASE2,154.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Hidradenitis Suppurativa,adalimumab|Placebo,DRUG|BIOLOGICAL,1,8,18 Years,,ALL,False,Abbott,INDUSTRY,0,26,Germany|Denmark|Netherlands|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.043425116919247,medium,0,1,1,0,0,0,1,1,1,1,1,1,1,1,9,1,1,1,0,2,1,2009-04-01,2010-11-01,579.0,2009.0,0,3,1
NCT03136055,Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas,A Pilot Study of Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas,COMPLETED,2017-06-20,2021-10-31,2022-12-27,INTERVENTIONAL,PHASE2,36.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,High Grade Malignant Neuroendocrine Carcinoma (Diagnosis),Pembrolizumab|Irinotecan|Paclitaxel,DRUG,1,3,18 Years,,ALL,False,"University of California, San Francisco",OTHER,1,3,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.6109179126442243,small,1,1,0,1,0,1,1,0,1,0,0,0,1,1,4,1,1,0,0,3,1,,,,,0,1,0
NCT00709826,APRiCOT-P: Study of Apricoxib With Gemcitabine and Erlotinib to Treat Advanced Pancreatic Cancer,APRiCOT-P (Apricoxib in Combination Oncology Treatment - Pancreas): Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Gemcitabine and Erlotinib in the Treatment of Patients With Advanced Pancreatic Cancer,COMPLETED,2008-08,2011-05,2012-11-07,INTERVENTIONAL,PHASE2,109.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Pancreatic Cancer|Metastatic Pancreatic Cancer,gemcitabine|placebo|Erlotinib|apricoxib,DRUG,1,1,18 Years,,ALL,False,"Tragara Pharmaceuticals, Inc.",INDUSTRY,0,39,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,2,4.700480365792417,medium,0,1,1,0,0,0,1,0,1,0,1,1,1,1,2,1,1,0,0,4,1,2008-08-01,2011-05-01,1003.0,2008.0,0,2,0
NCT04955626,"To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age.",A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSE(S) OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2,COMPLETED,2021-07-01,2023-05-25,2025-11-10,INTERVENTIONAL,PHASE3,16372.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,SARS-CoV-2 Infection|COVID-19,BNT162b2|Placebo|BNT162b2 OMI|Combination BNT162b2 and BNT162b2 OMI|Combination (Bivalent) BNT162b2 and BNT162b2 OMI,BIOLOGICAL|OTHER,100,11,12 Years,,ALL,True,BioNTech SE,INDUSTRY,1,154,United States|Germany|Brazil|Israel|South Africa,1.0,0,0,1,0,0,3.0,0,0,0,0,2,9.703388915639492,,0,1,1,0,0,1,1,1,1,1,1,1,0,1,111,1,0,1,0,5,1,,,,,0,4,1
NCT00819585,A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study),"A 24-week, Dose-ranging, Multicenter, Double-blind, Double-dummy, Active-controlled Core Study to Evaluate Canakinumab for Prophylaxis of Signs and Symptoms of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy and a 24-week Open-label, Multicenter Extension Study to Assess Safety, Tolerability and Efficacy of Canakinumab in Patients With Gout Who Are Given Canakinumab at the Time of Gout Flare",COMPLETED,2008-12,2010-08,2018-07-17,INTERVENTIONAL,PHASE2,432.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Gout,Canakinumab|Colchicine|Allopurinol|Placebo Matching Canakinumab|Placebo Matching Colchicine,DRUG,1,11,18 Years,80 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,89,Belgium|Argentina|Russia|Guatemala|Hungary|South Africa|United States|Germany|Slovakia|Spain|Turkey (Türkiye)|United Kingdom|Poland|Czechia|Portugal|Taiwan|Colombia|Singapore,1.0,0,1,0,0,0,2.0,0,0,0,0,1,6.07073772800249,large,0,1,1,0,1,0,1,1,1,1,1,1,0,1,12,1,1,0,0,5,1,2008-12-01,2010-08-01,608.0,2008.0,0,3,1
NCT00000643,Primary Prophylaxis of Cerebral Toxoplasmosis in HIV-Infected Patients,Primary Prophylaxis of Cerebral Toxoplasmosis in HIV-Infected Patients,COMPLETED,,1994-05,2021-11-02,INTERVENTIONAL,PHASE2,150.0,,,,PREVENTION,DOUBLE,"Toxoplasmosis, Cerebral|HIV Infections",Pyrimethamine|Leucovorin calcium,DRUG,0,0,13 Years,,ALL,False,National Institute of Allergy and Infectious Diseases (NIAID),NIH,0,24,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,5.017279836814924,medium,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,2,1,,1994-05-01,,,0,2,0
NCT03327844,Regenerative Endodontic Therapy (RET) for the Management of Immature Non-vital Permanent Teeth in Children,Regenerative Endodontic Therapy (RET) Using Antibiotic Pastes or Calcium Hydroxide Disinfection for the Management of Immature Non-vital Permanent Teeth in Children: A Randomized Controlled Clinical Trial,COMPLETED,2017-03-01,2021-07-31,2021-10-21,INTERVENTIONAL,PHASE2,40.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Infected Immature Permanent Teeth,RET using antibiotics (Ciprofloxacin and Metronidazole)|RET using non-setting Calcium Hydroxide,DRUG,2,4,6 Years,16 Years,ALL,True,"National University Health System, Singapore",OTHER,2,2,Singapore,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.713572066704308,small,1,1,0,1,0,1,1,0,0,0,1,1,1,1,6,1,1,0,0,2,1,,,,,0,2,0
NCT00005044,Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer,COMPLETED,2000-02,2022-05-20,2022-06-15,INTERVENTIONAL,PHASE3,1579.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Prostate Cancer,Casodex|Eulexin|LHRH agonist|radiation therapy,DRUG|RADIATION,1,6,18 Years,120 Years,MALE,False,Radiation Therapy Oncology Group,NETWORK,1,261,Canada|United States,1.0,0,0,1,0,0,3.0,1,0,0,0,1,7.365180126021013,xlarge,0,1,0,0,0,1,1,1,1,0,1,0,1,1,7,1,1,0,0,4,1,2000-02-01,,,2000.0,0,3,1
NCT00547534,"Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma","Pilot Study of Bortezomib, Bendamustine and Rituximab for Patients With Relapsed or Refractory, Indolent or Mantle Cell Non-Hodgkin's Lymphoma",COMPLETED,2007-10,2009-10,2015-08-06,INTERVENTIONAL,PHASE2,31.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Non-Hodgkin's Lymphoma,bortezomib|bendamustine|rituximab,DRUG,1,2,18 Years,,ALL,False,University of Rochester,OTHER,2,3,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.4657359027997265,small,1,1,0,1,1,1,1,0,1,0,0,0,1,0,3,1,1,0,0,3,1,2007-10-01,2009-10-01,731.0,2007.0,0,1,0
NCT01945944,Nebulized Hypertonic Saline for Mechanically Ventilated Children,Nebulized Hypertonic Saline for Mechanically Ventilated Children,COMPLETED,2013-10,2014-05,2016-06-28,INTERVENTIONAL,PHASE1|PHASE2,18.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Respiratory Failure,Hypertonic saline (3%)|Placebo (0.9% saline),DRUG,1,8,,18 Years,ALL,False,University Hospitals Cleveland Medical Center,OTHER,0,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,2.9444389791664403,small,1,1,0,1,0,0,0,0,1,0,1,1,1,1,9,1,1,0,0,2,1,2013-10-01,2014-05-01,212.0,2013.0,0,3,1
NCT01972464,Progesterone for Smoking Relapse Prevention Following Delivery,"Progesterone for Postpartum Smokers: Feasibility, Breastfeeding and Infant Safety",COMPLETED,2013-11,2016-09,2018-01-17,INTERVENTIONAL,PHASE2,41.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Tobacco Use Disorder,Progesterone|Placebo,DRUG,2,1,18 Years,42 Years,FEMALE,True,Yale University,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.7376696182833684,small,1,1,0,1,0,1,0,0,1,0,1,1,1,1,3,1,1,0,0,2,1,2013-11-01,2016-09-01,1035.0,2013.0,0,1,0
NCT01298999,Trial of a Gastrin Receptor Antagonist in Barrett's Esophagus,"Randomized Placebo-Controlled Trial of YF476, a Gastrin Receptor Antagonist, in Barrett's Esophagus",COMPLETED,2010-06,2017-12,2021-11-23,INTERVENTIONAL,PHASE2,27.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Barrett's Esophagus,YF476|Placebo,DRUG,2,1,18 Years,,ALL,False,Columbia University,OTHER,1,2,United Kingdom|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.332204510175204,small,1,1,0,1,0,1,1,1,1,1,1,1,0,1,3,1,1,0,0,2,1,2010-06-01,2017-12-01,2740.0,2010.0,0,2,0
NCT00024232,Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer,Pilot Trial of Humanized Monoclonal Antibody J591 in Patients With Progressive Androgen-Independent Prostate Cancer,COMPLETED,2001-06,2004-02,2013-06-18,INTERVENTIONAL,PHASE2,,,,,TREATMENT,,Prostate Cancer,monoclonal antibody huJ591,BIOLOGICAL,0,0,18 Years,,MALE,False,Memorial Sloan Kettering Cancer Center,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,0.0,,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,2001-06-01,2004-02-01,975.0,2001.0,0,0,0
NCT06681298,"A Multi-center, Two-arm, Phase 2 Clinical Study on the Perioperative Treatment of HER2-positive Resectable Esophagogastric Junctional Adenocarcinoma With Nabulimab Combined With FLOT and Trastuzumab VS FLOT Combined With Trastuzumab","A Multi-center, Two-arm, Phase 2 Clinical Study on the Perioperative Treatment of HER2-positive Resectable Esophagogastric Junctional Adenocarcinoma With Nabulimab Combined With FLOT and Trastuzumab VS FLOT Combined With Trastuzumab",ACTIVE_NOT_RECRUITING,2024-05-01,2029-05-01,2024-11-08,INTERVENTIONAL,PHASE2,36.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,NONE,Adenocarcinoma of the Esophagogastric Junction|Perioperative Period,The experimental group received Nivolumab,DRUG,1,6,18 Years,75 Years,ALL,False,xiaohua li,OTHER,0,1,China,,0,1,0,0,0,2.0,1,0,0,0,2,3.6109179126442243,small,1,0,0,1,0,0,0,0,0,0,1,0,1,1,7,1,1,0,0,1,0,,,,,0,2,0
NCT00604799,VALOR: The Talent Thoracic Stent Graft System Clinical Study,Evaluation of the Medtronic Vascular Talent Thoracic Stent Graft System for the Treatment of Thoracic Aortic Aneurysms,COMPLETED,2003-07,2011-06,2021-11-02,INTERVENTIONAL,PHASE2|PHASE3,379.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Thoracic Aortic Aneurysms,Talent Thoracic Stent Graft,DEVICE,2,0,18 Years,,ALL,True,Medtronic Cardiovascular,INDUSTRY,0,1,United States,1.0,0,1,1,0,1,2.5,0,0,0,0,1,5.940171252720432,large,0,1,1,0,0,0,0,0,1,0,0,0,1,1,2,0,0,0,1,1,0,2003-07-01,2011-06-01,2892.0,2003.0,0,1,0
NCT02878863,Paeoniflorin Combination of Hepatoprotective Drugs Versus Hepatoprotective Drugs Only for Auto-immune Hepatitis,Paeoniflorin Combination of Hepatoprotective Drugs Versus Hepatoprotective Drugs Only for Treatment of Auto-immune Hepatitis,WITHDRAWN,2016-08,2017-07,2017-07-13,INTERVENTIONAL,PHASE3,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Hepatitis, Autoimmune",Paeoniflorin + phosphatidylcholine or silymarin|Phosphatidylcholine or silymarin,DRUG,1,6,20 Years,70 Years,ALL,False,Xiaoli Fan,OTHER,0,1,China,0.0,0,0,1,0,0,3.0,0,1,0,0,1,0.0,,1,1,0,1,0,0,0,0,0,0,1,0,1,1,7,1,1,0,0,2,1,2016-08-01,2017-07-01,334.0,2016.0,1,2,0
NCT04670263,Evaluating the Efficacy of Dry Eye (DE) Disease Treatment Using Novel Tear Film Imager (TFI),Evaluating the Efficacy of Dry Eye (DE) Disease Treatment Using Novel Tear Film Imager (TFI),COMPLETED,2020-03-08,2021-09-23,2022-07-12,INTERVENTIONAL,PHASE2|PHASE3,70.0,ACTUAL,NON_RANDOMIZED,PARALLEL,DIAGNOSTIC,SINGLE,Dry Eye Disease,Tear Film Imager,DEVICE,3,2,18 Years,,ALL,True,Adom Advanced Optical Technologies Ltd.,INDUSTRY,0,1,Israel,1.0,0,1,1,0,1,2.5,0,0,0,0,1,4.2626798770413155,medium,1,1,1,0,0,0,0,0,0,0,0,0,0,1,5,1,0,0,1,1,0,,,,,0,1,0
NCT02633163,Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE),A Phase II Controlled Trial of Allogeneic Mesenchymal Stem Cells for the Treatment of Refractory Lupus,ACTIVE_NOT_RECRUITING,2018-11-18,2026-02-03,2025-08-21,INTERVENTIONAL,PHASE2,81.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Systemic Lupus Erythematosus,Low Dose Mesenchymal Stem Cells (MSCs)|High Dose Mesenchymal Stem Cells (MSCs)|Placebo Infusion,DRUG,1,11,18 Years,65 Years,ALL,False,Medical University of South Carolina,OTHER,0,9,United States,,0,1,0,0,0,2.0,0,1,0,0,1,4.406719247264253,medium,1,0,0,1,0,0,1,0,1,0,1,1,1,1,12,1,1,0,0,3,1,,,,,0,2,0
NCT00759863,LifeZig Personalized Reminiscence Video With Slideshows and Music for Individuals With Alzheimer's and Dementia,LifeZig System for Individuals With Alzheimer's Disease,COMPLETED,2006-08,2009-04,2010-03-02,INTERVENTIONAL,PHASE2,242.0,ACTUAL,RANDOMIZED,PARALLEL,SUPPORTIVE_CARE,NONE,Alzheimer's Disease|Dementia,Lifezig,BEHAVIORAL,1,2,21 Years,,ALL,False,"Photozig, Inc.",INDUSTRY,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,1,0,2,5.493061443340548,large,0,1,1,0,0,0,0,0,1,0,1,0,0,1,3,1,0,0,0,1,0,2006-08-01,2009-04-01,974.0,2006.0,0,1,0
NCT03781063,Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation,"An Open-Label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation",COMPLETED,2019-09-20,2025-05-08,2026-01-28,INTERVENTIONAL,PHASE2,100.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Locally Advanced or Metastatic Breast Cancer,Lasofoxifene|Fulvestrant,DRUG,1,4,18 Years,,FEMALE,False,Sermonix Pharmaceuticals Inc.,INDUSTRY,1,51,Israel|Canada|United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.61512051684126,medium,0,1,1,0,0,1,1,1,1,0,1,0,1,1,5,1,1,0,0,2,1,,,,,0,2,0
NCT00244998,Fulvestrant in Treating Patients With Advanced Prostate Cancer,Phase II Study of Fulvestrant (Faslodex®) in Androgen Independent Prostate Cancer,COMPLETED,2005-09,2012-06,2013-03-08,INTERVENTIONAL,PHASE2,20.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Prostate Cancer,fulvestrant,DRUG,1,1,18 Years,,MALE,False,Roswell Park Cancer Institute,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.044522437723423,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,2,1,1,0,0,1,0,2005-09-01,2012-06-01,2465.0,2005.0,0,0,0
NCT01821898,Eosinophilic Esophagitis Clinical Therapy Comparison Trial,Eosinophilic Esophagitis Clinical Therapy Comparison Trial,TERMINATED,2013-07-09,2018-09-24,2021-01-11,INTERVENTIONAL,PHASE2,3.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Eosinophilic Esophagitis,Oral Budesonide|Elimination diet,DRUG|OTHER,1,3,3 Years,17 Years,ALL,False,Baylor College of Medicine,OTHER,0,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,1.3862943611198906,small,1,1,0,1,0,0,0,0,1,0,1,0,1,1,4,1,1,0,0,2,1,,,,,0,1,0
NCT01717898,"A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer","A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer",TERMINATED,2013-01-31,2016-08-29,2018-03-27,INTERVENTIONAL,PHASE1|PHASE2,6.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Castrate-resistant Prostate Cancer,BEZ235|Prednisone|Abiraterone acetate,DRUG,4,5,18 Years,,MALE,False,Charles Ryan,OTHER,1,1,United States,0.0,1,1,0,0,1,1.5,1,0,0,0,1,1.9459101490553132,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,9,1,1,0,0,3,1,,,,,0,3,1
NCT00038987,Vaccinia Virus Vaccine (APSV) in Vaccinia- Naive Subjects: PILOT,"A Phase I/II Study to Evaluate the Safety and Preliminary Efficacy of Various Concentrations of Aventis Pasteur's Smallpox Vaccine, USP (APSV) in Vaccinia-naive Adults",COMPLETED,2002-05,2002-08,2010-08-27,INTERVENTIONAL,PHASE1|PHASE2,330.0,,RANDOMIZED,PARALLEL,PREVENTION,SINGLE,Smallpox,Wetvax (APSV),BIOLOGICAL,0,0,18 Years,32 Years,ALL,True,National Institute of Allergy and Infectious Diseases (NIAID),NIH,0,4,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,5.802118375377063,large,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,1,0,2002-05-01,2002-08-01,92.0,2002.0,0,1,0
NCT02989493,Testing Doxazosin to Treat Stress Mechanisms in Alcoholism,Randomized Controlled Trial Targeting Noradrenergic Stress Mechanisms in Alcoholism With Doxazosin,COMPLETED,2017-04-12,2020-03-13,2021-03-18,INTERVENTIONAL,PHASE2,61.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Alcoholism,Doxazosin|Placebo,DRUG|OTHER,2,0,18 Years,65 Years,ALL,False,"University of Wisconsin, Madison",OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.127134385045092,medium,1,1,0,1,0,1,0,0,1,0,1,1,1,1,2,0,1,0,0,2,1,,,,,0,1,0
NCT03240393,Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC),Phase II Multicenter 3-cohort Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Received 1 or 2 Prior Lines of Systemic Therapy for Advanced/Metastatic Disease,WITHDRAWN,2018-07-31,2021-10-26,2018-07-26,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Carcinoma|Non-Small-Cell Lung Cancer,INC280,DRUG,1,16,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,0,,0.0,0,1,0,0,0,2.0,1,0,0,0,2,0.0,,1,1,1,0,1,0,0,0,0,0,1,0,1,1,17,1,1,0,0,1,0,,,,,0,2,0
NCT07368114,Validity of Ozonated Olive Oil Gel Versus Injectable Bone Graft,Validity of Ozonated Olive Oil Gel Versus Injectable Bone Graft on Osseointegration of Immediate Dental Implants,COMPLETED,2023-12-10,2025-09-10,2026-01-26,INTERVENTIONAL,PHASE2,16.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Dental|Implant Osseointegration|Ozone Therapy|Bone Graft,Immediate implant placement|β-tricalcium phosphate Injectable Bone Graft|Ozonated olive oil gel,BIOLOGICAL|PROCEDURE,2,2,20 Years,60 Years,ALL,True,Suez Canal University,OTHER,0,1,Egypt,1.0,0,1,0,0,0,2.0,0,0,0,0,4,2.833213344056216,small,1,1,0,1,0,0,0,0,0,0,1,0,1,1,4,1,0,1,0,3,1,,,,,0,2,0
NCT00028704,Breast-Conserving Therapy Compared With Mastectomy Followed By Radiation Therapy in Treating Women With Locally Advanced Breast Cancer Previously Treated With Chemotherapy,Conservative Local Treatment Versus Mastectomy After Induction Chemotherapy In Locally Advanced Breast Cancer: A Randomized Phase III Study,TERMINATED,2001-10,,2012-07-18,INTERVENTIONAL,PHASE3,26.0,ACTUAL,RANDOMIZED,,TREATMENT,,Breast Cancer,conventional surgery|radiation therapy,RADIATION|PROCEDURE,0,0,,,FEMALE,False,European Organisation for Research and Treatment of Cancer - EORTC,NETWORK,3,13,Netherlands|Belgium|United Kingdom|Chile|Poland|Israel|Portugal,0.0,0,0,1,0,0,3.0,1,0,0,0,1,3.295836866004329,small,1,1,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,2,1,2001-10-01,,,2001.0,0,2,0
NCT00546104,Phase II Dasatinib Study in Advanced Breast Cancer,A Phase II Trial of Dasatinib to Treat Women With Stage IV or Inoperable Stage III Advanced Breast Cancer,COMPLETED,2007-10,2011-05,2013-07-17,INTERVENTIONAL,PHASE2,31.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Advanced Breast Cancer,Dasatinib,DRUG,1,5,18 Years,,FEMALE,False,Duke University,OTHER,1,3,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.4657359027997265,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,6,1,1,0,0,1,0,2007-10-01,2011-05-01,1308.0,2007.0,0,1,0
NCT03466333,Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia,Feasibility Study on the Effects of Postnatal Enalapril on Maternal Cardiovascular Function Following Preterm Pre-eclampsia.,COMPLETED,2018-09-05,2020-09-11,2021-02-24,INTERVENTIONAL,PHASE2,118.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Cardiovascular Diseases|Pre-Eclampsia Onset Less Than 37 Weeks (Diagnosis),Enalapril Maleate|Placebo oral capsule,DRUG,2,3,16 Years,,FEMALE,False,Manchester University NHS Foundation Trust,OTHER_GOV,0,1,United Kingdom,1.0,0,1,0,0,0,2.0,0,0,0,1,2,4.77912349311153,medium,0,1,0,1,0,0,0,0,0,1,1,1,1,1,5,1,1,0,0,2,1,,,,,0,2,0
NCT00021333,Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer,"Phase II Evaluation Of Paclitaxel And Cisplatin In Combination With Split Course Hyperfractionated Radiation Therapy And Granulocyte-Colony Stimulating Factor In Previously Irradiated Patients With Locally Recurrent Carcinoma Of The Head And Neck, And Lung",COMPLETED,1999-09,2008-05,2013-04-17,INTERVENTIONAL,PHASE2,29.0,ACTUAL,,,TREATMENT,,Head and Neck Cancer|Lung Cancer,filgrastim|cisplatin|paclitaxel|radiation therapy,DRUG|BIOLOGICAL|RADIATION,0,0,18 Years,,ALL,False,Fox Chase Cancer Center,OTHER,1,18,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,2,3.4011973816621555,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,1,1,0,4,1,1999-09-01,2008-05-01,3165.0,1999.0,0,2,0
NCT03697252,A Study to Assess Safety and Efficacy of KarXT in Adult Patients With Schizophrenia,"A Phase 2, Randomized, Double-blinded Study to Assess the Safety, Tolerability, and Efficacy of KarXT in Hospitalized Adults With DSM-5 Schizophrenia",COMPLETED,2018-09-18,2019-09-04,2020-10-26,INTERVENTIONAL,PHASE2,182.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Schizophrenia,Xanomeline and Trospium Chloride Capsules|Placebo Capsules,DRUG,1,5,18 Years,60 Years,ALL,False,Karuna Therapeutics,INDUSTRY,0,12,United States,1.0,0,1,0,0,0,2.0,0,0,1,0,1,5.209486152841421,medium,0,1,1,0,0,0,1,0,1,0,1,1,1,1,6,1,1,0,0,2,1,,,,,0,2,0
NCT00465452,Impact of Switching to Continuous Release Dopamine Agonists,The Impact of Switching to Continuous Release Dopamine Agonists on Non-Motor Side Effects,COMPLETED,2007-01,2011-12,2025-05-16,INTERVENTIONAL,PHASE3,11.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Parkinson Disease,Continuous Release Dopamine Agonists,DRUG,5,0,55 Years,,ALL,False,University of Toledo,OTHER,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,1,0,1,2.4849066497880004,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,5,0,1,0,0,1,0,2007-01-01,2011-12-01,1795.0,2007.0,0,0,0
NCT01223352,Effects of Two Dosing Regimens of Bosentan in Children With Pulmonary Arterial Hypertension,"An Open-label, Prospective Multicenter Study to Assess the Pharmacokinetics, Tolerability, Safety and Efficacy of the Pediatric Formulation of Bosentan Two Versus Three Times a Day in Children With Pulmonary Arterial Hypertension",COMPLETED,2011-03-08,2013-08-19,2025-02-04,INTERVENTIONAL,PHASE3,64.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Pulmonary Arterial Hypertension,bosentan,DRUG,1,0,3 Months,12 Years,ALL,False,Actelion,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,1,1,4.174387269895637,medium,1,1,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0,1,0,,,,,0,0,0
NCT01499849,Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy,"Phase 3, Multicenter, Randomized, Double Blind, Active-Controlled Study of the Safety & Efficacy of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Highly Emetogenic Chemotherapy (HEC)",COMPLETED,2012-02,2014-05,2016-05-19,INTERVENTIONAL,PHASE3,532.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Chemotherapy-induced Nausea and Vomiting,Rolapitant|Granisetron|dexamethasone|Placebo,DRUG,1,2,18 Years,,ALL,False,"Tesaro, Inc.",INDUSTRY,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.278521424165844,xlarge,0,1,1,0,0,0,0,0,1,0,1,1,0,1,3,1,1,0,0,4,1,2012-02-01,2014-05-01,820.0,2012.0,0,1,0
NCT02097849,Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.,An Open-Label Study to Assess the Immune Response to Vaccination in Tecfidera® (BG00012)-Treated Versus Interferon-Treated Subjects With Relapsing Forms of Multiple Sclerosis.,COMPLETED,2015-02-28,2016-05-02,2017-06-02,INTERVENTIONAL,PHASE2,71.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Relapsing Forms of Multiple Sclerosis,dimethyl fumarate|tetanus diphtheria toxoids vaccine|23-valent pneumococcal polysaccharide vaccine|meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent)|non-pegylated interferon,DRUG|BIOLOGICAL,1,15,18 Years,55 Years,ALL,False,Biogen,INDUSTRY,0,14,United States,1.0,0,1,0,0,0,2.0,0,1,0,0,1,4.276666119016055,medium,1,1,1,0,1,0,1,0,1,0,0,0,1,1,16,1,1,1,0,5,1,,,,,0,2,0
NCT03414047,A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer,A Phase 2 Study of Prexasertib in Platinum-Resistant or Refractory Recurrent Ovarian Cancer,COMPLETED,2018-04-10,2020-10-03,2022-08-19,INTERVENTIONAL,PHASE2,172.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Ovarian Cancer,Prexasertib,DRUG,1,6,18 Years,,FEMALE,False,Eli Lilly and Company,INDUSTRY,0,46,Italy|Belgium|South Korea|United States|Spain|United Kingdom|Australia|Israel,1.0,0,1,0,0,0,2.0,1,0,0,0,1,5.153291594497779,medium,0,1,1,0,1,0,1,1,1,1,0,0,1,1,7,1,1,0,0,1,0,,,,,0,2,0
NCT00366678,Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in France.",COMPLETED,2006-10,2008-11,2012-08-15,INTERVENTIONAL,PHASE3,613.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,"Vaccines, Pneumococcal",13-valent pneumococcal conjugate vaccine|7-valent pneumococcal conjugate vaccine|Pentavac,DRUG|BIOLOGICAL,9,4,42 Days,98 Days,ALL,True,Wyeth is now a wholly owned subsidiary of Pfizer,INDUSTRY,0,45,France,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.419994928147142,xlarge,0,1,1,0,1,0,1,0,0,1,1,1,0,1,13,1,1,1,0,3,1,2006-10-01,2008-11-01,762.0,2006.0,0,2,0
NCT02375685,Long-term Safety of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis (EYEGUARD-X),"A Safety Open-label Study of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis Disease, an eXtension Study. The EYEGUARD-X Study",TERMINATED,2014-08,2015-11,2020-01-03,INTERVENTIONAL,PHASE3,71.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Chronic Uveitis,Gevokizumab,BIOLOGICAL,1,0,18 Years,,ALL,False,Institut de Recherches Internationales Servier,OTHER,0,13,Italy|Turkey (Türkiye)|South Korea|Spain|Germany|Austria|Australia|United Kingdom|Tunisia|Taiwan|Portugal|France|Greece,0.0,0,0,1,0,0,3.0,0,0,0,0,1,4.276666119016055,medium,1,1,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,1,0,1,0,2014-08-01,2015-11-01,457.0,2014.0,0,1,0
NCT00999115,Allogenic Stem Cells Derived From Lipoaspirates for the Treatment of Recto-vaginal Fistulas Associated to Crohn's Disease (ALOREVA),Clinical Trial in Phase I-IIa to Study the Feasibility and Security of the Allogenic Use of Adipose-derived Stem Cells for the Local Treatment of Recto-vaginal Fistula in Crohn´s Disease,COMPLETED,2009-09,2011-12,2012-01-26,INTERVENTIONAL,PHASE1|PHASE2,10.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Rectovaginal Fistula|Crohn Disease,Expanded allogenic adipose-derived adult stem cells,DRUG,1,4,18 Years,,FEMALE,False,Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz,OTHER,0,1,Spain,1.0,1,1,0,0,1,1.5,0,1,0,0,2,2.3978952727983707,small,1,1,0,1,0,0,0,0,0,1,0,0,1,0,5,1,1,0,0,1,0,2009-09-01,2011-12-01,821.0,2009.0,0,2,0
NCT02319343,Effect of Methylprednisolone on Quadriceps Muscle Function in Patients Undergoing Total Knee-arthroplasty,Effect of Preoperative Intravenous High Dose Methylprednisolone on Quadriceps Muscle Function in Patients Scheduled for Total Knee-arthroplasty,COMPLETED,2015-01,2016-04,2016-04-08,INTERVENTIONAL,PHASE3,70.0,ACTUAL,RANDOMIZED,PARALLEL,,QUADRUPLE,Osteoarthrosis,Methylprednisolone|Isotonic Sodium Chloride,DRUG,1,4,55 Years,80 Years,ALL,False,"Rigshospitalet, Denmark",OTHER,1,1,Denmark,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.2626798770413155,medium,1,1,0,1,0,1,0,0,0,0,1,1,0,1,5,1,1,0,0,2,1,2015-01-01,2016-04-01,456.0,2015.0,1,1,0
NCT02745535,"Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA Experience","Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA Experience",COMPLETED,2016-05,2018-10-24,2022-03-10,INTERVENTIONAL,PHASE2,77.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Chronic Hepatitis C,Sofosbuvir/Velpatasvir/Voxilaprevir,DRUG,2,3,18 Years,,ALL,False,"University of Maryland, Baltimore",OTHER,2,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.356708826689592,medium,1,1,0,1,0,1,0,0,1,0,0,0,1,0,5,1,1,0,0,1,0,2016-05-01,,,2016.0,1,0,0
NCT02071225,A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic Leukemia,Phase II Trial to Evaluate The Efficacy of Obinutuzumab (RO5072759) + Bendamustine Treatment in Patients With Refractory Or Relapsed Chronic Lymphocytic Leukemia,COMPLETED,2014-04-09,2018-11-19,2020-02-07,INTERVENTIONAL,PHASE2,72.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Chronic Lymphocytic Leukemia,bendamustine|obinutuzumab,DRUG,1,14,18 Years,,ALL,False,Hoffmann-La Roche,INDUSTRY,0,21,Spain,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.290459441148391,medium,1,1,1,0,1,0,1,0,0,1,0,0,1,0,15,1,1,0,0,2,1,,,,,0,2,0
NCT02872571,Evaluation of the Efficacy of Intramuscular Islet Autograft After Extensive Pancreatectomy,Evaluation of the Efficacy of Intramuscular Islet Autograft After Extensive Pancreatectomy,ACTIVE_NOT_RECRUITING,2013-04,2026-04,2022-07-01,INTERVENTIONAL,PHASE1|PHASE2,35.0,ESTIMATED,,SINGLE_GROUP,PREVENTION,NONE,Disorder of Endocrine Pancreas,Intramuscular Islet Autograft,DRUG,1,4,18 Years,,ALL,False,"University Hospital, Lille",OTHER,0,4,France,,1,1,0,0,1,1.5,0,0,0,0,1,3.58351893845611,small,1,0,0,1,0,0,1,0,0,1,0,0,0,0,5,1,1,0,0,1,0,2013-04-01,2026-04-01,4748.0,2013.0,0,1,0
NCT00605644,Study Evaluating MOA-728 Oral for the Treatment of OIBD in Subjects With Chronic Non-Malignant Pain,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Nonmalignant Pain",COMPLETED,2008-01,2008-05,2020-08-20,INTERVENTIONAL,PHASE2,128.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Constipation,MOA-728|Placebo,DRUG,1,0,18 Years,,ALL,False,"Bausch Health Americas, Inc.",INDUSTRY,1,0,,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.859812404361672,medium,0,1,1,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,2,1,2008-01-01,2008-05-01,121.0,2008.0,0,1,0
NCT02440334,Two and Three Dimensional Contrast-enhanced Ultrasound for Screening of Renal Cell Carcinoma Recurrence Following Cryoablation,Two and Three Dimensional Contrast-Enhanced Ultrasound for Screening of Renal Cell Carcinoma Recurrence Following Cryoablation,COMPLETED,2015-04-23,2018-06-21,2025-05-04,INTERVENTIONAL,PHASE2,53.0,ACTUAL,,SINGLE_GROUP,DIAGNOSTIC,NONE,Renal Cell Carcinoma,Optison,DRUG,1,0,18 Years,,ALL,False,Thomas Jefferson University,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.9889840465642745,medium,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,,,,,0,0,0
NCT00022334,Vaccine Therapy in Treating Patients With Liver Cancer,A Phase I/II Trial Testing Immunization With Dendritic Cells Pulsed With Four AFP Peptides in Patients With Hepatocellular Carcinoma,COMPLETED,2001-01,2008-10,2020-08-03,INTERVENTIONAL,PHASE1|PHASE2,33.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Liver Cancer,AFP,BIOLOGICAL,1,3,18 Years,,ALL,False,Jonsson Comprehensive Cancer Center,OTHER,1,1,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,1,3.5263605246161616,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,4,1,0,1,0,1,0,2001-01-01,2008-10-01,2830.0,2001.0,0,1,0
NCT01328899,Feasibility Study of PneumRx's Lung Volume Reduction Coil (LVRC),"Feasibility Study of the PneumRx, Inc. Lung Volume Reduction Coil for the Treatment of Emphysema",COMPLETED,2009-12,2013-01,2021-07-21,INTERVENTIONAL,PHASE1|PHASE2,60.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Emphysema,Lung Volume Reduction Coil (LVRC) (PneumRx's),DEVICE,1,0,35 Years,,ALL,False,Boston Scientific Corporation,INDUSTRY,1,11,Germany|France|Netherlands,1.0,1,1,0,0,1,1.5,0,0,0,0,1,4.110873864173311,medium,1,1,1,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,1,1,0,2009-12-01,2013-01-01,1127.0,2009.0,0,2,0
NCT00457899,Rapid Versus Conventional Titration of Quetiapine in Schizophrenia/Schizoaffective Disorder,"RAPID-An Open-Label Randomized, Multicenter Phase IIIb Study to Evaluate the Efficacy and Tolerability of Quetiapine IR (Immediate Release), Over 14 Days, in Acute Schizophrenia/Schizoaffective Disorder (Rapid Versus Conventional Titration)",TERMINATED,2007-07,2007-09,2007-11-27,INTERVENTIONAL,PHASE3,234.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,NONE,Schizophrenia|Schizoaffective Disorders|Psychotic Disorders,Quetiapine IR (Immediate Release),DRUG,1,4,18 Years,65 Years,ALL,False,AstraZeneca,INDUSTRY,0,12,United Kingdom,0.0,0,0,1,0,0,3.0,0,0,1,0,3,5.459585514144159,large,0,0,1,0,1,0,1,0,0,1,1,0,1,1,5,1,1,0,0,1,0,2007-07-01,2007-09-01,62.0,2007.0,0,1,0
NCT00219232,An Open-label Extension to Evaluate the Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease,An Open-label Extension to Evaluate the Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease,COMPLETED,2003-02,2006-07,2017-02-23,INTERVENTIONAL,PHASE3,868.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Alzheimer's Disease,Rivastigmine Transdermal Patch,DRUG,1,5,50 Years,85 Years,ALL,False,Novartis,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,1,0,1,6.767343125265392,xlarge,0,1,1,0,1,0,0,0,0,0,0,0,1,0,6,1,1,0,0,1,0,2003-02-01,2006-07-01,1246.0,2003.0,0,1,0
NCT00241332,Postoperative Pain After Orthopedic Surgery: Does it Help to Give Fentanyl Before Start of Remifentanil Based Anesthesia?,Prophylaxis Against Postoperative Pain After Orthopedic Surgery: Does it Help to Give Fentanyl Before Start of Remifentanil/Propofol Based Anesthesia?,COMPLETED,2005-10,2006-07,2011-07-06,INTERVENTIONAL,PHASE3,100.0,,RANDOMIZED,SINGLE_GROUP,TREATMENT,DOUBLE,"Pain, Postoperative",fentanyl,DRUG,2,0,18 Years,70 Years,ALL,False,Ullevaal University Hospital,OTHER,1,1,Norway,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.61512051684126,medium,0,0,0,1,0,1,0,0,0,0,1,1,1,0,2,0,1,0,0,1,0,2005-10-01,2006-07-01,273.0,2005.0,0,0,0
NCT01637532,Feasibility of the Combination of Chemotherapy (Carbo/Caelyx or Carbo/Doxorubicin) With Tocilizumab (mAb IL-6R) and Peg-Intron in Patients With Recurrent Ovarian Cancer,"Chemo-Immunotherapy: Observational Trial of Carboplatin-pegylated Liposomal Doxorubicin (PLD) or Doxorubicin Combination Chemotherapy With Tocilizumab, a Humanized Monoclonal Antibody Against the Human Interleukin-6 (IL-6) Receptor, and Pegylated Interferon Alpha (Peg-Intron) for Patients With Recurrent Ovarian Cancer.",COMPLETED,2011-02,2013-09,2016-01-26,INTERVENTIONAL,PHASE1|PHASE2,21.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Recurrent Ovarian Cancer,tocilizumab and interferon alpha 2-b|Carboplatin and Caelyx or doxorubicin,DRUG,1,2,18 Years,,FEMALE,False,Leiden University Medical Center,OTHER,1,1,Netherlands,1.0,1,1,0,0,1,1.5,1,0,0,0,1,3.091042453358316,small,1,1,0,1,0,1,0,0,0,0,0,0,1,1,3,1,1,0,0,2,1,2011-02-01,2013-09-01,943.0,2011.0,0,2,0
NCT02991898,Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies,Adoptive Transfer of T Regulatory Cell for Suppression of Acute Graft-vs-Host-Disease After an Umbilical Cord Blood Transplant for Hematologic Malignancies,TERMINATED,2017-02-16,2019-06-20,2020-09-29,INTERVENTIONAL,PHASE2,3.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Acute Lymphoblastic Leukemia|Burkitt Lymphoma|Natural Killer Cell Malignancies|Chronic Myelogenous Leukemia|Myelodysplastic Syndromes|Large-cell Lymphoma|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Marginal Zone B-Cell Lymphoma|Follicular Lymphoma|Lymphoplasmacytic Lymphoma|Mantle-Cell Lymphoma|Prolymphocytic Leukemia|Hodgkin Lymphoma|Multiple Myeloma|Acute Myelogenous Leukemia|Biphenotypic Leukemia|Undifferentiated Leukemia,Infusion of Treg,BIOLOGICAL,1,13,18 Years,75 Years,ALL,False,"Masonic Cancer Center, University of Minnesota",OTHER,0,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,18,1.3862943611198906,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,14,1,0,1,0,1,0,,,,,0,2,0
NCT02526498,Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery,TRI-fraction Radiotherapy Utilized to Minimize Patient Hospital Trips : A Phase II Trial (TRIUMPH-T Trial),COMPLETED,2015-07-15,2021-03-31,2023-05-15,INTERVENTIONAL,PHASE2,200.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Ductal Breast Carcinoma In Situ|Estrogen Receptor Positive|Invasive Breast Carcinoma|Progesterone Receptor Positive|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage IIA Breast Cancer,Accelerated Partial Breast Irradiation|High-Dose Rate Brachytherapy|Questionnaire Administration,RADIATION|OTHER,1,3,45 Years,,FEMALE,False,"Rutgers, The State University of New Jersey",OTHER,3,10,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,7,5.303304908059076,medium,0,1,0,1,0,1,1,0,1,0,0,0,1,0,4,1,0,0,0,3,1,,,,,0,2,0
NCT02495298,Fascial Manipulation on the Treatment of Carpal Tunnel Syndrome,"Evaluation of Fascial Manipulation for the Conservative Treatment of Carpal Tunnel Syndrome: Double Blind Randomized Clinical Trial, Phase II",COMPLETED,2013-08,2014-04,2016-10-05,INTERVENTIONAL,PHASE2,14.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Carpal Tunnel Syndrome,Fascial Manipulation|Sham Fascial Manipulation,PROCEDURE,1,4,18 Years,65 Years,ALL,False,Marta Imamura,OTHER,0,1,Brazil,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.70805020110221,small,1,1,0,1,0,0,0,0,0,0,1,1,1,1,5,1,0,0,0,2,1,2013-08-01,2014-04-01,243.0,2013.0,0,1,0
NCT00161863,Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years,Open-label Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years,COMPLETED,2002-09,2003-01,2015-05-21,INTERVENTIONAL,PHASE3,,,NON_RANDOMIZED,SINGLE_GROUP,PREVENTION,NONE,Tick-borne Encephalitis,FSME-IMMUN NEW 0.25 ml,BIOLOGICAL,0,0,1 Year,15 Years,ALL,,Pfizer,INDUSTRY,0,8,Germany|Austria|Poland,1.0,0,0,1,0,0,3.0,0,0,0,0,1,0.0,,0,0,1,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,0,2002-09-01,2003-01-01,122.0,2002.0,0,1,0
NCT02390687,Evaluation of the Efficacy of Probiotics in Chronic Periodontitis Patients,Evaluation of the Efficacy of Probiotics in Chronic Periodontitis Patients-A Randomized Placebo Controlled Study.,COMPLETED,2015-04,2016-12,2017-01-10,INTERVENTIONAL,PHASE3,31.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Chronic Periodontitis,Probiotic|Placebo,DRUG,1,1,35 Years,49 Years,ALL,False,Next Gen Pharma India Pvt. Ltd.,INDUSTRY,1,1,India,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.4657359027997265,small,1,1,1,0,0,1,0,0,0,0,1,1,1,1,2,1,1,0,0,2,1,2015-04-01,2016-12-01,610.0,2015.0,1,1,0
NCT00379093,Healthy Living as You Age,Preventing Harm From Alcohol Use in Older Adults,COMPLETED,2003-08,2008-07,2009-07-13,INTERVENTIONAL,PHASE2,631.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,SINGLE,Alcohol Related Disorders|Alcohol Drug Interactions,Brief advice,BEHAVIORAL,1,2,55 Years,,ALL,True,National Institute on Alcohol Abuse and Alcoholism (NIAAA),NIH,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,6.448889394146858,xlarge,0,1,0,1,0,0,0,0,1,0,1,0,0,1,3,1,0,0,0,1,0,2003-08-01,2008-07-01,1796.0,2003.0,0,1,0
NCT01043393,"Desoximetasone Spray 0.25%, Hypothalamic Pituitary Adrenal (HPA) Axis Study","An Open Label, Safety/Efficacy Study to Assess the Potential for Adrenal Suppression Following Multiple Dosing With Desoximetasone 0.25% Topical Spray in Patients With Moderate to Severe Plaque Psoriasis",COMPLETED,2010-02,2010-06,2014-06-02,INTERVENTIONAL,PHASE2,24.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Psoriasis,Desoximetasone 0.25% spray,DRUG,1,2,18 Years,,ALL,False,"Sun Pharmaceutical Industries, Inc.",INDUSTRY,0,3,United States,1.0,0,1,0,0,0,2.0,0,1,0,0,1,3.2188758248682006,small,1,1,1,0,0,0,1,0,1,0,0,0,1,1,3,1,1,0,0,1,0,2010-02-01,2010-06-01,120.0,2010.0,0,0,0
NCT01258114,Maâthermes: Spa Treatment for Overweight and Obesity,Maâthermes a Randomised Controlled Trial of Spa Treatment of Overweight and Obesity,COMPLETED,2007-03,2010-12,2010-12-10,INTERVENTIONAL,PHASE3,400.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Overweight|Obesity,SPA treatment (ST)|Non SPA treatment (NST),OTHER,1,2,20 Years,70 Years,ALL,False,Association Francaise pour la Recherche Thermale,OTHER,4,5,France,1.0,0,0,1,0,0,3.0,0,0,0,0,2,5.993961427306569,large,0,1,0,1,0,1,1,0,0,1,1,0,1,1,3,1,0,0,0,2,1,2007-03-01,2010-12-01,1371.0,2007.0,0,2,0
NCT01535014,Clinical Trial of Safety and Efficacy of Various Dosage Schedules for Dietressa Drug in Treatment of Obese Patients,Multicentric Double-blind Placebo-controlled Randomized Parallel-group Clinical Trial of Safety and Efficacy of Various Dosage Schedules for Dietressa Drug in Treatment of Obese Patients,COMPLETED,2011-12-12,2013-06,2018-11-28,INTERVENTIONAL,PHASE3,493.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Obesity,Dietressa|Placebo,DRUG,3,4,18 Years,65 Years,ALL,False,Materia Medica Holding,INDUSTRY,0,17,Russia,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.202535517187923,large,0,1,1,0,0,0,1,0,0,0,1,1,1,1,7,1,1,0,0,2,1,,2013-06-01,,,0,2,0
NCT03768414,Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers,"A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers",COMPLETED,2019-02-07,2024-10-28,2026-01-12,INTERVENTIONAL,PHASE3,452.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Stage III Distal Bile Duct Cancer AJCC v8|Stage III Gallbladder Cancer AJCC v8|Stage III Intrahepatic Cholangiocarcinoma AJCC v8|Stage IIIA Distal Bile Duct Cancer AJCC v8|Stage IIIA Gallbladder Cancer AJCC v8|Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8|Stage IIIB Distal Bile Duct Cancer AJCC v8|Stage IIIB Gallbladder Cancer AJCC v8|Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8|Stage IV Distal Bile Duct Cancer AJCC v8|Stage IV Gallbladder Cancer AJCC v8|Stage IV Intrahepatic Cholangiocarcinoma AJCC v8|Stage IVA Gallbladder Cancer AJCC v8|Stage IVB Gallbladder Cancer AJCC v8|Unresectable Extrahepatic Bile Duct Carcinoma|Unresectable Gallbladder Carcinoma|Unresectable Intrahepatic Cholangiocarcinoma,Cisplatin|Gemcitabine Hydrochloride|Nab-paclitaxel,DRUG,1,5,18 Years,,ALL,False,SWOG Cancer Research Network,NETWORK,1,692,United States,1.0,0,0,1,0,0,3.0,1,0,0,0,17,6.115892125483034,large,0,1,0,0,0,1,1,0,1,0,1,0,1,1,6,1,1,0,0,3,1,,,,,0,3,1
NCT01277016,A Trial for Systemic Light-chain (AL) Amyloidosis,"A Randomized Open-label Multicenter Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients With Systemic Light-chain (AL) Amyloidosis",COMPLETED,2011-01,2016-07-31,2017-03-10,INTERVENTIONAL,PHASE3,110.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,AL Amyloidosis,BMDex,DRUG,1,1,18 Years,,ALL,False,European Myeloma Network B.V.,NETWORK,0,1,Italy,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.709530201312334,medium,0,1,0,0,0,0,0,0,0,1,1,0,1,1,2,1,1,0,0,1,0,2011-01-01,,,2011.0,0,0,0
NCT05178316,A Study of JZP150 in Adults With Posttraumatic Stress Disorder,"A Multicenter Phase 2, 12-week Double-blind, Placebo-controlled, Randomized, Parallel-group Study of JZP150 for the Treatment of Posttraumatic Stress Disorder",COMPLETED,2021-12-29,2023-12-05,2024-12-31,INTERVENTIONAL,PHASE2,282.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Post Traumatic Stress Disorder,JZP150|Placebo,DRUG,1,2,18 Years,70 Years,ALL,False,Jazz Pharmaceuticals,INDUSTRY,0,52,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.645446897643238,large,0,1,1,0,0,0,1,0,1,0,1,1,1,1,3,1,1,0,0,2,1,,,,,0,1,0
NCT00999804,Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy,"TBCRC 023: A Randomized Multicenter Phase II Neoadjuvant Trial of Lapatinib Pus Trastuzumab, With or Without Endocrine Therapy for 12 Weeks vs. 24 Weeks in Patients With HER2 Overexpressing Breast Cancer",ACTIVE_NOT_RECRUITING,2011-10,2026-01,2025-03-12,INTERVENTIONAL,PHASE2,128.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Breast Cancer,Lapatinib|Letrozole|Trastuzumab,DRUG,1,3,18 Years,,FEMALE,False,Baylor Breast Care Center,OTHER,2,8,United States,,0,1,0,0,0,2.0,1,0,0,0,1,4.859812404361672,medium,0,1,0,1,0,1,1,0,1,0,1,0,1,1,4,1,1,0,0,3,1,2011-10-01,2026-01-01,5206.0,2011.0,0,1,0
NCT01649804,A Long-Term Safety Extension Study of WA19926 in Participants With Rheumatoid Arthritis,"A MULTICENTER, OPEN-LABEL, SINGLE ARM, LONG-TERM EXTENSION STUDY OF WA19926 TO DESCRIBE SAFETY DURING TREATMENT WITH TOCILIZUMAB IN PATIENTS WITH EARLY, MODERATE TO SEVERE RHEUMATOID ARTHRITIS",COMPLETED,2012-07,2014-12,2016-11-04,INTERVENTIONAL,PHASE3,12.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Rheumatoid Arthritis,tocilizumab [RoActemra/Actemra],DRUG,1,8,18 Years,,ALL,False,Hoffmann-La Roche,INDUSTRY,0,3,Hungary,1.0,0,0,1,0,0,3.0,0,1,0,0,1,2.5649493574615367,small,1,1,1,0,1,0,1,0,0,0,0,0,1,0,9,1,1,0,0,1,0,2012-07-01,2014-12-01,883.0,2012.0,0,1,0
NCT02160704,Androxal in Male Infertility,"PHASE 2b RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED EXPLORATORY STUDY TO EVALUATE THE EFFICACY OF ANDROXAL IN IDIOPATHIC MALE INFERTILITY (PROTOCOL #01-14-40-08)",WITHDRAWN,2014-09-22,2016-08-02,2019-07-11,INTERVENTIONAL,PHASE2|PHASE3,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Infertility,Enclomiphene citrate|Placebo,DRUG|OTHER,1,3,18 Years,35 Years,MALE,False,Baylor College of Medicine,OTHER,0,1,United States,0.0,0,1,1,0,1,2.5,0,0,0,0,1,0.0,,1,1,0,1,0,0,0,0,1,0,1,1,1,1,4,1,1,0,0,2,1,,,,,0,2,0
NCT00004884,Docetaxel and Gemcitabine Compared With Docetaxel and Cisplatin in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer,Randomized Phase II Study of Docetaxel/Gemcitabine vs. Docetaxel/Cisplatin in Metastatic or Locoregionally Advanced Pancreatic Carcinoma,COMPLETED,1999-07,,2012-09-24,INTERVENTIONAL,PHASE2,96.0,ACTUAL,RANDOMIZED,,TREATMENT,,Pancreatic Cancer,cisplatin|docetaxel|gemcitabine hydrochloride,DRUG,0,0,18 Years,,ALL,False,European Organisation for Research and Treatment of Cancer - EORTC,NETWORK,0,19,Netherlands|Belgium|Turkey (Türkiye)|Germany|United Kingdom|Egypt|Poland|France,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.574710978503383,medium,1,1,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,0,3,1,1999-07-01,,,1999.0,0,2,0
NCT00029484,Tai Chi Chih and Varicella Zoster Immunity,Tai Chi Chih and Varicella Zoster Immunity,COMPLETED,,,2006-08-18,INTERVENTIONAL,PHASE2,70.0,,RANDOMIZED,,,,Varicella,Tai chi chih,BEHAVIORAL,0,0,60 Years,80 Years,ALL,True,National Center for Complementary and Integrative Health (NCCIH),NIH,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.2626798770413155,medium,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,,,,,0,0,0
NCT00542984,Comparison Medications in the Treatment of Postmenopausal Women With Osteoporosis,Comparison of Teriparatide and Calcitonin in the Treatment of Postmenopausal Women With Osteoporosis,COMPLETED,2003-08,2004-11,2007-10-12,INTERVENTIONAL,PHASE3,70.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Osteoporosis, Postmenopausal",teriparatide 20 micrograms/day subcutaneous|salmon calcitonin 100 IU/day subcutaneous,DRUG,1,3,55 Years,85 Years,FEMALE,False,Eli Lilly and Company,INDUSTRY,0,1,South Korea,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.2626798770413155,medium,1,1,1,0,1,0,0,0,0,0,1,0,1,1,4,1,1,0,0,2,1,2003-08-01,2004-11-01,458.0,2003.0,0,1,0
NCT00273884,Amonafide in Combination With Cytarabine in Secondary AML,Phase 2 Open-Label Study of Amonafide L-Malate in Combination With Cytarabine in Subjects With Secondary Acute Myeloid Leukemia (AML),COMPLETED,2005-08,2009-04,2007-02-19,INTERVENTIONAL,PHASE2,80.0,,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Acute Myeloid Leukemia,Amonafide L-Malate|Cytarabine,DRUG,1,7,18 Years,,ALL,False,"Xanthus Pharmaceuticals, Inc.",INDUSTRY,0,21,Canada|United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.394449154672439,medium,1,0,1,0,0,0,1,1,1,0,0,0,1,0,8,1,1,0,0,2,1,2005-08-01,2009-04-01,1339.0,2005.0,0,3,1
NCT02227784,A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol,"The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study",TERMINATED,2014-10,2015-12,2019-10-08,INTERVENTIONAL,PHASE3,366.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Hyperlipidemia,Evacetrapib|Atorvastatin|Ezetimibe|Placebo,DRUG,1,6,18 Years,,ALL,False,Eli Lilly and Company,INDUSTRY,0,64,Puerto Rico|United States,0.0,0,0,1,0,0,3.0,0,0,0,0,1,5.905361848054571,large,0,1,1,0,1,0,1,1,1,0,1,1,1,1,7,1,1,0,0,4,1,2014-10-01,2015-12-01,426.0,2014.0,0,3,1
NCT01908933,Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema,Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema,WITHDRAWN,2013-09,2013-11,2013-11-14,INTERVENTIONAL,PHASE3,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Emphysema|Chronic Obstructive Pulmonary Disease (COPD),AeriSeal Emphysematous Lung Sealant Syst,DEVICE,1,1,40 Years,,ALL,False,Aeris Therapeutics,INDUSTRY,0,0,,0.0,0,0,1,0,0,3.0,0,0,0,0,2,0.0,,1,1,1,0,0,0,0,0,0,0,0,0,1,0,2,1,0,0,1,1,0,2013-09-01,2013-11-01,61.0,2013.0,0,1,0
NCT04031833,Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT),Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial,COMPLETED,2019-10-24,2023-02-15,2023-03-31,INTERVENTIONAL,PHASE1|PHASE2,178.0,ACTUAL,RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,Cryptococcal Meningitis,MAT2203|Amphotericin B,DRUG,2,0,18 Years,,ALL,False,"Matinas BioPharma Nanotechnologies, Inc.",INDUSTRY,1,1,Uganda,1.0,1,1,0,0,1,1.5,0,0,0,0,1,5.187385805840755,medium,0,1,1,0,0,1,0,0,0,0,1,0,1,0,2,0,1,0,0,2,1,,,,,0,2,0
NCT01076452,Phase II Subthalamic Nucleus (STN) vs. Globus Pallidus (GPi) Trial,"CSP #468 Phase II - A Comparison of Best Medical Therapy and Deep Brain Stimulation of Subthalamic Nucleus and Globus Pallidus for the Treatment of Parkinson's Disease, Phase II",COMPLETED,2002-04,2009-04,2014-07-14,INTERVENTIONAL,PHASE3,299.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Parkinson's Disease,Bilateral Deep Brain Stimulation,DEVICE,1,3,22 Years,,ALL,False,US Department of Veterans Affairs,FED,2,14,United States,1.0,0,0,1,0,0,3.0,0,0,1,0,1,5.703782474656201,large,0,1,0,0,0,1,1,0,1,0,1,0,1,1,4,1,0,0,1,1,0,2002-04-01,2009-04-01,2557.0,2002.0,0,0,0
NCT07251452,Effectiveness of a Dual Program for Improving Sleep in Older Adults.,Effectiveness of a Dual Program of Physical Activity and Cognitive Intervention for Improving Sleep and Quality of Life in Older Adults.,ACTIVE_NOT_RECRUITING,2025-09-01,2026-02-28,2025-12-08,INTERVENTIONAL,PHASE1|PHASE2,66.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Sleep|Gerontology|Physical Therapy|Cognitive,Otago programme|Otago programme + Cognifit|Control,BEHAVIORAL,1,10,65 Years,,ALL,True,University of Castilla-La Mancha,OTHER,0,1,Spain,,1,1,0,0,1,1.5,0,0,0,0,4,4.204692619390966,medium,1,1,0,1,0,0,0,0,0,1,1,0,1,1,11,1,0,0,0,3,1,,,,,0,4,1
NCT00620347,Sunitinib as a Second-line Treatment for Patients With Recurrent Small Cell Lung Cancer,A Phase II Study of Sunitinib as a Second-line Treatment for Patients With Recurrent Small Cell Lung Cancer.,COMPLETED,2008-03,2012-09,2013-06-19,INTERVENTIONAL,PHASE2,25.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Lung Cancer,sunitinib,DRUG,1,3,18 Years,,ALL,False,"National Cancer Center, Korea",OTHER_GOV,1,1,South Korea,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.258096538021482,small,1,1,0,1,0,1,0,0,0,0,0,0,1,0,4,1,1,0,0,1,0,2008-03-01,2012-09-01,1645.0,2008.0,0,0,0
NCT01185847,A Study of RO5083945 in Combination With Chemotherapy Versus Chemotherapy Alone in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer,"A Randomized, Multicenter, Open-label Phase Ib/II Study of RO5083945 in Combination With Cisplatin and Gemcitabine/Pemetrexed Versus Cisplatin and Gemcitabine/Pemetrexed in Patients With Advanced or Recurrent Non Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy",COMPLETED,2010-11,2012-09,2016-01-01,INTERVENTIONAL,PHASE2,90.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Non-Squamous Non-Small Cell Lung Cancer,RO5083945|cisplatin|gemcitabine|pemetrexed,DRUG,2,5,18 Years,,ALL,False,Hoffmann-La Roche,INDUSTRY,0,32,Italy|Belgium|Spain|Germany|United Kingdom|Poland|France,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.51085950651685,medium,1,1,1,0,1,0,1,1,0,1,1,0,1,1,7,1,1,0,0,4,1,2010-11-01,2012-09-01,670.0,2010.0,0,3,1
NCT05512949,Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine,"A Phase 2 Randomized, Open-Label, Multisite Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Vaccine",COMPLETED,2022-09-09,2025-02-24,2025-04-20,INTERVENTIONAL,PHASE2,229.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Monkeypox,JYNNEOS,BIOLOGICAL,1,9,18 Years,50 Years,ALL,True,National Institute of Allergy and Infectious Diseases (NIAID),NIH,0,8,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.438079308923196,large,0,1,0,1,0,0,1,0,1,0,1,0,0,1,10,1,0,1,0,1,0,,,,,0,1,0
NCT01683058,"Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia","A 26-week, Multicenter, Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia",COMPLETED,2013-01,2014-02,2015-03-31,INTERVENTIONAL,PHASE3,74.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Schizophrenia,Aripiprazole IM Depot,DRUG,1,24,18 Years,66 Years,ALL,False,"Otsuka Pharmaceutical Development & Commercialization, Inc.",INDUSTRY,2,38,Croatia|Latvia|United States,1.0,0,0,1,0,0,3.0,0,0,1,0,1,4.31748811353631,medium,1,1,1,0,0,1,1,1,1,0,0,0,1,0,25,1,1,0,0,1,0,2013-01-01,2014-02-01,396.0,2013.0,0,2,0
NCT01116648,"Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer","Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer",ACTIVE_NOT_RECRUITING,2010-04-14,2026-02-13,2025-09-30,INTERVENTIONAL,PHASE1|PHASE2,155.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Fallopian Tube Carcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian High Grade Serous Adenocarcinoma|Ovarian Serous Adenocarcinoma|Ovarian Serous Surface Papillary Adenocarcinoma|Primary Peritoneal Serous Adenocarcinoma|Triple-Negative Breast Carcinoma,Biopsy Procedure|Biospecimen Collection|Cediranib Maleate|Computed Tomography|Echocardiography Test|Magnetic Resonance Imaging|Multigated Acquisition Scan|Olaparib,DRUG|PROCEDURE,4,4,18 Years,,FEMALE,False,National Cancer Institute (NCI),NIH,0,14,United States,,1,1,0,0,1,1.5,1,0,0,0,7,5.049856007249537,medium,0,1,0,1,0,0,1,0,1,0,1,0,1,1,8,1,1,0,0,8,1,,,,,0,4,1
NCT02873026,Adjunctive Steroid Combination in Ocular Trauma (ASCOT) Study,A Phase 3 Multi-centre Double-masked Randomised Controlled Trial of Adjunctive Intraocular and Periocular Steroid (Triamcinolone Acetonide) Versus Standard Treatment in Eyes Undergoing Vitreoretinal Surgery for Open Globe Trauma.,COMPLETED,2014-10,2021-01-31,2021-09-17,INTERVENTIONAL,PHASE3,300.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Eye Injury Trauma,Triamcinolone Acetonide,DRUG,1,1,18 Years,,ALL,False,Moorfields Eye Hospital NHS Foundation Trust,OTHER,0,1,United Kingdom,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.707110264748875,large,0,1,0,1,0,0,0,0,0,1,1,1,1,1,2,1,1,0,0,1,0,2014-10-01,,,2014.0,0,0,0
NCT06238778,Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec,"A Phase 2b Randomized, Double-blind Trial Comparing HDV-Insulin Lispro Versus Insulin Lispro Alone in Adults With Type 1 Diabetes Receiving Insulin Degludec",ACTIVE_NOT_RECRUITING,2024-01-23,2025-12,2025-08-19,INTERVENTIONAL,PHASE2,227.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 1",HDV-Lispro|Lispro,DRUG,2,1,18 Years,79 Years,ALL,False,"Diasome Pharmaceuticlas, Inc.",INDUSTRY,0,27,United States,,0,1,0,0,0,2.0,0,0,0,0,1,5.429345628954441,large,0,1,1,0,0,0,1,0,1,0,1,1,1,1,3,1,1,0,0,2,1,,2025-12-01,,,0,1,0
NCT01099878,Cycling Exercise With Functional Electrical Stimulation Improves Postural Control in Stroke Patients,Institutional Review Board of Chung Shan Medical University Hospital,COMPLETED,2009-01,2009-12,2010-04-08,INTERVENTIONAL,PHASE1|PHASE2,20.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Postural Control,Cycling Exercise with Functional Electrical Stimulation|cycling exercise,DEVICE,0,0,29 Years,70 Years,ALL,False,Chung Shan Medical University,OTHER,0,2,Taiwan,1.0,1,1,0,0,1,1.5,0,0,0,0,1,3.044522437723423,small,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,2,1,2009-01-01,2009-12-01,334.0,2009.0,0,2,0
NCT05184478,Is Medicinal Cannabis an Effective Treatment for Tourette Syndrome in Adolescents? a Pilot Study,A Pilot Randomized Placebo-controlled Crossover Trial of Medicinal Cannabis (MC) in Adolescents with Tourette Syndrome (TS),COMPLETED,2022-05-16,2024-01-04,2024-11-27,INTERVENTIONAL,PHASE1|PHASE2,10.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Tourette Syndrome in Adolescence,"Medicinal cannabis (MC): THC 10mg/mL : CBD 15mg/mL, manufactured by Cann Group Ltd.|Placebo",DRUG,9,2,12 Years,18 Years,ALL,False,Murdoch Childrens Research Institute,OTHER,0,1,Australia,1.0,1,1,0,0,1,1.5,0,0,0,0,1,2.3978952727983707,small,1,1,0,1,0,0,0,0,0,0,1,1,1,0,11,1,1,0,0,2,1,,,,,0,3,1
NCT00243685,Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis,Application of the Microculture Kinetic (MiCK) Assay for Apoptosis to Drug Testing Sensitivity of Solid Tumors,COMPLETED,2006-09,2009-05,2012-01-26,INTERVENTIONAL,PHASE2|PHASE3,150.0,ESTIMATED,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,SINGLE,"Breast Neoplasms|Lung Neoplasms|Ovarian Neoplasms|Sarcoma, Soft Tissue",Laboratory Assay|Mick Assay,OTHER,2,0,18 Years,85 Years,ALL,True,Pierian Biosciences,INDUSTRY,0,3,United States,1.0,0,1,1,0,1,2.5,1,0,0,0,4,5.017279836814924,medium,0,0,1,0,0,0,1,0,1,0,0,0,1,0,2,0,0,0,0,2,1,2006-09-01,2009-05-01,973.0,2006.0,0,3,1
NCT05318443,A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung Cancer,"A Randomized, Double-blind, Parallel-controlled Study Comparing the Efficacy and Safety of Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection (SIBP04) and Bevacizumab Injection (Avastin) in Combination With Paclitaxel and Carboplatin Respectively in Patients With Advanced, Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer.",COMPLETED,2020-04-17,2023-01-12,2023-12-27,INTERVENTIONAL,PHASE3,512.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Non-squamous Non-small-cell Lung Cancer,SIBP04|Avastin|Paclitaxel|Carboplatin,DRUG,1,4,18 Years,75 Years,ALL,False,Shanghai Institute Of Biological Products,INDUSTRY,1,1,China,1.0,0,0,1,0,0,3.0,1,0,0,0,1,6.240275845170769,xlarge,0,1,1,0,0,1,0,0,0,0,1,1,1,1,5,1,1,0,0,4,1,,,,,0,1,0
NCT03404115,"A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease","A Multi-Center, Phase 2b, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution (0.25% and 0.1%) Compared to Vehicle in Subjects With Dry Eye Disease",COMPLETED,2018-01-02,2018-07-11,2025-02-06,INTERVENTIONAL,PHASE2,300.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Dry Eye Syndrome,Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.1%)|Vehicle Ophthalmic Solution,DRUG,1,0,18 Years,,ALL,False,"Aldeyra Therapeutics, Inc.",INDUSTRY,0,6,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.707110264748875,large,0,1,1,0,0,0,1,0,1,0,1,1,1,1,1,0,1,0,0,3,1,,,,,0,1,0
NCT03989635,Mechanistic Study of Anti-inflammatory Effects of Fevipiprant in Patients With Eosinophilic Asthma.,"Randomized, Subject and Investigator Blinded, Placebo-controlled Study to Demonstrate the Anti-inflammatory Effect of Fevipiprant (QAW039) in Moderate to Severe Asthma Patients With High Sputum and Blood Eosinophils.",WITHDRAWN,2019-10-15,2021-06-14,2020-05-14,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,"Asthma|Asthma, Bronchial|Bronchial Asthma|Eosinophilia|Physiological Effects of Drugs",QAW039,DRUG,1,0,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,0,,0.0,0,1,0,0,0,2.0,0,0,0,0,5,0.0,,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,0,1,0,0,1,0,,,,,0,1,0
NCT02736435,Treatment of Uterine Fibroids With Magnetic Resonance Guided High Intensity Focused Ultrasound,Treatment of Uterine Fibroids With Magnetic Resonance Guided High Intensity Focused Ultrasound,WITHDRAWN,2018-01-18,2018-01-18,2018-02-06,INTERVENTIONAL,PHASE3,0.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Uterine Leiomyoma,Magnetic Resonance Guided High Intensity Focused Ultrasound|leuprolide acetate for depot suspension,DRUG|DEVICE,1,8,18 Years,50 Years,FEMALE,False,Thunder Bay Regional Health Research Institute,OTHER,0,1,Canada,0.0,0,0,1,0,0,3.0,0,0,0,0,1,0.0,,1,1,0,1,0,0,0,0,0,0,0,0,1,1,9,1,1,0,1,2,1,,,,,0,2,0
NCT00210535,A Study of the Effectiveness and Safety of Topiramate for the Prevention of Migraine Attacks in Children,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Topiramate for the Prophylaxis of Migraine in Pediatric Subjects 12 to 17 Years of Age",COMPLETED,2005-06,2006-11,2011-06-08,INTERVENTIONAL,PHASE3,110.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Migraine|Vascular Headaches,Topiramate; Placebo,DRUG,1,1,12 Years,17 Years,ALL,False,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,1,0,2,4.709530201312334,medium,0,1,1,0,0,0,0,0,0,0,1,1,1,1,2,1,1,0,0,1,0,2005-06-01,2006-11-01,518.0,2005.0,0,1,0
NCT00561535,"Effect of a Probiotic, Lactobacillus FARCIMINIS, in Diarrhea Predominant IBS Patients","Effect of a Probiotic, Lactobacillus FARCIMINIS, in Diarrhea Predominant IBS",COMPLETED,2007-10,2010-06,2011-01-27,INTERVENTIONAL,PHASE2,60.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Irritable Bowel Syndrome,Lactobacillus FARCIMINIS|placebo (starch),DIETARY_SUPPLEMENT,1,1,18 Years,65 Years,ALL,False,Assistance Publique - Hôpitaux de Paris,OTHER,1,1,France,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.110873864173311,medium,1,1,0,1,0,1,0,0,0,1,1,1,1,1,2,1,0,0,0,2,1,2007-10-01,2010-06-01,974.0,2007.0,0,1,0
NCT00138567,Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 Diabetes,Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 Diabetes,COMPLETED,2005-01,2006-08,2016-11-18,INTERVENTIONAL,PHASE3,530.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2",vildagliptin,DRUG,2,5,18 Years,78 Years,ALL,,Novartis,INDUSTRY,0,2,Germany|United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.274762021241939,xlarge,0,0,1,0,1,0,1,1,1,1,1,1,1,1,7,1,1,0,0,1,0,2005-01-01,2006-08-01,577.0,2005.0,0,2,0
NCT01533467,A Device Designed to Protect the Perineum During Labor,Study of Perineal Protection Device,COMPLETED,2010-11,2011-11,2012-02-15,INTERVENTIONAL,PHASE2,1200.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Perineal Tear,Perineal protection device,DEVICE,1,0,18 Years,45 Years,FEMALE,False,Helsingborgs Hospital,OTHER,2,1,Sweden,1.0,0,1,0,0,0,2.0,0,0,0,0,1,7.0909098220799835,xlarge,0,1,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,2010-11-01,2011-11-01,365.0,2010.0,0,0,0
NCT02535767,Determining a Tolerable Dose of Primaquine in G6PD-deficient Persons Without Malaria in Mali,Determining a Tolerable Dose of Primaquine in G6PD-deficient Persons Without Malaria in Mali,COMPLETED,2015-08,2016-01,2017-02-06,INTERVENTIONAL,PHASE1|PHASE2,28.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Malaria,Primaquine,DRUG,1,12,18 Years,50 Years,MALE,True,"University of California, San Francisco",OTHER,4,1,Mali,1.0,1,1,0,0,1,1.5,0,0,0,0,1,3.367295829986474,small,1,1,0,1,0,1,0,0,0,0,0,0,1,0,13,1,1,0,0,1,0,2015-08-01,2016-01-01,153.0,2015.0,1,2,0
NCT04414800,Intranasal Ketamine Versus Intranasal Fentanyl,Intranasal Ketamine Versus Intranasal Fentanyl on Pain Management in Isolated Traumatic Patients,COMPLETED,2017-04-01,2018-04-15,2020-06-04,INTERVENTIONAL,PHASE3,125.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Multiple Trauma|Pain, Acute",Placebo|Ketamine|Fentanyl,DRUG,1,4,15 Years,65 Years,ALL,False,Isfahan University of Medical Sciences,OTHER,0,1,Iran,1.0,0,0,1,0,0,3.0,0,0,0,0,2,4.836281906951478,medium,0,1,0,1,0,0,0,0,0,0,1,1,1,1,5,1,1,0,0,3,1,,,,,0,2,0
NCT00679900,Comparison of Eplivanserin and Lormetazepam in the Treatment of Insomnia Characterized by Sleep Maintenance Difficulties,"Comparison of the Safety and Efficacy of Eplivanserin and Lormetazepam in the Treatment of Insomnia Characterized by Sleep Maintenance Difficulties. A 4 Week, Randomized, Double-blind,Comparative, Parallel-group Study",COMPLETED,2008-04,2009-03,2010-11-30,INTERVENTIONAL,PHASE3,283.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Sleep Initiation and Maintenance Disorders,eplivanserin (SR46349)|lormetazepam,DRUG,1,3,18 Years,,ALL,False,Sanofi,INDUSTRY,0,8,Netherlands|Finland|Spain|Norway|Chile|Estonia|Portugal|France,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.648974238161206,large,0,1,1,0,1,0,1,1,0,1,1,1,1,1,4,1,1,0,0,2,1,2008-04-01,2009-03-01,334.0,2008.0,0,2,0
NCT00993967,Long-Term Safety and Tolerability of Idebenone in Friedreich's Ataxia Patients (MICONOS Extension),"A Phase III Open-Label, Single-Group, Extension Study to Obtain Long-Term Safety and Tolerability Data of Idebenone in the Treatment of Friedreich's Ataxia Patients.",COMPLETED,2007-06,2012-06,2018-03-05,INTERVENTIONAL,PHASE3,200.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Freidreich's Ataxia,idebenone,DRUG,2,0,9 Years,,ALL,False,Santhera Pharmaceuticals,INDUSTRY,0,11,Netherlands|Belgium|Germany|Austria|France,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.303304908059076,medium,0,1,1,0,0,0,1,1,0,1,0,0,1,0,2,0,1,0,0,1,0,2007-06-01,2012-06-01,1827.0,2007.0,0,1,0
NCT02636907,Assessment of the Handling Experience With the BI 695501 Autoinjector in Patients With Rheumatoid Arthritis Followed by an Extension Phase Using BI 695501 Prefilled Syringe,"Assessment of Real-life Patient Handling Experience of BI 695501 Administered Subcutaneously With an Autoinjector in Patients With Rheumatoid Arthritis: an Open-label, Interventional Clinical Trial Followed by an Extension Phase of BI 695501 Administered With a Prefilled Syringe",COMPLETED,2016-01-06,2017-06-29,2018-07-10,INTERVENTIONAL,PHASE2,77.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Arthritis, Rheumatoid",BI 695501 Autoinjector|BI 695501 Prefilled syringe,DRUG,1,5,18 Years,80 Years,ALL,False,Boehringer Ingelheim,INDUSTRY,0,19,Poland|United States,1.0,0,1,0,0,0,2.0,0,1,0,0,1,4.356708826689592,medium,1,1,1,0,0,0,1,1,1,0,0,0,1,0,6,1,1,0,0,2,1,,,,,0,3,1
NCT06671392,A Phase III Study to Efficacy and Safety of DWC202405/DWC202313 and DWC202314 in Patients With Hypertension,"A Multi-center, Randomized, Double-blind, Parallel Design, Phase III Study to Evaluate and Compare the Efficacy and Safety of DWC202405/DWC202313 and DWC202314 Combination Therapy to DWC202405/DWC202313 in Patients With Essential Hypertension Inadequately Controlled With DWC202405",ACTIVE_NOT_RECRUITING,2025-02-24,2026-10,2025-12-26,INTERVENTIONAL,PHASE3,192.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Essential Hypertension,"DWC202405|DWC202405, DWC202314|DWC202405, DWC202314P|DWC202313, DWC202314|DWC202313, DWC202314P",DRUG,1,0,19 Years,,ALL,False,Daewoong Pharmaceutical Co. LTD.,INDUSTRY,0,1,South Korea,,0,0,1,0,0,3.0,0,0,0,1,1,5.262690188904886,medium,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,1,0,0,5,1,,2026-10-01,,,0,1,0
NCT02142192,Natalizumab Subcutaneous Immunogenicity and Safety Study,"A Multicenter, Open-Label Immunogenicity and Safety Study of Subcutaneous Natalizumab 300 mg Administered to Subjects With Relapsing Multiple Sclerosis",TERMINATED,2014-12-01,2015-06-04,2024-06-03,INTERVENTIONAL,PHASE2,2.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Relapsing Multiple Sclerosis,natalizumab,DRUG,1,5,18 Years,65 Years,ALL,False,Biogen,INDUSTRY,0,2,Belgium,0.0,0,1,0,0,0,2.0,0,1,0,0,1,1.0986122886681098,small,1,1,1,0,1,0,1,0,0,0,0,0,1,0,6,1,1,0,0,1,0,,,,,0,1,0
NCT02155036,Effect of Exercise on Renal Function in Predialysis,The Effect of Exercise on Renal Function and Cardiovascular Disease in Pre-dialysis (Chronic Kidney Disease Stage 3-4) Patients With Chronic Kidney Disease; a Randomised Controlled Trial Pilot Study.,COMPLETED,2011-06,2012-06,2014-06-04,INTERVENTIONAL,PHASE1|PHASE2,20.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Chronic Kidney Disease,Exercise,OTHER,1,12,18 Years,,ALL,False,King's College Hospital NHS Trust,OTHER,0,1,United Kingdom,1.0,1,1,0,0,1,1.5,0,0,0,0,1,3.044522437723423,small,1,1,0,1,0,0,0,0,0,1,1,0,1,1,13,1,0,0,0,1,0,2011-06-01,2012-06-01,366.0,2011.0,0,2,0
NCT01957436,A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer,A Prospective Randomised Phase III Study Of Androgen Deprivation Therapy With Or Without Docetaxel With Or Without Local Radiotherapy With Or Without Abiraterone Acetate And Prednisone In Patients With Metastatic Hormone-Naïve Prostate Cancer,ACTIVE_NOT_RECRUITING,2013-11-13,2032-12,2024-11-12,INTERVENTIONAL,PHASE3,1173.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Metastatic Prostate Cancer,abiraterone acetate|radiotherapy|Androgen Deprivation Therapy|Docetaxel,DRUG|RADIATION|OTHER,2,13,18 Years,,MALE,False,UNICANCER,OTHER,4,77,Italy|Belgium|Spain|Romania|Switzerland|France|Ireland,,0,0,1,0,0,3.0,1,0,0,0,1,7.068172000388042,xlarge,0,1,0,1,0,1,1,1,0,1,1,0,1,1,15,1,1,0,0,4,1,,2032-12-01,,,0,3,1
NCT04899336,A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years,"Randomized, Double-blind, Placebo-controlled, Multicenter Phase 3 Study to Assess the Efficacy, Safety And Immunogenicity of Vaccination With ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years",COMPLETED,2021-06-30,2025-08-27,2025-12-05,INTERVENTIONAL,PHASE3,17935.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention,ExPEC9V|Placebo,BIOLOGICAL|OTHER,1,30,60 Years,,ALL,True,"Janssen Research & Development, LLC",INDUSTRY,0,374,China|Germany|Japan|Taiwan|Thailand|Italy|Netherlands|South Korea|Spain|Czechia|Canada|Sweden|India|United States|United Kingdom|Australia|New Zealand|Denmark|Israel|France|Colombia,1.0,0,0,1,0,0,3.0,0,0,0,0,1,9.79456514531194,,0,1,1,0,0,0,1,1,1,1,1,1,0,1,31,1,0,1,0,2,1,,,,,0,3,1
NCT04728711,"A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of Subjects With Mild Asthma Induced by the Bronchial Allergen Challenge (BAC)","A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of ADX-629 in Subjects With Mild Asthma Induced by the Bronchial Allergen Challenge (BAC)",COMPLETED,2021-01-09,2022-01-18,2025-02-17,INTERVENTIONAL,PHASE2,8.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Atopic Asthma,ADX-629|Placebo,DRUG,1,3,18 Years,65 Years,ALL,False,"Aldeyra Therapeutics, Inc.",INDUSTRY,0,1,Canada,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.1972245773362196,small,1,1,1,0,0,0,0,0,0,0,1,1,1,0,4,1,1,0,0,2,1,,,,,0,1,0
NCT00002244,A Study to Evaluate the Safety and Effectiveness of WF10 Given to Patients With Late-Stage HIV Disease,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Pivotal Clinical Study Evaluating the Safety and Efficacy of WF10 (TCDO) Intravenous Solution in the Management of Patients With Late-Stage HIV Disease",COMPLETED,,,2005-06-24,INTERVENTIONAL,PHASE3,240.0,,,,TREATMENT,DOUBLE,HIV Infections,WF10,DRUG,0,0,18 Years,,ALL,False,OXO Chemie,INDUSTRY,0,32,Canada|United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.484796933490655,large,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,0,1,0,0,1,0,,,,,0,1,0
NCT00157534,A Study to Evaluate the Safety and Efficacy of Celgosivir in Patients With Chronic Hepatitis C Genotype 1 Infection,"A Phase II, Randomised, Dose-Ranging, Open-Label, Multi-Centre Study to Evaluate the Safety and Efficacy of Celgosivir for 12 Weeks in Patients With Chronic Hepatitis C Infection",COMPLETED,2004-10,2005-08,2005-09-12,INTERVENTIONAL,PHASE2,43.0,,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Hepatitis C, Chronic",Celgosivir,DRUG,1,1,18 Years,65 Years,ALL,False,BioWest Therapeutics Inc,INDUSTRY,0,0,,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.784189633918261,small,1,0,1,0,0,0,0,0,0,0,1,0,1,1,2,1,1,0,0,1,0,2004-10-01,2005-08-01,304.0,2004.0,0,0,0
NCT02665234,A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye Disease,A Safety and Efficacy Study of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye Disease,COMPLETED,2016-01,2017-03,2019-08-16,INTERVENTIONAL,PHASE3,400.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Keratoconjunctivitis Sicca,1% Tavilermide Ophthalmic Solution|Placebo Ophthalmic Solution,DRUG,2,3,18 Years,,ALL,False,"Mimetogen Pharmaceuticals USA, Inc.",INDUSTRY,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.993961427306569,large,0,1,1,0,0,0,0,0,1,0,1,1,1,1,5,1,1,0,0,2,1,2016-01-01,2017-03-01,425.0,2016.0,1,1,0
NCT02292134,Improving Sleep Quality in ICU Patients,Benefit of an Individual Protection Against Noise and Light on Sleep Quality in ICU Patients,COMPLETED,2012-07,2013-12,2014-11-17,INTERVENTIONAL,PHASE3,64.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Intensive Care Unit Patients,earplug and sleep mask,DEVICE,1,8,18 Years,,ALL,False,Assistance Publique - Hôpitaux de Paris,OTHER,0,1,France,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.174387269895637,medium,1,1,0,1,0,0,0,0,0,1,1,0,1,1,9,1,0,0,1,1,0,2012-07-01,2013-12-01,518.0,2012.0,0,1,0
NCT00378664,Lumbar to Sacral Ventral Nerve Re-Routing,Lumbar to Sacral Ventral Nerve Re-Routing,COMPLETED,2006-09,2015-01,2015-10-14,INTERVENTIONAL,PHASE2,13.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Urinary Incontinence|Spinal Cord Injury|Spina Bifida,lumbar to sacral ventral nerve re-routing procedure,PROCEDURE,1,4,6 Years,,ALL,True,"Kenneth Peters, MD",OTHER,1,0,,1.0,0,1,0,0,0,2.0,0,0,0,0,3,2.6390573296152584,small,1,1,0,1,0,1,0,0,0,0,0,0,1,0,5,1,0,0,0,1,0,2006-09-01,2015-01-01,3044.0,2006.0,0,1,0
NCT00393809,Safety and Proof of Concept Study of Intravesical DTA-H19 in Patients With Superficial Bladder Cancer,"Phase 1/2a, Dose-Escalation, Safety and Proof of Concept Study of Intravesical DTA-H19 in Patients With Superficial Bladder Cancer",COMPLETED,2006-01,2007-12,2008-01-07,INTERVENTIONAL,PHASE1|PHASE2,18.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Bladder Neoplasms,DTA-H19,DRUG,1,3,18 Years,,ALL,False,Hebrew University of Jerusalem,OTHER,1,2,Israel,1.0,1,1,0,0,1,1.5,0,0,0,0,1,2.9444389791664403,small,1,1,0,1,0,1,1,0,0,0,0,0,1,0,4,1,1,0,0,1,0,2006-01-01,2007-12-01,699.0,2006.0,0,1,0
NCT00394199,Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone & Formoterol Administered Alone in Patients With Asthma,"A Randomized, Double-blind, Active-controlled, Parallel Group, Stratified, Multi-center, 12-week Study Comparing the Safety & Efficacy of Fluticasone and Formoterol Combination (FlutiForm(tm) 100/10 µg Twice Daily) in a Single Inhaler (SkyePharma HFA pMDI) With the Administration of Fluticasone (100 µg Twice Daily) and Formoterol (10 µg Twice Daily) Alone in Adolescent & Adult Patients With Mild to Moderate Asthma",COMPLETED,2006-06,2008-02,2011-06-23,INTERVENTIONAL,PHASE3,357.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Asthma,Fluticasone propionate/Formoterol Fumarate 100/10|Fluticasone propionate 100|Formoterol fumarate 10,DRUG,1,3,12 Years,,ALL,False,SkyePharma AG,INDUSTRY,0,41,Canada|United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.8805329864007,large,0,1,1,0,0,0,1,1,1,0,1,1,1,1,4,1,1,0,0,3,1,2006-06-01,2008-02-01,610.0,2006.0,0,2,0
NCT03425799,Efficacy and Safety of Tranexamic Acid in Spinal Fusion Surgery,Efficacy and Safety of Tranexamic Acid in Spinal Fusion Surgery,TERMINATED,2018-10-17,2020-01-21,2021-06-21,INTERVENTIONAL,PHASE3,5.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Spinal Fusion,Sodium Chloride 0.9% Inj|Tranexamic Acid,DRUG,2,3,18 Years,,ALL,False,"Exela Pharma Sciences, LLC.",INDUSTRY,0,4,United States,0.0,0,0,1,0,0,3.0,0,0,0,0,1,1.791759469228055,small,1,1,1,0,0,0,1,0,1,0,1,1,1,1,5,1,1,0,0,2,1,,,,,0,1,0
NCT01335932,Ganciclovir/Valganciclovir for Prevention of CMV Reactivation in Acute Injury of the Lung and Respiratory Failure,A Randomized Double-Blind Placebo-Controlled Trial of Ganciclovir/Valganciclovir for Prevention of Cytomegalovirus Reactivation in Acute Injury of the Lung and Respiratory Failure (The GRAIL Study),COMPLETED,2011-03-10,2016-10-28,2018-08-21,INTERVENTIONAL,PHASE2,160.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Acute Lung Injury|Acute Respiratory Distress Syndrome|Respiratory Failure,IV Ganciclovir|Placebo,DRUG,1,66,18 Years,,ALL,False,Fred Hutchinson Cancer Center,OTHER,2,14,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,3,5.081404364984463,medium,0,1,0,1,0,1,1,0,1,0,1,1,0,1,67,1,1,0,0,2,1,,,,,0,3,1
NCT02066987,The Effects of Two Volitional Interventions to Improve Oral Health Behaviour Among Iranian Adolescents,The Effects of Two Volitional Interventions to Improve Oral Health Behaviour Among Iranian Adolescents,COMPLETED,2014-02,2014-09,2014-09-16,INTERVENTIONAL,PHASE2,1110.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,SINGLE,Oral Health Behavior Change,Implementation intention|Action planning|active control group,BEHAVIORAL,1,5,14 Years,19 Years,ALL,True,Qazvin University Of Medical Sciences,OTHER,0,1,Iran,1.0,0,1,0,0,0,2.0,0,0,0,0,1,7.01301578963963,xlarge,0,1,0,1,0,0,0,0,0,0,1,0,0,1,6,1,0,0,0,3,1,2014-02-01,2014-09-01,212.0,2014.0,0,2,0
NCT02723487,Ultrasound Guided Transversus Abdominis Plane Block in Pediatric Surgery,Postoperative Analgesic Efficacy of Transversus Abdominis Plane Block by Bupivacaine With Two Different Concentrations in Pediatric Patient Undergoing Laparoscopic Surgery,COMPLETED,2016-04,2017-10,2017-12-08,INTERVENTIONAL,PHASE2,60.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Postoperative Pain,Bupivacaine 0.125%|Bupivacaine 0.25%,DRUG,1,6,1 Year,5 Years,MALE,False,"Abdelrady S Ibrahim, MD",OTHER,0,1,Egypt,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.110873864173311,medium,1,1,0,1,0,0,0,0,0,0,1,1,0,1,7,1,1,0,0,2,1,2016-04-01,2017-10-01,548.0,2016.0,1,2,0
NCT02917187,A Phase 2a Study of BIIB074 in the Treatment of Erythromelalgia,"An Exploratory, Randomized, Double-Blind, Crossover Study to Compare the Efficacy and Safety of BIIB074 Versus Placebo in the Treatment of Primary Inherited Erythromelalgia",COMPLETED,2016-09-09,2017-01-05,2018-01-10,INTERVENTIONAL,PHASE2,8.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,TRIPLE,Primary Inherited Erythromelalgia,BIIB074|Placebo,DRUG,1,15,18 Years,,ALL,False,Biogen,INDUSTRY,0,5,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.1972245773362196,small,1,1,1,0,1,0,1,0,1,0,1,1,1,0,16,1,1,0,0,2,1,,,,,0,2,0
NCT01278693,"Effect of Oral L-carnitine Supplement on Lipid Profile, Anemia, and Quality of Life of Patients",Study of Treatment of Dyslipidemia for Hemodialysis,COMPLETED,2009-08,2010-09,2011-01-19,INTERVENTIONAL,PHASE2,54.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Complication of Hemodialysis,L-carnitine|placebo,DRUG,1,2,18 Years,75 Years,FEMALE,True,Isfahan University of Medical Sciences,OTHER,0,1,Iran,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.007333185232471,medium,1,1,0,1,0,0,0,0,0,0,1,1,1,1,3,1,1,0,0,2,1,2009-08-01,2010-09-01,396.0,2009.0,0,1,0
NCT01827293,Promethazine vs. Lorazepam for Treatment of Vertigo,Promethazine vs. Lorazepam for Treatment of Vertigo in the Emergency Department: A Randomized Clinical Trial,COMPLETED,2013-04,2013-06,2013-06-14,INTERVENTIONAL,PHASE3,210.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Peripheral Vertigo.,Promethazine|Lorazepam,DRUG,1,1,18 Years,65 Years,ALL,False,Shahid Beheshti University of Medical Sciences,OTHER,0,1,Iran,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.351858133476067,large,0,1,0,1,0,0,0,0,0,0,1,1,1,1,2,1,1,0,0,2,1,2013-04-01,2013-06-01,61.0,2013.0,0,1,0
NCT00407121,Intravitreal Bevacizumab for Inflammatory Neovascular Membranes,Intravitreal Bevacizumab for the Treatment of Neovascular Membranes in Patients With Intraocular Inflammation,WITHDRAWN,2006-12,2006-12,2024-05-30,INTERVENTIONAL,PHASE3,0.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Vogt Koyanagi Harada Disease|Serpiginous Choroiditis|Multifocal Choroiditis,Bevacizumab|Intravitreal Injection of Bevacizumab,DRUG|PROCEDURE,3,0,25 Years,60 Years,ALL,False,Asociación para Evitar la Ceguera en México,OTHER,0,1,Mexico,0.0,0,0,1,0,0,3.0,0,0,0,0,3,0.0,,1,1,0,1,0,0,0,0,0,0,0,0,1,0,3,0,1,0,0,2,1,2006-12-01,2006-12-01,0.0,2006.0,0,2,0
NCT04842721,Effect of Hypertonic Saturated Saline Mouth Rinse on Covid-19 Virus in Vivo.,Effect of Prolonged Mouth Rinse With Hypertonic Saturated Saline Solution on the Naso-Pharyngeal Viral Load of Covid-19 Virus in Vivo.,WITHDRAWN,2021-07,2021-12,2022-07-25,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Covid19,Hypertonic Saturated Saline Mouth Rinse Active Arm|Placebo Plain Water Mouth Rinse Arm,DRUG|OTHER,1,1,18 Years,65 Years,ALL,False,Rafik Batroussy,OTHER,0,1,Canada,0.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,1,1,0,1,0,0,0,0,0,0,1,0,1,1,2,1,1,0,0,2,1,2021-07-01,2021-12-01,153.0,2021.0,1,1,0
NCT02724904,Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (HSCT) For Lymphoma,A Pilot Study of Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed CNS Involvement by Lymphoma,WITHDRAWN,2017-05,2021-12,2017-03-22,INTERVENTIONAL,PHASE1|PHASE2,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Lymphoma,Allogeneic stem cell transplantation|Fludarabine|Thiotepa|Methotrexate,DRUG|PROCEDURE,1,3,18 Years,,ALL,False,Massachusetts General Hospital,OTHER,2,2,United States,0.0,1,1,0,0,1,1.5,1,0,0,0,1,0.0,,1,1,0,1,0,1,1,0,1,0,0,0,1,0,4,1,1,0,0,4,1,2017-05-01,2021-12-01,1675.0,2017.0,1,2,0
NCT06601504,Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL,"A Phase II Randomized, Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma(R/R DLBCL)",ACTIVE_NOT_RECRUITING,2024-11-05,2026-11-12,2025-06-06,INTERVENTIONAL,PHASE2,61.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Relapsed/Refractory Diffuse Large B-Cell Lymphoma,HMPL-760 planned dose 1|R-GemOx|HMPL-760 placebo planned dose 1|HMPL-760 planned dose 2|HMPL-760 placebo planned dose 2,DRUG,1,13,18 Years,,ALL,False,Hutchmed,INDUSTRY,0,16,China,,0,1,0,0,0,2.0,1,0,0,0,1,4.127134385045092,medium,1,1,1,0,0,0,1,0,0,0,1,1,1,1,14,1,1,0,0,5,1,,,,,0,2,0
NCT01389284,Evaluate Efficacy and Safety of Extended Release (ER) Naproxen Sodium,"A Randomized, Double-Blind, Placebo Controlled Trial to Assess the Analgesic Efficacy and Safety of Extended Release Naproxen Sodium Tablets in Postsurgical Dental Pain",COMPLETED,2011-06,2011-09,2015-08-25,INTERVENTIONAL,PHASE3,300.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,"Pain, Postoperative","Naproxen Sodium ER (BAYH6689)|Naproxen Sodium IR (Aleve, BAYH6689)|Naproxen Sodium ER Placebo|Naproxen Sodium IR Placebo",DRUG,1,8,15 Years,,ALL,True,Bayer,INDUSTRY,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.707110264748875,large,0,1,1,0,0,0,0,0,1,0,1,1,1,1,9,1,1,0,0,4,1,2011-06-01,2011-09-01,92.0,2011.0,0,2,0
NCT02962284,"One-year, Open Extension to Evaluate the Treatment of Patients With Castration-Resistant Prostate Cancer With YONSA™","An Open-Label, Single-Arm, Multiple Center Extension Study to Evaluate One Year of Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer With YONSA™ 500 mg (4 x 125 mg qd) With Methylprednisolone (4 mg Bid)",COMPLETED,2016-11,2018-06,2021-11-19,INTERVENTIONAL,PHASE2,20.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Metastatic Prostate Cancer,abiraterone acetate with Methylprednisolone,DRUG,1,5,18 Years,,MALE,False,Sun Pharmaceutical Industries Limited,INDUSTRY,0,0,,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.044522437723423,small,1,1,1,0,0,0,0,0,0,0,0,0,1,0,6,1,1,0,0,1,0,2016-11-01,2018-06-01,577.0,2016.0,1,1,0
NCT00536484,Fesoterodine Flexible Dose Study,"A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial To Evaluate The Efficacy And Safety Of A Fesoterodine Flexible Dose Regimen In Patients With Overactive Bladder.",COMPLETED,2007-08,2008-03,2009-09-15,INTERVENTIONAL,PHASE3,896.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Overactive Bladder,Fesoterodine|Placebo,DRUG,1,12,18 Years,,ALL,False,Pfizer,INDUSTRY,0,95,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.799055862058796,xlarge,0,1,1,0,1,0,1,0,1,0,1,1,1,1,13,1,1,0,0,2,1,2007-08-01,2008-03-01,213.0,2007.0,0,2,0
NCT00563784,TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC),A Phase II Study of TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC),COMPLETED,2007-11,2018-05-30,2019-11-20,INTERVENTIONAL,PHASE2,68.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Non-Small Cell Lung Cancer|Lung Cancer,Erlotinib|Carboplatin|Paclitaxel|Radiation Therapy,DRUG|RADIATION,1,1,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,2,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,2,4.23410650459726,medium,1,1,0,1,0,1,0,0,1,0,0,0,1,0,2,1,1,0,0,4,1,2007-11-01,,,2007.0,0,2,0
NCT02464033,EDCR Study - Etanercept Diamyd Combination Regimen -Open Trial to Evaluate Safety in Children With Type 1 Diabetes,"Open Label Trial to Evaluate the Tolerability of a Combination Therapy Consisting of GAD-alum (Diamyd®), Etanercept and Vitamin D in Children and Adolescents Newly Diagnosed With Type 1 Diabetes",COMPLETED,2015-05,2019-02-25,2021-03-29,INTERVENTIONAL,PHASE2,20.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Diabetes Mellitus, Type 1",GAD-Alum|Vitamin D|Etanercept,DRUG,8,26,8 Years,18 Years,ALL,False,Johnny Ludvigsson,OTHER_GOV,3,8,Sweden,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.044522437723423,small,1,1,0,1,0,1,1,0,0,0,0,0,1,0,34,1,1,0,0,3,1,2015-05-01,,,2015.0,1,2,0
NCT00556452,Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen,Phase I/II Study of Myeloablative Allogeneic Stem Cell Transplantation for Aggressive Hematologic Malignancies Using Clofarabine and Busulfan x 4 (Clo/BU4) Regimen,COMPLETED,2007-10,2012-09,2017-12-05,INTERVENTIONAL,PHASE1|PHASE2,46.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Leukemia|Hodgkin Lymphoma|Non-Hodgkin Lymphoma|Multiple Myeloma|Myelodysplastic Syndrome,Clofarabine/Busulfan x 4|Peripheral blood stem cell transplant|Total Lymphoid Irradiation,DRUG|RADIATION|PROCEDURE,2,2,,70 Years,ALL,False,University of Michigan Rogel Cancer Center,OTHER,1,1,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,5,3.8501476017100584,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,4,1,1,0,0,3,1,2007-10-01,2012-09-01,1797.0,2007.0,0,3,1
NCT02673749,"Efficacy, Safety, and Tolerability Study of RP-G28 in Subjects With Lactose Intolerance","A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Two Doses of RP-G28 in Subjects With Lactose Intolerance",COMPLETED,2016-02,2016-10,2018-04-04,INTERVENTIONAL,PHASE2|PHASE3,377.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Lactose Intolerance,RP-G28|Placebo,DRUG|OTHER,1,0,18 Years,75 Years,ALL,False,"Ritter Pharmaceuticals, Inc.",INDUSTRY,0,1,United States,1.0,0,1,1,0,1,2.5,0,0,0,0,1,5.934894195619588,large,0,1,1,0,0,0,0,0,1,0,1,1,1,1,1,0,1,0,0,2,1,2016-02-01,2016-10-01,243.0,2016.0,1,2,0
NCT00000838,"Antiviral Activity of and Resistance to Lamivudine in Combination With Zidovudine, Stavudine, or Didanosine","A Phase II, Randomized Study of the Antiviral Activity and Resistance Interactions of Lamivudine (3TC) in Combination With Zidovudine (AZT), Stavudine (d4T), or Didanosine (ddI) Versus Monotherapy With ddI or d4T in HIV-Infected Individuals With 200 - 600 CD4+ Cells/mm3 and No Previous Nucleoside Experience",COMPLETED,,1998-03,2021-11-04,INTERVENTIONAL,PHASE2,256.0,,,,TREATMENT,,HIV Infections,Lamivudine|Stavudine|Zidovudine|Didanosine,DRUG,0,0,12 Years,,ALL,False,National Institute of Allergy and Infectious Diseases (NIAID),NIH,0,32,Puerto Rico|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.54907608489522,large,0,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,4,1,,1998-03-01,,,0,2,0
NCT01151748,Intra-arterial Chemotherapy for Advanced Intraocular Retinoblastoma,Intra-arterial Chemotherapy for Advanced Intraocular Retinoblastoma,WITHDRAWN,2010-09,2012-03,2012-05-14,INTERVENTIONAL,PHASE2,0.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Retinoblastoma|Eye Cancer,Intra-arterial infusion of chemotherapy,PROCEDURE,1,0,,18 Years,ALL,False,Stanford University,OTHER,0,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,2,0.0,,1,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,2010-09-01,2012-03-01,547.0,2010.0,0,1,0
NCT00575055,Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier),"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients With Mild to Moderate Alzheimer's Disease Who Are Apolipoprotein E4 Carriers.",COMPLETED,2007-12,2012-04,2013-11-25,INTERVENTIONAL,PHASE3,1121.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Alzheimer's Disease,Bapineuzumab 0.5 mg/kg|Placebo Control|Bapineuzumab 1.0 m/kg,DRUG,1,2,50 Years,88 Years,ALL,False,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",INDUSTRY,1,186,United States,1.0,0,0,1,0,0,3.0,0,0,1,0,1,7.022868086082641,xlarge,0,1,1,0,0,1,1,0,1,0,1,1,1,1,3,1,1,0,0,3,1,2007-12-01,2012-04-01,1583.0,2007.0,0,1,0
NCT00994955,Selective Retina Therapy (SRT) for Clinically Significant Diabetic Macular Edema,Selective Retina Therapy (SRT) for Clinically Significant Diabetic Macular,COMPLETED,2006-01,2009-10,2013-01-16,INTERVENTIONAL,PHASE1|PHASE2,39.0,ACTUAL,,SINGLE_GROUP,TREATMENT,SINGLE,Diabetic Macular Edema,selective retina therapy (SRT),DEVICE,1,1,18 Years,,ALL,False,University Hospital Schleswig-Holstein,OTHER,2,0,,1.0,1,1,0,0,1,1.5,0,0,0,0,1,3.6888794541139363,small,1,1,0,1,0,1,0,0,0,0,0,0,1,0,2,1,0,0,1,1,0,2006-01-01,2009-10-01,1369.0,2006.0,0,1,0
NCT03167255,Extension Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD),"A Phase II, Open-Label, Extension Study to Assess the Safety and Efficacy of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)",COMPLETED,2017-07-06,2021-11-15,2022-12-28,INTERVENTIONAL,PHASE2,16.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Duchenne Muscular Dystrophy,NS-065/NCNP-01,DRUG,3,11,4 Years,10 Years,MALE,False,"NS Pharma, Inc.",INDUSTRY,3,6,Canada|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.833213344056216,small,1,1,1,0,0,1,1,1,1,0,0,0,1,1,14,1,1,0,0,1,0,,,,,0,2,0
NCT00004755,"Allopurinol, Glucantime, or Allopurinol/Glucantime for Cutaneous Leishmaniasis in Brazil",Phase II Randomized Study of Allopurinol Versus Glucantime Versus Allopurinol/Glucantime for Cutaneous Leishmaniasis in Brazil,COMPLETED,1995-09,,2005-06-24,INTERVENTIONAL,PHASE2,375.0,,RANDOMIZED,PARALLEL,TREATMENT,NONE,Leishmaniasis,allopurinol|glucantime,DRUG,0,0,12 Years,,ALL,False,National Institute of Allergy and Infectious Diseases (NIAID),NIH,1,0,,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.929589143389895,large,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,2,1,1995-09-01,,,1995.0,0,1,0
NCT01968226,TRACER RGD-K5 Carotid Plaque Imaging Study,"An Exploratory, Phase II, Open Label, Single-Center, Non-Randomized Study Of [F-18] RGD-K5 Positron Emission Tomography (PET) In Participants With Carotid Artery Stenosis",TERMINATED,2013-11,2016-06,2017-09-12,INTERVENTIONAL,PHASE2,3.0,ACTUAL,,SINGLE_GROUP,DIAGNOSTIC,NONE,Carotid Artery Disease|Carotid Stenosis,[F-18] RDG-K5,DRUG,1,0,18 Years,,ALL,False,The Cleveland Clinic,OTHER,0,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,2,1.3862943611198906,small,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,2013-11-01,2016-06-01,943.0,2013.0,0,1,0
NCT02155985,Modulation of Immune Activation by Aspirin,Modulation of Immune Activation by Aspirin,COMPLETED,2014-08,2015-07,2017-06-12,INTERVENTIONAL,PHASE2,121.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,HIV-1 Infection,Aspirin|Placebo,DRUG,1,19,18 Years,,ALL,False,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections,NETWORK,1,15,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.804021044733257,medium,0,1,0,0,0,1,1,0,1,0,1,1,1,1,20,1,1,0,0,2,1,2014-08-01,2015-07-01,334.0,2014.0,0,2,0
NCT00912015,A Comparison of the Analgesic Efficacy and Safety of Once Daily Tramadol OAD Tablets to Twice Daily Tramadol BID for the Treatment of Osteoarthritis of the Knee (Extension Protocol) and Open Label Safety Follow-Up,A Comparison of the Analgesic Efficacy and Safety of Once Daily Tramadol OAD Tablets to Twice Daily Tramadol BID for the Treatment of Osteoarthritis of the Knee (Extension Protocol) and Open Label Safety Follow-Up,COMPLETED,2002-03,2003-07,2012-04-30,INTERVENTIONAL,PHASE3,238.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Pain|Osteoarthritis, Knee",Tramadol OAD|Tramadol OAD|Tramadol OAD|Tramadol OAD 100mg,DRUG,1,0,40 Years,75 Years,ALL,False,Labopharm Inc.,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,1,0,0,2,5.476463551931511,large,0,1,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,4,1,2002-03-01,2003-07-01,487.0,2002.0,0,2,0
NCT05635734,Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma,A Phase I/II Open Label Study to Assess Safety and Preliminary Evidence of a Therapeutic Effect of Azeliragon Combined with Conventional Concurrent Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma,ACTIVE_NOT_RECRUITING,2023-09-05,2025-12,2024-11-18,INTERVENTIONAL,PHASE1|PHASE2,18.0,ESTIMATED,,SINGLE_GROUP,TREATMENT,NONE,Glioblastoma,Azeliragon 5 mg|Azeliragon 10 mg|Azeliragon 20 mg,DRUG,1,7,18 Years,70 Years,ALL,False,Cantex Pharmaceuticals,INDUSTRY,0,4,Spain,,1,1,0,0,1,1.5,0,0,0,0,1,2.9444389791664403,small,1,0,1,0,0,0,1,0,0,1,0,0,1,0,8,1,1,0,0,3,1,,2025-12-01,,,0,3,1
NCT00083564,"Study Comparing STR (Skeletal Targeted Radiotherapy) Plus Melphalan to Melphalan Alone, With Stem Cell Transplant in Multiple Myeloma",A Randomized Multicenter Study to Compare the Safety and Efficacy of 166Ho-DOTMP Plus Melphalan to Melphalan Alone as Conditioning for Autologous Peripheral Blood Stem Cell Transplant in Subjects With Primary Refractory Multiple Myeloma,TERMINATED,2004-03,,2009-03-31,INTERVENTIONAL,PHASE3,240.0,,RANDOMIZED,PARALLEL,TREATMENT,NONE,Multiple Myeloma,"STR(TM) (Skeletal Targeted Radiotherapy, Holmium-166-DOTMP)",DRUG,0,0,18 Years,70 Years,ALL,False,Poniard Pharmaceuticals,INDUSTRY,0,21,Canada|United States,0.0,0,0,1,0,0,3.0,1,0,0,0,1,5.484796933490655,large,0,0,1,0,0,0,1,1,1,0,1,0,1,1,0,0,1,0,0,1,0,2004-03-01,,,2004.0,0,1,0
NCT02126332,Epidural Analgesia for Pancreatitis (Epipan Study),"A MULTICENTER, RANDOMIZED, CONTROLLED STUDY OF EPIDURAL ANALGESIA FOR SEVERE ACUTE PANCREATITIS",COMPLETED,2014-06-06,2019-02-26,2020-05-01,INTERVENTIONAL,PHASE3,148.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Severe Acute Pancreatitis,"ropivacaine and sufentanil|acetaminophen, nefopam, tramadol, opidoids",OTHER,1,7,18 Years,,ALL,False,"University Hospital, Clermont-Ferrand",OTHER,0,1,France,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.003946305945459,medium,0,1,0,1,0,0,0,0,0,1,1,0,1,1,8,1,0,0,0,2,1,,,,,0,2,0
NCT01346098,Islet Autotransplantation in Patients at Very High-risk Pancreatic Anastomosis,Total Pancreatectomy With Islet Autotransplantation as a Superior Alternative to Pancreatoduodenectomy in Patients at Very High-risk of Complications of the Pancreatic Anastomosis: a Single-center Prospective Randomised Clinical Trial,COMPLETED,2010-07,2019-04,2020-11-03,INTERVENTIONAL,PHASE2,60.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Postpancreatectomy Hyperglycemia,Pancreaticoduodenectomy with pancreatic anastomosis|Total pancreatectomy with islet autotransplantation,PROCEDURE,1,2,18 Years,,ALL,False,Ospedale San Raffaele,OTHER,1,1,Italy,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.110873864173311,medium,1,1,0,1,0,1,0,0,0,1,1,0,1,1,3,1,0,0,0,2,1,2010-07-01,2019-04-01,3196.0,2010.0,0,1,0
NCT00075998,The INSPIRE Trial: A Study of Interferon Gamma-1b for Idiopathic Pulmonary Fibrosis (IPF),"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis (The INSPIRE Trial)",TERMINATED,2003-12,2007-05,2009-07-02,INTERVENTIONAL,PHASE3,826.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Idiopathic Pulmonary Fibrosis|Lung Disease|Pulmonary Fibrosis,"Interferon gamma-1b (""Actimmune"")",DRUG,1,3,40 Years,79 Years,ALL,False,InterMune,INDUSTRY,0,1,United States,0.0,0,0,1,0,0,3.0,0,0,0,0,3,6.717804695023691,xlarge,0,1,1,0,0,0,0,0,1,0,1,1,1,1,4,1,1,0,0,1,0,2003-12-01,2007-05-01,1247.0,2003.0,0,1,0
NCT01221298,"A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)","An Open-Label Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV) in Treatment-Naive Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection",COMPLETED,2010-10,2012-04,2015-01-08,INTERVENTIONAL,PHASE2,11.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Hepatitis C|HCV|Chronic Hepatitis C Infection|Hepatitis C Genotype 1,ABT-450|ABT-072|Ribavirin|Ritonavir,DRUG,1,6,18 Years,65 Years,ALL,False,"AbbVie (prior sponsor, Abbott)",INDUSTRY,0,4,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,4,2.4849066497880004,small,1,1,1,0,1,0,1,0,1,0,0,0,1,0,7,1,1,0,0,4,1,2010-10-01,2012-04-01,548.0,2010.0,0,3,1
NCT05118763,Intranasal INNA-051 for Prevention of COVID-19 in Adults,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Efficacy of Intranasal INNA-051 for Prevention of COVID-19 in Adults Following Close Contact With Individuals With SARS-CoV-2 Infection",WITHDRAWN,2022-03-01,2022-12-31,2022-04-14,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,COVID-19 Pandemic,INNA-051|Placebo,DRUG|OTHER,2,8,18 Years,,ALL,True,ENA Respiratory Pty Ltd,INDUSTRY,0,0,,0.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,1,1,1,0,0,0,0,0,0,0,1,1,0,1,10,1,1,0,0,2,1,,,,,0,2,0
NCT02320487,A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL),"A Phase II, Open-Label Study of Obinutuzumab Plus Bendamustine (BG) in Patients With Previously Untreated Chronic Lymphocytic Leukemia",COMPLETED,2015-03-31,2019-02-06,2020-02-11,INTERVENTIONAL,PHASE2,102.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Chronic Lymphocytic Leukemia,Bendamustine|Obinutuzumab,DRUG,1,14,18 Years,,ALL,False,"Genentech, Inc.",INDUSTRY,0,26,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.634728988229636,medium,0,1,1,0,0,0,1,0,1,0,0,0,1,0,15,1,1,0,0,2,1,,,,,0,2,0
NCT01173887,"Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15","Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma (Untreated Primary Disease)",COMPLETED,2010-07,2012-04,2017-03-30,INTERVENTIONAL,PHASE2,44.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Adult T-cell Leukemia-Lymphoma,VCAP/AMP/VECP(mLSG15)|KW-0761,DRUG|BIOLOGICAL,1,5,20 Years,,ALL,False,"Kyowa Kirin Co., Ltd.",INDUSTRY,0,19,Japan,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.8066624897703196,small,1,1,1,0,0,0,1,0,0,0,1,0,1,1,6,1,1,1,0,2,1,2010-07-01,2012-04-01,640.0,2010.0,0,2,0
NCT03691987,The Comeback Study,Fecal Microbiota Transplantation in Chronic Fatigue Syndrome - an RCT,COMPLETED,2019-02-15,2023-12-31,2024-02-23,INTERVENTIONAL,PHASE2,80.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Chronic Fatigue Syndrome|Myalgic Encephalomyelitis,Preprocessed thawed donor FMT|Preprocessed thawed autologous FMT,BIOLOGICAL,1,9,18 Years,65 Years,ALL,False,University Hospital of North Norway,OTHER,4,1,Norway,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.394449154672439,medium,1,1,0,1,0,1,0,0,0,0,1,1,1,1,10,1,0,1,0,2,1,,,,,0,3,1
NCT03836287,Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-301),"A Multicenter, Randomized, Double-Blinded, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Topically Applied Sofpironium Bromide Gel, 15% in Subjects With Axillary Hyperhidrosis",COMPLETED,2020-10-09,2021-06-25,2024-06-06,INTERVENTIONAL,PHASE3,350.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Axillary Hyperhidrosis,"Sofpironium Bromide Gel, 15%|Vehicle",DRUG,2,0,9 Years,,ALL,False,Botanix Pharmaceuticals,INDUSTRY,0,39,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.860786223465865,large,0,1,1,0,0,0,1,0,1,0,1,1,1,1,2,0,1,0,0,2,1,,,,,0,1,0
NCT05207514,Compare the Efficacy and the Safety of Taxotere and Nanoxel M as Neoadjuvant Chemotherapy in Breast Cancer,"Open-label, Randomized, Active-controlled, Multicenter, Phase III Clinical Trial to Compare the Efficacy and the Safety of Taxotere and Nanoxel M as Neoadjuvant Chemotherapy in Breast Cancer",TERMINATED,2022-03-31,2024-05-09,2024-05-17,INTERVENTIONAL,PHASE3,26.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Breast Cancer,Nanoxel M|Taxotere|Doxorubicin|Cyclophosphamide,DRUG,1,0,19 Years,,FEMALE,False,Samyang Biopharmaceuticals Corporation,INDUSTRY,0,1,South Korea,0.0,0,0,1,0,0,3.0,1,0,0,0,1,3.295836866004329,small,1,1,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0,4,1,,,,,0,1,0
NCT00069316,Omr-IgG-am(Trademark) for Treating Patients With or at High Risk for West Nile Virus Disease,"A Phase I/II Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of Intravenous Immunoglobulin G (Omr-IgG-am) Containing High Anti-West Nile Virus Antibody Titers in Patients With, or at High Risk for Progression to West Nile Virus(WNV)",COMPLETED,2003-09-22,2007-06-27,2017-07-02,INTERVENTIONAL,PHASE2,2.0,ACTUAL,RANDOMIZED,,TREATMENT,DOUBLE,West Nile Virus,Omr-IgG-am,DRUG,0,0,18 Years,,ALL,False,National Institutes of Health Clinical Center (CC),NIH,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,1.0986122886681098,small,1,1,0,1,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,1,0,,,,,0,0,0
NCT01304316,Dose-Escalation Safety and Pharmacokinetic Study of K305,Cardiovascular Changes and Tetracaine Pharmacokinetics Following Intranasal Administration of Standard and High Doses of Kovacaine Mist (Tetracaine Hydrochloride With Oxymetazoline Hydrochloride) in Healthy Volunteers,COMPLETED,2010-09,2010-11,2017-08-31,INTERVENTIONAL,PHASE2,12.0,ACTUAL,,SINGLE_GROUP,SUPPORTIVE_CARE,NONE,Anesthesia,Tetracaine HCl 3% and Oxymetazoline HCl 0.05%,DRUG,6,4,18 Years,,ALL,True,"St. Renatus, LLC",INDUSTRY,2,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.5649493574615367,small,1,1,1,0,0,1,0,0,1,0,0,0,0,0,10,1,1,0,0,1,0,2010-09-01,2010-11-01,61.0,2010.0,0,1,0
NCT01020006,Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine,Phase II Study of Coagulation Factor VIIa Inhibitor PCI-27483 in Pancreatic Cancer Patients Receiving Treatment With Gemcitabine,COMPLETED,2009-11,,2014-04-24,INTERVENTIONAL,PHASE2,42.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Pancreatic Cancer|Ductal Adrenocarcinoma|Exocrine Pancreatic Cancer,PCI-27483|Gemcitabine,DRUG,1,0,18 Years,,ALL,False,Pharmacyclics LLC.,INDUSTRY,0,17,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,3,3.7612001156935624,small,1,1,1,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,0,2,1,2009-11-01,,,2009.0,0,2,0
NCT00698204,Cox-2 Inhibition in Radiation-induced Oral Mucositis,Cyclooxygenase-2 Inhibition in Radiation-Induced Oral Mucositis,COMPLETED,2003-07,2013-12,2014-06-05,INTERVENTIONAL,PHASE2,43.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Oral Mucositis,celecoxib|placebo,DRUG,1,1,18 Years,75 Years,ALL,False,UConn Health,OTHER,2,2,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.784189633918261,small,1,1,0,1,0,1,1,0,1,0,1,1,0,1,2,1,1,0,0,2,1,2003-07-01,2013-12-01,3806.0,2003.0,0,1,0
NCT01092104,"A Proof of Concept Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve Patients","A Proof of Concept, Multiple Dose-Escalating Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve Patients",COMPLETED,2009-02,2009-11,2013-07-10,INTERVENTIONAL,PHASE1|PHASE2,52.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,HIV-1 Infection,TBR-652|TBR-652 Matching Placebo|TBR-652 50 mg|TBR-652 75 mg|TBR-652 100 mg|TBR-652 150 mg,DRUG,1,0,18 Years,,ALL,False,"Tobira Therapeutics, Inc.",INDUSTRY,0,0,,1.0,1,1,0,0,1,1.5,0,0,0,0,1,3.970291913552122,medium,1,1,1,0,0,0,0,0,0,0,1,1,1,1,1,0,1,0,0,6,1,2009-02-01,2009-11-01,273.0,2009.0,0,2,0
NCT00002184,"A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patient","A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patients With CD4 Cell Counts >= 100/mm3 and HIV-1 RNA Copy Numbers >= 5,000 Copies/Ml and Prior RTI Therapy But No Prior PI Therapy",COMPLETED,,,2005-06-24,INTERVENTIONAL,PHASE2,120.0,,,,TREATMENT,DOUBLE,HIV Infections,Nelfinavir mesylate|Levocarnitine|Adefovir dipivoxil|Saquinavir|Lamivudine|Stavudine|Zidovudine,DRUG,0,0,16 Years,,ALL,False,Gilead Sciences,INDUSTRY,0,15,Puerto Rico|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.795790545596741,medium,0,0,1,0,1,0,1,1,1,0,0,1,1,0,0,0,1,0,0,7,1,,,,,0,2,0
NCT00280384,An Electrophysiological Study Of E2014 In Healthy Adult Male Japanese And Caucasian Subjects,An Electrophysiological Study Of E2014 In Healthy Adult Male Japanese And Caucasian Subjects,COMPLETED,2006-01,,2013-04-25,INTERVENTIONAL,PHASE2,48.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Spasmodic Torticollis,E2014 (Botulinum toxin type B)|E2014 (Botulinum toxin type B) Placebo,DRUG,4,0,20 Years,44 Years,MALE,False,Eisai Limited,INDUSTRY,0,1,Japan,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.8918202981106265,small,1,1,1,0,0,0,0,0,0,0,1,0,1,1,4,0,1,0,0,2,1,2006-01-01,,,2006.0,0,1,0
NCT01729884,Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer,Phase II Study to Evaluate the Development of HER2/Neu (HER2)-Specific Memory T Cells After HER2 Peptide-based Vaccination in Patients With Advanced Stage Her2+ Breast Cancer,TERMINATED,2012-12,,2017-04-11,INTERVENTIONAL,PHASE2,3.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer,HER-2/neu peptide vaccine,BIOLOGICAL,2,2,19 Years,,ALL,False,University of Washington,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,4,1.3862943611198906,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,4,1,0,1,0,1,0,2012-12-01,,,2012.0,0,1,0
NCT01254084,Effect of Gynostemma Pentaphyllum Tea in Insulin Sensitivity in Type 2 Diabetic Patients,Gynostemma Pentaphyllum Tea Improves Insulin Sensitivity in Type 2 Diabetic Patients,COMPLETED,2010-02,2010-11,2010-12-06,INTERVENTIONAL,PHASE1|PHASE2,16.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Type 2 Diabetes,Gynostemma Pentaphyllum tea|Placebo tea,DIETARY_SUPPLEMENT,1,5,40 Years,70 Years,ALL,False,Hanoi Medical University,OTHER,2,2,Vietnam,1.0,1,1,0,0,1,1.5,0,0,0,0,1,2.833213344056216,small,1,1,0,1,0,1,1,0,0,0,1,1,1,0,6,1,0,0,0,2,1,2010-02-01,2010-11-01,273.0,2010.0,0,3,1
NCT00774384,Regulation of Mucosal Immune Response to Systemic MenB Vaccine,"A Phase II, Open Label, Randomised, Single Centre Study To Evaluate The Importance Of Naturally Induced Immune Regulation On The Mucosal Immune Response To Meningococcal Serogroup B Outer Membrane Vesicle (Omv) Vaccine When Administered Intramuscularly To Adults & Adolescents",COMPLETED,2009-09,2011-11,2016-11-15,INTERVENTIONAL,PHASE2,9.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Meningococcal Infections,NZ MenB OMV vaccine (NZ98/254),BIOLOGICAL,1,3,16 Years,40 Years,ALL,True,University Hospitals Bristol and Weston NHS Foundation Trust,OTHER,4,2,United Kingdom,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.302585092994046,small,1,1,0,1,1,1,1,0,0,1,1,0,0,1,4,1,0,1,0,1,0,2009-09-01,2011-11-01,791.0,2009.0,0,0,0
NCT00787384,Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes,Therapeutic and Biological Effects of Imatinib Mesylate in Primary Hypereosinophilic Syndromes,COMPLETED,2004-10,2007-12,2010-12-29,INTERVENTIONAL,PHASE2,25.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Hypereosinophilic Syndrome|Chronic Eosinophilic Leukemia|Chronic Idiopathic Hypereosinophilia,Imatinib,DRUG,1,4,15 Years,,ALL,False,Northern Italy Leukemia Group,OTHER,0,4,Italy,1.0,0,1,0,0,0,2.0,1,0,0,0,3,3.258096538021482,small,1,1,0,1,0,0,1,0,0,1,0,0,1,0,5,1,1,0,0,1,0,2004-10-01,2007-12-01,1156.0,2004.0,0,1,0
NCT05146284,Study to Assess PXL770 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD),A Randomized Open-label Phase 2a Study to Assess PXL770 After 12 Weeks of Treatment in Male Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD),WITHDRAWN,2023-09,2024-09,2024-12-16,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Adrenomyeloneuropathy,PXL770,DRUG,4,0,18 Years,65 Years,MALE,False,Poxel SA,INDUSTRY,0,0,,0.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,1,1,1,0,0,0,0,0,0,0,1,0,1,1,4,0,1,0,0,1,0,2023-09-01,2024-09-01,366.0,2023.0,1,0,0
NCT00397033,Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder.,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Two Dosages of Paliperidone ER in the Treatment of Patients With Schizoaffective Disorder.",COMPLETED,2006-11,2008-02,2013-07-29,INTERVENTIONAL,PHASE3,316.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Schizoaffective Disorder|Psychotic Disorder,Paliperidone ER|Paliperidone ER|Placebo,DRUG,2,12,18 Years,65 Years,ALL,False,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INDUSTRY,1,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,2,5.75890177387728,large,0,1,1,0,0,1,0,0,0,0,1,1,1,1,14,1,1,0,0,3,1,2006-11-01,2008-02-01,457.0,2006.0,0,3,1
NCT01361633,The Cognitive Enhancing Effects of D-Cycloserine Among Non-Demented Elderly,The Cognitive Enhancing Effects of D-Cycloserine Among Non-Demented Elderly,COMPLETED,2008-01,2009-02,2021-02-18,INTERVENTIONAL,PHASE2,51.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Treatment|Placebo,d-cycloserine|Sugar Pill,DRUG,1,6,60 Years,,ALL,True,Hartford Hospital,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,3.9512437185814275,medium,1,1,0,1,0,0,0,0,1,0,1,1,1,1,7,1,1,0,0,2,1,2008-01-01,2009-02-01,397.0,2008.0,0,3,1
NCT00263952,Efficacy and Safety of a Purified Standardised Bee Venom Preparation,Immunotherapy of Bee Venom Allergy: Evaluation of a New Purified Bee Venom Preparation in Comparison With Already Published Studies.,COMPLETED,2003-03,2010-04,2013-03-04,INTERVENTIONAL,PHASE3,,,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Bee Venom Allergy,bee venom,BIOLOGICAL,0,0,18 Years,65 Years,ALL,False,Allergopharma GmbH & Co. KG,INDUSTRY,0,1,Germany,1.0,0,0,1,0,0,3.0,0,0,0,0,1,0.0,,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,2003-03-01,2010-04-01,2588.0,2003.0,0,0,0
NCT01582152,Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma,Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus TPI 287 in Adults With Recurrent Glioblastoma,TERMINATED,2012-07,2016-03,2019-06-05,INTERVENTIONAL,PHASE1|PHASE2,12.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Brain Neoplasms|Central Nervous System Neoplasms,TPI287|Bevacizumab,DRUG,1,1,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,1,United States,0.0,1,1,0,0,1,1.5,0,0,0,0,2,2.5649493574615367,small,1,1,0,1,0,1,0,0,1,0,1,0,1,0,2,1,1,0,0,2,1,2012-07-01,2016-03-01,1339.0,2012.0,0,3,1
NCT06485752,Phase 3 Lot Consistency Study of Trivalent Hemagglutinin Nanoparticle Influenza Vaccine,"A Phase 3, Randomized, Observer-Blinded, Study to Compare the Safety and Immunogenicity of 3 Lots of Trivalent Hemagglutinin Nanoparticle Influenza Vaccine With Matrix M™ Adjuvant in Participants ≥ 60 Years of Age",WITHDRAWN,2024-11,2025-02-04,2025-03-11,INTERVENTIONAL,PHASE2|PHASE3,0.0,ACTUAL,RANDOMIZED,CROSSOVER,PREVENTION,SINGLE,COVID-19,tNIV 1 and Matrix-M Adjuvant,BIOLOGICAL,5,3,60 Years,75 Years,ALL,True,Novavax,INDUSTRY,0,0,,0.0,0,1,1,0,1,2.5,0,0,0,0,1,0.0,,1,1,1,0,0,0,0,0,0,0,1,0,0,0,8,1,0,1,0,1,0,2024-11-01,,,2024.0,1,2,0
NCT00423852,"Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin","Phase I/II Trial of Sequential Paclitaxel/Ifosfamide Followed by Dose-Escalated, Dose-Intensive Carboplatin, Paclitaxel and Ifosfamide With Stem Cell Support in Cisplatin-Resistant Germ Cell Tumor Patients",COMPLETED,2006-08,2013-02,2016-05-18,INTERVENTIONAL,PHASE1|PHASE2,26.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Brain and Central Nervous System Tumors|Extragonadal Germ Cell Tumor|Ovarian Cancer|Teratoma|Testicular Germ Cell Tumor,filgrastim|carboplatin|ifosfamide|paclitaxel|autologous hematopoietic stem cell transplantation|peripheral blood stem cell transplantation,DRUG|BIOLOGICAL|PROCEDURE,2,0,18 Years,120 Years,ALL,False,Memorial Sloan Kettering Cancer Center,OTHER,1,1,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,5,3.295836866004329,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,2,0,1,1,0,6,1,2006-08-01,2013-02-01,2376.0,2006.0,0,3,1
NCT06383052,A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC,"A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, Radiation Dosimetry and Efficacy of 177Lu-NYM032 Injection in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer",ACTIVE_NOT_RECRUITING,2024-04-26,2026-06-30,2025-05-21,INTERVENTIONAL,PHASE1|PHASE2,30.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Metastatic Castration-resistant Prostate Cancer,177Lu-NYM032 injection,DRUG,2,0,18 Years,,MALE,False,"Norroy Bioscience Co., LTD",INDUSTRY,0,1,China,,1,1,0,0,1,1.5,1,0,0,0,1,3.4339872044851463,small,1,1,1,0,0,0,0,0,0,0,0,0,1,0,2,0,1,0,0,1,0,,,,,0,1,0
NCT05058638,Effectiveness of Aquamin® in Mitigating Halitosis,Evaluation of Halitosis Using a Multi-Mineral Approach (Aquamin®),ACTIVE_NOT_RECRUITING,2022-08-15,2026-12,2026-01-20,INTERVENTIONAL,PHASE2,15.0,ESTIMATED,,SINGLE_GROUP,TREATMENT,NONE,Healthy|Halitosis,Aquamin,DRUG,1,0,18 Years,99 Years,ALL,True,University of Michigan,OTHER,0,1,United States,,0,1,0,0,0,2.0,0,0,0,0,2,2.772588722239781,small,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,,2026-12-01,,,0,1,0
NCT03002038,Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients,"Comparison of Annual Relapse Rate, Expanded Disability Status Scale, and Side Effects Between Azathioprine and Rituximab in Patients With Neuromyelitis Optica Spectrum Disorders",COMPLETED,2015-09,2016-12,2020-09-30,INTERVENTIONAL,PHASE2|PHASE3,86.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Neuromyelitis Optica Spectrum Disorder,Azathioprine|Rituximab,DRUG,1,1,18 Years,50 Years,ALL,False,Isfahan University of Medical Sciences,OTHER,0,1,Iran,1.0,0,1,1,0,1,2.5,0,0,0,0,1,4.465908118654584,medium,1,1,0,1,0,0,0,0,0,0,1,0,1,1,2,1,1,0,0,2,1,2015-09-01,2016-12-01,457.0,2015.0,1,2,0
NCT06402838,A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD),"A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter, Parallel-Group Study to Investigate the Safety, Tolerability, and the Effect of RO7269162 on Amyloid and Non-Amyloid Disease-Related Biomarkers Following Daily Oral Administration in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease",ACTIVE_NOT_RECRUITING,2024-05-02,2026-11-10,2025-11-20,INTERVENTIONAL,PHASE2,256.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Alzheimer's Disease,RO7269162|Placebo,DRUG,2,8,60 Years,85 Years,ALL,False,Hoffmann-La Roche,INDUSTRY,0,48,Italy|South Korea|Spain|Germany|United Kingdom|Chile|Poland|Denmark|France,,0,1,0,0,0,2.0,0,0,1,0,1,5.54907608489522,large,0,1,1,0,1,0,1,1,0,1,1,1,1,1,10,1,1,0,0,2,1,,,,,0,3,1
NCT02931838,Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis,"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis",COMPLETED,2016-11-15,2017-11-16,2020-11-27,INTERVENTIONAL,PHASE2,268.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Psoriasis,BMS-986165|Placebo for BMS-986165,DRUG,2,5,18 Years,70 Years,ALL,False,Bristol-Myers Squibb,INDUSTRY,0,76,Latvia|United States|Germany|Australia|Poland|Japan|Mexico|Canada,1.0,0,1,0,0,0,2.0,0,1,0,0,1,5.594711379601839,large,0,1,1,0,1,0,1,1,1,1,1,1,1,1,7,1,1,0,0,2,1,,,,,0,3,1
NCT02407548,The Effects of Dietary Supplement of Coenzyme Q10（CoQ10） on Dyslipidemia,The Effects of Dietary Supplement of Coenzyme Q10 on Dyslipidemia,COMPLETED,2015-07,2017-04,2017-06-22,INTERVENTIONAL,PHASE3,150.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Dyslipidemia,coenzyme Q10 vitamin E softgel|coenzyme Q10 softgel|placebo softgel,DIETARY_SUPPLEMENT,1,2,18 Years,65 Years,ALL,False,Sun Yat-sen University,OTHER,0,1,China,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.017279836814924,medium,0,1,0,1,0,0,0,0,0,0,1,1,1,1,3,1,0,0,0,3,1,2015-07-01,2017-04-01,640.0,2015.0,1,1,0
NCT01554826,Clinical Trial of the Inactivated Influenza Vaccine (0.25ml Formulation for Pediatric Use),"A Double - Blind, Randomized, - Controlled Clinical Trial With Inactivated Influenza Vaccine (Split Virion)(0.25ml Formulation for Pediatric Use)",COMPLETED,2009-03,2010-02,2012-09-06,INTERVENTIONAL,PHASE3,810.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Influenza,Influenza Split Vaccine|Inactivated Influenza Vaccine,BIOLOGICAL,1,1,6 Months,36 Months,ALL,True,"Hualan Biological Engineering, Inc.",INDUSTRY,0,1,China,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.698268054115413,xlarge,0,1,1,0,0,0,0,0,0,0,1,1,0,1,2,1,0,1,0,2,1,2009-03-01,2010-02-01,337.0,2009.0,0,1,0
NCT00469885,Reduction of Smoking in Cardiac Disease Patients,Harm Reduction Treatment for Smokers With Cardiovascular Disease {Reduction of Smoking in Cardiovascular Disease Patients (ROSCAP)},COMPLETED,2001-01,2005-12,2017-01-10,INTERVENTIONAL,PHASE2,152.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Cardiovascular Disease|Tobacco Use Disorder,Nicotine replacement|Motivational counseling,BEHAVIORAL|DRUG,4,1,18 Years,,ALL,False,National Institute on Drug Abuse (NIDA),NIH,0,2,United States,1.0,0,1,0,0,0,2.0,0,0,0,1,2,5.030437921392435,medium,0,1,0,1,0,0,1,0,1,0,1,0,1,1,5,1,1,0,0,2,1,2001-01-01,2005-12-01,1795.0,2001.0,0,2,0
NCT02172443,Comparison of Tiotropium Inhalation Capsules and Atrovent Metered Dose Inhaler (MDI) in a Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease,"Comparison of 18 mcg of Tiotropium Inhalation Capsules and Atrovent Metered Dose Inhaler (2 Puffs of 20 mcg) in a Double Blind, Double Dummy, Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease (COPD)",COMPLETED,2001-06,,2018-08-31,INTERVENTIONAL,PHASE3,50.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Pulmonary Disease, Chronic Obstructive",tiotropium inhalation powder capsules|Atrovent|placebo to Atrovent|placebo to tiotropium inhalation capsules,DRUG,1,9,40 Years,,ALL,False,Boehringer Ingelheim,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.9318256327243257,small,1,1,1,0,0,0,0,0,0,0,1,1,1,1,10,1,1,0,0,4,1,2001-06-01,,,2001.0,0,2,0
NCT01963143,"Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases","A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases",COMPLETED,2014-02,2016-05,2017-03-29,INTERVENTIONAL,PHASE3,48.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Primary Immune Deficiency Disorders|Common Variable Immunodeficiency|X-linked Agammaglobulinaemia|Hyper-IgM Syndrome,Gammaplex (5%)|Gammaplex 10,BIOLOGICAL,1,2,2 Years,55 Years,ALL,False,Bio Products Laboratory,OTHER,0,17,United Kingdom|Hungary|United States,1.0,0,0,1,0,0,3.0,0,0,0,0,4,3.8918202981106265,small,1,1,0,1,0,0,1,1,1,1,1,0,1,0,3,1,0,1,0,2,1,2014-02-01,2016-05-01,820.0,2014.0,0,3,1
NCT06046443,A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity,"A Randomized, Placebo-controlled, Double-Blind Phase 2 Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity, With an Open-Label Extension",ACTIVE_NOT_RECRUITING,2024-07-11,2026-01-31,2025-07-22,INTERVENTIONAL,PHASE2,28.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Hypothalamic Obesity,LB54640|Placebo,DRUG,1,7,12 Years,,ALL,False,"Rhythm Pharmaceuticals, Inc.",INDUSTRY,0,10,United Kingdom|United States,,0,1,0,0,0,2.0,0,0,0,0,1,3.367295829986474,small,1,0,1,0,0,0,1,1,1,1,1,1,1,1,8,1,1,0,0,2,1,,,,,0,3,1
NCT02412735,Placebo-controlled Study to Evaluate Rexlemestrocel-L Alone or Combined With Hyaluronic Acid in Participants With Chronic Low Back Pain,"A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of a Single Injection of Rexlemestrocel-L Alone or Combined With Hyaluronic Acid (HA) in Subjects With Chronic Low Back Pain",COMPLETED,2015-03-06,2021-06-15,2022-10-19,INTERVENTIONAL,PHASE3,404.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Degenerative Disc Disease,Rexlemestrocel-L|Rexlemestrocel-L + HA Mixture|Placebo,DRUG,1,6,18 Years,,ALL,False,"Mesoblast, Ltd.",INDUSTRY,1,48,Australia|United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.003887067106539,large,0,1,1,0,0,1,1,1,1,0,1,1,1,1,7,1,1,0,0,3,1,,,,,0,3,1
NCT03663335,"Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients","A Partially-blinded, Active-controlled, Multicenter, Randomized Study Evaluating Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in de Novo and Maintenance Kidney Transplant Recipients (CIRRUS I)",COMPLETED,2018-11-28,2021-10-29,2022-06-13,INTERVENTIONAL,PHASE2,418.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Kidney Transplant Rejection,CFZ533 - MMF - CS|Tacrolimus - MMF - +/- corticosteroids,DRUG|BIOLOGICAL,1,5,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,74,Latvia|Germany|Norway|Japan|Switzerland|Italy|Netherlands|South Korea|Spain|Czechia|Canada|Argentina|Sweden|United States|United Kingdom|Australia|France|Belgium|Hungary|Brazil,1.0,0,1,0,0,0,2.0,0,0,0,0,1,6.037870919922137,large,0,1,1,0,1,0,1,1,1,1,1,1,1,1,6,1,1,1,0,2,1,,,,,0,3,1
NCT00812435,Eptifibatide and ST Segment Resolution Following Primary PCI,Eptifibatide and ST Segment Resolution Following Primary PCI,TERMINATED,2007-08,2011-03,2014-08-11,INTERVENTIONAL,PHASE3,22.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Myocardial Infarction,eptifibitide,DRUG,1,1,18 Years,,ALL,False,Medstar Health Research Institute,OTHER,0,1,United States,0.0,0,0,1,0,0,3.0,0,0,0,1,1,3.1354942159291497,small,1,1,0,1,0,0,0,0,1,0,1,0,1,0,2,1,1,0,0,1,0,2007-08-01,2011-03-01,1308.0,2007.0,0,0,0
NCT00213135,A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),"A Phase III, Randomized, Double-blind, Three-arm, Placebo-controlled, Multi-center Study to Evaluate the Safety and Efficacy of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)",COMPLETED,2005-04,2008-11,2014-02-07,INTERVENTIONAL,PHASE3,1326.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,"Multiple Sclerosis, Relapsing-Remitting",Cladribine 5.25 mg/kg|Cladribine 3.5 mg/kg|Placebo,DRUG|OTHER,1,3,18 Years,65 Years,ALL,False,EMD Serono,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,1,0,0,1,7.190676034332207,xlarge,0,1,1,0,0,0,0,0,0,0,1,1,1,1,4,1,1,0,0,3,1,2005-04-01,2008-11-01,1310.0,2005.0,0,1,0
NCT01685008,Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL),"A Phase IIa, Open-label, Multicenter Study of Single-agent MOR00208, an Fc-optimized Anti-CD19 Antibody, in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma",COMPLETED,2013-04-23,2022-04-06,2023-11-07,INTERVENTIONAL,PHASE2,92.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Non-Hodgkin Lymphoma,MOR00208 (formerly Xmab 5574),DRUG,1,27,18 Years,,ALL,False,MorphoSys AG,INDUSTRY,0,22,Italy|Belgium|Hungary|United States|Germany|Spain|Poland,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.532599493153256,medium,1,1,1,0,0,0,1,1,1,1,0,0,1,0,28,1,1,0,0,1,0,,,,,0,2,0
NCT02157376,Stress Ulcer Prophylaxis of Intravenous Esomeprazole in Chinese Seriously Ill Patients,"Effect of Intravenous Esomeprazole Versus Cimetidine in Prevention of Stress Ulcer Prophylaxis in Chinese Seriously Ill Patients - a Randomized, Double-blind, Parallel-group Study",COMPLETED,2014-07,2016-02,2017-03-10,INTERVENTIONAL,PHASE3,343.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Stress Ulcer Prophylaxis,Esomeprazole|Cimetidine,DRUG,1,1,18 Years,70 Years,ALL,False,AstraZeneca,INDUSTRY,0,15,China,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.840641657373398,large,0,1,1,0,1,0,1,0,0,0,1,1,0,1,2,1,1,0,0,2,1,2014-07-01,2016-02-01,580.0,2014.0,0,1,0
NCT00623376,Randomized Double Blind Cross Over Study for Nabilone in Spasticity in Spinal Cord Injury Persons,Randomized Double Blind Cross Over Study Assessing the Effect of Cannabiniods on Spasticity in Spinal Cord Injured Persons :A Pilot Study,COMPLETED,2007-07,2007-12,2008-02-26,INTERVENTIONAL,PHASE2,,,,,,,Spasticity in Spinal Cord Injured Persons,nabilone then placebo|placebo then nabilone,DRUG,1,1,18 Years,,ALL,False,University of Manitoba,OTHER,1,1,Canada,1.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,0,0,0,1,0,1,0,0,0,0,0,0,0,0,2,1,1,0,0,2,1,2007-07-01,2007-12-01,153.0,2007.0,0,1,0
NCT01286207,"Long-Term Exposure to Rizatriptan 5-mg and 10-mg Oral Tablet (Combined Extension Protocols MK-0462-022, MK-0462-025, MK-0462-029)","Long-Term Exposure to Rizatriptan 5-mg and 10-mg Oral Tablet (Combined Protocols 022, 025, 029)",COMPLETED,1995-03,1997-05,2022-02-03,INTERVENTIONAL,PHASE3,1959.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Migraine Disorders,Rizatriptan 5 mg|Rizatriptan 10 mg|Standard Care,DRUG,5,0,18 Years,65 Years,ALL,False,Organon and Co,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,1,0,1,7.580699752224563,xlarge,0,1,1,0,0,0,0,0,0,0,1,0,1,1,5,0,1,0,0,3,1,1995-03-01,1997-05-01,792.0,1995.0,0,1,0
NCT05405192,Dostarlimab in Chemoresistant Gestational Trophoblastic Neoplasia,Phase 2 Single Agent Dostarlimab in Chemoresistant Gestational Trophoblastic Neoplasia (GTN),WITHDRAWN,2023-03-01,2028-12-01,2023-02-28,INTERVENTIONAL,PHASE2,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Gestational Trophoblastic Neoplasia,Dostarlimab,DRUG,1,4,18 Years,,FEMALE,False,University of Miami,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,1,1,0,1,0,1,0,0,1,0,0,0,1,0,5,1,1,0,0,1,0,,,,,0,0,0
NCT00299936,Comparison of PEG-Intron and Two Different Doses of Ribavirin for the Treatment of Chronic Hepatitis C In Treatment Naïve Subjects,Comparison of PEG Interferon Alfa-2b Plus Ribavirin Given as a Fixed Dose or on a Weight Optimized Basis for Treatment of Chronic Hepatitis C in Previously Untreated Adult Subjects,COMPLETED,,,2006-03-07,INTERVENTIONAL,PHASE3,5000.0,,RANDOMIZED,PARALLEL,TREATMENT,NONE,Chronic Hepatitis C,"Ribavirin, PEG-Intron",DRUG,0,0,18 Years,70 Years,ALL,False,Weill Medical College of Cornell University,OTHER,1,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,8.517393171418904,xlarge,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,,,,,0,0,0
NCT04374136,A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3),"A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene",TERMINATED,2020-07-23,2026-01-06,2026-01-21,INTERVENTIONAL,PHASE3,119.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Frontotemporal Dementia,AL001|Placebo|Open label - AL001,DRUG,1,5,25 Years,85 Years,ALL,False,Alector Inc.,INDUSTRY,1,44,Italy|Belgium|Argentina|Netherlands|Sweden|Turkey (Türkiye)|United States|Germany|Spain|Australia|United Kingdom|Switzerland|Portugal|France|Greece|Canada,0.0,0,0,1,0,0,3.0,0,0,0,0,1,4.787491742782046,medium,0,1,1,0,0,1,1,1,1,1,1,1,1,1,6,1,1,0,0,3,1,,,,,0,3,1
NCT01473836,A Phase 3 Study Of Intravenous Metronidazole For Intrabdominal Infection,"A Phase 3, Multicenter, Unblind, Non-Comparative Study To Confirm Efficacy And Safety Of Intravenous Metronidazole In Patients With Intrabdominal Infection In Combination With Intravenous Ceftriaxone",COMPLETED,2011-11,2012-10,2014-01-24,INTERVENTIONAL,PHASE3,38.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Intra-abdominal Infections,Metronidazole|Ceftriaxone sodium,DRUG,1,5,16 Years,79 Years,ALL,False,Pfizer,INDUSTRY,0,15,Japan,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.6635616461296463,small,1,1,1,0,1,0,1,0,0,0,0,0,1,0,6,1,1,0,0,2,1,2011-11-01,2012-10-01,335.0,2011.0,0,2,0
NCT00803244,Safety and Efficacy on Phase III Study on 300 IR SLIT to Patients Suffering From Grass Pollen Rhinoconjunctivitis,"A Randomised, Double-blind, Placebo-controlled, Multi National, Phase III Study of the Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablet, Starting 2 Months Before the Grass Pollen Season Once Daily to Patients Suffering From Grass Pollen Rhinoconjunctivitis",COMPLETED,2009-01,2010-01,2016-05-25,INTERVENTIONAL,PHASE3,381.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Primary Disease,300 IR|Placebo,DRUG,1,0,12 Years,65 Years,ALL,False,Stallergenes Greer,INDUSTRY,0,6,Italy|France|Spain,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.945420608606575,large,0,1,1,0,0,0,1,1,0,1,1,1,1,1,1,0,1,0,0,2,1,2009-01-01,2010-01-01,365.0,2009.0,0,2,0
NCT02489344,"Evaluation of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-Naïve Adult Male Patients With Fabry Disease","An Open-label, Multicenter, Multinational Extension Study of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Adult Male Patients Diagnosed With Fabry Disease",COMPLETED,2015-07-07,2018-11-20,2021-03-23,INTERVENTIONAL,PHASE2,8.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Fabry Disease,GZ/SAR402671,DRUG,9,29,18 Years,,MALE,False,"Genzyme, a Sanofi Company",INDUSTRY,0,7,Russia|United States|United Kingdom|Poland|France,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.1972245773362196,small,1,1,1,0,1,0,1,1,1,1,0,0,1,0,38,1,1,0,0,1,0,,,,,0,2,0
NCT05767034,"Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)","A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)",ACTIVE_NOT_RECRUITING,2023-03-22,2026-02-17,2025-12-22,INTERVENTIONAL,PHASE3,381.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Polymyalgia Rheumatica,Secukinumab 300 mg|Secukinumab 150 mg|Placebo to secukinumab,DRUG|OTHER,1,5,50 Years,100 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,133,Germany|Lebanon|Japan|Switzerland|Italy|Netherlands|Spain|Iceland|Chile|Czechia|Ireland|Canada|Argentina|Sweden|United States|United Kingdom|Australia|Poland|Mexico|Denmark|Israel|South Africa|France|Belgium|Hungary|Brazil|Colombia,,0,0,1,0,0,3.0,0,0,0,0,1,5.945420608606575,large,0,1,1,0,1,0,1,1,1,1,1,1,1,1,6,1,1,0,0,3,1,,,,,0,3,1
NCT00694109,An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia,An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia,COMPLETED,2008-04,2014-09,2016-09-09,INTERVENTIONAL,PHASE3,144.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Lipid Metabolism, Inborn Errors|Hypercholesterolemia, Autosomal Dominant|Hyperlipidemias|Metabolic Diseases|Hyperlipoproteinemia Type II|Metabolism, Inborn Errors|Genetic Diseases, Inborn|Infant, Newborn, Diseases|Metabolic Disorder|Congenital Abnormalities|Hypercholesterolemia|Hyperlipoproteinemias|Dyslipidemias|Lipid Metabolism Disorders",Mipomersen Sodium,DRUG,4,17,12 Years,,ALL,False,"Kastle Therapeutics, LLC",INDUSTRY,1,33,United States|Brazil|United Kingdom|Taiwan|South Africa|Singapore|Canada,1.0,0,0,1,0,0,3.0,0,0,0,0,14,4.976733742420574,medium,0,1,1,0,0,1,1,1,1,1,0,0,1,0,21,1,1,0,0,1,0,2008-04-01,2014-09-01,2344.0,2008.0,0,3,1
NCT00094432,A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole in the Treatment of Patients With Bipolar I Disorder With a Major Depressive Episode. CN138-146 LT is the 26-week Open Label Extension Phase of the Above Titled Protocol, CN138-146 ST.",COMPLETED,2004-06,2006-11,2013-11-11,INTERVENTIONAL,PHASE3,650.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Bipolar I Disorder,Aripiprazole|Placebo,DRUG,1,3,18 Years,65 Years,ALL,False,"Otsuka Pharmaceutical Development & Commercialization, Inc.",INDUSTRY,1,40,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.478509642208569,xlarge,0,0,1,0,0,1,1,0,1,0,1,1,1,1,4,1,1,0,0,2,1,2004-06-01,2006-11-01,883.0,2004.0,0,1,0
NCT01289132,Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncomplicated Essential Hypertension,"A Phase 2, Double-Blind, Randomized, Placebo-Controlled Dose-Ranging Study of the Efficacy, Safety and Tolerability of TAK-536 in Subjects With Mild to Moderate Uncomplicated Essential Hypertension",COMPLETED,2007-07,2008-07,2011-02-03,INTERVENTIONAL,PHASE2,926.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Essential Hypertension,Placebo|Azilsartan|Azilsartan|Azilsartan|Azilsartan|Azilsartan|Candesartan cilexetil,DRUG,1,25,20 Years,,ALL,False,Takeda,INDUSTRY,0,0,,1.0,0,1,0,0,0,2.0,0,0,0,1,1,6.831953565565855,xlarge,0,1,1,0,1,0,0,0,0,0,1,1,1,1,26,1,1,0,0,7,1,2007-07-01,2008-07-01,366.0,2007.0,0,2,0
NCT02088632,Incobotulinum Toxin for the Treatment of Trigeminal Neuralgia,"A Randomized, Double-Blind, Placebo-Controlled, Add-on Therapy Study of Xeomin (Incobotulinumtoxina) Versus Placebo in the Treatment of Trigeminal Neuralgia",TERMINATED,2014-03-14,2016-10-19,2023-06-28,INTERVENTIONAL,PHASE2,6.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Trigeminal Neuralgia,Incobotulinumtoxina|Placebo Comparator,BIOLOGICAL|OTHER,1,1,18 Years,75 Years,ALL,False,Thomas Jefferson University,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,1.9459101490553132,small,1,1,0,1,0,1,0,0,1,0,1,1,1,1,2,1,0,1,0,2,1,,,,,0,1,0
NCT00679432,(CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis,"Efficacy and Safety of New Oral Budesonide-MMX™ (CB-01-02) 6 mg and 9 mg Extended Release Tablet Formulations in Patients With Mild or Moderate, Active Ulcerative Colitis. A Multicenter, Randomized, Double-blind, Double Dummy Comparative Study Versus Placebo, With an Additional Reference Arm Evaluating Asacol® 2400 mg.",COMPLETED,2008-06,2010-06,2019-12-10,INTERVENTIONAL,PHASE3,510.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Ulcerative Colitis,"Blood sampling, endoscopy|budesonide-MMX® 6 mg|budesonide-MMX® 9 mg|Placebo|Asacol® 400 mg",DRUG|PROCEDURE,1,2,18 Years,75 Years,ALL,False,"Bausch Health Americas, Inc.",INDUSTRY,0,105,Canada|Mexico|India|United States,1.0,0,0,1,0,0,3.0,0,1,0,0,1,6.236369590203704,xlarge,0,1,1,0,0,0,1,1,1,0,1,1,1,1,3,1,1,0,0,5,1,2008-06-01,2010-06-01,730.0,2008.0,0,2,0
NCT04561063,COVID-19 Prophylaxis South Africa (COVER HCW),"A Multi-center, Randomised, Open Label Study of Nitazoxanide (NTZ), or Sofosbuvir and Daclatasvir (SOF/DCV), Compared to no Pharmacological Intervention for the Prevention of COVID-19 Disease in Healthcare Workers and Inner City Inhabitants at High Risk of Exposure to SARS-CoV-2",COMPLETED,2020-12-08,2022-02-28,2022-06-07,INTERVENTIONAL,PHASE2,1950.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Covid19|SARS-CoV Infection,Nitazoxanide|Sofosbuvir/Daclatasvir,DRUG,1,6,18 Years,99 Years,ALL,True,"University of Witwatersrand, South Africa",OTHER,0,2,South Africa,1.0,0,1,0,0,0,2.0,0,0,0,0,2,7.576097340623111,xlarge,0,1,0,1,0,0,1,0,0,0,1,0,0,1,7,1,1,0,0,2,1,,,,,0,3,1
NCT00656487,Clinical and Neurobiological Effects of Cannabis Dependence in Young Adults,Translational Center on the Clinical Neurobiology of Cannabis Addiction,COMPLETED,2008-04-30,2011-01-06,2017-06-19,INTERVENTIONAL,PHASE2,66.0,ACTUAL,RANDOMIZED,PARALLEL,DIAGNOSTIC,TRIPLE,Cannabis Dependence|Cannabis Withdrawal,rimonabant|placebo,DRUG,6,0,21 Years,30 Years,ALL,True,The Scripps Research Institute,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.204692619390966,medium,1,1,0,1,0,1,0,0,1,0,1,1,0,1,6,0,1,0,0,2,1,,,,,0,3,1
NCT02724293,Efficacy and Safety of Peri-operative Pregabalin After Radical Cystectomy,"Analgesic Efficacy and Safety of Peri-operative Pregabalin Following Radical Cystectomy, a Prospective,Randomized, Double-blinded, Controlled Trial",COMPLETED,2014-09,2015-11,2016-03-31,INTERVENTIONAL,PHASE2|PHASE3,60.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,TRIPLE,Postoperative Pain Following Radical Cystectomy,pregabaline 300 mg once.|pregabaline 300 mg twice.|pregabaline 600 mg once.|placebo,DRUG,3,1,18 Years,60 Years,ALL,False,Assiut University,OTHER,0,0,,1.0,0,1,1,0,1,2.5,0,0,0,0,1,4.110873864173311,medium,1,1,0,1,0,0,0,0,0,0,1,1,1,0,4,1,1,0,0,4,1,2014-09-01,2015-11-01,426.0,2014.0,0,2,0
NCT02517593,Genetic Risk Estimation of Breast Cancer Prior to Preventive Medication Uptake,"Genetic Risk Estimation of Breast Cancer Prior to Preventive Medication Uptake: A Pilot Study to Determine if a Polygenic Risk Score Influences the Decision to Accept Breast Cancer Preventive Medications (Tamoxifen, Raloxifene, or Exemestane) Amongst Non-BRCA Women at Risk",COMPLETED,2016-03,2019-12-01,2020-12-30,INTERVENTIONAL,PHASE1|PHASE2,151.0,ACTUAL,,SINGLE_GROUP,PREVENTION,NONE,Breast Cancer,Polygenic Risk Score,GENETIC,1,4,35 Years,75 Years,FEMALE,True,Mayo Clinic,OTHER,1,2,Canada|United States,1.0,1,1,0,0,1,1.5,1,0,0,0,1,5.0238805208462765,medium,0,1,0,1,0,1,1,1,1,0,0,0,0,0,5,1,0,0,0,1,0,2016-03-01,,,2016.0,1,2,0
NCT00517621,Use of FACT-GOG/NTX Questionnaire in Peripheral Neurotoxicity & Validation of a French Version of This Questionnaire,A Multicenter Prospective Phase II Study Evaluating Peripheral Neurotoxicity by Using FACT-GOG/NTX Questionnaire in Patients With Ovarian Cancer in Relapse Treated by Paclitaxel +/- EPO. Validation of a French Version of This Questionnaire,COMPLETED,2006-02,2010-10,2011-02-25,INTERVENTIONAL,PHASE2,100.0,ESTIMATED,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Neoplasms,Paclitaxel|EPO,DRUG,1,3,18 Years,,FEMALE,False,ARCAGY/ GINECO GROUP,OTHER,0,1,France,1.0,0,1,0,0,0,2.0,1,0,0,0,3,4.61512051684126,medium,0,0,0,1,0,0,0,0,0,1,0,0,1,0,4,1,1,0,0,2,1,2006-02-01,2010-10-01,1703.0,2006.0,0,2,0
NCT00182221,Safety of a Diagnostic Strategy With D-Dimer Testing for PE,A Cohort Study Evaluating the Safety of a Diagnostic Strategy Involving D-Dimer Testing in Patients With Suspected Pulmonary Embolism,COMPLETED,2003-08,2008-04,2017-03-30,INTERVENTIONAL,PHASE3,1000.0,ESTIMATED,NON_RANDOMIZED,PARALLEL,DIAGNOSTIC,NONE,Venous Thromboembolism,MDA D-Dimer Testing,PROCEDURE,1,0,18 Years,,ALL,False,McMaster University,OTHER,1,4,Canada,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.90875477931522,xlarge,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,2003-08-01,2008-04-01,1705.0,2003.0,0,0,0
NCT03397121,Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH),"Placebo-Controlled, Double-Blind, Randomized Trial to Evaluate the Effect of 300 mg of Inclisiran Sodium Given as Subcutaneous Injections in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH) and Elevated Low-Density Lipoprotein Cholesterol (LDL-C).",COMPLETED,2017-11-28,2019-09-17,2020-10-28,INTERVENTIONAL,PHASE3,482.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Heterozygous Familial Hypercholesterolemia|Elevated Cholesterol,Inclisiran|Placebo,DRUG,2,6,18 Years,,ALL,False,The Medicines Company,INDUSTRY,0,45,Netherlands|Sweden|United States|Spain|Czechia|Denmark|South Africa|Canada,1.0,0,0,1,0,0,3.0,0,0,0,0,2,6.180016653652572,large,0,1,1,0,0,0,1,1,1,1,1,1,1,1,8,1,1,0,0,2,1,,,,,0,4,1
NCT05462821,Full-Time Occlusion Therapy for Intermittent Exotropia in Children,Randomized Trial of Full-Time Occlusion Therapy for Intermittent Exotropia in Children,COMPLETED,2022-11-01,2025-05-01,2025-12-02,INTERVENTIONAL,PHASE3,73.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Intermittent Exotropia,Eye Patch,DEVICE,1,0,3 Years,8 Years,ALL,False,Jaeb Center for Health Research,OTHER,2,25,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.30406509320417,medium,1,1,0,1,0,1,1,0,1,0,1,0,1,1,1,0,0,0,1,1,0,,,,,0,0,0
NCT04239014,"A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.","A Phase 2 Randomized, Multi-Centre Study to Investigate the Efficacy and Tolerability of a Second Maintenance Treatment in Patients With Platinum Sensitive Relapsed Epithelial Ovarian Cancer, Who Have Previously Received PARP Inhibitor Maintenance Treatment",WITHDRAWN,2020-08-07,2021-01-25,2021-03-10,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Ovarian Cancer,Olaparib|Ceralasertib|Placebo to match olaparib,DRUG,1,9,18 Years,130 Years,FEMALE,False,AstraZeneca,INDUSTRY,1,26,Italy|Canada|Spain|United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,0.0,,1,1,1,0,1,1,1,1,1,1,1,1,1,1,10,1,1,0,0,3,1,,,,,0,3,1
NCT05982314,Extension Safety and Immunogenicity Study of GPNV-001,A Safety and Immunogenicity Extension Study of GPNV-001,COMPLETED,2023-07-17,2024-08-30,2024-12-18,INTERVENTIONAL,PHASE1|PHASE2,60.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Pneumococcal Infections,Gamma-PN3|Pneumovax-23|Prevenar-13|Placebo,BIOLOGICAL,2,1,18 Years,69 Years,ALL,True,GPN Vaccines,INDUSTRY,0,1,Australia,1.0,1,1,0,0,1,1.5,0,0,0,0,1,4.110873864173311,medium,1,1,1,0,0,0,0,0,0,0,1,1,0,1,3,1,0,1,0,4,1,,,,,0,2,0
NCT00218816,Nebulizer Intervention for Minority Children With Asthma,Nebulizer Intervention for Minority Children With Asthma,COMPLETED,2000-08,2005-12,2008-09-05,INTERVENTIONAL,PHASE3,221.0,ACTUAL,RANDOMIZED,PARALLEL,,NONE,Asthma,Nebulizer Education Intervention|Standard Asthma Education Groups,BEHAVIORAL,1,0,2 Years,8 Years,ALL,False,National Institute of Nursing Research (NINR),NIH,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.402677381872279,large,0,1,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,2,1,2000-08-01,2005-12-01,1948.0,2000.0,0,1,0
NCT04867616,"A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)","A Patient- and Investigator-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Study Participants With Prodromal to Mild Alzheimer's Disease (AD), Followed by an Open-Label Extension Period",COMPLETED,2021-06-09,2025-08-01,2025-08-29,INTERVENTIONAL,PHASE2,466.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Alzheimer's Disease,Placebo|Bepranemab,BIOLOGICAL|OTHER,1,10,50 Years,80 Years,ALL,False,UCB Biopharma SRL,INDUSTRY,0,103,Italy|Belgium|Netherlands|United States|Germany|Spain|United Kingdom|Poland|France|Canada,1.0,0,1,0,0,0,2.0,0,0,1,0,1,6.1463292576688975,large,0,1,1,0,0,0,1,1,1,1,1,1,1,1,11,1,0,1,0,2,1,,,,,0,3,1
NCT01028716,Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies,"Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source",TERMINATED,2010-05-19,2021-10-07,2023-01-23,INTERVENTIONAL,PHASE2,46.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Acute Biphenotypic Leukemia|Acute Erythroid Leukemia in Remission|Acute Leukemia in Remission|Acute Lymphoblastic Leukemia in Remission|Acute Myeloid Leukaemia With Prior Myelodysplastic Syndrome|Acute Myeloid Leukemia in Remission|Acute Myeloid Leukemia With FLT3/ITD Mutation|Acute Myeloid Leukemia With Inv(3)(Q21Q26.2); RPN1-EVI1|Acute Myeloid Leukemia With Multilineage Dysplasia|Acute Myeloid Leukemia With t(6;9)|Acute Undifferentiated Leukemia|Adult Acute Lymphoblastic Leukemia in Complete Remission|B Acute Lymphoblastic Leukemia With T(1;19)(Q23;P13.3); E2A-PBX1 (TCF3-PBX1)|Ph+ ALL|Burkitt Lymphoma|Childhood Acute Lymphoblastic Leukemia in Complete Remission|DS Stage II Plasma Cell Myeloma|DS Stage III Plasma Cell Myeloma|Myelodysplastic Syndrome|Recurrent Anaplastic Large Cell Lymphoma|Blasts Under 5 Percent of Bone Marrow Nucleated Cells|Recurrent Follicular Lymphoma|Recurrent Hodgkin Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma|Secondary Acute Myeloid Leukemia|T Lymphoblastic Lymphoma|Hematopoietic Cell Transplant Recipient,Cyclophosphamide|Filgrastim|Fludarabine Phosphate|Mycophenolate Mofetil|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Peripheral Blood Stem Cell Transplantation|Tacrolimus|Total-Body Irradiation,DRUG|BIOLOGICAL|RADIATION|PROCEDURE,4,8,,,ALL,False,Fred Hutchinson Cancer Center,OTHER,0,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,30,3.8501476017100584,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,12,1,1,1,0,8,1,,,,,0,3,1
NCT03055806,"IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT), Patient Reported Outcomes and Safety in Men With Premature Ejaculation (PE)","A Phase 2b, 8-Week, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effects of 3 Different Dose Levels of IX-01 on Intravaginal Ejaculatory Latency Time (IELT), Patient-Reported Outcomes, and Safety in Men With Lifelong Premature Ejaculation (PE)",COMPLETED,2017-02-28,2017-12-06,2019-10-07,INTERVENTIONAL,PHASE2,239.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Premature Ejaculation,IX-01 400 mg|Placebo|IX-01 800 mg|IX-01 1200 mg,DRUG,1,8,18 Years,60 Years,MALE,False,Ixchelsis Limited,INDUSTRY,0,29,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.480638923341991,large,0,1,1,0,0,0,1,0,1,0,1,1,1,1,9,1,1,0,0,4,1,,,,,0,2,0
NCT03748706,PTI-125 for Mild-to-moderate Alzheimer's Disease Patients,"A Phase 2a, Open-label, Multiple Dose, Safety, Pharmacokinetic and Biomarker Study of PTl-125 in Mild-to-moderate Alzheimer's Disease Patients",COMPLETED,2019-03-07,2019-05-08,2021-07-07,INTERVENTIONAL,PHASE2,13.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Alzheimer Disease,"PTI-125, 100 mg tablets",DRUG,6,2,50 Years,85 Years,ALL,False,Pain Therapeutics,INDUSTRY,1,2,United States,1.0,0,1,0,0,0,2.0,0,0,1,0,1,2.6390573296152584,small,1,1,1,0,0,1,1,0,1,0,0,0,1,0,8,1,1,0,0,1,0,,,,,0,1,0
NCT04604704,Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome,Pilot Study Into Low Dose Naltrexone (LDN) and Nicotinamide Adenine Dinucleotide (NAD+) for Treatment of Patients With Post-COVID-19 Syndrome (Long-COVID19),COMPLETED,2021-01-28,2023-01-23,2023-01-25,INTERVENTIONAL,PHASE2,36.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Covid19|Long COVID-19|Post-COVID-19 Syndrome,Naltrexone|NAD+,DRUG|DIETARY_SUPPLEMENT,1,1,18 Years,65 Years,ALL,False,AgelessRx,INDUSTRY,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,3,3.6109179126442243,small,1,1,1,0,0,0,0,0,1,0,0,0,1,0,2,1,1,0,0,2,1,,,,,0,2,0
NCT00826384,Transarterial Chemoembolization (TACE) Therapy of Hepatocellular Carcinoma (HCC) With Blocking Tumor Blood Temporarily and Enhancing Perfusion,"Phase 1,Single-blind, Randomized, Controlled Study to Evaluate the Safety and Effectivity of TACE Therapy of HCC(Hepatocellular Carcinoma) With Blocking Tumor Blood Temporarily and Enhancing Perfu",COMPLETED,2008-10,2010-12,2016-04-01,INTERVENTIONAL,PHASE1|PHASE2,352.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Hepatocellular Carcinoma,balloon catheter,PROCEDURE,1,0,18 Years,70 Years,ALL,False,Eastern Hepatobiliary Surgery Hospital,OTHER,0,1,China,1.0,1,1,0,0,1,1.5,1,0,0,0,1,5.8664680569332965,large,0,1,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,2008-10-01,2010-12-01,791.0,2008.0,0,1,0
NCT04907084,Serine and Fenofibrate Study in Patients With MacTel Type 2,Phase 2a Study of the Effect of Serine Supplementation and Fenofibrate Treatment on Serum Deoxysphinganine Levels in Patients With Macular Telangiectasia (MacTel) Type 2 (SAFE Study),ACTIVE_NOT_RECRUITING,2022-04-07,2024-03,2024-03-13,INTERVENTIONAL,PHASE2,60.0,ESTIMATED,RANDOMIZED,FACTORIAL,OTHER,NONE,Macular Telangiectasia Type 2,Serine|Fenofibrate,DRUG|DIETARY_SUPPLEMENT,2,2,21 Years,,ALL,False,The Lowy Medical Research Institute Limited,OTHER,0,9,United Kingdom|United States,,0,1,0,0,0,2.0,0,0,0,0,1,4.110873864173311,medium,1,0,0,1,0,0,1,1,1,1,1,0,0,0,4,1,1,0,0,2,1,,2024-03-01,,,0,2,0
NCT00130884,Peroral Levosimendan in Chronic Heart Failure,"Effects of Peroral Levosimendan in the Prevention of Further Hospitalisations in Patients With Chronic Heart Failure. A Randomised, Phase II, Double-Blind, Placebo-Controlled, Multi-Centre, Parallel-Group Study",COMPLETED,2005-03,2006-03,2007-02-21,INTERVENTIONAL,PHASE2,300.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Chronic Heart Failure|Heart Diseases,levosimendan,DRUG,1,0,18 Years,,ALL,False,"Orion Corporation, Orion Pharma",INDUSTRY,0,1,Finland,1.0,0,1,0,0,0,2.0,0,0,0,1,2,5.707110264748875,large,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,1,0,0,1,0,2005-03-01,2006-03-01,365.0,2005.0,0,1,0
NCT07253584,"A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of SAL003 in Combination With Statin Therapy in Patients With Hypercholesterolemia and Mixed Dyslipidemia","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of Recombinant Human Anti-PCSK9 Monoclonal Antibody Injection (SAL003) in Combination With Statin Therapy in Patients With Hypercholesterolemia and Mixed Dyslipidemia",COMPLETED,2023-12-19,2025-06-30,2025-11-28,INTERVENTIONAL,PHASE3,720.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Hyperlipidemias, Hypercholesterolemia, Mixed Dyslipidemia",SAL003 140 mg|Placebo,DRUG,1,0,18 Years,75 Years,ALL,False,"Shenzhen Salubris Pharmaceuticals Co., Ltd.",INDUSTRY,0,1,China,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.580639137284949,xlarge,0,1,1,0,0,0,0,0,0,0,1,1,1,1,1,0,1,0,0,2,1,,,,,0,1,0
NCT03536884,A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis,"A Multicenter, Randomized, Double-Blind, Secukinumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis",COMPLETED,2018-06-13,2023-08-09,2025-12-23,INTERVENTIONAL,PHASE3,743.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Chronic Plaque Psoriasis|Moderate to Severe Chronic Plaque Psoriasis,Bimekizumab|Secukinumab|Placebo,DRUG|OTHER,1,7,18 Years,,ALL,False,UCB Biopharma SRL,INDUSTRY,0,77,Netherlands|Belgium|Turkey (Türkiye)|United States|Germany|Spain|Australia|United Kingdom|Poland|France|Canada,1.0,0,0,1,0,0,3.0,0,1,0,0,2,6.612041034833092,xlarge,0,1,1,0,0,0,1,1,1,1,1,1,1,1,8,1,1,0,0,3,1,,,,,0,4,1
NCT00260533,Efficacy and Tolerability of Atomoxetine (Strattera) in Adult Patients With Generalized Social Anxiety Disorder,Double Blind Placebo Controlled Parallel Group Comparison of Atomoxetine (Strattera) for Generalized Social Anxiety Disorder (GSAD),COMPLETED,2005-11,2008-07,2016-06-24,INTERVENTIONAL,PHASE2|PHASE3,27.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Generalized Social Phobia,atomoxetine|placebo,DRUG,1,0,18 Years,65 Years,ALL,False,"University of California, San Diego",OTHER,1,0,,1.0,0,1,1,0,1,2.5,0,0,0,0,1,3.332204510175204,small,1,1,0,1,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,2,1,2005-11-01,2008-07-01,973.0,2005.0,0,2,0
NCT05148533,A Study of Single Drug TJ011133 and Toripalimab Combine Treatment for Advanced Solid Tumor,"A Phase I/II Dose Escalation and Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of TJ011133 in Combination With Toripalimab in Subjects With Advanced Solid Tumors",TERMINATED,2021-12-30,2023-02-03,2024-04-15,INTERVENTIONAL,PHASE1|PHASE2,7.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Advanced Solid Tumor,TJ1133 Injection,DRUG,2,0,18 Years,,ALL,False,"TJ Biopharma Co., Ltd.",INDUSTRY,0,22,China,0.0,1,1,0,0,1,1.5,1,0,0,0,1,2.0794415416798357,small,1,1,1,0,0,0,1,0,0,0,0,0,1,0,2,0,1,0,0,1,0,,,,,0,1,0
NCT00363233,The Potential Effects and Mechanisms of Flax Lignans on Type 2 Diabetes Mellitus,The Effects of Flax Lignans on Lipid Profile and Glucose Management in Type 2 Diabetes: a Randomized Double-Blind Cross-Over Study,COMPLETED,2006-03,2006-12,2007-01-09,INTERVENTIONAL,PHASE2|PHASE3,80.0,,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Type 2 Diabetes|Hypercholesterolemia,flax lignans,DRUG,1,1,50 Years,79 Years,ALL,False,Chinese Academy of Sciences,OTHER_GOV,0,1,China,1.0,0,1,1,0,1,2.5,0,0,0,0,2,4.394449154672439,medium,1,0,0,1,0,0,0,0,0,0,1,1,1,0,2,1,1,0,0,1,0,2006-03-01,2006-12-01,275.0,2006.0,0,2,0
NCT03195452,QDISS Stud: QD Isentress as Switch Strategy in Virologically Suppressed HIV-1 Infected-Patient,QD Isentress as Switch Strategy in Virologically Suppressed HIV-1 Infected-Patient,COMPLETED,2017-11-08,2020-05-06,2020-05-19,INTERVENTIONAL,PHASE2,100.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Virus-HIV,Raltegravir and 2 Nucleoside/Nucleotide reverse transcriptase inhibitor (NRTI),DRUG,1,8,18 Years,,ALL,False,Nantes University Hospital,OTHER,0,17,France,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.61512051684126,medium,0,1,0,1,0,0,1,0,0,1,0,0,1,0,9,1,1,0,0,1,0,,,,,0,1,0
NCT00916552,Effects of Erythropoietin on Depressive Symptoms and Neurocognitive Deficits in Depression and Bipolar Disorder,The Effects of Erythropoietin on Depressive Symptoms and Neurocognitive Deficits in Patients With Treatment Resistant Depression and in Patients With Remitted Bipolar Disorder - a Proof of Concept Study,COMPLETED,2009-09,2012-10,2012-11-09,INTERVENTIONAL,PHASE2,83.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Mood Disorders,Erythropoietin,DRUG,1,1,18 Years,65 Years,ALL,False,"Lars Vedel Kessing, professor, MD, DMSc.",OTHER,4,1,Denmark,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.430816798843313,medium,1,1,0,1,0,1,0,0,0,0,1,1,1,1,2,1,1,0,0,1,0,2009-09-01,2012-10-01,1126.0,2009.0,0,0,0
NCT00314938,A Single Dose Study to Evaluate the PK-PD Response and Safety of PHA-794428 in Children With Growth Hormone Deficiency,"A Double Blind, Single Dose Study To Explore The Safety, Pharmacokinetics And Pharmacodynamics Of PHA-794428 In Pediatric Patients With Growth Hormone Deficiency",TERMINATED,2006-04,2007-11,2011-05-16,INTERVENTIONAL,PHASE2,32.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Growth Hormone Deficiency,PHA-794428,DRUG,1,1,6 Years,12 Years,ALL,False,Pfizer,INDUSTRY,0,7,Belgium|Germany|United Kingdom|Israel|France,0.0,0,1,0,0,0,2.0,0,0,0,0,1,3.4965075614664802,small,1,0,1,0,1,0,1,1,0,1,1,1,1,1,2,1,1,0,0,1,0,2006-04-01,2007-11-01,579.0,2006.0,0,1,0
NCT02904538,Perineural Versus Systemic Dexamethasone to Prolong Regional Anesthesia in Front Foot Surgery,Perineural Versus Systemic Dexamethasone to Prolong Regional Anesthesia in Front Foot Surgery,COMPLETED,2016-11-22,2017-05-23,2017-06-16,INTERVENTIONAL,PHASE3,100.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Pain Management After Surgery,Dexamethasone|isotonic saline,DRUG,1,3,18 Years,,ALL,False,"University Hospital, Clermont-Ferrand",OTHER,0,1,France,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.61512051684126,medium,0,1,0,1,0,0,0,0,0,1,1,1,1,1,4,1,1,0,0,2,1,,,,,0,1,0
NCT00591838,A Phase I/II Trial of Stereotactic Body Radiation Therapy,A Phase I/II Trial of Stereotactic Body Radiation Therapy (SBRT) Dose Escalation in the Treatment of Patients With Inoperable Stage I/II Non-Small Cell Lung Cancer Arising Within the Zone of the Proximal Bronchial Tree,COMPLETED,2006-09-21,2018-06-12,2019-07-30,INTERVENTIONAL,PHASE1|PHASE2,74.0,ACTUAL,NON_RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,Inoperable Stage I/II Non-small Cell Lung Cancer,Stereotactic Body Radiation Therapy (SBRT),RADIATION,4,4,18 Years,,ALL,False,Washington University School of Medicine,OTHER,0,1,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,1,4.31748811353631,medium,1,1,0,1,0,0,0,0,1,0,0,0,1,0,8,1,0,0,0,1,0,,,,,0,2,0
